AU2017212713A1 - Oncolytic viral vectors and uses thereof - Google Patents
Oncolytic viral vectors and uses thereof Download PDFInfo
- Publication number
- AU2017212713A1 AU2017212713A1 AU2017212713A AU2017212713A AU2017212713A1 AU 2017212713 A1 AU2017212713 A1 AU 2017212713A1 AU 2017212713 A AU2017212713 A AU 2017212713A AU 2017212713 A AU2017212713 A AU 2017212713A AU 2017212713 A1 AU2017212713 A1 AU 2017212713A1
- Authority
- AU
- Australia
- Prior art keywords
- mir
- cancer
- oncolytic virus
- pct
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013603 viral vector Substances 0.000 title abstract description 49
- 230000000174 oncolytic effect Effects 0.000 title abstract description 14
- 230000002100 tumorsuppressive effect Effects 0.000 claims abstract description 186
- 239000002679 microRNA Substances 0.000 claims abstract description 121
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 98
- 230000029812 viral genome replication Effects 0.000 claims abstract description 93
- 201000011510 cancer Diseases 0.000 claims abstract description 73
- 231100000590 oncogenic Toxicity 0.000 claims abstract description 37
- 230000002246 oncogenic effect Effects 0.000 claims abstract description 37
- 108091005804 Peptidases Proteins 0.000 claims abstract description 25
- 239000004365 Protease Substances 0.000 claims abstract description 25
- 230000003612 virological effect Effects 0.000 claims abstract description 25
- 238000007634 remodeling Methods 0.000 claims abstract description 14
- -1 UI..33 Proteins 0.000 claims description 308
- 108091070501 miRNA Proteins 0.000 claims description 272
- 244000309459 oncolytic virus Species 0.000 claims description 197
- 210000004027 cell Anatomy 0.000 claims description 138
- 230000014509 gene expression Effects 0.000 claims description 127
- 108090000623 proteins and genes Proteins 0.000 claims description 123
- 108700005077 Viral Genes Proteins 0.000 claims description 72
- 108091056924 miR-124 stem-loop Proteins 0.000 claims description 69
- 102000004169 proteins and genes Human genes 0.000 claims description 69
- 235000018102 proteins Nutrition 0.000 claims description 67
- 241000700584 Simplexvirus Species 0.000 claims description 63
- 108091029119 miR-34a stem-loop Proteins 0.000 claims description 52
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 48
- 108091028684 Mir-145 Proteins 0.000 claims description 47
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 46
- 108091025686 miR-199a stem-loop Proteins 0.000 claims description 46
- 108091024038 miR-133a stem-loop Proteins 0.000 claims description 41
- 210000001519 tissue Anatomy 0.000 claims description 39
- 108091061943 Mir-218 microRNA precursor family Proteins 0.000 claims description 37
- 108091040176 miR-218 stem-loop Proteins 0.000 claims description 37
- 108091027766 Mir-143 Proteins 0.000 claims description 36
- 108091073532 miR-143 stem-loop Proteins 0.000 claims description 36
- 108091053592 miR-145-1 stem-loop Proteins 0.000 claims description 34
- 108091056559 miR-145-2 stem-loop Proteins 0.000 claims description 34
- 108091092012 miR-199b stem-loop Proteins 0.000 claims description 33
- 108091034117 Oligonucleotide Proteins 0.000 claims description 32
- 108091083769 miR-199a-1 stem-loop Proteins 0.000 claims description 32
- 108091047470 miR-199a-2 stem-loop Proteins 0.000 claims description 32
- 108091048350 miR-199a-3 stem-loop Proteins 0.000 claims description 32
- 108091056793 miR-199a-4 stem-loop Proteins 0.000 claims description 32
- 230000010076 replication Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- 108091090583 miR-34c stem-loop Proteins 0.000 claims description 31
- 101150027427 ICP4 gene Proteins 0.000 claims description 30
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 30
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 30
- 102000040430 polynucleotide Human genes 0.000 claims description 30
- 108091033319 polynucleotide Proteins 0.000 claims description 30
- 239000002157 polynucleotide Substances 0.000 claims description 30
- 108091028141 MiR-203 Proteins 0.000 claims description 28
- 108091027943 miR-16 stem-loop Proteins 0.000 claims description 27
- 108091074450 miR-200c stem-loop Proteins 0.000 claims description 27
- 108091063340 miR-497 stem-loop Proteins 0.000 claims description 27
- 108091007773 MIR100 Proteins 0.000 claims description 26
- 108091028066 Mir-126 Proteins 0.000 claims description 26
- 108091047467 miR-136 stem-loop Proteins 0.000 claims description 26
- 108091062895 miR-144 stem-loop Proteins 0.000 claims description 26
- 108091082133 miR-34c-1 stem-loop Proteins 0.000 claims description 26
- 108091032770 miR-451 stem-loop Proteins 0.000 claims description 26
- 108091030646 miR-451a stem-loop Proteins 0.000 claims description 26
- 108091061974 miR-559 stem-loop Proteins 0.000 claims description 26
- 108091093189 Mir-375 Proteins 0.000 claims description 25
- 108091040501 miR-129 stem-loop Proteins 0.000 claims description 25
- 108091058688 miR-141 stem-loop Proteins 0.000 claims description 25
- 108091043187 miR-30a stem-loop Proteins 0.000 claims description 25
- 108091062154 Mir-205 Proteins 0.000 claims description 24
- 102000035195 Peptidases Human genes 0.000 claims description 24
- 230000002238 attenuated effect Effects 0.000 claims description 24
- 101710130522 mRNA export factor Proteins 0.000 claims description 24
- 108091027034 miR-148a stem-loop Proteins 0.000 claims description 24
- 108091023818 miR-7 stem-loop Proteins 0.000 claims description 24
- 108091007422 miR-98 Proteins 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 24
- 108091092839 miR-124-1 stem-loop Proteins 0.000 claims description 23
- 108091045380 miR-124-2 stem-loop Proteins 0.000 claims description 23
- 108091048120 miR-124-3 stem-loop Proteins 0.000 claims description 23
- 108091034147 miR-124-5 stem-loop Proteins 0.000 claims description 23
- 108091059199 miR-200a stem-loop Proteins 0.000 claims description 23
- 108091089775 miR-200b stem-loop Proteins 0.000 claims description 23
- 108091031479 miR-204 stem-loop Proteins 0.000 claims description 23
- 108091061970 miR-26a stem-loop Proteins 0.000 claims description 23
- 108091007772 MIRLET7C Proteins 0.000 claims description 22
- 108091091807 let-7a stem-loop Proteins 0.000 claims description 22
- 108091057746 let-7a-4 stem-loop Proteins 0.000 claims description 22
- 108091028376 let-7a-5 stem-loop Proteins 0.000 claims description 22
- 108091024393 let-7a-6 stem-loop Proteins 0.000 claims description 22
- 108091091174 let-7a-7 stem-loop Proteins 0.000 claims description 22
- 108091079012 miR-133a Proteins 0.000 claims description 22
- 108091057540 miR-133a-2 stem-loop Proteins 0.000 claims description 22
- 108091079016 miR-133b Proteins 0.000 claims description 22
- 108091043162 miR-133b stem-loop Proteins 0.000 claims description 22
- 108091032320 miR-146 stem-loop Proteins 0.000 claims description 22
- 108091024530 miR-146a stem-loop Proteins 0.000 claims description 22
- 108091079013 miR-34b Proteins 0.000 claims description 22
- 108091084018 miR-34b stem-loop Proteins 0.000 claims description 22
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 claims description 22
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 claims description 22
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 claims description 22
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 claims description 22
- 108091027966 Mir-137 Proteins 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 21
- 108091007423 let-7b Proteins 0.000 claims description 21
- 108091091360 miR-125b stem-loop Proteins 0.000 claims description 21
- 108091031484 miR-335 stem-loop Proteins 0.000 claims description 21
- 230000035772 mutation Effects 0.000 claims description 21
- 108091034054 MiR-138 Proteins 0.000 claims description 20
- 108091030496 miR-138 stem-loop Proteins 0.000 claims description 20
- 108091083275 miR-26b stem-loop Proteins 0.000 claims description 20
- 108091059135 miR-429 stem-loop Proteins 0.000 claims description 20
- 108091033773 MiR-155 Proteins 0.000 claims description 19
- 108091047557 let-7a-3 stem-loop Proteins 0.000 claims description 19
- 108091033753 let-7d stem-loop Proteins 0.000 claims description 19
- 108091044988 miR-125a stem-loop Proteins 0.000 claims description 19
- 108091047757 miR-133a-1 stem-loop Proteins 0.000 claims description 19
- 108091026807 MiR-214 Proteins 0.000 claims description 18
- 108091060585 Mir-31 Proteins 0.000 claims description 18
- 108091051828 miR-122 stem-loop Proteins 0.000 claims description 18
- 108091064138 miR-129-2 stem-loop Proteins 0.000 claims description 18
- 108091055145 miR-342 stem-loop Proteins 0.000 claims description 18
- 108091030938 miR-424 stem-loop Proteins 0.000 claims description 18
- 108091087492 miR-490 stem-loop Proteins 0.000 claims description 18
- 108091036400 miR-490-1 stem-loop Proteins 0.000 claims description 18
- 108091057695 miR-490-2 stem-loop Proteins 0.000 claims description 18
- 230000001965 increasing effect Effects 0.000 claims description 17
- 108091042844 let-7i stem-loop Proteins 0.000 claims description 17
- 108091037426 miR-152 stem-loop Proteins 0.000 claims description 17
- 108091063796 miR-206 stem-loop Proteins 0.000 claims description 17
- 108091047189 miR-29c stem-loop Proteins 0.000 claims description 17
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 claims description 17
- 108091028761 miR-409 stem-loop Proteins 0.000 claims description 17
- 108091028232 Mir-184 Proteins 0.000 claims description 16
- 108091047546 miR-124-4 stem-loop Proteins 0.000 claims description 16
- 108091028854 miR-124-6 stem-loop Proteins 0.000 claims description 16
- 108091029379 miR-139 stem-loop Proteins 0.000 claims description 16
- 108091053935 miR-212 stem-loop Proteins 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 15
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 15
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 15
- 108091093142 MiR-144 Proteins 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 15
- 108091047626 let-7a-2 stem-loop Proteins 0.000 claims description 15
- 108091007427 let-7g Proteins 0.000 claims description 15
- 210000004072 lung Anatomy 0.000 claims description 15
- 108091091207 miR-127 stem-loop Proteins 0.000 claims description 15
- 108091090860 miR-150 stem-loop Proteins 0.000 claims description 15
- 108091031326 miR-15b stem-loop Proteins 0.000 claims description 15
- 108091091751 miR-17 stem-loop Proteins 0.000 claims description 15
- 108091039097 miR-193b stem-loop Proteins 0.000 claims description 15
- 108091088477 miR-29a stem-loop Proteins 0.000 claims description 15
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 claims description 15
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 claims description 15
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 claims description 15
- 108091070038 miR-338 stem-loop Proteins 0.000 claims description 15
- 108091074070 miR-338-3 stem-loop Proteins 0.000 claims description 15
- 108091037327 miR-449 stem-loop Proteins 0.000 claims description 15
- 108091040525 miR-449a stem-loop Proteins 0.000 claims description 15
- 108091033331 miR-503 stem-loop Proteins 0.000 claims description 15
- 108091076732 miR-99a stem-loop Proteins 0.000 claims description 15
- 108091064318 miR-99a-1 stem-loop Proteins 0.000 claims description 15
- 108091086202 miR-99a-2 stem-loop Proteins 0.000 claims description 15
- 101150047390 MCP gene Proteins 0.000 claims description 14
- 108091007780 MiR-122 Proteins 0.000 claims description 14
- 101150109748 UL19 gene Proteins 0.000 claims description 14
- 108091024449 let-7e stem-loop Proteins 0.000 claims description 14
- 108091044227 let-7e-1 stem-loop Proteins 0.000 claims description 14
- 108091071181 let-7e-2 stem-loop Proteins 0.000 claims description 14
- 108091041587 let-7f-2 stem-loop Proteins 0.000 claims description 14
- 108091028466 miR-130b stem-loop Proteins 0.000 claims description 14
- 108091032382 miR-204-1 stem-loop Proteins 0.000 claims description 14
- 108091085803 miR-204-2 stem-loop Proteins 0.000 claims description 14
- 108091089766 miR-204-3 stem-loop Proteins 0.000 claims description 14
- 108091073500 miR-204-4 stem-loop Proteins 0.000 claims description 14
- 108091053626 miR-204-5 stem-loop Proteins 0.000 claims description 14
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 14
- 108091028108 MiR-212 Proteins 0.000 claims description 13
- 108091062140 Mir-223 Proteins 0.000 claims description 13
- 108091031103 miR-181a stem-loop Proteins 0.000 claims description 13
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 claims description 13
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 claims description 13
- 108091028397 miR-212-1 stem-loop Proteins 0.000 claims description 13
- 108091028945 miR-212-2 stem-loop Proteins 0.000 claims description 13
- 108091026331 miR-214 stem-loop Proteins 0.000 claims description 13
- 108091048888 miR-214-1 stem-loop Proteins 0.000 claims description 13
- 108091078347 miR-214-2 stem-loop Proteins 0.000 claims description 13
- 108091035552 miR-214-3 stem-loop Proteins 0.000 claims description 13
- 108091025543 miR-219a-2 stem-loop Proteins 0.000 claims description 13
- 108091086421 miR-223 stem-loop Proteins 0.000 claims description 13
- 108091055059 miR-30c stem-loop Proteins 0.000 claims description 13
- 108091079001 CRISPR RNA Proteins 0.000 claims description 12
- 108091028080 MiR-132 Proteins 0.000 claims description 12
- 108091062170 Mir-22 Proteins 0.000 claims description 12
- 108091028049 Mir-221 microRNA Proteins 0.000 claims description 12
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 12
- 208000020816 lung neoplasm Diseases 0.000 claims description 12
- 108091064157 miR-106a stem-loop Proteins 0.000 claims description 12
- 108091038720 miR-129-1 stem-loop Proteins 0.000 claims description 12
- 108091045757 miR-129-3 stem-loop Proteins 0.000 claims description 12
- 108091090758 miR-129-4 stem-loop Proteins 0.000 claims description 12
- 108091065139 miR-129-5 stem-loop Proteins 0.000 claims description 12
- 108091043612 miR-146b stem-loop Proteins 0.000 claims description 12
- 108091026495 miR-148b stem-loop Proteins 0.000 claims description 12
- 108091047758 miR-185 stem-loop Proteins 0.000 claims description 12
- 108091086416 miR-192 stem-loop Proteins 0.000 claims description 12
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 12
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 12
- 108091035328 miR-217 stem-loop Proteins 0.000 claims description 12
- 108091039135 miR-217-1 stem-loop Proteins 0.000 claims description 12
- 108091029206 miR-217-2 stem-loop Proteins 0.000 claims description 12
- 108091007432 miR-29b Proteins 0.000 claims description 12
- 108091036633 miR-370 stem-loop Proteins 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 108091007774 MIR107 Proteins 0.000 claims description 11
- 101150041636 NEC1 gene Proteins 0.000 claims description 11
- 108091028113 Trans-activating crRNA Proteins 0.000 claims description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 11
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims description 11
- 210000001072 colon Anatomy 0.000 claims description 11
- 201000007270 liver cancer Diseases 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 108091055152 miR-133a-3 stem-loop Proteins 0.000 claims description 11
- 108091026523 miR-135a stem-loop Proteins 0.000 claims description 11
- 108091047577 miR-149 stem-loop Proteins 0.000 claims description 11
- 108091035696 miR-149-1 stem-loop Proteins 0.000 claims description 11
- 108091031096 miR-149-2 stem-loop Proteins 0.000 claims description 11
- 108091063348 miR-193 stem-loop Proteins 0.000 claims description 11
- 108091036762 miR-193a stem-loop Proteins 0.000 claims description 11
- 108091046261 miR-198 stem-loop Proteins 0.000 claims description 11
- 108091058987 miR-199b-1 stem-loop Proteins 0.000 claims description 11
- 108091090366 miR-199b-2 stem-loop Proteins 0.000 claims description 11
- 108091073659 miR-199b-3 stem-loop Proteins 0.000 claims description 11
- 108091057431 miR-30d stem-loop Proteins 0.000 claims description 11
- 108091092564 miR-494 stem-loop Proteins 0.000 claims description 11
- 108010042407 Endonucleases Proteins 0.000 claims description 10
- 108091046841 MiR-150 Proteins 0.000 claims description 10
- 108091028695 MiR-224 Proteins 0.000 claims description 10
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 10
- 108091028606 miR-1 stem-loop Proteins 0.000 claims description 10
- 108091033783 miR-153 stem-loop Proteins 0.000 claims description 10
- 108091043953 miR-373 stem-loop Proteins 0.000 claims description 10
- 208000007538 neurilemmoma Diseases 0.000 claims description 10
- 206010039667 schwannoma Diseases 0.000 claims description 10
- 102100031780 Endonuclease Human genes 0.000 claims description 9
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 claims description 9
- 101710163270 Nuclease Proteins 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 108091047499 miR-1271 stem-loop Proteins 0.000 claims description 9
- 108091060382 miR-140 stem-loop Proteins 0.000 claims description 9
- 108091044046 miR-17-1 stem-loop Proteins 0.000 claims description 9
- 108091065423 miR-17-3 stem-loop Proteins 0.000 claims description 9
- 108091043222 miR-181b stem-loop Proteins 0.000 claims description 9
- 108091045665 miR-202 stem-loop Proteins 0.000 claims description 9
- 108091086642 miR-216a stem-loop Proteins 0.000 claims description 9
- 108091092722 miR-23b stem-loop Proteins 0.000 claims description 9
- 108091031298 miR-23b-1 stem-loop Proteins 0.000 claims description 9
- 108091082339 miR-23b-2 stem-loop Proteins 0.000 claims description 9
- 108091039812 miR-28 stem-loop Proteins 0.000 claims description 9
- 108091063344 miR-30b stem-loop Proteins 0.000 claims description 9
- 108091023108 miR-30e stem-loop Proteins 0.000 claims description 9
- 108091049902 miR-33a stem-loop Proteins 0.000 claims description 9
- 108091030670 miR-365 stem-loop Proteins 0.000 claims description 9
- 108091036688 miR-365-3 stem-loop Proteins 0.000 claims description 9
- 108091087125 miR-376a stem-loop Proteins 0.000 claims description 9
- 108091073138 miR-376a-3 stem-loop Proteins 0.000 claims description 9
- 108091048468 miR-383 stem-loop Proteins 0.000 claims description 9
- 108091029369 miR-410 stem-loop Proteins 0.000 claims description 9
- 108091090896 miR-506 stem-loop Proteins 0.000 claims description 9
- 108091056454 miR-625 stem-loop Proteins 0.000 claims description 9
- 108091047084 miR-9 stem-loop Proteins 0.000 claims description 9
- 108091086713 miR-96 stem-loop Proteins 0.000 claims description 9
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 claims description 8
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 101150081727 UL32 gene Proteins 0.000 claims description 8
- 101150029683 gB gene Proteins 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 108091023084 miR-126 stem-loop Proteins 0.000 claims description 8
- 108091065272 miR-126-1 stem-loop Proteins 0.000 claims description 8
- 108091081187 miR-126-2 stem-loop Proteins 0.000 claims description 8
- 108091030790 miR-126-3 stem-loop Proteins 0.000 claims description 8
- 108091092317 miR-126-4 stem-loop Proteins 0.000 claims description 8
- 108091045872 miR-135 stem-loop Proteins 0.000 claims description 8
- 108091046685 miR-139-1 stem-loop Proteins 0.000 claims description 8
- 108091049185 miR-139-2 stem-loop Proteins 0.000 claims description 8
- 108091059964 miR-154 stem-loop Proteins 0.000 claims description 8
- 108091038599 miR-181b-2 stem-loop Proteins 0.000 claims description 8
- 108091073055 miR-193a-1 stem-loop Proteins 0.000 claims description 8
- 108091040345 miR-193a-2 stem-loop Proteins 0.000 claims description 8
- 108091049679 miR-20a stem-loop Proteins 0.000 claims description 8
- 108091050113 miR-211 stem-loop Proteins 0.000 claims description 8
- 108091061917 miR-221 stem-loop Proteins 0.000 claims description 8
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims description 8
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims description 8
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims description 8
- 108091029750 miR-30a-1 stem-loop Proteins 0.000 claims description 8
- 108091030035 miR-30a-2 stem-loop Proteins 0.000 claims description 8
- 108091064010 miR-31 stem-loop Proteins 0.000 claims description 8
- 108091062761 miR-448 stem-loop Proteins 0.000 claims description 8
- 108091080309 miR-483 stem-loop Proteins 0.000 claims description 8
- 108091039994 miR-486 stem-loop Proteins 0.000 claims description 8
- 108091051048 miR-6080 stem-loop Proteins 0.000 claims description 8
- 108091024443 miRa-135-1 stem-loop Proteins 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 101150109586 Gk gene Proteins 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 7
- 101100427508 Human cytomegalovirus (strain AD169) UL39 gene Proteins 0.000 claims description 7
- 108091028076 Mir-127 Proteins 0.000 claims description 7
- 101150093191 RIR1 gene Proteins 0.000 claims description 7
- 101150030723 RIR2 gene Proteins 0.000 claims description 7
- 101150103019 SCP gene Proteins 0.000 claims description 7
- 101150048584 TRM3 gene Proteins 0.000 claims description 7
- 101150023000 UL35 gene Proteins 0.000 claims description 7
- 101150100826 UL40 gene Proteins 0.000 claims description 7
- 101150099321 UL42 gene Proteins 0.000 claims description 7
- 101150004685 UL48 gene Proteins 0.000 claims description 7
- 101150009795 UL54 gene Proteins 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 7
- 108091063986 let-7f stem-loop Proteins 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 108091064399 miR-10b stem-loop Proteins 0.000 claims description 7
- 108091055434 miR-124a stem-loop Proteins 0.000 claims description 7
- 108091082871 miR-124a-2 stem-loop Proteins 0.000 claims description 7
- 108091050112 miR-124a-4 stem-loop Proteins 0.000 claims description 7
- 108091054623 miR-124a-5 stem-loop Proteins 0.000 claims description 7
- 108091024680 miR-124a-6 stem-loop Proteins 0.000 claims description 7
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 claims description 7
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 claims description 7
- 108091074057 miR-16-1 stem-loop Proteins 0.000 claims description 7
- 108091092591 miR-181a-2 stem-loop Proteins 0.000 claims description 7
- 108091062109 miR-372 stem-loop Proteins 0.000 claims description 7
- 108091085620 miR-6130 stem-loop Proteins 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 6
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 6
- 108091093073 MiR-134 Proteins 0.000 claims description 6
- 108091033433 MiR-191 Proteins 0.000 claims description 6
- 108091060302 Mir-320 Proteins 0.000 claims description 6
- 108091061758 Mir-433 Proteins 0.000 claims description 6
- 108091027559 Mir-96 microRNA Proteins 0.000 claims description 6
- 101150098384 NEC2 gene Proteins 0.000 claims description 6
- 238000010459 TALEN Methods 0.000 claims description 6
- 101150110861 TRM2 gene Proteins 0.000 claims description 6
- 101150023763 UL12 gene Proteins 0.000 claims description 6
- 101150036407 UL14 gene Proteins 0.000 claims description 6
- 101150068034 UL30 gene Proteins 0.000 claims description 6
- 101150017804 UL33 gene Proteins 0.000 claims description 6
- 101150087430 UL34 gene Proteins 0.000 claims description 6
- 101150085237 UL36 gene Proteins 0.000 claims description 6
- 101150036065 UL37 gene Proteins 0.000 claims description 6
- 101150011902 UL52 gene Proteins 0.000 claims description 6
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091079786 miR-105 stem-loop Proteins 0.000 claims description 6
- 108091040341 miR-1236 stem-loop Proteins 0.000 claims description 6
- 108091070946 miR-128 stem-loop Proteins 0.000 claims description 6
- 108091084874 miR-128-2 stem-loop Proteins 0.000 claims description 6
- 108091030617 miR-140-1 stem-loop Proteins 0.000 claims description 6
- 108091023370 miR-140-2 stem-loop Proteins 0.000 claims description 6
- 108091069239 miR-17-2 stem-loop Proteins 0.000 claims description 6
- 108091041042 miR-18 stem-loop Proteins 0.000 claims description 6
- 108091064825 miR-181c stem-loop Proteins 0.000 claims description 6
- 108091044400 miR-181c-1 stem-loop Proteins 0.000 claims description 6
- 108091048818 miR-181c-2 stem-loop Proteins 0.000 claims description 6
- 108091032779 miR-181c-3 stem-loop Proteins 0.000 claims description 6
- 108091029500 miR-183 stem-loop Proteins 0.000 claims description 6
- 108091047641 miR-186 stem-loop Proteins 0.000 claims description 6
- 108091062221 miR-18a stem-loop Proteins 0.000 claims description 6
- 108091054642 miR-194 stem-loop Proteins 0.000 claims description 6
- 108091088515 miR-197 stem-loop Proteins 0.000 claims description 6
- 108091030639 miR-219a-1 stem-loop Proteins 0.000 claims description 6
- 108091085564 miR-25 stem-loop Proteins 0.000 claims description 6
- 108091080167 miR-25-1 stem-loop Proteins 0.000 claims description 6
- 108091083056 miR-25-2 stem-loop Proteins 0.000 claims description 6
- 108091084454 miR-302a stem-loop Proteins 0.000 claims description 6
- 108091066670 miR-31-1 stem-loop Proteins 0.000 claims description 6
- 108091054015 miR-31-2 stem-loop Proteins 0.000 claims description 6
- 108091028785 miR-31-3 stem-loop Proteins 0.000 claims description 6
- 108091075059 miR-3189 stem-loop Proteins 0.000 claims description 6
- 108091059501 miR-320a stem-loop Proteins 0.000 claims description 6
- 108091088570 miR-320a-1 stem-loop Proteins 0.000 claims description 6
- 108091070041 miR-320a-2 stem-loop Proteins 0.000 claims description 6
- 108091065447 miR-320a-3 stem-loop Proteins 0.000 claims description 6
- 108091054114 miR-320a-4 stem-loop Proteins 0.000 claims description 6
- 108091023968 miR-330 stem-loop Proteins 0.000 claims description 6
- 108091049667 miR-340 stem-loop Proteins 0.000 claims description 6
- 108091057189 miR-340-2 stem-loop Proteins 0.000 claims description 6
- 108091068963 miR-361 stem-loop Proteins 0.000 claims description 6
- 108091071616 miR-376c stem-loop Proteins 0.000 claims description 6
- 108091055954 miR-377 stem-loop Proteins 0.000 claims description 6
- 108091024291 miR-378 stem-loop Proteins 0.000 claims description 6
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims description 6
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims description 6
- 108091025661 miR-378a stem-loop Proteins 0.000 claims description 6
- 108091041657 miR-381 stem-loop Proteins 0.000 claims description 6
- 108091044721 miR-422a stem-loop Proteins 0.000 claims description 6
- 108091062429 miR-487b stem-loop Proteins 0.000 claims description 6
- 108091053306 miR-493 stem-loop Proteins 0.000 claims description 6
- 108091031190 miR-495 stem-loop Proteins 0.000 claims description 6
- 108091057331 miR-509 stem-loop Proteins 0.000 claims description 6
- 108091091880 miR-509-1 stem-loop Proteins 0.000 claims description 6
- 108091051359 miR-509-2 stem-loop Proteins 0.000 claims description 6
- 108091041877 miR-519d stem-loop Proteins 0.000 claims description 6
- 108091060330 miR-520a stem-loop Proteins 0.000 claims description 6
- 108091056921 miR-532 stem-loop Proteins 0.000 claims description 6
- 108091055140 miR-574 stem-loop Proteins 0.000 claims description 6
- 108091065430 miR-610 stem-loop Proteins 0.000 claims description 6
- 108091086737 miR-630 stem-loop Proteins 0.000 claims description 6
- 108091038240 miR-638 stem-loop Proteins 0.000 claims description 6
- 108091035662 miR-646 stem-loop Proteins 0.000 claims description 6
- 108091037014 miR-7-1 stem-loop Proteins 0.000 claims description 6
- 108091030520 miR-7-2 stem-loop Proteins 0.000 claims description 6
- 108091025113 miR-7-3 stem-loop Proteins 0.000 claims description 6
- 108091089851 miR-7-4 stem-loop Proteins 0.000 claims description 6
- 108091030569 miR-940 stem-loop Proteins 0.000 claims description 6
- 108091070961 miR-96-3 stem-loop Proteins 0.000 claims description 6
- 108091053257 miR-99b stem-loop Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 101150010802 CVC2 gene Proteins 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims description 5
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 5
- 102100026799 Matrix metalloproteinase-28 Human genes 0.000 claims description 5
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 5
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 101150037769 TRX2 gene Proteins 0.000 claims description 5
- 101150004957 UL25 gene Proteins 0.000 claims description 5
- 101150060044 UL26 gene Proteins 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 108091062447 miR-10b-1 stem-loop Proteins 0.000 claims description 5
- 108091069028 miR-10b-4 stem-loop Proteins 0.000 claims description 5
- 108091057630 miR-1264 stem-loop Proteins 0.000 claims description 5
- 108091056204 miR-16-2 stem-loop Proteins 0.000 claims description 5
- 108091023796 miR-182 stem-loop Proteins 0.000 claims description 5
- 108091028751 miR-188 stem-loop Proteins 0.000 claims description 5
- 108091063841 miR-219 stem-loop Proteins 0.000 claims description 5
- 108091090052 miR-219-1 stem-loop Proteins 0.000 claims description 5
- 108091073060 miR-219-2 stem-loop Proteins 0.000 claims description 5
- 108091079034 miR-219-3 stem-loop Proteins 0.000 claims description 5
- 108091054264 miR-219-4 stem-loop Proteins 0.000 claims description 5
- 108091024082 miR-32 stem-loop Proteins 0.000 claims description 5
- 108091042879 miR-326 stem-loop Proteins 0.000 claims description 5
- 108091029997 miR-328 stem-loop Proteins 0.000 claims description 5
- 108091084066 miR-34c-2 stem-loop Proteins 0.000 claims description 5
- 108091086215 miR-379 stem-loop Proteins 0.000 claims description 5
- 108091092877 miR-3943 stem-loop Proteins 0.000 claims description 5
- 108091023805 miR-411 stem-loop Proteins 0.000 claims description 5
- 108091063388 miR-4485 stem-loop Proteins 0.000 claims description 5
- 108091049470 miR-498 stem-loop Proteins 0.000 claims description 5
- 108091058133 miR-502 stem-loop Proteins 0.000 claims description 5
- 108091053449 miR-511 stem-loop Proteins 0.000 claims description 5
- 108091026036 miR-655 stem-loop Proteins 0.000 claims description 5
- 108091058491 miR-877 stem-loop Proteins 0.000 claims description 5
- 108091053417 miR-885 stem-loop Proteins 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 102000005600 Cathepsins Human genes 0.000 claims description 4
- 108010084457 Cathepsins Proteins 0.000 claims description 4
- 101150026402 DBP gene Proteins 0.000 claims description 4
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 claims description 4
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims description 4
- 101150027249 RL1 gene Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 101150087840 UL11 gene Proteins 0.000 claims description 4
- 101150050388 UL20 gene Proteins 0.000 claims description 4
- 101150003230 UL27 gene Proteins 0.000 claims description 4
- 101150072074 UL28 gene Proteins 0.000 claims description 4
- 101150008036 UL29 gene Proteins 0.000 claims description 4
- 101150019585 UL31 gene Proteins 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 108091045440 let-7a-1 stem-loop Proteins 0.000 claims description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 4
- 108091066112 miR-122-1 stem-loop Proteins 0.000 claims description 4
- 108091057488 miR-122-2 stem-loop Proteins 0.000 claims description 4
- 108091049641 miR-181-1 stem-loop Proteins 0.000 claims description 4
- 108091053227 miR-181a-1 stem-loop Proteins 0.000 claims description 4
- 108091047268 miR-208b stem-loop Proteins 0.000 claims description 4
- 108091080321 miR-222 stem-loop Proteins 0.000 claims description 4
- 108091091696 miR-331 stem-loop Proteins 0.000 claims description 4
- 101150046896 trm1 gene Proteins 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 claims description 3
- 101150018129 CSF2 gene Proteins 0.000 claims description 3
- 101150069031 CSN2 gene Proteins 0.000 claims description 3
- 241000709687 Coxsackievirus Species 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 3
- 229920002971 Heparan sulfate Polymers 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
- 108091007700 MIR543 Proteins 0.000 claims description 3
- 241001372913 Maraba virus Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 108091093085 MiR-338 Proteins 0.000 claims description 3
- 108091080933 Mir-192/215 microRNA precursor Proteins 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 101100494762 Mus musculus Nedd9 gene Proteins 0.000 claims description 3
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 108091023045 Untranslated Region Proteins 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 230000005975 antitumor immune response Effects 0.000 claims description 3
- 101150055601 cops2 gene Proteins 0.000 claims description 3
- 230000034994 death Effects 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 108091043994 let-7g stem-loop Proteins 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 108090000440 matrix metalloproteinase 25 Proteins 0.000 claims description 3
- 108091026955 miR-1180 stem-loop Proteins 0.000 claims description 3
- 108091090911 miR-1181 stem-loop Proteins 0.000 claims description 3
- 108091026501 miR-122a stem-loop Proteins 0.000 claims description 3
- 108091063365 miR-1247 stem-loop Proteins 0.000 claims description 3
- 108091070774 miR-1250 stem-loop Proteins 0.000 claims description 3
- 108091025483 miR-1258 stem-loop Proteins 0.000 claims description 3
- 108091023935 miR-1266 stem-loop Proteins 0.000 claims description 3
- 108091059786 miR-128-1 stem-loop Proteins 0.000 claims description 3
- 108091078862 miR-128-3 stem-loop Proteins 0.000 claims description 3
- 108091073005 miR-128-4 stem-loop Proteins 0.000 claims description 3
- 108091032903 miR-1285 stem-loop Proteins 0.000 claims description 3
- 108091074094 miR-1291 stem-loop Proteins 0.000 claims description 3
- 108091040930 miR-1295b stem-loop Proteins 0.000 claims description 3
- 108091048147 miR-1297 stem-loop Proteins 0.000 claims description 3
- 108091071567 miR-1307 stem-loop Proteins 0.000 claims description 3
- 108091047111 miR-135a-1 stem-loop Proteins 0.000 claims description 3
- 108091047375 miR-135a-2 stem-loop Proteins 0.000 claims description 3
- 108091040005 miR-135a-3 stem-loop Proteins 0.000 claims description 3
- 108091025226 miR-1469 stem-loop Proteins 0.000 claims description 3
- 108091072763 miR-151 stem-loop Proteins 0.000 claims description 3
- 108091085286 miR-181a-3 stem-loop Proteins 0.000 claims description 3
- 108091073628 miR-181d stem-loop Proteins 0.000 claims description 3
- 108091058104 miR-187 stem-loop Proteins 0.000 claims description 3
- 108091023683 miR-187-1 stem-loop Proteins 0.000 claims description 3
- 108091046933 miR-18b stem-loop Proteins 0.000 claims description 3
- 108091054189 miR-196a stem-loop Proteins 0.000 claims description 3
- 108091050874 miR-19a stem-loop Proteins 0.000 claims description 3
- 108091068975 miR-19a-3 stem-loop Proteins 0.000 claims description 3
- 108091073472 miR-202-1 stem-loop Proteins 0.000 claims description 3
- 108091038627 miR-202-2 stem-loop Proteins 0.000 claims description 3
- 108091088730 miR-215 stem-loop Proteins 0.000 claims description 3
- 108091074368 miR-216 stem-loop Proteins 0.000 claims description 3
- 108091051988 miR-216b stem-loop Proteins 0.000 claims description 3
- 108091089977 miR-2278 stem-loop Proteins 0.000 claims description 3
- 108091035591 miR-23a stem-loop Proteins 0.000 claims description 3
- 108091092825 miR-24 stem-loop Proteins 0.000 claims description 3
- 108091048857 miR-24-1 stem-loop Proteins 0.000 claims description 3
- 108091047483 miR-24-2 stem-loop Proteins 0.000 claims description 3
- 108091070404 miR-27b stem-loop Proteins 0.000 claims description 3
- 108091025088 miR-29b-2 stem-loop Proteins 0.000 claims description 3
- 108091040861 miR-300 stem-loop Proteins 0.000 claims description 3
- 108091029203 miR-301 stem-loop Proteins 0.000 claims description 3
- 108091026505 miR-301a stem-loop Proteins 0.000 claims description 3
- 108091030637 miR-301b stem-loop Proteins 0.000 claims description 3
- 108091039462 miR-301b-1 stem-loop Proteins 0.000 claims description 3
- 108091028786 miR-301b-2 stem-loop Proteins 0.000 claims description 3
- 108091050195 miR-302b stem-loop Proteins 0.000 claims description 3
- 108091056763 miR-302c stem-loop Proteins 0.000 claims description 3
- 108091091870 miR-30a-3 stem-loop Proteins 0.000 claims description 3
- 108091067477 miR-30a-4 stem-loop Proteins 0.000 claims description 3
- 108091090925 miR-30d-1 stem-loop Proteins 0.000 claims description 3
- 108091047055 miR-30d-2 stem-loop Proteins 0.000 claims description 3
- 108091027549 miR-30e-1 stem-loop Proteins 0.000 claims description 3
- 108091029213 miR-30e-2 stem-loop Proteins 0.000 claims description 3
- 108091085488 miR-30e-3 stem-loop Proteins 0.000 claims description 3
- 108091041555 miR-3182 stem-loop Proteins 0.000 claims description 3
- 108091087311 miR-320c stem-loop Proteins 0.000 claims description 3
- 108091054873 miR-320c-1 stem-loop Proteins 0.000 claims description 3
- 108091025794 miR-320c-2 stem-loop Proteins 0.000 claims description 3
- 108091062225 miR-323 stem-loop Proteins 0.000 claims description 3
- 108091089005 miR-329 stem-loop Proteins 0.000 claims description 3
- 108091090692 miR-337 stem-loop Proteins 0.000 claims description 3
- 108091065159 miR-339 stem-loop Proteins 0.000 claims description 3
- 108091023791 miR-339-1 stem-loop Proteins 0.000 claims description 3
- 108091037290 miR-33b stem-loop Proteins 0.000 claims description 3
- 108091088856 miR-345 stem-loop Proteins 0.000 claims description 3
- 108091040342 miR-34a-1 stem-loop Proteins 0.000 claims description 3
- 108091035608 miR-34a-2 stem-loop Proteins 0.000 claims description 3
- 108091041426 miR-365b stem-loop Proteins 0.000 claims description 3
- 108091057188 miR-369 stem-loop Proteins 0.000 claims description 3
- 108091047175 miR-374a stem-loop Proteins 0.000 claims description 3
- 108091079007 miR-376b stem-loop Proteins 0.000 claims description 3
- 108091056437 miR-376c-1 stem-loop Proteins 0.000 claims description 3
- 108091079015 miR-379 Proteins 0.000 claims description 3
- 108091090987 miR-425 stem-loop Proteins 0.000 claims description 3
- 108091053086 miR-4458 stem-loop Proteins 0.000 claims description 3
- 108091029599 miR-4487 stem-loop Proteins 0.000 claims description 3
- 108091056281 miR-449b stem-loop Proteins 0.000 claims description 3
- 108091070255 miR-4507 stem-loop Proteins 0.000 claims description 3
- 108091036674 miR-450a stem-loop Proteins 0.000 claims description 3
- 108091027743 miR-450b stem-loop Proteins 0.000 claims description 3
- 108091026346 miR-450b-1 stem-loop Proteins 0.000 claims description 3
- 108091041548 miR-450b-2 stem-loop Proteins 0.000 claims description 3
- 108091059056 miR-452 stem-loop Proteins 0.000 claims description 3
- 108091072779 miR-455 stem-loop Proteins 0.000 claims description 3
- 108091056879 miR-455-2 stem-loop Proteins 0.000 claims description 3
- 108091029231 miR-4723 stem-loop Proteins 0.000 claims description 3
- 108091088998 miR-4782 stem-loop Proteins 0.000 claims description 3
- 108091080700 miR-484 stem-loop Proteins 0.000 claims description 3
- 108091035982 miR-485 stem-loop Proteins 0.000 claims description 3
- 108091037417 miR-508 stem-loop Proteins 0.000 claims description 3
- 108091038238 miR-509-3 stem-loop Proteins 0.000 claims description 3
- 108091026919 miR-512 stem-loop Proteins 0.000 claims description 3
- 108091077010 miR-512-1 stem-loop Proteins 0.000 claims description 3
- 108091032013 miR-512-2 stem-loop Proteins 0.000 claims description 3
- 108091062489 miR-514a-1 stem-loop Proteins 0.000 claims description 3
- 108091046053 miR-514a-2 stem-loop Proteins 0.000 claims description 3
- 108091047994 miR-514a-3 stem-loop Proteins 0.000 claims description 3
- 108091032275 miR-517a stem-loop Proteins 0.000 claims description 3
- 108091024613 miR-520b stem-loop Proteins 0.000 claims description 3
- 108091086222 miR-520c stem-loop Proteins 0.000 claims description 3
- 108091076271 miR-543 stem-loop Proteins 0.000 claims description 3
- 108091040490 miR-545 stem-loop Proteins 0.000 claims description 3
- 108091049915 miR-551a stem-loop Proteins 0.000 claims description 3
- 108091047658 miR-564 stem-loop Proteins 0.000 claims description 3
- 108091087825 miR-5683 stem-loop Proteins 0.000 claims description 3
- 108091040489 miR-5694 stem-loop Proteins 0.000 claims description 3
- 108091058526 miR-573 stem-loop Proteins 0.000 claims description 3
- 108091045118 miR-576 stem-loop Proteins 0.000 claims description 3
- 108091048173 miR-577 stem-loop Proteins 0.000 claims description 3
- 108091059757 miR-582 stem-loop Proteins 0.000 claims description 3
- 108091046601 miR-584 stem-loop Proteins 0.000 claims description 3
- 108091041487 miR-584-1 stem-loop Proteins 0.000 claims description 3
- 108091091335 miR-584-2 stem-loop Proteins 0.000 claims description 3
- 108091072614 miR-584-3 stem-loop Proteins 0.000 claims description 3
- 108091042285 miR-584-4 stem-loop Proteins 0.000 claims description 3
- 108091035690 miR-584-5 stem-loop Proteins 0.000 claims description 3
- 108091059440 miR-584-6 stem-loop Proteins 0.000 claims description 3
- 108091082246 miR-584-7 stem-loop Proteins 0.000 claims description 3
- 108091088867 miR-584-8 stem-loop Proteins 0.000 claims description 3
- 108091024411 miR-590 stem-loop Proteins 0.000 claims description 3
- 108091041816 miR-6089-1 stem-loop Proteins 0.000 claims description 3
- 108091050321 miR-6089-2 stem-loop Proteins 0.000 claims description 3
- 108091038867 miR-612 stem-loop Proteins 0.000 claims description 3
- 108091080596 miR-614 stem-loop Proteins 0.000 claims description 3
- 108091090051 miR-615 stem-loop Proteins 0.000 claims description 3
- 108091041759 miR-622 stem-loop Proteins 0.000 claims description 3
- 108091062477 miR-627 stem-loop Proteins 0.000 claims description 3
- 108091046673 miR-628 stem-loop Proteins 0.000 claims description 3
- 108091079010 miR-632 stem-loop Proteins 0.000 claims description 3
- 108091056346 miR-642a stem-loop Proteins 0.000 claims description 3
- 108091089548 miR-656 stem-loop Proteins 0.000 claims description 3
- 108091063151 miR-660 stem-loop Proteins 0.000 claims description 3
- 108091041014 miR-663-1 stem-loop Proteins 0.000 claims description 3
- 108091050799 miR-663-10 stem-loop Proteins 0.000 claims description 3
- 108091038412 miR-663-11 stem-loop Proteins 0.000 claims description 3
- 108091062556 miR-663-2 stem-loop Proteins 0.000 claims description 3
- 108091036836 miR-663-3 stem-loop Proteins 0.000 claims description 3
- 108091056984 miR-663-4 stem-loop Proteins 0.000 claims description 3
- 108091064096 miR-663-5 stem-loop Proteins 0.000 claims description 3
- 108091089306 miR-663-6 stem-loop Proteins 0.000 claims description 3
- 108091074126 miR-663-7 stem-loop Proteins 0.000 claims description 3
- 108091074471 miR-663-8 stem-loop Proteins 0.000 claims description 3
- 108091053580 miR-663-9 stem-loop Proteins 0.000 claims description 3
- 108091025542 miR-668 stem-loop Proteins 0.000 claims description 3
- 108091040808 miR-675 stem-loop Proteins 0.000 claims description 3
- 108091024540 miR-7158 stem-loop Proteins 0.000 claims description 3
- 108091055142 miR-7515 stem-loop Proteins 0.000 claims description 3
- 108091080296 miR-758 stem-loop Proteins 0.000 claims description 3
- 108091049937 miR-759 stem-loop Proteins 0.000 claims description 3
- 108091043776 miR-765 stem-loop Proteins 0.000 claims description 3
- 108091029509 miR-802 stem-loop Proteins 0.000 claims description 3
- 108091084058 miR-874 stem-loop Proteins 0.000 claims description 3
- 108091034121 miR-92a stem-loop Proteins 0.000 claims description 3
- 108091041519 miR-92a-3 stem-loop Proteins 0.000 claims description 3
- 108091032902 miR-93 stem-loop Proteins 0.000 claims description 3
- 108091073613 miR-941-1 stem-loop Proteins 0.000 claims description 3
- 108091039878 miR-941-2 stem-loop Proteins 0.000 claims description 3
- 108091035558 miR-941-3 stem-loop Proteins 0.000 claims description 3
- 108091031187 miR-941-4 stem-loop Proteins 0.000 claims description 3
- 108091085604 miR-941-5 stem-loop Proteins 0.000 claims description 3
- 108091078206 miR-9500 stem-loop Proteins 0.000 claims description 3
- 108091028482 miR-96-1 stem-loop Proteins 0.000 claims description 3
- 108091090007 miR-96-2 stem-loop Proteins 0.000 claims description 3
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims description 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 108090000668 Annexin A2 Proteins 0.000 claims description 2
- 102000004149 Annexin A2 Human genes 0.000 claims description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 101100274575 Caenorhabditis elegans clh-3 gene Proteins 0.000 claims description 2
- 108010076667 Caspases Proteins 0.000 claims description 2
- 102000011727 Caspases Human genes 0.000 claims description 2
- 102000004225 Cathepsin B Human genes 0.000 claims description 2
- 108090000712 Cathepsin B Proteins 0.000 claims description 2
- 102000003908 Cathepsin D Human genes 0.000 claims description 2
- 108090000258 Cathepsin D Proteins 0.000 claims description 2
- 102000004178 Cathepsin E Human genes 0.000 claims description 2
- 108090000611 Cathepsin E Proteins 0.000 claims description 2
- 102000004171 Cathepsin K Human genes 0.000 claims description 2
- 108090000625 Cathepsin K Proteins 0.000 claims description 2
- 102000004172 Cathepsin L Human genes 0.000 claims description 2
- 108090000624 Cathepsin L Proteins 0.000 claims description 2
- 101800001224 Disintegrin Proteins 0.000 claims description 2
- 102000013128 Endothelin B Receptor Human genes 0.000 claims description 2
- 108010090557 Endothelin B Receptor Proteins 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims description 2
- 101001011896 Homo sapiens Matrix metalloproteinase-19 Proteins 0.000 claims description 2
- 101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 claims description 2
- 101000627861 Homo sapiens Matrix metalloproteinase-28 Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101001098352 Homo sapiens OX-2 membrane glycoprotein Proteins 0.000 claims description 2
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102100030703 Interleukin-22 Human genes 0.000 claims description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 2
- 102100030417 Matrilysin Human genes 0.000 claims description 2
- 108090000855 Matrilysin Proteins 0.000 claims description 2
- 102100030201 Matrix metalloproteinase-15 Human genes 0.000 claims description 2
- 108090000560 Matrix metalloproteinase-15 Proteins 0.000 claims description 2
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 claims description 2
- 108090000561 Matrix metalloproteinase-16 Proteins 0.000 claims description 2
- 102100030219 Matrix metalloproteinase-17 Human genes 0.000 claims description 2
- 108090000585 Matrix metalloproteinase-17 Proteins 0.000 claims description 2
- 102100030218 Matrix metalloproteinase-19 Human genes 0.000 claims description 2
- 102100029693 Matrix metalloproteinase-20 Human genes 0.000 claims description 2
- 108090000609 Matrix metalloproteinase-20 Proteins 0.000 claims description 2
- 101710082411 Matrix metalloproteinase-21 Proteins 0.000 claims description 2
- 102100024130 Matrix metalloproteinase-23 Human genes 0.000 claims description 2
- 102100024128 Matrix metalloproteinase-26 Human genes 0.000 claims description 2
- 102100024132 Matrix metalloproteinase-27 Human genes 0.000 claims description 2
- 108050005201 Matrix metalloproteinase-27 Proteins 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102100030411 Neutrophil collagenase Human genes 0.000 claims description 2
- 101710118230 Neutrophil collagenase Proteins 0.000 claims description 2
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 102000007374 Smad Proteins Human genes 0.000 claims description 2
- 108010007945 Smad Proteins Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims description 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 2
- 101001011890 Xenopus laevis Matrix metalloproteinase-18 Proteins 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 229940014144 folate Drugs 0.000 claims description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000029824 high grade glioma Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 230000002147 killing effect Effects 0.000 claims description 2
- 108091029710 let-7f-1 stem-loop Proteins 0.000 claims description 2
- 201000011614 malignant glioma Diseases 0.000 claims description 2
- 108091092359 miR-10b-2 stem-loop Proteins 0.000 claims description 2
- 108091041893 miR-10b-3 stem-loop Proteins 0.000 claims description 2
- 108091054928 miR-1293 stem-loop Proteins 0.000 claims description 2
- 108091087161 miR-1296 stem-loop Proteins 0.000 claims description 2
- 108091081029 miR-1298 stem-loop Proteins 0.000 claims description 2
- 108091027698 miR-18-1 stem-loop Proteins 0.000 claims description 2
- 108091090961 miR-18-2 stem-loop Proteins 0.000 claims description 2
- 108091074194 miR-181b-1 stem-loop Proteins 0.000 claims description 2
- 108091061809 miR-181b-3 stem-loop Proteins 0.000 claims description 2
- 108091084881 miR-182-1 stem-loop Proteins 0.000 claims description 2
- 108091078636 miR-182-2 stem-loop Proteins 0.000 claims description 2
- 108091085109 miR-203a stem-loop Proteins 0.000 claims description 2
- 108091045724 miR-203a-1 stem-loop Proteins 0.000 claims description 2
- 108091047324 miR-203a-2 stem-loop Proteins 0.000 claims description 2
- 108091047942 miR-203b stem-loop Proteins 0.000 claims description 2
- 108091030733 miR-205 stem-loop Proteins 0.000 claims description 2
- 108091048549 miR-29b stem-loop Proteins 0.000 claims description 2
- 108091066131 miR-30c-2 stem-loop Proteins 0.000 claims description 2
- 108091041315 miR-3195 stem-loop Proteins 0.000 claims description 2
- 108091048101 miR-374b stem-loop Proteins 0.000 claims description 2
- 108091063235 miR-4266 stem-loop Proteins 0.000 claims description 2
- 108091057166 miR-4327 stem-loop Proteins 0.000 claims description 2
- 108091083237 miR-451b stem-loop Proteins 0.000 claims description 2
- 108091069917 miR-491 stem-loop Proteins 0.000 claims description 2
- 108091048941 miR-499a stem-loop Proteins 0.000 claims description 2
- 108091040524 miR-518a-1 stem-loop Proteins 0.000 claims description 2
- 108091028747 miR-518a-2 stem-loop Proteins 0.000 claims description 2
- 108091045883 miR-518a-3 stem-loop Proteins 0.000 claims description 2
- 108091050322 miR-518a-4 stem-loop Proteins 0.000 claims description 2
- 108091063385 miR-526b stem-loop Proteins 0.000 claims description 2
- 108091056169 miR-770 stem-loop Proteins 0.000 claims description 2
- 108091071148 miR-935 stem-loop Proteins 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims description 2
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims 8
- 241000483002 Euproctis similis Species 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 102100035861 Cytosolic 5'-nucleotidase 1A Human genes 0.000 claims 1
- 241001673391 Entandrophragma candollei Species 0.000 claims 1
- 208000020322 Gaucher disease type I Diseases 0.000 claims 1
- 101000802744 Homo sapiens Cytosolic 5'-nucleotidase 1A Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102100024129 Matrix metalloproteinase-24 Human genes 0.000 claims 1
- 108050005214 Matrix metalloproteinase-24 Proteins 0.000 claims 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 claims 1
- 101001013152 Mycobacterium avium Major membrane protein 1 Proteins 0.000 claims 1
- 101001013151 Mycobacterium leprae (strain TN) Major membrane protein I Proteins 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 101710108790 Stromelysin-1 Proteins 0.000 claims 1
- 102100028848 Stromelysin-2 Human genes 0.000 claims 1
- 101710108792 Stromelysin-2 Proteins 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108091025084 miR-276 stem-loop Proteins 0.000 claims 1
- 108091041063 miR-488 stem-loop Proteins 0.000 claims 1
- 108091038030 miR-51 stem-loop Proteins 0.000 claims 1
- 108091071886 miR-51-1 stem-loop Proteins 0.000 claims 1
- 108091052534 miR-51-2 stem-loop Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 abstract description 77
- 238000011282 treatment Methods 0.000 abstract description 23
- 230000008685 targeting Effects 0.000 abstract description 6
- 239000002245 particle Substances 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000010348 incorporation Methods 0.000 abstract description 3
- 238000003780 insertion Methods 0.000 abstract description 3
- 230000037431 insertion Effects 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 description 43
- 230000006870 function Effects 0.000 description 23
- 239000005090 green fluorescent protein Substances 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 12
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 9
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108091033760 Oncomir Proteins 0.000 description 6
- 101150066971 UL49 gene Proteins 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000003463 hyperproliferative effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 5
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 5
- 101150090364 ICP0 gene Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 101150102071 TRX1 gene Proteins 0.000 description 5
- 101150090946 UL38 gene Proteins 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 238000010362 genome editing Methods 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 101150072608 CVC1 gene Proteins 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 4
- 229940123611 Genome editing Drugs 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 101150104047 UL17 gene Proteins 0.000 description 4
- 230000036952 cancer formation Effects 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 101150055782 gH gene Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000004055 small Interfering RNA Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 101000831266 Homo sapiens Metalloproteinase inhibitor 4 Proteins 0.000 description 3
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 108091027967 Small hairpin RNA Proteins 0.000 description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000012830 cancer therapeutic Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 108091064282 miR-125 stem-loop Proteins 0.000 description 3
- 108091037066 miR-125-1 stem-loop Proteins 0.000 description 3
- 108091062107 miR-125-2 stem-loop Proteins 0.000 description 3
- 108091079767 miR-125-3 stem-loop Proteins 0.000 description 3
- 108091031925 miR-138-2 stem-loop Proteins 0.000 description 3
- 108091047177 miR-199 stem-loop Proteins 0.000 description 3
- 108091031898 miR-199-5 stem-loop Proteins 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 108050005238 Collagenase 3 Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 2
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 101150026859 UL9 gene Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 108091023663 let-7 stem-loop Proteins 0.000 description 2
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 2
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 2
- 108091037074 miR-1251 stem-loop Proteins 0.000 description 2
- 108091029445 miR-432 stem-loop Proteins 0.000 description 2
- 108091091051 miR-4500 stem-loop Proteins 0.000 description 2
- 108091069529 miR-637 stem-loop Proteins 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101000990899 Caenorhabditis elegans Matrix metalloproteinase-A Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 1
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 208000032320 Germ cell tumor of testis Diseases 0.000 description 1
- 101150064935 HELI gene Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000700326 Human herpesvirus 1 strain KOS Species 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 1
- 102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108091093082 MiR-146 Proteins 0.000 description 1
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 101710173156 Type III endosome membrane protein TEMP Proteins 0.000 description 1
- 101150111135 UL1 gene Proteins 0.000 description 1
- 101150099617 UL5 gene Proteins 0.000 description 1
- 101150033660 UL6 gene Proteins 0.000 description 1
- 101150095805 UL7 gene Proteins 0.000 description 1
- 101150033561 UL8 gene Proteins 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- 102000036859 Zinc-dependent proteases Human genes 0.000 description 1
- 108091006973 Zinc-dependent proteases Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000676 anti-immunogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 101150015940 gL gene Proteins 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108091053410 let-7 family Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091092072 miR-100 stem-loop Proteins 0.000 description 1
- 108091063445 miR-13 stem-loop Proteins 0.000 description 1
- 108091023685 miR-133 stem-loop Proteins 0.000 description 1
- 108091045860 miR-152b stem-loop Proteins 0.000 description 1
- 108091088639 miR-16a stem-loop Proteins 0.000 description 1
- 108091057475 miR-29b-1 stem-loop Proteins 0.000 description 1
- 108091064225 miR-29e stem-loop Proteins 0.000 description 1
- 108091074487 miR-34 stem-loop Proteins 0.000 description 1
- 108091092493 miR-34-1 stem-loop Proteins 0.000 description 1
- 108091059780 miR-34-2 stem-loop Proteins 0.000 description 1
- 108091055699 miR-34e stem-loop Proteins 0.000 description 1
- 108091047102 miR-4 stem-loop Proteins 0.000 description 1
- 108091049748 miR-4-1 stem-loop Proteins 0.000 description 1
- 108091058497 miR-4-2 stem-loop Proteins 0.000 description 1
- 108091050819 miR-518a stem-loop Proteins 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 108010005597 ran GTP Binding Protein Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
Description
Field of the Invention [0003] The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. The viral vectors utilize one or more of the following aspects: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and/or cancer cell targeting by incorporation of proteaseactivated antibodies into the viral particle.
Background of the Invention [9994] Current targeted cancer therapeutics are efficacious in only a narrow range of cancers due to the heterogeneity of tumor protein expression profiles. Furthermore, many cancer treatments, including existing viral vectors, chemotherapy, radiation, and surgery lack the specificity to selectively treat cancerous cells, while maintaining the health and viability of normal, non-cancerous cells and can produce undesirable off-target effects. As such, there is a
WO 2017/132552
PCT/US2017/015417 need in the art for cancer therapies that are broadly efficacious in multiple cancers and are capable of selectively eliminating cancerous cells.
[0005] Oncolytic viruses are viruses that preferentially infect cancer cells and have been used in multiple pre-ci ini cal and clinical studies for cancer treatment. Use of oncolytic viruses carries the risk of non-specific viral infection of healthy cells, leading to the death of non-cancerous ceils and tissues. However, genetic manipulation of the viruses to exploit pathways, proteins, and genes that are differentially expressed in normal vs. cancerous tissue can increase the specificity of these viruses and limit off-target infection and cell death.
[0006] MicroRNAs (miRNAs or miRs) are small non-coding endogenous RNAs that regulate gene expression by directing their target messenger RNAs for degradation or translational repression. nnRNAs are intimately associated with normal cellular processes and therefore, deregulation of miRNAs contributes to a wide array of diseases including cancer. Many miRNA genes are located in cancer associated genomic regions, or in fragile sites, further strengthening the evidence that miRN As play a pivotal role in cancer. miRNAs are differentially expressed in cancer tissues compared to normal tissues and can have a causative relationship to tumorigenesis. By exploiting this differential miRNA expression in diverse tumor types, the cancer therapeutics described herein possess a broad spectrum safety and efficacy profile, wherein oncolytic viral replication is regulated based on the expression of a particular miRNA or group of miRN As. Further, the oncolytic viruses described herein may also express proteins that facilitate viral spread throughout a tumor, such as those altering the expression of genes and proteins that regulate the extracellular matrix, thereby increasing their therapeutic efficacy.
Summary of the Invention [0007] The invention relates to recombinant viral vectors that are useful for the treatment and prevention of cancer. The oncolytic viral vectors comprise the following aspects individually or in combination: restricting viral vector replication to cancer or tumor ceils by inserting tumor-suppressive microRNA (miR) target sequences into the viral genome; incorporation of one or more genes into the viral genome whose product(s) disrupt the function of oncogenic miRNA and/or the cancer extracellular matrix; and highly selective targeting of the vectors to cancer/tumor cells by incorporating protease-activated antibodies into the viral particle.
WO 2017/132552
PCT/US2017/015417 [0008] In some embodiments, the present invention provides for a recombinant oncolytic virus comprising one or more copies of one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication. In some embodiments, the virus is a herpes simplex virus, an adenovirus, a polio virus, a vaccinia virus, a measles virus, a vesicular stomatitis virus, an orthomyxovirus, a parvovirus, a maraba virus or a coxsackievirus. In some embodiments, the virus is a herpes simplex virus and wherein the one or more viral genes required for viral replication is selected from the group consisting of UL1, UL5, (.4.6. [ .1.7. [.1.8. 14.9. UL11, UL12, UL14, (.1.15. 144 7.. 144 8. 144 9. 14.20. 14.22. 1.4.25. 1.4.26. UL26.5, 14.27. 14.28. 14.29. 14.10. 14.5 i. UL32, UL33, TJL34, UL35, UL36, UL37, UL38, UL39, UL40, UL42, UL48, UL49, UL52, UL53, UL54, ICP0, ICP4, ICP22, ICP27, ICP47, gamma-34.5, US3, US4, USS, US6, US7, USS, US9, US 10, US11, and US 12. In some embodiments, the tumor-suppressive miR target sequence is a target sequence for a miR selected from Table 3. In some embodiments, the one or more tumor-suppressive miR target sequences is incorporated into the 5’ untranslated region (UTR) or 3’ UTR of the one or more viral genes required for viral replication.
[0009j In some embodiments, the present invention provides for a recombinant oncolytic virus comprising one or more copies of one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication, wherein replication of the virus is reduced or attenuated in a first cell compared to replication of the virus in a second cell. In some embodiments, the first cell has an increased expression of a tumor-suppressive miR capable of binding to the one or more tumor-suppressive miR target sequences compared to the expression of the tumor-suppressive miR in the second cell. In some embodiments, the expression level of the tumor-suppressive miR in the first cell is at least 5% greater than the expression level of the tumor-suppressive miR in the second cell. In some embodiments, the second cell has a reduced expression of a tumor-suppressive miR capable of binding to the one or more tumor-suppressive miR target sequences compared to the expression of the tumor-suppressive miR in the first cell. In some embodiments, the expression level of the tumor-suppressive miR in the second cell is at least 5% less than the expression level of the tumor-suppressive miR in the first cell. In some embodiments, the second cell is a cancerous cell.
J
WO 2017/132552
PCT/US2017/015417 [0010] In some embodiments, the present invention provides for a recombinant oncolytic virus comprising one or more copies of one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication, wherein the tumor-suppressive miR target sequences for miR-124, miR-451a, miR143-3p, and miR-559. In further embodiments, the oncolytic virus is used for the treatment of pancreatic, lung, and/or colon cancer. In some embodiments, the oncolytic virus comprises the tumor-suppressive miR target sequences for miR-124, miR-451, miR-143-3p, miR-Ι, and miR559. In some embodiments, the oncolytic virus comprises the tumor-suppressive miR target sequences for miR-124, miR-451, miR-145-5p, and miR-559. In further embodiments, the oncolytic virus is used for the treatment of a tumor derived from any type of cancer. In some embodiments, the oncolytic virus comprises the tumor-suppressive miR target sequences for miR~205p, miR-141-5p, miR-31-5p, and miR-124. In further embodiments, the oncolytic virus is used for the treatment of schwannoma. In further embodiments, the tumor-suppressive miR target sequences are inserted into the ICP4, ICP27, UL19, and/or UL30 locus.
[0011] In some embodiments, the present invention provides for a recombinant oncolytic virus comprising one or more copies of one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication, wherein the tumor-suppressive miR target sequence is a target sequence for miR136-3p, miR-432-5p, miR-l-3p, miR-127-3p, miR-379-5p, miR-493-5p, miR-223-5p, miR-2235p, miR-136-5p, miR-451a, miR-487b-3p, miR-370-3p, miR-410-3p, miR-431-3p, miR-44853p, miR-4485-5p, miR-127-5p, miR-409-3p, miR-338-3p, miR-559, miR-411-5p, miR-133a-5p, miR-143-3p, miR-376b-3p, miR-758-3p, miR-Ι, miR-101, miR-1180, miR-1236, miR-124-3p, miR-125b, miR-126, miR-1280, miR-133a, miR-133b, miR-141, nuR-143, miR-144, miR-145, miR-155, miR-16, miR-18a, miR-192, miR-195, miR-200a, miR-200b, miR-200c, miR-203, miR-205, miR-214, miR-218, miR-23b, miR-26a, miR-29c, miR-320c, miR-34a, miR-370, miR409-3p, miR-429, miR-451b, miR-490-5p, miR-493, miR-576-3p, and/or miR-99a. In further embodiments, the oncolytic virus is used for treating bladder cancer.
[0012] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-1251-5p, miR-219a-5p, miR-219a-2-3p, miR-124-3p, miR-448, miR138-2-3p, miR-490-5p, miR-129-l-3p, miR-1264, miR-3943, miR-490-3p, miR-383-5p, miR133b, miR-129-2-3p, miR-128-2~5p, miR-133a-3p, miR-129-5p, miR-l-3p, miR-885~3p, miR4
WO 2017/132552
PCT/US2017/015417
124-5p, miR-759, miR-7158-3p, miR-770-5p, miR-135a-5p, miR-885-5p, let-7g-5p, miR-100, miR-101, miR-106a, miR-124, miR-124a, miR-125a, miR-125a-5p, miR-125b, miR-127-3p, miR-128, miR-129, miR-136, miR-137, miR-139-5p, miR-142-3p, miR-143, miR-145, miR146b-5p, miR-149, miR-152, miR-153, miR-195, miR-21, miR-212-3p, miR-219-5p, miR-222, miR-29b, miR-31, miR-3189-3p, miR-320, miR-320a, miR-326, miR-330, miR-331-3p, miR340, miR-342, miR-34a, miR-376a, miR-449a, miR-483-5p, miR-503, miR-577, miR-663, miR7, miR-7-5p, miR-873, let-7a, let-7f, miR-107, nnR-122, miR-124-5p, miR-139, nnR-146a, miR146b, miR-15b, miR-16, miR-181a, miR-181a-l, miR-181a-2, miR-181b, miR-181b-l, miR181b-2, miR-181c, miR-lSld, miR-184, miR-185, miR-199a-3p, miR-200a, miR-200b, miR203, miR-204, miR-205, miR-218, miR-23b, miR-26b, miR-27a, miR-29e, miR-328, niiR-34e3p, miR-34c-5p, miR-375, miR-383, miR-451, miR-452, miR-495, miR-584, miR-622, miR656, miR-98, miR-124-3p, miR-18ib-5p, miR-200b, and/or miR-3189-3p. In further embodiments, the oncolytic virus is used for treating brain cancer.
[0013] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-Ι Ob-5p, miR-126-3p, miR-145-3p, miR-451a, miR-199b-5p, miR-5683, miR-3195, miR-3182, miR-1271 -5p, miR-204-5p, miR-409-5p, miR-136-5p, miR-514a-5p, miR-559, miR-483-3p, miR-l-3p, miR-6080, miR-144-3p, miR-10b-3p, miR-6130, miR-6089, miR-203b-5p, rmR-4266, miR-4327, miR-5694, miR-193b, let-7a, let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-l, let-7f-2, let-7g, let-7i, miR-100, miR-107, miR-lOa, miR10b, miR-122, miR-124, miR-1258, miR-125a-5p, miR-125b, miR-126, miR-127, miR-129, miR-130a, miR-132, miR-133a, miR-143, miR-145, miR-146a, miR-146b, miR-147, miR-148a, miR-149, miR-152, miR-153, miR-15a, miR-16, miR-17-5p, miR-181a, miR-1826, miR-183, miR-185, miR-191, miR-193a-3p, miR-195, miR-199b-5p, miR-19a-3p, miR-200a, miR-200b, miR-200c, miR-205, miR-206, miR-211, miR-216b, miR-218, miR-22, miR-26a, miR-26b, miR300, miR-30a, miR-31, miR-335, miR-339-5p, miR-33b, miR-34a, miR-34b, miR-34c, miR374a, miR-379, miR-381, miR-383, miR-425, miR-429, miR-450b-3p, miR-494, miR-495, miR497, miR-502-5p, miR-517a, miR-574-3p, miR-638, miR-7, miR-720, miR-873, miR-874, miR92a, miR-98, miR-99a, mmu-miR-290-3p, and/or mmu-miR-290-5p. In further embodiments, the oncolytic virus is used for treating breast cancer.
[0014] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-143, miR-145, miR-17-5p, miR-203, miR-214, miR-218, miR-335, s
WO 2017/132552
PCT/US2017/015417 miR-342-3p, miR-372, miR-424, miR-491-5p, miR-497, miR-7, miR-99a, miR-99b, miR-100, miR-101, miR-15a, miR-16, miR-34a, miR-886-5p, miR-106a, nuR-124, miR-148a, miR-29a, and/or miR-375. In further embodiments, the oncolytic virus is used for treating cervical cancer.
[0015] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-133a-5p, miR-490-5p, miR-124-3p, miR-137, miR-655-3p, miR-376c3p, miR-369-5p, miR-490-3p, miR-432-5p, miR-487b-3p, miR-342-3p, miR-223-3p, miR-1363p, miR-136-3p, miR-143-5p, miR-l-3p, miR-214-3p, miR-143-3p, miR-199a-3p, miR-199b-3p, miR-451a, miR-127-3p, miR-133a-3p, miR-145-5p, miR-145-3p, miR-199a-5p, let-7a-l, let-7a2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let~7f~l, let-7f-2, let-7g, let-7i, miR-100, miR-101, miR126, miR-142-3p, miR-143, miR-145, miR-192, miR-200c, miR-21, miR-214, miR-215, miR22, miR-25, miR-302a, miR-320, miR-320a, miR-34a, miR-34c, miR-365, miR-373, miR-424, miR-429, miR-455, miR-484, miR-502, miR-503, miR-93, miR-98, miR-186, miR-30a-5p, miR627, let-7a, miR-Ι, miR-124, miR-125a, miR-129, miR-1295b-3p, miR-1307, miR-130b, miR132, miR-133a, miR-133b, miR-137, miR-138, miR-139, miR-139-5p, miR-140-5p, miR~148a, miR-148b, miR-149, miR-150-5p, rniR-154, miR-15a, miR-15b, miR-16, miR-18a, miR-191, rniR-193a-5p, miR-194, miR-195, miR-196a, miR-198, rniR-199a-5p, miR-203, miR-204-5p, miR-206, miR-212, miR-218, miR-224, miR-24-3p, miR-26b, miR-27a, miR-28-3p, miR-28-5p, rmR-29b, miR-30a-3p, miR-30b, rniR-328, miR-338-3p, miR-342, miR-345, miR-34a-5p, miR361-5p, miR-375, miR-378, miR-378a-3p, miR-378a-5p, miR-409-3p, miR-422a, miR-4487, miR-483, miR-497, miR-498, miR-518a-3p, miR-551a, miR-574-5p, miR-625, miR-638, miR-7, miR-96-5p, miR-202-3p, miR-30a, and/or miR-451. In further embodiments, the oncolytic virus is used for treating colon or colorectal cancer.
[0016] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-101, nuR-130a, miR-130b, miR-134, miR-143, nuR-145, miR-152, miR-205, miR-223, miR-301a, miR-301b, miR-30c, miR-34a, miR-34c, miR-424, miR-449a, miR-543, and/or miR-34b inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating endometrial cancer.
[0017] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-125b, miR-138, miR-15a, miR-15b, miR-16, miR-16-1, miR-16-l-3p, miR-16-2, miR-181a, miR-181b, miR-195, miR-223, miR-29b, miR-34b, miR-34c, miR-424,
WO 2017/132552
PCT/US2017/015417 miR-lOa, miR-146a, miR-150, miR-151, miR-155, miR-2278, miR-26a, miR-30e, miR-31, miR326, miR-564, miR-27a, let-7b, miR-124a, miR-142-3p, let-7c, miR-17, miR-20a, miR-29a, miR-30c, miR-720, miR-107, miR-342, miR-34a, miR-202, miR-142-5p, miR-29c, miR-145, miR-193 b, miR-199a, miR-214, miR-22, miR-137, and/or miR-197 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating hematologic cancer.
[0018] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-Ι, miR-145, miR-1826, miR-199a, miR~199a-3p, miR-203, miR-205, miR-497, miR-508-3p, miR-509-3p, let-7a, let-7d, miR-106a*, miR-126, miR-1285, miR-1293p, miR-1291, miR~133a, miR~135a, miR~138, miR-141, miR-143, niiR-182-5p, miR~200a, miR-218, miR-28-5p, miR~30a, miR-30c, niiR-30d, miR-34a, miR-378, miR-429, miR-509-5p, miR-646, miR-133b, let-7b, let-7c, miR-200c, niiR-204, miR-335, miR-377, and/or miR-506 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating kidney cancer.
[0019] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for Iet-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, Iet-7d, let-7e, let-7f, Iet-7f-l, let-7f2, let-7g, let-7i, miR-Ι, miR-100, miR-101, miR-105, miR-122, miR-122a, miR-1236, miR-124, miR-125b, miR-126, miR-127, miR-1271, miR-128-3p, miR-129-5p, miR-130a, miR-130b, miR-133a, miR-134, miR-137, miR-138, miR-139, miR-139-5p, miR-140-5p, miR-141, miR142-3p, miR-143, miR-144, miR-145, miR-146a, miR-148a, miR-148b, miR-150-5p, miR-15b, miR-16, miR-181a-5p, miR-185, miR-188-5p, miR-193b, miR-195, miR-195-5p, miR-197, miR198, miR-199a, miR-199a-5p, miR-199b, miR-199b-5p, miR-200a, miR-200b, miR-200c, miR202, miR-203, miR-204-3p, miR-205, miR-206, miR-20a, miR-21, miR-21-3p, miR-211, rniR212, miR-214, miR-217, miR-218, miR-2I9-5p, rniR-22, miR-223, miR-26a, miR-26b, miR-29a, miR-29b-l, miR-29b-2, miR-29c, miR-302b, miR-302c, miR-30a, miR-30a-3p, miR-335, rniR338-3p, miR-33a, miR-34a, miR-34b, miR-365, miR-370, miR-372, miR-375, miR-376a, miR377, miR-422a, miR-424, miR-424-5p, miR-433, miR-4458, miR-448, miR-450a, miR-451, miR-485-5p, miR-486-5p, miR-497, miR-503, miR-506, miR-519d, miR-520a, miR-520b, miR520c-3p, miR-582-5p, miR-590-5p, miR-610, miR-612, miR-625, miR-637, miR-675, miR-7, miR-877, miR-940, miR-941, miR-98, miR-99a, miR-132, and/or miR-31 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments,
WO 2017/132552
PCT/US2017/015417 the oncolytic virus is used for treating liver cancer. In further embodiments, the liver cancer is hepatocellular carcinoma.
[0020] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-143-3p, miR-126-3p, miR-126-5p, miR-1266-3p, miR-6130, miR-6080, miR-511-5p, miR-143-5p, miR-223-5p, miR-199b-5p, miR-199a-3p, miR-199b-3p, miR-451a, miR-142-5p, miR-144, miR-150-5p, miR-142-3p, miR-214-3p, miR-214-5p, miR-199a-5p, miR145-3p, miR-145-5p, miR-1297, miR-141, miR-145, miR-16, miR-2Q0a, miRYOOb, miR-200c, miR-29b, miR-381, miR-409-3p, miR-429, miR-451, miR-511, miR-99a, let-7a-l, let-7a-2, let7a-3, let-7b, let-7c, let-7d, let~7e, let-7f-l, let-7f~2, let-7g, let-7i, miR-Ι, miR-101, miR-133b, miR-138, miR-142-5p, miR-144, miR-1469, miR- 146a, miR-153, miR-15a, miR-15b, miR-16-1, miR-16-2, miR-182, miR-192, miR-193a-3p, miR-194, miR-195, miR-198, miR-203, miR-217, miR-218, miR-22, miR-223, miR-26a, miR-26b, miR-29c, miR-33a, miR-34a, miR~34b, miR34c, miR-365, miR-449a, miR-449b, miR-486-5p, miR-545, miR-610, miR-614, miR-630, miR660, miR-7515, miR-9500, miR-98, miR-99b, miR-133a, let-7a, miR-100, miR-106a, miR-107, miR-124, miR-125a-3p, miR-125a-5p, miR-126, miR-126*, miR-129, miR-137, miR-140, miR143, miR-146b, miR-148a, miR-148b, miR-149, miR-152, miR-154, miR-155, miR-17-5p, miR181a-l, miR-18la-2, nuR-lSlb, miR-181b-l, miR-181b-2, miR-181c, miR-ISld, miR-184, miR-186, miR-193b, miR-199a, miR-204, miR-212, miR-221, miR-224, miR-27a, miR-27b, miR-29a, miR-30a, miR-30b, miR-30c, miR-30d, miR-30d-5p, miR-30e-5p, miR-32, miR-335, miR-338-3p, miR-340, miR-342-3p, miR-361-3p, miR-373, miR-375, miR-4500, miR-4782-3p, miR-497, miR-503, miR-512-3p, miR-520a-3p, nuR-526b, miR-625*, and/or miR-96 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating lung cancer.
[0021] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for Iet-7b, miR-101, miR-125b, miR-1280, miR-143, miR-146a, miR-146b, miR-155, miR-17, miR-184, miR-185, miR-18b, miR-193b, miR-200c, miR-203, miR-204, miR-205, miR-206, miR-20a, miR-211, miR-218, miR-26a, miR-31, miR-33a, miR-34a, miR34c, miR-376a, miR-376c, miR-573, miR-7-5p, miR-9, and/or miR-98 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating melanoma.
WO 2017/132552
PCT/US2017/015417 [0022] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for iet-7d, miR-218, miR-34a, miR-375, miR-494, miR-100, miR-124, miR1250, mIR-125b, miR-126, miR-1271, miR-136, miR-138, miR-145, miR-147, miR-148a, miR181a, miR-206, miR-220a, nnR-26a, miR-26b, miR-29a, miR-32, miR-323-5p, miR-329, miR338, miR-370, miR-410, miR-429, miR-433, nnR-499a-5p, miR-503, miR-506, miR-632, miR646, miR-668, miR-877, and/or miR-9 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating oral cancer.
[0023] In some embodiments, the tumor-suppressive miR. target sequence is a target sequence for let-7i, miR-100, miR-124, miR-125b, miR-129-5p, miR-130b, miR-133a, miR-137, miR-138, niiR-141, miR-145, miR-148a, miR-152, miR-153, miR-155, miR-199a, miR-200a, miR-200b, miR-200c, niiR-212, miR-335, miR-34a, miR-34b, miR-34c, miR-409-3p, miR-411, miR-429, miR-432, miR-449a, miR-494, miR-497, miR-498, miR-519d, miR-655, miR-9, miR-98, miR-101, miR-532-5p, miR-124a, miR-192, miR-193a, and/or miR-7 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating ovarian cancer.
[0024] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-216a-5p, miR-802, miR-217, miR-145-3p, miR-143-3p, miR-451a, miR-375, miR-214-3p, miR-216b-3p, miR-432-5p, miR-216a-3p, miR-199b-5p, miR-199a-5p, miR-136-3p, miR-216b-5p, miR-136-5p, miR-145-5p, miR-127-3p, miR-199a-3p, miR-199b-3p, miR-559, miR-129-2-3p, miR-4507, miR-l-3p, miR-148a-3p, miR-101, miR-1181, miR-124, miR-1247, miR-133a, miR-141, miR-145, miR- 146a, miR-148a, miR-148b, miR-150*, miR150-5p, miR-152, miR-15a, miR-198, miR-203, miR-214, miR-216a, miR-29c, miR-335, miR34a, miR-34b, miR-34c, miR-373, miR-375, miR-410, miR-497, miR-615-5p, miR-630, miR-96, miR-132, let-7a, let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-l, let-7f-2, let-7g, let-7i, miR-126, miR-135a, miR-143, miR-144, miR-150, miR-16, miR-200a, nuR-200b, miR200c, miR-217, miR-218, miR-337, miR-494, and/or miR-98 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating pancreatic cancer.
[0025] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for let-7a-3p, let~7c, miR-100, miR-101, miR-105, miR-124, miR-128, miR9
WO 2017/132552
PCT/US2017/015417
1296, miR-130b, miR-133a-l, miR-133a-2, miR-133b, miR-135a, miR-143, miR-145, miR146a, miR-154, miR-15a, miR-187, miR-188-5p, miR-199b, miR-200b, miR-203, miR-205, miR-212, miR-218, miR-221, miR-224, miR-23a, miR-23b, miR-25, miR-26a, miR-26b, miR29b, miR-302a, miR-30a, miR-30b, miR-30c-l, miR-30c-2, miR-30d, miR-30e, miR-31, miR330, miR-331-3p, miR-34a, miR-34b, miR-34c, miR-374b, miR-449a, miR-4723-5p, miR-497, miR-628-5p, miR-642a-5p, miR-765, and/or miR-940 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating prostate cancer.
[0026] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-101, miR-183, miR-204, miR-34a, miR-365b-3p, miR-486-3p, and/or miR-532-5p inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. In further embodiments, the oncolytic virus is used for treating retinoblastoma.
[0027] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-143-3p, miR-Ι33b, miR-1264, miR-448, miR-1298~5p, miR-490-5p, miR-138-2-3p, miR-144-3p, miR-144-5p, miR-150-5p, miR-129-l-3p, miR-559, miR-l-3-p, miR-143-5p, miR-223-3p, miR-3943, miR-338-3p, miR-124-3p, miR-219a-5p, miR-219a-2-3p, miR-451a, miR-142-5p, miR-133a-3p, miR-145-5p, and/or miR-145-3p. In further embodiments, the oncolytic virus is used for treating glioblastoma.
[0028] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-143-3p, miR-223-3p, miR-6080, miR-208b-3p, miR-206, miR-133a-5p, miR-133b, miR-199a-5p, miR-199b-5p, miR-145-3p, miR-145-5p, miR-150-5p, miR-142-3p, miR-144-3p, miR-144-5p, miR-338-3p, miR-214-3p, miR-559, miR-133a-3p, miR-l-3p, miR126-3p, miR-142-5p, miR-451a, miR-199a-3p, and/or miR-199b-3p. In further embodiments, the oncolytic virus is used for treating head and neck cancer.
[0029] In some embodiments, the tumor-suppressive miR target sequence is a target sequence for miR-133b, miR-208b-3p, miR-6130, miR-141-5p, miR-31-3p, miR-1293, miR-129-2-3p, miR-129-5p, miR-124-3p, miR-219a-5p, miR-219a-2-3p, miR-490-3p, miR-4883p, miR-935, miR-124-5p, miR-122-3p, miR-122-5p, miR-l-3p, miR-133a-3p, miR-375, miR141-3p, miR-31-5p, miR-205-5p, miR-200c-3p, and/or miR-203a-3p. In further embodiments, the oncolytic virus is used for treating a Schwannoma.
WO 2017/132552
PCT/US2017/015417 [0030] In some embodiments, the present invention provides for recombinant oncolytic viruses comprising one or more of (a) one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication; (b) one or more polynucleotides encoding one or more proteins or oligonucleotides, wherein the proteins or oligonucleotides reduce the expression or inhibit the function of a miR, a gene, or a TEMP; (c) at least one protease-activated antibody; and/or (d) a polynucleotide encoding at least one protease activated antibody. In some embodiments, the miR is an oncogenic miR or a microenvironment remodeling miR. In some embodiments, the oncogenic miR is selected from the miRs listed in Table 4. In some embodiments, the gene is an oncogenic gene. In some embodiments, the oncogenic gene is selected from the genes listed in Table 7. In some embodiments, the microenvironment remodeling miR is selected from the miRs listed in Table 5. In some embodiments, the TEMP is selected from TEMPI, ΊΊΜΡ2, TIMP3 and TIMP4. In some embodiments, the oligonucleotide of (b) is an shRNA or a decoy oligonucleotide. In some embodiments, [0031] In some embodiments, the present invention provides for recombinant oncolytic viruses comprising one or more of (a) one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication; (b) one or more polynucleotides encoding one or more proteins or oligonucleotides, wherein the proteins or oligonucleotides reduce the expression or inhibit the function of a miR, a gene, or a TEMP; (c) at least one protease-activated antibody; and/or (d) a polynucleotide encoding at least one protease activated antibody, wherein the protein is a nuclease, a bispecific T-cell engager (BiTE), an anti-immunosuppressive protein, or an immunogenic antigen. In some embodiments, the nuclease is selected from a Clustered Regulatory Interspaced Short Palindromic Repeats (CRESPR)-associated endonuclease, a zinc-finger nuclease (ZFN) or a Transcription activator-like effector nuclease (TALEN). In some embodiments, the CRISPRassociated endonuclease is selected from SpCas9, SpCas9-HFl, SpCas9-HF2, SpCas9-EEF3, SpCas9-HF4, SaCas9, FnCpf, FnCas9, eSpCas9, C2C1, C2C3, Cpfl, Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl 6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, and Csf4. In further embodiments, the oncolytic virus further comprises a heterologous polynucleotide encoding an
WO 2017/132552
PCT/US2017/015417 tracr-RNA (trRNA) and a crispr-RNA (crRNA), wherein the crRNA is targeted to a genomic
DNA sequence encoding a miR or a TIMP and wherein the trRNA facilitates binding and activation of a CRISPR-associated endonuclease.
[0032] In some embodiments, the anti-immunosuppressive protein is an antiregulatory T-celi (Treg) protein or an anti-myeloid-derived suppressor cell (MDSC) protein. In some embodiments, the anti-immunosuppressive protein is a VHH-derived blocker or a VHHderived BiTE.
[0033] In some embodiments, the protein induces an anti-tumor immune response. In further embodiments, the protein is selected from EpCAM, folate, ΙΡΝβ, antiCTLA-4, anti-PDl, A2A, anti-FGF2, anti-FGFR/FGFR2b, anti-SEMA4D, CCL5, CDI37, CD200, CD38, CD44, CSF-1R, CXCL10, CXCL13, endothelin B Receptor, IL-12, IL-15, IL-2, IL-21, IL-35, ISRE7, LFA-1, NG2 (also known as SPEG4), a SMAD protein, STING, ΤΟΡβ, and VC AMI.
[0034] In some embodiments, the present invention provides for recombinant oncolytic viruses comprising one or more of (a) one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication; (b) one or more polynucleotides encoding one or more proteins or oligonucleotides, wherein the proteins or oligonucleotides reduce the expression or inhibit the function of a miR, a gene, or a TIMP; (c) at least one protease-activated antibody; and/or (d) a polynucleotide encoding at least one protease activated antibody, wherein the at least one protease-activated antibody is incorporated into a viral glycoprotein envelope. In some embodiments, the proteaseactivated antibody is activated by a protease selected from a cysteine cathepsin, an aspartic cathepsin, a kallikrein (hK), a serine protease, a caspase, a matrix metalloproteinase (MMP), and a disintegrin metalloproteinase (ADAM). In some embodiments, the protease is selected from cathepsin K, cathepsin B, cathepsin L, cathepsin E, cathepsin D, hKl, PSA (hK3), hK10, hKl 5, uPA, uPAR, MMP-1, MMP-2, M.MP-3, MVP-7, MMP-8, MMP-9, MMP-A). MMP-11, MMP12, MMP-13, MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20, MMP-21, ΜΜΡ-23.Λ. MMP-23B, M.MP-24. MMP-25, MMP-26, MMP-27, MMP-28, or a protease listed in Table 6.
[0035] In some embodiments, the protease-activated antibody binds to a protein expressed more highly by a cancer cell or in a cancer microenvironment than by a non-cancer
WO 2017/132552
PCT/US2017/015417 cell or in a non-cancer microenvironment. In some embodiments, the protease-activated antibody binds NKG2D, c-met, HGFR, CDS, heparan sulfate, VSPG4 (also known as NG2), EGFR,
EGFRvIII, CD133, CXCR4, carcinoembryonic antigen (CEA), CLC-3, annexin II, human transferrin receptor, or EpCAM.
[0036] In some embodiments, the miR target sequence and/or the one or more polynucleotides is inserted into a gene locus of the viral genome. In some embodiments, the virus is a herpes simplex virus and wherein the at least one polynucleotide is inserted into or between one or more viral gene loci selected from the group consisting of the internal repeat joint region (comprising one copy each of the diploid genes ICPO, ICP34.5, LAT, ICP4, and the ICP47 promoter), ICPO, LAT, E4. I, UI.5. UL6, UL7, UL8, ET9, U!.! E 144 2. 1444. UL15, 1.4.17.. ITT. 1.4.19. LI.20. 1.4.22. E4.25. E4.26. EJL26.5, 14.27.. 14.28. 1.4.29. 1.4.20. 1.4.2 E UL32, UL33, TJL34, UL35, UL36, UL37, UL38, UL39, UL40, UL42, UL48, UL49, UL52, UL53, UL54, ICPO, ICP4, ICP22, ICP27, ICP47, gamma-34.5, US3, US4, USS, US6, US7, USS, US9, US 10, LSI 1, and US 12.
[0037] In some embodiments, the invention provides for a nucleic acid molecule encoding an oncolytic virus described herein. In some embodiments, the invention provides for a viral stock of an oncolytic virus described herein. In some embodiments, the invention provides for a composition comprising an oncolytic virus described herein and a pharmaceuticallyacceptahle carrier.
[0038] In some embodiments, the invention provides a method of killing a cancerous cell, comprising exposing the cancerous cell to an oncolytic virus described herein or compositions thereof under conditions sufficient for the oncolytic virus to infect and replicate within said cancerous cell, and wherein replication of the oncolytic virus within the cancerous cell results in ceil death. In some embodiments, the cancerous cell has a reduced expression of a tumor-suppressive miR capable of binding to the one or more tumor-suppressive miR-target sequences compared to the expression of the tumor-suppressive miR in a non-caneerous cell. In some embodiments, the expression level of the tumor-suppressive miR in the cancerous cell is at least 5% less than the expression level the tumor-suppressive miR in the non-cancerous cell. In some embodiments, replication of the oncolytic virus is increased or maintained in cancerous cells with a reduced expression of the tumor-suppressive miR capable of binding to the one or more tumor-suppressive miR-target sequences. In some embodiments, viral replication is at least
WO 2017/132552
PCT/US2017/015417
5% greater in the cancerous cells compared to the viral replication in the non-cancerous cell. In some embodiments, the ceil is in vivo. In some embodiments, the ceil is within a tumor.
[0039] In some embodiments, the invention provides a method of treating cancer in a subject in need thereof, comprising administering an oncolytic virus described herein or compositions thereof to the subject. In some embodiments, the subject is a mouse, a rat, a rabbit, a cat, a dog, a horse, a non-human primate, or a human. In some embodiments, the oncolytic virus or compositions thereof are administered intravenously, subcutaneously, intratumorally, intramuscularly, or intranasaliy. In some embodiments, the cancer is selected from lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). In some embodiments, lung cancer is small cell lung cancer or non-small cell lung cancer. In some embodiments, liver cancer is hepatocellular carcinoma (HCC).
Brief Description of the Drawings [0040] FIG. I illustrates a. heat map of an miRNA expression profile in cancerous and non-cancerous brain tissue corresponding to 25 selected miRNAs.
[0041] FIG. 2 illustrates a. heat map of an miRNA expression profile in cancerous and non-cancerous bladder tissue corresponding to 25 selected miRNAs.
[0042] FIG. 3 illustrates a heat map of an miRNA expression profile in cancerous and non-cancerous breast tissue corresponding to 25 selected miRNAs.
[0043] FIG. 4 illustrates a heat map of an miRNA expression profile in cancerous and non-cancerous colon tissue corresponding to 25 selected miRNAs.
[0044] FIG. 5 illustrates a heat map of an miRNA expression profile in glioblastoma and non-cancerous brain tissue corresponding to 25 selected miRNAs.
[0045] FIG. 6 illustrates a heat map of an miRNA expression profile in cancerous and non-cancerous head and neck tissue corresponding to 25 selected miRNAs.
[0046] FIG. 7 illustrates a heat map of an miRNA expression profile in cancerous and non-cancerous lung tissue corresponding to 25 selected miRN As.
WO 2017/132552
PCT/US2017/015417 [0047] FIG. 8 illustrates a heat map of an miRNA expression profile in cancerous and non-cancerous pancreatic tissue corresponding to 25 selected miRNAs.
[0048] FIG. 9 illustrates a heat map of an miRNA expression profile in schwannoma and non-schwannoma tissue corresponding to 25 selected miRN As.
[0049] FIG. 10 illustrates downregulation of miR-451a expression in all tumor types (CA) compared to non-cancerous tissue (Norm).
[0050] FIG. 11 illustrates downregulation of miR-1 expression in all tumor types (CA), moderate expression of miR-1 in non-cancerous tissue (Norm), and high expression of miR-1 in non-cancerous head and neck tissue (H&N).
[0051] FIG. 12 illustrates downregulation of miR-559 expression in all tumor types (CA), low expression of miR-559 in non-cancerous tissue (Norm), and high expression of miR-559 in non-cancerous lung tissue.
[0052] FIG. 13 illustrates downregulation of miR-145-5p expression in all tumor types (CA) and high expression of miR-145-5p in the majority of non-cancerous tissue (Norm).
[0053] FIG. 14 illustrates downregulation of miR-143-3p expression in colon lung, and pancreatic tumor types (CA) and high expression of miR-143-3p in the majority of non-cancerous tissue (Norm).
[0054] FIG. 15A- FIG. 15C illustrate a miRNA expression and attenuation reporter gene system described in Example 2. FIG. 15A shows a schematic of a pTetiR tet repressor plasmid that induces expression of an miRNA expression plasmid. FIG. 15B shows a schematic of a pTF-002 miRNA expression plasmid containing a tet-inducible mCherry and miRNA expression cassette. FIG. ISC shows a schematic of a pTF-004 miRNA attenuation reporter enabling the read-out of destabilized GFP (dsGFP).
[0055] FIG. 16 illustrates miR-122 expression and attenuation using the reporter system shown in FIG. 15 and described in Example 2.
[0056] FIG. 17 illustrates miR-122, miR-184, miR-34a, and Let7a-mediated GFP attenuation using the reporter system shown in FIG. 15 and described in Example 2. Circled wells indicate reduced GFP expression levels.
[0057] FIG. 18 illustrates expression of miR-122, miR-184, miR-34a, and Let7a, indicated by mCherry expression, using the reporter system shown in FIG. 15 and described in Example 2.
WO 2017/132552
PCT/US2017/015417 [0058] FIG. 19 illustrates miR-122, miR-124, miR-145, miR-199, and miR-451mediated GFP attenuation using the reporter system shown in FIG. 15 and described in Example
2. Circled wells indicate reduced GFP expression levels.
[0059] FIG. 20 illustrates expression of miR-122, miR-124, miR-145, miR-199, and miR-451, indicated by mCherry expression, using the reporter system shown in FIG. 15 and described in Example 2.
[0060] FIG. 21 shows quantitation of miR-122 and miR-184 attenuated GFP fluorescence.
[0061] FIG. 22 shows quantitation of miR-34a and miR-184 attenuated GFP fluorescence.
[0062] FIG. 23 shows quantitation of Let7a and miR-184 attenuated GFP fluorescence.
[0063] FIG. 24 shows quantitation of miR-124 and miR-184 attenuated GFP fluorescence.
[0064] fluorescence.
[0065]
FIG. 25 shows quantitation of miR-145 and miR-184 attenuated GFP
FIG. 26 shows quantitation of miR-199 and miR-451 attenuated GFP fluorescence.
FIG. 27 shows quantitation of miR-125 and miR-451 attenuated GFP fluorescence.
[0067] fluorescence.
[0068] fluorescence.
[0069] fluorescence.
[0070] fluorescence.
FIG. 28 show's quantitation of miR-126 and miR-451 attenuated GFP
FIG. 29 shows quantitation of miR-127 and miR-451 attenuated GFP
FIG. 30 show's quantitation of miR-133 and miR-451 attenuated GFP
FIG. 31 show's quantitation of miR-223 and miR-451 attenuated GFP
FIG. 32 shows miR-attenuated HSV constructs with target sequences for various imRNAs inserted into the ICP27 and ICP4 genes.
WO 2017/132552
PCT/US2017/015417 [0072] FIG. 33 illustrates HSV attenuation by miR-125 in non-cancerous (postmitotic king) and cancerous (A253) cells.
[0073] FIG. 34 shows qPCR-based quantitation of HSV attenuation by miR-125 in non-cancerous (PM Lung) and cancerous (A253) lung cells.
[0074] FIG. 35 illustrates fluorescence-based quantitation of HSV attenuation by miR-145 in HCC1395 vs. A253 ceils.
[0075] FIG. 36 shows qPCR-based quantitation of HSV attenuation by miR-145 in HCC1395 vs. A253 cells.
[0076] FIG. 37 illustrates fluorescence-based quantitation of HSV attenuation by miR-199a-5p vs. miR-143-3p in normal lung cells.
[0077] FIG. 38 shows qPCR-based quantitation of HSV attenuation in normal lung cells by miR-199a-5p vs. miR-143-3p.
[0078] FIG. 39 illustrates a schematic of an ICP4-TmiRNA-attenuated HSV vector for the treatment of cancer or benign hyper-proliferative disorders.
[0079] FIG. 40 shows a schematic of an ICP27-TmiRNA-attenuated HSV vector for the treatment of cancer or benign hyper-proliferative disorders.
[0080] FIG. 41 shows a schematic of a UL19-TmiRNA-attenuated HSV vector for the treatment of cancer or benign hyper-proliferative disorders.
[0081] FIG. 42 shows a schematic of an UL19-TmiRNA and ICP27-TmiRNAattenuated HSV vector for the treatment of cancer or benign hyper-proliferative disorders.
[0082] FIG. 43 shows a schematic of an UL19-TmiRNA and ICP4-TmiRNAattenuated HSV vector for the treatment of cancer or benign hyper-proliferative disorders.
[0083] FIG. 44 shows a schematic of an UL19-TmiRNA, ICP27-TmiRNA, and
ICP4-TmiRNA-attenuated HSV vector for the treatment of cancer or benign hyper-proliferative disorders.
[0084] FIG. 45 shows a schematic of an ICP4-TmiRNA-attenuated, genomeediting HSV vector for the treatment of cancer.
[0085] FIG. 46 shows a schematic of an ICP4-TmiRNA-attenuated, genomeediting, microenvironment-remodeling HSV vector for the treatment of cancer.
[0086] FIG. 47 shows a schematic of an ICP4-TmiRNA and ICP27-TmiRNAattenuated HSV vector for the treatment of pancreatic, lung, and colon cancer.
WO 2017/132552
PCT/US2017/015417
FIG. 48 shows a schematic of an ICP4-TmiRNA and ICP27-TmiRNAattenuated HSV vector for the treatment of multiple cancer types.
FIG. 49 shows a schematic of an ICP4-TmiRNA and ICP27-TmiRNAattenuated HSV vector for the treatment of schwannoma.
[0089] In some aspects, the present invention utilizes differential miRNA expression profiles to effectively restrict viral vector replication to tumor ceils. In some embodiments, the viral vectors described herein also disrupt the expression of specific miRNAs for reduced tumor proliferation, metastasis, and/or remodeling of the tumor microenvironment to enable enhanced viral spread. In some embodiments, the viral vectors described herein encompass the use of surface molecules on viral vectors to facilitate targeting to tumor cells. These aspects can be applied individually or in combination to develop viral vectors potentially capable of treating a wide array of cancer types with a single viral vector. As such, the invention further encompasses recombinant oncolytic viral vectors for use in the treatment and prevention of diseases and disorders (e.g., cancer). In some embodiments, this invention utilizes endogenous microRNA (miRNA) to enable a safe and efficacious recombinant viral vector suitable to treat a broad array of cancers.
[0090] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited herein, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose. In the event that one or more of the incorporated documents or portions of documents define a term that contradicts that term’s definition in the application, the definition that appears in this application controls. However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as an acknowledgment, or any form of suggestion, that they constitute valid prior art or form part of the common general knowledge in any country in the world.
[0091] In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an
WO 2017/132552
PCT/US2017/015417 integer), unless otherwise indicated. It should be understood that the terms a” and an” as used herein refer to one or more” of the enumerated components unless otherwise indicated. The use of the alternative (e.g., or) should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the terms include and comprise are used synonymously. As used herein, “plurality” may refer to one or more components (e.g., one or more miRNA target sequences).
Oncolytic Viruses [0092] In some embodiments, the present invention provides for recombinant oncolytic viruses, wherein one or more copies of one or more tumor-suppressive micro-RNA (miR) target sequences are inserted into a locus of one or more viral genes required for viral replication. As used herein, the term “oncolytic virus” refers to a virus that has been modified to, or naturally, preferentially infect cancer ceils. Examples of oncolytic viruses are known in the art including, but not limited to, herpes simplex virus, an adenovirus, a polio virus, a vaccinia virus, a measles virus, a vesicular stomatitis virus, an orthomyxovirus, a parvovirus, a maraba virus or a coxsackievirus. In some embodiments, the oncolytic viruses described herein are incorporated into a viral vector. The term “vector” is used herein to refer to a nucleic acid molecule capable transferring or transporting another nucleic acid molecule. The transferred nucleic acid is generally linked to, e.g., inserted into, the vector nucleic acid molecule. A vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into host cell DNA. A viral vector may sometimes be referred to as a “recombinant virus” or a “virus.” The terms “oncolytic virus” and “oncolytic vector” are used interchangeably herein. In particular embodiments, the recombinant viral vector is a herpes simplex virus capable of tumor-selective vector replication as described in International PCT Publication No. WO 2015/066042, which is incorporated by reference in its entirety, [0093] The terms “microRNA,” “miRNA,” and “miR” are used interchangeably herein and refer to small non-coding endogenous RNAs that regulate gene expression by directing their target messenger RNAs (mRNA) for degradation or translational repression. miRs are differentially expressed in a broad array of disease states, including multiple types of cancer. In some aspects, cancer cells of a given cancer type or tissue demonstrate differential expression of miRs compared to non-cancerous control cells. As used herein, the term “oncomiR” refers to
WO 2017/132552
PCT/US2017/015417 miRs that are associated (either positively or negatively) with carcinogenesis, malignant transformation, or metastasis. In some aspects, the expression level of a particular oncomiR is associated with the development or maintenance of a particular cancer. Such miRs are referred to herein as “oncogenic miRs.” [0094] In some embodiments, the expression of an oncogenic miR is increased in cancerous ceils or tissues compared to non-cancerous controls. For example, the expression of an oncogenic miR in a cancerous cell may be increased by at least 5% compared to the expression of the oncogenic miR in a non-cancerous cell or tissue. In some embodiments, the expression of an oncogenic miR is increased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 1000% or more compared to the expression of the oncogenic miR in a non-cancerous cell or tissue. In some aspects, a cancerous cell or tissue may express an oncogenic miR that is not expressed in noncancerous control cells or tissues. In some embodiments, the expression of an oncogenic miR is increased in cancerous cells or tissues compared to cancerous cells derived from a different cancer type. For example, the expression of an oncogenic miR in a cancerous cell may he increased by at least 5% compared to cancerous cells derived from a different cancer type. In some embodiments, the expression of an oncogenic miR is increased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 1000% or more compared to cancerous ceils derived from a different cancer type. Examples of oncogenic miRNAs that are frequently over-expressed in cancer tissues include, but are not limited to, miR-21, miR-155 and miR-17-92. Additional examples of oncogenic miRs are listed in Table 4.
[0095] In some embodiments, the expression of a particular oncomiR is associated with the prevention and/or delay of carcinogenesis and/or metastasis. Such oncomiRs are referred to herein as “tumor-suppressor miRs” or “tumor-suppressive miRs,” as their expression prevents or suppresses the development of cancer. In some embodiments, underexpression of tumor-suppressive miRs can lead to cancer. As such, in some aspects, tumorsuppressive miRs are expressed in healthy ceils and are not expressed in cancerous ceils. In some aspects, the expression of a particular tumor-suppressive miR is increased in a healthy cell compared to a cancerous cell. For example, the expression of a tumor-suppressive miR in a healthy (e.g., non-cancerous) cell may be increased by at least 5% compared to the expression of
WO 2017/132552
PCT/US2017/015417 a tumor-suppressive miR a cancerous ceil. In some embodiments, the expression of a tumorsuppressive miR is increased by at ieast 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 1000% or more compared to the expression of the tumor-suppressive miR in a cancerous cell. In some embodiments, the expression of a tumor-suppressive miR is increased in normal cells or tissues compared to normal ceils derived from a different tissue type or location in the body. For example, the expression of a tumor-suppressive miR in a normal cell may be increased by at least 5% compared to normal cells derived from a different tissue type or location in the body. In some embodiments, the expression of a tumor-suppressive miR in a normal cell is increased by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 1000% or more compared to normal ceils derived from a different tissue type or location in the body. Examples of tumor-suppressive miRNAs include, but are not limited to, miR-15a, miR-16-1, miR-34, as well as miRNAs of the let-7 family. Additional examples of tumor-suppressive miRs are listed in Table 3 and Table 8.
[0096] Cancer pathogenesis is a heterogeneous and multigenic process. As such, activation of particular pathways and the expression of particular genes may lead to cancer development in one context, and result in distinct or opposing results when activated or expressed in a different context. Therefore, the characterization of a particular gene or miR as an “oncogene” or “oncogenic miR” or as a “tumor-suppressor” or “tumor-suppressive miR” is not a binary distinction and is often context dependent. For example, miR-152b functions as an oncogenic miR in the vast majority of hematologic malignancies, but functions as a tumorsuppressive miR in many solid tumors. Further, a particular miR may be highly expressed in both cancerous and non-cancerous cells. For example, miR-155 is highly expressed in normal cells, playing an essential role in macrophage polarization, and is also highly expressed in cancer cells. As such, the development of the miR-attenuated, genome-editing, and microenvironmentremodeling oncolytic viruses described herein is based on the differential expression of a particular miR or group of miRs in one cell population or tissue compared to another cell population or tissue. One of skill in the art wall understand that the term tumor-suppressive miR generally refers to a miR that is more highly expressed in a non-cancerous ceil or tissue compared to a cancerous cell or tissue, and that the term oncogenic miR generally refers to a miR that is more highly expressed in a cancerous cell or tissue compared to a non-cancerous cell or
WO 2017/132552
PCT/US2017/015417 tissue. One of skill in the art will further understand that a miR characterized as a tumorsuppressive miR in one type of cancer may or more may not function as a tumor-suppressive miR in a different type of cancer, and that a miR characterized as an oncogenic miR in one type of cancer may or more may not function as an oncogenic miR in a different type of cancer.
[0097] Table 1 shows the relationship between 12 select oncomiRs (9 tumor suppressors and 3 oncogenic miRNAs) and numerous cancers. A list of 3,410 oncomiR-cancer relationships is shown in Table 2. miRNAs regulate many transcripts of proteins that are involved in the control of cellular proliferation and apoptosis. Regulated proteins include conventional proto-oncoproteins and tumor suppressors such as Ras, Myc, Bcl2, PTEN and p53. Aberrant expression of miRNAs therefore often is involved in development of cancer and can therapeutically be corrected by either inhibiting oncogenic miRNAs or replacing the depleted tumor suppressor miRNA. Further, the differential expression of particular oncomiRs in cancerous vs. non-cancerous cells can be exploited as a means to target cancer therapeutics specifically to cancer cells. As such, in some embodiments, the oncolytic viral vectors described herein can comprise the following properties individually or in combination: insertion of tumorsuppressive miRNA target sequences into the viral genome, thereby restricting viral vector replication to cancer or tumor cells; one or more polynucleotides incorporated into the viral genome whose product(s) disrupt the function of an oncogenic miRNA and/or the cancer extracellular matrix; and/or protease-activated antibodies incorporated into the viral particle in order to highly selectively target the vectors to cancer and/or tumor cells.
[0098] One aspect of the invention comprises a recombinant oncolytic virus (or viral vector) comprising a plurality of copies of one or more tumor-suppressive miRNA target sequences (e.g., an miRNA selected from the miRNAs listed in Table 3 or Table 8) inserted into a locus of one or more viral genes required for viral replication. In certain embodiments, a recombinant oncolytic virus may comprise tumor-suppressive miRNA target sequences inserted into a locus of at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten viral genes required for viral replication. Tumor-suppressor miRNAs expressed in normal (non-cancerous) cells can bind to such target sequences and suppress expression of the viral gene containing the miRNA target sequence, thereby limiting viral replication in healthy, non-cancerous cells. Such recombinant oncolytic viruses and/or vectors are referred to herein as “miR-attenuated” or “replication-restricted” as
WO 2017/132552
PCT/US2017/015417 they result in reduced or attenuated viral replication in cell that express a tumor-suppressive miR capable of binding to the incorporated tumor-suppressive miR target sequence compared to cells that do not express, or have reduced expression of, the tumor-suppressive miR. By incorporating tumor-suppressive miRNAs into key genes required for viral replication, viral replication can be conditionally suppressed in normal diploid ceils expressing the tumor-suppressive miRNAs and can proceed normally in cells that do not express the tumor-suppressive miRNAs. In such embodiments, healthy, non-cancerous cells are protected from the normal cells from lytic effects of infection by the recombinant viral vector.
[0099] In cerium embodiments, the one or more tumor-suppressive miRNA target sequences is incorporated into the 5’ untranslated region (UTR) and/or 3’ UTR of one or more genes one or more viral genes required for viral replication. In normal diploid cells, tumorsuppressive miRNAs can bind to the engineered 3’ or 5’ non coding sequence which comprises a tumor-suppressive miRNA target sequence, but these tumor-suppressive miRNAs are lacking in transformed or malignant cells. Thus, viral replication can proceed in cells that lack, or have reduced expression of, the tumor-suppressive miRNAs. In some embodiments, at least one tumor-suppressive miR target sequence is incorporated into one or more viral genes required for replication. In some embodiments, the oncolytic viral vector may comprise multiple copies of an identical tumor-suppressive miR target sequence incorporated into one viral gene required for replication. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more copies of a tumor-suppressive miR target sequence may be incorporated into a viral gene required for replication. In particular embodiments, 2 to 6 copies of a tumor-suppressive miR target sequence are incorporated into the 3’ or 5’ UTR of a viral gene required for replication. In further embodiments, 4 copies of a tumor-suppressive miR target sequence are incorporated into the 3’ or 5’ UTR of a viral gene required for replication. In some embodiments, the oncolytic viral vector may comprise multiple copies of the same tumor-suppressive miR target sequence incorporated into a plurality of viral genes required for replication. For example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more copies of a tumorsuppressive miR target sequence may be incorporated into 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more genes required for viral replication. In particular embodiments, 2 to 6 copies of a tumorsuppressive miR target sequence are incorporated into the 3’ or 5’ UTR of two or more viral genes required for replication. In further embodiments, at least 4 copies of a tumor-suppressive
WO 2017/132552
PCT/US2017/015417 miR target sequence are incorporated into the 3’ or 5’ UTR of two or more viral genes required for replication.
[00100] In some embodiments, the oncolytic viral vector may comprise target sequences for more than one tumor-suppressive miR incorporated into one viral gene required for replication. For example, target sequences for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different tumor-suppressive miRs may be incorporated into a single gene required for viral replication. In some embodiments, the oncolytic viral vector may comprise target sequences for more than one tumor-suppressive miR incorporated into a plurality of viral genes required for replication. For example, target sequences for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different tumor-suppressive miRs may be incorporated into 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more genes required for viral replication. In some embodiments, the oncolytic viral vector may comprise multiple target sequences (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 copies of one target sequence) for at least two different tumor-suppressive miRs (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 different tumorsuppressive miRs). In such embodiments, the multiple target sequences for a first tumorsuppressive miR may be incorporated into a first gene required for replication, the multiple target sequences for a second tumor-suppressive miR may be incorporated into a second gene required for replication, the multiple target sequences for a third tumor-suppressive miR may be incorporated into a third gene required for replication, etc. In particular embodiments, the oncolytic viral vectors described herein comprise at least 2 to at least 8 copies of first tumorsuppressive miR target sequence incorporated into the 3’ or 5’ UTR of a first gene required for replication, at least 2 to at least 8 copies of second tumor-suppressive miR target sequence incorporated into the 3’ or 5’ UTR of a second gene required for replication, and at least 2 to at least 8 copies of third tumor-suppressive miR target sequence incorporated into the 3’ or 5’ UTR of a third gene required for replication.
[00101] In some embodiments, the miR-attenuated oncolytic viruses described herein result in reduced viral replication in a cell that expresses a tumor-suppressive miR capable of binding to one or more of the incorporated miR-target sequences. “Viral replication” refers to the total number of viral replication cycles that occur in a particular ceil or population of cells during a given amount of time. In some embodiments, viral replication can be measured directly by assessing the total viral titer present over the course of the given amount of time, or by assessing the number of viral genome copies present (e.g., by sequencing). In some
WO 2017/132552
PCT/US2017/015417 embodiments, the viral vector may additionally comprise a detectable label, such as a fluorescent reporter. In such embodiments, viral replication may be assessed by measuring the fluorescence intensity of the reporter, or the number of cells that express the reporter. In some embodiments, viral replication can be measured indirectly by assessing the number of viable cells over the course of the given amount of time. For example, the level of viral replication would be expected to inversely correlate with the number of viable ceils over time.
[00102] “Reduced viral replication” as used herein, refers to a level of viral replication that is lower in a first cell or first population of cells compared to a second cell or a second population of cells. In some embodiments, the level of viral replication in the first cell or first population of cells is reduced by at least 5% compared to the level of viral replication in the second cell or population of cells. In some embodiments, the level of viral replication in the first cell or first population of cells is reduced by at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to the level of viral replication in the second cell or population of cells. In some embodiments, viral replication in the first cell or first population of cells is completely inhibited compared to the viral replication in the second cell or population of cells.
[00103] In some embodiments, the reduced viral replication in the first cell or first population of cells correlates with the expression of a tumor-suppressive miR capable of binding to the one or more miR-target sequences incorporated into one or more viral genes required for replication. In some embodiments, expression of a tumor-suppressive miR corresponding to the incorporated miR-target sequence therefore inhibits or reduces the expression of the replication gene, thereby inhibiting or reducing viral replication. In some embodiments, the second cell or second population of cells does not express, or has a reduced expression level, of the tumorsuppressive miR. In some embodiments, absent or reduced expression of a tumor-suppressive miR (e.g., in a cancer ceil) corresponding to the incorporated miR-target sequence allows for viral replication to proceed. In some embodiments, the expression level of the tumor-suppressive miR in the second cell or population of cells is at least 5% lower than the expression level of the tumor-suppressive miR in the first ceil or population. In some embodiments, the expression level of the tumor-suppressive miR in the second cell or population of cells is reduced at least 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to the expression level of the tumor-suppressive miR in the first cell or population. In
WO 2017/132552
PCT/US2017/015417 some embodiments, the second ceil does not express the tumor-suppressive miR. In particular embodiments, the first ceil is a non-cancerous ceil and the second ceil is a cancerous cell.
[00104] In some aspects, the multiple copies (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, or more copies) of a tumor-suppressive miRN A target sequence are inserted into a locus in the viral genome in tandem. In such embodiments, the multiple copies of the target sequence may be separated by a linker sequence or a space sequence. In some embodiments, the linker and/or spacer sequence comprises 4 or more nucleotides. For example, a space or linker sequence may comprise 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or more nucleotides. In some embodiments, the linker sequence or the spacer sequence comprises about 5 to about 20 nucleotides. In further embodiments, the linker sequence or the spacer sequence comprises about 8 to about 16 nucleotides. As an illustrative embodiment, and not meant to limit the present invention in any way, an oncolytic virus may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten of one or more of the following subunits inserted in tandem into a locus of one or more viral genes required for viral replication: (a) target sequence for a first tumor-suppressive miRNA - linker or spacer sequence --- target sequence for the first tumor-suppressive miRNA; or (b) target sequence for a first tumor-suppressive miRNA - linker or spacer sequence - target sequence for a second tumor-suppressive miRNA. In some embodiments, the miRNA target sequence is the reverse complement of the miRNA, [00105] In some embodiments, an oncolytic virus is a herpes simplex virus (HSV), and the viral gene required for viral replication UL1, UL5, UL6, UL7, UL8, UL9, 14.11. UL12, UL14, UL15, UL17, UL18, UL19, UL20, UL22, UL25, UL26, UL26.5, UL27, 14.28. 14.29. UL30, UL31, UL32, UL33, UL34, UL35, UL36, UL37, UL38, UL39, UL40, UL42, UL48, UL49, UL52, UL53, UL54, ICP0, ICP4, ICP22, ICP27, ICP47, gamma-34.5, US3, US4, USS, US6, US”, USS, US9, US10, US11, and/or US12. In some embodiments, an oncolytic virus is a herpes simplex virus (HSV), and the one or more tumor-suppressive miRNA target sequences is incorporated into one or more of ICP0, ICP4, UL19, and ICP27 genes. In certain embodiments, an oncolytic viral vector is an HSV that comprises one or more tumor suppressive miRN A target sequences (e.g., any of the tumor-suppressive miRs listed in Table 3) incorporated into the 5’ or 3’ UTR of one or more genes (e.g., UL1, UU5, UL6, UL7, 14.8. UL9, UL11, UL12, UL14, UL15, UL17, UL18, UL19, UL20, UL22, UL25, UL26, UL26.5, UI.27, UL28, UL29, UL30,
WO 2017/132552
PCT/US2017/015417
UL31, UL32, UL33, UL34, UL35, UL36, UL37, UL38, UL39, UL40, UL42, UL48, UL49, UJL52, UL53, UL54, ICPQ, ICP4, ICP22, ICP27, ICP47, gamma-34.5, USS, US4, USS, US6, US7, USS, US9, US10, US11, or US12) that are required for viral replication (e.g, FIGs. 39-49).
[00106] In some embodiments, a replication-restricted viral vector (e.g., a miRattenuated viral vector) comprises at least one let-7 target sequence and is used to treat lung cancer. In some embodiments, a replication-restricted viral vector comprises at least one miR15a and/or at least one miR-16A target sequences and is used to treat B-ceil chronic lymphocytic leukemia. In some embodiments, a replication-restricted viral vector comprises at least one miR125b, at least one miR-145, at least one miR-21, and/or at least one miR-155 target sequences and is used to treat breast cancer. In other embodiments, a replication-restricted viral vector comprises at least one miR-143 and/or at least one miR-145 target sequences and is used to treat colorectal cancer. In certain embodiments, a replication-restricted viral vector comprises at least one miR-181a, at least one miR-181b, and/or at least one miR-I81c target sequences and is used to treat glioblastoma. In some embodiments, a replication-restricted viral vector comprises at least one miR-199a*, at least one miR-195, at least one miR-199a, at least one miR-200a, and/or at least one miR-125a target sequences and is used to treat liver cancer (e.g,, hepatocellular carcinoma), [00107] In particular embodiments, a replication-restricted viral vector comprises at least one miR-451a target sequence, at least one miR-143-3p target sequence, at least one miR-559 target sequence, and at least one miR-124 target sequence and is used for the treatment of pancreatic, lung, and/or colon cancer. In such embodiments, the target sequences for miR451a, miR-143-3p, miR-559, and miR-124 are incorporated into two or more genes required for viral replication (e.g., ICP4 and ICP27). In further particular embodiments, a replicationrestricted viral vector comprises at least one miR-451a target sequence, at least one miR-145-5p target sequence, at least one miR-559 target sequence, and at least one miR-124 target sequence and is used for the treatment of any type of cancer described herein. In such embodiments, the target sequences for miR-451a, miR-145-5p, miR-559, and miR-124 are incorporated into two or more genes required for viral replication (e.g., ICP4 and ICP27). In further particular embodiments, a replication-restricted viral vector comprises at least one miR-205p target sequence, at least one miR-141-5p target sequence, at least one miR-31-5p target sequence, and at least one miR-124 target sequence and is used for the treatment of schwannoma. In such
WO 2017/132552
PCT/US2017/015417 embodiments, the target sequences for miR-205p, miR-141-5p, miR-31-5p, and miR-124 are incorporated into two or more genes required for viral replication (e.g., ICP4 and ICP27).
[00108] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-136-3p, miR-4325p, miR-l-3p, miR-127-3p, miR-379-5p, miR-493-5p, miR-223-5p, nnR-223-5p, miR-136-5p, miR~451a, miR-487b-3p, miR-370-3p, miR-410-3p, miR-431-3p, miR-4485-3p, miR-4485-5p, miR-127-5p, miR-409-3p, miR-338-3p, miR-559, miR-411-5p, miR-133a-5p, miR-143-3p, miR376b-3p, miR-758-3p, miR-Ι, miR-101, miR-1180, miR-1236, miR-124-3p, nnR-125b, miR126, miR-1280, miR-!33a, miR-133b, miR-141, miR-143, miR-144, miR-145, miR-155, miR16, miR-18a, miR-192, miR-195, miR-200a, miR-200b, miR-200c, miR-203, miR-205, miR214, miR-218, miR-23b, miR-26a, miR-29c, miR-320c, miR-34a, miR-370, miR-409-3p, miR429, miR-451, miR-490-5p, miR-493, miR-576-3p, and/or miR-99a inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating bladder cancer.
[00109] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-1251-5p, miR219a-5p, miR-219a-2-3p, miR-124-3p, miR-448, miR-138-2-3p, miR-490-5p, miR-Ι 29-l-3p, miR-1264, miR-3943, miR-490-3p, miR-383-5p, miR-133b, miR-I29-2-3p, miR-128-2-5p, miR133a-3p, miR-129-5p, miR-I-3p, miR-885-3p, miR-124-5p, miR-759, miR-7158-3p, miR-7705p, miR-135a-5p, miR-885-5p, let-7g-5p, miR-100, miR-101, miR-106a, miR-124, miR-124a, miR-125a, miR-125a-5p, miR-125b, miR-127-3p, miR-128, miR-129, miR-136, miR-137, rniR139-5p, miR-142-3p, miR-143, miR-145, miR-146b-5p, miR-149, miR-152, miR-153, miR-195, miR-21, miR-212-3p, miR-219-5p, miR-222, miR-29b, miR-31, miR-3189-3p, miR-320, miR320a, miR-326, miR-330, miR-331-3p, miR-340, miR-342, miR-34a, miR-376a, miR-449a, miR-483-5p, miR-503, miR-577, miR-663, miR-7, miR-7-5p, miR-873, let-7a, let-7f, miR-107, miR-122, miR-124-5p, miR-13 9, miR-146a, miR-146b, miR-15b, miR-16, miR-181a, miR-181a1, miR-181a-2, miR-181b, miR-181b-l, miR-181b-2, miR-181c, miR-181d, miR-184, miR-185, miR- 199a-3p, miR-200a, miR-200b, miR-203, miR-204, miR-205, miR-218, miR-23b, miR-26b, miR-27a, miR-29c, miR-328, miR-34c-3p, miR-34c-5p, miR-375, miR-383, miR-451, miR-452, miR-495, miR-584, miR-622, miR-656, miR-98, miR-124-3p, miR-181b-5p, miR-200b, and/or miR-3189-3p inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral
WO 2017/132552
PCT/US2017/015417 replication. This oncolytic virus may be used in methods and compositions for treating brain cancer. In certain embodiments, the brain cancer is astrocytoma, glioblastoma, or glioma.
[00110] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-10b-5p, miR-1263p, miR-145-3p, miR-451a, miR-199b-5p, miR-5683, nnR-3195, miR-3182, miR-1271-5p, miR204-5p, miR-409-5p, miR-136-5p, miR-514a-5p, nuR-559, miR“483~3p, miR-l-3p, miR-6080, miR-144-3p, miR-10b-3p, nuR-6130, miR-6089, nnR-203b-5p, miR-4266, nnR-4327, miR5694, miR-193b, let-7a, let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-l, let-7f-2, let-7g, let-7i, miR-100, miR-107, miR-lOa, miR-10b, miR-122, miR-124, miR-1258, miR-125a5p, miR-I25b, miR~126, miR-127, miR-129, miR-130a, miR-132, miR-133a, miR-143, miR145, miR-Ι46a, miR-146b, miR-147, miR-148a, miR-149, miR-152, miR-153, miR-15a, miR16, miR-17-5p, miR-181a, miR-1826, miR-183, miR-185, miR-191, miR-193a-3p, miR-195, miR-199b-5p, miR-19a-3p, miR-200a, miR-200b, miR-200c, miR-205, miR-206, miR-211, miR216b, miR-218, miR-22, miR-26a, miR-26b, miR-300, miR-30a, miR-31, miR-335, miR-339-5p, miR-33b, miR-34a, miR-34b, miR-34c, miR-374a, miR-379, miR-381, miR-383, miR-425, miR429, miR-450b-3p, miR-494, miR-495, miR-497, miR~502~5p, miR-517a, miR-574-3p, miR638, miR-7, miR-720, miR-873, miR-874, miR-92a, miR-98, miR-99a, mmu-miR-290-3p, and/or mmu-miR-290-5p inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating breast cancer.
[00111] In some embodiments, a recombinant oncolytic virus comprises a plurality7 of copies of one or more tumor-suppressive miRNA target sequences for miR-143, nuR-145, miR-17-5p, mrR-203, miR-214, miR-218, miR-335, miR-342-3p, miR-372, miR-424, miR-4915p, miR-497, miR-7, miR-99a, miR-99b, miR-100, miR-101, miR-15a, miR-16, miR-34a, miR886-5p, miR-106a, miR-124, nuR-148a, miR-29a, and/or mrR-375 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating cervical cancer.
[00112] In some embodiments, a recombinant oncolytic virus comprises a plurality7 of copies of one or more tumor-suppressive miRNA target sequences for miR-133a-5p, miR490-5p, miR-124-3p, miR-137, miR-655-3p, miR-376c-3p, miR-369-5p, miR-490-3p, miR-4325p, miR-487b-3p, miR-342~3p, miR-223-3p, miR-136-3p, miR-136-3p, miR-143-5p, miR-l-3p,
WO 2017/132552
PCT/US2017/015417 miR-214-3p, miR-143-3p, miR-199a-3p, miR-199b-3p, miR-451a, miR-127-3p, miR-133a-3p, miR-145-5p, miR-145-3p, miR-199a-5p, let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-l, let-7f-2, let-7g, let-7i, miR-100, miR-101, miR-126, miR-142-3p, miR-143, miR-145, miR-192, miR-200c, miR-21, miR-214, miR-215, nuR-22, miR-25, miR-302a, miR-320, miR320a, miR-34a, miR-34c, miR-365, miR-373, miR-424, nuR-429, miR-455, miR-484, miR-502, miR-503, miR-93, miR-98, miR-186, miR-30a-5p, miR-627, let-7a, nuR-1, miR-124, miR-125a, miR-129, miR-1295b-3p, miR-1307, miR-130b, miR-132, miR-133a, miR-Ι33b, miR-137, miR138, miR-139, miR-139-5p, miR-140-5p, miR-148a, miR-148b, nuR-149, miR-150-5p, miR154, miR-15a, miR-15b, miR-16, miR-18a, miR-191, miR-193a-5p, miR-194, miR-195, miR196a, miR-198, miR-199a-5p, miR-203, miR-204-5p, miR-206, miR-212, miR-218, miR-224, miR-24-3p, miR-26b, miR-27a, miR-28~3p, miR-28-5p, miR-29b, niiR-30a-3p, miR-30b, miR328, miR-338-3p, miR-342, miR-345, miR-34a-5p, miR-361~5p, miR-375, miR-378, miR-378a3p, miR-378a-5p, miR-409-3p, miR-422a, miR-4487, miR-483, miR-497, miR-498, miR-518a~ 3p, miR-551a, miR-574-5p, miR-625, miR-638, miR-7, miR-96-5p, miR-202-3p, miR-30a, and/or miR-451 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating colon or colorectal cancer.
[00113] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-101, miR-130a, miR-130b, miR-134, miR-143, miR-145, miR-152, miR-205, miR-223, miR-301a, miR-301b, miR-30c, miR-34a, miR-34c, miR-424, miR-449a, miR-543, and/or miR-34b inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating endometrial cancer.
[66114] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-125b, miR-138, miR-15a, miR-15b, miR-16, miR-16-1, miR-16-l-3p, miR-16-2, miR-181a, miR-181b, miR-195, miR-223, miR-29b, miR-34b, miR-34c, miR-424, imR-10a, miR-146a, miR-150, miR-151, miR155, miR-2278, miR-26a, miR-30e, miR-31, imR-326, miR-564, miR-27a, Iet-7b, miR-124a, miR-142-3p, let-7c, miR-17, nuR-20a, miR-29a, miR-30c, miR-720, miR-107, miR-342, miR34a, miR-202, miR-142-5p, miR-29c, miR-145, miR-193b, miR-199a, miR-214, miR-22, miR137, and/or miR-197 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for
WO 2017/132552
PCT/US2017/015417 viral replication. This oncolytic virus may be used in methods and compositions for treating hematologic cancer. In some embodiments, the hematologic cancer is leukemia, lymphoma, or myeloma.
[00115] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-Ι, miR-145, miR1826, miR-199a, miR-199a-3p, nnR-203, miR-205, miR-497, miR-508-3p, miR-509-3p, let-7a, let-7d, miR-106a*, nuR-126, miR-1285, miR-129-3p, miR-1291, miR-133a, miR-135a, miR138, miR-141, miR-143, miR-182-5p, miR-200a, miR-218, miR-28-5p, miR-30a, miR-30c, miR30d, miR-34a, miR-378, miR-429, miR-509-5p, miR-646, miR-133b, let-7b, let-7c, miR-200e, miR-204, miR-335, miR-377, and/or miR-506 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating kidney cancer.
[00116] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for let-7a-l, let-7a-2, let7a-3, let-7b, let-7c, let-7d, let-7e, let-7f, iet-7f-l, let-7f-2, let-7g, let-7i, miR-Ι, miR-100, miR101, miR-105, miR-122, miR-122a, miR-1236, miR-124, miR-125b, miR-126, miR-127, miR1271, miR-128-3p, miR-129-5p, miR-I30a, miR-130b, miR-133a, miR-134, miR-137, miR-138, miR-139, miR-139-5p, miR-140-5p, miR-141, miR-142-3p, miR-143, miR-144, miR-145, miR146a, miR-148a, miR-148b, miR-150-5p, miR-15b, miR-16, miR-181a-5p, miR-185, miR-1885p, miR-193b, miR-195, miR-195-5p, miR-197, miR-198, miR-199a, miR-199a-5p, miR-199b, miR-199b-5p, miR-200a, miR-200b, miR-200c, miR-202, miR-203, miR-204-3p, miR-205, miR-206, miR-20a, miR-21, miR-2U3p, miR-211, miR-212, miR-214, miR-217, miR-218, miR219-5p, miR-22, miR-223, miR-26a, miR-26b, miR-29a, miR-29b-1, miR-29b-2, miR-29c, miR302b, miR-302c, miR-30a, miR-30a-3p, miR-335, miR-338-3p, miR-33a, miR-34a, miR-34b, miR-365, miR-370, miR-372, miR-375, miR-376a, miR-377, miR-422a, miR-424, miR-424-5p, miR-433, miR-4458, miR-448, miR-450a, miR-451, miR-485-5p, miR-486-5p, miR-497, miR503, miR-506, miR-519d, miR-520a, miR-520b, miR-520c-3p, miR-582-5p, miR-590-5p, miR610, miR-612, miR-625, miR-637, miR-675, miR-7, miR-877, miR-940, miR-941, miR-98, miR-99a, miR-132, and/or miR-31 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and
WO 2017/132552
PCT/US2017/015417 compositions for treating Ever cancer. In some embodiments, the liver cancer is hepatocellular carcinoma.
[00117] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-143-3p, miR-1263p, miR-126-5p, miR-1266-3p, miR-6130, miR-6080, miR-511-5p, miR-143-5p, miR-223-5p, miR-199b-5p, miR-199a-3p, miR-199b-3p, miR-451a, miR-142-5p, miR-144, miR-150-5p, miR142-3p, miR-214-3p, miR-214-5p, nuR-199a-5p, miR-145-3p, miR-145-5p, miR-1297, miR141, miR-145, miR-16, miR-200a, miR-200b, miR-200c, miR-29b, miR-381, miR-409-3p, miR429, miR-451, miR-511, miR-99a, let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f1, let-7f-2, let-7g, let-7i, miR-Ι, miR-101, miR-133b, miR-138, miR-142-5p, miR-144, miR1469, miR- 146a, miR-153, miR-15a, miR- 15b, miR-16-1, miR-16-2, miR-182, miR-192, miR193a-3p, miR-194, miR-195, ntiR-198, miR-203, miR-217, miR-218, miR-22, miR-223, miR26a, miR-26b, miR-29c, miR-33a, miR-34a, miR-34b, miR-34c, miR-365, miR-449a, miR-449b, miR~486~5p, miR-545, miR-610, miR-614, miR-630, miR-660, miR-7515, miR-9500, miR-98, miR-99b, miR-133a, let-7a, miR-100, miR-106a, miR-107, miR-124, miR-125a-3p, miR-125a5p, miR-126, miR-126*, miR-129, miR-137, miR-140, miR-143, miR-146b, miR-148a, miR148b, miR-149, miR-152, miR-154, miR-155, miR-17-5p, miR-Ι81a-l, miR-181a-2, miR-181b, miR-181b-l, miR-181b-2, miR-181c, miR-ISId, miR-184, miR-186, miR-193b, miR-199a, miR-204, miR-212, miR-221, miR-224, miR-27a, miR-27b, miR-29a, miR-30a, miR-30b, miR30c, miR-30d, miR-30d-5p, miR-30e-5p, rniR-32, miR-335, miR-338-3p, miR-340, miR-342-3p, miR-361-3p, miR-373, miR-375, miR-4500, miR-4782-3p, miR-497, miR-503, miR-512-3p, miR-520a-3p, miR-526b, miR-625*, and/or miR-96 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating lung cancer.
[00118] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for iet-7b, miR-101, miR125b, miR-1280, miR-143, miR-146a, miR-146b, miR-155, miR-17, miR-184, miR-185, miR18b, miR-193b, nuR-200c, miR-203, miR-204, miR-205, miR-206, miR-20a, miR-211, miR218, miR-26a, miR-31, miR-33a, miR-34a, miR-34c, miR-376a, miR-376c, miR-573, miR-7-5p, miR-9, and/or miR-98 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required
WO 2017/132552
PCT/US2017/015417 for viral replication. This oncolytic virus may be used in methods and compositions for treating melanoma.
[00119] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for let-7d, miR-218, miR34a, miR-375, miR-494, miR-100, miR-124, miR-1250, miR-125b, miR-126, miR-1271, miR136, miR-138, miR-145, miR-147, miR-148a, miR-181a, miR-206, miR-220a, miR-26a, miR26b, miR-29a, miR-32, miR-323-5p, miR-329, miR-338, miR-370, miR-410, miR-429, miR433, miR-499a-5p, miR-503, miR-506, miR-632, miR-646, miR-668, miR-877, and/or miR9inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating oral cancer.
[00120] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for let-7i, miR-100, miR124, miR-I25b, miR-129-5p, miR-130b, miR-133a, miR-137, miR-138, miR-141, miR-145, miR~148a, niiR-152, niiR-153, miR-155, niiR-199a, miR-200a, miR-200b, miR-200c, miR-212, miR-335, miR-34a, miR-34b, miR-34c, miR-409-3p, miR-411, miR-429, miR-432, miR-449a, nuR-494, miR-497, irtiR-498, miR-519d, miR-655, miR-9, miR-98, miR-101, miR-532-5p, irtiR124a, miR-192, miR-193a, and/or miR-7 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating ovarian cancer.
[00121] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-216a-5p, miR-802, miR-217, miR-145-3p, miR-143-3p, miR-451a, miR-375, miR-214-3p, miR-216b-3p, miR-4325p, miR-216a-3p, miR-199b-5p, miR-199a-5p, miR-136-3p, miR-216b-5p, miR-136-5p, miR145-5p, miR-127-3p, miR-199a-3p, miR-199b-3p, miR-559, miR-129-2-3p, miR-4507, miR-13p, miR-148a-3p, miR-101, miR-1181, miR-124, miR-1247, miR-133a, miR-141, miR-145, miR-146a, miR-148a, miR-148b, miR-150*, miR-150-5p, miR-152, miR-15a, miR-198, miR203, miR-214, miR-216a, miR-29c, miR-335, miR-34a, miR-34b, miR-34c, miR-373, miR-375, miR-410, miR-497, miR-615-5p, miR-630, miR-96, miR-132, let-7a, let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-l, let-7f-2, let-7g, Iet-7i, miR-126, miR-135a, miR-143, miR144, miR-150, miR-16, miR-200a, nuR-200b, miR-200c, miR-217, miR-218, miR-337, miR494, and/or miR-98 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for
WO 2017/132552
PCT/US2017/015417 viral replication. This oncolytic virus may be used in methods and compositions for treating pancreatic cancer.
[00122] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for let-7a-3p, let-7c, miR100, miR-101, miR-105, miR-124, miR-128, miR-1296, miR-130b, miR-Ι33a-l, miR-133a-2, miR-133b, miR-135a, miR-143, miR-145, miR-146a, miR-154, miR-15a, miR-187, miR-188-5p, miR-199b, nuR-200b, miR-203, miR-205, miR-212, miR-218, miR-221, miR-224, miR-23a, miR-23b, miR-25, miR-26a, miR-26b, miR-29b, miR-302a, miR-30a, miR-30b, miR-30c-l, miR-30c~2, miR-30d, miR-30e, miR-31, miR-330, miR~331~3p, miR-34a, miR~34b, miR-34e, miR~374b, miR-449a, miR-4723-5p, miR-497, miR-628-5p, miR-642a-5p, miR-765, and/or miR-940 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating prostate cancer.
[00123] In some embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences for miR-101, miR-183, miR-204, miR~34a, miR-365b-3p, miR-486-3p, and/or miR-532-5p inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication. This oncolytic virus may be used in methods and compositions for treating retinoblastoma.
[00124] In some embodiments, an oncolytic virus described herein is a herpes simplex virus and wherein the one or more viral genes required for viral replication is selected from the group consisting of UL1, UL5, UL6, UL7, UL8, UL9, UL11, UL12, UL14, UL15, UL17, UL18, UL19, 14.20. 14.22. UL25, UL26, UL26.5, UL27, UL28, UL29, UL30, 14.31. UL32, UL33, UL34, UL35, UL36, UL37, UL38, UL39, UL40, UL42, UL48, UL49, UL52, UL53, UL54, ICP0, ICP4, ICP22, ICP27, ICP47, gamma-34.5, USS, US4, US5, US6, US7, USS, US9, US 10, US11, and US 12.
[00125] In some cases, the recombinant viral vector of the invention is a herpes simplex virus (HSV) and further comprises a deletion of the internal repeat (joint) region comprising one copy each of the diploid genes ICP0, ICP34.5, LAT, and ICP4 along with the promoter for the ICP47 gene.
[00126] In certain embodiments, the recombinant viral vector of the invention is an HSV that exhibits enhanced entry into cells, either through direct infection and/or lateral spread.
WO 2017/132552
PCT/US2017/015417
In one aspect, HSV vectors of the present invention can directly infect cells through interaction with cell proteins other than typical mediators of HSV infection (e.g., other than neetin-1, HVEM, or heparan sulfate/chondroitin sulfate proteoglycans). In certain embodiments, the recombinant viral vector of the invention is an HSV and further comprises a mutation of the gB or gH gene that facilitates vector entry though non-canonical receptors. In another aspect, the invention provides an HSV vector further comprising mutant gH glycoproteins that exhibit lateral spread in cells typically resistant to HSV lateral spread, such as cells lacking gD receptors. In some embodiments, an HSV vector of the invention comprises one or more of the mutant gB or gH proteins as described in U.S. Patent Publication No. 2013/0096186, which is incorporated herein by reference in its entirety'. In certain aspects, the mutant entry protein within an HSV vector is a glycoprotein involved with viral entry, such as gB, gH, and the mutant HSV vector can comprise mutated versions of both. However, the mutant entry protein can be any protein effecting entry of the HSV vector into cells. In certain embodiments, the mutant entry' protein is other than gD, although the HSV vector can additionally comprise a mutant gD, such as containing a ligand or other desired mutation. Non-limiting mutations of gB or gH glycoprotein for use in the inventive HSV vector occur at one or more of the following residues: gB:D285, gB:A549, gB:S668, gH:N753, and gH:A778. In some embodiments, the inventive HSV vector comprises mutations at both gB:D285 and gB:A549, at both gH:N753 and gH: A778, and/or at each of gB:S668, gH:N753, and gH:A778. In certain embodiments, the HSV vector contains two or more of such mutations (e.g., 3 or more, 4 or more), and the HSV vector can comprise mutations in all five of these residues. In one embodiment, an HSV vector has mutations at gB:285, gB;549, gH:753, and gH:778. The mutations are referred to herein relative to the codon (amino acid) numbering of the gD, gB, and gH genes of the HSV-1 strain KOS derivative K26GFP. The sequences for gB and gH of K26GFP differ from the sequences for gB as disclosed in GenBank (#AF311740 (incorporated herein by reference)) and for gH (GenBank #X03896 (incorporated herein by reference)) as reflected in the following table:
Amino acid position | AF311740 | K26GFP | Nucleotide position(s) | AF311740 | K26GFP | |
gB | 313 | T | S | 938-939 | ACG | AGC |
315 | A | T | 943 | GCC | ACC | |
515 | H | R | 1,544 | CAC | CGC | |
X03896 ΧΌ3896 | ||||||
gH | 1 12, | I | L | 1,011 | ATT | CTT |
WO 2017/132552
PCT/US2017/015417
no | P | S | 1,305 | CCG | TCG | |
127 | T | I | 1,357 | ACC | ATC | |
138 | S | A | 1,389 | TCG | GCG | |
150 | A | T | 1,425 | GCC | ACC | |
532 | A | A | 2,573 | GCT | GCG | |
633 | R | R | 2,876 | CGT | CGC |
[00127] However, K26GFP may contain additional differences in the region of the gene corresponding to nucleotides 2,079-2,102 of GenBank X03896. Thus, it will be understood that the sequence of either KOS derivative K26GFP or GenBank Accession No. AF311740 can serve as a reference sequence for the gB mutations discussed herein. Also, the sequence of either KOS derivative K26GFP or GenBank Accession No. X03896 can serve as a reference sequence for the gH mutations discussed herein. However, HSV vectors of the invention may include homologous mutations in gB and gH of any HSV strain.
[00128] In some aspects, the mutation of the entry protein for inclusion in an HSV vector is a substitution mutation; however, mutations are not limited to substitution mutants. In certain embodiments, mutant gB or gH glycoproteins for use in an HSV vector are selected from the group of substitution mutations consisting of gB:D285N, gB:A549T, gB:S668N, gH:N753K, gH:A778V. In certain aspects, an HSV vector includes combinations of these substitutions (such as two or more of such substitutions (e.g., 3 or more, 4 or more, or all)), with the gB:D285N/'gB:A549T double mutant, the gH:N753K/gH:A778V double mutant, and the gB:S668N./gH:N753K/gH:A778V triple mutant being examples of embodiments. In one embodiment, an HSV vector comprises gB:D285N/gB:A549T/gH:N753K/gH:A778V.
[00129] In certain aspects, an HSV vector comprises a mutant gB and/or a mutant gH glycoprotein, wherein the mutations in the glycoproteins are substitution mutations in at least two residues, wherein, when the vector is HSV -1 K26GFP, the at least two residues are selected from the group consisting of gB:D285, gB:A549, gB:S668, gH:N753, and gH:A778, or wherein when the vector is a homologous HSV, the at least two residues are selected from amino acids that correlate to gB:D285, gB:A549, gB:S668, gH:N753, and gH:A778 wherein the gB:D285 residue correlates to X in VYPYXEFVL (SEQ ID NO: 1), the gB: A549 residue correlates to X in KLNPNXIAS (SEQ ID NO:2), the gB:S668 residue correlates to X in ITTVXTFID (SEQ ID NO:3) the gH:N753 residue correlates to X in VDTDXTQQQ (SEQ ID NO:4), and the gH: A778
WO 2017/132552
PCT/US2017/015417 residue correlates to X in VPSTXLLLF (SEQ ID NO: 5); and wherein the HSV vector is an HSV-1 or HSV-2 vector.
[00130] In one aspect, the invention encompasses a recombinant oncolytic virus comprising at least one polynucleotide encoding a protein or an oligonucleotide (e.g., an shRNA, a decoy oligonucleotide, or an antagomir) that reduces the expression or inhibits the function of an miRNA, a gene, or a tissue inhibitor of metalloproteinases (TIMP). Such recombinant oncolytic viruses are referred to herein as “genome-editing” or “microenvironment-remodeling” viruses or vectors. The encoded protein or oligonucleotide may reduce expression or inhibit the function of a miRNA, gene, or TEMP in any number of ways including targeting the protein (e.g., a TIMP) for degradation (e.g., by ubiquitination and proteosomal degradation or targeting for lysosomal degradation), blocking interactions with cognate receptors (e.g., blocking antibodies or antigen binding fragments thereof or peptide inhibitors), degrading messenger RNA transcripts (e.g., a short interfering RNA or short hairpin RNA), and/or altering the genomic DNA sequence encoding the specific miR, gene, or protein (e.g., by an endonuclease).
[00131] In particular embodiments, the protein or oligonucleotide reduces the expression of a miR or a gene involved in carcinogenesis or metastasis (e.g., an oncogenic miR or an oncogene). In some embodiments, a recombinant oncolytic virus comprises at least one polynucleotide encoding a protein or an oligonucleotide that reduces the expression or function of an miRNA that is an oncogenic miRNA (e.g., one or more of the miRNAs listed in Table 4). In some embodiments, the recombinant oncolytic virus comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polynucleotides encoding for a protein or oligonucleotide that reduces the expression or function of an oncogenic miRNA. In some embodiments, the recombinant oncolytic virus comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polynucleotides encoding for a plurality of proteins or oligonucleotides that reduce the expression or function of a plurality of oncogenic miRNAs. In some embodiments, the protein or oligonucleotide reduces the expression of miR17-92 and is used to treat lung cancer (e.g., small-cell lung cancer). In other embodiments, the protein or oligonucleotide reduces the expression of miR-221 and/or miR-21 and is used to treat glioblastoma. In certain embodiments, the protein or oligonucleotide reduces the expression of miR-155 and/or miR-17-92 and is used to treat lymphoma (e.g., Burkitt's lymphoma, diffuse large B cell lymphoma, marginal zone lymphoma, or chronic lymphocytic leukemia). In some embodiments, the protein or oligonucleotide reduces the expression of miR-221, miR-222,
WO 2017/132552
PCT/US2017/015417 and/or miR-146 and is used io treat thyroid cancer. In some embodiments, the protein or oligonucleotide reduces the expression of miR-372 and/or miR-373 and is used to treat testicular cancer (e.g., testicular germ cell tumors). In some embodiments, the protein or oligonucleotide reduces the expression of miR-18 and/or miR-224 and is used to treat liver cancer (e.g., hepatocellular carcinoma).
[00132] In some embodiments, a recombinant viral vector described herein may be used to degrade the tumor extracellular matrix (ECM), which in some aspects leads to enhanced viral spread. Matrix metalloproteinases (MMPs) are zinc-dependent proteases that are classified, based on their activity, into collagenases, gelatinases, stromelysins and matrilysins. These proteases are generally secreted as pro-enzymes (zymogens) and are activated by proteolytic removal of the pro-peptide pro-domain. The primary role that MMPs play in cancer is in the degradation of the ECM, which facilitates tumor invasion and metastasis. MMPs are also involved in tumor progression, epithelial to mesenchymal transition (EMT), and angiogenesis. MMPs are regulated by miRNAs as well as TEMPs, which comprise a family of four protease inhibitors (TEMPI, TIMP2, TEMP3, and TIMP4). A broad array of tumor microenvironments can be degraded by disrupting miRNAs or TEMPs that negatively regulate the MMP family with the recombinant viral vectors of the invention. Examples of miRNA/MMP interactions are shown in Table 5. Many of these interactions show that multiple MMPs are regulated by a single miRNA: e.g. let-7 regulates MMP-2, MMP-9, and MMP-14; nuR-143 regulates MMP-2, MMP-9, and MMP-13; miR-218 regulates MMP-2, MMP-7, and MMP-9. Furthermore, the vast majority of MMPs may be regulated by a single TIMP master switch: e.g. TIMP1 is known to inhibit most all of the known MMPs and also promotes cell proliferation in a wade range of cell types; TIMP2 interacts with MMP-14 and MMP-2.
[00133] In some embodiments, a recombinant oncolytic virus comprises at least one polynucleotide encoding a protein or an oligonucleotide that reduces the expression or function of an miRNA that is a microenvironment remodeling miRNA (e.g., one or more of the miRNAs listed in Table 5). In some embodiments, the protein or oligonucleotide reduces the expression or function of one microenvironment remodeling miRNA. In some embodiments, the protein or oligonucleotide reduces the expression or function of at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more microenvironment remodeling miRNAs. In some embodiments, the recombinant oncolytic virus comprises a plurality of polynucleotides encoding a plurality of protein or
WO 2017/132552
PCT/US2017/015417 oligonucleotides that reduce the expression or function of a plurality of microenvironment remodeling miRNAs. In some embodiments, strategies described herein may be utilized by recombinant viral vectors of the present invention to knockdown or disrupt expression or function of miRNAs or TIMPs winch negatively regulate MMPs. In some embodiments, a recombinant oncolytic virus reduces the expression of a TIMP selected from TIMP1, ΊΊΜΡ2, ΊΊΜΡ3 and TIMP4.
[00134] In some embodiments, the recombinant oncolytic viruses described herein comprise at least one polynucleotide encoding a protein or an oligonucleotide that reduces the expression or function of a gene. In some aspects, the gene is an oncogenic gene (e.g., a gene selected from the genes listed in Table 7). In some aspects, the gene encodes an oncogenic miR (e.g., a miRNA listed in Table 4), a microenvironment remodeling miR (e.g., a miRNA listed in Table 5), or a negative regulator of ECM-degradation (e.g., a TIMP). Reduction of gene expression and/or function may be accomplished by at the level of transcription (e.g., mutating, deleting, or silencing the genomic DNA sequence) or at the level of translation (e.g., by inhibiting the production of the gene product through mRNA degradation). In some embodiments, the recombinant oncolytic viruses described herein comprise one or more polynucleotides that encode for nucleases that reduce the expression or function of a gene by enabling the mutation, deletion, or repression of transcription of a gene sequence. In specific embodiments, the nuclease is selected from a Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR)-associated endonuclease, a zinc-finger nuclease (ZFN) or a Transcription activator-like effector nuclease (TALEN). In non-limiting examples, a CRISPRassociated endonuclease is selected from SpCas9, SpCas9-HFl, SpCas9-HF2, SpCas9-HF3, SpCas9-HF4, SaCas9, FnCpf, FnCas9, eSpCas9, C2C1, C2C3, Cpfl, Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), CaslO, Csyl, Csv2, Csy3, Csel, Cse2, Csel, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Crnrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbi, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, and Csf4.
[00135] Recombinant viral vectors of the invention may utilize the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas (CRISPR Associated) nuclease system, winch is an engineered nuclease system based on a bacterial system that can be used for mammalian genome engineering. Generally, the system comprises a Cas nuclease and a guide
WO 2017/132552
PCT/US2017/015417
RNA (gRNA). The gRNA is comprised of two parts; a crispr-RNA (crRNA) that is specific for a target genomic DNA sequence, and a tracr RNA (trRNA) that facilitates Cas binding. The crRNA and trRNA may be present as separate RNA oligonucleotides, or may be present in the same RNA oligonucleotide, referred to as a single guide-RNA (sgRNA). As used herein, the term “guide RN A” or “gRNA” refers to either the combination of an individual trRN A and an individual crRNA or an sgRNA. See, e.g., Jinek et ai. (2012) Science 337:816-821; Cong et ai. (2013) Science 339:819-823; Mali et ai. (2013) Science 339:823-826; Qi et ai. (2013) Cell 152:1173-1183; Jinek et ai. (2013), eLife 2:e00471; David Segal (2013) eLife 2:e00563; Ran et ai. (2013) Nature Protocols 8(11):2281-2308; Zetsche et al. (2015) Cell. 163(3):759-771; PCT Publication Nos. WO 2007/025097, WO 2008/021207, WO 2010/011961, WO 2010/054108, WO 2010/054154, WO 2012/054726, WO 2012/149470, WO 2012/164565, WO 2013/098244, WO 2013/126794, WO 2013/141680, and WO 2013/142578; U.S. Patent Publication Nos. 20100093617, 2013-0011828, 2010-0257638, 2010-0076057, 2011-0217739, 2011-0300538, 20130288251, and 2012-0277120; and U.S. Patent No. 8,546,553, each of which is incorporated herein by reference in its entirety.
[00136] Multiple class 1 CRISPR-Cas systems, which include the type I and type III systems, have been identified and functionally characterized in detail, revealing the complex architecture and dynamics of the effector complexes (Brouns et ai., 2008, Marraffmi and Sontheimer, 2008, Hale et al., 2009, Sinkunas et ai., 2013, Jackson et ai., 2014, Mulepati et ai., 2014). In addition, several class 2-type II CRISPR-Cas systems that employ homologous RNAguided endonucleases of the Cas9 family as effectors have also been identified and experimentally characterized (Barrangou et al., 2007, Garneau et ai., 2010, Deitcheva et ai., 2011, Sapranauskas et al., 2011, Jinek et ai., 2012, Gasiunas et al., 2012). A second, putative class 2-type V CRISPR-Cas system has been recently identified in several bacterial genomes. The putative type V CRISPR-Cas systems contain a large, -1,300 ammo acid protein called Cpfl (CRISPR from Prevotella and Francisella 1).
[00137] In some embodiments, an oncolytic virus described herein further comprises at least one polynucleotide encoding a trRNA and crRNA targeted to the miRNA or the TIMP. In some cases, the at least one polynucleotide encoding a trRNA and crRNA is inserted into a locus on the viral genome. In some embodiments, the polynucleotide is an insulated sequence comprising a synthetic insulator or a native viral (e.g., HSV) insulator. In
WO 2017/132552
PCT/US2017/015417 certain embodiments, an oncolytic virus is a herpes simplex virus and the at least one polynucleotide encoding an RNA binding site is inserted into or between one or more loci including the internal repeat joint region (comprising one copy each of the diploid genes ICPO, ICP34.5, LAT, ICP4, and the ICP47 promoter), ICPO, LAT, UL1, UL5, UL6, UL7, UL8, LI.9. 14. H. 144 2. 144-4. UL15, UL17, UL18, 144 9. UL20, UL22, UL25, UL26, UL26.5, UL27, 14.28. 14.29. 14..30. UL31, UL32, 14.33. UL34, 1.4.35. 14.36. 1.4..37. 14.38. 14.39. 1.4.40. UL42, UL48, UL49, UL52,14 A3. UL54, ICPO, ICP4, ICP22, ICP27, ICP47, gamma-34.5, US3, US4, US5, US6, US7, US8, US9, US10, US11, and US12. In one embodiment, an oncolytic virus is a herpes simplex virus (HSV) and the at least one polynucleotide encoding an RNA binding site is inserted into a locus between the UL3 and the UL4 open reading frames (e.g., FIG. 45 and FIG. 46).
[00138] In some embodiments, the recombinant oncolytic virus comprises at least one polynucleotide encoding a protein that is a bispecific T-cell engager (BiTE), an antiimmunosuppressive protein, or an immunogenic antigen. As used herein an “antiimmunosuppressive protein” is a protein that inhibits an immunosuppressive pathway. The invention encompasses an oncolytic virus expressing an anti-immunosuppressive protein that is an anti-regulatory T-cell (Treg) protein or an anti-myeloid-derived suppressor cell (MDSC) protein. In some embodiments, the anti-immunosuppressive protein is a VFIH-derived blocker or a VHH-derived BiTE. As used herein, an “immunogenic antigen” refers to a protein that increases an inflammatory or immunogenic immune response. In particular embodiments, the anti-immunosuppressive and immunogenic antigens induce an anti-tumor immune response. Examples of such proteins include antibody or antigen binding fragments thereof that bind to and inhibit immune checkpoint receptors (e.g. CTLA4, LAGS, PD1, PDL1, and others), proinflammatory cytokines (e.g., IFNy, IFNa, ΙΡΝβ, TNFa, IL-12, IL-2, IL-6, IL-8, GM-CSF, and others), or proteins that binding to and activate an activating receptor (e.g., FcyRI, Fcylla, Fcyllla, costimulatory receptors, and others). In particular embodiments, the protein is selected from EpCAM, folate, ΙΡΝβ, anti-CTLA-4, anti-PDl, A2A, anti-FGF2, anti-FGFRzFGFR2b, antiSEMA4D, CCL5, CD137, CD200, CD38, CD44, CSF-1R, CXCL10, CXCL13, endothelin B Receptor, IL-12, IL-15, IL-2, IL-21, IL-35, ISRE7, LFA-1, NG2 (also known as SPEG4), SMADs. STING, f'GFp. and VCAM1.
WO 2017/132552
PCT/US2017/015417 [00139] In certain embodiments, a polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of an miRNA, a gene, or a TIMP is inserted into a locus on the viral genome of a recombinant oncolytic virus. In some embodiments, the polynucleotide is an insulated sequence comprising a synthetic insulator or a native viral (e.g., HSV) insulator. In certain embodiments, the oncolytic virus is a herpes simplex virus and the at least one polynucleotide encoding an RNA binding site is inserted into or between one or more loci including the internal repeat joint region (comprising one copy each of the diploid genes ICPO, ICP34.5, LAT, ICP4, and the ICP47 promoter), ICPO, LAT, UL1, UL5, L4.6. UL7, UL8, I.':/).. ULll, 1..142.. 14 4 4. 144 5. 1..14 7. 144 8. 144 9. 14.20. 1.1.2.2.. 14.2V 1.4.26. 1.1.2.6.5. UI.,27, UL28, TJL29, UL30, UL31, UL32, UL33, UI.,34, UL35, UL36, UL37, UL38, UL39, UL40, UL42, UL48, UL49, UL52, UL53, UL54, ICPO, ICP4, ICP22, ICP27, ICP47, gamma34.5, US3, US4, US5, US6, US7, USS, US9, US 10, US11, and US12.. In one embodiment, the virus is a herpes simplex virus (HSV) and the at least one polynucleotide is inserted into a locus between the UL3 and the UL4 open reading frames (see, e.g., FIG. 45 and FIG. 46).
[00140] In some embodiments, the recombinant oncolytic virus comprises at least one protease-activated antibody. Protease-activated antibodies, such as those described by Metz et al, (Protein Eng Des Sel, 25(10):571-80, 2012) are activated and bind only to targets following protease cleavage of a protective cap. In some instances, tumor microenvironments possess an array of proteases that are well differentiated from surrounding healthy tissues. For example, the protease cathepsin B is overexpressed in numerous cancers, including breast, cervix, colon, colorectal, gastric, head and neck, liver, lung, melanoma, ovarian, pancreatic, prostate, and thyroid cancer. The human degradome, comprised of a complete list of proteases synthesized by human cells, is made up of at least 569 proteases that are distributed into five broad classes (in order from greatest to least number): metalloproteinases (MMPs), serine, cysteine, threonine, and aspartic proteases (Lopez-Otin et al., Nat Rev Cancer, 7(10):800-8, 2007). In particular, protease antibodies specifically cleaved by MMPs can serve as an excellent means of targeting the recombinant viral vectors described herein to the tumor microenvironment, as MMPs are found in the extracellular and pericellular areas of the ceil. Table 6 summarizes proteases that are overexpressed in cancers which can be exploited to enable specific binding of recombinant viral vectors pseudotyped with protease-activated antibodies.
WO 2017/132552
PCT/US2017/015417 [00141] In certain embodiments, the protease-activated antibody is incorporated into the viral glycoprotein envelope. Protease-activated antibodies can be incorporated into the glycoprotein envelope of a recombinant viral vector of the invention (e.g., an HSV vector) to increase the therapeutic index and reduce off-target infection. In the case of an HSV vector, in some embodiments, the glycoprotein may be gC or gD. In some embodiments, the recombinant oncolytic viruses described herein comprise at least one polynucleotide encoding a proteaseactivated antibody. In certain embodiments, a protease-activated antibody is activated by a protease selected from a cysteine cathepsin, an aspartic cathepsm, a kallikrein (hK), a serine protease, a caspase, a matrix metalloproteinase (MMP), and a disintegrin and metalloproteinase (ADAM). In some embodiments, a protease is selected from cathepsin K, cathepsin B, cathepsin L, cathepsin E, cathepsin D, hKI, PSA (hK3), hKIO, hKI 5, uPA, uPAR, MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10. MMP-11, MMP-12, MMP-13. MMP-14, MMP15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20, MMP-2I, Μ.ΜΡ-23Λ. MMP-23B, MMP24, MMP-25, MMP-26, MMP-27, MMP-28, or a protease listed in Table 6.
[00142] In some embodiments, the protease-activated antibody binds a protein expressed more highly by cancer cells or in cancer microenvironments than by non-cancer cells or in non-cancer microenvironments. In certain aspects, a protease-activated antibody binds NKG2D, c-met, HGFR, CDS, heparan sulfate, VSPG4 (also known as NG2), EGFR, EGFRvIII, CD133, CXCR4, carcinoembryonic antigen (CEA), CLC-3, annexin II, human transferrin receptor, or EpCAM. In certain instances, multiple protease activated antibodies may be incorporated into a single viral vector particle to ensure that diverse tumor histotypes are targeted. For example, at least 1, 2, 3, 4, 6, 7, 8, 9, 10, or more protease activated antibodies may be incorporated into the viral glycoprotein envelope. In some embodiments, the recombinant oncolytic virus comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more polynucleotides that encodes for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more protease activated antibodies. In some embodiments, an oncolytic virus comprises a first protease-activated antibody that binds a first protein expressed more highly by cancer cells or in cancer microenvironments than by noncancer cells or in non-cancer microenvironments, and a second protease-activated antibody that binds a second protein expressed more highly by cancer ceils or in cancer microenvironments than by non-cancer cells or in non-cancer microenvironments. In further embodiments, an oncolytic virus comprises a plurality' of protease-activated antibodies binding a plurality of
WO 2017/132552
PCT/US2017/015417 protein expressed more highly hy cancer cells or in cancer microenvironments than by noncancer cells or in non-cancer microenvironments. An oncolytic virus comprises, for example, a protease-activated antibody that is a human antibody, a humanized antibody or a chimeric antibody. In some embodiments, an oncolytic virus comprises an antibody that is a full-length immunoglobulin, an scFv, a Fab, a Fab', an F(ab')2, an Fv, a diabody, a triabody, a minibody, a single-domain antibody, or a multispecific antibody.
[00143] In some embodiments, a recombinant oncolytic virus comprises one or more of: one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication; one or more polynucleotides encoding one or more proteins or oligonucleotides, wherein the proteins or oligonucleotides reduce the expression or inhibit the function of a miR, a gene, or a TIMP; at least one protease-activated antibody; and/or a polynucleotide encoding at least one protease activated antibody. In some embodiments, a recombinant oncolytic virus comprises: a plurality of copies of one or more tumor-suppressive miRNA target sequences inserted into a locus of a viral gene required for viral replication in non-cancerous cells; and/or a first polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of an oncogenic miRNA or an oncogenic gene; and/or a second polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of a microenvironment remodeling miRNA or a TIMP. In some embodiments, a recombinant oncolytic virus comprises: a plurality of copies of one or more tumor-suppressive miRN A target sequences inserted into a locus of a viral gene required for viral replication in noncancerous cells; and/or a polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of an oncogenic miRNA or an oncogenic gene; and/or at least one proteaseactivated antibody. In further embodiments, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences inserted into a locus of a viral gene required for viral replication in non-cancerous cells; and/or a polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of a microenvironment remodeling miRNA or a TIMP; and/or at least one protease-activated antibody. In one embodiment, a recombinant oncolytic virus comprises a plurality of copies of one or more tumor-suppressive miRNA target sequences inserted into a locus of a viral gene required for viral replication in noncancerous cells; and/or a first polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of an oncogenic miRNA or an oncogenic gene; and/or a second
WO 2017/132552
PCT/US2017/015417 polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of a microenvironment remodeling miRNA or a TIMP; and/or at least one protease-activated antibody. In some specific embodiments, an oncolytic virus described in this paragraph is a herpes simplex virus and the viral gene required for viral replication in non-cancerous cells is 144. (.4..5. 1.1.6. UL7, (..1.8. til.9. UL11, (.1.12.. UL14, (..1.15. 14.17. (.4.4 8. (.1.19. 14.20. UL22, UL25, UL26, UL26.5, 14.27. UL28, 14..29. UL30, UL31, UL32, UL33, UL34, UL35, 14.36. (4.37. (.4.38. 14.39. 14.40. UL42, 14.48. 14.49. (4.52. [4..53. UL54, ICPO, ICP4, ICP22, ICP27, ICP47, gamma-34.5, US3, US4, USS, US6, US7, USS, US9, US10, US11, and US 12.
[00144] In certain aspects, the invention relates to a recombinant oncolytic virus comprising a first polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of an oncogenic miRNA or an oncogenic gene; and a second polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of a microenvironment remodeling miRNA or a TIMP. In other embodiments, a recombinant oncolytic virus comprises a polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of an oncogenic miRNA or an oncogenic gene; and at least one protease-activated antibody. In some embodiments, a recombinant oncolytic virus comprises a polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of a microenvironment remodeling miRNA or a ΉΜΡ; and at least one protease-activated antibody. In one embodiment, a recombinant oncolytic virus comprises a first polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of an oncogenic miRNA or an oncogenic gene; and/or a second polynucleotide encoding a protein or an oligonucleotide targeted to reduce expression of a microenvironment remodeling miRNA or a TIMP; and/or at least one protease-activated antibody.
[00145] In certain embodiments, an oncolytic virus described herein is a herpesvirus (for example, herpes simplex virus (e.g., HSV-1 or HSV-2)), an adenovirus, a polio virus, a vaccinia virus, a measles virus, a vesicular stomatitis virus, an orthomyxovirus, a parvovirus, a maraba virus or a coxsackievirus. HSV-based vectors and methods for their construction are described in, for example, U.S. Pat. Nos. 7,078,029, 6,261,552, 5,998,174, 5,879,934, 5,849,572, 5,849,571, 5,837,532, 5,804,413, and 5,658,724, and International Patent Applications WO 91/02788, WO 96/04394, WO 98/15637, and WO 99/06583, which are
WO 2017/132552
PCT/US2017/015417 incorporated herein by reference in their entireties. The sequence of HSV is published (NCBI
Accession No. NU 001806; see also McGoech et al., J. Gen. Virol, 69 (PT 7), 1531-1574 (1988)), which may facilitate designing HSV-based vectors of the invention.
[00146] The invention also encompasses a nucleic acid molecule encoding an oncolytic virus described herein.
Compositions and Methods of Use [00147] Certain aspects of the invention relate to stocks and compositions comprising the oncolytic viruses described herein. In some aspects, the invention relates to a viral stock comprising an oncolytic virus described herein. In some embodiments, a viral stock is a homogeneous stock. The preparation and analysis of viral stocks is well known in the art. For example, a viral stock can be manufactured in roller bottles containing cells transduced with the viral vector. The viral stock can then be purified on a continuous nycodenze gradient, and aliquotted and stored until needed. Viral stocks vary considerably in titer, depending largely on viral genotype and the protocol and cell lines used to prepare them.
[00148] In particular embodiments, the titer of a viral stock (e.g., an HSV-based vector viral stock) contemplated herein is at least about 105 plaque-forming units (pfu), such as at least about 106 pfu or even more preferably at least about 107 pfu. In certain embodiments, the titer can be at least about 10’ pfu, or at least about ICT pfu, and high titer stocks of at least about 1010 pfu or at least about 1011 pfu are most preferred.
[00149] The invention further contemplates a composition comprising an oncolytic virus or a nucleic acid molecule described herein and a pharmaceutically acceptable carrier. The phrase “pharmaceutically-acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a subject (e.g., a human). The term “composition” as used herein refers to a formulation of one or more oncolytic virus or a nucleic acid molecules described herein that is capable of being administered or delivered to a subject and/or a cell. Typically, formulations include all physiologically acceptable compositions including derivatives and/or prodrugs, solvates, stereoisomers, racemates, or tautomers thereof with any physiologically acceptable carriers, diluents, and/or excipients. A “therapeutic composition” or “pharmaceutical composition” (used interchangeably herein) is a composition of
WO 2017/132552
PCT/US2017/015417 one or more agents capable of is capable of being administered or delivered to a patient and/or subject and/or cell for the treatment of a particular disease or disorder.
[00150] The compositions disclosed herein may be formulated in a neutral or salt form. “Pharmaceutically acceptable salt” includes both acid and base addition salts. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, eaprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hy dr oxy ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid,ptoluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived from organic bases include, hut are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, /V-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine,
WO 2017/132552
PCT/US2017/015417 dicyclohexylamine, choline and caffeine. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.
[00151] As used herein, “carrier” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is web known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
[00152] As used herein “pharmaceutically acceptable carrier” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible, including pharmaceutically acceptable cell culture media and/or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans and/or domestic animals. Exemplary pharmaceutically acceptable carriers include, but are not limited to, to sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffins, silicones, bentonites, silicic acid, zinc oxide; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and any other compatible substances employed in pharmaceutical formulations. Except insofar as any conventional media and/or agent is incompatible with the agents of the present disclosure, its use in therapeutic
WO 2017/132552
PCT/US2017/015417 compositions is contemplated. Supplementary active ingredients also can be incorporated into the compositions.
[00153] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[00154] Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[00155] In one embodiment, a composition comprising a carrier is suitable for parenteral administration, e.g., intravascular (intravenous or intraarterial), intraperitoneal or intramuscular administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with a viral vector or nucleic acid molecule, use thereof in the pharmaceutical composi tions of the invention is contemplated.
[00156] The compositions of the invention may comprise one or more polypeptides, polynucleotides, vectors comprising same, infected cells, etc., as described herein, formulated in pharmaceutically-acceptable or physiologically-acceptable solutions for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy. It will also be understood that, if desired, the compositions of the invention may be administered in combination with other agents as well, such as, e.g., cytokines, growth factors, hormones, small molecules or various pharma ceutically-active agents. There is virtually no limit to other components that may also be included in the compositions, provided that the additional agents do not adversely affect the ability of the composition to deliver the intended therapy.
WO 2017/132552
PCT/US2017/015417 [00157] In the pharmaceutical compositions of the invention, formulation of pharmaceutically-acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens. Upon formulation, solutions are administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective to result in an improvement or remediation of the symptoms. The formulations are easily administered in a variety of dosage forms such as ingestible solutions, drug release capsules and the like. Some variation in dosage can occur depending on the condition of the subject being treated. The person responsible for administration can, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations meet sterility, general safety and purity' standards as required by FDA Center for Biologies Evaluation and Research standards. The route of administration will vary, naturally, with the location and nature of the disease being treated, and may include, for example intradermal, transdermal, subdermal, parenteral, nasal, intravenous, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intratumoral, perfusion, lavage, direct injection, and oral administration.
[00158] In certain circumstances it will be desirable to deliver the compositions, recombinant viral vectors, and nucleic acid molecules disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally as described, for example, in U.S. Patent No. 5,543,158; U.S. Patent No. 5,641,515 and U.S. Patent No. 5,399,363 (each specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypiOpylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[00159] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Pat. No. 5,466,468, specifically incorporated herein by reference in its entirety). In all cases the form should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture
WO 2017/132552
PCT/US2017/015417 and storage and should be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabenes, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.
[00160] For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermociysis fluid or injected at the proposed site of infusion (see, e.g., Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, MD: Lippincott Williams & Wilkins, 2000). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and the general safety and purity standards as required by FDA Office of Biologies standards.
[66161] Sterile injectable solutions can be prepared by incorporating the active compounds in the required amount in the appropriate solvent with the various other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are
WO 2017/132552
PCT/US2017/015417 prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterilefiltered solution thereof.
[001 62] In certain embodiments, the compositions may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering polynucleotides and peptide compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat No. 5,756,353 and U.S. Pat. No. 5,804,212 (each specifically incorporated herein by reference in its entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts. Likewise, transmucosal drug delivery in the form of a polytetrafluoroetheylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety).
[00163] In certain embodiments, the deliver)/ may occur by use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, optionally mixing with CPP polypeptides, and the like, for the introduction of the compositions of the present invention into suitable host cells. In particular, the compositions of the present invention may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, a nanoparticle or the like. The formulation and use of such delivery vehicles can be carried out using known and conventional techniques. The formulations and compositions of the invention may comprise one or more polypeptides, polynucleotides, and small molecules, as described herein, formulated in pharmaceutically-acceptable or physiologically-acceptable solutions (e.g., culture medium) for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy. It will also be understood that, if desired, the compositions of the invention may be administered in combination with other agents as well, such as, e.g., cells, other proteins or polypeptides or various pharmaceutically-active agents.
WO 2017/132552
PCT/US2017/015417 [00164] In a particular embodiment, a formulation or composition according to the present invention comprises a cell contacted with a combination of any number of polynucleotides or viral vectors, as contemplated herein.
[00165] In certain aspects, the present invention provides formulations or compositions suitable for the delivery of viral vector systems.
[00166] Exemplary formulations for ex vivo delivery may also include the use of various transfection agents known in the art, such as calcium phosphate, electroporation, heat shock and various liposome formulations (/. e., iipid-mediated transfection). Liposomes are lipid bilayers entrapping a fraction of aqueous fluid. DNA spontaneously associates to the external surface of cationic liposomes (by virtue of its charge) and these liposomes will interact with the cell membrane.
[00167] Particular embodiments of the invention may comprise other formulations, such as those that are well known in the pharmaceutical art, and are described, for example, in Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, AID: Lippincott Williams & Wilkins, 2000, [00168] In certain aspects, the present invention provides pharmaceutically acceptable compositions which comprise a therapeutically effective amount of one or more viral vectors or polynucleotides, as described herein, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents (e.g., pharmaceutically acceptable cell culture medium). .As used herein, a “therapeutically effective amount” refers to the amount of a composition or recombinant virus described herein required to achieve a desired physiologic and/or biological outcome. A “therapeutically effective amount” of a virus, a viral stock, or a composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the stem and progenitor cells to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the virus or transduced therapeutic cells are outweighed by the therapeutically beneficial effects. The term “therapeutically effective amount” includes an amount that is effective to “treat” a subject (e.g., a patient). The therapeutically effective amount may be quantified by the total number of plaque forming units (pfu) (e.g. at least le1 to at least le20, particularly about le“ to about le15, more particularly about le6 to about le*2 pfu), or number of viral genomes (e.g. at least le1 to at least le20, particularly about le4 to about Ie15,
WO 2017/132552
PCT/US2017/015417 more particularly about le° to about le12 viral genomes). One of skill in the art will understand that the therapeutically effective amount will vary based on the type of virus being administered, nature of the formulation, route of administration, nature and/or severity of the disease to be treated, and/or general health and well-being of the subject.
[00169] Some aspects of the invention encompass a method of killing a cancerous ceil, comprising exposing the cancerous cell to an oncolytic virus described herein or compositions thereof under conditions sufficient for the oncolytic virus to infect and replicate within said cancerous cell, and wherein replication of the oncolytic virus within the cancerous cell results in cell death. In certain embodiments, the cancerous cell has a reduced expression of a tumor-suppressive miR compared to a non-cancerous cell. In some embodiments, a cancerous cell killed by this method is in vivo. In certain embodiments, a cancerous cell killed by this method is within a tumor.
[00170] The invention relates to a method of treating cancer in a subject in need thereof, comprising administering a prophylactically effective amount or a therapeutically effective amount of an oncolytic virus, a viral stock, or a composition as described herein to the subject. A “subject,” as used herein, includes any animal that exhibits a symptom of a disease, disorder, or condition that can be treated with the recombinant viral vectors, compositions, and methods disclosed herein. Suitable subjects (e.g,, patients) include laboratory animals (such as mouse, rat, rabbit, or guinea pig), farm animals (such as horse or cow), and domestic animals or pets (such as cat or dog). Non-human primates and, preferably, human patients, are included.
[00171] “Administration” refers herein to introducing an oncolytic virus, a viral stock, or a composition thereof into a subject or contacting an oncolytic virus, a viral stock, or a composition thereof with a cell and/or tissue. Administration can occur by injection, irrigation, inhalation, consumption, electro-osmosis, hemodialysis, iontophoresis, and other methods known in the art. The route of administration will vary, naturally, with the location and nature of the disease being treated, and may include, for example auricular, buccal, conjunctival, cutaneous, dental, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-articular, intra-arterial, intra-abdominal, intraauricular, intrabiliary, intrabronchial, intrabursal, intracavernous, intracerebral, intracisternal, intracorneal, intracronal, intracoronary, intracranial, intradermal, intradiscal, intraductal, intraduodenal, intraduodenal, intradural, intraepicardial, intraepidermal, intraesophageal, intragastric, intragingival, intrahepatic, intraileal, intralesional,
WO 2017/132552
PCT/US2017/015417 intralingual, intraluminal, intralymphatic, intramammary, intramedulleray, intrameningeal, instramuscular, intranasal, intranodal, intraocular, intraomentum, intraovarian, intraperitoneal, intrapericardial, intrapleural, intraprostatic, intrapulmonary, intraruminal, intrasinal, intraspinal, intrasynovial, intratendinous, intratesticular, intratracheal, intrathecal, intrathoracic, intratubular, intratumoral, intratympanic, intrauterine, intraperitoneal, intravascular, intraventricular, intravesical, intravestibular, intravenous, intravitreal, larangeal, nasal, nasogastric, oral, ophthalmic, oropharyngeal, parenteral, percutaneous, periarticular, peridural, perineural, periodontal, respirator)', retrotubular, rectal, spinal, subarachnoid, subconjunctival, subcutaneous, subdermal, subgingival, sublingual, submucosal, subretinal, topical, transdermal, transendocardial, transmucosal, transplacental, trantracheal, transtympanic, ureteral, urethral, and/or vaginal perfusion, lavage, direct injection, and oral administration.
[00172] The term treating and treatment as used herein refers to administering to a subject a therapeutically effective amount of a recombinant virus or composition thereof as described herein so that the subject has an improvement in a disease or condition, or a symptom of the disease or condition. The improvement is any improvement or remediation of the disease or condition, or symptom of the disease or condition. The improvement is an observable or measurable improvement, or may be an improvement in the general feeling of well-being of the subject. Thus, one of skill in the art realizes that a treatment may improve the disease condition, but may not be a complete cure for the disease. A “prophylactically effective amount” refers to an amount of a virus, a viral stock, or a composition effective to achieve the desired prophylactic result. As used herein, prophylaxis can mean complete prevention of the symptoms of a disease, a delay in onset of the symptoms of a disease, or a lessening in the seventy of subsequently developed disease symptoms. Typically, but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount is less than the therapeutically effective amount.
[00173] Cancer herein refers to or describes the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma (including iiposarcoma, osteogenic sarcoma, angiosarcoma, endotheliosarcoma, leiomyosarcoma, chordoma, lymphangiosarcoma, lymphangioendotheiiosarcoma, rhabdomyosarcoma, fibrosarcoma, myxosarcoma, chondrosarcoma), neuroendocrine tumors, mesothelioma, synovioma,
WO 2017/132552
PCT/US2017/015417 schwannoma, meningioma, adenocarcinoma, melanoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g. epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, small cell lung carcinoma, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary’ gland carcinoma, kidney or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, tumors of the biliary tract, Ewing's tumor, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal ceil carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumor, lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, leukemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, myelodysplastic disease, heavy chain disease, neuroendocrine tumors, Schwannoma, and other carcinomas, as well as head and neck cancer.
[00174] In certain embodiments, an oncolytic virus (e.g., an HSV), a viral stock, or a composition as described herein are used to treat a cancer selected from lung cancer (e.g., small cell lung cancer or non-small cell lung cancer), breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma (HCC)), gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL).
[00175] In certain aspects, the invention relates to an oncolytic viral vector as shown in any one of the figures or embodiments disclosed herein.
WO 2017/132552
PCT/US2017/015417 [00176] The following examples for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. The present examples, along with the methods described herein, are exemplary7, and are not intended as limitations on the scope of the invention. Alterations, modifications, and other changes to the described embodiments which are encompassed within the spirit of the invention as defined by the scope of the claims are specifically7 contemplated.
[00177] Differential miR expression is a hallmark of many cancers (Lu et al. Nature, 2005). Experiments were performed to determine the miRs that were mostly highly differentially7 expressed in eight different cancer cells lines. Differential expression was determined by comparisons to non-cancerous control tissues. In total, 108 samples were sequenced. Sample details are provided in the following table.
Cancer Type | # of Cancer Cell Lines | # of Control Tissue Samples |
Bladder | 8 | 4 |
Colon | 8 | 3 |
Breast | 12 | 4 |
Pancreatic | ‘I I | 3 |
Lung | 8 | 5 |
Head and N eck | 6 | 6 |
Schwannoma | 7 | 4* |
Glioblastoma | 14 | 4* |
Additional Controls | ||
Normal Liver | '7 | |
Normal Bone Marrow | J |
*Same control samples used for both Schwannoma and glioblastoma analysis [00178] To facilitate the identification of appropriate miRNA target sequences suitable for HSV attenuation in select cell types, miRNA sequence profiling of cancer lines and non-cancer control tissue was performed. Sequencing libraries of dicer-processed RNAs were generated for cancer and non-cancer cells, including bladder, colon, breast, pancreas, lung, head and neck, schwannoma, glioblastoma, brain, liver, and bone marrow. These miRNA sequencing libraries were normalized to total RNA, and sequenced using a HiSeq 2500 ultra-high throughput sequencing system with HiSeq V4 chemistry reagents for sequencing reads up to 3e8 reads/run (Illumina). FASTQ files from sequencing runs were analyzed using the miRNAs Analysis tool in Basespace (Illumina). Rankings were made by calculating the mean of normal, the mean of
WO 2017/132552
PCT/US2017/015417 cancer and sorting the ratio of normal/'cancer from high to low. Heat maps were generated with natural logarithmic values with zero and negative values converted to zero (scale: black is high, white is low expression). Normalized data across samples were expressed as normalized miRNA read counts in a given sample. Normalization is related to total number of reads in a given sample relative to other samples in the comparison.
[00179] FIG. 1 exemplifies the miRNA expression profile heat map in noncancerous and cancerous brain tissue of twenty-five miRNAs. Additional examples of miRNA expression profile heat maps are shown for non-cancerous and cancerous bladder (FIG. 2), breast (FIG. 3), colon (FIG. 4), brain (FIG. 5), head and neck (FIG. 6), lung (FIG. 7), pancreas (FIG. 8), and schwannoma (FIG. 9) tissue corresponding to twenty-five miRNAs in each example. FIG. 10 shows that miR-45Ia levels are down regulated in all tumor types compared to non-cancerous tissue, representing a pan-tumor suppressor miRNA. FIG. 11 shows that miR-1 is downregulated in all tumor types tested, present at moderate levels m non-cancerous tissue, and present at high levels in head and neck tissue. FIG. 12 shows that miR-559 is down-regulated in all tumor types tested, present generally at low levels in non-cancerous tissue, and present at high levels in non-cancerous lung tissue, FIG. 13 shows that miR-145-5p is down-regulated in ail tumor types tested and present generally at high levels in the majority of non-cancerous tissue types tested. FIG, 14 shows that miR-143-3p is down-regulated in colon, lung, and pancreatic tumors, and is present at high levels in all normal tissue types and some breast tumor lines. miRNA data analysis revealed at least eleven miRNAs that represent novel and unexpected miRNA expression profiles, not previously identified in the literature.
[00180] Many of these identified miRNAs are pan- or multi-tumor specific. For example, expression of miR-451a, miR-559, miR-Ι, miR-145-3p, and miR143-3p were generally down-regulated across all cancer cell lines tested compared to control tissues. This was particularly notable for miR-451a, which was highly expressed in all normal tissue type and substantially down-regulated in all cancer types, thus representing a pan-specific tumorsuppressive miRNA. The expression of miR-559 was lower in normal tissue types, except for normal lung tissue, and expression of miR-Ι and mir-145-3p in normal tissue was variable. Despite the variability in the magnitude of differences and absolute expression levels, mean expression of each miR in cancer cells lines was substantially lower compared to levels in the
WO 2017/132552
PCT/US2017/015417 corresponding normal tissues. These miRNAs are candidates for generating pan-tumor HSAr virions that are capable of broadly treating a variety of cancer types.
[00181] Although the mean expression for miR-451a, miR-559, miR-Ι, miR-1453p, and miR143-3p was lower in cancer cell lines compared to normal controls, the decreased expression was not fully penetrant across all cancer cell lines. For example, 2/3 of the normal bladder samples tested showed increased expression of miR-145-3p, while expression in the remaining sample was substantially similar to the average observed in the cancer ceil lines. Similar results were observed in breast cancer cell lines. Although the average read count for all breast cancer samples was 106, 5/12 samples had a normalized read count of > 1000 counts, 2 of which were > 40,000 counts.
[00182] These data indicate the potential to generate a single miR-attenuated oncolytic virus capable of targeting a broad array of tumor types. For example, a construct comprising target sequences for miR-124, miR-451 a, miR-559, miR-Ι, and miR-145-3p may be used in the treatment of all the tumor types tested (e.g., bladder, colon, breast, pancreatic, lung, head and neck. Schwannoma, and glioblastoma). The variability in expression levels of miRs in different cancer types indicates the potential need to stratify patients by miR expression or through the use of an additional biomarker.
Example 2- Construction and use of a reporter system to rapidly assay miRNA-based gene attenuation [00183] A reporter system was developed to assess miRNA-based gene attenuation using virtually any miRNA target sequence and cognate miRNA. In this system (shown in FIG. 15), the target sequence recognized by miRNAs (i.e. hsa-miR-122) was inserted into the 3’ UTR of de-stabilized green fluorescent protein (dsGFP). The cognate miRNA was then expressed via a tetracycline (tet) inducible promoter using mCherry as a control for miRNA expression. All expression vectors were cloned into a tet repressible vector pcDNA5 Frt/'To that also expresses mCherry (pTF002). All miRNAs for expression generated by gene synthesis from human genomic DNA and were cloned into pTF002. To generate attenuation reporter vectors, dsGFP was cloned into cDNA3.1+, generating vector pTF004. Attenuation vectors contain four tandem repeats of the reverse complement of the miRNA sequence of interest separated by 8-16 nucleotides. Plasmids were constructed by insertion of synthetically generated oligonucleotides
WO 2017/132552
PCT/US2017/015417 into the 3 'UTR of the dsGFP gene of pIF004 using standard molecular biology techniques. On day one, HEK293TetR cells were transfected with the miRNA attenuation and reporter expression plasmids (0.15 qg each, for a total of 0.3 qg of CMV promotor-containing plasmid) using Lipofectamine 2000 per manufacturers protocol (Invitrogen). On day two, ceils were treated with Tetracycline at 5 ng/ml and allowed to incubate for up to 72 hours. After incubation, GFP and mCherry fluorescence signals were detected daily using a SpectraMax© i3x Minimax multi-mode microplate reader (Molecular Devices) and analyzed using Softmax Pro or Metamorph imaging software (Molecular Devices). Phase images were acquired with an exposure of 5-6ms, GFP (541nm channel) exposure 10ms, and mCherry (713nm channel) 2001500ms.
[00184] FIG. 16 exemplifies miR-122 mediated attenuation of GFP expression upon induction of miR-122 expression via tet at 24 hours. The control constructs miR-184, miR34a, and Let7a do not attenuate GFP levels, nor is GFP attenuation observed in the absence of tet. FIG. 17 shows miR-122, miR-184, miR-34a, and Let7a expression and GFP attenuation using each miR target sequence individually and in cassette combinations of miR-122/Let7a, miR-122/Let7a/miR-34a, or miR-122/Let7a/miR-I84. Decreased GFP is only observed when the appropriate miR and cognate target sequence are present together (circled wells). FIG. 18 serves as a non-attenuated control and shows miR-122, miR-184, miR-34a, and Let7a expression and mCherry expression.
[00185] FIG. 19 shows miR-122, miR-124, miR-145, miR-199, and miR-451 expression and GFP attenuation using each target sequence individually (circled wells). FIG. 20 serves as a non-attenuated control for the above example and shows miR-122, miR-124, miR145, miR-199, and miR-451 expression and mCherry expression using each target sequence individually. FIG. 21 shows that miR-122 and miR-184 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-122 or miR-184 target sequences are present. FIG. 22 shows that miR-34a and miR-184 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-34a or miR-184 target sequences are present. FIG. 23 shows that Let-7a and miR-184 attenuate GFP fluorescence at 72 hours post transfection when the cognate Let-7a or miR-184 target sequences are present. FIG. 24 shows that miR-124 and miR-184 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-124 or miR-184 target sequences are present. FIG. 25 shows that miR-145 and miR-184 attenuate GFP fluorescence at
WO 2017/132552
PCT/US2017/015417 hours post transfection when the cognate miR-145 or miR-184 target sequences are present. FIG. 26 shows that miR-199 and miR-451 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-199 or miR-451 target sequences are present. FIG. 27 shows that miR-125 and miR-451 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-125 or miR-451 target sequences are present. FIG. 28 shows that miR-126 and miR-451 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-126 or miR-451 target sequences are present. FIG. 29 shows that miR-127 and miR-451 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-127 or miR-451 target sequences are present. FIG. 30 shows that miR-133 and miR-451 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-133 or miR-451 target sequences are present. FIG. 31 shows that miR-223 and miR-451 attenuate GFP fluorescence at 72 hours post transfection when the cognate miR-223 or miR-451 target sequences are present.
[00186] As such, these data indicate that miR expression can result in the specific attenuation of genes expressing the cognate miR target sequence.
Example 3- Generation of miRNA-attenuated HSV [00187] Following reporter gene-based validation of miRNA target sequences and cognate miRNA pairs, HSV-based viruses were generated containing miRNA attenuation cassettes. A series of modifications were made in KOS-37 BAG, a full-length genomic clone of the KOS strain of HSV-1 on a bacterial artificial chromosome (BAG) as described (Mazzacurati et al., Mol Ther., 2015). The product, KGB AC, was deleted for the internal repeat (joint) region containing one copy each of the diploid genes JCPO, ICP34.5, LAT and ICP4 along with the promoter for the ICP47 gene. This deletion facilitates manipulation of the remaining copies of the 4 deleted genes, provides abundant space for the potential incorporation of transgenes that enhance the oncolytic activity of the virus, and increases tumor specificity by reducing expression of the neurovirulence factor ICP34.5; elimination of ICP47 expression benefits immune recognition of infected cancer cells by virus-specific T cells. KGBAC also contains the GFP open reading frame (ORF) fused to the glycoprotein C (gC) ORF via a 2A peptide sequence to allow monitoring of late (post-replication) viral gene expression. Lastly, KGBAC contains a pair of mutations in the gB gene shown to enhance HSV entry through non-canonical receptors. The miRNA target sequence cassettes were recombined into the 3' UTR of the ICP4 and/or
WO 2017/132552
PCT/US2017/015417
ICP27 genes of 2A5B-MMP9 to generate ONCR-003, ONCR-010, ONCR-011, ONCR-012, ONCR-013, ONCR-014, ONCR-015, ONCR-016, ONCR-017, ONCR-018, ONCR-019, ONCR020, ONCR-021, and ONCR-022 as shown in FIG. 32. All BAG constructs were converted to virus particles with simultaneous removal of the BAG sequences located between loxP sites by transfection of Vero-Cre cells. Following plaque purification, virus stocks were prepared and titered on Vero cells.
Example 4- Viral infectivity assay using miRNA-attennated HSV [00188] To assay for viral infectivity7 and replication in normal and cancerous cells, miRNA-attenuated HSV particles were tested in the following in vitro assay. On day one, for each cell type infected, HSV particles were introduced to achieve a multiplicity of infection (moi) of 0.01. On days two through five, viral infectivity was assayed by GFP detection using a SpectraMax® i3x Minimax multi-mode microplate reader (Molecular Devices) and analyzed using Softmax Pro or Metamorph imaging software (Molecular Devices). Phase images were acquired with an exposure of 5-6 ms, GFP (541 nm channel) exposure 1 0ms, and mCherry (713 nm channel) 200-1500 ms was used to evaluated any potential nonspecific autofluorescence signal.
[00189] ONCR-011 replication was significantly attenuated in post-mitotic lung tissue due to the presence of the miR-125 cassette in the ICP27 gene and high levels of miR125a (>3000 counts) in these cells, as shown in FIG. 33 (read out by GFP positive cell quantitation) and FIG. 34 (read out by quantitative PCR). .Although ONCR-011 and the control virus, ONCR-003, contain miR-124 target sequences in the ICP4 gene, miR-124 is present at low levels (<100 counts) which were insufficient to attenuate viral replication. Both ONCR-011 and ONCR-003 replicated freely in head and neck cancer cells (A253) because these cells contain low levels of both miR-125a and miR-124 (<100 counts). ONCR-013 replication was significantly attenuated in HCC1395 ceils, but not in A253 cells as shown in FIG. 35 (read out by GFP positive cell quantitation) and FIG. 36 (read out by quantitative PCR). ONCR-014 replication was significantly attenuated in non-cancerous lung tissue as shown in FIG. 37 (read out by GFP positive cell quantitation) and FIG. 38 (read out by quantitative PCR).
WO 2017/132552
PCT/US2017/015417
Example 5- Treatment of a patient suffering from pancreatic cancer, iimg cancer, or colon cancer [00190] A patient suffering from pancreatic cancer, lung cancer, or colon cancer is treated using the compositions and methods disclosed herein. HSV-based viral stocks may be generated that are attenuated by incorporating one or more miRNA target sequences into UL19, ICP4, ICP27 (or other viral genes) as shown in FIGs. 39-44. In some cases, genome-editing capabilities for tumor destruction and/or microenvironment remodeling are engineered into the virus in addition to miRNA target sequences, as shown in FIGs. 45-46. In a specific example, an HSV-based stock containing miR-124, miR-451a, miR-143-3p, and miR-559 attenuation cassettes incorporated into ICP4 and ICP27 is generated according to the methods described in Example 3. The miRNA target sequence cassettes are introduced into the 3! UTR. of the ICP4 (miR-124) and ICP27 (miR-451a, miR-143-3p, miR-559) genes as shown in FIG. 47. BAG constructs are converted to virus particles with simultaneous removal of the BAG sequences located between loxP sites by transfection of Vero-Cre cells. Following plaque purification, virus stocks are further purified, buffer exchanged, and titered on Vero cells. For in vivo administration to a patient suffering from pancreatic cancer, lung cancer, or colon cancer, HSV particles are prepared in phosphate buffered solution (PBS) along with pharmaceutically acceptable stabilizing agents. On the day of treatment, 1(F vector genomes in a volume of 1.0 mL pharmaceutically acceptable earner are administered via intra-tumoral infusion. The patient is monitored for tumor regression using standard of care procedures at an appropriate time interval based on that patient’s particular prognosis.
Example 6- Treatment of a patient suffering from brain cancer., bladder cancer, breast cancer, or head and neck cancer [00191] A patient suffering from brain cancer, bladder cancer, breast cancer, or head and neck cancer is treated using the compositions and methods disclosed herein. An HSVbased viral stock is generated containing miR-124, miR-451a, miR-145-3p, and miR-559 attenuation cassettes according to the methods described in Example 3. The miRNA target sequence cassettes are introduced into the 3' UTR of the ICP4 (miR-124) and ICP27 (miR-451 a, miR-145-3p, miR-559) genes as shown in FIG. 48. BAG constructs are converted to virus particles with simultaneous removal of the BAG sequences located between loxP sites by
WO 2017/132552
PCT/US2017/015417 transfection of Vero-Cre ceils. Following plaque purification, virus stocks are further purified, buffer exchanged, and titered on Vero cells. For 'm vivo administration to a patient suffering from brain cancer, bladder cancer, breast cancer, or head and neck cancer, HSV particles are prepared in phosphate buffered solution (PBS) along with pharmaceutically acceptable stabilizing agents. On the day of treatment, 109 vector genomes in a volume of 1.0 mL pharmaceutically acceptable carrier are administered via intra-tumoral infusion. The patient is monitored for tumor regression using standard of care procedures at an appropriate time interval based on that patient’s particular prognosis.
[00192] A patient suffering from schwannoma is treated using the compositions and methods disclosed herein. An HSV-based viral stock is generated containing miR-124-3p, miR-205-5p, miR-141-5p, and miR-3i-5p attenuation cassettes according to the methods described in Example 3. The miRNA target sequence cassettes were recombined into the 3' UTR of the ICP4 (miR-124) and ICP27 (miR-205-5p, miR-I41-5p, miR-31-5p) genes as shown in FIG, 49. BAG constructs are converted to virus particles with simultaneous removal of the BAG sequences located between loxP sites by transfection of Vero-Cre cells. Following plaque purification, virus stocks were further purified, buffer exchanged, and titered on Vero cells. For in vivo administration to a patient suffering from schwannoma, HSV particles are prepared in phosphate buffered solution (PBS) along with pharmaceutically acceptable stabilizing agents. On the day of treatment, 109 vector genomes in a volume of 1.0 mL pharmaceutically acceptable carrier are administered via intra-tumoral infusion. The patient is monitored for tumor regression using standard of care procedures at an appropriate time interval based on that patient’s particular prognosis.
[00193] While preferred embodiments of the present invention are shown and described herein, it wall be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions can be implemented by those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the
WO 2017/132552
PCT/US2017/015417 invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
WO 2017/132552
PCT/US2017/015417
Table 1. Summary of relationships between 12 select oncomiRs (9 tumor suppressors and 3 oncogenic miRNAs) versus cancers.
i4> κοίίΡο f ϊ χ·>ίί ;<!o »>'1 5Λ> flWWKj&fofc# x<H W «fcKftwatfUiixi· xoHiOf ϊ «ΛΛ? xoiii :
o>«« ί
WO 2017/132552
PCT/US2017/015417
J 4 nite ^Λοκ-κ«>^»:ΐί<·Λ) : ^fc'Wx-K'^oisfc'si: neuroblastoma ! | «>& ffi papillary thyroid carcinoma | x<&{ »ft<»x« >M 'ϊί; | ίήηχ·χ«^>Λ*:·{·Λ) hepatocellular carcinoma | x<& 'W «5> £<·χί·κϊ· | x<& : nite f ί-i A «^oi into >sk&r>x % osteosarcoma 1 neuroblastoma | <«>>!%· : xoK-i? 1 nasopharyngeal 1 cancel' | («> x# i < y l> head and neck s nt o s 1 i.uicmomu | $x$o 'j; hepatocellular carcinoma |
oon-smail cel! i lurur cancer ! | prostate cancel' | lung cancer | ovarian carcinoma l non-small cell | ! non-small cell lung ! cancer | llCilJlI'CCIIIlGU uu. mnmu | liver cancer | ||
oral cancer ! | ler.al cell | mali gnarit melanoma | pancreatic cancer 1 oral squamous | 1 osteosarcoma | hypopliaryrigeal suns 1 iciicmoiui | lung | ||
osteosarcoma ! | squamous carcinoma | neuroblastoma | papillary tliyioid 1 osteosarcoma carcinoma 1 | ! pancreatic cancer | 1 | lung cancer | ||
non-small c elt lung cancer | prostate cancer j ovarian c ancer | 1 pituitary carcinoma | iciicmoiui | malignant melanoma | ||||
pancreatic ductal i adenocarcinoma ! | oial cancer | 1 cancer | ! t-cell lymphoblastic 1 lymphoma | laryngeal squamous | malt lymphoma | |||
papillary tliyioid carcinoma j | osteosarcoma | j prostate cancer | ! | UVC UI'ICOI | mantle cell lyrnuhoina | |||
prostate cancer ! | ovarian cancer | 1 | 1 | lung cancer | nasopharyngeal carcinoma | |||
carcinoma j | pancreatic cancer | ! | ! | nab. gnarit melanoma | tuna cancer | |||
renal dear cell ! carcinoma ! | pancreatic ductal ade no c arc ino ma | multiple myeloma | oral squamous cell carcinoma | |||||
papillary thyroid carcinoma | nasopharyngeal carcinoma | ovarian, cancer | ||||||
prostate cancer | non -small ceil lung cancer | papillary thyroid carcinoma | ||||||
! | rectal cancer | 1 | 1 | oral cancer | prostate cancer | |||
renal cell carcinoma | oral squamous ceil carcinoma | racial cancer | ||||||
retinoblastoma | osteosarcoma | renal clear cell carcinoma | ||||||
! | squamous carcinoma | 1 | 1 | ovarian, cancel | squamous carcinoma | |||
! | uveal melanoma | ! | ! | pancreatic adenocarcinoma | ||||
! | ! | ! | pancreatic cancer | |||||
; | ; | ; | pancreatic ductal adenocarcinoma | |||||
1 | 1 | 1 | papillary thyroid carcinoma | |||||
! | 1 | 1 | nrostate cancer | |||||
! | 1 | 1 | rectal cancer | |||||
! | ! | ! | renal c ell carcinoma | |||||
! | 1 | 1 | retinoblastoma | |||||
! | ! | ! | squamous carcinoma |
WO 2017/132552
PCT/US2017/015417
Table 2. List of examples of oncomiR-cancer relationships.
J tt&w s | Bi-Kawcy | raitt | ϊ'ίκΚΊΝΤ | ί'Λί^ | Bpiwttw· | Cwu.'gr | ΪΑ$Κ | gbfrlVttfC | |||
diWvO O-·-·-·-·-·-·-·-·-·- | j jn?> lOdj.^tpttf.pSJAi-tO'' ftfcseiidiyiBai transition and dawnreipiteiinn of letA'a ht | mir- 16-1 | oeuro-blastoma | up | miR.-J5a/l6-l enhances retinoic acid-mediated differentiation of leukemic ceils and is unregulated by' retinoic acid. | <!’!.- 24--2.- 1111 | breast •'tnue-.r | υρ | eAlYC regulated unite ?5a- 24--2.-2 7a cluster promotes mammary hepatic metastasis by targeting Kproutv? | ||
dWy | idowrip | ΡΜ&ί^ suppresses breast cancer ceii tingra-tion and invasion through do wrragulation of C-C vipmokme revepOi bte^/2CCCCCCCCCCCC0P0: | mir- 16-1- 3p | chronic lymphocytic leukemia | down | Aberrant tnicroRMA expression in Chinese patients with chronic lymphocytic leukemia. | νίΩΙΙΥ::::?: 24-3p | bbte^ffidhbeCbbbb | iOiAA | miRNA-24Ap promotes inhibits apnpm>t>«5 human bmast cancer tw targeting i^^^lAiAiAiAiAiAAAA | |
AofAaif: | breast Paftcet | dOun | The heterocbrarac ίΙήΒίί;φΚ^Α:Ιδ$(7:ηύ^ΐί5:ί:ί:ί ::<?limoHiity:t<y:feaeia!ir4C·:·:·:·: the genes m the aciit: mmAekOt pititt » tn braw pjn.tr. | mir- 16-2 | chronic lymphocytic leukemia | down | miR-Ιό and miR-16 induce apoptosis by targeting BCL2. | brbiibbbb | colorectal cancer | down | fy.wu mguhtionoi mR24-3p inoolyrectalcancer biOgii^ |
L’!‘3 | idhteite | bb^teSAbObrib | mir- 16-2 | chronic lymphocytic leukemia | down | Defective DROSHA processing contributes to downregulation of MiR-35/16 in. chronic lymphocytic leukemia. | mir- | ehoiuii | np | mil >v tnd miR-2 'a- ψ ptuPu'f eri orAJerdmt, tn glioma neils via cooperative regulation of | |
AofAaif: | colorectal cancer | Pddteiii | Association of nbctoRNA mK-osoteiine instability /^^ii^iui.^'Qic^iiifMh/hhhhhhhhhhh ?.νΛ6Λνηκ!ηοηιη | uiir- 36-2 | lung cancer | down | Histone deacetyiases inhibitor trichostatin A inc reases the expression of Dleu2/miR15a/16-1 via HDAC3 in nonsmall cell lung cancer. | bibifbblb 25 | CcbiiibdfCCCbbbb: CiAfcihbindCCbbbb | /TfCbA | [miR -25 promotes ceil proliferation by targatotg RECK in human cervical eafvit^iua FteLa cells·! |
/defATf/: | eolmecial i,WCT | K-xAA-w- bOibib | bi«^^i^:B^Sb^b:b:b:b:b itueroRNAa as Stomarkerfe | inir- 16-2 | neuro-blastema | up | miR-15a/16-l enhances retinoic acid-mediated differentiation of leukemic cells and is upregulated by retinoic acid. | AbirAA bbkbbbb | colon cancel· | dow n | MicroR24A-25 feme items as suppres Λ·τ m Cuko can> er /bCAt^tiii^/sOlbCCCCbbb |
L’!‘3 | SqUirfilull j vP'd iiAteiikiinbPTTTTTi: | idhteite | •rNiJIC' Jl.lpsapj gurralatu-ra. of Jef-^a and ciiAfrnO Squamous ceB carcinoma] | mir- 37 | acute myeloid leukemia | down | HIF-1? downregulates miRί 7/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell, differentiation. | 1551!- b25bbbb: | eoWtcUi varivCi | up | Assootauott of mteroRNA bOlOOO^bbbb rnura atellnem tabthiv YAbigihAdfe^ b^dhbraibihbhAbbbbbbbbbbb |
ki*“3 | gastric cancer | :ΑΟΑ | E.enttVirtB \‘ecior*tr.ediated bu£ttegblO h-iitbits gastric: carcinoma ceil giw Bi it: vitro and at b^teCCCCCbbbC | mir- 37 | b-cell lymphoma | up | MicreRNA miR-i7-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion | bibifEbb 25 | colorectal cancer | AiibCCb | The expression οΐ roilte25 blgifete&bdAiCA^^ cancer and is assocT3!.e4 |
pteiyApi: | idhteite | Lvft -fe\ el e\pre;avfi vi kt-’a tp. gastric cancel and ita nwohanterj in mmorigeuesk bv inrgetmg | mir- 37 | breast cancer | up | MicroRMA expression profiles in human breast cancer cells after multifraction and singledose radiation, treatment. | bteii-bbb b2$bbbb: | C^biiktndiCbbbb CbiitebibCCCCCCb | l!^ll | b'ES&AikO 93-25 Cluster Expression itbfbbgkiOid^^Oibidi::::: hfy Carat Inhibits Proliferation and induces bA^btb8iij:iii:i3bhihh:^Rife;b::: |
WO 2017/132552
PCT/US2017/015417
303/33 | 3/Ol/3^3/333:3:3 | 3/3//3 | ifiiRMA-22' promotes p?zriv tin vrnwa.Dnatn metastasis fry targeting ϋΟδίί/Ο^Ο//////// 3Ο3ϊϋ/3333333333333333 | niir- 17 | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis by targeting LATS2. | 3/3/3:3: :::3Α:7:7:7 | /i/bpi/^di//://:: squidituim veil 3;έ//3//ρ./333333: | O|33 | MternRNA“25· promotes cell migration and invasion in esophageal squamous 3/3/////1//)/33333333333:3 |
3ί//3/33 | gastric cancer | down | Im estimation and Lida^iiOO//0/^//::// related functional proteins wi gastric earcntoott by 3/l/t33i3i3S333333333333333: | roir- 17 | cholangio- carcinoma | up | miR-17 -92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and EL6/Stat3 as upstream activator. | 3/3/333 | esophageal squamous cell 3:3//:///:/3:3:3333 | 3/1/333 | Chia?/ igmfnaoce ni semro naR-22>, miR-25 and uuR-/75 in patterns vote oohagvd spurn 3:3b///te!//ri/33y333333333: |
Li-t | gastric cancer | down | Drifetentialte expressed /ΟΟ/ίΟρίΜό/ΐ/////:/ ον wspreaovd ict-’a g <$ τ··< •carethctna cells by two- OiO^ibii^/////////// 3^1/33^133/^:/3/3333:3:33 33i33ttai/tbf3//33333333333: | mii- 17 | colorectal cancer | up | MicroRNA expression profiling of exfoliated colonocvtes isolated from feces for colorectal canc er screening. | 3/3/333 7//7777 | zastuv v«xtca | 1^11 | nnPNA-223 promotes gastric cancer invaaion and me tt Λ asts by totge «no tumor Suppressor 3θ^|/////::/ |
:yle/7a:yy | gastric cancer | dOwft | Circulating i'oiCfoRNAs to plasma of patients with gastric cancers. | 17 | colorectal cancer | up | Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma | 3/3/333 73$///: | gastric cancer | 3//:/33 | miR-25 promotes gastric cancer cel Is growth and monfrte be taigeteua 003333333333333333333 |
yte/3/33 | 3^1/^/333333333333 | down | Cverexpigssed let-7a 3/ίί/ίΐ/)θ///έίί3333333:3 malignancy by dtrectiv tttyetsng 1·· -ras. inriependenfiy of LIEN | mii- 17 | colorectal carcinoma | up | Up-regulated miR-17 promotes cell proliferation, tumour growth and cell cycle progression bytargeting the RND3 tumour suppressor gene in colorectal carcinoma. | 3/3/33·: 7//7777 | zastin v«xtca | 1^11 | 3Mi/i/RNA://ipi3/i3f$/3333 gastric cancer rntgratmu. mv asmn mxi profiler rum bv tirrectly targeting jfnsJue. otfRfrfr5 J and correlates with poor y//ty33&333333333333333333 |
:yle/7a:yy | noso-plnnyngeni 3/ί1///^333333333 | dOwft | Let -7 a itdiibits proliferation arud tndnves apoptosis by CiOSiO^O/:®///////: n? m jh in t gvaf mmook· -..-ciis | 17 | esophageal squamous cell carcinoma | up | 3/3/333 73/7//: | yg/0/3/333333333 | 3//3// | miR~25 promotes glioma 3^ih/r/i^te/^i//33333333 targeting f DkNJC | |
303/33 | 3:iib/A/iiiJl/3ii/diii/:3 3iOibi333333333333: | 3/3//3 | < neutering nacio-Ri TA v vpre*sinu ptuiric* tn carte stage neusmaiteeb teog cat-cer | niir- 17 | gastric cancer | up | MicroRNA profiling of human gastric cancer. | mu- :::3/:7:7:7 | 3:/3/////:/33/33:3 squamous veil /ita.tetebita////// | O|33 | •'^rupuhensi' 0 MicroRNA omitting M bead and tte/\ sqtta.i.taps Nil vujvntattttz |
te'-a | osteosarcyfiia | y///hy | ltw/o^oo^/////// microRNAder-7a inhibits //aifOOOb//ip/////:: 3i3ig3iinig/i:S2^ 3/333:3333 osleosnit oma celts | mir- 17 | gastric cancer | up | Overexpression of miR-17 in gastric cancerrs correlated with proliferation-associated oncogene amplification. | 3/3/333 725///: | 3//3/3/0//31:/333 /ita.tetebita////// | 3^/3/ | 3/Ep/l//i/ri//:/£y3y33333333: miOtuteN A*?5 ^ςν UttvS yr//th:^//3p5l3//y3y3333333 3:////3/3//1/3/31/)3/3//33:3: |
:yle/7a:yy | pancreatic ductal ;00i:0$fi'/0/i:/ | dOwft | XMDK-92 inhibits 3®333ί33///3/ίΡ/333333333 Xenygiafi. Grey, fh via /βΟ^ίίΟ^ΟΟ////// 3/^b3frd/i3i/33y33333333333:: | 17 | gastric cancer | up | inhibition of microRNA-Ι 7/20a suppresses ceil proliferation in gastric cancer by modulating UBE2C expression. | 3/3f333: 33//// | oofi-smalicell :7ΐ3/££//ί3ί777777 | 3//3// | Dow oitagubticm ol mR -2^ modulates nyn-smali cell y:i//g////r///ii///y3333333 3:tai^imgtiO/i//////:/33 |
!;: i | renal tell caminoma | 333//3 | 3//33:/1^/333//3:313/*333 y33ip3te^33:m/3i/i/3i:i33333: earetnonm celt lines by s mudne ·- -nuc | mir- 17 | glioma | up | identification and functional characienzaiion of microRNAs involved in the malignant pronression of gliomas | 3/33333: 33//// | 7:/3////1/:3311333:: /iite/bO////// | yii|y| | y3t/Rj//)3ig3//3)/33333333) 3/)/^//i/3///ji(/ii//3/3333 g<ne tt. lung 'jmer |
WO 2017/132552
PCT/US2017/015417
/feir^/O^///// | /^/// | Lrcas >iXvf soxifu ::/^/i///^/id//////:/: :/l/O^/b///fe?i//////::: resp(?t!&e okmonts of kt-7 i/i/:/^/i/2////////;// | nsir- 17 | glioma | up | increased expression of mjcroRNA-17 predicts poor prognosis in human glioma | ί::///// xjgy????? | ovarian cancer | :O||: | ?a1iR-2^ regulate* apoptosis bv tart' mg Dim m tun at ihhh/3h/3hc31/i//////// | |
de/Badt Β//:/:/: | bronchiole» -alveolar /(^fel/jia^///////: | dowh | let-? mieroRNA expression /1δ://ΰ$έ/ί///////////: bronchioloalveolar carcinoma. a non-iuvasive carcinoma. and i* not correlated with prognosis. | mir- 17 | long cancer | up | .A pclycisuonic microRNA cluster, miR-17-92, is overexpressed in human lung cancels and enhances cell proliferation | ///// | ovatian cancer | ί://:// | RftR 2 < promotes Otaron cancer pfpidbraiipn and niottlny b' 'argetrng |
kL-:l- :ί|ί////: | /^ί^/^ϊέϊ/////: | /^Oi: | kt-’ itacioRNA functions as a potential growth suppressor ut human eoloh ::/0//0/:/// | nsir- 17 | lung cancer | up | Apoptosis induction by antisense oligonucleotides against miR15p and miR.-20a in lung cancers overexpressing miR-1792. | mu- xjgy????? | p..,s: ϋ·. <i».u | Jem n | 3hal^2/bkd/i3^//////3 /(ίί33/3έ3έ//Ο//////// Dissernmafioo of Homan Ficstate Cancer Cells via Regulation of ?v- and X>integiin Expression- |
/f/t///·//: /|://// | esopftegeal /^ii/i//4S//ii///:/: /^i«/^//////$ | down | Rote ofmieroRNA tet-7 and elfeet io KKf<5A2 tn esophageal sgtiaiitotis cell :/)0/30//////////:/: | 17 | lung cancer | up | MicroRNA. iniR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved io cancer ceil proliferation and invasion | :///// :/:///$ | small call lung //1/3//////// | O/:/: | MieroRN.A-25 regulates small cell lung cancer cell developmeui anti cell e> de /tbiOtigb/y/bh/////////:: |
ic:- .»·· B/lll | i^dpfei/aa!/////:/: StpruniuU j vO'd /(^fel/jia^///////: | i/O/: | INprccsiuit oi err uktOng mumRUA-Aa mdL'-^j la. esophageal scjua&xnis i/dl///id/////////// | mir- 17 | malignant melanoma | up | Comparative analysis of melanoma deregulated miRNAs in the medaha and Xiphophonis pigment cell cancer models. | ϊί//// ί/////: | acute m.vefotd /leid/ihi//////t | dow o | /Ciitih3hR0k^//ti3/:iii/3/: A 'die Mv do-d 1 ^tiheuna /(3///3///////// Regulation ·»£ ufiR-2t>a and Histone bkthvitran&fera&e |
/^i«/^//////$ | Oi/OOOiO/////:// Pancreatic Cancers. | 37 | melanoma | growth by stimulating T-cell mediated host immune response. | ://///: | proliferation and luNthtv in bladder oautter bv targeting Il^iCAi//////////////:/// | |||||
3*033/ Β/::///: | /ί/ί^/^/έ////;//: | /^Oi: | Let- ’a eie\ afcs p2 it WaF O lev da by targeting ci NIRJ? and xtpptesse.dM growth «fz\5i‘; ktfig.Mftcet.tells | nsir- 17 | mantle cell lymph onsa | up | The miRNA-1’792 cluster mediates chemo resistance and enhances tumor growth in mantle ceil lymphoma via PI3K/AK.T pathway activation. | mu- | ib/^hS^hb/;/:// | Jem n | miR-2ba autagotRtes apoptosis- and facilitates carcinogenesis by targeting /:/:^1/1///////////////////// |
/f/t///·//: /|://// | /hiag/a/ipii////// | down | Reduced expression of the tet-7 mnioRNAs iii rpuman long cancers in association //0:0/0^///////// postoperative survival | 17 | medullo-biastoma | up | The miR-17/92 poiycistron is up-regulated in sonic hedgehogdriven medulloblastomas and induced by N-myo in sonic hedgehog-treated cerebellar neural precursors | :/31/// :/§///: | breast caoeer | down | MiR-2oa Inhibits : :Rfoiife£ationand:Riigiat!»n:: of Breast Cancer through Reptessmu p-f |
!C:-;i- /|://// | ϊί/όέ/^/ϊέ/////:/: | 3&3Ο: | 1 vducvd cxorc stvtt vi Da er a* x« tared s uh puAr prognosis in lung cancer ii^it/it////////////// | mit- 37 | naso-pbaryngeal cancer | up | Circulating miR-17, miR-20a, miR-29c, and miR-223 Combined as Non-Invasive Biomarkers in Nasopharyngeal Carcinoma. | 83!· i/'h///: | breast cancer | down | AbcroRNA-2ba inhibits prolifetationby targe ting 3Sih3:hih^ihi(hfehp;A3h333/ /h3bi3i3h)3ih3^/h3$3h3//:::: |
/I//// | naso-pltaryngeal carcinoma | CdOi/hC | KbetoKNA let -7 suppresses JX’Sopbar> ngeal carcinoma downugtikting - Mu | 37 | osteosarcoma | up | Upregulation of microRNA-1792 cluster associates with, tumor progression and prognosis in osteosarcoma. | imd/::::::: :|hh//: | //tei/ii^h/i//::/: /i)hfcih0ih3///// | O/:/: |
WO 2017/132552
PCT/US2017/015417
OP^^ldh//////////:/te | |||||||||||
:/iete7d/:// Βυ/ϋυ | Yh^ip/bbsiG^/////// | :/ddO/ | /®βθί;^ /ΗΗ^ΙΗΦ^ enhnunesMi CN kuels via /:ί$(/?:^^$$ί0ίΐ///////////////: | mir17-5p | bladder cancer | up | Micro-RNA profiling in kidney and bladder cancers. | /:&£///:// :/262///// | chrome up eldgenous- leukemia | down | Appptonufis expression moduhd'd bi EyT-AR! ss Puked to O3L progression andimatinip resistance. |
/dst/?a/// τηττττ | paocreufic ductal StdeiK-camiuomn | ddwO | )' -7 Evin ruRte A w zer m paoerctej? earner derrced eeiis inhibits in >rlro Yl alter temior progression. | mir- l7-5p | breast cancer | down | Mir-l7-5p regulates breast cancer cell proliferation by inhibiting translation of AIB 1 rnRNA. ~ | :/biif///// | gastric cancer | don n | n«B-2nrS.>ppf'z^ tun/w Growth and Metastasis by Targeting FGF7 in Gastric |
:/Ηί/?η/:// | bigast cancer | down | Breast cancer-specific TRAIL expression mediated by mifi/NA remonse elements of let-? end m-R-i >?. | mir- 17-5p | breast cancer | up | miR17-5p promotes human breast cancer ceil migration and invasion through suppression of HBPl. | 1^11 | //Tudtbl/GiPw/thhhd////////:////: Angiogenesis in Glioma b^ Ptfdvbhin | ||
ic:-;*- 02////////0 | /bipiGhmlh/Ph/iOiG | //dbO: Yfcfcfcfc | kte? rnicroRNA expression hfonchroi<<alveohd· eafOijiomrc, a non-invasive correlated with prognosis | mir17-5p | cervrcal cancer | down | MiR-17-5p targets ΤΡ53ΣΝΡΪ and regulates cell proliferation and apoptosis of cervical cancer ceils. | 83!· :/262://// | //iiOfe^iihidte://: tei^ddihdj^h:///////// | down | MicwENAGoa Inhibit:. Angiogenezsin (JownRegulating YEGPzk Cibfongb4jtP//////////////////////: PIf:3C2?/AkvHIF-i? Pathft?? mliepatvvelhdai 2G22ihbO62626262626////// |
sunprsosoi· 1» human colon | 17-5p | up | plasma of patients with gastric cancers. | :/522:////: | //^Smh^/////////: | angmgaoesife nt human hepatocellular > vrcmci. ,a b\ tan mop Hi Earner /pidRi^G/////////////////://////// | |||||
/Hte?:te// | //^fiph^g^////////////; o^piihSpHTsh///////// careioomn | ddwO | /:RW0£&i^ and effect to EMGA2 in esophageal snoamcfseeh :/sateaP0hH/2 | mir- l7-5p | gastric cancer | Up | Prognostic impact of circulating miR-2 J. in the plasma of patients with gastric carcinoma. | :/122///// | Yh^idtG^glOir;:/// carcinoma | C/Wh// | Mm mRE 1 A- ma ργλι. .ctes //^ifeldbi/^dSdbtetetetetetete:/ hepatoceihdnr canfiuomn //O^h-Ttetetetetetetetetete:////: |
/HOP-/// | //eHiHHKPG///://////// /£<0*000?:?:?:? | dowG | Expression of circulating uneroRNA-Hs and k?l-?a in esophageal aguamous | mir- 17-5p | gastric cancer | up | miR-17-όρ promotes proliferation by targeting S0CS6 in gastric cancer cells. | 612ίί///// | hepato-cehular //caiPmOihd:///////// | dbwn | Tumor-specific expression //pffiftOibR^Ay^Stetetetete:///: hepatocellular carcinoma independent pathways |
le | h>.patorttolhtlar careioomn | //dfliPh/: | YMiiO^^/i^tetetetetetetete:/: Hepatobiliary arcd | mir- 17-5p | hepato-celhilar carcinotna | up | miR-l7-5p Promotes migration oi' human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway | /Hit/·//// | bepato-eehniar 2Hfeih012x^2//////// | down | microRMA-2oa oppresses recruitment of macrophages i/Sighd·^^ expreszvn through the PBK/AJd pathway in hepatocellular carcinoma. |
ki*“3* | k!^0g:^tiSSt//////////// | //dfliPh/: | Redmed e\pre?>tvn vi the let-? tuioroRNAs in hantatt lung carreers in assoc ialion wteh shortened | mir- 17-5p | hepato-celhilar carcinoma | up | miR-l7-5p as a novel prognostic markerfor hepatocellular carcinoma. | /Hit/·//// | bepato-eehniar 2Hfeih012x^2//////// | down | //tt//6:iihO^^h/////////////// contributes to the redaction of rnik-’oa expression ή' //bhphfedSRhldftediteihdihd/////: |
WO 2017/132552
PCT/US2017/015417
postonerative smvtval. | |||||||||||
/:ί01/2ίί:/// 02((((((((0 | (ifi^kPkkt//////////// | //ddO | 1 vducvd e\ore *mn vi Du <r a« λλ med s rti< pvAr prognosis it· ltmg cancer (^i^k((((((((((((((((((((((((((( | mir17-5p | malignant melanoma | up | Regulation of cancer aggressive features in melanoma ceils by microRNAs. | (£uf((((( (26(1((((( | //bepik/psihiiiif///: Aik.f^hdkh/////////: | down | MicroRNA-dha suppresses /2/(^6^1½½ ^1^//////////////^ metastasis of bumao /(hgpdkPSiihlauikpkki^A///: by targeting IL-k-Slat? /pdO^i((((((((((((((((((((((((((( |
//kt-tyi-/// | /(iiitg:Sak(gi(((((((((((( | down | Ly-7a yle·. ates pd li^ AH < lev els tw targeting of NERF aid siipy*·' *vs ihv gmwtb of a’m.v lung saucer veils | roii - 17-5p | malignant melanoma | up | Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotie activity of miRNA 155. | /^^A(^^feaOt((((((((((((((( Licensing. Ttmiorigeueaia md Ρ··Λdr*, at® bv atd' mp COCti in lung Cancer. | |||
!C:-a- 72///////// | ((^khORth/////////////: | ((3½½½ | MldORNA idf-7 SUPiSfCobCfe nmmpltan ng^al vamumma celts prohferatimr tbipugh do wt-regulating c -Myc /0000(((((((((((((((((((((( | mir17-5p | non-small ceil lung cancer | down | •Circulating micro-RNA expression profiles in early stage nonsmall ceil lung cancer. | mn- (26(1((((( | ((rkdi£i&$((((((((((: /Oiid^kh//////:/// | down | MictuRNAHk» Is Strnngb ^1:0½^½½½½½^½½½½½½½½^ Melanoma-and induces Ceil //iOe^fkihkmgfeRb^f^^mi////; /(bLSikik^/^S^th//////////// DvinmnsdSOLdO |
/mH | /(a^fo/blasipisd/////// | dowo | LIN?ri8 mduoes ((r000000&((((((((((((i enhances MVCN levels via (:0?:00^i0(((((((((((((((( | mir- 17-5p | pancreatic cancer | up | miR l 7 -5p inhibitor Enhances Chemosensilivity to Gemcitabine Via Upregulating Bim Expression in Pancreatic Cancer Cells. | ((pi6/(((: | oral squamous ceil carcinoma | down | MicroRNA expression cell omomomn. functional role vi nucrvPN *.-?na/h m (ri^fkb&^Oik^Sd^i/////// cancer pathways.. |
(;kO((2 | paocreaiic ductal adenomarcinnma | diWvO | 1' -7 Eviu roRA A trap zer jp pancreatic cwer-Jem ed ceils tuiiibits iftvitbxell :/0^00000^0((((((( (0000^00^00(((((((: | mir- l7-5p | pancreatic cancer | up | MicroRNA raiR-J7-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | /kit///// (0(((( | osteosarcoma | νΟ'Λ n | (fppA:(ity:^(kfifl:tidi: ((((((((((((( uncroRMA-km t> associated with metastatic potential and the poor prognosis of osteosarcoma 7p/diekfc:////////////////////////// |
((RLyh///: | :/bkSSt:0SitC:^/////:///// | dyn it | (:gi^sOO^OOOi(((((((((( ((10.0^0000½½½½½½½^ medmtedbv miRNA response eie-ntents of iej>7 (:Od(SO00((((((((((((((((((((: | mir- 17-5p | pancreatic cancer | up | MicrcRNA-lOa is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXAl gene. | (kii((((( /2Sa///// | (pipimiH^(Pi(((( | O||: | :MiR:-26a:piOmOtCS:Ova££ari·:·:·: omioer proliferation anti (:tiii(((iri^ii£(iik(((((((((((((((((((: |
Wy | bfni!ci!^fo-alveiJaf //00½½ :///////7///:/ | //doO | kt-7 nucroRNA expre&sidn O^^OcO:k((((((((((((((((((((( (;00000}k0i0((((((((((((( (OOO £0000000^(((( (^^00^000:0:½½½½½½½ | mir- l7-5p | pituifaty carcinoma | up | MicroRNA involvement in a metastatic non-functioning pituitary carcinoma. | mu- (0(((( | /^ajfiBityih^itd/: carcinoma | dov n | mtR-^a and it* target CKK? modulate ceil growth and tumorigenesis of /^^ilkl$:iilO^(((((((((((((((( ((^d«kRk(((((((((((((((((((((((( |
((RLyh///: | colon cancer | dyn it | kt-7 uuciuRNA functions OOiOOO^OOOO((((((((((: suppressor m fcjnuau colon 00020^½½½½½½½½½½½ | mir- 181a | acute myeloid leukemia | down | MicroRNA 181a influences the Expression of HMGBl and CD4 in Acute Leukemias. | (kii((((( /2Sa///// | primary thyroid ((i^^bbktk////////: | dow f | A d-MkryRNA. signature can discummate primary lymphomas from anaplastic carcinomas in thvrotd :/6/fois^:Ah^3ik/////::://///////: |
Wy | //^Qpfei^dL///////////: /^O^’^i^ii///////// careirOma | //0½½ | E vprc*smt. of uuaiaang tniei-oRNAH;u and kt-?a jn esophageal squamous (:syOygi^ikty4((((((((((((((((((: | mir- 181a | acute promyeiocyiic leukemia | up | PML/RAR? -regulated miR18la/b cluster targets the tumor suppressor RASSF1A in Acute Promyelocytic Leukemia. | mu- (0(((( | /^ίόΟ^όίάόέί//// | dov n | (^fek/^Rpki^//////////////////// overexpressmnM fZH2 m early prostatic neoplasia via transcriptional and pyst-irawseriptiottal mechanisms. |
WO 2017/132552
PCT/US2017/015417
eareiooma | ?dPR<b | end effect to J i M< iA? m esophageal souamooseeli | tuir18 fa | breast cancer | down | Decreased serum miR-181a is a potential new tool tor breast cancer screening. | IbuiA:?:: ?04 | prostate «.anus | dm? n | MiR-2ba inhibits prostate cancer progression by yfgprpSjip^ | |
k | iupatuivlhtlnr eareiooma | oddO | yMibiriO:^iib?bb Hepatobiliary aid Paaereatte Cancers. | mir- 381a | breast cancer | up | Transforming growth factor-? regulates the sphere-initiating stem cell-like feature in breast cancer through iniR.NA-181 and ATM. ’ | oiPbCA? ?.ob | bladder oabeer | Νϊ^ΑΑί | Mipru-RN A pmfibnp jn. kidney and bladder caooers |
dyu it | Let-?aelevates p21lWAFl> tevete by targeting yf NIR? and suppresses» the growth <4 \5:$ !γ«ψ 'ituer xJk | mir- 181a | cervical cancer | up | MicryRNA-lSla enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. | :::βύΐχ:::::::: | breast «.amer | dop n | MiRNA Tobnduyns proliferation by targeting | ||
kt-Ot- | :mw can.cr | bdoOi | Reduced expression oi the kt-7 naforoRWAs in bpmafi lung caooers io. aasoabtion yWhteO^^d;AAAAAAA?b postoyeiati'-e survival. | tuir18 fa | chronic lymphocytic leukemia | down | Aberrant rnicroRNA expression in Chinese patients with chronic lymphocytic leukemia. | mu- | breast cancer | dm? n | <clhdar proliferation by targeting CBK8 in. breast oedikefAAAAAAAA?^ |
JO? | :/bihg:Yfeer:///::::::::::: | dvWO | Reduced expression of Dicer associated with poor prognosis in hxig cancer /^i^^aaaaaaaaa | wir- 181a | chronic lymphocytic leukemia | down | miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple antiapoptosis genes. | TbitrA?? | breast •'amer | Odbteb? | bl^pife^Ax^dAAAAAAA::: underexpressed in human breast yaacer and induces veil apoptosis b\ targeting |
naso-pharyngeal /^έ«^^ϋϋϋϋϋϋ$ | down | MlcmRNA tel-? suppresses oascfpteuyngeyl carcinoma v dH probf 'n<4j tt mipn dnwrregpdanng v-bbc t xprt.'ZUOt·. | mir- 181a | colon cancer | up | miR181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway | ?hin;T:?: | cnlortvtJ | Association of navroRNA microsatelbie mstohiiitv | ||
:tteb7dkA | /^ίό/'βί^ΪΩ^ϋϋϋ:: | ydpO: | enfcnnoesMY CN lea els via :::^ΐ^:$ϋΐ^ί^^ίώΐ&::ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ | mir- 181a | colorectal cancer | up | MieroRN A-181 a pro mote s tumor growth and liver metastasis in colorectal, cancer by targeting the tumor suppressor WtF-l. | οίΡίΡΑΑ: | down | Role of mioroRNA-^b in pt.on a dew eRpment mb t ® mediated regulation on | |
ϊ:Ο^/ϋ: | pancreatic ductal | dOun | kt TbinnakNAiiPosferio y^fkteOj^i^StidSitijSd:/::: after tumor progression | 181a | gastric cancer | up | MicrcRNA-18la promotes gastric cancer by negatively regulating tumor suppressor KLF6. ' | yndryA? | hepafy-ealluiar | down | AhnroRN.A-7.db inhibits epitl«ltel-mesenehyniai transition in hepatocellular eurvttmmj by tarcotmg |
!;; ·ΐ>· | 7pfp$iatecam0f<777 | Tl« miRNA let-?al inhibits jiiirbdkfO^W^ prostate cancer RC-o ceils. | mir18 fa | gastric cancer | up | Genetic polymorphism at mrR181a binding site contributes to gastric cancer susceptibility. | omlriAA | dop £' | :MicroRNA-:7i>a?h· Regulate·:·:·: Lueusing. 3TwnvPgenesis and Prognosis by Targeting CDCb «. Lung Cancer. | ||
:<ΗΑ?ρ:<3 | acute lymplxtbinsbe | dvWO | Suppresstoitof the let-?h mioroRNA pathway by DNA ίο penne tb lotion io tenkemia wbh MIX gene rearmngentents | wir- 181a | gastric cancer | down | MicroRNA-181a Inhibits Tumor Proliferation, invasiveness, and Metastasis and is Downregulated in Gastric Cancer. | CbitrA/A | AhPhiS^ifgelfAA? AlbfigCahPerb:?:?:?: | dm? n | CDdteikfegpHPdridfAAAAA::::: mi<roRNA.-?bb modulates ::rton-:prriallteoli:hlHg:eaf!liOr·:·:·:· ceils chemoresistance and mrvrafton thtougb the csx« u 'unU Pjf s |
WO 2017/132552
PCT/US2017/015417
:ί:ίΟθ | Attas? bis- of «aR-irt? and ν\νΓ'Λ!Ρ0 tt 'Qf* | tiiir18 la | glioma | down | mir-181a and mir-l81b function as tumor suppressors in human glioma cells. | EfittbC::: | oial squamous -.ell varunoma | dm? n | MumRNA cyptessrow stonamre M oral squamous celt -carcinoma iur-ottonai -•de of onueRNA-ina/b nt the modulation of no' el cancer pathwau | ||
•tkC/bxy· | breast aaftcer | Jpwft | Breast cancer-specific mediated bv miRNA response elements of kt-7 | 181a | glioma | up | MiR-18Ja regulates blood-tumor barrier permeability hy targeting Kr?ppel-iike factor 6. | ?ίρΕ:;:3:3 | osteo-sarcoma | down | /miib2SEnib&^ xprolkoEatiOHCHtigiatiOK;:·:·:·:·:·:·:· >sd0gdii&^ bt Ui^vbumiN-'<&'«< ghcnhsis !tto>teo>amoma celU |
let-·:. | i/Tikth^idihfeiftiTT mioroRNA tet-’ inhibits cell tuotdity hy rapKlating tfcn gem at die actin cy iySkektyo pathway in 7^d^fekkdt.TTTTTTTTTT | tiiir18 la | hepato-cellular carcinoma | up | Up-regulated MicroRNA-18 la induces carcmogenesis m Hepatitis fl virus-related hepatocellular carcinoma by targeting E2F5. | mu- | osfeo-sarcoraa | dm? n | MnmRNA-2nb uditims metastasis of osiposan.oma | ||
•tkC/bxy· | bronchiolbakaoJar | Jpwft | kt-7 mkroRWA e^press-on Ci$;i^&i££dA&:hhhhhhhhhhhhhhhhhhhh /fe^o-itfi^i^^^^^f^/hhhhhhhhhhhi car-.inoma.a ηοίΜηνη^νο cafouiowa. atxf is nor torrelaiTd vj& prognosis | 181a | hepatocellular carcinoma | up | Polycyclic· aromatic hydrocarbon (PAE)-mediated upregulation of hepatic microRNA-181 family promotes cancer cell migration by targeting M APK phosphatase -5, regulating the activation of p38 MAPK. | Ovyrexpiession of E2H2 hi eatb pmstatu, neoplasia ua trans-.npyor.ai anti posttranscriptu.nai mcvhantsms | |||
•tkC/bxy· | cornu career | Jpwft | kt -7 mkroRWA fuuoteans suppressor in ianren; colon | 181a | oral squamous ceil carcinoma | down | miR-lSia shows tumor suppressive effect against oral squamous celt carcinoma cells bv downregutatmg K-ras. | :::mir:-:3:3 1B1I | acute kid et-ua | down | MiR-27a bnctioos ScSa tunK<ru-ippi?SC-orin acute ieukenyaby reeniaang 14- —--, |
7:^$P^^^:+++:::::::::::: fequarnuas cell | and egecf to HMGAi tn esophageal fequarnuus eeh | ISla | up | with pathogenesis and progression of osteosarcoma. | 21a-24-2- 2a cluster pmnmtes mratynan carcinoma eel! invasion and TSgpCiiiCdikiC^t^k:^^ | ||||||
T^flph^g^fTTTTTT Τ^ίώώώύέΐδίΤΤΤΤΤ | duWU | P qya ,\mt of * tn. ib «» micioRNA-Tha and kt-?a in esypitagoal squamous | mir- 18la | osteo-sarcoma | Up | MicroRNA 181a improves proliferation and invasion, suppresses apoptosis of osteosarcoma cell. | :Ob:7:::: | • . . · ^r | dm? n | Ttttmr Suppressor Cotofectaf Csnai-ygeoesis audPmoressrot. bi Targeting SCPP1 and | |
3^έίίΐΦ:Φ0(ίίέί:3:3:3:3:: | ttipti-ic | proliferation, migration. targeting Ctl-mi in gastric | mir18 la | pancreatic cancer | up | LPS Induced miR-18ia Promotes Pancreatic Cancer Celt Migration via Targeting PTEN andMAP2K4 | /Τη!-//// | O;!| | ctticttiniu, and ho&wNhc T^f^iTti^iic^Thhhhhhhhhhhhhhhhhhh; chemoprevcntion through regulation of miR-Ma and tthkR82?hui^ TtkhitShCCCCCCCCCCC |
WO 2017/132552
PCT/US2017/015417
$k£$b$£ | ££^£t£$$t$££££$/£ | $£$££: | $M£i£i$£A^ ettppresaes humatt gjsstn.2 oancoi maiighahcy by //taigdirrt^SST///////////////// | mir18 la3 | glioma | down | MicryRNA-183 inhibits glioma ceU?prolileration bv targeting cyclic. BI ’ | $£$$£//: :$£$££ | £$$£ί$$$$$////£ £$£$££££$£££ | /£$///// | £·$$£$£ί$ί££$$$$£$ϊ::££ miRNAs m esophageal //$££e££i’k£k£$£$£$£$£$£$/// |
ki*“b | gastric nr;<7 | /$0$$/ | kt-7b/g silencing activates ART signaling to promote gastric carcinogenesis | mir- 381 a1 | hepato-celhilar carcinoma | up | identification of mrcroRNA-J 81 by genome-wide screening as a critical player in EpCAMpositive hepatic cancer stem cells. | /:$£$//// £££$££ | esophageal spuaroous oek camtooroa | down | roieroRMA-27a lunefions //$£;££$rir££$p$$££$$///// esophageal STjumitous ceB £(^£;«kfpa:t^/iSf^riii£g££:///: /$$A$££££££££££££££££££ |
$kW/// | £^$£$££^$££££// £ί£$ί£$££££££££$ | dyu it | $Mt£l£i^Ab:ih£$£$£$£$7$/7 Paocreatn, Cancels | mir- 181a- 1 | non-small cell long cancer | down | MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. | iiii | £$£££$££$£$$£/ £££$m$$£$/////£ | £t£$g$$^A$$/£$$$$£$£ proliferation m esophageal ζΜικ4ηυΚί vOO ?hrewk4fia | |
kt-’itacioRNAnin human lung cancers ip. asstxuaht>n $$y£B£$£h£^d$£$£$£$£$////: /:$):£££$ϊ$:ΐ£$:£ύ£/ΐύ££://///// | 381 al | carcinoma | up | Papillary Thyroid Carcinomas Is Associated with BRAE Mutation and Clmicopathoiogical Features in Chinese Patients. | £££$m$$£$/////£ | $$£//$/ | as an oncogene fit gastric adenocarcinoma by //t$^$$g$£$/.$it$£$£$/////// | ||||
ki*“b | //idh££££ssf££$//////: | /$0$$/ | Redtaced e\ptes>um vi Db if v> Λλ ireii y ni. puAr prognosis tu ktngeancer £$i($O£££££££££££££££/// | mir- 181a- 1 | prostate cancer | up | mjcroRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. | /feiF:::/: $£$£$£/: | gastric cancer | ££$$//£ | DuWW'dKbUuMvi mdN £?ί£$1$$$$£$££££££/£ :$$(^£$$£/$:i$££k$£$£$/£: resistance yf gaslrtc cancer £$ίί$££££££££££££££££££££ |
:/ί£ί/7£$/: | $&££$£$$$£$$$/:$///: | doun | Let-?a elevates p>l(\VAFb l$vei$ by targeting of bkRF ard aupptessca tbc growtb <4 A5i$ htnp 'liuer Nib | 181a- 2 | glioma | down | MicroRNA-181 inhibits glioma cell?proliferation by targeting cyclin BI. | /:t£ir:-//// Bill | gastrte cancer | $$£///$ | biiR-2? promotes hubran gastric ^aticei cell $£k$ri£$£b$$i$£$$£$£$// epithchhtAo-uteScnvte mai £$££££$££$£$£$£$£$/://////$/ |
ki.·':- | £h£ihgt$t£££££$££ $££$ίώί££££££/££: | $£$££: | hricroRNAkt-’b tat$st& «ypyptaiit cell ct ck jik3iN«!e>w makgnant melanoma ceBs aod interferes with anehyfgaew<dcpct.dvntxrouli. | mir- 181a- 2. | hepato-celluiar carcinoma | up | identification of microRNA-181 by genome-wide screening as a critical player rn F.pCAMoositive hepatic canc er stem, cells. | mis- $3y£/££ | dm? n | £$$£$«$:$$£££££££$££ Survival via targeting of /:£££$££$£$$$$$$$$$$$$$$/// | |
:/ί£ί/7£$/: | noso-pltaryngeal £ί£$ί£$££££££££$ | doun | MtcroKN.A kt -7 suppresses •:-HSSOpfca«*Eg?3l:oa£Clf!»in3·:·:·: veils prokiemtunt through downteguhtmg c-Mvc $£$$$$$/£$£$£$£$£$£$£$/: | 181a- 2 | non-small cell lung cancer | down | MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. | /:t£ir:-//// iiii | hepate-cslhilaf $££$$££$///////// | $$£///$ | MiR-2 7a promotes £$$$£$£U£$£££$i£$$£££ £££$$£$fi$ridk£$£dg$£/£ suppression of its target g«.rte p^ro^tzmie $:$c£$0b£//////////////////////// |
:/RF?b/// | £h££o$$Sf0$A/£££ | down | ££i$^g:$$t$^£££££$££ £;k$i£ri$$k£$^£$d$£$£$///// enitanees MYCN levels via | roir- 181a- | papillary thyroid carcinoma | Up | Expression of miRNAs rn Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Cliuicopathological Features in Chinese Patients. | $£$$///: | £1$££$$.Τ$////////: camtooroa | /£$///// | idicroRNA-27a promotes proliferation and suppresses apoptosis $ rargetuig I'LK2 «. lap ngeal $££$«££$£$£$£$£$£$£$£$/£ |
$$£££/// | pancreatic duv'di atlene-eaiOli'OiOa | down | •:d$t-£:MtcroRNA:tfgngfeEin·:·: pypyroatiy cauc$r-d$n\ed yeite mbihiu ro vitro cell probteraiktn bmfada to abet tut'tef progression | mir- 181a- 2 | prostate cancer | up | microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. | $$£///// | ££$£££$·$£££$ | /$>///$ | vAdipOSeiissUe-UOCiated·:·:·:·:·:·:·:· £££RO$:$$£$$£H£$££/£ cruvetbv ktcerotghQMri £id££££$$d$r$$$$$£$£££ |
le:-:; | £:$[$/:$$$£$£££$££: $£$£$£$£$//////////// | /££$$/ | £$££$$!$Ο&$?$£££££/// determinants of tntrinsu chentoteststaiKS in ienal | ffiit- 181a- 2* | gastric cancer | up | MicroRMA profiling of human gastric cancer. | 83!· $£$£££: | uon-smaB cell £k$$£$l$£$£££: | down | Circulating mtom-RNA ewpressmnprofite’ meant stage npnsroaU call Bing |
WO 2017/132552
PCT/US2017/015417
780377777777^ | |||||||||||
/+/+1/7 | /ίΟΟ | down | miRRA tei^c promotes gisriulixA im diilercftharioft «. u+nto υρ,ρίνίίί teukemta | mii- 181a- 5p | gastric cancer | up | miR 18 !a-5p Expression and Effects on Cell Proliferation in Gastric Cancer | /ίί-Πί///: | //PStgb/8d^3ih3/7: | 1^11 | Pviewtub of muroRMA2“ j it. Ozie-^zvO-umj |
pmftW ClOC> 3C | /dOh: | A wstricted signature ol miRMAs distinguishes APL blast·., from uomoaf 7^^^ένΐ$^++++++:7+: | mh- 181a- 5p | hepaio-celltilar carcinoma | down | miR-l81a-5p is downregulaied in hepatocellular carcinoma and suppresses motility, invasion and branching-moqjhogenesis bv directly targeting c-Met. | /£&/:/:/ | osteo-sarcoma | /Oz/z | MjcroRNA-2 'a Promote* Picbleraucn. Migration and (m asms ht Tsrgefmg MAR2K-1 in Human Osteosarcoma Cells | |
Ict-X | htoas; 'jiuer | /7/0: | Brea>t ..aacer-tfwcjiSe :::>^2?ϊ^+$:^5ί^$^ί3ίΐ+7:+:+:+:+:+ mediated h> miRNA response elements of lei-? /diid/imici^te/:// | mir- 181b | acute pro myelocytic leukemia | up | PML/RAR? -regulated miR181 a/b cluster targets the tumor suppressor RASSF1A in .Acute Promyelocytic Leukemia. | 70777: | ovarian cancer | :7^777 | Ot.eugenu Ms roRNA-'Ά is a Target for Gemsteirt in OvftriaftCatteer CsUs |
•/ief+C/:/ | hfORcbtold-aiv eolar 7(^1^^777777777 | dpuft | k:-7 iBicfoRHA e+toesStett 7;i$;it^^ti?i^d7£3ti;;7777777777777777777 7:^^ύώ&ί^ί^^^έ$^:777777777::::: cammoma.a upu-iftsa>we OaiPUKtnid, arid is nol correlated wiffc prognosis | 181b | breast cancer | up | Transforming growth factor-? regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM | 7mif777: 1B1I | ovarian cancer | /0777 | Mi/ioRNAs overdressed in yvarran ALOHl-poshive cells arc associated whit OoO |
!·.'·· ·, | /::^07^07++7+7 | /7/0: | ki-7 muroRHA rim +mns as a potential grou th suppressor in litunan colOtt /03ft7^ | mir- 181b | cervical cancer | up | miR-l8:b promotes cell proliferation, and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. | 70777 | pancreafic :00:7:7:7777777 | :7^777 | ?:GgOeih:lbOif?7Ceb77:?:?: /:73dAtriri0ri:O^rip;777:?:? +T^3^:fe^ii^ri:p£:77777 MiR-2 ?a hi Pancreatic 7Gah/bfG3ilS777777777 7 77 |
•/ief+C/:/ | esorihrige^ | dpuft | Rote of mi/roRNA tet-7 Utid effect io KM<5A2 m esophageal sguan+us ceil /7ki7iribiti£///:/ | 181b | chronic lymphocytic leukemia | down -1 | Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. | 7mif777: 1B1I | /teO/All////////// ?Oilh$O?7?7?7 | /O////7 | uhR-2?a promotes cell proliferation atfti metastasis ht renal cell carcinoma, -, |
/^όρΙρ^ΡΡ/:/:/:/:///: SpuamoaS vCO /OthhO^^CCCCCC | microRMAAiva and lei-7a m esophageal >quauK>us /0:0^½^ | 181b | lymphocytic leukemia | enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple antiapoptosis genes. | 7Ote2f?7?7?7?7? | renewal cl the E-M* amal) cell lung cancer cell line m | |||||
!c-c | //ΟΟέέΙΟί/////////: | /7θΟ: | 7:ΜΐίΟ^^::ΡίΫΫΫΫΫΫΫ::7: 7:^^^^feiii^t^:^ijti7777::::::::::::::::::: 7^itek^ii0:g3ikONNNN:7:: | mir- 181b | gastric adenocarcinoma | down | MicroRNA-18 lb targets cAMP responsive element binding protein 1 in gastric adenocarcinomas. | ?O7?:? | :70O0?:?7?7? :θ8θόΟ?:?:?77 | /NJ?//// | :::CO^A:ISiiei0lO^7777777 t'xprpSzum Rroiiies jr Cervtcal Cancer. |
Gate?/:// | hepatocellular /Ο^ΟΟ///////////// | dvW‘0 | MicroRNA tetGc Intehttv /^i/fet^O Induces Ceil Cycle Anest by laigetKig CdX'25 A its /jimbhri^ /Cdrihiidh^/:/// | mir- 181b | gastric cancer | down | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. | 7077:7 | 7:hO:3rid/hO7+: squamous vOU ?Oi:h:i$O?777?7 | dOO ft | Coordinated Targeting of die EGFR Signaling Axis by Mic:pRNA-2?a* |
12:-7,- | /ibh^eO^ccccc^ | /:3/)77/ | Let-?aelevates p21fWAFl> ie\ els b\ targeting ol NfRJ? and zUppNssPztf+grootf. «fz\Sip burg cancer ceils | mir- 181b | glioma | down | mir-lSla and mir 181b function as tumor suppressors in human glioma cells. | ZhUi///// /3+877/ //III | g:n..p'. | Ο||: | mtR-24-3p audmiR--2?a-0p promote cell pmliferatmft :7:i:ti:^ii6jd^:C$O^::kii^:777777777::::::::: cooperate regulation bi iOii?7:7?7?7?7?7?7 |
/date?/:// | 7hihg7OSft777:77:7: | dvW‘0 | Reduced eapressson of the let -7 nhcroRWAs in human lung cancers u< association | mir- 181b | glioma | down | MiRNA-381b suppresses IGF1R and functions as a tumor suppressor gene in gliomas. | /Elite/// | gastric cancer | /Ο//// | nwR-27 promote> human /«Οί:ίΟί:?^7/7//+:77 metasiasrs bj inducing |
WO 2017/132552
PCT/US2017/015417
postoperenve sun tvaf | opitltelial-tU'fpeseaehvrdul 5:tf^hldh555555555555555:5: | ||||||||||
5O558k0e0:5555555: | CdoO) | I vducvd e\ore sure vl Db if a« λλ is'ed s nh puAr progoysis ib lung cancer 5^ίϊ^^555555555555555555555555555 | mir- 181b | glioma | down | MiR-lSlb suppresses proliferation of and reduces chenioresistance to temozolomide iuU87 glioma stem ceils. | CkufkcC 50555 | pghpihbyppppp:::::: | 5Ο555 | f xpiessreu and fup.vfion vi mfR->7b m human gimma | |
5ίρϋ5*555 | nosy-pliaryngeal 55:aiPmbi^555555555 | dOun | MtcreiRNkA lei -7 suppresses MKiSOpharvngenfcarornoiria·:·:·:· downregulatreg c-Myc 5:^N^t5ji55fGjd55555555555555555555555: | 181b | hepato-celhdar carcinoma | up | Polycyclic· aromatic hydrocarbon (PAE)-medtated upr egulation of hepatic nu.cioRNA.-181 family promotes cancer cell migration by targeting M APK phosphatase-5, regulating the activation of o38 MAPK. | cipir5:55 505:5: | pghpmakytppppp | 50555 | MiOroRNA--2.7h inhibits 5:5^^:$^g$^ibb5hr^55555:5: promotes cell invasion in 5giOiO$£ V5^i555555555 |
5iph5*555 | nosy-pliaryngeal careiroma | 5dsrek5 | Knocking dowit ( DK 4 mediates ike ele\ anon of iet->e suppressing yell growth re oasophary ttgeal | 381b | non-sinall cell lung cancer | down | Down-regulation of micrcRNA181b is a potential prognostic marker of non-small cell lung cancer. | :::ihif:-:0y: 50555 | oor.-smalicell lung cancer | down | MioroRNA--2.7h Suppresses growth and invasion wi N^CLC yells tre targeting <5S&£55555555555555555555555555555555 |
b:--; | 5:hSPi55bi^i5^55:5:5 | 5:355555 | neureblasiorea and er-hames MYCN level* via | rnir- 181b | oral squamous cell carcinoma | up | Relationship between microRNA. expression levels and histopathological features of dysplasia in oral leukoplakia. | 5imi5:55 50555 | CiibiidOiibhtdVVi: | 5B555 | Genomey.ide Study of Salrvan MtuoRNAafoi Dreeynon of < htri Gamer |
!C:-C | 5110^55^185511:805: 5Ο555555555555555 | MicroRNA ki“‘R nJnbra. migration and mvasiob of human norewmall cell lung cancerb> targeting ϊΤβΒ.ί | mir- 183b | osteo-sarcoma | up | MicroRNA signatures associate with pathogenesis and progression of osteosarcoma. | mn- 50555 | ovarian cancer | l!^ll | MicroRNAs overexpres&od m 'artinAI bill vwrtwe cells are associated with c-hemc-resistance. | |
5iph5*555 | puncreattc ductal hdeno -carcinoma | 5dsreh5 | let ThJnrekNAfiat.sferM. pancreatic cancer-derived colly inhibits in vitio yell 5£fb&OtO alter remorpregressren | 181b | ovarian cancer | up | MicrcRNA-l81h promotes ovarian cancer cell growth and rnvasionby targeting LA.TS2. | :::ihif:-:0y: 28-50 | colorectal cancer | down | Sfrand-itpeciftc miR-28-5p 55^5i0ife7^p:f^':^5555555 5^tm55:SW$5tii:«5555555555 Colorectal Cancer Cells. |
50^555; | prostate cancer | dyu it | suppresses andtogon revereotcxpres ure and < .uh repil<mt Af >3\*. expre^siot. inprc-Shne /:55^έΐΐθ5$58<<<<0:0:0:0:0:0:0:0 | rnir- 181b | prostate cancer | up | MicioRNA-18 lb expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3. | CnillACv 28-3p | 555>Ο555555555555555 | 5B555 | Ddferei'traiexp'espon of reiLNAs hi esophageal :5^^^^5^^^-55555555555555555555: |
ict*·”^ | prostate oaocer | MuroRNA lct-7< r> tic.wnregnlated in prosiare prest i e cat vet growth | mir- 181b | retinoblastoma | up | Hypoxia-induced iniR-J 81b enhances angiogenesis of retinoblastoma cells by targeting PDCDIO and GATA6. | •tiPifyyy: 28-5p | colorectal cancer | down | MrubdRpe. tire mrR-'X-V 5i^5i0ife7^p:f^d5':^5555555 5^tm55:SW$5tii:«5555555555 Colorectal Cancer Cells. | |
renal dear cell | dc-wo | Jet-?h and let-7c are determinants of intrinsic vheaiofesisiaaye m renal | mir- 181b- 1 | glioma | down | MicroRNA-381 inhibits glioma cell?prolrferatiou by targeting cyclinBl. | 5ipir555: 28-5p | 5reOrelf5555555: tjcaiOmOipaCCCCC??: | down | A panel of Five sennit miRNAs os a potential 5:di^bO5^bffbi:^O5555 stage reral -ell carewretta | |
50^55; | cbhi^foShepiCO???????: | dyu it | 5^^£^5£^Ol$555555555 modiaied bv reiRNA response elements oflet-7 | rnir- 181b- 1 | Iiepato-cellular carcinoma | up | identification of rnicroR.NA-18! by genome-wide screening as a critical player rn EpCAMposi live hepatic cancer stem | 5ίϊΡί55:5: 50555 5B5555 | gastric cancer | 5B555 | MioroRNA-2<>6-Sp 55ri£rep£gk^ 55^^i>ijre?c5-5^i;c^^:f^6id^i;;55555555: repressmnN ( indui- |
7
WO 2017/132552
PCT/US2017/015417
30/0/1/2//////////: | cells. | ((fO/d^hte/b//(h(((((((((((( | |||||||||
8:ΐίίό/ό/ΐ0ΐ/(/ΐ/ί/ί1/ί8( ((έ^/ί///ί5/(((((((((((((: | ((&///(: | tei-7 microRNA expression (fS//d///d//(((((((((((((((:((((( bronchiokiaivCohtr am-noma, a η··»η «λ a»' e carcinoma. and ts not correlated with prognosis. | mir3 83b1 | non-small cell lung cancer | down | MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. | (:///(((( (:2//((((( | 3:he/f///eJptd:((((( 81ύ////ι1/(((((((((((; | (0(8(8 | ((^bS/h/S/^(^h////(((((((((( capacity m hematopoietic pr-cgem- oi n biased eimd developmeuk and acute myeloid leukemia. | |
8&ο((( | 8ό/1θ/^/ί/ίΡί8:3:3:3:3::: | down | tel-? microRNA iaiKlkais asapO'er-Uai growh aapprcssor nt human cofnu (/8/3////:1/((((((((((((((((:((((( | mir- 181b- 1 | papiiiaiy thyroid carcinoma | up | Expression of miRNAs in Papillary Thyroid Carcinomas is Associated with BRAF Mutation and Clicicopathoiogical Features in Chinese Patients. | :::ύ:ΰυ:::::::: | acute myeloid ((!///////((((((((((( | ::////8 | yM/;8pR^A2//:/e//i/te/?????: the expression of the unclear oncogene Ski |
•cM'd | ((¢/3///^//(((((((((((( ζ^ΚύίΠυΙΙ J vC'l (j(/^ihjiap//:((((((((( | (////3 | Expression of circulating ma^roREfA-2da and ict-?a in esojibagcai 5<ba&xms :/ό/:/ί/όϊ/θί//?83555:::3:3:3:3:3 | mir3 83b1 | prostate cancer | up | microRNA.-181 promotes prostate cancer cell proliferation by regulating DAX-l expression. | urn- (/-//((((( | breast cancer | l!^ll | Ne 0-cet.etmivn sequencing of pjicrcRNAs for breast ((^k//^/O((((((((((((((((: |
((/Sflph^g/l((((((((((((j (//////5////11((((((((( carcinoma | dvWO | 30/00//00(03/::(:::::::: and eSfeet to EMG.A.2 in esophageal squamous ceil (////////(((((((((((((((((((((((j | mir- 181b- | glioma | down | MicroRNA-3 83 inhibits glioma cell?pro3iferation by targeting cyclic BI | 3///(((( 29a | breast cancer | //1/((((( | mmruBNAC't negate eh teguiates EM'f regulator Nittye interactof io. breast ((¢/1///((((((((((((((((((((((((((((: | |
:(0^/(( | /he^:3hi(hO:(((((((( ((^/ij/ip0i//0e!f((((((((; ((////m/hi/(((((((((((((: | ((&8R/3 | Low-tev ei expression of (://3i/RO/:ipt(id///((((((((: ((i/^82//3///i/g//$(ii3((((((( matkety of head and neck squantnus ceB earcinoma. | 383b- 2 | iiepato-celiular carcinoma | up | identification oi' microRNA-J.81 by genome-wide screening as a critical player in EpCAMpositive hepatic cancer stem ceils. * | ::://188:8 (I////: | ((e///0//(((((((((((( squamous ceil 803///8/(/838383:: | down | ((3nO/O^Os//((((((((((((: imcroRNA-iOa inhibna ((////te///il(l/ig//ii/ii:///(((((: unasionxia targeting /1/^1//7:2////83//1((((((((((((((: s^uaniuiL· veil earcHkona |
•cM'd | ΪΟ^^ΐΟί////: :(έ///ί/0/(/((((:((((((((: | (////( | (00/00(0(((((((((((((((((: (:H00OiO(/0(i((((((((((((( /00κ00(ί/0/0:(((((((((((: | mir3 83b- 2 | non-small cell lung cancer | down | MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. | mn- (/-//((((( | odRie.tai ^arivet | l!^ll | mivml NAexptvx^ton ipkiiifefh/ta^ifi//////// colorectal cancer; Circulating mrR-l8aand ((hkR((2S/:///iP///»hg////:: (:/mi///O((((((((((((((((((((((( |
8te/?d/(( | ((!Opg:0a//®i;(((((((((((( | dowG | Reduced expression of the ::iet>5nMC4eRhiAslE:huCian:·:·: lung cancers hi assouadoit (O0:0d0i0(((((((((((((((((( postoperative sun ivaf | mir- 181b- 2 | papillary thyroid carcinoma | up | Expression of miRNAs in Papillary Thyroid Carcinomas is Associated with BRAF Mutation and Clinicopathoiogieai Features in Chinese Patients. | :(/p/:(((: | colorectal cancer | (0((((( | MicrcRMA -29a promotes colorectal canter metastasis bv regulating mattiy ((^teiiPpihi/iii//8(2/^:^((((: 838//0/(//00((((((((((((( |
(βϊ(( | 3:/8ji/8if/i////::// | (////( | Reduced expresaion di' Dicer associated whhpo^t propo-Nutt. lung 'jitter (/^0/((((((((((((((((((((((((((( | mir- 181b- 2 | prostate cancer | up | microRNA.-181 promotes prostate cancer cell proliferation by regulating DAX-l expression. | :(///:(((: (///((((( | odlorectnl cancer | (0((((( | P \ ahjatfoo of rntt roRi TAsa. 92a and 14> in <oioreeta: ^ar^momaas candidate diagnostic Qiaikeiy AnEgyp'iat·p'tet (/&////((((((((((((((((((((((((((( |
8te/?d/(( | /biag:/a///i;(((((((((((( | dowG | Lct-?a elev ates p? It Yv AE 1 > levels b> targeting of NERF ad sirpo*·' *vs thv gmwth of A54P hatgcaocer cells. | mir- 181b- 5p | astrocytoma | down | MiR-181b-5p downreguiates N0VA1 lo suppress proliferation, migration and invasion and promote apoptosis in astrocytoma | (8(//(((( | gastric cancer | down | MicroRMA-29a mhtbits ::ceii:miaratio:n:and:tIKasion·:·:·: via iargeHngRoundahout hutnoioc i m castue ^anvet ..ells. |
8teO((/ | naso-pharyngeal ((ί/ί//«ί/^(((((((((((((: | down | MkioRNA tel-? suppresses nasHpiiatyngsai oatt/ioma eefte probfersdon through | mir383 c | gastric cancer | up | Upregulation of MicroRNA. 181 c Expression in Gastric Cancer Tissues and I’lasma. | 8///(((( (///((((( | gastix vdocei | (:////(( | Effects of microRNA-23 8ia/iii/:h//5/8i///((((((((((((: omiiiemmu, mdmvazUH |
WO 2017/132552
PCT/US2017/015417
ilowweguiafhtg c-hly c | of gastric cancer cell lines- | ||||||||||
Ari^iqYsbsiG^+A:::::: | cdpO:: | enfcaonesMi CN levels via | mit- 181c | glioma | down | MicroRNA-181 inhibits glioma cel3?proitferation by targeting cyclinBl. | yftbto/i | gastue cancer | down | MiR-zfta Inhibits cell ptobieiauuit and induces cell cvJo arrest through die doy.niegulationof p4>3 in human gastric cancer- | |
tptolpatiecftRRRRRR | down | Let -7>j iuoePOOS as rtoval regulator of cphhelial- ::-mescnohymai:transhionuriri:·: obemomsisiant propeip in | 181c | hepatc-ceiiular carcinoma | up | identification of mieroRNA-J.8l by genome-wide screening as a critical player in EpCAivi·· positive hepatic cancer stem cells. | fftril:-:?:? i^ll | gastric cancer | down | miR-TPa suppresses growth and invasion of gastric cancer ceils hi ' tiro by | |
Α^ίίίΐ^ίίί^ίίδί^/:::::·: acleijo-cajciroroa | (Olf | let-7 MkroRNA transfer <£; paucrcafic eancct-dctrced cells tnhuhbs ut vitro cell ptoriferatton fct-f laris to after tumor progress ton | mir- 181c | neuroblastoma | down | MiR-181c modulates the proliferation, migration, and invasion of neuroblastoma cells by targeting Smad7 | fmiriLL | dow n | MicroRMA-LAs could target ΑΚΪ2 to inhibit pjsiik «tf Hbto\jsmt | ||
Meri?dM | paoereaiie ductal adflK-eSfCtr'nfoa | down | MuttA-v «petit? Oncogenes Are LtowttRcgulated k Pancreatic ϋ^<^11^^ίΐ;ΐ::Τΐ^·^ίώ^ί^1δΐΐίϋ:ϋ | ttiir- 181c | con-small cell lung cancer | down | MicroRNA-l 83 functions as a tumor suppressor in non-smart cert lung cancer (NSCLC) by targeting Bcl-2. | :ΟΡϋ::::: 29a | //hi^ahdOifeifi squamous cert Lhdfcihpih^LLLLL | daw n | Tttmonr-snppreswve rnicmRNA-Fto tohtbit cancer cell migratton and invasion by targeting laimmu-mtegrin >wnaJbitc ut head and m.A spuatuous cell iar.inom-j. |
!C-d | renal cell carcinottia | Lel-7d stippresaes growth, me tastasis. and tumor meurophagc mirttratmt; m mnalceli catcinamaby targeting COL3A1 and | mit- 181c | osieo-sareoma | up | MicroRMA signatures associate with pathogenesis and progression of osteosarcoma. | mn- | Abakibdjtb^AAA:::::::: | down | Effects of microRNA-2y <m apoptosis. tumongenioi tv, hepatocellular csfCMOo a | |
TRAIL expression mediated by miRNA ?e>ponse elements of let-? and mIM.R | 181c | papillary thyroid carcinoma | up | Expression of miRNAs in Papillary Thyroid Carcinomas is Associated with BRAE Mutation and Clinicopathoiogical Features in Chinese Patients. | ymftA:?· | hepatc-ceiiular ypaipmoipayyyyytt: | down | nacroBNA-fha suppresses hepatvediniar > ^rcumn -a | |||
•c-'c | ibfphihtdibidtoiOiR: | iel-7 microRNA espressiou hhi$T$jjijiit:!i^:iiifhhhhhhhhhhhhhhhhhhh/ caremctroa, a non-k.vasive ysapi^ correlated with prognosis- | mit183 c | prostate cancer | up | micioRNA-18i promotes prostate cancer ceil proliferation by regulating DAX-l expression. | mir- | down | Negative-feedback of miR29 Ramify 7ΕΠ involves in hepatocellular cancer. | ||
colon aoncet | down | let-? mieioRNA functions asapO'enfta! growh suppressor m human colon ί:έ^^:έθ^/ΑΑΑΑΑΑΑΑ:::::::: | mir- ISlci | glioma | down | MiR.-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. | ymftA:?· | hepatc-ceiiular ypaipmoipayyyyytt: | down | Erratum to Negate e feedback Ά itflR-29 fponiy hepatocellular cancer | |
yhiifiuih^RRRRRRy | and effect tohlMGA2 in esophageal sguato^us eeii /LhfoIhrtOTTTTTTT | 18 Id | glioma | down | MicioRNA-lSl inhibits glioma celi?proliferation by targeting cyclinBl. | profiler and ideiitdfeatlon of miR-wP as a prognostic murker and pathogenetic factor hy targeting CBE.6 in mantle call ft mpi-oma |
WO 2017/132552
PCT/US2017/015417
ckt^icT | caicincron | t/djOR | hvprc*85nt ofmuifiiug microRNAAds arid kt-?a in esophageal squamous $£0Ρ£ΐ:^ | itiir18 Id | hepato-cellular carcinoma | up | identification of microRNA-181 by genome-wide screening as a critical player in EpCAMoosilive hepatic canc er stern cells. | SimiA::::: | meson-toy inal | duv n | miR-2f> Acts as a Decoy m Sarcomas to- Prote f ik. Tumor Suppressor A2f> mRNA from Degradation Chy:GyRC/////////////////////////; |
fiet-Tcyy | cS^itopSilpiafcCccC y£dkiikibhcTTTccc | down | MicroRNzks tn ciicphid^ii^RtdiidccccTTT: ra-uieaiK Callers | mir- 181d | hepato-cellular carcinoma | up | Polycyclic aromatic hydrocarbon (PAH)-mediated upregulation of hepatic tnicroRNA-181 family promotes cancer cell migration by targeting M APK phosphatase-5, regulating the activation of p38 MAPK. | CimrCcc 2Pa | titonocy tu | down | Altered e v press ton partem of miR.-c^a. miR-RAh and the target genes hi my elphi |
fiet-Tcyy | /bthgcaucerfyfyfyfy | cdokik: | Reduced cxpressipti of Dicer associated wuli poor prognosis hi hxig caneer hhF^ii^^Rhhhhhhhhhhhhhhhhhhhhhhhhhi | mir- 181d | non-small cell lung cancer | down | MicroR.NA-381 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2. | CimrCcc 2Pa | Th^tirbvbk^chmcv | down | C©e^:MihrbRWcCCCT:T:::::: sequencing reveals ::dowmegulat£On:oirfiiR:-2ya·:·:· |
down | Let-?a ale·, ates p2 litt AFi) levels b> kigebng of NiRF •slid suppresses the growth of A5oy lurtg cancer cells | mir181 d | papidaiy 'thyroid carcinoma | up | Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAT Mutation and Clinicopathological Features in Chinese Patients. | yhuryxy: 30/// | thpht5irtaif0glL:8:8: | CtlORiR: | Suppression of Wnt signaling by the mtR-29 familv js mediated bv demethylation of WIF-I in ncn-smoli ceil lung \.ancef | ||
ic:- ·, | ThibgC^hSSrCCCCC:::: | cdOfe | Reduced expressuoi vf the kt-? microRNAs m human lung cancers in association postoperative survival, | mir3 81 d | prostate cancer | up | microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression. | CkirAT:: | CbrSl/S^i-ih-O/CC ceil carcinoma | dow | MtomRNA-2'A. ’iprmni res \fMP' to of d’^to’NUz cell carcinoma to promote cancer invasion and antl- |
nasc-pliaiyngeaf yCdfCihpf^yCCCCCC | dPuh | RhcfoKNA. let -7 Suppresses •:iK}SOphaffrHg03l:ca£Olf!»iria·:·:·:· cells proliferation through tfownregalatipg c-M>c | 182 | bladder cancer | up | Sy nthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and mduce apoptosis in bladder cancer cells | ChiifTcC /Oil | gastric cancer | down | Reduced miR- 29a-jp xexpressrariislrnkeJxo/tlie·:·:·:·:· cell proliferation ap.j ceil iinpm.ttoii m jftztru «.anoer | |
ie-e | CddO·: | enhcoeesMY CN Jm els via vigRTipp^^iOiPttCC?????????: | mir- 182 | breast cancer | up | νίΡηΝ/Τ | iymphocy be Cl^itkqtbxfeTTT/TT: | down | yAbdif^fthftjkROcTTT:::::: e-'.pressmnmCbmese pauents with chrome iv mphocytic leukemia | ||
paocreaik dnctal 3$«ΙΟ-03ί·0ίΟΰί'ί& | diWvO | 1' -7 Rk roRR A trap zer tr parcreadc caixer derned cells kdtlbits Ik >itro call | mir- 182 | breast cancer | up | Suppression of M1M by mi.croR.NA-1.82 activates RhoA and promotes breast cancer metastasis. | νΙΡίίΑΤ: | Jop n | miR-29bsuppresses minor jtgibAgkbii^ dywrireguiaUng Ttaml c\or' sivnapd mlPbdiPJ eptth'diai-mesemte mat i.unsmon | ||
L-;-c | papsJJa^tfejroaJ | /w|l | Ciroufaiing mieroRNA prof In is pu'euual kpmarkars for diagnosis of ypapiiia^ /•ίΡίίκΐόΙΐίή/ΫΫΫΫΫΫΫΫΫ::::::::·: | mir- 182 | breast cancer | up | Higher expression of circulating miR-182 as a novel biomarker tor breast cancer. | mn- | esophageal squamous ceil eorctncioa | down | progress tort of esophageal squamous cell carcinoma by targeting R1MP-2 |
cdoRhy | Let -7f inhibits Glioma Cell Pmltfefation. Ritgraiion, and Invasion by Targeting | 182 | colorectal adenocarcinoma | up | Enhanced. miR-182 transcription is a predictor of poor overall, survival in colorectal adenocarcinoma patients. | /:ίήΐ£0:::::: | gastric cancer | down | MicroRNA-RPs could targei AKT2 to inhibit ::gastr£c:caneer:celisirwasion·:·: |
WO 2017/132552
PCT/US2017/015417
Β/|/)/ | //O/^//u///// //ί/.ϊ/ό/'/////:/:/: | ))99//:) | Expression of serum twJN fix tet-7£ anti mtR-2Ί m patients with hepatocellular carcinoma and thetrckiucai 99ig//te3/ibS9999999999999 | itsir- 182 | colorectal cancer | up | tnlR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer. | )9//)))) 29b | /g/SO//i/5/:/9 | don n 92:5429:: )/3/// | ?a hcroRNA“2V& could /t//^):AR?/?/9ti9:^b/////:: gastric cancer ceils invasion /^ii////////////////) |
9ί9/?£-99 j/jjjjjjjj): | breast cancer | dowh | Breast cancer-spocific ):/^ΑΪ////(//(ο/)))))))))))) mediated by miRNA. response elements of kt-’ :::/’/O;^|?////////:/:: | mir- 182 | colorectal cancer | up | Up-regulation of m.iR-182. expression in colorectal cancer tissues and its prognostic value. | ::9//999 :/§/:// | gastric cancer | down | Deregulation between mtR ’vb caurikNMTkkm associated with epigenetic stlertcine nf the G>fB gene uttMmdv'fl migration and invasion to 9:§^)///9/έέ/999999:999:999 |
kl-7k /|//// | hronchfolo-aia color carcinoma | ::/9//::: | k'-7 mroroRBA e.press.rtn ):(Ο//9/·Ο/////////): hronchiAioafvnolar «,ait,mqi'ia, a nm «<> asn e carcinoma. and is not | mir- 182 | colorectal cancer | up | mrcroRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis. | ::1/19999 )O)jjj) | glioblastoma | down | mtR-2.99 and miR-Ί ?5a regulate podopfanm and /^//i/s/ii/’/^/i/i/))))))))))): ))/(//)1/51///))))))))))))))))))))) |
9&/?ί// ill/l | 9Ρ/1/ί9ό3ίίί:/ί:9999999 | down | tel-? ttiicroRNA functions as a potential growth suppressor in hrnnan colon )/3/)(//eii/))))));)))))))))))))) | mir- 182 | colorectal cancer | up | Circulating miR-182 is a biornarker of colorectal adenocarcinoma progression. | )///)))) | meg adenocarcinoma | :)9///): | ::MicmRNA:-2Pb:is:invoived·:·:· ))1///9)//9/(///(^(//9))))): )/9/)/9//9///////////9 dy sreguiated in human Jung 9///t)//99in0i9/:9999:999:999 |
k:-“i- ///:/// | ))/9/pfi/g9/i9))))))))))): j vC'd )//19/90(9/))))))))))))9 | ::/9//:: | Rote olndcroRNA tet-7 nr-ri effect to flMGAd io esophageal squamous cell l/gi/mP/////////////: | miit- iS?. | colorectal cancer | up | SATEs 1 and 2 in colorectal cancer | ::/599:9:9 )O))): | mantle vdl lymphoma | doo ¢1 | murcRNA '\prcsamn profile and idennfrositon of mtR- 2 9 as a prognostic marker and pathogenetic T nW n i Mgvttnd < Ukb m mantle cell kmpftoroa |
/////| | ))9δ0ρ/3£9//))))))))))9 feqwnuiii» ceO //ί/.ϊ/ό/'/////:/:/: | microRBA-zOa and tei-?a :r esophageal >qaanmns )/9ii)99f/f/h/))))))))):)))))))) | 1S2 | carcinoma | up | 182 in colorectal carcinoma: an independent and tissue-specific prognostic factor. | /te/ik//////// | of n9R-2Qa. nuR-QVb and the target genes :n tin efoid ))/1://9//))))))))))))))))))))))))) | |||
919/91/)) //////: | //O/^i/tU///// ))C/fm9/(9/t))))))))))))i) | ))99/)/:) | 9Mi/O/A//t///////:/: Bepafobtfian Mid I’ancreatlc Careers. | itsir- 182 | endometrial cancer | up | MicroRNA-182 Promotes Tumor Cell Growth by Targeting Transcription Elongation Factor A-like in Endometrial Carcinoma. | mn- )25/)))9 | /9//-/9)////11//: ))/91/991///))))))) | don n | )^(9/(//9/(:////(/19:///)):)))): );ί/ί/////(ί///:/έί/ϊ/))))))))))) ))0^0)(/:^/////////9) eisplatta/gemcttabtiie for the treatment yf NSCLC |
9kE?159:: //////: | )bi9/99il9/99)))))))))) | dvWO | deduced expression of the kt ·? mkroRWAs in human lung cancers «< association ))///^ί/ί?/ί/9))))))))))))))))): | tuir- 182 | gallbladder carcinoma | up | TGF-? upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1. | ::(91/999 :/§/:// | /9/9^9//:9/1:1//: jjlrihgkance/jjjjjjj | don n | btippresston of Writ Signaling b\ the mtR ?fj family 1$ mediated by demefhviatiytiyf 'ATF-l it' noo-smali-eeif lung cancer. |
91//71/9: //////: | ))l/9g/9d9S/))))))))))) | down | Reduced expression of bttei assocaa-ed w dfc pyn prognosis «; lung cancer 9//i/it/////////////9 | mir- 182 | gastric adenocarcinoma | down | MicroRNA-182 targets cAMPresponsive element-binding protein?! and suppresses ceil growth in human gastric adenocarcinoma | ::///:/9 29h | /9/ )//9////11999 ))1///9/99//))))))) | :)9///): | ::MicmRNA:-2Pb:3ttemiStes·:·:·:· nyr-smail cell lung cancer metastasis 'ro largttine mams metaik.protewnw 2. -md ί/Ί-Ν |
k:-i- //////: | ))1///9/999/))))))))))) | :)///99 | Lck?a elevates ;o2 lOYAf ί > kveteby targeting of NlRb and suppresses the grow tit Ot pjttg cSAVt cOtiS | mit- 182 | gastric cancer | down | MicroRNA-182 inhibits proliferation through targeting oncogenic ANUBLT in gastric: | wu- (O/:/ | osteosarcoma | down | MrcroRNA rdgnatares associate· with pathogenesis ):/h/(///k(///(te/))))))))))))) osteosarcoma |
WO 2017/132552
PCT/US2017/015417
8k/?f/8 ::|:////: | riaso-pliaryrtgeaJ /^ϊίΡ/ί//////::/:/ | (:/8//:( | MicroRNA kt-7 anppresfees tv* ,o k m t pvtf itMWk Ceils proliferation ihrough <Dh megt/a--ng v Mat (/(/^8/6//(((((((((((((((((((((: | mir- 182 | glioma | up | The miR-183/96/182 Cluster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas. | :(///(((: 29b | prostate «.ancer | dnv n | miRNA-i'k suppresses pm state cancer metasbuu mese itchy mpl tiyrtsitiyti ((grgn8lm/((((((((((((((((((((((((( |
0k/?f-C0 :|::////: | (//irOtblastpipa///:: | dowo | L1N78E mdoOes :tife0O!/sOiS/^id//////t erdtances MYCN levels via 8k/./k8//km/((((((((((((((( | mir- 182 | glioma | up | miR] 82 as a prognostic marker for glioma progression and patient survival. | ymif-::·:::·:: (/O|(( | breast cancel· | O//(: | mmroRNA-29 negatively regulates EM'F regutetorN- /irty/gjO^^/k-bkO//:/: fO/b/////////////// |
tk/xf/x /|://// | pancreatic ductal /^gr®^ty:«//ia//:: | dyu it | kt x MicioRiT A transfer in (/8i/ind/b///i//id////:(( proliferation hat tails to alter tuntof progression | mir- 182 | hepato-cellular carcinoma | up | OucomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephri;iA5 in hepatocellular carcinoma | :-:mir:-:·:·:·:· :(0/(( | gastric cancer | d«w n | Effec ts yf micro Rt4a.-29 family members yn proliferation and invasion of gastric career ceil lines |
kt-f- | (bk^fpO^///// | (:/8//(: | K.^.s «ws «.da. ::/^Aik//^k^kti/////:/:: rt-spousa elements oi let -7 (/i/(t/lR( 1//(((((((((((((((((((( | mir- 182 | hepato-cellular carcinoma | up | W nt/b eta-Catenm ac tiv ate s MiR-383/96/182 expression in hepatocellular carcinoma that promotes cell invasion. | fi’U- (/|||(( | ((hO/hd(h88k://: ?quamuu,vO'd /ij/fcih0iph///// | dnv n | /0^0//^00/////:/: mumRN 4- 29, inhibit cancer cell migratton ate: invasion by targeting laminin- tate.gr in signalling in head arid rtecs squamous t:Cd//hi/hib/^k//////://: |
0/(//// | /^i«/^//////$ | $j/kdiiiid:«/////////:/:: (:/θ8θ/?.ί^όί/ί//////:: carcinoma. a Rui!*ttn««v€ :AdfeitidO:^:i/fei///// correlated with oroar-ysis. | 182 | carcinoma | up | as diagnostic and prognostic markers in patients with hepatocellular carcinoma. | 29b-l | ((8/km8k/(((((((((( | feedback nf mrR-29 fartub ((tkf/ik8///i:/((((((((((((((: hepatocellular cancer. | ||
xk/?!// | κΛ>η •'jn^e-r | down | kt-7 microRNA funvtipns as a potential growth suppressor in laimao colon (/8/(^/8//((:((((((((((((((((((( | tnir- 182 | hepato-cellular carcinoma | up | MicroRNA-] 82 downregulates metastasis suppressor 3 and contributes lo metastasis of hepatocellular carcinoma. | νΡ/ύϋ::::: (/Ol/ | hepatvwxllnlitr camioomn | (0//(( | 1 newt, vi nuwrvR N A-29 «η apoptosis, temortgenicity, ((/id-prpghp///1/((((((((((((((( hepatocellular carcinoma- |
(kikk/: | esophageal /^U/iU/US//ii///:/: /^i«/^//////$ | drmn | Expression ofcir-cuiaong mieioRbiA-’vy and let-7a a: esophageal squamous coil carcinoma. | 182 | hepato-cellular carcinoma | up | MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. | /•mir:-::::·:·: :(0/(( | hepaty-enllular /^kuk/ig///// | down | Negativ e feedback of mtR29 family TET i involves in hepatvvcbulai cartvCt |
(k//i/(( 0/(:///0 | /^^fe^Si:////// aquarnons cell ((C/i/k/k/(((((((:/// | down | (;Rdi//f/ki8RNA(lpf(/(((((( and effect to HMGA2 m esophageal squamous ceil (/kh^b////////////:((( | mii- 182 | lung cancer | up | Differential MicroRNAs Expression in Serum of Patients with Lung Cancer, Pulmonary Tuberculosis, and Pneumonia | 29b-l | /bdiky//////// | ar vpus nlhoevfd e •/T/hi//5dppk^0fA3/////: triR NA from Degradation bx ! (...R | |
!C:-i- 0/((((((((( | ((h/j/dg8iO///// (/k/tbhh//((((((((((((( | (////:( | (:^dh0r8//0:/3i((O(((((((((((( | mir- 182 | lung cancer | up | Downregulation of microRNA182 inhibits cell growth and invasion by t argeting programmed cell death 4 in human lung adenocarcinoma cells. | nm- :(0((((: | /8/0(/0/(// ((Ok//////// | down | mil -2^ A.t? wa DecOi m aarcomas to Protect the Tumor Suppressor A2k mRNA from Degradation (h^^hi^/hhhhhhhhh^hhhhhhhhhhhhhh |
bncf assocra-ed w & pO'U prognosis u: lung cancer :t//i//s:0ttttttttttttttttttttttttt | 182 | lung cancer | down | Methylation Status of miR-182 Promoter in Lung Cancer Cell Lines]. | :::U5ipy:::::: 29b-2 | breast cancel’ | (:^((((( | iinoioRNA--29 negate ely regulates EMT regulaior'N/hi///hO9k/m::bkdij////: //ίί/ό/////////////// |
WO 2017/132552
PCT/US2017/015417
:ί:ίΟθ | Let- ’a eiev ak> p2 it WaF D kvusiri urivtt<guiN!Pl·’ and suppresses tbs growth of A54 7 lyng viitcei v^ib | mir- 182 | malignant melanoma | up | Aberrant miR-182 expression promotes melanoma metastasis by repressing F0X03 and microphthalmia-associated transcription factor. | 2^b-2 | dtm n | Effected' ηη«υΚΝΑ-29 familv member vn prohiorarion and invasion of gastric cancer cell lines. | |||
4//31 | :thihg:CapOef://///$ | dc-wo | Reduced expressiott of the kt -7 microRMAs in human lung cancers «< association postoperative sun tvaf | mir- 182 | malianacl melanoma | up | Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophorus pigment cell cancer models. | tdgity$:$: >fr.> | head and neck squamous v oil /OtePmPipa////$ | dhwn | Turnout supples no micJORNA-N$ inhibit cancel coll nagra- ·ηκ and invasion b> large tmp teroinin-integrm signalling itt bead arid neN squamous |
Ui*.7U | naso-pbon. ngeal carcinoma | Evil r«R\* k s 5sy<r?s>'* haaopbaty ngeai carcinoma /00)03WOOiiOO:::::::: iiawnreguigting c -My e :::έΐ?έΐ^^ϊόΐ^::ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ | mir- 382 | mesenchymal cancer | up | MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. | yfeii/::::::: 29b-2 | bepato-cefiniar | ricKvti | btfovk N mumkNA-fv on apoptosis fumongenjc-fv thh-Oi^hosis:^//////// | |
fteuto-hbsioma | dOun | crJittfiv-eaMYCN levels via kt-7 supprc^ion. | 182 | ovarian cancer | up | Micro-RNAs and ovarian canc er: the stale of art and perspectives of clinical research. | /OtePmPipa////$ | 29 family TETi involves ia hepafovcllulai caiivCt | |||
pancieain dm-ml | down | •:tet-:?:h'EoroFtNA:tfgnsfei:in:·:· paficrcatic ear-ccf-derived cells mlufcits m vitro cell prcrhleratin» but fail* to alter tumor progressioh | mir- 182 | ovarian cancer | up | Anti-M1R182 reduces ovarian cancer burden, invasion arid metastasis: An in vivo study in orthotopic xenografts of nude mi.ee. | $iph$$:$: 29b-2 | /hgpteSteSbiipi::::::: | /down/ | Erratum to, Negatw e feedback nf «ait-29 fuimp t-iYYkib/dbiekih//////// hepatocellular cancer. | |
k'-‘te | 3U bofrtv'i'r'tw' muroRElA kf-“ sphsbru cell motility by regulabng the groties hi the actin a m»kektot. pathw av m. | mir3 82 | ovarian cancer | up | The upregulation of signal transducer and activator of transcription 5 -dependent microRNA.-182 and microRNA96 promotes ovarian cancer ceil prolif eration by targeting forkhead box 03 upon leptin stimui | yfeii/::::::: ί:ίθ?ί:ί: | uiesen-chymal | driu n | nak-29 vw a Do. 0¼ «. ttercomas to Protect the Tumor Suppressor A2b mRNA from Degradation | ||
!C'-C | jfr^i/^^//:::::::::::: | Breast caocer-specilic mediated h> miRNA response elements of tel-? | mii3 82 | ovarian carcinoma | up | MicroRNA-182 promotes ceil growth, invasion and chemoresistance by targeting programmed ceil death 4 (PDCD4) in human ovarian carcinomas. | yimf·/::::: ί:ί0ΥΫ | bladder cancer | down | 29c m human bladder cancer and the jnlahitiort oi proliferation in T24 eeli via | |
xtettyg:/:· | down | tel-? microRNA expression /iSEjcyOlO^iiOhhhhhhhhhhhhhi:/:/:/ E/OiPPiKtyi^ii/pO::::::::::::::::::/ eammowa. a Ruikimaaave :/$ΟΟΐΟ:^:ώ:ί/&ί///// correlated with «roanysis. | mir- 182 | papillary thyroid carcinoma | up | miR-182 targets CHL1 and controls tumor growth and invasion m papillary thyroid carcinoma | :::bur::::::::: | breast cancer | $^/// | «hcroRNA--29 negatw ely regulates EMT legulytorNEthtyE/mtteEiCtdkiifbEkh^ | |
xtety?/// | dv'VO | let-? mleroRNAf«Rvt!ri»s as a potential growth suppressor in laiman colon :;:<Aiii$i?:f:?i^U^k$$$/:::::::::::::::::::::::::::::::: | mir- 182 | prostate cancer | up | iniR-J 83-96-382 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. | $^0pbags8k//// squamous v oil /^ίρ«ίρίίίρ////$ | dPri n | •utR->k«dr. tHio te by modulating cyclm E |
WO 2017/132552
PCT/US2017/015417
eaieir.oma | <md effect to)! M< ίA? in esophageal sgoamoosceh CSgtemph&ti | mir- 182 | prostate cancer | up | Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 fNDRGl). | ShurA:?: | dm? n | MumRNA-zhi. mediator, carcinogenesis by directly targeting ITGB i. | |||
//^te///// | esophageal //^i«k^/////////////: | dPun | Evpresston of cimuladng mieioRRA-2va and let -?a m esophageal squanwa /Oi/O/OiO?:? | 182 | uveal melanoma | down | Role of mi.croRNA-J.82 in posterior uveal melanoma: regulation of tumor development through Ml '13·. BC1.2 and cyclrn D2. | cmif·///? :/2^:///0 | gastric cancer | down | MictoRNA-T.-Ps cCntld gastric cancer eelfo tn\ asmt. |
!2l--y | ::£θ&£θ^υ:ί:ί:ί:ί:ί:ί:ί:ί | Ϋ^Οί: | L\ “··» ./{.··<.<«.'..«Mb .»·> AL t siguaimp m pm. .ote gastnc csmtijoget'nsts. | mir- 182- 5p | bladder cancer | up | Oncogenic miR.NA-182-5p targets Sraad4 and RECK in human bladder cancer. | mu- | dm? n | familv member vn proliferation and invasion Digastric cancel cell lines | |
k'-Y | Yhep^G^giOtYY::::::::: eai-eir.oma | Cdtiteh/: | Hepatobiliary and Pancreatic Cancers. | mir- 182- 5p | prostate cancer | up | MicroRMA-l82-5p Promotes Ceil invasion, and Proliferation by Down Regulating P0XF2, RECK and MTSS 1 Genes in Human Prostate Cancer. | ι^ό/// 29C | gastric cancer | dot' n | Dcmjufotumb‘'iucen twR2‘fp/c and DNMTjA is associated with epigenetic silencing yf the CDHt migration and mvasmn m pisiri; cancer |
!2l--y | /•ίίΟίΟίίώ^ΫΫΫΫί ΥΫ^^^3?Ϊ^Υ^Ϋ:Ϋ:Ϋ:ΫΥΫ: | Ϋ^Οί: | MieroRNAkc-’g andlei-?r mhihit hepatoma ·.:'!□ growth cancnn-endv \ ia downregidatton of the Hrupiimtia-ext» forge. | mir- 182- 5p | renal cell carcinoma | down | Downregulation of mrcroRNA182-5p contributes to renal cell carcinoma proliferation via activating the AKT7Fi)XO3a signaling pathway. | mu- | dm? n | mumRNA-2te k dowtiregnfoted and restored by ceteccvrifr in human gastric ^gncei tells | |
//^te///// | Ehipgte3nder?LLL://// | dPun | Reduced expression of the fot-? kjmoRNAs «ι tnimati hutg cancers in association postoperative survivai | 1826 | breast cancer | down | MicroRNA-1826 targets VEGFC, bela-calenin (CTNNB1) and MEkl (M AP2.K:) in human bladder cancer | Cmif:///? :/2^5:///0 | gastrtc cancer | down | MiR-29c is dowitfegufated rn nastm «'dk'UQt'ias ai'd regulates cell proidemtrnri |
/ϋθ/// | //RthgtetiitePh///////////: | Ϋ^Οί: | Reduced ecptessmw Λί Dicer associated w uh poor prognosis in hmg «.anoer /:^ίίέί^/////////////:::::::::::::::::::::::::::: | mir- 1826 | kidney cancer | down | MicroRNA-1826 directly targets beta-catenin (CINNB1) and MEK1 (MAP2KI) inVHLinactivated renal cancer. | mu- :::O:A:::: | dm? n | Reiationahrp between the e\ore sum lev el J miR?.Sc and biological behavior oi gastric cancel] | |
fo-te | //dtiteh/: | Leti?a elevates p2 ItAYAf i i levels by iai-geyngof NtRr and suppresses the growth of A5ds lung cancer ceils | mir- 183 | bladder cancer | up | MicroRNA expression signatures of bladder cancer revealed by deep sequencing. | :/&«/////: ::ί0/Α: | //0^////////////// | down | MiR-29c, inhibits gbotua migration, imasic-n and angiogenesis. | |
/3/Og/// | oaso^teirvugee} /:^^5ίί·ί>1ίί^ϋ;ϋ;ϋύ:ύ:ύ:ύ: | ddvvO | MitiORNA 5't-7 4,’iyprtsks nasophaty agent can mo ms :eetk-pK0iifeiatte^Kihf0Wgh:::: dow «resida·-ng v Live | niir- 183 | bladder cancer | Up | Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. | Ohiip////: | ih^/ahd/h^k://:::/: squamous ceU //^fshiph^////////// | dm? n | 'Armcnir-snpprosiive mrtipRMA-Ns tohtbtt cancel cell nngra· ·οκ ai'd invasion by targeting bummn-mtegrni sumahme m head and meb squamons cell enrdnoma. |
/h^ib/bfoStd^::/::::::/:: | tidtiteh/: | enhnoaesMi CN levels via | mir- 183 | breast cancer | down | Dvsregulated tniR-183 inhibits migration rn breast cancer cells | mu- ::ί0/Α: | //&Ofe^ifofoL:::/:: i^foihbitefo:////////? | down | PKCaipba mediated mdiutumul m-R-Nl m human hepatoma HepG2 ?^fe////////////////////c |
WO 2017/132552
PCT/US2017/015417
7^όίί^ίέ:Ο^/:/ί adeno-caremoma | :3θθ | kt 7 MicioRi ·Α transfer ip. pamtreabe caacer-Jem ed cells ioliibits iftvttbxall alter tumor proare&sion | mir- 185 | colorectal cancer | up | Association of microRN A expression with microsatellrts instability status in colorectal adenocarcinoma. | 3kii773: ?k: | Τ^^ΑδίΟί////: carcinoma | dun n | MmmRMA-z^c furivtinus as a tanmr suppressor by dtteci targeting oncogenm SIRTl in hepatocellular 3(akliktik/CCCCCCCCC33:3 | |
deOc | //gtioltia^ma//////////; | dowo | miRNA mteroarray tev eals specific/ esproaston ti the 77777777 glioblastoma pytierrta. | mir- 185 | colorectal cancer | up | Overexpression, of microRNA. 183 in human, colorectal, cancer and its clinical significance. | όίηίί///// | hepato-ceiiular earciooma | down | Npgaiw e k^dbacl of t-JiR fhmfiy ΤΓΤ1 mv oiv es in 3ikpSk^ |
:::tjte3$77aiiiei7?:7:7:7:7 | dyu it | 7gC^S77^$fi^pS^777:777: 3j^^^;y:^k$^kh//////////33 mediated bv miRNA response ekmems of ki*7 nod m:Rl?> | mir- 183 | colorectal cancer | up | Plasma miR-183 predicts recurrence and prognosis inpatients with colorectal cancer. | 33^3:77 | :3^kllkhia3//3:3:3 | feedback of miR--30 family 3:TE0 hepatocellular career. | ||
kt-’i | bmiicbmioalveoku :7:^^itiG3iii^:7777777777777 | :3θθ | kt-’ imeioENA expre&siyn 7fckib^ tar rAr ii ·υ ηΛ tvirebv^ tali ^v«i<pais | mir- 185 | esophageal cancer | up | miRNA-183 suppresses apoptosis and promotes proliferation in esophageal cancer by targeting PDCD4. | mu- ?k: | carcinoma | dun n | O^ti^h^^/ibkkf 3:3:3:3:3: /3si6i^iffi^3^^i^iGjti333333333:::::::::::: response enttR-Τη κ< the //•^’^lo^bOibfkyor/////////// carcinoma via targeting ic^^iichhhhhhhhhhhh/chhh/ch/:/:/: |
Cki/yi//// | eoioh caooer | dOun | kt -7 microRNA fiwettons 7^:S:^k^Si;:g^^^:7:77777 suppressor in human enlon :7^^ίώ^ΐ:ώ$ύ·^777777777777777777777: | 183 | esophageal squamous cell carcinoma | up | MicroRNA-183 promotes proliferation and invasion in oesophageal squamous cell carcinoma by targeting orocraramed ceil death 4. | 3)01(/3/3 33^3:33 | hepatocellular :3^kllkhia3//3:3:3 | down | Effects Of toicroRNzwlv on :3:iiEj;d3F3t^jfi0$t$:^i:33333333333333::: bepatocNbfiar enrcinuim» |
/iO//// | 7^^h^ai7:7777777 >7ό^^^ίή^^7777777777777: | 3dbkii3 | /^k/dfimOkRNA·^ and effect to)i M< ί A? in esophageal sqaammss ceil 33dkiribOc///////////////////3 | mir- 185 | follicular thyroid carcinoma | up | Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. | ........... ::411117:::7: ?k: | ......................... rung cancer | dun n | miRNA-2'k Suppresses i one t uUacrC ell Adhes.on to hxtrjccffuhu· hhdnx and Metastasis by Targeting tnlegrln?! aud Matrix ?a letaikproimnas^ //^M^TCCCCCCCCCy////: |
3^epte^Si;3///3:3333 feqwnuas ceO :7:^^ijciQ^i^:7777777777777 | microRMA-zva and ki-7a in esophageal squamous 7:5/:όίϊ7ώ^ό:ϊ^·ό:ί^777777777777777777 | 383 | gastr ic cancer by targeting Ezriu. | /:0/:3:3 | :7:i^iifi^^fricii555555555: | profile and identification of iuiR-2‘> as a prognostic marker and pathogenetic (actor bv argwnog <kRn in mantle coli Ivmphoma. | |||||
3ki^i/33 | hepatocellular 77^ii7j^////7777: | dvWO | 7^ii^R:O^^/////:7:777: 3iiephtd^ii^N/NidCCCCCC:3 ra-uieaiK Cai^ers | mir- 185 | gastric cancer | up | MicroRNA-183 inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells by targeting PDCD4. | 3tiiii337: :ί:Ο/:/ί | me >en-cby mat //cdtiis)/ //3333333: | don n | miR-’/Aes-jsaketov m Sarcomas to Protect ihe Tumor Suppressor A3d «uRNa fi»in Degradation |
7|$fy^:7:7 | >7^3E7iui0iLia7777777777777: | down | MicroRNA lyt-?a ond let--7l 77£jEiiufeii:ii^^^t>iii^:‘i^U7777777777 growth coneutreniR via dowrregpfiaimn N the antiapoptofio protein &-cett ly rnyl-yrna-extro bias. | rnir- 183 | gastric cancer | down | MicroRNA-183 inhibits gastric cancer proliferation and invasion via directly targeting Bmr-1. | 3im£837: | nusy-phsiy ugeal //gbkac/////////333: | 330tyh:3 | //Cti;biiiating:idiR3iuTnt!R-T33 3i!a. ioiR 2\, andmiR 333 Combined as Moo-fin asivc :Ci:3:j:08itid^:i^:jiii333333333333333333::: /Na^pb^i^a^h//////////////// /Cakidph^/:///////////:::::::::::::::::::/: |
7^^/77 | 7bitig:7O^//77777: | dvWO | Reduced e-Apresston of Dicer associated wlili poor prognosis in lung caooer 3paiiS^CC///////////////////3:3 | mir- 185 | glioma | up | The miR-183/96/182 ('luster Regulates Oxidative Apoptosis and Sensitizes Cells to Chemotherapy in Gliomas. | 3tiiii337: :ί:Ο/:/ί | naso-pharvngeaf earciooma | don n | MiR*2‘fe suppresses invasion and metastasis by targeting T1AM1 in ::nasopiiaryiigeai: carcinoma:·:·:·: |
WO 2017/132552
PCT/US2017/015417
Lot- ’a ele\ aks p2 it WaF 13 L\cii.bs urivtt.guiNiPl·’ add suppresses tbs growth of a94*; iyng viitcei veiU | mir- 183 | hepato-cellular carcinoma | up | 3buf3:33 | Ch0b>8hidif $2113:3:3 lung «.amer | dim n | ^uppiessmu f rn smnabng ht the nuR*2fa iannly is mediated by deox’lhdaopnof VAF-l«. non-small-eeli lt®g vancei | ||||
31.$Ρ?ί:3:8 | 3:!bngkahpepppp3:3:3 | down | Reduced expression of the kt -7 mkroRWAs hi human hn-g cancers m association postoperative ?ur\ wal | mir- 183 | hepato-cellular carcinoma | up | miR-183 inhibits TGF-betalinduced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. | 3mii338: | non-small ceil T!pfigb:ahPer:T3:3:3: | Expression of miR-?vc, nnR 93 md nuR-UP as Detection of Emit «.tage Nuin-mao nop father | |
!ι?-Ί | naso-pharyngeal /chRikQkpx////::: | down | MxtoRNa lei-? suppresses oasupliatyngsyl caiutatnia cells proliferation through do wOreguiating c -Myc 3kk^ssibh3/3//3:::3:3:3:3:3:3:3:3: | rnir- 183 | hepato-cellular carcinoma | up | Expression and Significance of MicroRNA-183 in Hepatocellular Carcinoma. | 8mn$8:8: 303:33 | 3bbib£malh$Sdtt3:3 3dhb£O&Gtt3:3:3 | 1^11 | Ck enisling micro-RNA expression prefiiea nt carb «tip., twi a‘d cell bn g |
!C:-“i | 3hetird3hia^tflfepy3:3::: | 3:dOi3 | tieurobiasuama and enhar&e&MY CN levels via | mir- 383 | kidney cancer | up | microRNA-183 plays as oncogenes by increasing ceil proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells. | 3feh$:3:3 29P | pancreatic :3(^hbgbtTTTT3:3:3 | dou n | nriR*29e suppresses pancreatic cancer liver metastasis in an orthotopic ::iffipUntation:£nodeliniiude·:·:· mice anti affects survival in pauerearie cancer patient. |
vancor the stale of art and perspectives of clinicel | 183 | carcinoma | up | and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. | ?0R | m tnesenciunial transition and n/uasiuists bv tare-nmp 'fpist m human epithelial | |||||
!C:-“i | pan<reatu dmtal atfeno-carcinoma | 3:dOi3 | kt-7 MicroRNA ttansfer ir paKpj’u. tia.\Mv»\td tells inhibits bi v itro celt alter tumor progression. | mir- 183 | osteo-sarcoma | down | Down-regulation of miR-183 promotes migration and invasion of osteosarco ma hv targeting Ezrin. | 3181:3:3:3 | head and neef C^OWdk^li3:3:3 cantiOOioa | dou n | ............................ unR-dth1 inhibits epithelial to mesenohvmaf transition and metastasis by targeting T:?c^fbP^ir33333333333333333333333333333 |
bladder cancer | dOun | The binvaur-soppressive 13 3a targeting TAUtN2 in | 183 | papillary thyroid carcinoma | up | miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4. | 30iir3:33 3vb | osteo -sarcoma | 8Ο838 | Up-Regulation of MiR -3 Gt; :Rfoniof?s:Rmiiferat!»nand::: bv Targeting BRD7 | |
bladder cancer | down | •:nuR-:-l:dowQiegulatesiona·:·:·:· non-coding RNA urofitciial cancer associated 1 in 3bi8ddhf:b^3hfTTTTTTT:3:3 | rnir- 183 | prostale cancer | up | miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. | 3ipn$3:3: 30 la | c-okneua! | 1^11 | ::MiOipRhiA>3ttiapfOniOf?S·:·:·:· migiutmt. anti tm a>ivU A human colorectal cancer | |
3:ή3ί8ί:3:3 | 3^Ρί3Ρ^ΤΤΤΤΤ:3:3 | <d0w:t3 | ::Rroar!t5Stk:Siafiiliear£Ce:«f :·:·:·: esprts’tup mpat.er.tsw.th chordoma | mir- 183 | prostate cancer | up | microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. | 8ίϊηί3:3:3 | tb^br^^i3iSiic:bi3 | 3^|| | growth and invasion b> direetlv targeting SGCSb |
!UK- I | 3Oid0iilhTTTTT3:3: | 2ds3Rh3 | MtcioRNA-1 (UflR-b jt'ljbt e . ΡοΜηΉνΌ migration and invasion by 3iptg$i;;p£^ | mii- 183 | retrno-blastoma | down | MicroRNA-183 suppresses retinoblastoma cell growth, invasion and migration by targeting LRP6. | mn- 33i038 | T^dipbt«dU3:3:38 TO^f3ATT3:3:3:3 | down | Mutant p>3 gain-ofτ it ·ηη mdrv' z cp-tl eb A mesenchymal iraostuan ::througb:modulation:of:tiie·:·:·:·:· miR-fSiib-ZEBl axis |
2iibh-:i8:8: | coku-ectal cancer | Tt-nior suppresso r mtR- 1 restrains epidtelial::rriesonobtinni:iransil£On:aHd:·: ruotasiasta of ceioreciad earcmoma via the ΪΜΑΡΚ and RI3X/AKTpathway | 383- 3p | lung cancer | up | Up-regulation of microRNA183 -3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. | :::i8if33:3 ίΐίόίόί: | gastric cancer | Οττό | Gterexpre sednuR-Ola promotes cebproitfemuon and invasion by largeling RUNX' in gastric cancer |
WO 2017/132552
PCT/US2017/015417
carcinoma | trooroRNA-J in esophageal squamous cell carcinoma correlates with an advanced ον eicvpressmtt attohits eeii uugrsnctn and im asmn | mir- 184 | glioma | down | identification and functional characterization of microRNAs involved in the malignant progression of gliomas. | dimiLLt | mik- hl nt pjs iv m <r ass<fCbtcrt with progression | ||||
gastric cancer | down | MicioRNA-i iitflR-1) wilubiU gastue cancel cert proliferation and wigratmn (ί&ΙΟιΟ | mii- 184 | glioma | down | MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNEACP2 in Glioma. | imhLci: Xia | LhgprttS/bSRiiaf:::::::: | 1^11 | nnP- >tt la L> 4 Candidate Oriv^netie that Targets the !ί«..ΗΝΛ&Λ\<4«ν* ( v\ itt | |
/SjriLy | heart and neck L^ij^hiLakOOldriLLiL yridkimtihrtLCLLfiL: | i:dOfe | E.ow-fev el expression of microRNAs iot-?d anti miR-2v5 am prognostic nuukets of head and neck squamous cert carcinoma. | mir- 384 | head and neck squamous cell carcinoma | up | Co-targeting of multiple microRNAs on factor-inhibiting hypoxia-inducible factor (FIB) gene for the pathogenesis of head and neck carcinomas. | /XirA::?: | panemafic arteiio-esmir-cma | miRMhlaas an Mi-X'B sectrvator in pancreatic cchiLaLc^}R:LLLLLLLLLi:i: | |
heart and neck | daw η | yhyR-ftrtsta^thmoLLLLLLLt snppmssive rnicroRNA targeting TAGl N2 in head and neek ^quautons cell ..•.•remumw | 184 | itepato-cellular carcinoma | up | Mir-184 Post-Transcriptionally Regulates S0X7 Expression and Promotes Ceil Proliferation in Human Hepatocellular Carcinoma. | cniirycy AOl'a'··'· | yphHrmqiRLLLLL: | <W><6 | miR-30io promotes pancreatic cancer cell m-Jper-nof' by rtiu <Jh inhibiting Bint expression. | |
T&Ofe^iirtidfTTT::::: | yhhjpOAA^/nth hrpaio-.aNww>nta <eils hy targeting endottelm-l | mir- 184 | itepato-cellular carcinoma | up | MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNF A1P2 in Glioma. | mu- 3la- Bill | path, rcatx | up | MicroRMA- 'bla-Ap promotes partcreatie cancer ptyurtsstor’ y\. mgru ' regulation of 9MA1>-! | ||
/SjriLy | /kidhtoA^^TT:::::::::: | i:dOfe | LM^Tiydrt^btO^ftrthLLL:: ceil carcinoma where h mteiferes nit -ell cv cic remdaiinn and metastasis | mir3 84 | malignant melanoma | down -1 | Regulation of cancer aggressive features in melanoma ceils by mi.croP.NAs. | /XirA::?: | dow n | τ it -on mdi'v' z cp-tf eh 4mesenchymal transition xthiOUgRmodulatiomofthe·:·:·:·:· -1 | |
RNA-1 imiR-Dmhmg vat c Supons «νί vi tm -vRj'tu prupem rt (wig cancer cells and tteir y$ehshihhiitNihQd//////////dd:d: rtovotubunt-tndtjced | 384 | neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. | celt tm aoivcucos through pamrentu lammoma -.ertls | ||||||||
naso-pharyngeal yi&Rmqp^^ | down | yE2HT:i?iphi0tssLLLLLL:Li Tifiiafeiiis^fh^fhi^hhhhhhhhhhhhT: LErdothehn-l axis in nasophary nseat care-no ms | mii- 184 | nenre-biastoma | down | MicroRNA-184-medialed inhibition of tumour growth in an ortho topic murine model of neuroblastoma. | 1ΒΙΪ | suppressor in colon cancer | |||
USH- I | yhdhtS^ifSdlhiO::::: | MtR-i targets PIKX'A and properties ofAS-i# ceils | mir3 84 | non-small ceil lung cancer | down | MicroRNA-184 Deregulated by the MicroRNA-25 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc. | mn- ?02a | down | xMmtoROiOTLLLLLLL huppresse> Tumor CoO Proliferation. hy inl-ihiUiig ALT in Prostate Cancer. |
WO 2017/132552
PCT/US2017/015417
osteosarcoma | /:ίΟθ | MiereRNA-1 fitncuous ax a pmerti rf jw , tvprcsa ζ 4HcbHb^fH2kby///////////4 targeting Medl and Model | mir- 184 | squamous carcinoma | up | MicioRNA-184 inhibits cell proliferation and invasion, and specifically targets TNEAIP2 in Glioma. | :/2iiii///// %?b | //^ppiihpHi:////////: tj v 'll 2(^212012.^22/////: | d<P? P. | mjR-'b2b is a potential molecular market of esophageal -squamous celt carcinoma and functions as a tumor suppressor bj | |
CUUr-T///: | renal celt o-srcmoma | dOwh | The foncriottal sigmikaoce of miR-Ι oadiniR-lHa in renal veil carcinoma | 185 | bladder cancer | up | Micro- RNA. profiling in kidney and bladder cancels. | 3v2b | :/HGljipbig:///////// | twcivRNA. m Gastric /:AHh2dh2ihb^fTTTT2://// | |
•UK· | bigast earner | down | miR- 120 xnppigssex IGF2 4H.te^hdb^$yR^2//////////////4 proliferation and st-Alval | mii- 185 | breast cancer | down | MicroRNA-185 inhibits proliferation by targeting c-Mef. in human breast cancer cells. | /•buf///// ?v2b | TlibpatdHgRidaf///: | OdbGii/: | suppress -ell omlifeiutiot. b\ tatptmgbid-R m human hepatocellular ramuPioa^MMC 7~>f /HllG:/://////////////////////////// |
:/122////// ΤΟίΑΑ: | CbG^i-cO^?////////: | //dblgii:/ | mtR J< 'b Induce Epithelial -Mesenchymal Tranx-bon but Suppresses Tuniotfgstiexix. Migration /:62^:12^202////////////////////: | tnir- 185 | breast cancer | down -1 | MiR-185 is involved in human breast carcinogenesis by targeting Vegfa. | TmtrcTT 322b | hepato-celhilar carctooma | dbw-n | n«PNA--30’b Suppresses /Ht^2H6pmbiR^iERC/8////: Carcinoma b> Targetma eOlllllllililli -, |
earentonta coil proliferation by targeting fRfB? | 185 | squamous cell carcinoma | effect of micioRNA185 on proliferation, migration and invasion of esophageal squamous ceil carcinoma] | ://///////|/S | grow tb oi hepawxcliulat carcittoroa by suppressing mesenchy mal transition of Tbbdbtii^igi:HH$T/////////////c | ||||||
:/&2////// ΤΟίΑΑ: | chondro-xarcouKi | down | Anah sis of muroRNAs 2e2pi25Si$ii$H$T/////////////// :/e^:r^ipSd202:ia/://////////////: | tnir- 185 | gastric cancer | Up | MicroRNA profiling of human gastric cancer. | :/2i2///// 3222 | gastric cancer | /Rif///// | MrcroRNA ptufihngoi humauga tm. tai-cei |
:/^2/:///// ΤΟίΑΑ: | chondro-xarcouKi | down | C^^hiaekRPfisfant: ://////// •:Gllondrosorooma:Geib:tO:·:·:·:·:· CispUfop. tbrougli Direct Targeting of mfOR, | tnir- 185 | gastric cancer | down | iniR-J 85 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. | :/2i2///// 32a | breast cancer | dOtt P. | ntiP-tpa z.tpptessex breast canter cell proliferation and |
7i2i2////// | //CdibrfeHcH//////////: | down | Klicioki’A H'f· faivoib ax a tutp.or sirppre&xui by ip. colon •'amerceib | mii- 185 | glioma | down | LRRC4 inhibits glioma cell growth and invasion through a nuR-l85-dependen: pathway. | /•buf///// '0a | breast cancel’ | odbGii/: | TMiiitbRNAGfiadHibliSTT/// celt mtcration anti tin asmt. \ tmer.utt e cprexsmtt and is 0 potential prognostic marker mbieaX1 ^aneei |
:/1224///// ΤΟίΑΑ: | colorectal cancer | down | Downregulation. of mmioRNA--lbb cone totes ^xyitlibaniorproaressionafid·:·:· xpoorprogno^sinootorectol:·: Τ^·2ί;.ώ<^Α:ΤΤΤΤΤΤΤΤΤΤΤΤ::::::::::::::::: | tnir- 185 | hepato-cellular carcinoma | down | iniR-J 85 inhibits hepatocellular carcinoma growth by targeting the DNMTl/PTEN/Alct pathway. | :/2i2///// 32a | breast cancer | dOtt P. | TDp2G2^tilhHri2fTTT////// miRMA- >ha in human plasma is a novel maikei |
:/12i2////// | colorectal cancer | down | MkioicNA-ii!v regulates SV/O20 colorectal cancer ipyazon fcv targeting RAPJR | mii- 185 | malignant melanoma | down | Regulation of cancer aggressive features in melanoma ceils by microRNAs. | ·:·2·Η£-:·:·:·:· H0d:////: | breast cancer | cdbiH/: | MicreRNA-otta suppresses metastasis by targeting TOHhdtiRTTTTTTTTTT:// |
WO 2017/132552
PCT/US2017/015417
earcioeraa | tdbifii:· | MieroRNA-WJ 0” prompts -qropm as in targeting mTOR it· human | mir- 186 | colon carcinoma | down | [Expression of miR-186 and its role in human colon carcinoma cells]. | AiuNTT B^^l | TOiidfe^hiOdfiEi::::: | Jrm n | As v uivf J 0\4 r<pi}h<ted bv pjfivf suppressor mtR-3;;a with poor pro gnosis in lowgrade chondrosarcoma | |
yriab-::::::::·: | TeS$plia^altTTTTT3 Τέίίίίί4ρί^ΤΤΤΤΤΤ7 | MicroRNA- 1; ;b promotes migration and invasion •:tiaough:-ma£nmahail· target·:·:·:· of rapamyeui in esophageal squamous cell carcinoma | toir- 186 | non-small cell lung cancer | down | miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. | νίβίΑ::·:·:· 3t;a | coioroctnl eamttmroa | down | fttiB-gfa suppresses cel! roigtatton and rnv aSiOtt through downregulation of >::0^fN*filjdfEi^TTTTTTTTTTT::::::::::::::: | |
•UK· | squamous ceO | down | 3PtegfiS$tkAhltii:tii:TTTT7:7 hh^^^:E^^Ai^;uiThhhhhhhhhhhh; esophageal squamuu> νθ8 .;-.·η'··!ίίυκι | mir- 186 | non-small cell lung cancer | down | MiR-186 targets ROCK! to suppress the growth and metastasis of NSC3.C cells | 8mn$7:7: 'Oa | Thg^atprogR^itf:::::·:: TiidfemOmh:::::::::::::::::::: | OdptyijT | Effects of mkio&NA-3ba on migration. inv asion and prognosis of hepatoeeihilaipiftBM::·) |
BiBiAA: | Bill | miRMAAU' promotes gazm. to? vf uros.onma metastasis by targeting tumor suppressor h^^^o^hhhhhhhhhhhhhhhhhhhhhhhh^ | mir- 186 | pancreatic ductal adeno-carcinoroa | up | miR-186 and 326 Predict the Prognosis of Pancreatic Ductal Adenocarcinoma and Affect the Proliferation and Migration of Cancer Cells. | mu- B^^l | hmg «.areer | Jew n | epnhelralAo-'mesenchymai transition by targeting Snail and is dounregulttted 3θ9έί·ΤΤΤΤΤΤΤΤΤΤΤΤΤΤ: | |
CnafTTT: BiBAiAi | VgtitiblaStdiPdTTTTT: | JpW tt | mietoRNA-ltib Targets SMR£/NC0R2. Reduces PmlJciatim and’mo^u^ Survival in<thob!a>roma | 187 | prostate cancer | down | MiR-187 Targets the AndrogenRegulated Gene ALDE1A3 in Prostate Cancer. | yimr:-::·:·:·: bbii | ter·-small cell | down | MiR-3 ba suppresses non- >40ίί;ί^ύ::έ^1ί:1ώίί^:ώίίίίί;έΐΤΤ::::::::::::: progression through .A&T signaling pathw ax bv 4fN^tihgti:GhiS:TTTTTTT:::: |
BiBiAA: | 7hepatflCSihil0f:::::::: | tdbifii:· | Sequential anab sis of ix-paio^arcmogene>!s reveals iJiei naR-ittO and ILxt dv>rcgokt£onisa£ earh every maitiiained along tumor progression | mir- 188- 5p | hepato-cellular carcinoma | down | MicroRNA-188-5p Suppresses Tumor Cell Proliferation and Metastasis by Directly Targeting PGP5 in Hepatocellular Carcinoma. | mu- B^^l | Jew n | 8ltilOti:0:lh^ suppressor votuicets -1 ) S-ς ?gnd «1 Rumrt :O||||||||||||| | |
VfPinTTT | down | Downiegulation of inuroRMA-tiJb vmreiate* with humor progressron and Nf^^^^£ftibBHBfiAhhhhhhhhhhhhN hepatocellular eaminona | mir- 188- 5p | prostale cancer | down | miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4R expression. | vipiRTT 'Oa | TiidfemOmh:::::::::::::::::::: | OdptyijT | KRRNA-3ti^UiediaLe4 | |
!UH- BiBccc | mesenehv mN | j/dtiO: | MuroRN.A Expies&wri Profiles m Rapo>fs | mlr3 8a | b-cell lymphoma | up | MicroRNA KBR-i7-5p is overexpressed in pancreatic cancer, associated with a poo r prognosis, and involved in cancer cell proliferation and invasion. | :^6¾¾ ?0a- B||;| | cbloroctal cancer | down | Candidate microRNA /ce^l^fi^i^fspi^id^iiTTTTTTTTTT Xvaroma··.. re. £θό profiling «studies: ande&petime-ntal·:·:·:·:·:·: >::-k^is.jdtii;i^itf;TTTTTTTTTTT::::::::::::::: |
VfPinTTT ΒίΒίΑίΑ | non-small coll lung | down | MicroRNA-ii!v k- a ::potont£al:£no!eoulai:-marher·:·:·: T^AiM:Ejtyj>jcfi^dhc^^i:;ifi^hhhhhhhhh capper and ftinvirons as a tumor suppressor by targeting poly-hke kinase I | mir- 18a | bladder cancer | down | microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer 724 cells | vmhMtv: ΒΟίόο B||| | Thg^atprogR^itf:::::·:: 3:0ρίθίήόή^3:3:3:3:3: | OdptyijT | xMieioRNA-atia-Gpuniubits:·:·:· nivasiveness and metastasis and is downregulated in hepatocellular carcinoma. |
Ε&ΪΤΜ:::::::: | ora! squamou? cell V^dfeiikipfTTTTTT? | dvWU | Decreased expression of ttaR-l2<haod miR Pt m oral cancer teds contributes oiStmghgiig^ | tnir- 18a | breast cancer | up | MicroRNA expression prof iles in human breast cancer celts after muitifraction and singledose radiation treatment. | OmitT:::::: 30a- B||:| | cokm «.arcrooroa | Jou n | MtRMK t-sp supuf' c-e® tumor growth in colon carcinoma bv targeting |
WO 2017/132552
PCT/US2017/015417
55553-55555: 55055555 | osteosarcoma | 5535535 | 5RB553RO55555i33iOi5i5i5 5&ίέΟΟΟθ555555555ί proliferation by targeting | nsir- 18a | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis by targeting L.ATS2. | 5:33355555 E-^ 5B5555 | 53Ο353Ο5555555 qjMPb υ-.'β 55533543543-3555555555: | :O555| | Expression of nu-cro-RNAs re *qua*reous cell camreoreo of human bead and nock ;0050^0θ5555555 55255553d 5r55R52:3-5i5555555555555 specific markers far :ΐϋ 11 red ’ ‘(4 |
:5θ||5 | vaucei the state of art and perspectives cf clinical 5;ί5δΟ555555555555555555555555555 | 38a | up | choiangrocarcinoma growth: evidence for PTEN as downstream target and IE6/Stat5 as upstream activator. | ?0a- 505555 | gastric cancer irreatioe and ret ta 2 jsjs bv totge tiny tumor Suppressor 5:0^5(33:25555555555555555555555555 | |||||
5:05555 | ox arum oarere.uma | :53θ5: | i'-roguostic impiicatious cf mtcibR.biA-O.3nd its functional roles in Jutom 5:5p43i5553555i5i3553:35135555555 | mir- 38a | color) cancer | up | MicroRNA-l8a Attenuates DNA. Damage Repair through Suppressing the Expression of Ataxia Telangiectasia Mutated re Colorectal Cancer. | :::134455:5: 5:20355555 |3|5| | :5:gii044)555555555555555 | 5055555 | Anab sis of ttuR- sOaAp Expression in Human 5533i3O-55555555555555555555555555: |
5:β#ύ555:: 5:05555 | prostate caocer | down | Loss ofmiR-ltiO enhances. 5:33§ί5Ο5555ί33ίό 3555555555555: cprihcind-rnesenelw real iranxtton and properties to prosfate 5:555555:5:5555533-5^55555555555 targeting Argyiiaule 2 | 18a | colorectal cancer | up | microRNA expression profile in stage ill colorectal cancer: Circulating miR-lSa and triiR29a as promising biomarkers. | /•mir:-::::·:·: 550555: 505555 | head and neck :553333355535355555 5:35i3m3i53:555555555 | 5055555 | E ’.pressren of nixreRNz'S 5535553555535 55133:5551:35543::5: of Itnrean bead and neck and the esophagus1 nuR 552G5555553iiO:E555555555555555: spevrik atari·ers for 5·ϊθ3θ5ί55θΙθ;555555555555 |
:505555 | renal cull carcinoma | 50:555 | tixerexpmsuonvf mioioRNA-ltib predicts an ρκίίΛ oiable prognosis in renal veil varcu-on-a | mir- 18a | colorectal cancer | Up | Plasma miR-200c and mjR-l8a as potential biomarkers for the detection of colorectal carciuonsa. | 3t;b | t ok rev <! am er | 5:05555 | 2:MiR33i^^^354^555:::555555555 migration and invasion Of :·:·3ηηΐηΐ·1·0θΐ0Γί0!^1·θηΠ€·0£·νΐη:·:· 5:^3555355555555555555555555555555 |
5:^445555: 5:05555 | bladder cancer | down | KltcroSNA -101 suppresses •:-mo|ility:yf:bUdder:oan<er·:·:·:·: veils Iw targeting v-Met | 18a | colorectal cancer | down | miR-18a Inhibits CDC42 and Plays a Tumour Suppressor Role rn Colorectal Cancer Cells. | 5:13445555: 505555 | esophageal 5553555555555555555555 | down | Differential expression, cf rtaPN ks m esophageal 555555353555355555555555555555555: |
5:h?445555: 505555 | bladder cancer | down | miR-WI Suppresses 5:Mas55i34:B3d5ii^it0f555555555: 50050φ00555555: inhibits Migration. and irev astoo and Enhances Cisplatin Chentoscositiv Ify of Bladder Camei Ce!is | 18a | colorectal cancer | up | MicroRNA. expression profiling of exfoliated colonccytes isolated from feces for colorectal cancer screening. | 5:134455555 505555 | gastric earner | down | miR~30b Down-Reguhited 5555SON5:^5555r555555555555555: Eureivtc* Apoptosis and Suppresses TtwoorCtiowtu by Targeting ITasmreogon 555355535355:155433545255555555555 |
044)445:::::::::: 5Ο5555 | <yrvua! ?arcim<ma | down | yMibfriENAyEif 35310:55555: tel' prolueratmn in·.a ton and promotes apoptosis bj re aula ·η~ vMov 0 g«-ta>c 5:2545:N5i33Oi55L5555:55555555: camreouia ceils·. | mir- 18a | esophageal squamous cell carcinoma | up | 3f;b | medullofclasiorua | 5055555 | 55Αθΐ5!ό5ίί35:53ί4:::555:555555555 ον ere .press-tin or nuR lob riaR-Sttd and KHDRBS3 al 8q24 22-<j2a 2^ in 553ri^^55O5i535555555555555:55 | |
-535435-5555: 5Ο5555 | x-diolangtocgiomoma·: | 55535355: | 5-3tnR5itif 33343^555555555555555 ohobtigiycarcreoma 5505^505ί535θ5έ3:::ί5ί5ί5ί5 5f3^eti3^/5dO135555555555 endothelial prow tfc factor 5OO555355555555555555555555: | mir- 18a | esophageal squamous cell carcinoma | up | Clinical impac t of circulating miR-l8a in plasma of patients with oesophageal squamous cell carcinoma. | 513355555 5Ϊ5Ϊ555 | 55535535353331155555 55303555335555555: | d«w £' | MlyroRNA-ottb/'c mitibrts iicii-sreali cell hang ureccr cull proliferation bv 5;335^iOOb:f35:555555555555555: |
Citiiil-::::::::::: 5Ο5555 | 25305355^35555555555: | 55555335 | 5LO5d5:biB5O5555555555 Expression Promotes 5:Wi3535t3542ai3i33555555555: Signalling Pathway | 18a | gastric cancer | up | Diagnostic and prognostic value of circulating nuR-lSa in. the plasma of patients with gastric cancer. | :::4344:-::::::-: 505555 | prostate cancer | down | 5555:R33:3:53:5:54tiio55555555555555: suppressor connects EOF/Sry signal io ERG and 5^05555555555555555555555555555 |
WO 2017/132552
PCT/US2017/015417
Actuation and Malignancy (//33/16/(/:///(/////((((((((( | |||||||||||
!UK- | 8/0/0^(((((((((3 | :(/0//8 | MutoRNANf·^ inhibit* proliferation and invasion «Γ colorectal cancer hy (//ig/ini^^^(/0/(((((((((( oncogene scriue/threoiwrieprotein kinase, | mir3 8a | gastric cancer | up | MicroRNA profiling of human gastric cancer. | 8///385: (:///8((( 5://555555 | pancreatic ductal adeno-coroinoroa | /^(/// | 8€/i/i/tt//:/fi/6R/A3:t/((8 cfiin oi 1 lorn 1« k-ras Oncogene Transgenic Rats (:^^^/^^///β//ί^/((3/( /y/d///d///t//i///((((((((((((((: |
5///8(((5 BB(((((( | colorectal cancer | down | Gene modulo based regulator hderence rile 1: t dy mg miR-1 '9 na a ((/:////////6//6///((((((((((: colorectal career. | mir- 18a | glioblastoma | up | MiR-lSa regulates the proliferation, migration and invasion of human glioblastoma cell by targeting nsogenin. | :::ύ:ήρ:::::::: (////((( | acute myeloid ((1///6///(((((((((((: | 8^///5: | Tiam-cription factor (/(^://md////(((((((((((((((: uftvmRNA-'(te nncmates /://///////6/(((((((((((((((((: 55gO/Oteri/d//5i//((((((((: doy.meguteted m acute my eionl leukemia |
5///5555 /0/(((/ | endometrial x.ao,'er | (///:/(: | KfteroSNA -131 targets E2B2.MCL4 and EOS 59 (:/6///^:/1/1^//////((((((((: invasion at.d clem -eli-iiKe phenotype of aggressive endometrial eshchr cells. | 18a | lung cancer | up | A. polycistronic microRNA cluster. miR-17-92. is overexpressed in human lung cancers and enhances cell proliferation. | (:///(((( | endometrial 8//f/e/(((((((((((((5 | down | microRNA.-She negatively (:reg/idte/e//0|/ftri3//(555(((: canepr ceils by targeting motariasis-assoctated gene- /)/////////////////////((((: |
!UK- BB(((((( | endometrial cancer | /////8 | MicioRNA-i3{ target* E/IP M<3 -i and Ό 0 ttuhsiori and stem cell-like phenotype of aggressive enJontelrial cancer ceils | mir3 8a | lung cancer | up | Apoptosis induction by antisense oligonucleotides against raiRJ.7-5p and mLR-20a in lung cancers overe>,pressing miR-17 92. | «nr- | ((60///////(((((( /:0///8((((((((((((: | down | Estrogen regulates thetumour oppressor MjRNA~?oc and bs target /:/6//^B/i((i//((((((((((((((: 5(g////i/tri/f 3///6/(((((((((((3 |
8///8(((( BB/// | esophageal cancer | ((//((((( | Dtffcrehtial e\pr? snri of miRNAs m esophageal ///ί///ί///6/((((((((((((((((((( | mir- 18a | lung cancer | up | MicroRNA miR-1.7-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | :(///:(((: (////((( | non-small ceil ((i//g:////gr((((((((( | down | MkmRWA-2/b/< inhibits nyu-smail cell lung cancer ///r/e/O®^//(/((((((((((((((: |
8///5855: ((0(((((( | 5(6/opfc/£g///(((((((((8 (000/0(((((((: canrinoma | down | miR-lul suppresses tumor proliferation and tutgratiun and mdoces apoptosis by targeting E2H2 in esopliageal cancer ceiis | n;ir- 18a | malignant melanoma | Up | Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophcrus pigment ceil cancer models. | 8/1//((/ | /:/6/83///:8611(5(((: bmg vatioer | (:/6//(: | Low expression of •mivfoRMA-'lte promotes imastonby inducing epithelial mesenc hy mai transition in non-small cufi /:1//////////((((((((((((((((((((: |
(:///(((((: BB|(| | /£/έ//////////(((((8 | dyw n | hficroRNA-iOl is downregubterirn gastric cancer 8:3/^/i8i/i/i/si/i^cf:jiii8i0:i/ij/888888888::: migration and invasion. | mir- 18a | malignant melanoma | up | Altered expression of selected microRNA.s in melanoma: antiproliferative and proapoptotic activity of miRNA 155. | 5:fnii85555 | /:1///1:/6/(((((((((((: ((///1///5/(((((((((( | dewy f | dmuiieguiafioti of mlR-3Bo pfuntutes opiihchalmesenchy mai trar-iubon in 8/6ia//:3///i/eh((((((((((((5(((: 550dteiite/te555555555555555555555555 |
5///55555 BB/(/ | gastric cancer | 8/0(//(: | MuroRNA-ini t? downregulated ir gastric cancer and involved tri c ell mrgra- ·οη ar J i«i« asrvr | mir- 18a | mantis cell lymphoma | up | The raiRNA-17792 cluster mediates chemo resistance and enliances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. | :5/5/8555: Boi( | prostate cancer | down | •miEWO as a tumor suppressor connects EGF/Sic sigtipl to ERG and /ίΟί////////////////////( |
WO 2017/132552
PCT/US2017/015417
CkuR:::::::: | CdJkik: | functional deregulatnon ytfoppgifEEHS/difTTTTTTT: regulation in intestinal gastric oariceu | mir- 18a | medulio-blastoma | up | The miR-17792 polycistron is up-regulated in sonic hedgehogdriven medulloblastomas and induced by N-rnyc in sonic hedgehog-treated cerebellar neural precursors. | fait- | prostate «.arwet | Jup n | suppressor connects EGE/Src signal to ERG and Olllllllllllll | |
gastric cancer | down | Dcwn-regulaflcu ctfiniR- njncfoi.es » ith CON-2 ov crux presstun and laifivf •trouth | 18a | nasc-pharyngeal carcinoma | up | miR-lSa promotes malignant progression by impairing rnicroRNA biogenesis in nasopharyngeal carcinoma | hepatocellular | /0/3/// | MicmRNA 3pdprouK4?z metastasis by targeting Galphaid ui heparn Niluhw i arc «>.·»::·> | ||
i!!ll* | /glfohfostflriU/////// | TdJkii/: | mtR-fri is do» n-regnfotod m ghob!a>toma resulting tu proliferatuon mtgraiicn, yfotd/angidg^hesiSTTTTT/T/y | mir- 18a | ueuro-biastoma | up | MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation inhuman neuroblastoma. | mu- gllTA | :3ifoO^Of333333 | up | Ev aluation of Jy rtartuc change of scrum miE-21 and ntiR-24 us pre- and |
CiriiF-:?:/// | riglitdiid^OTyyyy | Cddfib:/ | Expresslonnf 19 /:ihlOOO vompamonrath other ftratu neoplasia of grades N | mir- 18a | non-small cell lung cancer | up | Peripheral Blood miR -328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC. | ::ύϊίίϋ3:3: 3ricl | ϋ^^ΐίόΤϋ:0/:0:0:0 /|i^toh^/////3/////: | ίόί|| | lO^iRO^kd^y////////////: overe.presStonot miR 3';h uaR-Sttd and KHDRSS3 at iq24 22-o/N 2' tu υ»Αΐ0Λ&λ9ζΚυΡ* |
i!!ll* | TdJkii/: | CKlitoiR^jiPd/iifoiOiT carcinoma progression ikuvnreguiation and nivfeascdvGvsrafo. drug | mir- 18a | osteo-sarcoma | up | Upregulation of microRNA-1792 cluster associates with tumor progression and prognosis in osteosarcoma. | mu- gllTA | //hP^hfolhtoif///// lung «.arcer | Jup n | $GlOtiOti&^ mumRNA 'vptes-ston profiling in non small cuff | |
ί^ιιι | 3·ί^ΜΡ£$|·^ΐ3ί///////7 | down | Systemic Delivery of MicroRNA-i'U Fotenth /ϋί^ϊ^ίέίΐ^^ίόέ^ϊΐίΐΐΐΐ^!::::::::::::::::: cTargaisi////////////////////////// | mir- 18a | pancreatic cancer | up | Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer | yimuyy· | pro&fole cancer | ydbPiij// | :;8ίίΐν^^:^:3:ί^ϊ^ΐ:::ϋ:ϋ:ϋ:ϋ:ϋ:ϋ: ;ϋί53^^ΐ^^ί:$0ΐτΰώ^:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ ΚίΛ·· s.gnd nf RGsnJ |i|||||||||||| |
bopatocoliufor yridkiikin^yyyyyy·/ | down | PECafpha meJiatetf human hepatoma KepG2 | mir- 18a | pancreatic ductal adeno-carcincma | up | Circulating MicroRNAs in Serum, of Human K-ras Oncogene Transgenic Rats With Pancreatic Ductal Adenocarcinomas. | Cbife:://: 3ricl | prostate cancer | Jnu n | Dounregulauonof unR- >:-Ci>Ii!i:!l>KtoS:tO:patl'l0gef!nsk·:·:·:· 3pf/pOhO ^forikithA-SfoiSiTriririririri::::·:: | |
yimpyyy BBlili | 3·ί^ΜΡ£$|·^ΐ3ί///////7 u^^ui-iiiiiahhhhhhhhhhhhhi | down | yMii^RNAs/nttyyyyyyy/y Hepatobiliary and f’ancreattc Cancers | mir- 18a | prostate cancer | up | MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo | 3fon$3:3: | Τί^Ρΐ/^Π//////////3 :3CSf$iif0fifo:3:3:3:3:3 | ydbPiij// | :/Pfollfemtroiiinlubittonaad::: die unjeriymg molecular Ukwidt is» vl s •'ΚΙΟΚί A 3ltd us renal varemo-ma • tlis |
!UK- BBilil | nuF-idl tthfops untopfoig. and enhances eispforincihritided/O^ ;:;ΐ^^ΐ$§^ΐ^ί^ί:$&!Τβί;ΰώΐΐΐΐ^::ϋ:ϋ: ysei!$;Tyyyyyyyyyyyyy/y | mir- 18b | breast cancer | up | microRNA-18b is upreguiated in breast cancer and modulates genes involved in cell migration. | 83!· Y8dk::3: mi; | uou-suiaJl cell :3hfo^d8h3hi3:3:3/:3 | down | MicruRNA-3fid-5p uihibits tumour crtf! prvldenuun and motilnv bv dift.uK small cell lung cancer. | ||
/:Ρ<Ιί-:::3:3: ilBilil | 31Ε$ή:όδΙΚ$ί//////3:3:3: | 3:dStoh3 | MiR-id 1 functions as a tumor Suppressor by ^directly targeting nemo:-iil-o·:·: kinase tu itvei cancer | 18b | malignant melanoma | down | The Role of miR-18b in MDM2p53 Pathway Signaling and Melanoma Progression. | 330:3/: | chrome myelogenous teukrinn | down | MiRGOe mduces apoptosts and sensitizes ΚΛ-7 chits to ;ϋϊ^^ΐϊί^:ί<Γ^ΐίίΐέίΐΐ^’Λ3ϋ:ϋ:ϋ:ϋ:ϋ tegulatmu of the BCR-AJ&f |
WO 2017/132552
PCT/US2017/015417
);/(/(/(/)))))))))))))))))))))))))))) | |||||||||||
Util- ))(Β)ΙΙ | 9:1///:///9//9999::::::::::: | ))3///5 | «ycioRNA-ldl inhibits bmg ^ancer invasion through (lie regulation oi :erdlsno?r»f:-20Ste:ho-iriO-io:g:·:·:· 929:9:9:9:999999999999999999 | mir- 190b | hepato-cellular carcinoma | up | Up-Regulation of MicroRNA190b Plays a Role for Decreased IGF- That Induces insulin. Resistance in Human Hepatocellular Carcinoma. | :)((/(5))): (2(3/))))): | ))0(//)))))))))))))): | )))*!))))))))))) | ))ίό(///ί(/(//(//^ roR-ifie promotes glioma stabilization by directly );///έ///:(>Β(ΫΒ)))))))))))))))) |
5:///-5:5:5 ))(B)))))) | 5mahgn3n555))))5555: ))/(/(//////9)))))))))))) | down | 5/iR)f/d)inbihft$))))))))))))))) : melanoma yeU invasion: and: ::pmiiferat!»Kbytai:gellHg:·:·:·:·:·: )if/(i^)///:^m)))))))))))))))i | 191 | breast cancer | up | Differential expression of miR21, mR-125b and miR-191 in breast cancer tissue. | :)//(:5))) | prostate cancer | down | )///)/0:39//:///))))))))))))): )///p((/(////////(()))))))))))); EGf/Sic signal to ERG and )^(2)))))))))))))))))))))))))))))5 |
9///5559 BBl(l | naso-pharyngeal );//h/((l/((i/))))))))))))): | down | •:nuR-:-ibi:seilSi!izes:itmuan·:·:·:· nasophaiy naeal vaic moma )2/((()(/)///(/((//)(((9))))))))))): targeting stathroan I | rnir- 191 | breast cancer | down | Estrogen mediated-activation of miR-191/425 cluster modulates tumongenicity of breas t cancer cells depending on estrogen receptor status. | BBII | III! | ))(i/(///)gi(/(////(()))))))))))))) ))O^t/3/^O)Ojjjjjjjjjjjjj ))/)///(//(/)))))))))))))))))))))))) vcootionsplamafien model (:ΐ(9|/^(ϊ((//|/:ί||////)) ’B/DB ’ negaro e leedbavl 91///))))))))))))))))))))))))))))))): | |
5ii//5555 BB)))))) | net'-snxdi cell lung ))//(/)/()))))))))):)))))))): | dowh | MleroRNzk-iiil e-vena ))(/(//():$((//(/(/(//)))))))))))))) funetmns in uon-snmli ceil ))(//)/://////2/////)/)))))))))))) cbrovtiy targeting enhancer ol zeste hpmalog 2. | mir- 191 | breast cancer | up | HlF-inducibie miR-191 promotes migration in breast cancer through complex regulation of TGF'7-signaling in hypoxic microenvironment. | 5///)))5 BB//(( )|B)))))))))) | non-small ceil ))i//g://///r))))))))) | down | Clinmal evaluation of ))^MSit5i^^i^:$^i(S^i0ii))):):):):):):) )/(/((((//:(/)//((/(//:((^ )):((//)/////())))))))))))))))))))))) |
5///5555 BBBB | non-tuna!! cell hang ))////9()))))))))))))))))): | down | MiE-Rll and hfeM in nonsmali-ceB lung cancer expression profile and clinical signitkatiye. | tnir- 191 | colorectal cancer | down | Association of microRMA expression with inicrosatellite instability status in colorectal adenocarcinoma. | 9//t993: )))/)())))))))))))) | breast •'am.er | Jon n | Concurrent suppression ol mregrro alpha:-. rad:\tn, and RhftA phenoeopies the ))/(((/(5)/() :/(ίβ)-)$ ί://)))):):):):):):):) :5/te:te/t///5555555555555555 |
5///5555 BB)))))) | ))0Si/0S/k$i//jjjjjjjj9 | dowh | Effect of roicroRNA -Id 1 ))(/()(/p)((f/(^//((;//d)))))))))))) ):)ii^$(fei/i/):di^)i/e^(c^/))))))))))):): osteosarcoma eeliv&v ί dfu-sn»·«.?i ·ίρ | mir- 191 | colorectal cancer | up | miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBP? | /mi/)))) ))1)()))))/ | breast cancer | down | mR-31 and us best gene liitRNA L0£5.Wi£ are regulated by promoter mpcrnwthc \Uioo m ‘pie..'Mw h. \.s ' !·< ^r |
UUI- ))(/()))))) | oyanaw careuioma | ))3/(//)) | 5/((0)(()/://^ epttbehal-to-mesencin roai ttanattonbv tarroimg 21:131 and ZEE? in Ovarian 9ό/ϊό1η0ηίά;999999:999999999 | mu- lti] | colorectal carcinoma | up | MicroRNA-191 eoiTelat.es with poor prognosis of colorectal carcinoma and plays multiple Piles by targeting tissue inhibitor of metailoprotease 3. | nm- )))/!))))))))))) | u t: amM | op | j/ftR(2(j(g(iO oncogene in cer, icai ))://(///)))))))))))))))))))))))))))): |
5///-5:55: ))(/()))))) | pancreatic earteer | ))3/(//9 | wtRNA-dfil snpprea>es ef/theiial-to-mesenchyntai transition by targeting ))£O/^ 9//i^t/t://i^999999999999:9:9 | mu- lti} | colorectal carcinoma | up | MicroRNA-191 corre3at.es with pcorprognosis of colorectal carcinoma and plays multiple roles by targeting tissue inhibitor of metailoprotease 3. | 9(//999:: )))/)())))))))))))) | mai cancer | 5(:(())))5 | MiR-.: 1 is an independent ):/(ό^/(///9//ό(ό(///))))))))))^ functions an an oneomir in ))(/(/i//(/2b(/(9t/)))))))))))))i ):ΐί^ίί//:^((((/ΪΑ))))))))))))): |
5///4555 (IB)))))) | papillary thyroid ))//()9(//(//))))))))))))): | dyw π | miR-lvl iiiliibnacell proliferation by targeting Rav I in papfiiurc tin void ):)//(/:)//(//))))))))))))))))))))))): | inir- 191 | gastric cancer | up | inRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPfi-HE.3. | :)(m(9))): Bill | ))/1/(/(/(//))))))))))) | d«w f | MferoRNA expression (/(/((((////////((i/)))))))))))) potential funUmu of ))(/1/(οΟΑ92 ()((:9))59:959595 (;(((//(b(//(5)))))))))))))))))))))) |
WO 2017/132552
PCT/US2017/015417
/kak://: (:///(((((: | ((ph/i/8ty/tOO//(: ((k./k///(((((((:/// | :(/8//(: | muroRNA- ί of suppresses trngraupnand mtasmnbv targeting Racl tn thyroid (/ai/e/s8H/(((((((((((((((((((((: | mir- 191 | hepato-cellular carcinoma | up | Hypornethylation of the miR191 locus causes high expression of mir-191 and promotes the epithelial-tomesenchymal transition in hepatocellular carcinoma. | :(///:(((: (///// | clftonic nn otogenous leukemia | dm? n | DowuieguJaPow of miR-31. miR-155 atidmiR'-pMu! ehronie nA eloid leukemia /β((((((((((((((((((((((((((((((: |
((//(((((( | prostate cancer | doun | Enforced C’.press-onaf (;/'M(//////k:/j/O/((((: cancer .ell ctoothb' modulating the CCC/2 »x-ii:ua\ υ» | 191 | cstec-sarcoma | up | MicroRNA-199a-5p is downregnlaled in human osteosarcoma and regulates cell proliferation and migration. | :(ί/Ρ/(((: (/2((((((: | colon cancer | (//(((((: | The tumor suppressor gene ((R/pfe/^:/i/a:8898i/k^/:(( ((0f(toM(/i(«(/d^h/8i//(((: ((kkk(((((((((((((((((:((((((((((( |
HiU- :(2//(((((: | ieiuto-bbdvtikt | :(/8//(: | miR-lM downregulated m rednohtesioma. nwteoana a> (/kh///i/p//ki/(;(((((((( human, fettnebiastomp cells (;///ig/diig^2://((((((((((((( | mir- 191 | osteo-sarcoma | up | MicioRNA-191 promotes osteosarcoma cells proliferation by targeting checkpoint kinase 2. | mu- (///// | colorectal cancer | up | MutoRNA signature; ((k(/l/j8ikikk///((((((((((( cwiorecfal cancer1 |
ό/η/-·:::::::·: :(2//(((((: | cotorAAai cancer | (//((((( | PER3 a howl target of ((/02//:/1/2//((((((((((((((( (//pp/Si·////: //(((((((((((( coloiectai cancer »< vitro. | mir- 191 | pancreatic cancer | up | MicroRNA-191 promotes pancreatic cancer progression by targeting USP10. | :/Αί·/::::::: (///// | colorectal cancer | (://((((( | Expression of re.iR.-2J. bxR-3i. miR-^8 and miR135b is correlated with the clinical papanicteta of cotoreetai cancer. |
(:////// i/iii | ccdoieUai cancer | (//2/2 | MicroRNA-iri3 Pmnxqes Color eetai. Career fn (//iO///////:(((((((((((((( Suppressor DKPR and H's-N | mii- 192 | bladder cancer | down | Expression of microRNAs in the Urine of Patients With Bladder Cancer. | (:Ρίηϋ:((( (//(((((( | tokutAJ vdoca | (//((((( | Elevated nucroRNA--3 1 e-epresstou recuiatos otoreetil ...ox or pmgrcsstonb> repre,srec ts large, pene hYPB? |
ckf-CtOC :(2/2(((((( | gastric cancer | (://((((: | tmRNA-323 promote* gastttc earnertp.oa-uouarJ metastasis by targeting (//Pk(/i/iO-//((((((((((((((: 2//0//(((((((((((((((((((((((( | mir- 192 | bladder cancer | down | Regulation of growth of human bladder cancer by miR-192 | tkiri·:::::::: (//(((((( | colorectal cancer | (2(/(((((: | ((tk8ii/8kd/ri/(((((((((((((((( mtoiuRNA-l 35b mSktoi as ((//btkki(N/<hlkk/'/((((((( Biomaikei for CMore^ud Cancel and Adenoma |
:(///((((( | gastric cancer | doun | MicroRNA -JO ja inhibns /gp/d/;/3//pkU((((((((((((((i proliferation, migration and uoasmwb· fargebnc cM\b. | 192 | colon cancer | down | Prognostic significance of miR·· 215 in colon cancer. | :(8482:(((: (//(((((( | colorectal cancer | (//(((((: | Cb-nicopatbological ::signifieariCC:-8f:miC18RNA:-:·:·:· ((2ϊ(/ί/2(Ο2ϊ2/((((((((((((((: expression in colorectal L enu-cer |
(ί////:/: :://2/:00 | (bi^/(/d///:((((((( | /1/ | Micrn-RNA profiling in kidney and bladder cancers. | mir- 192 | colorectal cancer | down | Association of microRN A expression with microsatellite instability status in colorectal adenocarcinoma | mu- (//(((((( | colorectal cancer | :(////( | SATBJ and 2 ht colorectal (:///2/(((((((((((((((((((((((((((( |
!UK- :(2//((((2 | (/^/00//(((((((( (:ktre/p/g//////:( | (////(ί | MuioRNA-i/s ’supptesse» (/0/^/1/8//^(/8/(((((((((( /inf(ihit/R(3K(AKk//////: (/<:gi/k!^:i//(/iria/((((((((;(((( hepatocellular cgivmoina | mii- 192 | colorectal cancer | down | microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. | mu- (//(((((( | ooWeeUi varjv« | up | Assocrayott of microRNA (:OkOR:(2'//(((((((((((((((( micro atelhiejn tahibiv ((3(/2^( ift/8188^//(((((((((((( (:/dk8kklh5iPh((((((((((::::::::::::: |
0///:000 :(2//(((2( | prostate cancer | :·/$/:/( | miR-W5 kthibits Prostate OTphiap/ikdAih:byO:OCO:O:O:O Suppressing CDklti Levels. | 192 | epithelial ovarian cancer | down | Gain-cf-functicn microRNA screens identify miP.-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. | :(8482:(((: (//(((((( | jkci/keksssscjjj ((k/g/(((((((((((((( | (//(((((: | Differential expression of naPN ks to esophageal ((8di/k(a/d/((((((((((((((((((((: |
0/1/((((( /0/// | cervical squanws (k//8///p/:(:/// | dan a | MiRNAs and theii (Okt/j8d(///((((((((((((((((: lovoregmnal waging and surviv al following sufgbhr | inir- 192 | gastric cancer | up | MicroRNA-192 and -215 are unregulated in human gastric cancer m vivo and suppress ALCAM expression in vitro. | SfUliyyS:: (//(((((( | ((838^^2222((((((( squamous veil ((kkikjt//(((((((((( | (:////( | The ynoogenctic iplc of (:/ft8k!RNA43/:d//((((((((((((( putenttal bmmatfemn oesophageal squamous cell |
WO 2017/132552
PCT/US2017/015417
far esopbageal caretooma. | 33OZZO3Z3Z3Z3Z3Z3Z3Z3 | ||||||||||
!UK- 3/////33 | colorectal caucor | 30333 | [Expression of plasma miRΒιΜηΚ rf 3/tid3it/c/ai/3/33333333333i 3$OOi/W333333333333:: | mir- 192 | gastric cancer | up | Plasma miR-122 and nuR-192 as potential novel biomarkers for the early detect io n, of distant metastasis of gastric cancer. | 7/ίηΑ::7: 3///3/3: | gastric, cancer | down | Dvwn-moutanvrivi mrR-'l ewpmssmn m g.tetr.e. w i.ttSttts and its clinical 3ilgmri3gh3s33333333333333t |
7hiff77:7::: :30//3/ | colorectal cancer | 30333 | Candidate microRN A 3$OOO3/O/£/333333 colorectal cancer Systematic rev-tew prcfdina studies and experimental 7/d/datid/?7:y:y:y:y:y:y:y:y:y:<y | tnlr- 192 | gastric cancer | Up | MiR-2J5/192 participates rn gastric cancer progression | 7/1/77:7 3//3:3/3 | pltrtfrtaztvtfia | dote n | Human nuR-B targ-we, ////0:///:0/3/333/3/3/3: 3jjftO/3/3/)/:/'///i////3:3: ///////: 0/33/3/3/3/3/3/3) |
333/3333: 3////33/ | endometrial cancer | /Oil | TSA Suppresses miR- iriob-i'iustei Expression ttaungb Dotvnregtitation of MYC and inbibite Proliferation and Induces ::-AuoptosisinilmnanRMC;·:·:· | mir- 192 | lung cancer | down | MicioRNA-192 targeting retinoblastoma I inhibits cell proliferation and induces cell apoptosis in lung cancer ceils. | 3///333: Bill | 3g/s/id////i33:33 | dewy n | 3S/03303///3/3:3Z3Z3Z3 /////0//03/3/3/3/3/3/ glioblastoma arxf comparison with other 3/f^i/3igd/i///3/;^ig/;/33 |
333/3333: 3////333 | 3///tri/3/r/://333333 | 30333: | Circulating lOiCfhENAs to 3]/?3///0^O/:Ait:h)y3y3 3O/Z//O/33Z3Z3Z3Z3Z) | 192 | pancreatic ductal adeno-carcinoma | up | Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma. | 7ύ/Ρ-7??: 3///3/3: | head and neck sqnainous ceii ypatempidgy???????? | 3/|3:33 | Cn targeting of muhtale mteroPNAs on factofinitlbitina hjpyxiantducihlc factor tFllR gene for fix pathogenesis of head and neA cafdnonjas |
!UK- 3/////3/ | 3/330/330333333 | 30333 | MicroRNA profiling of human gastoc cancer | mir193 a | epithelial ovarian cancer | down | Gain-of-functiou microRNA. screens identify miR-l93a regulating proliferation and apoptosis in epithelial ovarian cancer c ells. | nm- 3///3/3: | 3/έρΟ33//Ο3:ί 33/^///)//33/3/3: | 303/3 | Expression of microRNAs, nuR-21 mtR-B,mtRA2?. miRB/5 mtR-i-lfa.miRx v i iK Ή htR 'ta and tniR-223 in patients 30/////13/303/3/3/3/3: carciituma or jmrahepatu . hostaptavatertoitea md ·ΐζ 7ρ/ό///7:77<<<<<<<<<<<<<<<<7:7:77 |
333/3333: 3////33/ | gastric cancer | 30:333 | miR-dtioa is frequently upreguteted tn. gastric eanect nod tnhihits the extrinsu. upopOti; pathway 3/3/Zi/l/«££A/33Z3Z3Z3Z3 | tnlr193 a- 3p | breast cancer | down | Global microRNA level regulation of EGER.-driven cellcycle protein network in breast cancer. | 7/1/77?:: 3//3/3:3 | 3/3/3:33//3333333 | 3////3:: | MuroRHA-'I hutetmitz is 33/3 /ί//://^///έ//://33/3/3: regulating ctikvvleand ////////1/1////////////33:3 transition. regulatory ptoiems in liver cancer. |
3////33/ | 3/13/3 | vtf ttatmentdC^) » he plasma of patterns te nit 3^33/3:03003333:3:3:3:3 | 193 a3p | tumor suppressor in lung cancer by downregulating ERBB4 | Bill | /3^/1///)/:3333/3 | //1/33 | Presence off?, mph Node hktasfases and I uno at m Rv.et.tew.th : one Adenooafginoma | |||
H!H- 3////33/ | 3^303/330333333 | hhWHhh: | miR-R'/a confers cisplatiu rexttiance by regidattog PTEN/Akt pathway in 7/^Rii/ai/ii/Si!S5777:7:7:7: | mir193 a- 3p | renal cell carcinoma | up | A panel of five serum miRN As as a potential diagnostic tool for eariy-stage renal ceil carcinoma. | mu- 3//3/3:3 | y:/tditg///3333333: 30//0/5/333333: | d<m n | ‘jenetic and tpuenetie loss ol mmtuRNA-Gl Kuris to ieed-foiward ή’.preSS-on of 7£^$<Kfiiii5idhdriid7:777:7:7:7 |
3/33/333 3////333 | gastric cancer | 30333: | MuroRN A-lOa targets TBvIP2 to regulate invasion and metastasis of gastric y3di//3333333333333333333 | m.ir- 193 a5p | colorectal cancer | down | Downregulation of raiR-193a-5p correlates with lymph, node metastasis and poor prognosis in colorectal cancer. | 7/1/-7:7: 3///3/3: | •malignant 3O//te/p/333333 | down | Regulation of earner aggressive leatwes in 3:/teia/)/te/sli/:^33333/3/3 3itift3ri!/:/A/33333333333333t |
WO 2017/132552
PCT/US2017/015417
EiAARR·: | :A]ORORAbbbbbb | :iAABR | giSdABARBkAAARRbRRRi ttJufei's plmn-oosll tl κλλ uptake and pnaitfemijcn by ::W2eH«g:&L<S2A3:i!n:l3BM·:·:·: | mir193 b | breast cancer | down | Downregulation of mrR-l93b contributes to enhance urokinase-type plasminogen activator (uPA.) expression and tumor progression and invasion in human breast cancer. | brrrr | AhAdbildRRRRRR: iAiBAiAtRRRRR? | dm? n | MlcmRNA-'l suppresses οκΒηΰΛ&1η3υίΉνΊ! growth by tithilxtingDWA iARWBRABlAR^lRRRRRRi 3drAtAbARA$dhAAAAA:RRR: chiAtedhdhddRRRRRRRRRR:: |
ymiiAAA X:fQfA:b:b: | ^glAdARRRRRRRRR | down | MtR-i”t-a mh-bns glioma cell growth by targe’dng B2FI independent of p>3 AiAdARRRRRRRRRRRRRR·: | 193b | breast cancer | lines: Ml) MB- 231, mCF | Tumor suppressive microRNA193b promotes breast cancer progression via targeting DNAiC13 andRAf!22A. | BRRRR | :ΑΑί£ρΑΐίΑ:0:0:0:0 | /||RR/ | beatf-bpsed suspension TdfARilRBiARdARRRRRR? mtcroRMA in NSC! C iaAbeAdBARiAhBbdRRRi dOiAAtdrRARRRRRRRRRR |
ymiiAAA X:fQfA:b:b: | ηοη-umnll oeii lung RO^RRRRRRRRRi | down | Circulating micro-RNA •:e*pfesS10Hpieilles:ifi:eariy:·:·:· stage nousmali celt bang | 193b | glioma | up | miR-193b promotes cell proliferation by targeting Smad3 in human glioma. | sArAA BRRRR | oral carcinoma | /rirr/ | Γ. ’.ploiting Saliv ary mtR- 31 as a cinucai biptnacker yf CdAf^ddhAdAAlRRRRRR:: |
ίφΑΑ'ί:? ibiiObbb | AdRdisRR^ReARRR::· | 1111 | Differential miciuRNA expies&ron tugnamrcs and <.N! iypn-SfKMik ίΑΑΡΑΟΑΑΑΑΑΒρίΑΑΑΑ res-srame in rw anan cancer ibAAcARRRRRRRRRRRRRi | rnii- 193b | hepatocellular carcinoma | down | miR 193b acts as a cisplatin sensitizer via the caspase-3dependent pathway inllCC chemotherapy. | ipiiARR Bill | AdAiR^rAiAARR | llll | Dj simulation of tniR-3 i and nnR-3 expression is associated wrih dttueai fAABhAAiARAiRRRRRRRR: ccaiAiAAhARRRRRRRRRRR |
iiAdA:i:i aBBIR | renal cell carcinoma | down | ifiiR-b'lna* inhibits the C^iifeAtAhABAAlRRRRR:: carcinoma cells bj RAAAAAQRAARRRRRRRRi | mir- 193b | malignant melanoma | Up | rniR-J93b Regulates Md-l rn Melanoma. | ibidA/i: brrrr | orai squamous cell carcinoma | aIRRc | mOtexI m up*ragniaied ir oml premaiigram : epithelium and contributes·:·:·:· tu the immortalo-aucri oi normal oral fceraiatocvLes. |
ίφΑΑ'ί:? ibiiObbb b:5ifbb:b:b | clear cell renal cell iedORRRRRRRRRd | down | Exploring the miRNAniRNA regulator; network m clear cel! renal ceil carcinomas by next·* generatioo sequencing e vpression -profiles. | rnii- 193b | malignant melanoma | down | Slathmin ί is a potential novel oncogene in melanoma. | AhiARR Bill | AdAbAbiddAiAiRR AA|$dA:aAhARR | llll | through the ί ESP9 signal cascade· in oral carcinoma. |
iiAdA:i:i BiBlRR | gastric cancer | i:i|lAR | Cintdau/ju roR-Asm plasma of patterns with AgssAiRRARbARRRRRRRRR; | mir- 193b | non-small cell lung cancer | down | MicroRNA-J93b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. | ίΑάΑΑ: brrrr | panvreatn. Jintal ralerp-carcinoma | aIRRc | Cireuktfing MtcroRNAs in B$AiR:dRAhAAAl?AtAARR:: Oncogene Transgenic Rats Willi pancreatic Dacral Adenocarcinomas. |
imAA'i·? ROaaa | gastric cancer | |||| | MkioRN^profihng Ά liumai' uostix vaacei | rnii- 193b | primary cm lymphomas | down | Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. | AmARR brrrr | prostate cancer | dAdRbR | fDAAiAs^ARdRrtRAAdRRRRi 29$ andnuR-31 confers ^srstw c <.0ν1νί\4η«Λψν induced apoptosis in /pAAatAbdAAAcdiiAi/:?:?:?:?: |
!UK- BBbRRi | 3gdAAAOBR:RRRR | R^lAR | etnulatreg mtR-? 1 m the plasma of patterns with | mir- | colorectal cancer | down | microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. | rau- BRRRR | coaaaoaar·: | llll | Screening Btotnarkers of 3iO^lAAdtAAB3RRRRRRR Integrating m&roRN.A and |
iiAdA:i:i RBBRRi | i:gldOAAAAA3RRR: | RR^RRi: | Dowraregnlatton ol'milte Ibtfc suppresses the growth (A^iAABilBIABiBRRRR | mir- 194 | colorectal cancer | down | MiR-194. commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jua/MDM2 signaling pathway. | iKIiM:::: brrrr | prostate cancer | dow n | itelvvorah protem EZH2 Suppresses apoptosis by sticking the prospoptohC EhufeAARRRRRRRRRRRRR/ |
WO 2017/132552
PCT/US2017/015417
:(Βί«(-(((((: ((^0(((: | ((&^:0(0k(((((((( 2sOW^^6!:i((((((((( carcinoma | < comprehensive MteuRNA profiling for head and neck squamous cell carcinomas. | nsir- 194 | gastric cancer | down | miR-194 targets RBX1 gene to modulate proliferation and migration of gastric cancer cells | (:fmi((((( N?7 | ((hdb^6^diihii((((: curctuoiua | Ο||: | MumRMA-·'127 promote* (:^ObhfekiihRhiid((((((((((( (:^ii^j^^^:iii((((((:((((((((: hepatocellular carcinoma by disrupting of RiSK/aKT negative regulation. | |
:(:mif::((((( | hepatocellular ((CkOm;oi(te(((((((((((((; | :(^((((( | 0' ef e .pressmn ct t. uk Itfob promotes cell migration and metastasis jp. hepatocellular carcinoma (;Β^:0^0ί^έ:0^ί08ΐρΒ(1(((((; mesenchyjnal transition (^0(½½½½½½½½½½½½½. | 194 | gastric cancer | down | MicrcRNA-194 Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Targeting 3-oxMl. | (:hte;((((( 3189- | astrocytoma | down | Artfi-Tumoral EffeOte t>f ((kftfeHi:8S(3p3h((((((((((((((((( ((cimbi^i0hte;(((((((((((((((((((: |
(($0(((: | (:bep&O$h3h(((((((( ((^fedh0kxT((((((((((((( | ((0(½½ | (;ti^kgniga0h:0h(((((((((((((((( i:00(iOW(OOtOiiO^((:(((((((((: associated with poor prognosis m hepatocellular idhfo!h6h^;((((((((((((((((((((((( | mir- 194 | lung cancer | down -1 | miR-194 suppresses metastasis of non -small cell lung cancer through regulating expression of BivlPl and p27(kipl.) | 3189- iill | ((^Bs^h5:t0in3((((((( | driwn | Anti-Tumoral Effects of ((ifiR((3(l:S^:3^:k((((((((((((((((( ((Gimbl^Wr^(((((((((((((((((((( -, |
((^i«k^(((((((((((((: | (:(00((((: | prold'etarionta targeting RE m huvngenl carcinoma | 194 | osteosarcoma cell proliferation and metastasis in. vitro and in vivo by targeting CDH2 and 1GF1R. | (4/9:(((((( | ((ted:ikimii(((((((((((: | :(^:((((( | bt J 25-dilndmovnanuri CU inbiunsn mvelowj leukemia cells leads to Bim targetmg and inhibition of AmC mduvod apou-osis | |||
(000(((: | ((fetyBgd31:((((((((((((((: ((^fedh0kxT((((((((((((( | (0(:((( | Mrcn>kNA-ibh rcpulatez iOtO^OO^OOoO^OOOOOOOO RUNX3 in laiynaeal (:iakOi00£hi^(((((((:((((((((( | tuir- 194 | pancreatic ductal adeno-carcincma | Up | Upregulation of miR-194 contributes to tumor growth and. progression in pancreatic ductal adenocarcinoma. | Oklt/:/::::: :(3½½½½ | inkfOv d user | :0(:(((( | The relationship between and ciinteN sigoifkanee of ((Mii:ibRNAT32tehd((((((((:((((( phosphatase- and tettstn homologue expres&iim m Τ:^(δ(ϊ(6ΐ^ί^ϋά^Ε(ίό(β^::::::::(((((((((((: |
(000i((( | (0<w0i0o(((( | (1(1: | miR-fowb i* uVvfexptvs^ed in metfuiluhiasfotnasand menmt^JiKstR %i'h (|BB(((((((((((((((((((((((((((( | nsir- 195 | adrenal cortical carcinoma | down | miR-195 and nsiR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. | mu- :(1½½½½ | ((hdb^6^diihii((((: curctuoiua | Ο||: | 9ΜΜ(32:«^^(2ίί(έ9:ΐϋ((((((((((: omlrterAmu imgtwun T^d3O^bh:ih(((((((((((((((((: hepatocellular carcinoma tby/tdi^rrt^kTEN:.//:::::::::::::::::::::: |
(000i((( | pKUffftty ViHMiWm | ((00((((( | MrernkNAmvolvemeui tn lkO^OA^Oi((((((((((((: fonetroninii pituhaty (tehkhkirk(((((((((((((((((((((((: | tuir- 195 | adrenal cortical carcinoma | down | The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. | Oklt/:/::::: :(3½½½½ | (pph/smalfpeit///// ((!Ahgk:abhgi:((((((((: | Jow n | f mshm-n.' z ztipprevs ((i;bgpiatr9h(bEkt^432((((((((((; ecptessmn jp. non-smud «.eO ((hih^O^ted!(((((((((((((:(((((((((( |
:(i£ik((((( (000((( :(^:((((((( | /(gl^ia(((((((((((((((((( | (i!0((((( | ΜκίοΕΝα- ritob- 5p boosts gbvma iui^vfigcnzs In targeting multiple rumor suppressor genes | mir- 195 | bladder cancer | down | Cyclin-dependent kinase 4 is a novel target in micoRNA-195medrated cell cycle arrest in bladder cancer cells. | ^ηπίΑ::::::: (½½½½½ | ((hbh(5hkallteg!f((((( ((lphg:sahogr((((:((((: | :(dptyil(( | Expression of miR->2 in human non-small cell lung ((^te^(^:k^(^rihikdbk((((( wkh tumor progression and (phtiebt-^iridvdl:::::::::::::::::::::::::::::::::::: |
!UH- (|B(((((i | acute promvulocy fie (kiri:^ibih((((((((((((((( | (:½½½½ | A restricted signature of miRiiAstiiztirpUfsfxa API i^h^kOk<0^hbkhO((((((((((((: (;prh^0lO^((((((((((((((((((: | mir- 195 | breast cancer | down | Analysis of MiR-195 and MiR497 expression, regulation and role in breast cancer. | mn- :::(13:::::::::::( | ((0ihi:^fii^iidi^((((( cell carouxmjs | down | hhRC'2 functions as a rumor suppressor and directly targets EZlkfon ((ikhiak^rdi(^ddkbd^$rMlT(:( ((Cdteittehte((((((((((((((((((((:(((: |
Ckifr-::::::::::: :(0(((((: | breast cancer | (:d$A:0(: | lRli^(A/fo7(ijkfti!fel((((((((( proliferation and migration by targeting C&xh m (:½½^½½½½^½½½½½½½½½½^ | 195 | breast cancer | down | Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of | 30iif/(((( | ((b^eb^tfo$ibh(((((( | down | MieroRNA~3 ? inhibits osteosarcoma cell : proliferation: and invasion: : : |
WO 2017/132552
PCT/US2017/015417
Raf-1. | |||||||||||
!Wi· | 1/(303^/)3/:33:3:3 | 3||:|3 | MicivRNA-197 pmiuntes pmbferaiinn of gastric cancer cells by targeting vVvbudPpgt’tient kinase 8 | mir- 195 | breast cancer | down | Serum microRNA.-! 95 is downregulated in breast cancer a potential marker for the diagnosis of breast cancer. | /:buf///// | //3t3d3:3333e(3:3:3:/ | down | iuiR-32'! enhances the sensitivity of human colon )/ό6ί336ό3((336/////////////////// cheuioiudiOthpopv homo bv targeting FOXM1. |
//nah-:///// 6B6551 | gastric cancer | 366/555 | //MtcnyRNA/IQyyan//////////// -oncogene mivfoPNA tbaregyla-es tumour u* asiyn and metasiaAohv tatgefisg DfCERi :n gastric earner | 195 | chronic lymphocytic leukemia | down | miR-15 and miR-16 induce apoptosis by targeting BCL2. | 3(3((333: 320 | 5gli6bi/O/O6565 | down | miRNA mt^roarrso reveals spevtfiv expression tn the peripheral blood of /3(3^33(36313^3(6333////:3: |
3:33/3// BB/|3 | //3/(/333/33/:3:3:3 | 366|| | miRNA-225 promotes gastric cancer invasion and metastasis by targeting tumor suppressor /:(66(6565////////////////////////: | mir- 195 | chronic lymphocytic leukemia | down | Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia. | //(6((5//// 32b | $!μ;ί | dow f | MicroRNA-dSP htl-ibtls 36i)(i/bib36^ by targeting E?L1 |
/:(6(6/////: /B///3 | gastric cancer | 56|/;5;5 | :/iipiggi333/3:3i33333333333 /|b33BBA/03iB33333333: 3θ^/ίΐθ33θ(θ33333:· 5666((6/ oo(3B&B333333 targeting tire tmnseriptroii iauorFOKOi | mir- 195 | colorectal cancer | down | microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. | :/(36/:///: 3?.b | osteo sarcoma | dma n | MnmRNA- ;?0 inhibits //3333^63333®(k/://////////// proliferation by directly 'grgettne fptU avid 3(3(0^33333333333333333/ |
333/3:3:3 /Bill | /:gi3333t//////////////:3:3 | dpw π | PS3-mdeeed mkroRMARt? miabits proliferation of gkuttta veOs and den nregtdates the e\pres*mn vi <DKo and Notch-?. | mir- 195 | colorectal cancer | down | Downregulation of tnrR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. | //(6((5//// 32ba | colon cancel· | dow n | |
:/(6((3///// /B///3 | 33(/3/3/:3/:3:3:3:3:3:3: | dowu | 5/Μ(356Κ/63^5(63/((6(6(ί6////// glioma ceil uiigtation and invasion b\ modulating Nylch2 expression. | mir- 195 | colorectal cancer | down | M/icroRNA-J95 inhibits colorectal cancer cell proliferation, colony-formation and invasion through targeting CARMA3. | :/(36/:///: 3?.ba | tok.rev'ud cancer | 3(033 | |
Cffiib////// /BI/33 | 33(133/3/:3/:3:3:3:3:3:3: | down | Low -emresstonof :-:-miC£oRNA-:-ib7:-inhihitSCeli·:·: apoptosis m glioma by upregulation of SALL4 | mir- 195 | esophageal squamous cell carcinoma | down | Differential expression of miR195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor ceil proliferation and invasion by targeting of Cdo42. | 313((3:3:/ 3BB33 | coic-rectal cancer | dbwn | nuR->2tia suppresses //3616(6)(3(/(^(03333333333/ progression by targeting /03(33333333333333333333/ |
SUH* :|B/// | 3&e33/i3i/333///3:3:3: //SOW<i/3//33:3:3: esrcwoma | 333333 | microRMA-ib functions as a candidate tumorSuppressor gene in Jjead and neck squamous ceil 33O33d(3ii33333333333333: clou weouiafion of pic tent 566^/56/5/5/5/5/5/5/5/5/5/5/5/5/ | mir- 195 | gastric cancer | down | MicroRNA-395 and microRNA378 mediate tumor growth suppression by epigenetrcal regulation in gastric cancer. | mi:- Uba | colorectal cancer | Jov n | Couigetidumj microRNA- 33^96(660/(6(66(//////////:3: //(6(/(6(6665/3666^62//://////// 5666(303:1666 /(655/5/5/5/5/5 associated with liver /5066666(6/66(6(66^5/5/5/5 •xmeu |
!Wi· /B///3 | //h33d3/£//3//333/:3: squamous ceO 5(66/(666655:5:5/555 | :33333 | 33/id/d/d)0O^iirete33/3 deliv ery of Pre-nuR-VD inhibits the tuntonpenritt of head ami neck squamous 33$/3a(iOb)a)333333333333 | mir- 195 | glioblastoma | down | MicroRNA-195 plays a tumorsuppressor role inhuman glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. | 6(663/5/5 ?2ba | 3Oi(33O6^333:3: | down | MicroRNA-529a suppresses in <?8M patiertts and modulates gimma «ret! tut'Cupns bv targetujg JC(F- BBlIIIIIIIIIIII |
WO 2017/132552
PCT/US2017/015417
$££«$$:$:$ | non-smail ceil king £O£$£££££$:$:$:$: | $0$$ | Ebnieoparhologival arid ρίΟΡΙ-ΜΐΚ s'/O'lxat M microRbiA-lOTir human $h0hS$£b: £$;$£$££$$ j$$$ | mir- 195 | glioma | down | MicroRNA-195 Inhibits the Proliferation of Human Glioma Ceils by Directly Targeting CyclinDl and CyclinEl. | $$«$$:$: 32bn | naso-pharyngeaf carotonroa | doo n | MumRNA- '20a inhibits ceil proliferation migration andtma iohbv ror^uta BMI-1 In nasopharyngeal $O0$ih£h$$$$$$$$$$$$$$/$$ |
$1ίϋί$:$:$:: | prostate carcinoma | dowo | Dy sreguiatio g «Γ the rokogco granukn in butnan cance >- through the miRf5/ffP inicroRNA gene $$$$i££££££££££££$:$$ | mir- 195 | hepato-celluiar carcinoma | down | MicroRNA-3 95 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of W, VA.V2 and CDC42. | $mif$:::$: 32da | osteosarcoma | £$$£$ | identification of a plasma four-roicroRNA panel as potential nouim, ash e £b$$$£$;$i£££££££$$:$: >$&Ρόέ£$Ρ$Ρ$£$$$$$$$$$$:$ |
•ηκ· | bieast cancer | down | MxioRNA i 'a t> reutived ni breast cancer and regulated in part through $mdpd$p$$$££££££$$$$$ | rnir- 195 | hepato-celluiar carcinoma | down | MicroRNA-195 acts as a tumor suppressor by directly targeting Wnt3a in HepG2 hepatocellular carcinoma cells. | $mn$:$:$ ?2db | colortctJ vdoca | 1^11 | ::MiCioRNA:-3:2ybptO£no$es:·:·:· $£01$$$i£$i$i£££££$:$:$ oroftrorotmr rodirwozun //by£$$b$i$g/wh$b££££:$:$ homologous microRNA$5233$$$$$$$$$$$$$$$$$$:$·$ |
$ίίϋ£$:$:$ | $$$fe£fo££$i$:$:$:$ | >3icroRNzvkla targets CBLi and promotes cell £towd\ migration and im aslon in human cervical | mir- 195 | hepato-celluiar carcinoma | down. -1 | microRNA-195 functions as a tumor suppressorby inhibiting CBX4 in hepatocellular carcinoma. | $mif$:::$: 32.de | bladder cancer | down | MicroRbiA-.igOe inhibit tumorous behaviors of bladder cancer by targeting Cv^fwi-du'pemfcrtf kinase ft -, | |
£$£$£$£$$£$:$:$:$ $ί$!$ϊ$1$£$£$£$£$:$: | £ib$$£htbh$/$M£td£££:$ leufetum Ci>; 1· celts imnc'e I S^-'-nedmed /:$$£:£$£$£/////:::$:$:$:$:$:$:$:$: | 195 | trichostatin A increases the expression of Dieu2/mrRI5a/J6-1 via HDAC3 in nonsmail cell lung cancer. | $B$$$ | 2££$£$$t$k$$2$ | ^ahv ary hhvfoKN Ac for Detection of Ora! Cancer. | |||||
gastric cancer | ££$££: | nuENA e\pre® ztvfi profile in primary gastric cancers and paired f> mph node metas-ases -udwates that naR-lr,apfa>s a role m metastasis from gnmatA gastrt · uuxer to t> mph t«xk·· | mir- 195 | lung cancer | down | MiR-195 suppresses non-small cell lung cancer by targeting CHEKI. | /:££:$:$:$ 524- 1$|:| | naso-pbarynpeal £$$$$!$£:$:$:$:$ | dow n | $£O££p$$$k££d£££:::$:$: significance of mtRNA- $k$O$$$$g$$£££££$$$$ $££$ι$ί$ί$$$$$$$$$$$$$$:$ | |
!Ο1Γ- | £g£s0£$t$£$:::$:$:$: | $dg££$ | MicroRNA-lOa bs DowuRegulated bv ONA Methylation and FuhCUObS as 3 Tmnor Suppressor in Gastric Cancer Cells. | mir- 195 | neuro-blastoma | up | miR-15a/16-l enhances retinoic acid-mediated differentiation of leukemic ceils and. is upregulated by retinoic acid. | :::£;£$:$:$ 524- 1$|:| | nasu-plar ngeai earomuma | down | Mi«oRNA-324-;s regulates nasopbarv ngeal carcinoma radroresistartee by directly targeting |
$££$$:$:$ | pancreatic cancer | ££$:££ | $Mt0i0RNA:AGkm£££££$:$: o·. erexpres&ud in human pancreatic cancemud invoked in its rovasivertess purtnOv iitsupimrounU she > Κi-enc | 195 | non-small ceil lung cancer | down | MiR-195 suppresses non-small cell lung cancer bv targeting CHEKI. | $hilf:::$:$ 52o | $$itiroak$$$$$$$/:$: $$$$$$$$:$$$$ $$££$$$$$$:$$$$ | down | Targeting oi the signal $t£$£d£o£l$s$$ $$$$$$$$$$ £hn£fb:RKA-A26:t£:fik£££$$: $0hb0$w£$^b^$££$$$$ pi’hfMy jr (D'-u >Ch8 stenVpropenitor cells. |
!Ο1Γ- ΒίΒΫίΫί | £bi$dO££$$$/:$:$: | B$$$$ | MicioRNA-Rk promotes $0#O$0d$$$$$:$:$::$ through KLE3 and : HQXDltt mhumambiadder: $£a£o££$$$$$$$$$$$$$$$$$$: | mir- 195 | non-smail cell lung cancer | down | MicroRNA-195 inhibits nonsmall cell lung cancer cell proliferation, mxigrati.cn and invasionby targeting MYB. | mu- £?$$££ | cokrectai >.anv« | up | MicroRNA-32h functions as a tumor suppressor in colorectal cancer by targeting the nin one $bik$k$$pRih£$$$$$$$$$:$: |
/:££$::$:$: | breast cancer | :$£$$£$ | .Analysts of ft«R-2t)$ and jniR-155 oppression jn the blood of breast cancer | 195 | non-small ceil lung cancer | down | miR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF IR. | $hilf:::$:$ $32$$:$: | $gk0$3$p$k:$:$:$: | down | Expression and clinical significance ofmicroRNA52$ in human glioma naR326 eapiessimtingiroma. |
WO 2017/132552
PCT/US2017/015417
Ε:ΐίίέ^:$Ο3ΐ:////$ | ΒΙΙιι | E'vvSvpae-meJiated tmiisfei of n«R-!b ptuntufes <eB jmnsiem «· breast cancer | mir- 195 | osteo-sarcoma | down | MicroRNA profiling identifies MiR-195 suppresses osteosarcoma cell metastasis by targeting CCNDi. | $Βίΐί/::$: ιόίίίίί | $0^11/111 | dov n | Targeting rite SMO on^Ao«cbv mtR-3/* inhibits glioma biological behaxiO's and sternness | |
iSiFtll: | coioreotai cancer | ίΐ^ΑΫ | upieguiated and lias an invasive rote to cdomctal veancerihroygli^nh-anoed·:·:·:·:·:· Rhoo expression. | mir- 19? | osteo-sarcoma | down | microRNA-195 suppresses osteosarcoma cell invasion and migration invitro by targeting FASN. | i/2&iiii | IlgriqOllllllllllllll | down | The neuronal nn «oRNA n<tP-5>is s?t$ m a it-ejbaol loop with notch arid has again*!. brain tiioivfc |
3:ipn/:0:0: iiOlAA | esopbagsai cancer | ill! | MicroFNA-lfh promotes nugra· ·ηκ and m« asmi1 through KLF4 inhumafi esophageal ameer cell Sines. | inir- 195 | papillary thyroid carcinoma | down | rnic roRNA-33 9- 5p mo dulates Na+/I·· symporter-mediated radroiodide uptake. | iighpmaiiiiiiiiiiiiii: | dow £’ | :<MiofoRNA-:-32-6fu£ictiOHS:':'::': giioma h\ (meeting the Nfn | |
i;Bll | an assort ifctungb RhoCART Signaling patbvmv hv targeting HOXDlb th | mir- 195- 5p | hepato-cellular carcinoma | down | MieioRNA-195-5p acts as an anti-oncogene by targeting PKF19 in hepatocellular carcinoma. | mu- ίίόίίίί | colorectal cancer | Joy n | ?a lu mRNA expression omfif mg f den. rf m, t< ,j« 32h teguiains earner stent | ||
0bihf/$3:$ | gasm. ^u<ncnr | :::έ33ΐήί$άΐΐί$ί4ί$ί^^:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ: sigoifkatice of mtR-idb | mir- 195- ?P | osteo-sarcoma | Up | identification of a plasma fburmicroRNA panel as potential nomnvasrve bio marker for osteosarcoma. | Ifriii/I/ 32$ | gastric cancer | $ίΟΤ/: | Macrophage-derived reactive oxygen species suppiess miR 328 'yrgetinn CD44 m cancet'celte and promote rcdv\ adaptattun | |
:::φίί/:::::::: | gastric cancer | :::DNA:ipethyite:iPb:tttt:?????????: dowryciptiaied ink-lOb acts vs n Unt^r .oppressor rt· | rnii- 196a | breast cancer | up | MicroRNA-196a posttranscriptionally upregulates the UBF2C proto-oncogene and promotes cell proliferation in breast cancer. | ?:bur::::::::: | Sgliorfja??????????????: | |20?||||| | :MiEx-32SpfO:mof?S:glioma·:·:·:· dependent Wnt- agnvbng | |
!Wi· | ίΐ^ΑΫ | Oncogenic effects nf roiRIbbrn pboblnavffia stem | mii- 196a | cervical cancer | up | MicroRNA-196a promotes cervical cancer proliferation through the regulation of FOXO1 andp27(Kipf). | AS | IlghpRhTTTTTTyl | down | /fi«ofdRNA6328as:a//////////2:· favorable prognostic tnarkef in human glioma ::via:soppressingmvasive·:·:·:·:·:·:· phenotvpes- of malignant L cell- | |
liar- ΙΐΟίίίίίί | /ill | /K^t3d^i>i-riff:ijiif:;f:966666666666666/ /:^ύίίί^ί^£ίΐή^ύί^:Α^ίΓϊΙΙΙΙΙΙΙΙΙΙΙΙ/:::: comparison wfih other brain nyoplgsia yf grades i- | mir- 196a | colorectal cancer | down | Association of microRN A expression with microsatelirfe instability status in colorectal adenocarcinoma | mu- 32« | i?ip|| | Kfiphetai BI'ZN nuR-Ati t cpiessmn a> a Pofeuliai Biotuarker lor the Fatly | ||
iiOlAA | $g(Og$|||||||||||||||:| | 101113 | MicfoRNA-ivh ihduCes glioma cell im asion by myduUiing MMP -14 and «PAR expression via | 196a | colorectal cancer | up | Upregulation of microRNA196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer. | chiir/lll 329· | gastric cancer | dowu | Sty clovjtfeguiritmgTlAk.il expression, naoroRNA-329 invasion and growth. |
!Wi· | iwll | naR-tOh is overespresserl m hepatocellular carcinoma prolderarioh. migration and /iii/asibrfilkpp^iRlfeiSi///: uPAR and MMFs. | mii- 196a | esophageal adenocarcinoma | up | MicroRMAs in Barrett's esophagus and esophageal adenocarcinoma | mn- -:?9 | cell careifxiujd | down | Dowitfegnlated tniR-329 and miR-Ι lb promote the pfObfefatJOi' and invasion carcinoma by targeting $?^i^3^/3333333333333333333333333: |
100
WO 2017/132552
PCT/US2017/015417
(:&«8(:0:0: ((737(((((( | 7&OiO^'4^7777i ((carihh0te^(((((((((((((: | ((37333: | MicruRNA-i'te promotes tUigt3I!<tn and UR a?luR through CADtMl te human hepatocellular oaiymoma (7sb777777777777777i | mir- 196a | gastric cancer | up | MiR-196a Is Up-regulated m Gastric cancer and I’romotes Ceil, proliferation by Downregulating p27kipl. | :(bu777 (777(((7 | ghNitosfoma | dm? n | (iEOO^ikRRf 77(((((((((((((((: (:ύ(θ7:ΝΑΑ(7((((((((((((((((((: ((Cbh^ariSdhlAkffbih^hllllllll brain neoplasia of arades I- |
((0:(((((: | yinngcnhccillllllllllll | ((37333: | ||OP3RN-A(phRld:TB7(((:77::: (7iii777Of7777777^((((((((( probferatiou and promotes upuptusts m non-sinaRoN! Jung .atnter .NSCί ( ; crfK | 196a | gastrc-intestteal stromal tumor | up | Upregulation of miR -196a and HOTAIR Drive Malignant Character m Gastrointestinal Stromal Tumors. | CteRIIIII 7777777 | prostate cancer | down | lARcfoRN^ (fqh4i:$Abpte38bi(8r7l(((((((((( (:mdkb83::^?77^te(3f((((((((((:( prostate cancer ceiU (:^O70eO77(((((: Ι3^$ίίώϊ^θ^3ο7ΐΑέί|||||||||||||: yhysyhyrvfaliyn |
:::bnA-:AA: :(3:33(((((( | naso-pharyngeal :0(hridh0ia^|||||||||||||: | ((37333^ | 0-. ci-expressio o of mtR- :yon«iatio»:wkh:bMRi:ar4:: i:?7kSi77777777777777::: | mir- 196a | glioblastoma | up | MiR.-196a exerts its oncogenic effect in. glioblastoma multiiorrne by inhibition of I?B ? both in vitro and in vivo. | Gmtrm 7777((((; | prostate cancer | down | mtcroRN A-3 inhibits cell motility by doworegulatteg Spl in piosfaie csncyr ceils. |
|::miite:0:0: (:3:33:(((((: | nasc-pliaryngenf ((pdiymOf(te(((((((((((((; | ((37333: | (:kpR.(:l:$7R7 Mig- atiou and tm asmn ni Nasopharyngeal Carcinoma 7:c^^7hhhhhhhhhhhhhhhhhhhhhhhhhhhhh | 196a | head and neck squamous cell carcinoma | up | MicroRNA-196a promotes an oncogenic effect in head and neck cancer ceils by suppressing annexm Al and enhancing radioresistance. | |:teif:y|:0 7777777 7777777 | esophageal ((^tiaiO738k(((((; ((Cdtembhte(((((((((( | 777777( | MicroRNA-Gob-Sp funylions us an oncogene in human esophageal cancer bv targeting programmed roll dead. ·: |
MU* :(3:33(((((( | non-small ceil Jaag 7ΟέέίΓ777777777: | ((37333: | (:knbibRi77;7ai77777(((((((((; inlubmon reduces cell pmbferatinn and promotes apoptosis in t-yt-SteNl t at! lung canter -NSCLCl cells. | mir- 196a | non-small cell lung cancer | up | MicroRNA-196a promotes nonsmall cell lung cancer ceil proliferation and invasion through targeting H0XA5. | mu- UO- 7777777 | ((h0te2h4H43:;i:((((( bmg «.aucer | up | miR-?30-3p controls cell proliferation by targeting early growth response 2tu oca-small -cell lung cancer. |
TbiriAAA: :(3:33(((((( | non-small cef! bang 7^7^7777:::77777 | 777(77 | MicroRNA-n'ti indicates a 3:^7p^(tgite^7:$77pi7:::777: (77^i7777777(®77777£(7(((( ((ί7777(7ίΤ^7777«7(((((((((((((; | tnir- 196a | pancreatic cancer | up | MiR-l96a Promotes Pancreatic Cancer Progression by Targeting Nuclear Factor Kappa-BInhibitor Alpha. | Imit-:!:! 77777(((: | acute myeloid 3dbOki&(((((((((((: | 777(((((: | H\ptes>:on vl nueroR NAll33k:O:bS|t^S^h5:3|||||||||||: (:^<Γ^ίέίδί(;3Γ$ΐτ;ΐδέ^δίϊ$$:ϊίϊ!:((((:::: 'horapy «4 um'ofin a«.ute mieteid kufm-.u 0 Hk!’!- |
mu- :(3:33(((((( | :/0biRO^7777777 | /ill | Oncogenic function and eatft efctectmu potential of imRE-lA-tOb in oral -.anc-w as identified by rnicroRNA | mir- 196a | pancreatic ductal aderio-carcinoma | up | MicioRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic: intraepithelial neoplasm. | mu- 391- 7777777 | ((00:8330(((((: | dm? n | nuRNA-3'U3p direcfh (^(^^:^277:3^(7^^833((:((( growth arrest m human Ggdkrij:CdhO(((((((((:::((((((((: |
TbiriAAA: :(3:33(((((( | pancreatic cancer | 777:77; | |:Ali77R7Aii7777777777:: ovd-expressed m pancreatic (7ai7:7t((7f777^7777(((((((((( Imari'eness, and correlates nil a poorprogttosi» | tnir- 196a | squamous carcinoma | up | Unique MicroRNA Expression Profiles in Cervical Cancer. | Imit-:!:! 77777(((; 7777777 | pltoblntnms | dm? n | nuR-Ό i-?p regulates expression of neuropilm-2 (ak^783^tbh^(((((((((((((((((: |
:::miic:::::::::: :(3:33(((((( | pancreatic «.aiieei | 777(77 | Mki»RNA-k!b is ::oveiexpressed:!ii:panyroalic·:·: (70^7((((((((((((((((((((((((((( | mii- 196a* | gastric cancer | up | MicroRNA profiling of human gastric cancer. | 77777(((: 7777777 | ((OO78O&(((((( CbSfPiifebte:::::::::::::::::::: | 3773(33 | Serum aaR-182 su<l uiiR>U-5pas diagnostic and prognostic, markers in Ί up « wt b hep?tj ^dula. carcteoma |
tUIf· ((7333337 | •pancreatic «luvial atfeno-caruinoma | 777((((( | rtueioRNAs as markers of i77T(7777777(((((((((((((((((((((; (77iSi77^k7t-5ni:7R7(((((:::77::: y^Nktepticl ;7ί77ί(:7777777 |:adsks$ai7mppi77777777::: | mir- 196a- 1 | glioblastoma | up | MiRMA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance | um- :(((7f((((; 7777777 | (:008:00(((( | down | mill· J H-3p regulates EkBB-2 expresuon and androgen receptor signal-jig ynfj^t^tgkhfesnllllllllllllll; |
101
WO 2017/132552
PCT/US2017/015417
:/3333///// /|^////// | 33733373/337/71/://// adem-csreitinma | 33SII | muroRNA-ibb enhances panereabn ewer eel: jmasionby suppressing TIPS/ expression and 7prd7&iitlg:^^/i34::i^/?:/: //33:3787/7/7/7/7/7/7/7/7/:: | mir- (196a- 3 | oral cancer | up | OuccmiR-196 promotes an invasive phenotype in oral canc er through the NME4-JNKTIMPI-MMP signaling pathway. | /:733////: Gl- :/0333 | prostate «.anus | jop n | h ccnliteun ol ul Deoxy hypusme Hydroxylase tFATJ-iK}. die Enzyme That Catalyzes the Activation ofelFfA., by miR-GlGp and miR-rAN 5p in Prosfate Cancer Cette |
/333/:///7 | colorevtor cancer | 33§|| | MicroRNA e ypressiou profiles in human colorectai 7303/3/7773173/7/7/7/7/:/: •sx mst-jsc* | rnir- 196a- l | oral squamous cell carcinoma | up | miR-196a Overexpression and miR-J 96a2 Gene Polymorphism Are Prognostic Predictors of Oral Carcinomas. | /:371///// ?35 | adrenal cortical //33i3i73i77////////// | :/3333/: | naR-19? sndmiR-483-Λρ identified as Predictors of (:3337iT7|707te37(////////////// Adreneteoriicai Cancer |
i!!U- :/^33//// | 37873333371////////////: /303533333::1///////:7 carcinoma | 33SII | iraR-l {?·> promotes cell /0377/73θΐθ77777:/:/3 SLiTARGFiOl axis in esophageal squamous cnf /30370///////////////////7/: | mir- (196a- | glioblastoma | up | MiRNA-196 is upreguiaied in glioblastoma but not m anaplastic astrocytoma and lias prognostic significance. | fait- | astroci torna | rip | Targebnc oncogenic niiBt a mbifcus grvuiband //17^3333333:3)33^777//////////( astrocytoma cells |
ciTiGZ//: /|;O//// | bladder cancer | /707/ | /0:0303337////////////:/ {ύ. J ·’ WAF 1 /CI R1 > by (:(3τΕΝΑ$ :373:33////////////////: iraplicahona m bladder | mir- 196a- | oral cancer | up | OncomiR-196 promotes an invasive phenotype in oral canc er through the NME4-JNK-TIMPI-MMP signaling pathway | /•Thr///// | breast cancer | down | MicmRMA -2 3 5 inhibits tumor reinitiation and is silencer· through genetic and epigenetic meclmnivms |
/333/:////: | pancreatic cancer | down | MiR-llbl inhibits stern vcll-ltee phenotypes and suppresses 9ΟΣ2 and //03’333i:3i03////////:// pancreatic eanent | rnir- 196a- 2 | oral squamous ceil carcinoma | up | miR-196a Overexpression and miR-J 96a2 Gene Polymorphism Are Prognostic Predictors of Oral Carcinomas. | /:371///// ?35 | breast cancel’ | :/3333/: | Analysts of nuR-2iG and miR-i?? eypressmn ra the /31773333/3333333333////////: Zpadeht///////////////////////////: |
/377/:/:/ /|03//i hh+Shhhhhhh^ | gastric cancer | :/3733/: | tw3M277A« andt-aPt?fm suppreo gastric career growth and invasion by targeting telomerase reverse irarrsenpiase. | mir- 196a- 5p | gastric cancer | up | Clinical significance of upregulation of tnir-J 96a-5p in gastric cancer and enriched KEGG pathway analysis of target genes. | 73877:7:·: | breast cancer | dow o | MrR- . ·* 5 nfmi's migrteuou //hi 3/0/37773337333/////// dtroughtargeiing (/OhdOpiS^nfS/feO///////////// |
/:777/:/:/ //^3////// | breast cancer | down | MtR-i22 InbihiteGell (/Ribiifgrq/ibh/ai/d://///////////// /:T733n37377i3(bi::^h778i(/////: Cancer by Tat%etmg :/00://///:/3 | 196b | colorectal cancer | up | Upregulation of microRNA196a and microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer. | /mir/:// /3333/// | cewical cancer | down | MioroRNA~G 5 represents an independent prognostic ntatket tn vcn real carpet |
!IU1- /|?|/////i | /(3/783/:777053////////// | :/3/3/7/ | Breast canccr-speedrc /:/ι:3θ/3333θθ33///////////3 mediated h> miRNA response elements of let-? 7333330223/////////////////3 | mir196b | esophageal cancer | up | Differential expression of miRMAs in esophageal cancer tissue. | /huG/:/: | //7hd7^3?7/:////////// //873333//////////// | down | Analysis of microRMAa //70^03837/////////////////// //ii^^/^^^^ihhhhhhhhhhhhhhhh |
/:777/:/:/ //^3////// | gastric cancer | down | Plosmo oiiR-I?2 and miR- //00/330000*3//////// biy markers for die early /(0i3O33f/3i3i^////////////: jpcMSiasis ct pterin'. <,mcf | 196b | gastric cancer | up | Transcriptional regulation of mrR-196b by ETS2 in gastric cancer c ells. | /mir/:// /3333/// | //gh333i////////////// | /33///// | Tumor mioioRN.A-32? ::expressioriis:assocrgteii:·:·:·:·:·:·:· //333/33773^3733:33///////: //33333^733/////////////////// |
/'Tub/://// Bllll | /:^7^:/:/:/:/:/:/:/^ | (/3/)33/ | tuiR -12 SATiit/beta-catenin icgulatofv cuvtiUn saTaiiK, ghumiprogmssmn | mir- 196b | gastric cancer | up | Epigenetic regulation of miR196 b expression in gastric cancer | /333////: /3233/// | /:^71333103//// //73333733/////////: | dop n | Epigenetic silencing of mil - /' χ ?wd n bo >f cone (/teft/3T/73^33f727h7l7r(//////( //33(313333//////////////////////// |
102
WO 2017/132552
PCT/US2017/015417
5rihk/555 | //bOiOkkO 55^^^/////////555 | BI/55 | < j Kuhntis mtctoRi LAs. mriKzh miJMlL and mtR 27 / m patient u ith hepatocellular cgiyinyina yr chronic hepatitis. | mir- 196b | glioblastoma | up | MiRNA-196 is upregulaied in glioblastoma hut not rn anaplastic astrocytoma and lias prognostic significance. | fait- | ihbpOOhO)]))] carotontua | dm? a | hRR-3 acta as a potential tumor rappressur stuBNA vta dPw nreguiating RQCKl expression in neyatOveliu’ar esiuiOma |
5ίΡί05555 | 5:&^ί^0${1ώΐ3η//////// //(^f3rit0^555555555 | dO'Vb | :;:3/ίχίϊίώ^ί.^ίί<3^.έ;ίίί;:ύ:ύ:ύ:ύ:ύ:ύ:ύ: Hepatocellular C ait ·ηοηχ· by Taiget»igAK3'3. | mir- 196b | glioblastoma | up | Upregulation of miR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. | 5mil55]] | meningioma | ίΟίίίίίί | ftdP- 33 5 promotes Ceil proliferation by cbroctiy //iriigeimg/Rdf /ih;]]]]]]]]]]]]]]]] |
•UK· Bllll | Τ^ΜΡδΡίΐ^ί///:///// /W5«ibk/ri////////////5 | down | Κίκ»>ϊύ·ΐΑ-ι22 sensitizes adriamyem and vsrmnsbne ύίϊί^ίί^?ίί:ί^^ίϊ:ί^ΐίί«:ύ:ύ:ύ:ύ:ύ:ύ exprasslyr· ofMDR and inducing vefc«Acte angst | mir- 196b | oral cancer | up | OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4-J Mis ΊΊΜΡΙ.-ΜΜΡ signaling pathway | ikai/]/// '535 | mesenchymal //itrikdfo))))))))))))))) | ydkkk)] | //MipiyRNA/B^iP^Si^f 5////// Profiles in Kaposi’s /6^AVCiriiiiii666666666666666666:::::::::::::::: |
5ίρίΡ5555 | 5:Sppdtd^gilki3f://////// //(^f3rit0^555555555 | //d0raii5 | >3ieroRNA-i22 inhibits tontorigente properties of ceils and sensitizes these | mir- 196b | oral squamous cell carcinoma | up | mlR-196a Overexpression and miR-196a2 Gene Polymorphism Are Prognostic Predictors of Oral Carcinomas. | irair///// | 5;hPuiri/biO$bia//5 | down | MiRNA -5 3 5 Supprasses ittvasiveness By Direct //GdbyhiPdl^^ :5:^^^^3.^^:^.^1:^:^9-5/:///////555^ |
5briri55/5 | //hepdtotiglOt////://// :/^tifotifoh/////////////: | 5'B///// | EApresstun oi n« 'toRNA.». mtRtei.miRGb wtR-d n, nak-H< miR Ϊ4Ί toiR 2kbc; UflR-22KiniR-222. and miR-223 nt patients v nh hepatocelhtlai earomoma nr mtrahepaue eholar.groyarcineJno and its Wgik//////////////////////////// | mir- 197 | breast cancer | up | Role of mrcroRNAs -2.9h-2. 155, -197 and -205 as diagnostic biomarkers in serum of breast cancer females. | •/ktiri//// 535 | uon-smsrivo'd /tihri&O&f////////: | dtiw n | hjfect of mtR-315 apragufotu-n utt the apoptosis aod invasion of long cqncyi cell _k54'> gt-d |
5ri5ib5555 | b?pu4/'v‘'f!nl3J· //^tedapia3/////////////: | down | imR*}2? affects the viability and apoptosis ed 552&/]]]]]]]]]]]]]]]]]]]]]]]]]]]]:5 | mir- 197 | esophageal cancer | down | implications of microRNA-197 downregulated expression in esophageal cancer with poor prognosis. | mir- | osteosarcoma | :/iOih// | mtR - 33 5 suppresses migratmn and tm- aston hv targeting ROCKi In osteosarcoma veils |
Smif;/////: | hepatokehttlar /PgiCihyi^;///////////// | dCuil | KheroKN A -1 22 suppiesSOs cell prylrfeiatlyii and uidttces veB apoptosis nt hepatocellular carcinoma hv dtreodv targeting ’wm/neta-catenin pathway. | 197 | follicular tityroid carcinoma | up | A. limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. | :/mif///// :/3^://// | ovarian cancer | down | miR~3 >5 represents an xiiwasionauppi^ssyrgyny in·:·:· ot auan cancer ht targeting |
!UK- | Th^kteribihiirih://////// :/^tifotifoh/////////://// | 53/05 | i/hiiPibR/^COid^d///////////: regulator of mitochondria! mntaboiic gene ootwofk to :/ikpaiyiphdiai/0atii:h0hih/:::::::: | mii- 197 | gastric cancer | down | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. | 83!· 535 | ovarian cancer | down | Micro-RNAs and a«an cancer. the state of an and poispncrives of obnical tiyseafch/::::::::::::::::::::::::::::::::::::::::::::::::::: |
5ri5ib5555 | bopatoeehnlar //^tedapia3/////////////: | down | :/Mi^K:O^/^////////////////// :ύέίφρ>ίίώ^ίίώ^:::^ί4:ύ:ύ:ύ:ύ:ύ:ύ:ύ: Pancieain. Cancers | mir- 197 | hepato-celhriar carcinoma | down | Anti-mrR-197 inhibits migration in KCC cells by targeting KAI 1/CD82. | :/0///// | IprihbteOiS///////: //ediidak////////////// | dm? n | mtR - 33 5 f nocuous a> a yikri^r-stkipfg^bf 1^5555555/: pancreatic cancer by 5ra^khg/©fi/^55555555/555 |
5Ρίί:ί555// Bliss | hepatocellular caiCrrama | 5:dsO5 | A novel GSK--3 hetaGricBP alpha-mix-I22-h-suih-like growth iaciyr ί receptor leguhtorv | 197 | lung cancer | up | Differential MicroRNAs Expression in Serum of Patients with Lung Cancer, Pulmonary Tuberculosis, and Pneumonia. | :/mif///// :/30//// | /pih^&/////////://// ]]^Bb^Ber]]]]]]]]] //carathyirid////////// | down | inoieased expression of mraroRN A-3 >5 predicts. a fa. enable prognosis in primary gallbladder |
103
WO 2017/132552
PCT/US2017/015417
hepatocellular eaminotna | :ϋΟ^ίΟ^Ο^33333333333333::::::::::::::::: | ||||||||||
!0ΙΓ- | 35)^^03010)·://////// | :/41):///: | //Epmehi^ mtR*l2? bv REAR and hepatitis B vttos X prokro •:in:bepafycelluiai· carcinoma:·: 3:£:2ί&·33333333333333333333333333333:: | mir3 97 | multiple myeloma | down | miR-13 7 and miR-197 Induce Apoptosis and Suppress Tumongenicity by Targeting MCL-1 in Multiple Myeloma. | /bilk//// ?35 | //tehakbietiiteell://// //teidiihtikA:))))))))) | down | 3:OO^:O^mg:ipi:diO://3 ceil renal fed utotmo bioroarker discovery and controls and consequences of n«RNA dvsregulatton- |
3(0))3///// τΟίίΤΤ | //&έί)&)ΐ£έί//////////3 | down | MictoRNa ;22. a turner suppressor rtnyroRNA that regulates fntrahepatic ιν.ί$ asisoibepulNdliim | rnir- 197 | uterine leiomyoma | down | Upregulation of miR-197 inhibits ceil proliferation by directly targeting IGFBP5 in human uterine leiomyoma ceils. | /huiS////: /jO/33 )1)//33 | gastric carreer | :/408:3 | The eirrdyni significance of dywtireguiaUun ofnur-i24>punii-i4ba-5p. iinr-1^5?p and mir.to35.sp jR 3:g^ific/0^(^hTTTTTTTT//3 //tohidte^itegte///////////////////· |
:/&))·*:///// | /bOOTO)://///// | dvWO | T inttot tmcrosiv factor* related apnpksis-inducing ligand induces c> ktoxroitv specific ty osteosarcoma by etemems | roir- 1974 | adrenai cortical carcinoma | down | The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma | /8)893/3 )^3))://// | parroreatro diuial adeno -carcinoma | dpp n | nuRG3’ regulates the prohferaiion and invasion //iR^fiteOiS^O////////////: /3ί^ίί^ίίύ^3Είέ^^?333333333333333 |
/'finb/////: Bllll | priurtaiy carcinoma | i||/ | MrcroRNA expression in //ΑΟ&ρρό ):b^dfe/:ti^^^toh:)^////3 mktoRNA~kk nod -Is* 3 in pituitary carcinomas | mir- 198 | colorectal cancer | down | MiR-198 represses tumor growth and metastasis in colorectal cancerby targeting iucosyl transferase 8. | tfini///// IB))))) | 3g^i^/3giteyi3//3 | O||: | 3MiyipRNA/piyfiinigtot3//3//3 human gastric cancer. |
:/&))·*:///// | renal cleateeli | :0//// | miRNA profiling for Near v '8 rroa! eR v.r tom a biomaikef chscOvSty and Identification yf potently! vmdroUapJ co.nccgjot.*es of miRNA dvsregulation | roir- 198 | hspato-celiular carcinoma | down | mlR-3 98 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. | /8)89://3 i)||)))) | gastric ta-nee-f | dpp n | 3:!^3kROO?:O^8/////3 :3iyiisiii^t^i^3^^r^i^333333333N Cancerby Targeting NRRl /3S/?^it2i>$rjdiV:3333333333333333:::::::::::: |
3θ;ίίώ)^:3:3:3:3:3:3::: | /Τ|:/// | prrfiifcratKftt and metastasis of hepatoma «.ells throiigb a ps - forward reedlx-fi. mop | 198 | Proliferation and Induces Apoptosis of Lung Cancer Cells Via Targeting FGFR1 | 338 | 3iO:^OO3// | growth and metaatasis nf OSCC ceils bv targeting NR Pi | ||||
roir- 122** | 3ds3tei): | Etestoratmn nf miR-l 22 8V expression suppresses ephbcliabinesenchy mal iiPi'SiiiPi' «< g3SiiiC.tom.ef | mir- 198 | pancreatic cancer | down | A Tumongeriie Factor interactome Connected Through Turnor Suppressor MicroRNA198 in Human Pancreatic Cancer. | mir- //O///3 iin | coWt-tai .arvet | down | Reiufionsliip between miRNA-3'x-3p· exprossiun >3^0:^:^6^F^£;As/0:0::^ii2l333333333:::::: prognosis of human cdlorectei carcinoma | |
3)8113:///3 LEN | eoinrecfa! cancer | :/91):///: | (Tmiiiarntg Rvp>puiuI mlckRNAs as fltomarkers 3^^)S)l/G^ | mir- 398 | pancreatic ductal adeno-carcinoma | up | MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma | 3fLiir93333 338- 1111 | 3:^003/33333 //)8)<ΰί)0|η^////////3 | down | MicroRNA*/ '8*3p inhibits Cotokctal Caroif oma Celt It» a&iyn and Migration b' Targeting Smoothened. |
!UH- | 3j)hOi)Othhi)T/33: >3ί^ίίώώΕ:333333333ϋ:::::::::::::: | 3ds3tei): | MtereRt4A-L22a functions as a novel tumor suppressor 3^5)0))0 adenomatous pol> posts eoli m gasfiomtes'mai carvers | mir- 399a | chondrosarcoma | down | CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by downregulating miR199a in human chondrosarcoma ceils. | /Ruf///// /0333 iin | gastric cancer | down | >31Κΐ3ϊ^^ίίΡίίς3^ίώώί2«ί:^:^33333:::::: nuR-)38-3p contiibates to funtorigew ntc tn pastru. cartoefhy targeting )|Β1ΒΐίΙίΙίΙίΙίΙίΙ)ί))))) |
104
WO 2017/132552
PCT/US2017/015417
3rii«8:383 ma | j3i73b^jriG3iii^:2222222222222 | 3dkRii8 | < \ dm G1 ts a target of mriGl 22$. a nmemR NA frequently down-regtdaied dCgirimdkiatTTTTTTTTTTtd | lilir- 199a | gastric cancer | up | miR-199a regulates the tumor suppressor mitogen-activated protein kinase kinase kinase 1 J. in gastric cancer. | 3riiif88:3 338- | Tg^OTbfkhf8383 | dm? n | miR-Us- 'p xuppresse* Gastric Cancer progression, through, a RTEN-AKT Axis by Targeting P-R£X2a |
3iikb8383 | 8ljepntSget!ui3i8T3:3:3 8^kiit0ia3:TTTTT38 | down | pJKfokNApibftbHg in patina w t Ji hepa-rxnftutei 3;ίί^ίϋ·^^>ρίίίϊ]:ύ:33333333333333333333; | mir- 199a | hepato-cellular carcinoma | down. | [MicroRNA profiling in patients with hepatocellular carcinoma]. | 3mif383: 338- iill | gastric cancer | down | MtR 3-g-3p uth.bns ep.fbehaJ meseucl* t- >ai transition in gastric cancer ceil b\ lauetwg/fcB/ md MAC C I'Met'Akt smnahna |
H!H- ma | 3&Ofe^iibUhT3:383 j3i73b^jriG3iii^:2222222222222 | 3dkRii8 | Pmtenuiiv ufcutrikatton. of nueroENA-4d?n target proteins in hepatocellular •AdkkiriOTTTTTTTTTTTt | mir- 199a | hepato-cellular carcinoma | down | Circulating microRMAs as biomarkers for hepatocellular carcinoma | mu- 338- | coretuotua | dm? it | miR-338-3p is Dowm R^guh<md bv Hepatitis B Yims X and hthihns Cell jFmitferauonhy Targefbtg 8iii$^:^TR:^gi3k:3iTTT3:3 TfXdii^fTTTTTTTTTTTTt |
8nab-:383: | renal cell eammotna | τ^ίτϋ | MntroKNAs in renal ceil caremoma. diagnostic implications of serum miR- | 199a | hepato-cellular carcinoma | down | Lentivirus-mediated overexpression of micToRNA199a inhibits cell proliferation of human hepatocellular carcinoma | 338- tOII | hepatocellular Τ^3μί3ίίί3ΤΤ3838 | down | Mik-338-3p inhibifs hepato^arvinoi'ia veiis and SvmfcPxtb by targeting hvboxia-induced factor 17. |
H!H- 1236 | 3bi^^LkkthtT8383 | 3ddRii8 | 3U^^^hi^dri:dfT:TTTT383: implications in bladder 833ί^:3δύδΤΤ:ΤΤΤΤΤΤ3:3:3 | mir- 199a | hepato-cellular carcinoma | down | MiR-199a regulates cell prolif eration and survival by targeting RZD7. | mu- 338- Bill | coretuotua | dm? it | ' «Rf'R * Λ $ \ «Ι ,'S T^R^rihfeihkbbdhTTTT^ hepatoeehniar camtnorua by target forkheatl box R4 8O^^:.:TTTTTTTTTTT |
3riiib8383 133 6 | bepANNiniar 8^kiit0ia3:TTTTT38 | down | mtR-4236 dm? n-regulates aipha-fetoprciein, thus ^Ο^ΟΙίϋίϋίϋίϋίϋίϋί accumulation, whn.lt mhihits the P: ;R/Akt psifcn at and malignant pheixtype tn hepatoma 3$έί!383338383838383838383:: | mir- 199a | kidney cancer | down | Re-expression of raiR-J 99a suppresses renal cancer ceil proliferation and survival by targeting GSK-37. | 3mif883: 338- iill | liver cancer | 3iOib8 | miR - 3 ‘ 8- φ snppres z s uivasioo of liver caocer ceU bv targeting satoo· he ned |
3riiih8383 | Ο?Ο^ίϋί38383838 3^1ί383θίδΤ:Τ3:383: | down | miR*124 and uuRH 3“ 8i0babi3ppjiifefathjh:$f 3:33:38 gimbhstuma maitifo· me 30S:^&i0^ 8ki^k^i^rehi0fbimkTT3:3: 3ri^dt:^ifb:h^iTTTT88:8:8 | mir- 199a | con-small cell lung cancer | down | MiR-l99a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells tbroughtargefing HIF1? | 3mif883: 338- iill | nenro-hlastorua | do·? it | miR - 3 ‘ 8- φ snppres z s 88ήύΐ$&ί^ίό|ιώ8ό8ό8ό8ό8ό8ό: xprolifeaatiomiavasioroand:·:·:·:· migration through targeting |
8ηύί3383: Bllll | 3bhk&3ciki3&8838383 | 3dkri:k8 | miR-124 suppresses multiple steps of breast earner mc'is.nni, th 8t3i^3tki^:3:3sbriri:0i8pf08T38 nietasmtre genes m '.ιίιρ | mir- 199a | ovarian cancer | down | Roles and Mechanism of miR199a and nuR-l25b in Tumor Angiogenesis | 3imf383: 338- BBBBB | Thbh8$hhiib3$!l:8:88 Thht^:3O^:TTTT | doxy n | Τρκ3ίΡ:ΚΝΑ-:35833^ΤΤΤΤό:ό8 3O2b^:^iTOtbt:TTTT38 3ri^0^fdbbtiiO8TTi383 83dit35ihkil38aifin3^TTTTT3: carcinoma and targets Ras TigBi$d:i^kiktiATTTTT888: |
3bO333 | breast cancel- | :3d$kb3 | 8^k4i34;dhhi&iK:3eif:TTT38 proliferation in breast Τ$&!^έί:ίί^5^^:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ | 199a | ovarian cancer | down | Micrc-RNAs and ovarian canc er: the stale of ari and perspectives of clinical research. | 8mir80:0 33^838 | oon-smahcell :8k3igo3k£&383838 | Peripheral Blood niiR-3?K Expression as a Rolential Bio marker for the Early Diagnosis of NSCLC |
105
WO 2017/132552
PCT/US2017/015417
((((2ί«2(((((((((( //(///(/(/( | )(22222(20/))))))))))( | (((d2(2(2() | Global mivioRNA Jet cl /O)OOB/000O2/(: oeft-cvtte protein netuori /))(00020/2/2/2/(((((( | mir- 199a | primary ens lymphomas | down | Differential micro-RNA. expression in primary CNS and nodal diffuse large B-cell lymphomas. | (:2ni/(((( 3.;p- /0//// | (/bi(222222h22i((((((((((((( | dun n | MiR-3 ;9-5p inhibits breast cancer cell migratioB and ift% aston bi * κ ro and u ax ::beap(?teidiahbiomaikei:foi:·:·: breast cancel’ prognosis |
5:(082855555: )(/(//)))))) | breast caooer | down | MiR -12-4 targets Mug to regulate eptdiebal•Muesencbyinaltranslironjand·:· Hicrastasis ofbieaot ^auv« | mir- 199a- 3p | esophageal adenocarcinoma | up | MicroRNA 223 is Up-regulated in tire Muitistep Progression of Barrett's Esophagus and Moduiates Sensitivity to Chemotherapy by Targeting PARPl. | :(:42255555 /222/((8 11((8 | papdJaty thyrotd carcinoma | //)/(/(/(( | nncioPN k 33v sp (((/2)/2)dte/)/2/2)/((((((((((((((((((((((((((((( sj mporfer-mediated (8(h22)l//i))3^i/^((i2i/)^/^i(////////((((((((( |
list· :/):////// | (b//^//h?)O/((((((((: | ((2/0(: | (:0000/2/)))000/( breast cancer cell growth and mottlrtvfcv targeting ?1. | mir- 199a- 3p | gastric cancer | down | MicroRNA-399a-3p is downregulated in gastric carcinomas and moduiates cell proliferation | mu- )///))))( | gimmn | up | miR-Ga promotes gitomauunatmg «.ell seb-renert a! vea RKA and NOTCH (:(ρ222828/(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( |
(:(222555555 /Ο//// | /0000(((((((((: | (:/20/ | Mtcmma-ll-l targets (;Β2ίί/42/(ί(ί0:22Ο·5(2:(((((((((( praitferatnan and migration /«OOZOO/2/2/2/2/((((: | mir- 199a- 3p | gastric cancer | up | MiR-3 99a-3p promotes gastric cancer progression by targeting ZHXl. | (529:8(555: )///)))() | bepuriv 'liubr ((/2)/2)9)2/(((((((((( | dow n | ΑίΙθίοΜηΒΙ Negatively )(///|2)/t//^0/i2/(((((((()(((( C atemn ‘•iguahng Patbw ay through Activating miR- ((((3/2((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( |
(:/9/(((((: /Ο//// | breast cancer | dourt | MteroRNA-124 inhibits /0))00/0000(((((: Hivaswulw targeting Els-i m breast cancer | 199a- 3p | glioma | down | MicrcRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway. | (50 9 25558 :(:/1/:/:/:( | ((22)§(/2ή26/((((((((( | down | |
:(/11/((((( :/O//// | //ΟίΟΟΟΟ/Ζ ((<831(0Α0;«0η5ύ(((((((5 | down | Dov.n-iegutation of uuRI24'-214 in cutaneous squamous cell carcinoma tpvdt res AbtkrB'aiv '8 /0000):/)3:0(((((((((((( indue trot’ cTERF | mir- 399a- 3p | kidney cancer | down | miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. | (:(42))/:(:(:(: 33 a | :(((2)2l)g222)(:(:(:(:(:(:(:(:(:(:( (((h2ii/h2))i2((((((((((( | (((2//(2(((( | (5i2iK/322(&962222(2223(3((((((((( (5/22422/)^222^22(213(3(3(3(((((((((( melanoma by targeting )/))1)//))))))))))))))))))))))))))(() |
:(:(23(25:(:(:(:(: ((Ο//// | colorectal cancer | down | Mrt-l’i Supo^zs /G)0i00h).2O/(((((((((((: Z)0)O000/0z2z2z(: (:OOOg(S(Oi/((((((((((((((: | mir- 199a- 3p | osteo-sarcoma | down | MicroRNA-J 99a-3p is downregulated in human osteosarcoma and regulates cell nroliferation and migration. | 3421253(55 /////// | breast 'aruer | Jon n | /:/b6^RO20)/^^/)))))) Breast Ganger Metastasis by Targeting BMGA.2. ((((3(Ah/(4((32)i((T2*k(i(h((((((((((((((((((((((((( |
(:/9/(((((: /Ο//// | colorectal cancer | dourt | MtR 1 > 1 RadlOyei ItWtS Haitian Colorectal Cancel Cells bv TarsetiugPRJUXl. | 199a- 3p | cstec-sarcoma | down | A. three-plasma miRNA signature serves as novel biornarkers for osteosarcoma. | (549428555: //0/((( | osteosarcoma | down | MroroRN.A-3/h Suppresses (2(rft^r(ai2/(2^(2/2s(i2t2h/((((((((( (5/2(2im///O2(n2(5(5(5(5(((((((((( osteosarcoma cells, |
:(//)/((((( ((Ο//// | colorectal cancer | down | (;KiiW®)00/g(((((((((((( MicroRNA GN Suppresses Colorectal Cancel Ceil (00))/(20((((((((((((((((((((( Τυ.ΙΜΉΜΚΜΧ | mir- 199a- 3p | osteo-sarcoma | up | identification of a plasma fourmicroRNA panel as potential noninvasive bio marker for osteosarcoma | 34b | ;/g|i)222/2j2(22i2(5(5(5(5(5(5((((((( pmitieudmr b\ suppressing •IXM) v\vi:n-D3 and .;ν.;ίίη·)>2 | ||
!Uif- ))/?/)))))) | colorectal cancel | (:/20/ | Gene module based (:)2OO/)202//i/((((((((((((( idontuy mg -miR-1.«9 as a (//0)())>000/2/((((((((((( (:0/12/0/222/1(((((((((((((((: | mir3 99a3p | osteo-sarcoma | down | Polymeric nanopaiticle-based delivery of microRNA-J 99a-3p inhibits proliferation and growth of osteosarcoma cells. | mu- ///)):(/(/ | ((6h2bl2/t2t)2(:(:(:(:(:(:(: | down | (5222/3//22(22/222(5(5(5(5((((((( phoblaBOBia mniufumte |
5/9/5:5:5 ////)))))( | colorectal cancer | /:/20:( | /0009)000/((((((((((: BiicroRNA-lN« an independent prognostic factor in patients with colcrectpl cancer | 399a- 3p | papillary thyroid carcinoma | down | miR-l99a-3p displays tumor suppressor functions in papillary thyroid carcinoma. | (549428555: )(3//(// | ((gh//23/t2(hi2(:(:(:(:(:(:(: | ////;/;/ | miRNA. mtefoarray reveals speotRc exprossioB to tbs peripheral blood of (521^1222/2)//222)/(5(5(5(((((((( |
106
WO 2017/132552
PCT/US2017/015417
B^BBBB | wrifftuxtal vancet | cancer «.eO gtuwfb through P7BDBLMVPKM? | mir- 199a- 3p | renal cell carcinoma | down | miR-Ι 99a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma | (B^BiBB | bmg vancet | dem n | miR-Nf! inhibits, mtoor veil omitfemtmn axfindnvU apoptosis by targeting ::niulfiple:negativeipgulatoi^·:·: yofpjitriyhbmi-hiaRiSUTTyT (OgNtihibiTTTTTTTTTTT: | |
•titanyTT· | coierecfal oortcer | JpWft | Mu t&RN A l N R^-wdt·* yriiStRiSitfObMibifbfTTTTycy Colorectal C ancer f cbs bt | 199a- 5p | colorectal cancer | down | The deoxychciic acid targets miRNA.-dependent CA.CI gene expression in multidmg resistance of human colorectal | SbriuT·/ xBiBB | osieosarcoma | down | MioroRNA~34ri Suppresses and metastasis b\ titre·.riy |
SUH* | uttorectai cancer | Downregulation of rltovSSu ua-Kd protein xtoasv 1 by miR-124 incoioreotoi ΧΟ^ΒΤΤΤΤΤΤΤΤΤΤΤΤΤΤ | mir- 199a- 5p | esophageal adenocarcinoma | up | MicroRNA 223 is Up-regulated in the Multistep Progression of Barretts Esophagus and Modulates Sensitivity to Chemotherapy hy Targeting PART I. | mu3-If}' | up | buiUu<o gaztriv vat-Nr | ||
•titanyTT· (BBbBB | esophageal cancer | JpWft | :ΰ§3ίΑ3'3:1^:ί^Χ;<<Ιν^^:ί»::ί»11^<:ΰ: l24-me<lialeil snppipssc· e effects on esophageal | 199a- 5p | gastric cancer | up | Up-regulated mLR-199a-5p in gastric cancer functions as an oncogene and targets klotho. | ζίβΐυ??? xBiBB | :<3ίρί8:3:3:3:3:3:3:3:3: p>--»my etocytrc | down | A restricted signature of miRNAs rtislingulshes APT TbirtstyirbtR ^OBiBBBBBB |
ymipT-y-y BOBBB | gastric cancer | down | microRNA-1'24 inhibits <qk-ptvS.s by daicth mpm>smp EZfl?. m gastru cancer | rnir- 199a- 5p | hepatocellular carcinoma | down | P.ole of mici'oRNA-I99a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. | yipiuTT '342 | (.oioitctJ urco | yiSpiytjy: | MieroRNA-342 inhibits omitiemimn aidinvuutt by tfirevtiy iargeonpDNA |
fkife:::::::::: βϊββββ^ | gastric cancer | sdOU | twiM?'-’ inhibits cX probfotanon in gastric cancer through dowureguhtRm of SPUR! | mir- 199a- 5p | hepato-cellular carcinoma | down | identification of differentially expressed microRNAs m human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as bioraarkers. | B^BiBB | glioblastoma | dow u | toutotton il profiftng oi ptoenrs-w kb WvRN As identifies MicroRNAs |
ymipT-y-y BOBBB | gastric cancer | down | [miR~124 suppipsses ceil TpfbWeftttOhhri in gastric carcinoma anti hs | rnir- 399a- -P | hepato-cellular carcinoma | down | increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2i'3, sensitizing mesenchymal tumor ceils to anti-cancer agents. | 8mn$8:8· 342- iBBBB | c-ervivai cancer | yiSpiytjy: | nhR-342-3p suppresses proliferation, migration and owasmnbt targeting FOWl m human emmai |
UUf· βϊββββ^ | CdoO/ | ϋί1«5Α4:ί2?44^ίίί8ί::ϊίίίί34^ί:3?ϋύϋύϋ:: gliobiastomo muftiforme ::4lffereEtiatiOE:oft<£air£·:·:·:·:·:·:·:·: tumor stem cods. | mir3 99b | chorio-carcinoma | down | Decreased expression of microRNA-i99b increases protein levels of SET (protein phosphatase 2A. inhibitor) in human choriocarcinoma. | yttufysy: sXTU/y IBBBB | non-smab ceil | down | ............................Ί uftR-342-3p targets RAR2B to suppress proiiferaPon ortd invasion ef non-smali cull lung cancer cells | |
ymipT-y-y tOBBB | down | Downregulation of miR124 premxAes the growth and invastrcncss of involving upregnlatoort of | rnir- 199b | follicular thyroid carcinoma | down | Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. | liBBi | me tin lalloti-sonskw e micro RNA rs invoived it; etrif probfetarion and uivosion io. human | |||
OtPihU/ty: BOBBB | Τ§ΐ!ίθΤΤΤΤΤΤΤΤ:0 | down | microRNA-f74- Erdiihns Migration. and invasion h> Dowfi-RogutatkgROCK 1 TriyjSitOhtP-TTTTTTTTTTyT: | mir- 199b | hepato-cellular carcinoma | down | MicroRNA profiling in patients with hepatocellular carcinoma]. | oriOoy (BBBBB | orai squamous cell carcinoma | ;OBB^ | Relationship between micioRMA expression levels aod histopadK-togmai :ibafufespf:dysplasis:i«prai:·:·: |
107
WO 2017/132552
PCT/US2017/015417
:/2ί«82/2 205555 | 5202555555555555 | 2633/: | Mil· -124 vrr s«<s altvp.ta growth and ap.giegm·* x, 555233055555555555555555 efceniosenshivily by targeting R-Rps and N-Ras. | nsir- 199b | hepato-cellular carcinoma | down -1 | Underexpressed mlcreRNA199b-5p targets hypoxiainducible factor-1? in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. | 52u3255 3¼ | folhcular thyroid carctuetua | 50555 | 52500:02030555555 MicroRNA is deregulated cOdaOcOhiTO-OldycCcC///// 5500505555555555555555 -, |
microRNA-ldti predicts poor pregp.osts Ip. glioma path ms | 399b | of Hypoxia-Inducible Factor 1? (H1F-1?) inl’rostate Cancer Ceils. | 50555 | 50555 | hi o', atian ALDHl -positive cells are assoetaretf with cbemoresistaiKe. | ||||||
5505555 | /SOfeHibHb//////// 50053622555555555 | 26335 | 522:55200025555555 stippressuf«« WuRN A*) 24 modulates hepatocellular 62233O3d222222:////// uggressiv eness 2 reprexsip.g R0CN2 and 5ΟΟ5555555555555555555 | tair- 199b- 3p | esophageal adenocarcinoma | up | MicroRNA 223 is Up-regulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PART I. | mu * Na | b-cell lympbvina | d<A' P. | 5θ5ΟΟ0Ο55Ο555555ί . f ΡΛ y-n-dn· tri tumor suppressor niicreRNA 800:32/0^20666//////// ::promothig:inEBV:-irFepted·:·:· 60006666656666666666666 |
/:2112/2:2 | 5505165500555555 /:2>2«22R:222222i | down | MiR-124 suppresses cell 5O050562:t355555555555: hepatoceliu Jar earcrumua by targeting RIK3CA. | mir- 199b- 5p | breast cancer | down | MiR-199b-5n targets HER2 in breast cancer cells. | 5332555 5/0555 | bladder vdKcei | 550505 | MicipRNA-jdjy fanctrnns 6:55033250053555555555 uncreENA and suppress^ 8ί0έ0έ50·02θ03·όί///////: cancer by directlv targeting 55££O055555555555555555555555555555: |
:/226///// 5505555 | 3ορ.3ΛνΛ11η1θΓ >/(22232x36//////////// | down | Mh'roRNA-d24 suppresses 50θ5ΐθΟθθ5555555555: 505605^005505050555 by taigetirig STATK | tuir- 199b- ?P | hepato-cellular carcinoma | down | identification of differentially expressed ml.croP.NAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. | :/1236///: 34 & | breast 'amer | :/6333:/ | MureRHA-' la ztippresse^ tite breast cancer stem cellhire characteristics by ddwnregutaiittg Notch/l /0505055555555555555555 |
5505555 | /3221122226232// | 5^633/: | »aR-U4 is Ipeqncp.tb 50000^0255555555:5 medtiliobiastop.ta and i> a negatrc e regulate r of 5θθΟί5555555555555555 | mir- I99h- 5p | medulloblastoma | down | The micro-RNA 199b-5p regulatory circuit involves lies:, CD 15. and epigeneti c modifications in medulloblastoma. | i!’U- Na | 50600005556:6 | dtp? P. | •'«yulutfru nuR- Aa level* are reduced in ctalvrevt.d 6000666666666666666666: |
:/226///// 5505555 | uaso-pharyngeal //22R22x38326//////: | down | ΜήΜ 24 suppresses tup.tor growih and toetastssia by 5000:00055555555:5 nasopfcan p.geal caicinonta | tuir- 199b- ?P | mesenchymal cancer | down | MicroRNA Expression Profiles in Kaposi's Sarcoma | :/2i36///: 3-4 & | breast 'amer | dun p. | MureRBA-' 1 supyfe^es breast v3t\vrasmo and metastasis 2 diuretic 855000004848484868// |
84622////: 5505555 | neuro-hlasfema | Jpun | bdei-x-iGn 01 nuk-lN 50005050005500055 N-SH cell differentiairen,. 50005000005555555 830056000>505555555555: 5WO3O00/5555555555 | 199b- 5p | papillary thyroid carcinoma | up | Expression profile and clinical significanc e of microRNAs in papillary thyroid carcinoma. | 462:6//// 50555 | breast cancer | down | I argmed E \presSipn cf miR- S-A Using die T-VtgA stem Suppresses Breast Cancer Cell Growth and 65050066666666666666666:: |
!UK- 5505555 | 5000050005: 5662355555555555555 | 56225 | 5050050505 055555555 regulates SQX8 expression and suppresses cell 5055050502530223055:5 55000060 055555555555 | mil- | b-cell lymphoma | up | MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | mn- 50555: | breast cancer | down | MpcroRNA-fdu Suppress* 6i30dOOe062/038368//// Targeting TbffKti in Human Breast < sneer 5&OO0O5555555555: |
108
WO 2017/132552
PCT/US2017/015417
635(6((((( 6/06/6/6/ | uon-small ceil Jaag /6065(/6/6/6/6/6/6/6/6/6/ | :/:/36/3/6/:/ | 6/3i(OW/2&^ regulates KGXK expression ///66d//5336(5666536R///////////////////////// ::pU>hfeiat!»riin:!QO£i:-S£lK}ii:·:·:·:·: ///6gU//(36g//663666/6/6/6/6/6/6/6/6/ | tuir- 19a | bladder cancer | up | iniR-3 9a acts as an oncogenic microRNA and is up-regulated in bladder cancer. | 6(66/6/6/:/ No | /666(66(516/6/6/6/6/6/6 curetnoma | dov n | MremRNA-Na suppiessc* /((33^(36^35316(((((((((((((((( downregulation of Notchl and Jagged! m Verv ((533/((3331/6366/6/6/6/6/6/6/(6/6/ choiioearcmoma ceils. |
///3365////////// BB/!/! | non-small ceil long (/66(366//////////////////////////////////// | dOwn | bcwft mpuiafict of ////335(3R/NA6i2/4/356/6/6/6/6/6/6/ vorreiaied rath tumor metastasis and poor prognosis in patieots with /tittiigPdhChhC/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | 19a | breast cancer | up | MicroRNA. expression profiles in human breast cancer ceils after muhifractroii and singledose radiation treatment. | /:/(66/-/:/:/:/: ////116/6/ | (/533(35(636(/6(((((( | down | /MicroR/NA-obS and nncroRNA-J-ia regulate cboidniua muhguarwv he tarpetingEftfP BN-d 5/^d/Billlllllll//6/6 |
/:/((3/3/:/:/:/:/:/ BB/!/! | ora: squamous cob carcinoma | /636/3/5:/: | Evb, roRNA-124 A-ppresse, oral squamous ceil carcinoma riotdity by /((5(g6(6i^/BI§i66/6/6/6/6/6/6/ | mir- | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis bv targeting LATS2. | ///(33(//////// ///366///6/6 | 6/6h3(i6(66/6/6/6/6/6/: /6(5(5/(65(6-56/6/6/6/6/ | down | MicroRNA--Na suppresses ////i/3i/r5656/B/i6r65l////////////////////////////// downregulation of Notch! /(3(3/35/255353(((35:3:66/6/6/6/ /666(516633/3636/6/6/6/6/6/6/6/(6 choriocarcinoma cells. |
/:/((3/6/6/6/:/ ////Bill | /53616366(36(33/:/6/6/6/6/ | down | Mkix>RNA-l24 functions as a tumor suppre&soi and «.dream z propno a, to human osioosarccma | mir- 19a | cervical cancer | up | MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting GUI,5. | /:/((3((/6/6 (356/6/6/ | /666(516633/6/6/6/6/6 | (/5/336/6 | ::-MioreR/NA>34u:ts:a:himor·:·:·:· /63135(6(3)6366/6/6/6/6/(6/6/6/6/6 choriocarcinoma via /fr6gti(3(i56:/6i>66!/i6-/(8<;:5i:/:/:/:/:/:/: |
SUU* B/Bl/I/ | osteosarcoma | :/:/363/6/:/ | 'Hie rumor sirppressor rote ό/ΟίΒ/ίΒΙΙΙΙΙ/Ι/Ι/ 6(^(6^6(666(66/6/6/6/6/6/6/6/6/6 | tuir- 19a | chclan giocarc ino ma | up | iniR-J 7-92 cluster promotes eholangiocarcinoraa growth: evidence for PTEN as downstream, target and IL6,'StatS as upstream activator. | mu- No | /66/3163/63636(/:/6/6/6 | dov n | MrercRNA- Na inhibit* nngmtiun and invasion N colon cancer cells via ///65633356/31/1^66:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
:/:(6((6/:/:/:/:/: 6/06/6/6/ | ovarian cancer | down | M«M 2-1 inhibit* the migration and invasion of O', artgn cancer ceils hv taigetirigSpb&t | tuir- 19a | colorectal cancer | Up | MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. | :/:/3t6(:/:/:/:/ M & | coko cancer | 6(135/66/ | Exprcsuortvl ituR-N « test in colon cancer whteh. can he re-expressed by a 6665565656631336/6/6/6/6/6/6/6 |
6/33(6/6/6/: BB/I/I | pancreatic cancer | dOwn | Methy iaiinr -mediated silencing of the miR-i24 gvivs iavduitvx puPvr'itu career progiessmu and metastasis by targeting | 19a | esophageal squamous cell carcinoma | up | /:/(66/-/:/:/:/: 6/116/6/ | colorectal cancer | down | Circulating miR-N-a levels are reduced in colorectal :(/0(666/6/6/6/6/6/6/6/6/6/6/6/6/6// | |
UUr- 6/Bll/l | /:/(((0331(5/636366/:/:/:/:/:/:/:/ | /636(66:/: | /(MiR(f 23/6(1((3(66666/655/6/6/6 motility and adhesion hy targeting taiin I in prostate /(66(356/6536//////////////////////////////////////////// | mil- | gastric cancer | up | MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. | 663(6/////// /:/635/6/5/ | cbloiectai cancer | down | //:/Dy6i665l63o6:3f/:/:/:/:/:/:/:/:///:/:/:/:/:/:/ MreroRHA-Naf -.press,on tn Colorectal Cancer /((36(6(3/33666/6/6/6/6/6/6/6/6/6/ Phosphorylation of FAR /:(3ΐ5/5(363/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ |
////III/ | ctebipcO1:^:/:/:/:/:/:/:/:/:/:/:/: | down | /(366363565/(3/33////////////////////////////// expression of miR-iS-t-Jp. ituR-US-L and miR-221(5(5/ih(5Bi3t56///////////////////////////////////// asfroevtomasare related to /((33^56^6/653(3(66656(61(/(((( and recurrent tumors tn Mexixufi children | mir- 19a | gastric cancer | up | miR19a Promotes Cell Growth and Tumorigenesis through Targeting S0CS1 in Gastric Cancer. | /:/((3((/6/6 /16/566(/ | coloievtai v«xreei | 5633/66 | Novel evidence foi curcumm and bosu dire /(3)(1353563(6/6/6/6/6/6/6/(6/6/6/ ebemoprevemion through regulation of miR- N a and ////Ι/Γη35556:(63/6!6(66(51:/:/:/:/:/:/:/:/:/:/ :(/66(3666/6/6/6/6/6/6/6/6/6/6/6/6/6// |
109
WO 2017/132552
PCT/US2017/015417
5://9995 INAp | 5/1////9/////(9))))(:) | 99(0/) | cob migration andinvavion mbladder cancer cells hy :9:ί/ί90ίΐ9/:&ί/ε^/7:7:7:7:7:7:7: | nsir- 919a | gastric cancer | up | MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXDl. | 59bu/4995 Ns | 95/άί3Ο«//((((((( ((//////(((((((((((((( | duv n | 9;9^/i/9bf;i^5/$/9//;ti((((((((((; ((έ^^^/9/ίϊ(9ΐ9έ;ΑΕ^/ΐΐ;(())) 9999^/05//0//519///(/)999999999999999 |
59//9:5:5: i>4-3p | gastric cancer | ):://(4/:: | T' 4» uai «t Wb MV' of dcwviu-eguiatktii of mu-ί 243p, mir-d4t.ia-5p, roir-I?5~ 5p and imr--335-$p m (:^/(α/(((/ώέ/:(((((((((((((((((( 9)5^9/j//i/&i/494949494949494949: | mir- | gastric cancer | up | MiR-19a promotes epithelialmesenchymal transition through P13K/AKT pathway in gastric cancer. | :)/90 9 9 9 )9 (9///((((( | esophageal squamous cell cammoma | down | :999/5/054/9(//////)1/44999999999999999999999 migration and invasion of esophageal squamous ceil carcinoma by targeting Ym :(1/((/5/9)((((((((((((((((((((((((((: |
iill: | ((5((//(((((((((((((((((((( | down | MiR-l24-5p inhibits due growth oftftgii-giade· :(^(/(//9(/////(((((((((((((((((: posttronscriptrooaf regulation of ί. AKffi i. | mir- 19a | gastric cancer | up | MiR-19a promotes epithelialmesenchymal transition through R13K/AKT pathway in gastric | 9)90m5)))9 (/(Β))))) | gastriv ..atwei | (949/9/(( | ((SiB9^^k$9^d/!^9((((((((( cancer growth and inhibits apoptosis hy epigercttcslh 9(;j5^^^9;//O5d:((((((((((((; |
99//4959 1246 | colorectal cancer | (09(((( | CTrcufarmg fivovonxti mkroRNAs as Eiomarkers :93f(5s:i0i5G3ik/?999999999999999: | mir- | glioma | up | miR-l9a and miR-19b Overexpressiou in Gliomas. | //rite/;;); (9///((((( | gaatng ..ancer | 9((3/9((((( | :9;jdi/^B9^:9pir/fifirig:i5f;9:9:9:9:9:9:9:9 human gastrin cancer |
59//9555: ((90(((( | pancreatic cancer | 4309 | miR- 1 ?4 7 is Correlated (($/((/:///////(/://(:((((((((((((( 99^/9cOk9G3ik/(9(/i99999999: •:illl£!hrtS:Geli:Rn>iifeiat!»r£·:·:·:·: by laigeung Nettroptlna, | mir- | glioma | up | MicroRMA-l9a promotes glioma cell growth by repressing LRIGl. | :)/9//5999)9 (559//(((( | gaatng ..ancer | dow n | :99):9://9///9^/^(/9////50/99999999999999 nyP-ttaexpre-zsion ro eotnpteteiy msentecl gasfrm cartcer tumor ipcurrence and overall attiviva:. |
59//-995 | 94ι//ί$/29/(1/ά9!αδη2) 5:1/3/////:5:5:5:5:5:5:59 | down | I pi-‘•ere t rit-ixiig ΛΓ Jx 9(i/9r/h9r9$9/ppi//S/r9((((((((((((((9 49/5t/f/&/4^ remhaest )! nevpre^rot (:///(://///(/:/:^(((((((((((((( prognosis m aeuie b mpbpblasttc leukemia | 19a | lung cancer | up | Apoptosis induction by antisense oligonucleotides against mixi?'-5p and miR-20a in lung cancers overexpressing miR-1792 | 9:9/51:5595 9(0((((9 | gasttic caiKgr | down | E xpresS-on and tegulafOry function yf miRNTA-34a in iMgvtmjsnr nib mgastrrc 9(//////9//((/(9((((((((((((((((((((( |
::/t995:5:·: (0/((((9 | epithelial ot anas ))///9///:))))))))))))))))): | down | 596/:95/0^ miotoRNA screens identify miR IsGarcpulaang proliferation and apopiosis in epitfcsiraf ovarian cancer (://(:/((((((((((((((((((((((((((((((9 | mir- 19a | lung cancer | up | AlicroRNA ra:R-J7-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | :9/:5159:9:9:9 3-4 & | gastric cancer | Jon n | : \ aitatton of fv hcroR \ 4 Expression Patfoiu of >(<^^jj;t9ri‘i9^/f9/i:t9dkai:d(i4i9d9!(iitii(;9;9;9;9;9 94O//t/i/d(i/ti/:((((((((((((((((: 598()/(//////(//:(((((((((((((((((( 9(::ih/ii//i^ (9/9/9//1^ Nyrtbw estein H jnspiy |
::/t995:5:·: (0/((((9 | 99g(j((/!a/ta9/i::::::::::::::::::::: | down | mtR-12-te ts frequently 99^/)/94/^id/kfi9i/99:9:9:9:9:9:9:9:9:9:9:9:9 9)§1ί//ίάέ(/9ί//23/(!/(((((((((((( In' ol' od in migration and 9(w///i9/i/9((((((((((((((((((((((((: | mir- 19a | lung cancer | up | A polycistronic raicroRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances ceil proliferation. | :9/:5159:9:9:9 34 a | gastric cancer | Jon n | microRN4- t-m luitibik the 9)9/1//9/1^ Metas-asis oTGasfix Cancer· hy Targeting :(|^^9|/|9^|||||(((( 5t:'9Ni59FSSsi09/95959595959595959595959: |
5:///:995 BlBII | )^(/(//i(((((((((((((((((( | ((//(/(ί) | mir- 19a | mantle cell lymphoma | up | The miRNA.-17792 cluster mediates chemo resistance and enhances tumor growth in mantle cell lymphoma via PI3K/AK.7 uathway activation. | :9:9d5f59:9:9:9 34a | )9g/$(d/(//ik/9/((((( | d«W £’ | 9999^^/4-45-3949/91191/1/11/9999999999999999999999 t C ER sun ahtte-d^p^nd '<r MMP7 activation in gastric 9999(/((///999999999999999999999999999999999999999999999999999999999 | |
::/t/95:5:·: ((O/:)))) | 99(0((/9/(()))))5)))))) iy mphntoa | (0((((9 | mkroRMA expression profile and identification of marker and pathogenetic 9:99&/t3/fe/99t/i//(ifig9/2.iK,d:9:9:9:9: | mir- 19a | raedullo-blastoma | up | The miR-:/92 polycistron is up-regulated in sonic hedgehogdriven medulloblastomas and induced by Ν-rnyc in sonic hedgehog-treated cerebellar | :9/:5159:9:9:9 34 a | pbAftlazKtifia | Jon n | Mr. mRNA- Aa inhibits glioblastoma growth hy targeting multiple ::::Qh£0gpfteS:95959595959595959:9595959 |
110
WO 2017/132552
PCT/US2017/015417
κι tuartfie yell b ujpliousa. | neural precursors. | ||||||||||
:05-2:::::2 Ι25;ϊ | on: squamous cell eareinoma | 553302: | Oenotuewide Stud? of Sam are MmroRNAs for Doiectioii of Oral Cancel’ | mir- | neiiro-hlastoma | up | MYCN-reguiated rojcroRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation inhuman neuroblastoma. | :2:3254432:2:2:2 5315^55555 | glioblastoma | down | MioroENAAda jargets 22223045333332i3h3i3s22503 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 253ίρί43ίό42ΐ325 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5: ebyblasroua uiUlbPrme |
55333352222 53105555 | :2:3iS3St:$d3i:3i2222222222: | dyu it | MieredkNA-PdR eapprysses breast canye-r 5:O33:35O0Oi05555555555555 targeting hepatunase | inir- 19a | uou-suiaii cell lung cancer | up | Serum iniR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer | 2ifiU;i2:2:2:2:2: 34a | ;52g3d33i3l323i325 5 5 5 5 52 | dow £' | 252432^2524333344343333255555552 5234O3533i333f 555555555555555 25234dd343d3323433l3ii455555555552 ghobi<.smna muiuPrme |
125« | breast cancer | down | The expres&iyi< andylmicyl sigmficap.ye of reiyroRNA1258 and heparanase re human breusf cancer | mir- 19a | osteo-sarcoma | up | Upregulation of microRNA-1792 cluster associates with tumor progression and prognosis in osteosarcoma | 2:22f43ii2:2:2:2: 5353355555 | 22gHO23i322 2 2 2 2 2 2 2 2 2 2 2 2 2 | 524332352 | 2 2 2 MisreRNA234524h3ib342222222222222 glioblasiuma giowtb tw 5:234^3332^434355555555555555 un.-.x-wncs. |
SUU* 55405555 | 55333«33O3555555555 | 253355555 | MiemENA profiling of 550O3<3333i2333333555555555: | tuir219a3p | breast cancer | down | MicroRNA-19a-3p inhibits breast cancer progression and metastasis hy inducing macrophage polarization through downiegulated expression of Fra-1 protooncogene. | mu- Nu | gimren | dm? p. | microRNA-24a ts huuor suppress!' c in hram hintor, and glioma stem cells. |
•UK- 5005555 | breast cancer | 53355555 | •:Mia»RiiA<i2da:mfi.ijef£ces:·:· breast vanyet stem ceils Iw targeting leatenua ii hbf-ore ί odor •x^fUOr which regulates (he hippo S'gnaiK'g padiwa* | mir- 19b | b-ceii lymphoma | up | MicroRNA miR-17 -5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | 2:22(43442:2:2:2: 5353355555 | 22gHO23i322 2 2 2 2 2 2 2 2 2 2 2 2 2 | 524032352 | 2 2 2 MisreRNA234524hddO352222222222222 apoptosis- in flic banian glioma cell line. API through enhanced EOS pfOdutfiOh anelNOxz 22333£S44Gii222222222222222222222222 |
:23)1322:22: 554505555 | •.oioreetai vancer | dO'VO | Candidate relcroRN A 25340433354323334335555555555 colorectal cancer $\ sfyp.taftv ttucw prefibnc sntd'esatm. exo'nmcPtJ· 2:2334 idaii03;22222222222222222222222: | mir- 19b | breast cancer | Up | MicroRNA expression prof iles in human breast cancer cells after muitifraction and single dose radiation treatment. | 2:23)3:22222 3-1 & | head and rteeh squamous coll 55^4:33335555555555 | :2:433:3:2: | 2:2:D24s4sgl33i332332:2:2:2:2:2:2:2:2:2:2:2:2:2:2: sutreR 1A -Aacxpre riOi ::i«head:aHd-neok:sqeam(jas·:·:· ceil vapentorna promotes 5234O4i332t332i3423i333255555 :2:3334035353432:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2: |
Ii!U- 555^5:5555 | 55$i0bO3355555555552 | 55035: | m.iR-29b and iniR-J2da regulate potfopiarun and SUpp'O UAvS.aniP 222^40333552554)3222222222222222222222 | nsir- 19b | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis by targeting UATS2. | mu- Nu | 25:h3t43t3$34iti3i325 5 5 52 carcinoma | dm? p. | QiivNt tic adenor trn* vOe\o'r'’J«.g U m'MAA-b <0x1 ilMU reduces superior antnmoor Otiiviv m experimental tumor model. |
2:33352:2:2: 554β555 5:3:.35555555: | gaorn v.rerer | dO'VO | Dowri'-rognlatiop. oi'relic 125o~3p in. human gastric 25343435 343 335555555555555555555 5333134)334333343345555555555552 25313303332555555555555555555555 | mir- 19b | cervical car.cer | up | MicroRNA-l 9a and-l9b regulate cervical carcinoma cell proliferation and invasion by targeting CUL.5. | 2:3)3:22222 3-1 & | heparereliBar eamnmma | :2:433:3222 | Untlerexpressjou of miR>fo in hepatocellular 25^4:33335534234255555555555555 25o43343334)35tb33r2d355555555552 enhancement of ptobieiaub? mh.bitui' effects of agents targeting 535θ£5555555555555555555555555552 |
in
WO 2017/132552
PCT/US2017/015417
):))/)755555 33////)333: | uco-suja)) ceil hang 55O/55Z5Z5Z5Z5Z5Z | miR-)2>a-3p and miR12?a-?psre downregulsied 5))i5/$/3/OO/3 /)//555555555 vatxer gucl ha·, e «> eise •^effopiSUHinvasloilvand:·:·:·:·:·:·:·: migration of hung cancer 5O&555555555555555555555555555555 | mir- 19b | clwlangio- carcinoma | up | miR-17-92 cluster promotes cholangiocarcmoraa growth: evidence for PTEN as downstream target and IL6,'StatS as upstream activator. | ):)/))7555: Ns | 55//)3/)///)1)///55555 carcinoma | dm? n | Micr'RMA-Aa Targets Bel*? and Scnsitmes 53i/))h)//)i/s//l///i//i//55555555: Caieinoma Cells to Sorafenib Treatment. | |
3;)h))555555: 425a- 3p | non-small cell lung 5//)5/5/55/5/5/5/5/5 | down | nuR-125u-op targets KfTAi to suppress NSCLC ceil proliferation migration, nod υ.ν-κηοο. | rnir- 19b | colorectal cancer | up | MicroRNA expression profiling of exfoliated colonocvtes isolated from feces for colorectal cancer screening. | 5:13/5)5555 5/4//55555 | 33////t///ll/l//33555 55//)/)//)//5555555555 | :5/333)1)3: | Methylation-associated sflencmg of uncroRNA-Nh m hepatocellular caremonia ;an..xr |
SUU* //:3//33/ ::33/5:5:5:5 | 3)355//550//55/55/5 | )5//)//3: | Arab sis of naR-ND aud tuJM*<».W',aiontt me )/ai0)3dto5:/l5//55//dsf:55555555 •))i/))//i/55555555555555555555555555: | mir- 19b | esophageal squamous cel: carcinoma | up | mu- Na | 55////1///)/))//55555 carcinoma | dm? n | miR-Nu inhibits nugmifon and invasion by dawn- 53)/gtli/)i/h5/i:/::bl/t555555555555: expression in human 53i)///t//glibla)5//l/))te)//55555: 5Ο3/555555555555555555555555555555 | |
5:1/)55:5:5:: //0//3/ 5:5/5:5:5:5 | 55gl50fr!ast)j)ii35555555555: | dOteft | MtRNA i'<s <pinlahtte 5505)//3/)5//5/555555555555555 proliferation and pturnotefe cel! differentiation in ):W/W:5fe/^555555555555555555i | 19b | gastric cancer | up | MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXDl. | 7mif:-7:4: 3/^/3/ | /fbhg'/ajioe))))))))): | down | Dtv tlopmen. of a lung ::eafrcertiiefapeutic:based:on·:·:· 5//////)/////1///3/)33535353)35 353/)/)d:R:/lA/:/)5555555555555555555 |
SUU* //0/53/ | uco-suja)) cell hang 55O555Z5Z5Z5Z5Z5Z | 55/5)5/5: | miR-)2>a-3p and miR12?a-?psre downreguisied 5/55///5//3/)5/51/5)//:55555555: cancer and have invef&g •zefieetsoaiiivusioii^nd:·:·:·:·:·:·:·: migration of lung cancer 5:5)055555555555555555555555555555 | mir- 19b | gastric cancer | up | MicroRNA-19a'b regulates muitidrug resistance in human gastric cancer cells by targeting PTEN. | mu- Na | ntaiununt 55/l/l//o)//5555555555 | dm? n | MicmRMA-iob represents an independent prognostic parameter and ts <orrds:ed 55Μΐ&/)/ηό/ρ/ΐ4555555555535555555 ::pfOilleiation:aild:npOptOSrS·:·:·:· it malignant melanoiua, -, |
425a- 5:5/5:5:5:5 | 5//O5Z5Z5Z5Z5Z5Z5 | 5/0/5/ | i-tSardnuR-i-foaas dmum-sf b'voktitarsm mm-smili xoB lung '«toer | 19b | up | Overexpression in Gliomas. | 53)//55555 | 55/3/3///)//5555555555 | 55///)///)/////)))r///)3555555555: nxlanoma Celia hy 55b)i/)/ii/4A^5555555555555555555555 | ||
liar- 5/05/5 | 5//5)500t/Z5Z5Z5 5150505/5/5/5/5: | [miR-)2>b promotes /)/:/0)/1/0 ixnte uwclotii iettfenna cSltSby targeting BaMj | mir- 19b | lung cancer | up | A polycistronic microRNA cluster, miR-17-92, is overexpressed inhuman lung cancers and enhances cell proliferation. | mu- 34s | 55/3/4)////):5555555555 33/)/)///)//3333333333 | dm? n | Overexpres&ton of'the miR>4 faitaiy suppresses 33://^///^))3θ:/ί5)))))))))5555 hKdignani melanoma with the wtld-ty pe p5> gene | |
4)/))77:4::: 5/0/55/ | bitvkier cancer | down | Micro# NA-1 25b suppresses the ds% Chapment 5:///)/////3/////))/55555555555 33t/l/s)i))g:E2F555555555555555555i | mir- 19b | lung cancer | Up | Apoptosis induction by antisense oligonucleotides against miR17-5p and miR-20a in lung cancels overexpressing miR-1792. | 4btlf74:4 3-4 & | 33/3/4)g/h/)5555555555: melanoma | dm? n | ten dt run Λ ii O '* x a novel target far 53)rn/)/RNA5A/a:4)):5555555555555: 33/)/4//0)//533333333333333:55555555: |
3^4)/)555555: 3/0//5 | bladder cancer | down | •MUlCioRNA-fkS-binfn/itS·:·:·:·:·: cell nrigrattoii and invuskm fry targeting matrix metaBopepfidase 43 in 5:)///de/;3/////55555555555555555: | rnir- 19b | lung cancer | up | MicroRNA miR-l7-5p is overexpiessed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | 5:)5/535555 53//:/33 | 33////3/)0)//^5555 | j://))))): | 5:3/:////1/)//3//)///3333333:55555 identifies rntfi-cAa a candidate neuroblastoma ntuRA a jpvr' λογ gem |
7)/5/774:4: 5/0/5// | 50/3550/)355555555: | down | 4Mb<Wd7:4:4:4:4:4:4:4:4:4:4:4 5i)//Oi3feO)/i55555555555555 EXPRESSION IS 55g/ii3/^5fe/3^35i5^55555 | mir- 19b | mantle cell lymphoma | Up | The miRNA-1792 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PE3K/AKT pathway activation. | 7)5t)f74:4 3-4 a | neuroblastoma | dm? n | 'tumRElA- ofjm'xnfs suppressor by inducing xapoptosisiiimeutobiasfoiria·:·:·: )))5/11)5555555555555555555555555555555: |
112
WO 2017/132552
PCT/US2017/015417
(kuCtttV: :(2/2/(((: | 2ftkk22O2/222222 | 2/2//(: | miR- J 2>b is tuethy lated and lunations as a armor Suppressor by reflating ((//B////r/s/-:/222222i22((( in human im asn e breas· 8/kbk8888888888888888888888888:3: | tnir- 19b | medulio-blastoma | up | The miR-i7/92 polycisiron is tip-regulated in sonic hedgehogdriven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. | (dht/:·:·:·:: Ma | ((h0h/h/ii//:i(((((: hmg «.oncer | 2//2((( | • rreutairncttaR /2 nt<R24 and roi-f. -34a as novel nredtctw e fctomaikefs to (/8h///te//3^/(((((((((((((: chemotherapy m advanced nor. small cell lung cuncor. |
804888:8:8:: (//2/2(( | breast cancer | down | MreroRNA -: 25b indiu ns metastasis by tametmg STARJ>i3mbKT-7and Μ0Α-ΜΒ-2.Π breast 8/ks//®ib8888888888888888888888; | 19b | osteo-sarcoma | up | Upregulation of microRNA-1792 cluster associates with tumor progression and prognosis in osteosarcoma. | |/|2| | :8E//N3he/i888888888 | regulatory axis decreases survival advantage and ensure * b3vdej/u dent apoptosis of non-smab ceil hrng tarmnoma «.ells | |
8^/88:8:8:: (//2/2(( | btCuiSi NnuCT | 3//2/: | Dlifcrentrei eypressinnof mtR-2k miR-i?.5band itnR-VM in breast cancer (////((((((((((((((((((((((((((((( | mir- 200a | bladder cancer | down | Expression of microRNAs in the Urine of Patients With Bladder Cancer. | 8//88:8: 2//((((( | non-small veil lung cancer | down | tire mn roRN *. nuR- · ta Intubita Non-AmaH Cell I»ng Cancer ·’ NSCLC) Grow tit and he CD441u tembduVy L· < oils |
804888:8:88 (//2/2(( | breast cancer | down | (:(^(/////:/22/2/2(((((((( mioxhoi'diu taspaso-3 pathway i« doxorubicin resistance atxi therapy re. human breast career | 200a | breast cancer | up | Direct targeting of Sec23a by miR-200s influences cancer cell secietome and promotes metastatic colonization. | 880188888: 20/(((( | ((//////(((((((( | down | xeafrcerproaressionpadially·:·:· 8(/2//i/2//2///(((((((((((((((( tnterlenktn-^-ucceptor |
i!Ul* (////((2 | dUOiib. h, nrpbocv be 2ί/2/θ2((((((((((((((( | ((22//(: | The down-regulation oi nuB-C^hm chrome bl pi K »· OHvS leads to metabolic adapiatiyn of ceils to a ((ktkpiih/i:3tai8(8((((((:8:8:8: | tnir- 200a | breast cancer | up | MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP! in Human Breast Cancer. | mu- Ma | osteosarcoma | dm? n | Mu mRNA-' 4a inhibit* the proliferation anti «Niasta*u> ofosieosamomut Nil, femb 88/4/ff$/ka28/k(8888888888888 |
8:10888:8:8:: 20/2:2 | iotheular cancer | (//((((: | MtcroRNA expression. (/tbf///83(/2///2i/2((((((((: diagnostic tool for thyroid 22222/((((((((((((((((((((((((((((: | 200a | breast cancer | down | mi.croRNA-200a Inhibits Cell Proliferation by Targeting Mitochondrial Transcription factor A in Breast Cancer | 880188888: 20/(((( | osteosarcoma | down | MiCroRN.A-3-i-a itthibtf S ((/4h//k?(//aOh/((((((((((( (//8/0////:^(((((((((((((((((: downregniadng ether a gu((g/2(k/te8kh8(((((((:8:8:8:::8: |
liar- (////((2 | 2/0//2///(((((((( | 8i88 | tniRMAAU' promotes gastric cancer invasion mid metastasis b> targeting tureor suppressor (|//k|j((((((((((((((((((((((((: | tnir- 200a | esophageal adenocarcinoma | up | Gastric adenocarcinoma lias a unique microRNA signature not. present in esophageal adenocarcinoma | mu- 34a | osteosarcoma | dm? n | ((/ii//8O/2/i^2//(((((((( related apoptosis-inducing hganri tndu ns evn«m\i 'itv Spemik to OsteOsSiteoma b> ((/ftk3////s/tohi2(((((((((((: 8:///ri2/8888888888888888888888888: |
8:10888:8:8:: 20/2:2 | gastric cancer | ((//((((: | MtR-i2$fc promotes cob migration and invasion by targeting RPPlCA-Rb signal pathways in gastric earner resulting in a pot r pOKtta ,i, | 200a | esophageal cancer | up | Differential expression of miRNAs in esophageal cancer tissue. | 880188:8:·: 20/(((( | ovarian cancer | down | Prequent dowitreguiaiioo of naR-34 bre-ily in human ((k/a//2k(/8822(((((((((((((((i |
!UH- 220222 | 2//0/2//(((((((((2 | 2/2/22 | Mt c-associated zinc itnget protein (MAX) is regulated by roiR -125b and mediates 8k/GE8mk82d8((((((((:8:8:8:8 ((/1^0^8(83/222(((((((((((((((( | mli- 200a | esophageal cancer | up | miR-200a/miR-141 and miR205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas. | Uii!- 222/((((: | ovarian cancer | down | MtR-; 4a suppresses ovarian cancer prollihration and inotihiy by targeting 2/^2((((((((((((((((((((((((((((( |
113
WO 2017/132552
PCT/US2017/015417
E-tinteRR·: | //^imbihtifeRitiTT:RRR | /rr/rr | »nR-J2>b prontotes ceil | mir- | gastric adeno- | down | Downregulated microRNA-200a | :RtiiiiR:R: | ARiRRtiiR:RRRRR | Jon n | TQRwARtRuihtbiARAlAAAA::: |
/^bhtebtrbpEy/diteORRR/ targetmp 1 m?d Pi glioblastoma stem ceils with low expression te\ els /B:R?RIB?IRRRRRaR:RR3 | 200a | carcinoma | -1 | promotes EMT and tumor gro wth through the wnt/betacatenin pathway by targeting the E-cadherin repressors ZEBI/ZEB2 in gastric adenocarcinoma | No | tiAhosRARRRRRR | growth and nxhjco> EiAiAfdAAA^ti^lWRRR-R:: egnlaUun ofnuR 34am pancreatic cancer ceils- -, | ||||
R^IrI | <i>nnexin43 and Promotes lljROiORRRRRRRRRR/R | 200a | adenocarcinoma | unique microRNA signature not present in esophageal adenocarcinoma. | :R|tiRR: | RO^iRRRRRR/R | human pancreatic cancer /RiiRbO'Bti^R^RBRRRRRR | ||||
»!«- B|B|r | C'UOimi | RdhO/ | SertjntMicroRNA-125b as a Roiential Riomsrksr fnr (ΒίΒΒΒΙΟΙΙΪΙίΙΪΙ | mir- 200a | glioma | down | MiR-200a impairs glioma cell growth, migration, and invasion by targeting SiM2,-s. | mu- Na | pancreatic direral attenoeareinonu» | up | MlR-21. miR-34a. ntrR-198 and ttdR- H as dtapno ztte vafidprognostiobiomaikers:·:·:·:· for cbrohic pancreatitis and adcrjocarcttiomn, |
BBlRR | AglAhARRRRRRRRR | RtiEll | MtR-l25fc exprassioh •:-affee£S<die:protlleiUHonUHd:·:· apoptosis of buruan glioma ceils b> targeting Bntf. | 200a | hepato-cellular carcinoma | down | The histone deacetyiase 4/SPl/micronta-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. | /:mif///// iBIl | papillary tbvPxcl AraAthbiptiRRRRR | ;OR/R | ABR-j-ta targets GASi m promote cell proliferation and inhibit apoptosis tit paptliarv tbyroul carcinoma vta RDR/Akt/flad pathway. |
»!«- B|B|r | :/&ORBiR^R:RRR3 Rd?.teARAARRRRR::R: | RdhO/ | /:MidAOR^|2Sb:F:tiO^iRA vsa -mt^r Super'«,οπη 1 lepatvOclittlar Carcmoma ΟΪΒΪΙΪΙΪΙΪΙΪΙΪΑ | mir- 200a | hepato-cellular carcinoma | down | The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma? | mu- Na | pi.ix! ii·. i. <i<.u | Jov n | The microR-NA miR-34a urhsbiu prostate earner stem cells and metastasis b\ direCtl} repressing ROrRRRRRRRRRRRRR/R |
iAiteR::::::::: rBBir | 1)Ρρ.4ΛνΛί!η1θ1· ifbtelRABAAiRRRR | dOwil | /d/liStd^-lyS^/////////////////// mmhyhranaferase. SW3sHl. promotes H<C AiRRgAAiRARpRaRRRRRRR::: nocptteeb tepBand A mtercREiAM.^h | mir- 200a | hepato-cellular carcinoma | down | miR-200a suppresses cell growth and migration by targeting MACCi and predicts prognosis m hepatocellular carcinoma. | :/biiti////: 34 a | prostate cancer | /•dbteti:/ | itlteroRHA- Ma modulates cungalexes to suppress malignancy in human prostate cancer cells. |
liar- BO:RR | :/&ORBiR^R:RRR3 gdARiAjiAsRRRRRR·:· | RdhO/ | Ourexom oioiivi nucroRNA-122>b sensitizes human hepatocoihjior carcinoma cells to5fluorouracfi tlnoygh miubttmn A ub vol; sts b tergotittgitexokmase IP | mir- 200a | hepato-cellular carcinoma | down | MicroRNA-200a suppresses metastatic potential of side population cells inhuman hepatocellular carcinoma bydecreasing ZEB2. | mu- 34a | Jov n | gteEETT^^ Emsftte< iiKvf itw t R egufated by jrtiR-34-a | |
•RbiRRAA BrBrI | Ab^MbAi^RRRRR AraAraAiARRRRgRR | down | Diagnostic and prognostic ::irnpl!Oatio:ns:of:niicioR.NAs·:·: /Rhiti^tiRitiRRRRRRRRRR:/// | mir- 200a | lung adenocarcinoma | down | miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by' targeting Fltl/VEGRRI. | •RtiiRRR bBir | levtal cancer | /Tl//// | The quantnutte e anab sis 0' stem-loop real-time PCR revealed lire mteroRNA3-ia ntiotuR VA-dand ROOllB^GRRRRRRRR::· O\ e· expression «· naman colorectal cancer |
BBrrr | hepatoceiktlar AdARARi^RRRRRR·:· | RdWR·:· | Regulation of placenta growth faU'U b\ ArAdAR^BdR5RdtiAAA:RRR i&jpAdidiittitiiRdORRRR/R | 200a | malignant melanoma | up | MicroRNA-200 family members differentially regulate morphological plastic ity and mode of melanoma ceil invasion. | /:mif///// iBIl | ?Ah|BI;RRRRR; AraAthbiptiRRRRR | down | AlmroRNA~34a suppresses yipihpi-oi^ktmtiRBRRRR/R metastasis by targeting (ilBittCiteOhRiBRRRRR RitdteiitebRiRtiRRRRRRRRRR |
114
WO 2017/132552
PCT/US2017/015417
TTi-ijfiitsa^iiiOilti^hhhhhhhN | MicroRNA-12$b promotes apoptosis by regulating the TvprtSSron oi Md J BJ-w | mir- 200a | meningioma | down | Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/belacalenin signaling pathway. | MmtiEE Ma | carcinoma | dov n | MureRNA-Ma yuppiessc* malignant transformation BEtiii^etitigk^BiEEEEEEE: transciiptiynal compie vs?s >:;Η<ίίΐϋ^ί^ίί:ΐέίώΐ::ώ^ίί:ύ:ύ:ύ:ύ:ύΤύ E5/ditii^bih-EEEEEEEEE:EE:: | ||
hnaf-::::::::::: | •Jaw a | MtcroKNA roiR-l25h proer' sutoIa drexf esprtsUoft | 200a | mesen-chytnal cancer | down | MicroRNA Expression Profiles in Kaposi's Sarcoma. | :·:ήϋη·:·:·:·: iill | yrehai/celUEEEEE: | down | Ί-ufttor suppressor uamoRNk Ma rnluonx «,eti proliferation by targeting Xfvttid mrcralvOO ζ«<ΧΗ5·.·»Ρ.> | |
i!!U- | miR-120b induces cetiulut senescence tn malignant | mir- 200a | ueuro-blastoma | down | miR-200a inhibits tumor prolif eration by targeting AP-2? in neuroblastoma cells | mu- No | Eititibd4bl^tdti^N:i | dov n | Dilietentiai mivmRNA- '4a e\pres>uroanJ ramm· suppressor function m /feahp^d5f0tit3TsiRX///////::::::: | ||
htiiife:::::::::: | Xheitid/biaSiofedEX/E: | B|:EE | Mb raRN A-J 2*8 is .< nroel negative regulator of p?3. | mir- 200a | non-small ceil lung cancer | up | Mi.R-2.00a enhances the migrations of A549 and SKMES-l cells by regulating the expression of TSPAN1. | ?ti5irE:X:: | SqKirfftuU j E^dfcitiairifEEEEE | :tiiti::EE: | Τίρ^ίτέ^δΐΐρί^^ιώίέ'ίϊ^έ^ΛύΤ::::::::::::: Cervical Cancer. |
ora! squamous «til X^tifeiikiafEoTExEE: | down | Decreased expression of naR-t2<haud toiR J'! m vorufcauoercollsoontrrbutes:·:· | mir- 200a | ovarian cancer | Up -1 | Upregulation of microRNA200a associates with tumor proliferation, CSCs phenotype and chemosensltivity in ovarian cancer. | Xirife::·:·:: 3-1 & | uveal melanoma | /•dbAbE | MtiroRHA- Ma inhibits 3;:ύΕ'^υί;ϊ^ί3Λ?ρίϊί3:^$1^ύΤ:::::::::::::::: ::pfotiiea.ation:arid:migmtron:·:·:· dttongli dm» megulaimr of | |
E^dti^tiBiEEEEEE:: | significance of plusmu microRNAMTob level tn puberrs t ph Aral sqoatooos /EstiE^^ktita|x///////:::X:X:X: | 200a | prognostic marker in advanced ovarian cancer. | m|dE:E: | cokroMtl aiiom PKtitstOsU and predi tie, redurreird tn patients with stage ildil ccdoreetai cancer. | ||||||
!UK- | osteosarcoma | •MptitiX | ttaR-{2 Tp suppresses the proliieranon and migration of osteosarcoma celts : Ιίί0ΐιρ^4σ»ητί0Κ:[ίΐ3ΐ:!»ίί»ί:: | mir- 200a | pancreatic ductal adeno -carcinoma | down | XMD8-92 Inhibits Pancreatic Tumor Xenograft Growth via DCLKl-Dependent Mechanism. | /:tiHrE:X:: | breast dancer | down | MicrcRNA-34 suppresses hn.<s imerimazun mJ metastasis hy directly |
hnaf-::::::::::: | Ov attan oancer | •Jaw ft | Redos and MtChainsiftbi uaR- iO9p and naR-llSb in | 200a | renal cell carcinoma | down | Tumor suppressive microRNA200a inhibits renal cell carcinoma development by directly taraetmg TGFB2. | ximrExx | breast ca&oer | down | The Regulation and >:Ediktidh::^tiftR?:-2dEEEEE7/ ΕΟλΟ Μ-πιΚ-ΜΙΑ Signaling in Breast Cancer. |
Χρΐί^/ΕΕ | ΕΡ^ί^ΡΕ^^ΕΕΕΕ·:· | down | Micro -RNAs and ox ariaii cancel. Ihs? state of art and perspectives Ά etiweat :::^^fe|:E::EEEEEE | mir- 200b | astrocytoma | down | Prognostic value of coexistence of abnormal expression of mrcro-R’NA-200b and cyclic adenosine monophosphateresponsive element -binding protein 1 in human astrocytoma. | xtitiEEE | Ei^pmPEEEEEEX El^h^OtiEE/EE | tidOWiE: | Ep· genetic rax (natron of mir-.Mbrc in addition to roir-.MaandDAEKl hi chronic IvmphOvvtiv xRdk^ift^EExEEEEEEEEEx^ |
VtiitiM:::::::: | /:byarkti:0^hdbT::::::::::: | down | PEAR? inhibits ovarian cancer colls probforatiem •:fiKOngh:[ipiega!at£On:of:·:·:·:·:·:·:· $h^:-d2^h;EEEEEEEEE:EE:: | mir- 200b | bladder cancer | down | Expression of raicroRNAs tn the Urine of Patients With. Bladder Cancer. | XitiiiE:::X: :ί:Β|:|:ί | Eiti^tftdtiia:E::EEE: | don n | MicroRNA- Mb functions E^:a;pd^^i&^bEEE7:7:7: suppressor in end&nxdtiai serous adoiiycarcitionip |
ΧίίϋΐΜΧ::/: | prostate caacer | ί:||:ί:|: | V\ nJaspread dorogoiafiOi· of jnicroRNA expiesstOttin | 200b | breast cancer | up | Direct targeting of Sec23a by miR2O0s influences cancer ceil secretome and promotes metastatic colonization. | ·::10ΐΕ:Χ:Χ | gastfte cancer | down | Epigenetic regulation of mtR-Mb andmtR-129 expression m gastric |
115
WO 2017/132552
PCT/US2017/015417
$$£$$$:$ | $$£$££££$$$$$$: | Bill | $$$£$$$$$£$$$$$$$$$: suppresses pi b ARrj to modulate p5?-3ependent £$l$p5$$^p$££$$££$$:$: $£$§$$/$$$$$$£££:$$$ $£££$$$$$$$$$$$$$$$$$$$$$ | mir- 200b | breast cancer | down | Regulation of the MicroRMA 200b (nuRNA-20i!b) by transcriptional Regulators PEAS and ELK-1 Protein Affects Expression of Pil’d Protein to Control Anoikis. | $$£$$$: | £hb£$$$l£$i$:$:$ carcinoma | dov n | Metip Jatmu-aos^viated stiem Ute ui mi 'roRN Ain hepatoecBular carcinoma |
$n£$$$$: $Ol$$$ ion | mesenchymal | uni | miR-29 Aits ns a Decoy in Sarcomas to Protect the Tumor Suppressor A2n mRNA from Degradation bv Dust | 200b | breast cancer | down | miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. | $£££$$:$ BOl£ | $:!££g£an£e£$:$:$:$: | down | Dt\ tiopmeft· of a lung ::eancenthefSpeutte:bas$d:on·:·:· $£$$$$;$$$£$$££$:$:$$ $££c$RMA$$L$$$$$$$$$$$$ |
ιι:η· I2?!> | ualoreotui cancer | lie | $$ii£$RNAte$££$££h££:$:$ profiles inhuman eOtorectal $$£$$$$£&£$£$££££:$:$:$ $£$idk$S$:$:$:$:$:$:$:$:$:$:$$: | mir- 200b | cholaugio- carcinoma | down | Direct targeting of SLZ3 2/ROCK2 by miR.-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. | nm- | $££$$ite$£$i$:$:$ lung «.arcer | dov n | MuteRMA- Nb funUtebs as a tumor suppressor and acts as a nodal point in the feedback loop with Met. |
$££$$$$: B|l|l | bladder cancer | :·£$££$ | MmroRNAte > tuhtbitz tin asion io bladder cancer vta regulation of zkD AMh | mir- 200b | colorectal cancer | up | nucroRNA-20i!b and micrcRNA-200c promote colorectal cancer ceil proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs. | $££r$:$$ BBl£ | osteosarcoma | dow n | $£$£$η£έ$θ$!£ΐρθ$$$£:$:$: roteted apoptosis-inducing ligand induces cytotoxicity spe^dra ό osteosarcoma by ££££$ί^Α££$$:£$££££$:$ $$£$£££$$$$$$$$$$$$$$$$$: |
$££$$$$: | breast cancer | down | •:Ei’4otheltahppeeifiOiHtrom-:·:· derived miR-i2b is dow»rcgtrlaietf irt human breast cartecr and terpen bml. \B;GEAandPiK5R2 | mir- 200b | endometrial cancer | -1 up | MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MM3’2 activity by downregulating ΊΊΜΡ2 in human endometrial cancer cell line HEC-lA cells. | $££$$:$ :|B^I | ox a· ran vd»-Ci | $£££$$ | ::Froqt<ef!i:dOWlKO:guladoni>f:·:· miR-34 fattuh tn human $£$£fi$i£h£$$$$$$$$$$$$:$: |
$££$$:$$ £θ:$:$ | colon cancer | dOwft | Expression of n«R-f'2.6 smpprasses migration and im asten of colon cancer edisba fa. r\( Ri | 200b | esophageal squamous cell carcinoma | down | miR-200b suppresses invasiveness and modulates the cytoskeletal and adhesive machinery in esophageal squamous cell carcinoma ceils via targeting Kindlin -2. | $£££$$:$ BOl£ | $£y£fi$$$$$:$:$:$:$: $££$$££$$$$:$$$ | down | MioroRN.A-3-i-h and MieryRNA-3-L; are targets of ppt and corporate m urotroi of <cB proliferation and aJheteiott-sndependcnt growth |
UU1- Βί?Ι$$ | $$1$$£££$$$$$:$:$: | :·££££$ | $j££ft$$$£&$$£$q$$$$$ cartecr proBteratron and invasion through targeting m,$l. SLC>A5 and TOMl $w$$$$$$$$$$$$$$$$$$$$ | mir- 200b | gastric cancer | up | MioroRNA-200b Regulates Cell Proliferation. Invasion, and Migration by Directly Targeting ZEB2 in Gastric Carcinoma. | $£££$$$ £?l$£| | $$$£$£$$$$$$$$ $$.££$$$$$$$:$:$:$ | down | AhcroENA roiR-34 inhibits human pancreatic cancer minor muiadng ME |
$££$$:$$ | colon cancer | dOwft | MtR-12o suppresses colon •:caHcer$eh:proide-rafio£i:aiid·:· £in£a$!£r$$$:i$Hb£ih$££$::$ RhoAdiOCK signaling $l$tl££O$$$$$$$$$$$$$$$:$ | 200b | gastric cancer | down | miR-200b and m.iR-200c as prognostic factors and mediators of gastric canc er cell progression. | $£££$$:$ BOl£ | /£££<00$$:$:$:$ $£$$$$$$$$:$:$$$ | down | MioroRNA-S-i-h inhibits $p$$i$i$$;$t$i£££££$$:$ $££$$£££$$£g$£££$:$:$$ repressing SmaJ?, |
$££$$:$$ Bliii | $$$&$$$$$$$:$$ | $&·£$£$ | $£$£$££$$$$$$$$$$$$$/ £££$£>O$$£££££££££$$ $.$0$$£$$£$:$$$££:$:$:$ prognosis it· colorectal $££i0$$$$$$$$$$$$$$$$$$$$ | mir- 200b | glioma | down | miR.-200b as a prognostic factor targets multiple members of RAEs family in glioma | $££i$$$: ίΟΪΙί: | papillary thyroid < $$$$£$£$:$:$:$:$: | d«w n | $Mio$R£LA $!$$$££$$$$$$$: disfiugut&hes the degree of uteprossivenvss oi papdkux thyroid OsfOUiOma |
$$££$$$ £O$:$: | colorectal cancer | down | Down-rogufatmn of miRLed expression ui colorectal cancer and ns eluiical $£$;$$$$$$$$$$$$$$$$$:$: | roir- 200b | glioma | down | Decreased expression of microRNA--20i)b is an independent unfavorable prognostic factor for glioma patients. | $$£$$$: :|£l|£ | prostate cancer | Jon n | miRNA* «Φ -nh-hitz pro state cancer through demethylation. active chromatin modifications., |
116
WO 2017/132552
PCT/US2017/015417
//til////://: 330((((( | wRmevtal camel | :/333(3(: | bplCOtOcW llciwtgcd n8R*f?8coniributes tn tumor invasion and ::angiegef!esis:in:Ci>ioiect:al:·:·:·:·: /te&lO/////////////////////////4/: | nsir- 200h | glioma | down | :TtiiR-200h suppresses glioma cell invasion by targeting PROMlj. | 4k«/7://: (333(((( | uveal inelaiteiua | dnv n | MiemRNA-Ab'O suppresse* meat mekmoutn //33(/338188/38/(8843//////////: ::nuglUt£OnrdKOuah:iriuitipie·::·: 7teO/k473737373737373/777 |
:/8018////// 330((((( | cc.loreetai cancer | dc-wo | MicnaEN/A-i’o functions as a tumor suppressor tn coiymctei cancer cells by targeting CKC R4 \ ta the ART and ERki/2 signaling pnihwiw·· | mir- 200b | hepato-cellular carcinoma | down | The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma? | 488////7 :(333:((((: | hieast cancer | down | The Regulation and (^8:838.84/.8/8(^433-///////////: //88X8/8/333.75888////;/////// Signaling in Breast: Cancer. |
mtt- ((0(((((( | esyohagcal cancer | :/3333(: | Differential expression of nuRNAzin esophagi: /h3iO3i(O;//////////////4////: | nsir- 200b | lung adenocarcinoma | down | mrR-200 inhibits lung adenocarcinoma cell invasion and metastasis bv targeting FltL'VEGFRk | mu- :(333((((( | bieast cancer | dnv n | MicmRNA- A suppresses breast cancer im asms and metastasis by directly :/00^3:^01://////////////////: |
/:88/-/////: ((0(((((( | //^0p8^3!424A:4:4:4: 43333(348/8/8/4/////// 433/((308^3434///////: | /:33(33/: | insulin receptor substrate* I and Golgi phospfeoproieto 3 am downstrestu targets of miR?l2d in esophageal squamous cell carcinoma. | mir- 200b | malignant melanoma | up | MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. | cZBr///// Tty | breast cancer | dow n | b -.press-on N tusk-A? induces G2/M cell cycle arrest inbreast cancer cells |
/:888/////: ((0(((((( | gastric cancer | down | miR-128 functions as a 3(3/333(:3333(3((33(3((((((((((: btnnari pawns cancer. | 200b | mesenchymal cancer | down | MicroRNA Expression Profiles in Kaposi's Sarcoma. | /:/88/4/ 3333((((( | /8//088((((((4////// lymphocytic 3:130/333(((((((((((: | down | Epigenetic tnactuat-bnof 3r/ft3-3:4b.G 3½ 333//½½ (3(((((((: (:33W333/^:i/^/W:8/(((((((: • hhypb 8 mohu λ c 7i3/:O&£7343434343434343/ |
mtt- ((0(((((( | 330(333333/ ((((((((( | /I//:/ | (:83(3303(333((33(3(8((((:(( ς O\ ’ e\pres ,mr md eomributes to gastric | nsir- 200b | naso-pharyiigeat carcinoma | down | mrR-20oh Suppresses Cell Growth, Migration and invasion by Targeting Notchl in | mu- :(333((((( | 38813833(333((((((: | dnv n | Expression of P.8RG4 is ins: in colon cancer tvhiefc can he re-expressedby a |
!18Γ- ((0(((((( | 43330:33333/((((((((( | 33(3333 | ttuRNA-222 prohjotea ; Net .tv πρμο mJ metastasis by targeting /3di3p//O3(^^((((((((((((((( (:^3ii(34((((((((((((((((((((((( | mir- 200b | ovarian cancer | down | A mrR-200 microRNA. cluster as prognostic marker in advanced ovarian cancer. | /:888//// :(333((((( | ((8333(33(33((((((((( ((333333((((((((((((((: | down | MiR-;A uligonuctcvbde enhances 8ΐΛΐηοζεηζΐΐΛ rtv ((83:13388½½ :333d8/0kp!848//: by inducing apoptosis |
/:8884///: ((0(((((( | gastric cancer | down | Rltr-i2t> inhibits growth ef ((iOO3j(00((((((((((((( <iPergt ttcslb tatcetnig the oncogenes Pl IKR2 and (:/3//883333(333(3/((((((((((((( sujt-nrcss'.n :d.K.· | 200b | pancreatic ductal adeno -carcinoma | down | XMD8-92 Inhibits Pancreatic Tumoi Xenograft Growthvia DCLK1 -Dependent Mechanism. | /:/88//4 3333((((( | endometrial (((8/(88(((((((((((((: | down | tniR-Sdo ploys a rede of ((158(3338.83(3338333(((:((((((((( BEC’i-B ceils by targeting 3ese3/333/33(((((((((((((((((((((: |
!18Γ- ((0(((((( | 433(0:33333/((((((((( | 33(3333 | 3003((33(03((((((((((((((:( espresstuit facilitates angingeoesi ol nsstnc (88(3(33(33333 3((((((((((((((((: regulation pa VEGF-A | mir- 200b | prostate cancer | down | miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer be regulating Brni-l. | mn- :(333((((( | gasttie cancer | down | Regulation nf uacmtubuleassoeiated protein fan .’MARE by mtRGacAp 3331/8/883/((/3/((((((((((((((((( ehetucseiisitn. 8' of gastric carivet rn paclitaxel |
488/7:4// ((0(((((( | gastric cancer | down | Mki»RNA-i2o inhibits ::e?liproiiferation:m:gastfk·:·:·:·: vuncerbr targeting f AT 1 | mii- 200b | prostate cancer | down | miR-200b inhibits prostate cancer EMT, growth and metastasis. | /:8817///: :(333((((( | xhmgCanceT:::::::::::::::: | (:/(8/8(( | Uncovering grew tbsuppressb’e MicroRNAs in |
488/////// ((0(((((( | 4:SgpatSeSlbii3f 4:4:4:4/ 000^(((((((((((((: | dc-wo | Decreased expression of a8R-l28 correlates with metastatic recurrence ef Itepomcehufar carcinoma. | mir- 200b | tongue cancer | down | MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells bv targeting BMIl. | 3333333((/3/3333(/3:33333(33((( 3/33:3//3333333333333((((((((((: /(0383^3885((((((((((((((((((( |
117
WO 2017/132552
PCT/US2017/015417
318.))8))))): | /:&OiO)i'48b)))))))) ))000))))))3))))): | )iO)?)): | ):0&090b&)0)))))))8) pmhlcratrort and induces Ifepatoyellniar cgncmoma ceils partially b> tameimg ))S8k2)))))))))))))))))))))))))))))): | mir- 200c | bladder cancer | down | Expression of niicroRNAs in the Urine of Patients With Bladder Cancer. | ):8iiii))))) ))||)))) | //hiditgkihi)))))))))): ))ί8έΝί) fifed)))))))))) | dnv n | Qveroxpies&ton of tire intRt( fattuh suppm^es /8fE)Vi^iV$;^^:8S'AS:^fiV888:::::::::::::::::: ηη·1ΐ2£'3£'ί roelatfoniu wrtb the wlld-iy pa p5> gene |
:)(8()9))))) | );malign3nt)))))))))))))) ))8)Ρ^8θ)ΡΡ))))))))))))); | :)O))))) | Cobipaoiive analysis of •Mlielaiioniadeioguhted·:·:·:·:·:·:·:·:· naRMAs ip. the medaU and \ipbApKrusj. -iww tell ..-.•a.t · murids | 200c | breast cancer | up | Direct targeting of Sec23a by miR--200s influences cancer ceil secietome and promotes metastatic colonization. | :)88(9))9 )ίό)))) | octio-pharyngeal ))^)8u)b)(ia)))))))))) | down | MiE-jdg suppresses tumor growth and metasias£S m nasophan ttgeal vanctiimiia )b^)td)^itod:MBi)))))))))))))): |
i!!U- | /OifOh))))))))))))))) | )ίθ)?)): | MiernRNA-i2v Suppresses EvRsNf dtottg MaitPiawv ):B)tOO^iiB|)id8^)))))))) //lO)feOg)O:h////:)))))))))))): •:Mk^fe»Kdaal:FeiKiipfi;·:·:·:·:·:·:· | mir- 200c | breast cancer | down | MiR-200e suppresses TGF-? signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB 1 in breast cancer. | mi:- ))||)))) | o&tcoaafcoma | dnv n | 3:M)R)34)):m^^ osmosnrcorua metastasis and 8harootesisfance |
38))))-///// | 00t'-SGiafi<etliu0g )888882))))))))))))))))))) | /OO/ | Expression. of roicmRMA miR-128 and rmE-fribeis ·:·9»δθΝ&ί?!ΐ:··Λίύΐ·ρί^ί105Ϊ$·:·:·:·:· tn patients wnh noii-swah :8θίΕίί^ίέ^ώΟώ$^88888888:::::::::::::::::: | roir- 200c | cholangio- carcinoma | down. | Direct targeting of SUZ12/ROCK2 by miR-200b/c ΐηίlib its c ho langiocarc ino ma tumouiigenesis and metastasis. | :/88897/9 | osteosarcoma | driven | Tutno r necrosis fac torrelakd six<ptc<StS-M'duCtbg ligand indnyes cytotydyhy specific tn osteosarcoma bv uiumRMA rwpnnpc t lame..!·. |
i!!U- | iioo-srnah ceil hag ))Ο^έ8)):))))))))))))))) | )ίθ)?)): | nnR-Umpiu'pna non-snath cab lung csmatneha preliktaimn bv targeting EGF!?. | mir- 200c | colon cancer | down | miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB) | mi:- ))||)))) | ovauan, cancel- | dnv n | Fiequed do w «regulation nf unRGn family tn human ))0)^))^:388^)3))))))))))))))))): |
8))88.////8 | nu8-m»il Nli bmu ))0)0)))))))))))))))))) | ))888)87 | tniR-Cfi enhances the sensitivity of rxm-smah ^eB //iO:OOOBO))))))))))): aafk^ncersaents bj :/:O$))^AO0i/:)))))))))))i)) endothelial growth factor A | mir- 200c | colon cancer | up | The roles of miR-200c in colon, cancer and associated molecular mechanisms | /:18)(97// :)/))18))))) | ))b9arih8)))))))))))))) //bdlhihiikA/)///:)))): | dww n | MirtoRNA-N b and MteroRMA·.arefargets of p53 and cooperate to criiitroi of cell proliferation and adhysinit-indepeitdeni ))|kAf:h)))))))))))))))))))))))))))) |
liar- | ))0800i:^i!i:h0)) ))O$^8)))))))))))8)))))) | )ίθ)?)): | ):Μίώ)Ο^)Ϊ2δ)ί!®ίΟ))))ί)) tumor cell growth. and its expressron le vri evfrelates with pc-or sutviv al ui noa- t^iiO/////////////////:))))))))): | mir- 200c | colorectal cancer | down | iniR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1 ’ | mi:- | )^^ί^8ίκ):))))))))) ))&O)))))))))))))))) | dnv n | MuroRMA msR-M inhibits hnniaii pauereaoc cancer 3))))0))8:))^ |
:))8))9))))) | non-omalt ceil bag ):OO)))))))))i)))))))): | Jowa | Use of Eumlnev xMAF )^ad)h3$^EB^SkSi8B)))))))) //8i(p9/fy8d^8:T:i:ti^))))))))))))i) tissues and its clinical utiply.jriun | 200c | colorectal cancer | up | MicroRNA.-200c modulates epilhelial-lo-mesenchymai transition (EMT) in human colorectal cancer metastasis. | :)88(///// )ίό)))) | prostate oorieer | down | tniR~34o is doworegu Voted ):®;jl^^:8^i)(:i^))))))))8 exerts tnmor syppressrvy ):fii8ch))ris/)))))))))))))))))):)))))) |
UUf- | oral squamous cell ))OOO)t))))i))))))))) | /W///// | Pwutresulatmo of naRi?Mndtrt\.s angiogenesis and iyropbaogrogeitesis b> activation of V£GP-A in /:fiiai/i3ik$i///////////////////:))): | mii- 200c | colorectal cancer | up | Plasma mjR-200c and miR-lSa as potential bioraarkers for the detection of colorectal carcinoma. | till!· :)/))18))))) | uveal melanoma | dawn | /MicipROOhA))))))))))))))) suppresses uveal nueiattrima /•cNOblifeidtO-dhd))))))))))) ::iffl§raiip£i:tiffoagh:muifryle·:·:·:· 8)aOte//////////////////////////// |
118
WO 2017/132552
PCT/US2017/015417
//irith-/////: ;;IB;|;| | oral s<giamon& coll | 3d8Rri;/ | Suppressive effect f microRNA-12o or oral squamous cell carcinoma w 38v?iiixi!/888888888888888888888888888888: | mir- 200c | colorectal cancer | up | triicroRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich nrotein with Kazal motifs. | 3&«3//// Me* Bill; | doo n | DdTetenliaf effects ofttyR3R* φ and raiR-Mv-Ap the prcltferaiiOR apoptosis /;;^:^^!^;Ο;§^^:3:3:3:3 /^^^15555555555555555555555555555555 | |
ΟΡΟ////: /|;B|;|; | osteosarcoma | dOnft | Mt r<R\4 '< tnrb t osteosarcoma cells proliferadonbr targeting | 200c | endometrial cancer | up | The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. | BBII Bill | 34c-3p and nuR-34c-5p on he vrcftKntrcm apupkzt m>l ir.v<.s.on Λί ebook· cells | ||
IUU- ;;IB;|;| | osteosarcoma | 3d8Rri;/ | miR-lzb fuuettona as a :8^iaGif:£ii:i^>i^^^3ja88888888888:: osteosarcoma by targeting T^ii>N;2;888888888888888888888888888888 | mir- 200c | gastric cancer | down | miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression | mu- BBlI Bill; | ;/BBBIIBI;//// hmg «.atver | doo n | cireuforing miR *381 *3 p and a«R-62$A as blood-hasod markers for discriminating minaligngni from benign lung:·:· /5^^3^^/5555555555555555555555555555 |
ΟΡΟ////: /|;Β|;|; | pancreatic ductal /^grto/iRRttkmh///// | dOnft | MtcroSNAs Targeting Oncogenes Am DownRegulated tu Pancreatic Maiignant Transformation from Borage Tumors. | 200c | gastric cancer | down | The downregulation of miR·· 200c/141 promotes ZEB 1/2 expression and gastric cancer progression | bbii Bill; | colorectal cancer | down | MiR -3o 1 -5p inhibits colorectal and gastric ;5/ic;rifpdkjr;/^fkiY;ii|^irici;555555555555/;/ me ta 2 ists by 'tope «no staph-, Jo -0 .cal Puckast dot-jam cotaamtog J |
i/ihiG///// /;|;?Ι|| | renal ceft earcinowa | //8θΑΡ5 | E vw F vprcaarct. of utiR* f?n la a Rmgnosiie Marker feu· Metastatic Clear ( eli Renal Cell Carcinoma. | mir- 200c | head and neck squamous cell carcinoma | down -1 | MicroRMA-200c attenuates tumour growth and metastasis of presumptive head and neck, squamous cell carcinoma stem ceils. | :/feii$://3 338*3/// nil; | gastirc cancer | don n | 8MiRs3bf83p;:itoikik3;///////// colorectal and gastrin ;:;|BBO|l;Bl||;||| metastasis by 'prgetmg stapht k-.o-.cai uncieaie domain cotfaniittg-J |
;/Ρΐί0////// ;Ι;$ΙΙΙ | small cell lung /8O^$t:88888888888888888: | down | /touRylltiaidiipdb;/////////////// prold'etadon of small cell IW’p.'jkerMfzbv targeting SLC7A5 | mir- 200c | hepatocellular carcinoma | down | Expression of mic roRNAs, miR21, miR-31, miR-122, miR-145, miR-l46a, miR-200c, miR-223, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic choiangrocarcinoma and its progno | ;/OM;:^//;///////// 3030^/333333 | /:0///// | /AparigiPf ;ri3e;sdto;^;///////// ;3^Bi|^^;h;Odridhi////^ diagnostic mol for eariy stage rcraf ceil carcinoma | |
3imi3;///// ;Ι;ΒΙ/Ι/ | nyti-snujil cell lung /8O^$t:88888888888888888: | down | vCltmiial/^'-hldditdtoPfTTTT:/ muroRMA ecpressmit profiling nt ttoit small eeO 83iifi/^:CPcri^t/888888888888888888::::::: | mir- 200c | hepatocellular carcinoma | down | Expression Profile of MicroRNA-200 Family in Hepatocellular Carcinoma With Bile Duct Tumor Thrombus | 3fmf8:/// 362- ;ll;;/;/ | gastric cancer | II;//// | Erratum tri, A_ntr-miR-3o23p Inhibits Migration and ItAUsrcnnf hlunaip Gastfi. •'aocericlkbv Itziirget Cl.«8 2 |
USH- ί?.6*5ρ | :30^:^81.^0^^388888888 /8!/^^:^jdi^:888888::::::::::::::::: | II//// | :3Ϊ^ί·^^}^Η^ϋ$€:3888888888:::::::::::: mrcroRBAM ?d*?p n associated with drug resistance Ocy-ambine and 7piiitiiitkATTTTTTTTTTT:/3 | mir- 200c | lung adenocarcinoma | down | miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Fltl/VEGFRl. | 83!· 382* 1111; | gastric cancer | up | Atin-miR-A'G- 'p Inhibits Migration and imasionof Human Gastrin Cancer Cells by Rs Target M |
yumy///// zzl-gUOp;.;.;. | renal ceil carcinoma | |||| | Genrsiern downregulates· onco-naR-ldoiib and | mir- 200c | malignant melanoma | up | MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion | ’:::ίήίί32:2 3ί·,2- ;ΙΙΙ;Ι | //hBOBB&l;//// //eafpmpfha;/////////: | II;//// | Upregulation of miR-3o2~ ::3p:modu!aies:proiifeiption·:·:·:·: and aiivhvfave-tt.dcpendet.f gtuwthbv Jirc-ib targeting Toh? tn hepatocellufor ;5;qiii^iii0ii;iii/55555555555555555555555; |
119
WO 2017/132552
PCT/US2017/015417
/:(ΐ2«3/://// lhA | 7223223322033///////// | 2(322322 | rniR-lzfP-cp anti maR12ob suppress gastric Cancer growth and invasion by targeting telomerase reverse. transcriptase. | mir- 207c | malignant melanoma | down | Differential expression of microRNAs during melanoma progression: mi(R.-200c, miR-205 and miR-211 are downregulaied in melanoma and act as tumour suppressors. | /:(333//// 2222322( 2B2222 | //232322222332233///// carcinoma | 32032222 | MteraRMA-teNop promotes tiwfivr grow tb and ittetasiask by targeting CYLD in hepatocellular (323233333321//////////////////////// |
3:7333:3:3 1269 | hepatcteelktlar (((3232223223/////////////: | 3(232(22 | Unregulated MiR-1277 io. 232332203220222223222/ aud its ciinieai significance, | 200c | malignant melanoma | down | miR-200c Inhibits Melanoma Progression and Drug Resistance through Down-Regulation of Bmi-l. | :/337/://( 2022(2 | head and heck 7222223222:223222/ 223232232222////////// | down | DyStegolated in.R-AA 223^32:32:32233(2322(:322233(222222222: cancer invasion and ox to g jsjs hv trad (:::p0dd(2f3i727(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: |
mu- 320/23 | (((32223222232122(//////// (/22322222222/////////////: | (321222 | Micrc>R.NA-12vQ promotes pro-iteration in human liepafOcolhdar carcinoma via Bowritegmafioo of 2^0122222222222222222 | mir- 200c | malignant melanoma | down | miR-200c/'Bmil axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. | mu- 7'5 | 22323222222322/3222222 | dote n | nuctoRNA-JbA downregulated tr colon cancer. (/(:(23233322(2231/22222////////://////( progression and promotes apoptosis of colon canter ceils b\ probabh targeting Cvcbn 01 audBcte? |
:/377/://// 1269a | colorectal cancer | 231222 | miR-12bO promotes metastasis and Joints a poom c teedb xk foOu n nh Ί <A-: | rnir- 200c | mesen-chymal cancer | down | MicroRNA Expression Profiles m Kaposi’s Sarcoma. | (/377(///: | 222323222232233232222: 2232322222232222222222 | 233333/( | Prognostic sagififieaiiee and arra-prnhfcratimi effect f micraRMA-kA m hepntocelhdar .'ammoma |
mu- /1223333 | /(32202222323////////// | 2(322322 | MjciO'-MA-G' is Dowttreguteicd 3> dlsttevSN Protein and ContnJmteir :((2ό:?3232ίΟ32(233(//////////////: (:(3i73£3r(3id7/r7(Bi$33///////// C ancer Cell Line MDA- /(02/32/////////////////////////( | mir- 200c | non-small cell lung cancer | up | Expression of microRNA miR126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. | mu- G5 | 22032 2 2 2 3 222222222 | dote n | MroroRMA- teA regulates NK''» Ή < kc\ uxdts'oro’ (/32222(222222//////:///////////////( |
:/377/://// 2Bl3(32 | breast earner | down | mrR 12 RegybtesCell 22j2iRo37i32(0///////////////: Senescence ip Targeting 20122222222222222222(22 | rnir- 200c | non-small cell lung cancer | -j up | High expression of serum miR21 and tumor miR-200c associated with poor prognosis m patients with lung cancer. | (/377///: | 7(133/57/23(222(7///( 22032 2 2 2 3 322222222 | /(33333/( | (((2223222232332(22///:////////////// deregulation ofn77?b5 and ns target mRNA TTF-1 and survival tr patients with NMT C |
Ρ7Γ- (32222222 | ((((2203(233222:////////: | (/:23/22(/ | (:(T33/T73i7r(S73p3?^22///////: Rotes of mrRMG and nuJG 127 in GaSdriO Garteef | mir- 200c | ovarian cancer | down | A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. | 73777:(:(: AAh- 22122222 | reiioo-b-lasloma | duwu | MriC tiAb-Jp, duwuregitfatedin teimobteiioma. regulates cell cyclo :·: progression urid:apoptos7·:·:·:·:· of human teitetoblastuina cells bt targeting RA» |
0(077/777 2(221(222 | (23333222022/(2/(2/ 2232233 2/3/////////////: | down | A Feedback Irdnyitlon between nnPN k KN and (2t132O32322W332:322///// /33tete(3te!:i:22i8gi3ti07(33//////: | rnir- 200c | ovarian cancer | down | Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. | 7377:7:(:( 2233/22( | gastirc cancer | /(33333/( | 'Ti»- ro ctoR>tA >'? Inhibits the Iro asion and Metastasis of Gaatnc Cancer bv DitecOv Repress..suRg,.:.'· |
Ρ7Γ- (32222222 | (233/3222022/(2/(2/ :/2222222223/(2(2(2(2(2(2( | 2222222 | ((((M2332WO22(:222222/////////: /20220323^2222222222 Ddwttteg.nafds Sept? and Suppresses Cell Growthm Hepatocellular Carcinoma 22^1111111111112 | mir- 200c | ovarian cancer | up | Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. | mir- | 2(223322222:2/:2/:2:2: (/(322222222222222/ | np | 2((32(033(:32223223232222222222222: cp'thdteiAu-mesn, bvma! transition and tm nsioo of (2322322233322(3323^//////////////// adenocarcinoma eelk by targeting the Smad'NTGF-? signalling pathwdv. |
120
WO 2017/132552
PCT/US2017/015417
GRinA::::::::: 1 27 Ap | (;giibbi^tepia((((((((((: | 377333 | (:AO3WO?33(k(((((((((((( promo eaNto-tii·» om< el mlgrat-on and tevasiou h> ((tgiggtikg 377 37^7(((((((((((( suppressor gene SEPT7. | mir- 200c | ovarian cancer | up | tniR-200c modulates ovarian cancer cell metastasis potential by targeting zinc finger E-boxbinding homeobox 2 (ZEB2) expression. | :(tiui$(((: Rti- 3373333 | psucieatb. dtKtal atieuo-caminuma | 37733(3 | •'irculutmc MuioRi-As ra Serum of Human R-ras Oncogene Transgenic Rats W-tfcPai-vteaa., Duvtel Adenocarcinomas |
Gffiik-:::::::::: (133173 | ((gliNiia$ibmA|||||||||| | dowo | Next Generation Sequeocuig Analysis of ;|ni^NA$(;M:lR4i2j(Gp|||||||: (0&73θ33θ303((((((( I'Toliferattonand Activates TCSP-5 Signal-light* | rair- 200c | pancreatic ductal adeno-carcincma | down | XMD8-92 Inhibits Pancreatic Tumor Xenograft Gro wth via DCLKl-Depeudent Mechanism. | Oiaif-TT: 3337((((: | aeute myeloid ;(:!£dk4ini4((((((((((( | 3773(33 | Integration of SNR and (:PiRNA;ti^y5:Rith((((((((;((((: na^roPN k piofdrag reveals that MiR-3 ’! is unregulated and mtu-os MR1 in acute myeloid |
Ckiife:::::::::: ((§W3 | osteosuioonta | ((doteh: | Mb. CORN A-Ί 9te>- :p is tic-wmegubteti k- human «steoaareoma and regulates coli proliferation and (:ira(tigi^(((((((((((((((((((((((( | mir- 200c | recta! cancer | up | The quantitative analysis by stem-loop real-time PCR revealed the mi.croR.NA-34a, microRNA_-155 and microRNA200c overexpression in human colorectal cancer. | :(kti((((( (:337:(((( | bladder cancer | down | p2ft W.AFl/CJRJ) by /(pii7.?37^:777di^((((((((((((((((( ((Ctiti£bi(C£7^((((((((((((((((((((((: |
3371333 | gastric cancer | down | nuR- 12Ή ReKula’es (7θΐ33737^Ο38έ(όί((((((( BimaoGiS-i (M\er<eff Une&hv Targeting IGFJR •RSkmTfM aod J3CE? | mir- 200c | renal clear cell carcinoma | down | miRNA profiling for clear ceil renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA. dysreguiation. | (:ititi((((( 37ti | gastric vixicei | 3773(33 | 0' eip vpressron of miR-3 Ti and ilowurcgubtiivn of hs ntu-lfarget f- ,R'-R.fi coatr-bute na the pmgre siOt-e-fgaatil? ((caRiik!tiia(((((((((((((((((((((((( |
:07(::::::::: | bepu4/'v‘N!nl3J· Tbdkin0ia4|||||||||||||: | down | A functional screening controlling glj piyan-T l337i3(8i:3k7-303:730((((( rcgulatwra in hepatocellular $£4001332((((((((((((((((((((2 | mir- 200c | renal clear cell carcinoma | down | Genome-wide rnicroRNA expression profiling in renal cell carcinoma, significant downregulation of tniR-141 and miR- | ό&ίίΤ::::: 3337((((: | gastric caneer | 377333( | HpreguJat ton of miR -3 7d i(i^^!ii^^i$;7^((((((:((((((((( progression of gastric carcinoma via suppression ((^1^07((((((((((((((((((((((( |
SOU* (113333 | (kteS(hiOO(((8H((( ((b?.kiii0jteA(((((((((((((: | (((Oii( | intR-1271 inhibits QSCC cN! gtvwtbaiid metastezn by targeting A31·. | mir- 202 | follicular lymphoma | down | Targetome profiling, pathway analysis and genetic association study implicate rniR-202 rn iymphomagenesis | mu- 3337((((: | ((h4pktb$blltiigt(((((: esmtooma | dm? n | •vrintbatron Ή mil· : !Ν?8Α-ΝΤ-'Έ i-egtilumty cireuit contributes to the ((»f^b!bk0^77df:2(((((((((((::::::::(: nepatevelndar eaminoioa |
Ghiife:::::::::: 33733333 | gastric cancer | 377333 | iK rote ui mrtuPNA12 74a in die tu-noilgeiieS-S (;tii(:^Oc(3aiiOpr(((((((((((((((( ?v ckrtuig racvr elf proliferation and migration Matf-rem·? ta.c'tnp roxo-i. | mir- 202 | bspato-cellular carcinoma | down | rniR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 posttranscriptionally. | ό&ίίΤ::::: 3337((((: | ((O^b?.f((((((((((: squamous «.ell ((^Rmptiia(((((((((: | dm? n | •wR-f''tsriM'd I j\MI functions as a tumor suppressor in laryngeal squ-unus «.-Uuvumua (((7s777((((((((((((((((((((((((((( |
!UIi- ((0(33(( | acute bn<phobla»iiv (:i0O33((((((((((((3 | 337333 | Ibs'-nmi mu-'ft*’ k signature ss n>so«.iated with the diagnosis aod prognosis of acute leukemia | rair- 202- 3p | colorectal carcinoma | down | MicroRNA-202-3p Inhibits Cell Proliferation by Targeting ADPRihosyiation Factor-Like 5 A. in Human Colorectal Carcinoma. | mn- 33373((( | ((0((11:^4114^:(((( ceil caremoma | down | miR-P modulates inaulin ((ίΒίΑ(^0ίτ(^:73ί^(:3(((((((:((((: expression and inhibits the turner phenotypes of oml |
CkkiG::::::::: ((0(33(( | acute myeloid | 377333 | Distinctive: tnicroRNA •:S£gnUtere:£SUP&Uoiate4:witil·:·: ::tL«iliagriosis:a!adpro:gnosis·:· (;^:^^ί^;ϊ^όΰΐΐίί^^;3((((((((((33; | 202- 3p | gastric cancer | down | Decrease of ntiR -202-3p Expression, a Novel Tumor Suppressor, in Gastric Cancer. | :(ktif|(((( 33333((3 3373333 | ((S^jdiri0sl!tii3ti(((( ((^Rmptiia(((((((((: | 377333( | (:pii^4?f($^4oRb(((((((((((((( ((f$giii^$:^:£777?7((((((((:(((: pipvesstr-gfav'-oi 4 bomoiog B tPRRRBJ and (:40iO^:7^(G733(((((((((((:(: bansttion. in human nepato^elni-ar eauu-pma |
WO 2017/132552
PCT/US2017/015417
:/:/O||||||||||/|/|/ | |||||||||||
/:/htiis/$/$/:/ Β/^Ϋ/:/:/:/ | pbnblnavma | ///doji/h// | Mnro-RNA-l ?h itrnKMA13.8) clown-fegulmaon in gliybiastomo targets ARE? iANGRih/’.Bini-} and BiF-Ja, key regulator* of brain cell probRraticth | mir- 203 | basal cell carcinoma | down | MicroRMA-203 functions as a tumor suppressor In basal ceil carcinoma. | ///feiri·//////// | utn nai cnu<rr | down | MicmRNA-3'72.is dvwo* /:/reghihte^/:hi^:Dr^etg/:/:/:/:/:/:/:/:/:/:/ cy dm-dependent kinase 2 (C PE2 ’ and vSvhxt Al in humanccrvual xatu.cn wfneb may contribute to $iuiiktfi/^biib3lk$$$$$$$$$$$$$ |
HlU- :/:/0/:/:/:/:/:/: | //glmbh^tpiixh///////////////////// | /dpO: | cfownregtilniion of wsR-rt jjew insights wio HXrf signaling in nk'-Obsioma | mir- 203 | bladder cancer | down | inicroRNA-203 suppresses bladder cancer development by repressing bcl-w expression | mu- /:/3/72////////// | /$epUiisi!gi$/$/$/$/:/$ ovarian cancer | /0/:/:/:/:/:/ | /;/;i3:ri«fSG^^E/ic/t/iG/ii/;/;/;/;/;/;/;/;/;/;/;/;/;/;/;/; microRNA screens identity n<fB - W 3a mpsbiiftg ptokfemUoi' and apoptosis in opttlielm · anan xatxer 2^33232323232323232333:/: |
/$iiai:-/:/$/$/ | /igil^lPStSmhkkk///////// | dow it | KiiR-l2« and mlR-i-tp Uietnosur&hiYny of tcmo?oiciundoby BnplBmedloteri eyhoskeietal ::renioaeRKg:tf£gl!»t<laste!aw: | inir- 203 | bladder cancer | down | Curcumin modulates rnic roRNA_-203-mediated regulation of the Src-Akt axis m bladder cancer. | ;O;|| | ::-3?2<upregaia!iof!;wiihpoor·:·:· prognosis hi human glioma. | ||
/:/htiis/$/$/:/ Β/^Ϋ/:/:/:/ | ///gilOi/$/$/$/$/$/$/$/$/$ | ///doji/h// | MiR-i28 inhibits fumor :/:/1/3^^1^^:^7^^:^1:/:/:/:/:/:/:/:/:/:/:/:/: | mir- 203 | bladder cancer | up | Micro-RNA profiling in kidney and bladder cancers. | ///feiri·//////// | bead and neck squamous ceil eamt&oma | :/3^:/:/:/:/:/: | nnR*3?2mhthit>ph2 in head and neck xpaftxus ceB carcinoma m -Jim and /iih/$i$d$$/$/$/$/$/$/$/$/$/$/$/$/$/:/ |
$/hhi$/$/$/: | /:/:g}i^p3:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | c/d&o/ | Proteoinic screening and //ridehiiO nucioRNA-128 targets in /όίο/ϊέί^ | mir- 203 | breast cancer | up -1 | Anti-iniR-2(!3 Upregulates S0CS3 Expression in Breast Cancer Cells and Enhances Cisplatin Clieniosensitivity. | $ihii$/$/:/ 373. | hepatc-ceihtlar eamt&oma | /0/////////// | :/:/U^gOidh/bf$/$/$/$/$/$/$/$/:/ micmRNA.->72 associates :·:··Λίύΐ4υ«ίΟί·:ρΐΡ81«Ρ610η:·3β(1·:·:· prognosis ai hcpafueoihtlai $/C^iiihb/5h$:$:$:$:$:$:$:$:$:$:$:$: |
/ί/^|/|/ | biomarkcrfoi diagnosis of ///^1/0^/////////////////////////3 | 203 | Growth and Angiogenesis by' Targeting VEGF A in Cervical Cancer. | 372 | /$CdRih0ihk////////////////// | die vnvnnci.c Ai AP2 m mrhtencv hepnu-rcilular carcmmaa proliferation and $^0^233$/$/$/$/$/$/$/:/$/$/$/ | |||||
/0/^/:/:/:/:/:/ Β^ΫίΫί | ///gilOi/$/$/$/$/$/$/$/$/$ | ///doji/h// | Mn.roRNA-3 ?h inhibit* glioma cells proiB'eration by targeting transcription /ί^δίΦί/Ε^Ε3^/$/$/$/:/$/$/$/$/$/$/ | mir- 203 | cervical cancer | down | BAN/F'l Is Downreguiated by IRFI -R egulated M icroRNA-203 in Cervical Cancer | ///101/0-//////// | breast cancer | :/3^:/:/:/:/:/: | BiemuroRNAs nuB-373 and miR-?2f>c promote tumour tm asion and /3ηΟ2&2&2/2/2/2/2/2/2/2/2/2/2/2/ |
$/biii$/$/$/: Βΐ^ΫίΫ | ///giited^:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | down | 'larc-nmp Λΐ the Bmt-} «ncogerte'stem ceil renew ni ·:·£ηο·ΙΟΓ·Ρ¥·ΐηΐΟΙ·θΕΝΑ:-:Γ2«·:·:·:·:· $/mii&ii^ prouRra .onato Λ!τ· mutual. | tnir- 203 | colorectal cancer | up | Association of rnicroRMA expression with microsatellite instability status in colorectal adenocarcinoma. | $mir$/$/:/ ////30/////// | ///cery/tdai///////////////////////// eamt&oma | /O$/$/$ | MicroRNA-173 functions os an oncogene and targets YODi gene in fool 3/023^22/2/2/2/2/2/2/2/2/2/2/2/2/2 |
mu- | /$!$«U | 3ΜίέίΟ^^2«3$/$/$/$/$////////// dbwnrcguhtes Bax and mducex apoptosis in human embryonic kidney ceils | mir- 203 | colorectal cancer | down | MiR-203 Suppresses ZNi'23 7 Upregulation in Colorectal Cancer and its Oncogenicity. | mu- 373 | /$Ot/l/[/$0^:/:/:/:/:/:/ | dm? n | Epigenetic stiencmg of microRNA-373 plays an m^xtrtiuc role in reguhattnp eeB ptbiif'eratyxt in colon $/^/tWSk/$/$/$/$/$/$/$/$/$/$/$/$/$/$/ |
122
WO 2017/132552
PCT/US2017/015417
5ίίί«5/5//: Bllll | //hp^iO/hO://////// ί/^οο^^Βίίίίίίίίί carcinoma | 5iOO | inroctiotiis of MtRN A-128 tin the rognhmtia vi luad and neck squamous cell 5:<At‘iW3C(>fij^:g^:»Vi*;i:A3EiU:5:::::::::::::: ΤΑ^^ί^έϊ055555555555555555ϋ555555 | mir- 205 | esophageal adenocarcinoma | down | Deciphering the Unique MicroRNA Signature in Human Esophageal Adenocarcinoma. | 5riui/5/:5: 373 | //PigihPiiriLkkk:///: ovarian cancer | O||; | Τΐ3^ίύ4$^^ΕΪύ:ίί$ίΐ:888888888888::::::: uncroRNA screens identify rwR - W 3a regulating proliferation and apyptesis in epithelial · anan cancer |
OttUr-/////: B^ill | ]]akPiiWti?hk]]:5:5:5:: | down | Serum mioroRNA- J’S as a :btOnwherf(?£x)taaf£0£4S:(jf:·:·: 5:^ύό^ί^;555555555555555555:::::::::::::::5: | 203 | esophageal cancer | up | Alteration oi miRNA Expression Correlates with Lifestyle, Social and Environmental Determinants in Esophageal Carcinoma. | /:1811///// | esophageal //^wOki/r4l///i //tritemdrifo/////////: | Oil; | MicroRNA--? 73 (nriR-37 3) pos-t-tianacripiiynally suppressor h^mofog ' (LATS2) and stimulates proliferation inhuman esophageal cancer. |
:/iitik////:5 Bllll | ]:6^$6^fc$k^5::5:5:::5: | killl | MicroRNA- J’S promotes /•J^iifoiationaipk]]]]]]]]]]]]/::: osteosarcoma yells by | mir- 203 | esophageal cancer | down | MiR.-203 suppresses tumor growth and invasion and dcwnregulales MiR-21 expression through repressing Ran in esophageal cancer. | 5mif5///: /O///5 | gastric adenocarctnoma | ;0BI | MicroRNA-37$is upregulated and targets TNFAlRi in human gastric |
5pu0////:5 B|||| | 3Ρί0^ί5:03ίίίδΕ///8:8: | down | MkroRNTA-i2$ mritiOvS ftpnpinzuw. human embryome kidney cells | rnir- 203 | esophageal cancer | down | miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like ceils by suppressing stem renewal factor Bmi-L | /:idti/:5:5 '5?' | //bppatp$gJi^dk:5:5 //tritemdrifo/////////: | III! | MieioRNA-373. ρηρη phosphatase9*, function* as /:8^:0^0^89/1/9:3:3:3:3:3//////// hepatocellular carcinoma |
/:181155///: B;?lll | prostate caocer | 5:driteri5 | mlRNA-128 suppresses | mir- 203 | esophageal squamous cell carcinoma | down | MicroRNA-205 inhibits cell proliferation hy repressing ?Np63 expression in human esophageal squamous cell carcinoma. | /:181858// | aon-smull «.ed //hfogk^hbbf///////: | dtiw n | bpspeneti· alenunguf :8O88^A83?lki/9:8:8:8:8:8:8:8 ep.fheJiaJ mesencbx u .a! ::transitton:£n:non-:smalloeil·:·:·:· lung cancel through IRAK.2 and LAMPi avcs |
5puk/5/:5: !2S-3p | //i^M058i!^kk8:8:8: 5^i«kkttikkkk5:5:5 | down | nuR-i 2S.-3p suppresses heparocel hilar carontoma prottterat-onhy rrouirrog PIL :R5 and is <orreh:ed with the prognosis of BCC /^1^//////////////////////////^ | rnir- 203 | esophageal squamous ceil carcinoma | down | miR-203 is a Direct Transcriptional Target of E2F1 and Causes (31 Arrest in Esophageal Cancer Cells. | /:idti/:5:5 '5?' | ypakifidkk////////// //OO/////////////: | OiSkkkS | Micro RNA-373 Is Downregulated wi Raiteroatte ( «roer and lohtbn, 1 w 3G0|:i:h8d^bhk5:5:5:5k |
59518////// | bkvkler cancer | down | MicroENA-!28ti Inhibits invasion ami Metastasis by Targeting RGCK1 in | mir- 203 | glioma | down | MicroRNA 203 Modulates Glio ma Cell Migration via Robol/ERKMMP-9 Signaling. | 893858//: 37-ra | breast cancer | don n | Effect* of Differential Distribution oi Micro vessel Regulated bv iuiR-3 tea, on Dieast L atwcr Prognosis |
8pu0////:8 | :5^^^^5:5:5:5:5:5:5: 5irk^kPk:iaikkkk5:5:: | down | :Afttl-:-tomo:r activity ofmiR:-:·: I2SU in melanoma by k^^^.^^ip:jpi:S:ric5;5555555::::::::::::::: | rnir- 203 | hepato-cellnlar carcinoma | down | miR-203 inhibits proliferation of HCC cells by targeting survivin. | /:idti/:5:5 :/BBk// | gastric cancer | III! | unR-3?-la promotes cell :proliferalrom:imamtioii:ancS:·:·: no asnti. bt targeting -Rt IN I m gaariv vat. 'er |
5kni5:5:55 1280 | ]]ilpip-Siriaii:$SU::hiiig::5 //OoLiiiiiiiiiiiiiiL | i||// | ::VpreaoiaPynyf:MiR:-:h2:8ri·:·:· Exprosferon in Mon-small Cell J ongi'am-er Tissues | mir- 203 | hypo-pharyngeal cancer | up | Effect of microRNA-203 on tumor growth in human hypopharyngeal squamous cell carcinoma. | sipif///// 374a- iln | /:pg|p^ii:0fdd/:5:5: | :O||: | identification yf a plasma fynr-roicroRNA panel as puienttal roninv asn e /BbiiiiBB/fer/ 5:5//////////////// //ysisd^tePtea/5;5;5;5;5;5;5/////; |
39518////// | renal cell carcinoma | down | AkfOkk^^Ok//////////// mioroRNA-i ’85 regulates rand molecular targets 5:^^δίί^^ί:έ^ί$έ$ϊ<Ϊ!ΕΪ::ίΐίϊ^::::::::::: functmual significance in | mir- 203 | kidney cancer | down | miR-203 inhibition of renal cancer cell proliferation, migration and invasion by targeting of FGF2. | 893858//: BOil | prostate cancer | don n | Global ar-afy sis of the duierentjall' expr?·, ed naRN As of prostate canker hiGlmteye patients. |
123
WO 2017/132552
PCT/US2017/015417
renal veil carcinoma | |||||||||||
«•if· | 8:|ί^ύΐόέόΐΟί883838 | i«uh-12S« rs «p-remiiated tn bepatocNinlar carcutivtiiu and proinofcs bnnor cell prcihfsfatKai fc> -atgeting | mit- 293 | laryngeal squamous cell carcinoma | down | MiR-203 is dowrireguiated in laryngeal squamous ceil carcinoma and. can suppress proliferation and induce apoptosis of tumours. | 8riur8:38 97^ | rcrv sea: C^OW<ik83i:f383: eanUGoma | down | uiiR-3’9 is down-regulated m sipaamons cere rcai cancer and inhibits call 8j:rft^MmP8^:ih8hSiSb:8mC8 targeting transcription 3^bfeh:SRi8838383838383838 | |
3nuh3383 | Thk^d!idbla^ma38:8 | down | MicroRNA 12.8a increases virgiaceilular ROS level by : : 8^iO^:^«3itakdTTTT8:8 tnhufcits uterindoblastonto career cell growth by pnanKuing senescence. | mir- 203 | lung cancer | down | miR-203 Suppresses the Proliferation and Migration and Promotes the Apoptosis of Lung Cancer Cells by Targeting SRC. | 31911883: 8^5:383 | colorectal career | 3i$0i8k8: | Expression levels of 3:pkiip:feNA-:33$:iih83838383t colmectal carcirenrei |
3biii8838: 179 | 3bife^feSdg^:8:88888 | down | [The down-regnteiion of «uR-129 tn bieast cancer 8dbdtiik:b^cttoiibk^i883:3:3 8iik!itirt8i38383838383838383: | tuir- 203 | lung cancer | down | The expression and function of mi.croRNA-203 in lung cancer. | 3biii8:83: ΒΤ$:8:8: | • . . · ..r | dou n | 83debt^8^i0b:3^8383838383 functional screening of mreroRNAs highly deregulated in colorectal 3£kbO38383838383838383:3: |
3ffiib8383 | coloreotai cancer | down | intR-i 29 promotes :8jdj^jrii6^^fti38it:38:iU::$38888888:::: ibivtomuctl in colorectal career | mir- 203 | malignant melanoma | down | .Analysis of microRNA-203 function in CR£B/MiTF/RAB27a pathway: comparison between canme and human melanoma cells. | 8mii883: 8^5:383 | colorectal cancer | down | MicmRWA-375 inhibits colorectal cancer gre n th by targeting P1K3CA |
uur- | Tg{^!h^p^TT8:838 | 8dbO | premrewr Ma roRNAs idetmiies MicroRMA? 8^$^i^:^i^q^8TT888:8 3^hfeihi:!bh83838383838383 | mit- 203 | malignant melanoma | down | MiR-203 inhibits melanoma mvasive and prolif erative abilities by targeting the pclycomb group gene ΒΜΠ. | nm- 97^ | esophageal :3έ^έί888888888: | down | P oigeuetrc siienciwe vi ntreroPNA-3?c regulates PDKJ C'.prcss.onm. 8:^0^^3ik:Odi88383:3838 |
8ibii8:::8:8 BOBBB | non-oiitall ceii lung 8cbji3sf88383838383:3 | 8:dW:d:: | MtR-129 regulates iviMP*/ to control metastasis of non-small cell lung cancer. | 203 | malignant melanoma | down | Anti-oncogenic MicroRNA-203 induces Senescence by Targeting E2F3 in Human Melanoma Cells. | 8hiif88:3 327^333 | 8bs$^b3^edf83838: 8bOsf8383:38383 | down | I be C · preSSion 01 n uR 7 I prognosis of esophageal 3£khO38383838383838383:3: |
3ffiib8383 83:it83838 | gasirtc cancer | down gCCCCCCCTC. | Growth ioitibitoiy effects of T;tiU$S8tjiii^Ai^^:i^iiii!i>'8888888888 members on gusfnc u«cvf | mir- 203 | malignant melanoma | down | MicroRNA-203 inbib its malignant melanoma ceil migration by targeting versicau. | 8mii883: 8^5:383 | esophageal CtOlbbh;dCC3:3:3 | down | Circulating mreroRNAs «. plasma oipaoerts with oesophageal squamous ceil 8:8dhdiik5^8383838383838383 |
::3kp38383 | three «uh-ί 2,J family members on. gastric cancer | 203 | carcinoma | up | new prognostic marker of pancreatic adenocarcinoma. | 3“> | squamous ced CCdi8md^C83838 | mil - A1' cloa«regulation ™t oi-'d'vtme heomstreo of esophageal squamous cell carcinoma by m-RNA 8m:jhg::h8h«4i2h:tl0h88383838 | |||
8hit 18383: ί20-5ρ | gastric cancer | 3:dOB | Epigenetic regulation, of nitR~3Tb ard miR--J 7s* expression in gastric | mir- 203 | pancreatic cancer | down | miR-203 inhibits tumor cell migration and invasienvia caveolin-d in pancreatic cancer cells. | 3^038 337^838 | esophageal squamous ceil 8:eaipm0ipa8:83838 | down | (fmrcaf srerait iicCAf serum miR--273 mtR-7? pnd miR-575 m patrems with esqpliageai squamous ceil carcinoma |
8«nt8838 129-3p | ie«al tail caremoma | dyn n | miR-l29--3pK as a •:digaf!astic:ail(ipro:gnostiO·:·:·:·:· hiomarkerfor renal cell carcinoma, attenuate* «.ed | inir- 203 | pancreatic ductal adeno-carcinoma | up | Circulating MicroRNAs in Serum of Human K-ras Oncogene Transgenic Rais 'with Pancreatic Ductal | 8imi838: 337^838 | gastric cancer | doxy £' | MicroRNA-3?:' is doy, «regulated in gastric carcinomas and regulates >eb xmre ι· K «grew? |
124
WO 2017/132552
PCT/US2017/015417
nacratKftt and m\ asmt. \ is downregulatuig muldpie metaatasis-mlated genes | Adenocarcinomas. | POKI and 14-3-3ze:a | |||||||||
(:(229(55555 ΙίΟΑρ | gasrrie cancel- | /9292:: | Growth inhibitor, effects of three ndR-d 22 family myinbers on gastric cancer. | mir- 203 | prostate cancer | down | MiR-203 down-regulaies RapIA and suppresses cell proliferation, adhesion and invasion in prostate cancer. | /99/((((((( /399/555 | gastric ^ftik'er | riowu | /MB2929992/999(/(/(5555555: downregulated in gastnc ()29)9999222)9))92())))))))))): proliferation bv targeting //922)(/(/(/(/(/(/(/(/(5/(/(/(/(/(/ |
(5229(5/(/ }2ί>-5ρ | /)92)2)22)9)9())))))/ | dyu ii | invRNA-ACi3v?iy targeting bv uriR-f27-3pis upiegulaied in gastric caucerand aswv:ia:cs with 5:i2t2f::t922h2 59:5555555555555555: | mir- 203 | prostate cancer | down | Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. | /92/(/(5 375 | gastric cancer | d«w n | ((((22(259/3(222219(/26(5555555555: omlttetution ofgastru cancer cells bv repressing ERRfUe.presxmn |
mu1 >9Ap | /20202222////:/: /)99222499:/:/:/:/:/:/:5 | :)9292: | Micron NA-U^p fiiiabita hepatocellular eureumma ceil metastasis and invasion via targeting ETSi | mir- 203 | rhabdo- myosarcoma | down | miR-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in Rhabdomyosarcoma. | mu- 375 | (/)33O23i2/2(/(/(: | dun n | Snail-regulated MiR-375 um-bu^nngrruu and im aston pi ga tm. cancer ceiis bv targeting ΪΑΗ2 |
(5229(55555 ΙίΟΑρ | Ian ngeal squumon* ceB carcinoma | /2/225 | Uow-n-RegulaBou of iniR* I/O ^p rnbihUS Growth and :/Γώ90^9/2$9$δ9:9;/:/:/:/:5 Laryngeal Rquamous CeB Carcinoma bv Targeting A PC. | mir- 203 | squamous carcinoma | down | MicroRNA expression profiles of esophageal cancer. | /92/(/(5 /399(/(/( | /(gliOrit/:/:/:/:/:/:/:/: | riowu | Correlation oi’ nueroRNA37< dowangulation with ((/(293909^92):2229/(/(/(/(5/ pateome of patterns wnh )2))929))))))))))))))))))))))))))))( |
•UK· iill: | ηκ-dullary thyroid :5)09929/:/:/:/:/:/:/ | down | (5^1^922/593/929:2//:/:/:/: regulated and involved nt the growth, apoptosis and migranon of medullary thyroid carcinoma ceiis through taiaetiug RET | rnii- 203 | squamous carcinoma | up | Unique MicroRNA Expression Profiles in Cervical Cancer. | (:(22///(/ '375 | /(2/22229()2/2/(/(5 squamous ceil carcinoma | )(2222/ | ::CyrnprehensiveMie£oRN(A·:·:· profiling for head and neck SvjuamurL· vO‘d carctnvtnas |
5:499/:5555: }?2-?p | ovarian cancer | duW0 | :(:A:92vb!(:if!i0(f29(55555555555555: )(2222ilBBBl2B))))))))( ird-ibrliiig y vyr iga cqnc yr )2399992pi2rib2232))))))))): (5/922/315/2/929))))))))))))))) )9i2299ibh(2f))))))))))))))))): transcriptional co-aeuvators )()O(222(B)T)))))))))))))))))( | mir- 203a | renal cell carcinoma | Up | miR-2.03a regulates proliferation, niigrati.cn, and apoptosis by targeting glycogen synthase kinase-3? in human renal cell carcinoma. | 5:42285555 ())(72/()): | hepatv-'viitilar carcinoma | /2992(((( | Mm roRNA- :7^ targets (((Afe98222&992932i!2i39(55/(/ carcinoma and suppresses ip et carmet call arm? rh in (5t)2929h9:)ri(999/))))))))))))))) |
5:499/:5555: | κΛ>η •'imer | );99)))) | 4 tp-m palatum M ()))2/922^)2229929222))): •mlyl-inesia and affeUs -he reprogiatmnma of colon cancer cods. | mir- 204 | gastric cancer | down -1 | MiR-204 downreguiates SIRTl and reverts SIRTl -induced epithelial-mesenchymal transition, anorkis resistance and invasion in gastric cancer cells. | 5:42285555 ())(72/()): | hepatv-'viitilar carcinoma | /2992(/ | mjR-375 tnbifuis amophagt and reduces viahdity Bf ))25/329/92(699999999)9))))): ceils under hypoxrc :(52222292^5/(/(/(/(/(/(/(/(/(/(/(5 |
10)11 | /:£S0p2O2/Z/Z/Z/555 squarnons ceO /)294944:9:/:/:/:/:/:/:5 | 11)/1 | esophageal squamous ceil earunoma «.cB proirferotron 5999)24)9239))))))))))))))))((((( | 204 | enhances glioma migration and stem cell-like phenotype. | 375 | squamous ceil curciooma | t.FiR t «.pressmuand (5922)22:223(9(32)322)9229(5 (5330239299232)9))):)))))))))( Laryngeal Squamous CeB (59ate:m22i2:::555555555555555555555: | |||
5:499/:5555: }?2· | renal cell carcinoma | duW0 | /51/:222/:999))29((((((((((((((((((((((( mioioRNA-d 201 dnnedy regulates glucose transporter1 'GLUTi/in | mir- 204 | malignant melanoma | down | Regulation of cancer aggressive features in melanoma cells by microRNAs. | 5:42285555 ())(72/()): | naso-phurvngeal carcinoma | dBW n | (:(:299)2ό992(:)9(55555555555555555 dj ^regulated metariherin and nucrpRNA-3 Tv in head ((((222(22δ2:222622(555555555555555: |
125
WO 2017/132552
PCT/US2017/015417
renal veil carcinoma | |||||||||||
!UK- 65555666 | 80600566666666/ S^UidltuU j vO'd 625522x544444444446/ | 4/225 | Dmin-Regulatreu of MtR1 ?94 is Refared to iksmal Prognosis rcfPafioots »kh vEsophageabSu.-uambtis-Gell·:·:· 4542523232252666446 646/ Elevating CfefYC 6562236564444444444444466446/ | mii- 204 | naso-pharyngeal carcinoma | down | Dowm-regulation of miRNA-204 by LMR-J enhances CDC42 activity and facilitates invasion ofEBV-associaled nasopharyngeal carcinoma cells. | 4:55:44444 57s | non-small cell 65556552666666 | down | Decreased expression of mremRNA*.,4; mt^nsmudJ 4/c25h5i3653c23236:4444444: clinical significance |
6:3626444: 129?b- | 52:.2226665666656: | 62022 | Decreased expression 2 fecal ns5M47$ and miR1? 9?b-3p in early -stage iafem·.:;·! iut'.c: | mir- 204 | non-small cell lung cancer | down | miR-204 functions as a tumor suppressor by regulating SKI in NSCLC | 62544444 37> | 6/3ρ6ί4$22566·144444: 565566555666664 | 551565 | Claudin-l is a novel target 6b56555'5555666665566444 6:2226555325666644444444444: |
!UK- 17.99 | 652622:6555665656 | 6225 | 6ΟΟΟ5Ο26444444444444444444 mmicbromosome maintenance gene family by nucroRNA-I'rit. and ::gef!isfeiii:if!;pres'rate:ca£ie:e-r:·:·: | mii- 204 | non-small cell lung cancer | down | MiR-204 inhibits human NSCLC metastasis through suppression of NUAK.1 | mn- 57s | ora: earner | down | MicroRNA alterations and as-oeiateri aberrant DMA tnetJryJatldri pdhenrs acrc-SS 6Oh22222®562555444444 62222622625665656564: 44225252444444444444444444444444 |
Citrifc-///// 650666 | 46l5hg:aden0664444444444 50662252666666666 | dc-wo | mtR. Ml andmiR I?·/1 44i22555i363 32244444444444: adenocarcinoma cell proliferation fee targeting 60000^000666666666: | mir- 204 | osteo-sarcoma | down | MicroRNA-204 inhib its proliferation, migration, invasion and epithelialmesenchymal transition in osteosarcoma cells via targeting Sintiin 1. | :/2458///: 6665665 | oral cancer | down | 66/5355356222244444466664 /;Rgae2iafe/Tmi2i/////////////// 44S6566255iO5566666444444 1 \pre« λλ m J onpuc 4/526252564444444444466446/ |
:/256///// 650666 | 462222266666664 | 650565 | identify, anon of miRBAs feat specfefeaBv target fix erxt.pi.t.^cjvc xJ Γ<? FL rather than oncogenic | mir- 204 | prostate cancer | Up | Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. | :/228///: 175 | oral ς. are mo ma | don n | Dvxregiriatmn ol nuR- Ί and miR-?7< expression rc associated with Clinical /665566656565666444444444444: 44525252444444444444444444444444 |
60445:6:6: ίόΰ3 | gastric cancer | 660666 | jniR-1333 Targets Claudm-18 Gene to Modulate Proliferation and Invasion of Gastne Cancer Cells | mir- 204 | renal clear cell carcinoma | down. | VEL-regulated MiR-204 suppresses tumor growth through inhibition of LC3Bmediated autophagy m renal clear cell carcinoma. | :/2458///: 6665666 | osteosarcoma | down | MkreRMA-575 functions 62/42262226262264656 osteosarcoma by targeting 446050666664444444444444444:6:6 |
!UK- 6β666 | colorectal cantor | 6225 | The polymorpluc teiminalbop of pre-nnR-1307 405^620006θ|45:6:6:6: contributes to colorectal 56265556223266644444444: interference with Dicer! 4:26222424444444444444444444444: | mii- 204 | retrno-blastoma | down | MiR-204. down-regulated in retinoblastoma, regulates proliferation and invasion of human retinoblastoma ceils by targeting CyciinD2 and MMP-9. | mir- •575 | 4563626ii6:4444444444 6665656666666666 | down | MicmRN-'.-- ''is /65b25625666i2444444444444444: pancreatic cancer and inhibits ceil proliferation in 655356444444444444444446666666/ |
634564446/ 650666 | :/b226$24c2////////// | duw π | MieraiRNA-Bba inhibits ceil prclueiation, invasion and migration in Imntati breast cancer by targeting 4:26^25052444444444444444444444: | mir- 204- 3p | hepato-cellular carcinoma | down | Growth inhibition of hepatocellular carcinoma tumor endothelial ceils by miR-204-3p and underlying mechanism. | , 37> | 655456666666644444: 445 5 6 6 6 64444444444444 | dew f | 6522222262266656565 445ifei6525665i644444444444444 6655665306656665656565 |
ιι:η· 555656:6: | :255550200606:: | 6:025/ | 3522532/222544444444444 function indues epnhUiab meseoefe mat 1i ansn in ¢. ^^ΐΙαο^ίΙΙϊΙΟ^ΐίΙηΙίΟί-Ι-Οϊ'^.?·:·:·:·: nuR-13^--2 FB 1 axis | mir- 204- 5p | colorectal cancer | up | tniR-204-5p expression in colorectal cancer: an autophagyassociated gene. | mu- 175 | /554566566444444444 carcinoma | dow n | MrercRMA- GA targets PJ>M mpsnercatre carcinoma and suppresses ceil growth duough the Ut signaling patbn ay |
126
WO 2017/132552
PCT/US2017/015417
4:123345555: 5304:4: | esophageal cancer | 25011 | Differential expression vf naENAzin eaopf.au'3 523334443433455555555555555555555 | mir- 204- 5p | colorectal cancer | down | iniR-204-5p Inhibits Proliferation and invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Ceils by Downreguiating RA.B22A. | 543345555 S“5 | pancreatic direral odruo-earernurnu | dov r. | Lmxkchren nf inureRNA21 inhibits prebferatrrre and :2:2i2hc2f33^3:3®i2h443t3 2332:25555555 vtargetinapiygrammedyeii·:·:·:·: death 4 < PDCD4 > in 25343433334:434t^5555555555555552 ocfeitoearernoma. |
2:233:4555555 553025552 | 2534344244133 33:55555555 5:434333355555555555552 | 5055555 | Upreguhted miR-1 Slip ifivrease; dnre recistanveb' regtitaiinpdDNY < and Win signaling in cispiafintreated HCCceli. | mii- 204- 5p | gastric cancer | down | MicroRNA--204-5B inhibits gastric cancer cell proliferation by downreguiating USP47 and RAB22A. | :5334:555: 575 | pancreatic ductal aderin-cafctnonia | 2533435: | Circulating MicroRNAs in ••emm of Human K-tas Crecvgcrte Tcsnsgeitk Rats with. Pane made hue tai :2:Ad33333f0i344i3s2:2:2:::::::::::::::::::2:2:2 |
:::334::2:::::::: 55045555 | hvpatvCvlh8ar carelueroa | :433353::2 | MuroRNk-l h<a is downregulated in hepatocellular carcinoma and associates W tih poor pro gnosis | mir- 204- 5p | papillary thyroid carcinoma | down | miR-204-5p suppresses ceil proliferation hy inhibiting 1GFBP5 in papillary thyroid carcinoma. | 5:30555 5:372.45555 | s«p:umuu j 25243443353434444455 | down | 525i432423s3332f4^i34555555555555: nucroRNA-375 regulates fcktam dehydrogenase B re ::itiaxidaiy:akiu&:&y.nymyns·:·:·:·:· celt carcinoma |
:2:24342:2:2:2:2: 554055552 | ooiofectal cancer | 553355555 | MnwoRYk H”b Wook-p 2543:344^43544343:4333:445 5223041354354023344555555552 [•rognosis re CnloreuB <an..xr. | 205 | bladder cancer | up | Micrc-RNA. profiling in kidney and bladder cancels. | 373a | 5543443333:555555555555 | :2:2434ίδέ3ό:ί4:3ΐ::::::::::::::::::::::::::::::::::2:2:2 2534333f333342bO5555255555555555 | |
mu- 55045555 | colorectal cancer | 553343:5 | Miemrna i <tib Suppresses Migration and (uvasion of Cbktrectai Cancer ί kite through Dow oregidation of 2533334ί35?45555555555555555555555 | tuir- 205 | bladder cancer | down | Expression of microRNAs in the Urine of Patients With Bladder Cancer. | mu- 3”nu | glioblastoma | dov n | tRhibddbftifltitifidhkibf :55555552 preenrsuf MumRNAa identifies MreruENAz 2:2:4i^33f42i34gi:id3i3555555555555: 252343134303455555555555555555555 |
:2:2ΐ334:::2:::2: 55055555 | «doreetu! vancer | 25055555 | a-· 'b Pronto· es Tumor Dereiopmeht and is 250443454323354 24434555555555 Prognosis ai Colorectal :5353433345555555555555555555555555 | tnir- 205 | breast cancer | down -1 | Suppression of cell growth and invasion by mi.R-205 in breast cancer. | :53342:255: 37ua | heparerelinlar esmtuoma | 5:334325: | mid - t7f>a suppre ^es pmbferafmu and induces apoptosis in hepatocellular 2533t3r3423i3i555555555555555555555552 -> |
2:2334:2:2:2:2:2 ίθ|55 | endonietiial vancei | down | 2:2M353i5s2:3532g3t3544:2:2:2:2:2:2:2:2:2:2: function induces ypitheiiaiiuex,r<vl·' mai ttarsitior through reotfuiBiou of the m3E-i3bh-ZEBlaxis. | mii- 205 | breast cancer | down | Analysis of miR -205 and miR155 expression in the blood of breast cancer patients. | 374a | 2:2l2r33ig3334:2:2:2:2:2:2:2:2:2:2 25331434:63:5555555552 | :53343:2:2 | Silencing of a large 252θί3θ3444ί343 33:5555555552 mu Wvhvirv-cvpk in meiannuja biological effects of mu-2 76a and nar-3 7ς>^· ya insulin growth 253343343532333133555555555555555: |
:2:24342:2:2:2:2: 55045555 | esophageal 2543.3431434443555555555 554344333 3355555555555552 | 553355555 | MtR-kAsbplays au oncogenic tyle hj 5533343342 3TB355555555555552 v vpreosmi. in esophageal sqnamoo, <ed caremoma calls | 205 | breast cancer | down | miRNA-205 affects infiltration and metastasis of breast cancer. | 5:3345555 373a | pancreatic ductal adeup-esryinyma | 43355554 | CitculatiGg MieroRNAs tu 555334445^N33i332 34443325555555 Onoogeae Trau&aeaic Rats With Eauereatrc Ductal :52.4d33434ir3i4332i33555555555555552 |
!UH- 3O35555 | 253^3344133 3 35:5555555 525343533455555555555552 | 5534335: | Repression of nucroRNAt3hhby thyroid hormone enhances cell motility. | mir- 205 | breast cancer | up | Role of microRNAs -29b-2. 155, -197 and -205 as diagnostic biomarkers in serum of breast cancer females. | mn- 542W555 | 5532331333345555555555 253^4340545555555 | down | 55Sd5333m^3f24iai34555555555555 mmre.RNA vhtsterou human chromosome 14cj>2 553433B34333240g43f 555555 effects of ηώ-3 7>>a and urn-' K vit tnsubt. grew th :a<rer I receptor |
WO 2017/132552
PCT/US2017/015417
6(6((6/6/6/: ΒΒίΙ) | /:6)6))85))))(16(/)))))))): /):563)(8633))))))))))))): | //;||;/;|; | )3(5(8^(665(538))))))))))))))/) cfiirerenttaih e cpreesed microRNAs inhuman hepatocellular adunuma associated with ij pa ί glycogen storage disease' a /)33888(6i)6(68>)8()))))))))))))) bkn:,,rku\ | mir- 205 | cervical cancer | up | Serum iriicroRNA-205 as a novel biomarker for cervical cancer patients. | 66(6/6/6/:/ Due | osteosarcoma | dov n | MtemRMA-'70e inhibits /(36:(:8(68(6(3653/3))6/((((((((( im asion to Osteosarcoma /(8836(26362/(6//:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ ////T(k(36(/rm(l6/iS(6/'6(h/((((:/:/:/:/:/ /)3W8()BB8)))))))))/))))))))))) |
mu- ΒΒίΙ) | /(60)666(66666/6/6/(6 /):563)(8633))))))))))))): | //;||;/;|; | )/£ft2833586((6888)))))))))))) tw?roRNA-J 'bbvonrelate^ wdh pcc-r prognosis of patterns wnh bepatorettufer | mir- 205 | cervical cancer | up | iriiR-205 Expression Pro motes Celt Proliferation and Migration of Human Cervical Cancer Cells. | mu- Nuc | osteosarcoma | dm? n | MtefeRMA-ib'bt-Ap is downreguteied m human osteosarcoma and regulates ////c68/3)6i/i(3((t66h/(t6ri////////////////////// ////hd^MtOh):/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ |
:/:86(6/:/:/:/:/: /6(0/6/6/ | ovarian cancer | :/:/666666 | Fpigenei··? sttenctt'S ni miR-Hstib in ovarian canter promotes the de' cdupmeib of maitidntg resistance by /0(0060(0/6666/6/6/6/( 666/6i6(66O(O36;(5;6;6;6;6;6/: | mir- 205 | cervical squamous ceil carcinoma | up | miRNAs expression profiling to distinguish lung squamous-ceii carcinoma from adenocarcinoma subtypes. | TmtreT?? /)(73)))): | gastric eanoer | /)83/))))) | MicroRNA-57? predicts poor Olinical Outtemte of gastric cancer and badnteS Lunjoiigeoesis by targeting mtdripte tumuresapuf'^or iren.:·. |
mu- ////(0/6/6/ | )666(868)((5((0)))/) /605(65656//////////////////////// | :/:/66666 | MteroRNA signature tftsoj’pxZnes the degree ui aggressb eoess of papdlaq /3O66ri//6O/i6ri/6i6/6//////////////////////// | mir- 205 | endometrial cancer | up | miR-205 promotes tumor proliferation and invasion through targeting ESRRG in. endometrial carcinoma. | mu- ////6/7///////// | /)36886(6(8888)))/) carcinoma | dm? n | MicmfC^ A- '· < upurejses /(36:(:8(68(6(3663/3))6:////////////////// /6(nyasipl(86/5phtbiti£66/:/:/:/:/:/:/:/ TfAM/l Expression m Hepatocellular Carcinoma. |
:/:/66(6/:/:/:/:/: :6(/0/6/6/ | prostate cancer | down | LhE-l Nfe suppresses prostate cancer metastasis :fiaongh:down-:-rea:ulad»nof:·:· /β||||||)||||///| | mir- 205 | endometrial cancer | down -1 | MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells. | :/:6i(te:/:/:/:/ :/37/7/:/:/:/:/ | renal clear cell eamtooma | :/:633/6:/: | miR -'7’ ftmotious a* a tumor suppressor in human /(863)(:63/)6(666/)3/////////////////////////// caivm.vmabv targeting |
/I/B)|8 | 63|:/5/5 | human gastric cancer. | 205 | up | Correlates with Lifestyle, Social and Environmental Determinants in Esophageal Carcinoma. | )/)||)))) | /((6((563)(6/:/:/:/:/:/:/:/:/:/:/:/ | /)86))))5 | is frequent and may affect treaimettt outcomes m patrent? w rib a'um my Nord /:/te628ih6/t:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | ||
!IU1- ////)31////////// | /(3(65(/66865(/6/6/6/6/6 | /6360( | (/33060(006/6/6/6/6/6/6 probfetatictn. invasion, migration. and metastasis tn •:breaSt:C’anesr:b¥fafg?ttng·:·:·:·:· 686(/6/6////////////////////////////////////////////////////// | mii- 205 | esophageal cancer | up | miR-200a/miR-141 and miR205 upregulation might be associated with, hormone receptor status and prognosis in endometrial carcinomas. | /:/(66^/:/:/:/: )60//66 | breast cancer | /)86)))))/ | A*sAviatmu beo? cert mtt?·} urKlmtr-Nx miormabnfi’.ed paraffin-embedded tissues of breast cancer. |
665(666/6 )))3)(((((( | eoinrecfal cancer | down | miR-132 inhibits colorectal /(33)666 3)56663/6666////////////////// metastasis via directly /((603326^6/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | 205 | gastric cancer | down | Down- regulation of MicroRNA205 promotes gastric cancer cell proliferation. | :/:(6((6/:/:/:/ /:/3/78///6/6 | colorectal cancer | down | ((idepfiripatiOn/apri/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: iunelioKoi screening of ////hup(6R/NAs/8i/888))))))))))))) deregulated iti colorectal L cancer |
665(6/6/6/: ////B||| | ////2(5(65)//////////////////////////////////// | ///11/6/6/ | ((OO6(5566/6£:OR6 (326/6/6 v vpreosmi, m ghomu ind rt> vhmeaf sigmtivame | mir- 205 | glioma | down | identification of microRNA-205 as a potential prognostic indicator for human glioma. | 66(((6/5/:/ )872)))): | //6316(66)61/ 333/6(6/ | il«W £’ | MreroR/N/A-d?S briny bs cull growth and enhances 101!Ρ-1ΓμΙΚλ3 Upopiosreui huroao colorectal cancer. |
!IU1- 6/BIII | !!' ClteiteCCl | 6306/:/ | Effects of MteroRN.AN, 32 (650(^0(66/36/((3/:/:/:/:/:/:/:/:/:/:/:/:/ Proliferation and Apoptosis of Human Lt% er Career Ceils in' tiro and in s 1'· 0 | mii- 205 | glioma | down | MicroRNA-205 functions as a tumor suppressor in human glioblastoma c ells bv targeting VEGE-A. | mn- )60//66 | gastric cancer | down | MjctoRNA-P? and mmruRNAN’' uxriiate tumor growth suppression h> epigonetteal regulation ////1((/262(36:366))(:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
128
WO 2017/132552
PCT/US2017/015417
(:80ΐ/:((((( 2/(/2222 | osteosarcoma | ((22/2(: | Less of microRNA-i33 pretit e re re nretdsis ·η patients with prkoaiy (:0/22/22/((((((((((((((((((2 | mir- 205 | head and neck squamous cell carcinoma | down | Low-level expression of microRNAs iet-7d and miR-205 are prognostic markers of head and neck squamous ceil carcinoma. | :(8//((((( 2//222 | 2(/////////222 | dov n | ((MmteR:O//3fih///f ((((((( bntOvcn gazriv ^anrer |
ink- | (pNito(/teotea((((((((( | dowO | nteR-lL* fargpijjtg CyCltn ((///l/ijr(333/$®if(((((((((((((( 2/022/22/ 222((((((((((((((((: (0/222222/2//((((((((((((( | roir- 205 | hepato-cellular carcinoma | down | MiR.-205 modulates abnormal lipid metabolism, of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSLI) mRNA. | taaif-::::::·:: 2//222 | naso-phaiyngeal carcinoma | down | kficiORNA-578 functions ((^2/ti(s/3d(/tiR(i/(((((((((((((( ::HasopiK}iyrigeuleaniiQonia·:·:·:· by repressing 7OE2 8fe//e^:kh?8:8:8:8:8:8:8:8:::::::::::::: |
•UK· iiin | pancreaik: twr | (02((2 | mreeased m panreeatre cancer and target the (O/22//9//k/2/8((((((( (:3/222//((((((((((((((((::::::::::::::: | mir- 205 | hepato-cellular carcinoma | down | Hepatitis B vims X protein inhibits tumor suppressor miR205 through inducing hypermethylation oi' miR-205 promoter to enhance carcinogenesis. | 8/(88((((( :|(/|2 | (Αυ··<υ< vix«.a | l!/ll | MiR-3 TR as a biy marker ibr response to arrti-angtegenre treatment m ovarian μηχλγ |
ink- | (p2Ok/(((((((((((((; (((332/3///((((((((((((( | (/0((/(: | Downregutetion of miR- ((2/2/:/22/2/2(((((((((((((((: •:metiiylafiofi<»lLi:!b[rte&:tO:·:·:·:· 2/2//222/2/22222222222( (022/2/2222222222222222( | roir- 205 | kidney cancer | down | MicroR.NA-205 inhibits Srcmediated oncogenic pathways in renal cancer. | taaif-::::::·:: 2//222 | Ovaraxt cancer | 2//(222 | Differential microRNA expression sighstiites. and cell / pe-Spetffiy association with Tavol resistance mtAudrat. cat.rer letts |
i!!U- B3a | (bi//j/t/(io(((((((( | ((22/2(: | 2/0//02///2/2/222( νΛί! prubiorawui! mtgmtton at a to\ jsmt ht rsr<vn * ejxdonnal growth factor receptor <nci its (:0(20/22///222222222222 pretem* ut bladder cancer | mir- 205 | lary ngeal squamous cell carcinoma | down -1 | MicioRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma. | mi:- 2//((2( | renal ceil carcinoma | dov n | (i(A/dbdkdi:i!//te/j/2222222i miRNAs a> a potemai diagnostn tooifor «.arkStage renal ell t areinotna -, |
(/((/22( | (:£tiO/8(22:/2i22/22(/2i2(i l i xpeutp JAG· SP m (Odkt(k/2t(:((((((((((((((((( | 205 | up | of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. | 3?Sa- 212222 | sigtafkanec of mtR-8 ’8atp and miR-37)ia-5p in ((8toi/8/(i/f 03/3//((((((((((((((( | |||||
liar1 >>3 | (////222222(((((((((( | ((22/2(: | microRNA-ί 3 ;a regulates (20/2/222//2/(((((((((((((( prolttetation ui breast cancer colls by targeting epidermal gm wth factor (/2222/22//222/02222222( ((2/220//220/2/2222222 (^2(2/((((((:(((((((((((((((((((( | mir- 205 | lung cancer | tip | miR-205 regulates A549 ceils proliferation by targeting PTEN. | mi:- 378a- iln | colorectal cancer | dov n | ((Gi!/mdi//i:/t0/2i/i/22222( significance ofrtaR-1TRa-p rent retR-AVXa^p in ((•/il/f/ii3i(Sh/O((((((((((((((( |
(:ίήΐϋ(((((: 1 >>3 | ((¢2/2///222222((((( | ((22/2(: | 71« clirucnpatltologtcal significance yf nuR-EBa in cclorectat cancer | inir- 205 | malignant melanoma | down | miRNA-205 suppresses melanoma cell proliferation and reduces senescence via regulation of E2F! protein. | (:8//((((( 2//222 | breast cancer | dow n | miR~3 Tv regmUtes cyclrn (®//2/i^sid///O2222222: decreased mbrtan ^rex^r |
!UK· 2:/2222((( | eniorectal cancer | (:2222/( | Decreased expression of miR-153n correlates with poor prognosis in colorectal (/3/2((//////(((((((((((((((((: | mir- 205 | malignant melanoma | down | Differential expression of microRNAs during melanoma progression: mLR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. | m·:- (///(22 | breas! cancer | down | Attaij sis of iuiR-205 and mtP -155 < qxessier in the blood pi breast cancer (/////222222222222222222: |
129
WO 2017/132552
PCT/US2017/015417
8riitiB:((((: l>3a | wRorectai varied | BdbBB( | (:OOBOB?3BBbB:BBBB suppresses eniureviai cancer ceil invasion hy (::thidbimg:F^$mi:((((((((((((((: | mir- 205 | malignant melanoma | down | Chemically Modified Synthetic microRNA-205 inhibits the Growth of Melanoma Ceils In Vitro and in Vivo. | (:riuB(((( B^BBiB | BWBBO^BBBBB? carcinoma | dwv n | Mu mRNA- '8f represses BiBBBrtBBBBtBOiiBBidBBBi: 8iftb^BB^^hfciB4h^(BB((((( |
:(ihlri:((((( B^BBB | enioreciai cancer | (BOB | Cumbrian mrcroRNA Jxc-maikefS in human (B^OObOIbBBBBBBB «Systdnauoreviowpfofriing:·: studies and eyperimer'dai (OiOO((((((((((((((((((((((: | mir- 20? | non-small cert lung cancer | up | Prognostic value of mature miercRNA-21 and microRNA205 overexpression in non-smart cert lung cancer hy quantitative leal-time RT-PCR. | :(fP3r3:(((: B^BBB: | osteosarcoma | down | mtR-382 inhibits Osteosarcoma Metastasis and Relapsebv targeting Y Byv-Butdutg Priueii’ 1 |
Β^ΒίΒΒΒ | celorevtai cancer | down | Tyri-yr suppressor functions nt tiuR-i3 ;a in colorectal (ΒΟΒ(ΒΒΒΒΒΒΒ:ΒΒΒΒΒΒ8 | mir- 205 | non-small cell lung cancer | up | miR-205 promotes the growth, metastasis and chemoresistance of NSCLC ceils by targeting PTEN. | 8bui((((( iBBBi | ((d^gd^i$pfdg(((((( | iOBB? | TiiaR-AS2(ii!luhiiSTdriidiBBB:( (BBB^B^jOB^BBBBBB cbemoseosjiiyhv in !!·?.:ο·λ·Γ.·..Ί::·ί |
SUH* l>3a | ((iBbBb^hBBBBBB? B^OBiB^BBBBBBB carcinoma | (BBBBi | nitR-145> miB-f33a and OO^SBBBiBibBBBBBBBi Suppmssive miRNAs target 3$d’dgiPddBOBBii:idPBia((((: | mir- 205 | ovarian cancer | up | The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion | mu- 383 | bieast cancer | dwv n | ?a bv mRNA- '8 3 Regulates tbeApoptostzui Τηυχν Certs fhrough Targeting Β^θ5|ΒΒΒΒΒΒΒΒΒΒ:ΒΒί: |
5hBB:((((( (BBsBtt | esophageal T^dBBBiBbB$®iLB:(((((: ((CgfdrhPi^((((((((((5(( | down | <D-1” expresnon rcgukVdf OjBjBBBBB^BBfiBB^BBBB y$5BOOBBOBOB((((((((( prognostic marker in esophageal s^mmiuiL· ve8 8gdri;to0Bih;BBBBBBBB:(((((( | tnir- 205 | prostate cancer | down | miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. | (:riiB((((( 383 | 5gbpmaTTT8:(((((8 | •(drtBBo | Do'anregiriabonoi tutRv 3 p. vmvt-S lUU 'iiAI invasion by targe hug iu&iirin-fike grow th factor 1 (iOBihBBBBBBBBBBBBBB |
SUH* B3a | Β^ΟιΒ^^ΒΒΒΒΒί | (BBBBi | MiR-14^, nitR-1 '3a and OO^BtBdBOBBBBBBBBi probidanon. tmgrauup (ΟΒΒθΟΟίό?0((((:8:( zprogiosslonwiafargetrng·:·:·:·:·: transcription factor Spf in .? !!* M‘t v! | mir- 205 | prostate cancer | down | Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic raiR- | mu- 383 | BOBBBBBBBBBi | d<m n | MtvmRNA- BG inhibits attchoragoumfependem growth and induces ceil cycle arrest of gbpmn ceils by targeting CCNDL |
8buh(((((( (BBBB588 | gastric cancer | down | :-Miei»RivTA-:i33afincdeiK·:·:·: as a tumor sirpprcssoi m oobbbb^bbbbbbbbbb | mir- 205 | prostate cancer | down | MicroRNA-205 inhibits cancer ceil migration and invasion via modulation of centromere protein 3' regulating pathways in nrostate cancer. | 8bui((((( IBBBi | ((^ΗύίΡίί:(((((((((((((( | iOBB? | ::MiCloRNA:-0S:5:expiession:·:·:· ((ip^BBbBB^BB^BbriBBBB? mieratiogv ma asion. and apoptosis- in human gboma ..ΐ’ίί:.............................. |
!Wi· (BBiBBB | 5gai>riiCmBi(BB8((((((( | (BOB | Tumor sirpprcssoi rule of miR*J13p m ga,tnv vat. \r eByCfPpfp^iagTBtBOBBBB? | mii- 205 | prostate cancer | down | Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer ceils. | :(fbiri:(((: 581 | fdririidiGfff((((((( hbutPbxs | down | Mrii- ;8 3 fa Duyvryerpjlafed m MedtrO/'blazK.ma vod Targets Reroxiredoxin 5 Β(ϊ^^ΒΒΒΒΒΒΒΒΒΒ(((((:( |
5hBB:((((( (BBsBbb | gastric cancer | down | Mitro^NA-· Ga mh-bitz prokfeianon and tm asion, and induces apoptosis in gastric carcinoma colls' ra targeting fascia actin- (ΟΟθΟ'θΒ((((((((((((( | tnir- 205 | prostate cancer | down | Epigenetic-induced repression of mi.croR.NA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. | •BIBB·:·::::: 392.8 | osteosarcoma | Jow n | Down-Regulation of miR* B^^BWO^BBBBbB^BBB Gs'eosat cornu Grovh |
4imb:((((( 132a | >(hg^:phd(hb<B(8((((((( (:OBBOBBB(((((((( BiiBr^fbhBiBBBB^BBBi | (:BOBi | Low-lev el expression of nacioRNAs let-7d and mtR-?';5 are prognostK markers of heart and neck squamous coB carcinoma | mir- 205 | prostate cancer | down | MicroRNA-205. a novel regulator of the anti-apoptotic protein 33cl2, is downreguiated in prostate cancer. | :(1011-(((( ΒδΒΒΒ: BBBBB | dewy n | MicroRNA-4tip-3p inhibits inigratfog and invasion of bfatfdor cancer ceifa via (:Β^ΒόΒ:ΒΒ^8ΝΝΝΝΝ8:((((( |
130
WO 2017/132552
PCT/US2017/015417
/:(ΐή//8///// B3a | 22203323022222222( 23222/2223202/////// careworoa | 2232332: | 2(223332:0333332222222222222: roicioENA-J ;3a regulate* iKnd targets hfoesin cuntaUales io cancer cell (2 £3232233302223333332222 hi bead and neck siRtantoua eel! carcinoma. | mir- 205 | renal cell carcinoma | down -1 | miRNA-205 Is a Candidate Tumor Suppressor that Targets ZEB2 in. Renal. Cell. Carcinoma. | /:&«/////: 2302222 2(0(2223 | colorectal cancer | dou n. | Micr*RNA-4V>-5p suppress* z vplorsx tel ((:(332222(i(32f3/2h(223//////////// (2:hki202:223^:22222222222222( targeting CaBI expression -1 |
22/3222222( | 220002222222222222( | veil pnNtferatmro vNorn fornioiron ahiim., migration anri tovaslnt' hy targeting rnnttix ictetailopeptidase 9 (223223232222032222222222222222 :(:33(3330/:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | 205 | carcinoma | of esophageal cancer. | 20/222( :21222222 | (23333322232222323:233222222 metastasis hy dtreeth targeting rfckxm t& ga tm (:(p2it2235///////////////////////////: | ||||
(/mif-:///// yi/G/tycy | hmg squamous cell (2:323302232222222222222: | •JOwft | Trnnor suppressive :n7croRNA:-:l-35arogulates·:·:·: novel moleeutai networks in lung squamous «.ell •.:..re;iioroa | 205- 3p | non-small ceil lung cancer | up | Relative expressions of miR205-5p, miR-205-3p, and miR21 in tissues and serum of nonsmall cell lung cancer patients. | (/mir///// 4v<>- 21222222 | gastric cancer | down | MicroRN.A-4P9.Sp regulates ceil proliferation and apoptosis targefiug Pl t b 10 m gui$iT.c - u |
mu- B3a | nou-sinaJl ceil Jang (2(2032222222222222222222 | 2232332: | Mfh-B m is dowriregulated (223(2223333222320222222222 eaacet a study of clinical :((Si(g2i2i2222®///////////////////// | mir- 205- 5p | non-small cell lung cancer | up | Relative expressions of tniR205-5p, rniR-2.05-3p, and raiR21 in tissues and serum os’ nonsmail cell lung cancer patients. | mu- 233322222 2(0/22222 | hum adenocarcinoma | dote it | 2020^ fummurs ax a tumor suppressor inhuman long adenocarcinoma by targeting c-Mc |
/:(233/////( (/(2232/(/// | (:(3802200(:(:(:(:(:(:(:(:(:( | dvW‘0 | MicroRMA.-· .¾ (((d3g3i22223233(i2(////////////// osteosarcoma, suppresses proliferation and prarnntea apoptdsrsbv targeting Bel- 2O0/00/////////////////// | mir- 206 | breast cancer | down | miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the upregulation of cyclmDz. | :(:ihit+:(:(:( 223322222 /01222 | or arum cancer | /:/3323/: | Differentind microRNA expression signatures and cull tj pe-$pecifiv association with Taxol resistan.e tn o\ arm. cau-vf L celi- |
ίϋΐι- B3a | //222023202222222( | 2232332: | miR-B3a suppresses to mat s.?t ^rv'fi proliferation be directly targeting wxuuo-hke growth factor 1 receptor | mir- 206 | clear cell renal cell cancer | down | Exploring the triiRMA-tnRNA regulatory network in clear cell renal cell carcinomas hy nextgeneration. sequencing expression profiles. | mu- :23232222( | 22233232222322222222 | dOte it | ?a lu mRNA-'·'· l Π Suppre sse; Migration and innamm bv (2(303^23^03222222222222( (:(3r3$3iO((Ga00eft(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: |
/:232/////( (/(2232/(/// | pancreatic cancer | dvW‘0 | innR-t1 >. f unaron* as a Trnnor Suppressor and Direclly Targets FSCNl in Pancreatic Cancer. | mir- 206 | colorectal cancer | down | microRMA-206 attenuates tumor proliferation and migration involving the downregulation of NOTCH? in colorectal cancer. | :(:ihit+:(:(:( 2(3332(222 | oral squamous cell carcinoma | dote n | Doteiitegnlated miE-B9 and roiR-Uh promote the proiifeiution and ima&iyK of oral squamous cell cawwaa by targeting |
/((tpif////// 1 >>3 | renal toil -carcinoma | 2222332: | ::TbeiuHCiroHSi:S4gcifkar!ee:·:· of miR-i andinOl'-Ga m rated edi n+nca | mir- 206 | gastric cancer | down | MkroRNA-206 suppresses gastric cancer cell growth and metastasis. | :(:(0-:(:(:(:( 210(2222 | 2ρ33323322222222222( 2223322222222222222222: | dote n | :<MicroRNA-:41PfuriCtlon5:·:·:·:·: (232:222/3222332222222232222222 targeting ong!oten>m 11 (((23(p2/i(/!;2?2i3s2(i(2(//////////////: uancreutic canter |
:(:23/2(:(:(:(:(: /2223223(2 | prostate cancer | dvW‘0 | nteroRNA 1 itiWusv 1 proliferation rntgrahon and •:invasroii:i£i:p£osfate:eaneer:·:·: 23(3^330233382322222222222 eptdennal grow 3t factor /:3238133(///////////////////////// | mir- 206 | gastric cancer | down | Activation of PAX3-MET pathways due to miR-2(!6 loss promotes gastric cancer metastasis. | :(:ihit+:(:(:( :23 3 32(22(2 | or anno cancer | dote n | Differential microRNA expression signatures and cull tj pe-specific assmia- ·οη w tit Taxor resistan.e tn o\ arm. cau-vf cell· |
131
WO 2017/132552
PCT/US2017/015417
59t9fjii59(((5 1 >3 a-?. | 9(/9r(;O9i9/ti//9r95959595 | 9(0/5 | raicroRNA-ί 3' inhibits ceil prahiciatran migration and un a ion mprosf aw* aixar (/9/i/9///igOg9/i/9((((((((( epidermal growth factor :9:9r9i;k!iGi:Git;9:9:;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9;9; | mir- 206 | gastric cancer | down | MiR-206 inhibits gastric cancer proliferation in part by repressing CyclinD2. | 59//959((( 9///9(/: | 9(:g///59ti5459r9((((( | ////// | increased expression of iniRA23 jn human gastric carcinoma and hscimtcrd 9(9te-^94dii5r59((((((((((((((((((((((: |
20959125959:9 /BB/// | bladder cancer | dawn | MrcroRNA-133 inhibits zoeliproltibiairoteHaafaHOQ:: anti tm ismt. b< fargvtiwe cpiduud grow his o·· 99:91/005)(159091/9999999999999999999999999999999999 dOnnstreato effector ·: proteins in bladdercancer·.: ·: ·: ·: | 206 | gastric cancer | down | Downregulation of niicroRNA206 is a potent prognostic marker for patients with gastric cancer. | BB// | 9(4/9(// | 9(ύρ5}4455ί/ΒΒΒ//Β/59(((((( gastric cawertf ceiK b\ targeting caspase-3 | |
5ii5/5:5:5 :5133:/:5:5: | cervical carcinoma | (//9((((: | >3ieroRNA-i33fc is al,s> promoter of cervical ogrohrama develop me rd through fbe activation of the 9ERk anti AR'if (({/9//0(((((((((((((((((((((((( | mir- 206 | hepato-cellular carcinoma | down | MicroRNA-206, down-regulated in hepatocellular carcinoma, suppresses cell proliferation and promotes apoptosis. | 5954/59:959 9///:/9/ | gastric cancer | 9(//9/9/9 | MreroRWA-ffi Is a naw 995p$te9/44tfrii3^5a-4ijS9((((((((((((( biornarker with higher sensitivity and specificity than varomoemhrtrturo uOmgrt. .Old •'amer antigen 595//:iti/3/i4p/3hckr5959595959:9 |
tt5f- | colorectal cancer | (//((((( | Association of ttucroRNA (fe2/r55/34t9:A4tS((((((((((((((((: 9(/fo04^/i9iit///2/ii9i/9(((((; 9(/α/$9/(4/θ9τδ$//(((((((((((: (:9//;Oh9////t/((((((((((((((( | mir- 206 | hepato-cellular carcinoma | down | MicroRMA-206, down-regulated in hepatocellular carcinoma, suppresses ceil proliferation and promotes apoptosis. | 245442595 :////9(( | nasopharyngeal 9(^55945:444459((((((((( | /4/((9((( | iniRAM intinee> «.eO prorireration anti apoptosis (ireriO559/9/iO9iiiiiiiiiii: xnasaphaiyrigeaiaarotocma·:·:·:· via d^megoiatmu Ά 9/i///iiiiiiiiiiiiiiiiiiiiiiiiiii |
25/95:5:5: ((505/5 | colorectal cancar | down | 9(5^(9/3/(/:9//4/4(9(((((((((: specific ttycroRNA, is a yo\ el pmanoctro marker that participates in the progression of human colorectal cancer vh regulation of CXCR4 9(49///5/059.((((((((((((((((((((((: | mir- 206 | laryngeal squamous cell carcinoma | down -1 | Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer hy regulating V9EGF expression. | 9(5//(((: BB// | 99(459tiib5i^4d//9(((: | ////// | 9 9 9p//555/il/ro95i95i/iii/i5959i suppressor memo by roiR421 promotes proliferation 9(:^/9//1///////5/5/5/9/9(( 9(5ού4ο545/ό44/((((((((((((((((((: -, |
((/0((((9 | 9(:e30ph3gS5l9(((((((((((( squamous cell 5έ/ί/ί9ιώί(ί/9((((((((((((( | (:9/Μ/·//(///ί//9(((((((((((( suppressive muRNAs target FtiOfi roesopbagrai squatoOuS ceil carctnctoa | 206 | melanoma | arrest in melanoma by inhibition ofCDK4andCyclmb. | 422a | firoctmuai soreeurog of 9(bft55d//A^/i/ii/59((((((((((( deregulated in colorectal | ||||
!UK- BO((((9 | 9(g5str4e9:!45i45559((((((((: | :9/5//:9 | MiR-145. itaR-13 ro and (:9/0(//////9(((((((((((((( proliferation migration, invasion anti tail cycle proof' ron' t taiceroig 9(5ah/9r//ro/9f/4itii(S9//i/9((: 59//0(459/5459(((((((((((((((((( | mir- 206 | medu lio -b iastoma | down | MiR-206, a Cerebellum Enriched miRNA I s Dcwnregulated. in All. Medulloblastoma Subgroups and its Overexpression is Necessary for Growtli [nliibttion of Medulloblastoma Cells | 245442595 -122a | bepateoeilular 9(:/.554/5//9((((((((( | down | ............................ (:9A(dp4$fe49fteg5tiy/(((((((((((((: feedback loop between Mm<oR9NA-422.a and Ρ棫5ί/Οΐ4ίι regulates hepatocellular carcumroa 9(it454tiOti/i/tii4d9(: 9(((((((((((( 9(:4itei5Std5i5;(((((((((((((((((((((((: |
59/ai595959: :y f339b:259: | 9(g35/OO£/9(((((((5 | (////9( | 9 9 9 (Flte9:i0i/(5f5ai9i/R9NA9-((((((( 1' sb and rs torgv*· cene 91--( ΝΊ ojoaan*. «.atcer | mir- 206 | oral squamous ceil carcinoma | down | MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. | (:9/5459((( BB// | bicast cancer | //I/// | 9(9Ggiigi44(^^S/:35d9((((((((((: orebmoitan fun.tmu stuck 9(5/5///9255451/45^4/99((((((((: earner |
!UK- BO((((9 | 9)£/ΟίΟθ9(((((((( | (9/5//9: | ityR-i3 ;b acts os a iwntor suppressor and negatives regulates FGFR.1 in gastric 99;9£9£4ί·4<^:9(((((((((((((((((((((555555 | mir- 208 | esophageal squamous cell carcinoma | up | Mir-208 promotes cell proliferation by repressing SOX6 expression in human esophageal squamous cell | nra- 9///:((( | bepateoeilular 9(:/.554/5//9((((((((( | ///9/9/9 | NbcroRNA-423 promotes ccti growth anti mguknes (;9^ϊ9^9^ί^ίί544?/:9(((((((((((: targeting plGCipDWail 5t |
132
WO 2017/132552
PCT/US2017/015417
carcinoma. | hepatocellular carcinoma, | ||||||||||
U-Jf- | /££$£$ | MtR-LBh j>. irogueniiy de •'roarod in an an*, vuo -*r and itsovemxpression ;£cd$:C£$£$£t3$£ai$£££$$ poter-rial of gastric, c-anccr :$έί£$£££££££££££££/£: | mir- 2.0a | acute rnyeloid leukemia | down | HIF-l? downregulates miRί7/203 directly targeting p2l and STAT3: a role in myeloid leukemic ceil differentiation. | /:££$//// 42 L //i////// | lar ngeal i.nromumi | IB///// | /:£ro$:RMA$42$5p:££££££: /:p$$$$/td$££££££££://// progi* srot· vte ηκ-dulatrnn of AdipoR2 in lap ngeal ££$£$£$£·£££££££££$££ | |
pro-sut'.i' ui molecnlea ;/M£f££:£h$^$E2$£i£££:£: $Β$:$£ί$θ££££££££££;/ | 20a | b-cell lymphoma | up | MicroRNA miR-17 -5p is overexpiessed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | BB$£ | Suppressed miR-424 xe-xpicssroiiviaupregnibiion:·:·: //0f$i£cf$ifi£:£££:f $:$:$:$:$:$: £OW£££f£l$£££££££;/ progression of cervical $:p$£;£i$//////////////////////////// | |||||
$$f$///// :$i:S3:b//:$: | prolate cancer | down | UKroRBA f «hVusv f itfOiifejatron nt-grairot- and nu asion to prosf ate cancer $:$$$$$$$ihg;$££££:££ epidmroal grow th factor $$£££$£££££££££££$££ | mir- 20a | breast cancer | Up | Diagnostic potential of ΡΪΕΝtargeting miR-214 in the blood of breast cancer patients. | :/$£$///: $iB///// | //i$i£$$$/////////// //!£$£$3$£i0£/////: leukemia | dun n | miRs-i.te and -424 euntroi pahnitoylarion-riepetyient CD^-mtikattikeU death b> targe- nig a<.> 1 protein thiuuteerases f and 2 m cbrcmic Jvmpfiocvtfc h.'uki mil |
U-Jf- | renal cuff carcinoma | $:&£££$ Bill tines; | ;/£a£$R^$b3b££££££/£: dwr-regMlarion and £i$i$ki£$£$d£$:££££££;£: prolBaradoo, migration and Iri'-asronby targeting mnttr·. roetaifopepudase-v in ronal - eB «.nromoma | mir- 20a | breast cancer | up | MicroRMA expression profiles m human breast cancer ceils after multifraction and singledose radiation treatment. | mn- 424 | Juom-. myelogenous //!$$$£$///////////: | IBII | Resrorarron of roaR-424 suppresses BCR-AflE, aciivrtv and scu&fizes €ML cells -P uoafnub treatment |
/:i£n$/////: Bill! | eiidometrnl cancer | dpw π | MicroRNA-134 suppresses enjometnal carram ctem $d£ii£^£8$£rit$££££££/£ [‘•CBLB'tl and Botch $£$ hka£:$$teihs:;$///////////// | mir- 20a | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis by targeting EATS2. | $hiii$$:$ BB^I | colyn cancel· | duw i' | MiR-42.4/5b3 -Mediated £^£$$$£££$£££££££££/ /O^££^b££££££££££/£: |
$$£$///// | :/:Bh$fO/£$&$:$:$:$: £$$t$£0S££i$/£££: carcinoma | ££$;££ | $$$£$££$li:0e£:£££££££ oocogenrotiv and metastasis m head and neck carcinoma through targeting WA’OX $W$$$$$$$$$$$$$//////////$ | mir- 20a | cervical cancer | Up | miR.-20a promotes migration and invasion by regulating tNKS2 in human cervical cancer cells. | $$£$///: BB$£ | eplutevtud cancer | Bonmegubtionof miRIvS correlates nnhlvmpb node mmostasts and poor $£$$li$$££;:pb$$3$:T$/:$ //$££έί$££££££££££££/£: | |
$££$///// Bislll | /BCphldcCtbildE//////// £$$$£££££££££$ | down | <tenome-w/ide Screening identified Ti<at iniR-io^ A*t« a* a Meliorates Suppressor to Targeting £i$£gri£:££££££££££££$£: Hepatocellular Catebio aia. | mir- 20a | cervical cancer | up | Circulating miRNA-zOa and miRNA-203 for Screening Lymph Mode Metastasis in Early Stage Cervical Cancer | $$££$/: BB$£ | endometrial £$O$;£;/////////// | dbwn | MicroRMA-42.4 ma> :;fe$iro££££$d$i£££$:$/:$ $£$ipi$$£$:C£$£h$indi£$/: £$.££££$£££££$£:£££££$/ /:£Ο£££Ε£Ε££££££££££: |
i!!U- ££$58////: | $$&$££$$$$$$// | Mir-J *5a enhances celfubr proliferation through pos:hauseripfiouallv regulating FHLFP2 and FQXCH in human bladder cancer. | mir- 20a | cervical cancer | up | MiR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo. | roii- BB$£ | £hbpa$fiCli£bf£/£ carcinoma | drro n | MieroRMA-4-24 ia downregubted m heparocelbter carcinoma and suppresses ::ceB:tuiaf3tron:3ndiiKiasion·:·:·: //di$£gl$b/$k$£££££££/£: |
133
WO 2017/132552
PCT/US2017/015417
3BOBOB:5:55555 | ||:33 | naRK4~135a pminotea brunet ? «s\.r t ulf mmn and tiivasipn bv targeting | mir- 20a | cholangio- carcinoma | up | iniR-l 7-92 cluster promotes cholangiocarcinoraa growth: evidence for PTEN as downstream targei and IL6/Stat3 as upstream activator. | 3R«53:3: | osteosarcoma | dov β | :5:?^fr^f:Si-t^ti^^^^:333333::::::::::::: uncrcRMA-42-ί inhabits osteosarcoma cell migration and im arion > la 55j><fft^kid:.55555555555555555555555555 | |
/nUi-T/d: | ooicu-ecial cancer | MtR-i3$a promotes growth ami invasion of colorectal cancer via tuetasiafek | 20a | colorectal cancer | up | MicroRNA. signatures: novel biomarker for colorectal cancer? | 3bhiS:S:S 424 | ovarian cancer | Oil; | MietoRNAs cweievpreased in yipriaii ALDHl-pyskive celts arc assooraied with chemoresistaneo. | |
•UK· | cnlorevtai cancer | |||| | •:AsgyciaiiynjofnKCiyRNA:·:·:·:· nuorosnteilite tusiabihty G^l^iy$Tii;^Gi$^a^L:555555555555; sdeiioParcutnma | rnir- 20a | colorectal cancer | up | MicroRNA expression profiling of exfoliated colonocvtes isolated from Rees for colorectal cancer screening. | 3i0n$5::3 424- Bll;l | :3hBOBB&i3353 3:totBBI^:5:55555 | /db|h:3 | MiR 42d-5p reversed epidteiiabmescucht mai transition of anchorage* independent 34C.C ceils by directly targeting (CAT and 5:TjfG^f^^i0iri3::::::::::::::::::::::::::::::::::::::::::: |
/nUi-T/d: | pancreatic ductal 3:^grto-:B£GbdR:k555: | JpWft | MteroKNA-I35a inhibits cell proliferation by pancreatic dnctal :3^/cS^di5GAbii:Ef6ii^3333333333333333 | 20a | esophageal squamous cell carcinoma | up | 3bhiS:S:S 424- BIII; | 5p^(^3iid:3:3:3:3:3: /ΒΒδί|::5:5:5:5:5:5: | Oil; | MioioRNA-42d-5p Suppresses the Expression of SIX'S* tn Pancreatic >3|'^ϊϊϋ^:3333333333333333333:::::::::::::::: | |
H!U- 5iO5:5: | Β&&8θ6θϋ5:555 | 3;OO | /BBIBIB^^B55555:5:5 nuero32NA-J.:5n decreases pre-state cancer red migration and invasion vtfoenghdowraeauiadng·:·:·:·:·:·:· ROCK) and ROC&2, | mir- 20a | esophageal squamous cell carcinoma | up | Expression of circulating microRNA-20a and let-7a m esophageal squamous ceil carcinoma. | mu- | breast cancer | dOV β | actwatrnnvi rnsR-lv-N’·' tnmorigerucity of breast cancer cells depending yn estrogen rcoupiorstaltis. |
/nUi-T/d: | renal cell -carcinoma | JpWft | Tunior-SoppJCssive 8n'4i:iyRNB:iS/Sd:ii:ihibit$:::3:3: cartel -eli pmittetan^t. b\ nrpv',ngti?c-bf$rt oncogene in renal cel: SddfCibbhih::::::::::::::::::::::::::::::::::::::::::::::: | 20a | gastric cancer | up | involvement of miR-20a in. Promoting Gastric Cancer Progression by Targeting Early Growth Response 2 (EGR2). | :/101:3:3:3 425 | gasttte cancer | Oil; | NF-LappaB -dependent gastra ^u<ncur^eB growth by targeting (‘·ϊΈΝηροβ |
!UK- | ecdureotal cancer | MureRNA expression colonocytes isolated from feves far tnlorevtal -.aireei diOdraOd | mir- 20a | glioma | up | [Expression of mlR-20a in human glioma tissues and its effect on the proliferation of human glioma cells in vitro!. | /toU//// 430 | bladder carreer | dvwn | £ yptessrcftt M torero! NA V/uhBladdef Career, | |
/nUi-T/d: | caiorecfal cancer | MteroSNA expression profiling yf exfoliated cylonocytes isolated fmm lecesfm cdkiectai varrect //Accb^ti/tGid^::::::::::::::::::::::::::::::::::::::::::::::::: | 20a | Itepato-ceilular carcinoma | down | Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma | 3bhiS:S:S 42<> | breast cancer | Oil; | Direct targeting of Seed >a bv naR-dthts influences cancer ceil seeretyrne and promotes metastauc ::::d^i/6^i:kAfs^fi::::::::::::::::::::::::::::::::::::::::::: | |
3:diii?3:3:3 :::^5:::3:3:3: | :5G:iiftidkjr:333333333333:::::::::::: | 3;BIB: | Exploring the miRNAraRNA regulatory network in · karcd· rerjl v 'll carcinomas by naageuerafon sequencing expression profiles | ntir- 20a | hepato-cellular carcinoma | up | MiR-20a Induces Celi Radioresistance by Activating the 3JTEiM/Pi33C'Akt Signaling Pathway in Hepatocellular Carcinoma. | /:hni/-//// BB^I | breast cancer | dow n | nilR--d2s inlabhs migration etraeet ccds in vitro |
134
WO 2017/132552
PCT/US2017/015417
i/ibuRR/R RiRsRRR: kBRRR? | fgti^«RR^tiiRRRRR | Ri'lRl | Regulation uf B«-823 /RRfiktitRitiGi^RRRRRRRRR:: aduamv cm. \ ii i- akNA RBiORRRRRRRRRiRRRR | mir- 20a | lung cancer | lip | MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | 0itiRR:R: BBiRR | Ti/biPb^tioRiRRR | dnv n | ?AltemRMA-^2‘imbmus die nngratrnn and krerasrcn N //^iRhT:O^RiR?BlRRRRRR: targeting PAKo/vofiitn TSiiihimgRRRRRRRRRRRR4 |
/•ttyt-::::·:::·:: RiR^RRR | colorectal cancer | RRBR/R | MteroRN A -135b regulates metastasis suppressor I expression and promotes migration and invasion in ojcteciid.; axe·· | 20a | lung canc er | up | A. polycistronic microRNA cluster, miR-17 -92, is overexpressed inhuman lung cancers and enhances celt proliferation. | 42<> | O^RR | colorectal cancer and exerts tx ai.ffMpoptoij · lumtrnn C:B/f3^bt:i:hg/SlxR//////////:::::: | |
RiRjbRR· | eulereetal cancer | Ri'lRl | R^^lRROiRhfRRRRRRRR micraBNA-l ;5b rn :ltopla> Riotnatkef for Colo tectal Cancer and Adenoma | mir- 20a | lung cancer | lip | Apoptosis induction by antisense oligonucleotides against miR15p and miR.-20a in lung cancers overexpressing miR-1792. | mu- BBiRR | TitdOteidRRRRR::: carcinoma | dnv n | miR-429 frdtibits cells grow th and inx asion and regulates EMT-related radkej Penes rw targeting /GiigPti|:ui:iidltii^|RRRR:R: kCtitetttettidRRRRRRRRRRRR |
/•ttyt-::::·:::·:: RiR^RRR | colorectal cancer | RRBR/R | MteroRNA -135b protnotPS cancer progression by acting as a downstream effector of oncogenic pathwaxs io A>toh cancer | 20a | malignant melanoma | up | Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA155. | 0ibR:R:R: 42<> | gastric catKCr | down | miR-a?^ OKfduhhesthe ::exp£eS5apripf:C-:-HiyciH·:·:·:·:·:·:·:·:· human gastric carcinoma R^|ARRRRRRRRRRRRRRi: |
RiRjbRR· | eulereetal cancer | Ri'lRl | :/Mt^OARR^^mbRRRR i^Oih^-BRBRbtiiBRRRR/ *Λλι>\λΚχ Abv· trap feces for colorectal cancer ?$iA^iimgi2RRRRRRRRRRR: | mir- 20a | malignant melanoma | down | Differential regulation of aggressive features in melanoma ceils by members of the miR-1792 complex. | mu- BBiRR | Th^^PtihlOiRRR carcinoma | up | MmmRWA-d?* Modulates Icpatoceffufar Carcinoma ::Tte:OSiS:RBRRRRRRRRR2 TTyaibdgeheidicTTTTTTTTT |
PbitiR::::::::: rBBir | cpsoreeiai cancer | rB/rr | miRG? 5b Promotes C'aneer Progression by Targeting Transforming Grow fit Factor Beta Receptor II iTGri: R2.) m Colorectal < ameer. | mir- 20a | mantle cell lymphoma | lip | The miRNA-17792 cluster mediates chemoreslstance and enhances tumor growth in mantle ceil lymphoma via PI3K/AK7 pathway activation. | ybtitf:::::: BIIrr | hepam telhilar earerhoraa | ;O;|;R | Epigenetic modification of AIIR -423? promotes iiv er /fhhi^iuinilBR^RBRRRRR properties by targeting Bb Bihditi|:^6teitiRRRRRRR::R: |
liar- RORRR | R^ii^teiteiAtetiRRRR: | /1/1 | ideuttticatmr and functmoaf saeewne N WiteftiOAsRti^lRRRRRRR deregulated in colcrectal igtiiwilililil/iT | mir- 20a | medullo-blasfoma | lip | The miR-17/92 polycistron is up-regulated in sonic hedgehogdriven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. | mu- B?|RR | hunt T|RfidCtitem0ttiitR: | dnv n | Thi^26RiiteiOiitii^RRRR:i T|l0WtiiRmbrahRtiRRRRRR: uw as tort and metastasis by tergetregFltlATGFRi |
BrBrI | colorectal cancer | RRliRR | E xpresston of n«R-21 miR-3l. mlR-Οό and miR::i3-5b:is:oeffelafed:withlfce:·:·:·: cbnteai parameters of ItidititeCttiiEhtiiitiRIRRRRRR:: | 20a | nasc-pharyngeal cancer | up | Circulating miR.-17, mlR-20a, miR-29c, and mJR-223 Combined as Non-Invasive Biomarkers rn Nasopharyngeal Carcinoma. | 0ibR:R:R: 42<> | Th^igbaiRTT:TTT Tir^itihPiiitiRRRRR | O^RR | AffOroRN.A-2.b0 family members differentially regulate morphological plasticity and mode of melanoma eel! invasion. |
$byiR:RR RORRR | TgaSiiiRcShiSRRRRR: | RRIRl | significance and function of jfitR-3:5bm the uCcnrrence and development of gasttte ί«ί«ί|ίίίίίίίίίίίίίίίίίίίίίίίίίί | mir- 20a | osteo-sarcoma | up | Upregulation of microRNA-1792 cluster associates with tumor progression and prognosis in osteosarcoma. | cmlryR/: BBRl | mesenehyuial r^orrrrrrrr | d«w £' | MicroRNA Expression /OB^RtiiB^BfRRRRRRR Riteti/bi^RRRRRRRRRRRRR |
ObiteR:/:::::: rBBir | /bitig-jOsERRRRR::· | RRIRR; | AberoEMA-TKb promotes lung cancer metastasis by •:£egul3ting:multt.ple:tcygeis·:·:·:· :Τ1ίί;^έ:ΗΛ^ΐί^:^ϊϊΐ·^δ^::δίΐΐί::::::::: iBRRsRRRRRRRRRRRiRRR | mir- 20a | ovarian cancer | lip | miff-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. | ybtitf:::::: BIIrr | tpomsnuillppiRTy/ TibhgTAbRsRRRRR | dow n | I’xpresxonvt miR-Tre. miR ο; >a.jayj>-4?3ss Potential Biotmukers for Detection of Early Stage xvtt i kd wgUmcvr |
135
WO 2017/132552
PCT/US2017/015417
0i/n0))00 3303/)))))) | 0000000/0000))) | 000/0 | Arab sis of unoroRNAs 0/0000/00000000000000 ):0^0000/03333333333333333 | mir- 20a | ovarian cancer | up | Ovarian tumor-associated microRNA-20a decreases natural killer cell cvtotoxichv bv downregulating MICA'S expression. | )///0:))) 0/00:0 | oral squamous «31 vareinoma | dm? n | MiR-42V mriubits oral s^namuUz vC'J camiitvma growth by targeting ZEB i |
0///33)))) 334360)))): | ))giifr0iO$:O)))))))))) | dowh | Furtattartai profiting cf precursor MicroRNAs Identifies MtaroRNAs 3OOi/0O)0iO000000000) 0pOOO/O)))))))))))))))))))) | mir- 20a | pituitary carcinoma | up | MicroRNA revolvement in a metastatic non-functioning pituitary' carcinoma. | 4ηΖί-:4:4: 0/0)0) | osteosarcoma | dbwn | Tunxta-taippressmg EtTeGS of HtfR-433 oh Human )Q/te/$/00/iO0)))))))))))))):0): |
•UK· 4:ί·36:4:4:4 | 5)giOi/0))))))))))))):0): | down | 5:MiR4i/3:0i/i0/O))))))))))))) 0000000000100) Targeting AEG-f and E$eN2 | rnii- 20a | prostale cancer | up | miR-20a promotes Prostate cancer invasion and migration through targeting AEsE.2. | :)//00)):) 0/0000 | (A <*«<* .,ηιΐνο | 0/0/0 | EcfOpta over -expression of ))0θθ2///^θ000000ί))))))))) inuse itchy maiAorepitbeiiai 00fta/iitiO0/Or)):///)))))))))): increased drug sensitivity in ))i0O/0Oi/OiO/fO)))))))))): ))0/////Ok)))))))))))))))))))))): |
3://40:)))0 0/0/333333 | fion-oittail cell tang 00O00000000000000 | ))00:0): | UpreguiatiOr- ofouR ΪΒ·ηι hunujnnpmsinalicelliuna:::: cancer cells prontot.es Eri.fr? axtri ηίκ>η by targeting PRP2R2 A | 20a- 5p | colorectal cancer | up | Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma | 3:/4/)3333 42<> | ovarian cancer | down | A roiR-20;i microRNA cluster as prognostic marker in advanced ovarian 0000)))))))))))))))))))))))))):0: |
inu- 0/30:0:0:0 | oral squamous cell 0000000000000)0 | 000/0 | Genome ide Study cf 0:0/R0O)00i0O0/'00))))): fN < ·οηΛΐ Ord · aoier | mir- 20b | breast cancer | up | MicioRNA-20b promotes cell growth of breast cancer ceils partly via targeting phosphatase and tensin homologue (PTEN). | mu- 0/00:0 | pi.is! lu. <!·.« | up | 000000/00000000000) bjutaRNA~Q9 inbifrtts ceii proBihtauoiiby targeting ρ2?Ε.ίρί in human prostafe 530///04/)))))))))))))))))))))) |
4//46::4:4: 33003330 | 3:/00/0)))))))))))))) 530/00/000:0:0))) | dvW‘0 | miR-DA and iniEW >“ 3OO0p®OmtO:df)))))))): gk^/lasiuma mnitifp· me 5000000/00000000))))))))) 00fii00ri0f0/0)/OOfr0))):0): )/0000000/000000000000) | mir- 20b | bepato-celtalar carcinoma | Up | Crucial Role for Early Growth Response·· 1. in the Transcriptional P.egniation of iniR-20b in Breast Cancer. | 4/04:4: 0/0)0) | tribabc/if))))))))))): caremoma | ):00//:/:): | MumR13AN?9 oppresses cell preitfemttait epitfceltah mesenchyiiial transition, and metastasis by direct 00000000/000000 i ?h · tnu-nataei! 4earet/rima:7:7:4:4:4:4:4:4:4:4:4:4 |
!UH- 00/0000 | 5fei/OO0O:))))))0 | 000:00 | 3040000/0))))))))))))))))) 1 tar'tad run ft tcuxx 3:|i/O0|/0/00:G0|)):)))))))) :)flOl!feraiion:andinvasio:n:·:·:·:· by Targeting RAQR3 | mli- 21 | adrenal cortical carcinoma | up | The role of microRNA deregulation in the pathogenesis of adrenocortical, carcinoma. | :::/0:4:4 -G2 | ovarian cancer | down | Differential microRNA e^pres<y/ut<ygitatw'z mJ ))0/0300//00))))))))))))))): association with Taxed resistance in ovarian cancer ))Oi/))))))))))))))))))))))))))))))) |
044//)))))) 0010)00 | eotarectai cancer | down | M/toRNa-IS?, an 0|0O0||/0O/0000000000) Suppresses Coloreetaf Career CeB invasion and Metastasis it· Mice hy Directly Targeting F0R4L2 | rnii- 21 | breast cancer | up | Next-generation sequencing of microRNAs for breast cancer detection. | :)//00)):) :)00):0:0 | gastric cancer | 0/0/0 | ::Down-:feguiated:miF;-:9:and·:·:· nuR—133 in human gastric 00//000000000000000000 |
400:44::: 0O0000 | cuioreetai cancer | dvW‘0 | < fr orexpmszicn vi paxt'Jm 3)i0dOdO)/O:/30:)))))))))): 0//OO0O0/0//0/000000: ))0)0/0/0//000//)/0)))))))): uietasrastfe in ctaurectal ):/^^)))))))))))))))))))))))))))): | mir- 21 | breast cancer | Up | Quantitative Measurement of Serum. MicroRNA.-21 Expression in P.eiation to Breast Cancer Metastasis in Chinese Females. | 0/0)))0 | gastric cancer | dote it | fneiomuf vppres^r Roles 01 itaR-d.N and imR127 in Gastric Cancer· |
136
WO 2017/132552
PCT/US2017/015417
(:ibu3((((: 35(385:55 | (((83/5:8043((((((((: | 5850( | niiR-1 '7 is. Ireq-icntb ifown^gtshveil m gaatw cancer and <s a negative rc-gula: or cf Cdi 4 2 | mir- 21 | breast cancer | up | Diagnostic potential of PTE’Ntargeting miR-214 in the blood of breast cancer patients. | :/4843(((( 4? 3 | 338058848583((((( cemtomna | dov n | ?a lu mRNA—J' inhibits ((58488588^48458838((((((((((((: henotocelndnr carcinoma by large· mg p21 av· waled kinase tRAK.4) |
Cmk/:////: ((388½½½ | ((gh018a3dm3(((((((((( | dowO | jniR-h?-i and miR--} S'? //iOOfOiifeOOdi:://////// gimblustyma ninltEo· me (:884ΐ3Ο-33838888((((((((((((((( (:θ38488ί058(53θ43(8(((((: futUdr Stent ceils | mir- 21 | breast cancer | up | Tissue specific expression, of extracellular micro RNA in human breast cancers and normal human breast tissue in vivo | :(4844///// | 53484/4^534:(((((((( | down | The micfoRNA-hUl mhtbits liver cancer cell nngraliot’ b\ repressing, die protein expression and lumuouvl cAMP response element binding profem |
as»· ((388½½½ | 58488088885((((((((( | //850(: | itaR-1 '7 js. Ireq-icntb (00008008(((((((((((: ((0000:80:18:8//////////: negate e regulato r -of Ge \ - | mir2 J | breast cancer | up | Differential expression of tniR21, miR-125b and mlR-191 in breast cancer tissue. | mu· 4? 3 | oral squamous <ell varunuma | dov n | nuR-433 inhibits oral s^uaniuuz «.ell carcrmuna riTSCC· cell growth and metastasis by targeting 8^^3/85((((((((((((((((((((((((( |
78837:7:7 ((388½½½ | 5g4ipbi88idO(((((((((( | :/:380:/ | (;OORO//5/(3(((((((((((((( /0080384803((((((((((((((: gimblustoma ana <und>it$ the sieniueas of glioma stem cells by targeting RiVI'-l. | mir- 21 | breast cancer | up | BMP-6 inhibits microRNA-21 expression in breast cancer through r epr essing deltaEFl and AP-l. | :/mir-////: 4-42.$ | iithg Cancer | 5885(53 | MicroRNA 4423 is a primate-specific regulator of airway epithelial cell difforemiabon and lung • u.'zu |
tnu- ((388½½½ | 38488088885((((((((( | ((8O3(: | (:00500088(((((((((((((( (08000808(((((((((((((((: (:8080800388((((((((((((( cempafisen with other brain neoplasia of grades i- | mir- 21 | breast cancer | up | Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer | mu- 445S | ((8585138848385((((( corctomua | dov n | Tumor-suppressing effect of nuR-Φΐ on human hepatocellular camitreiua |
CttUb//:/// ((3888(((8 | (;gl4434d3Pi34t((((((((((: | Jpwn | /:MtR(/5T3iSikO/////////////// (;3r308883O38388((((((((((((((: angiogenesis at burumt glioblastoma ceils by (:i0844000((((((((((((((((: | 21 | breast cancer | up | Up-regulation of miR -21 by HER2/neu signaling promotes cell invasion. | :/4453((((( 448 | hepatocellular ((5834884885((((((((: | down | Low Expression of mtP.((88S/4858$r8(EM3Z44d((((((((( (508050380588(((((((((( Regulating ib.XX? in ikpaioceliuhu-t arernumu |
liar- ((3388((((: | ((8403(((((((((((((((((( | ((8O3(: | Ourexore oeduurNA-l inhibits human gltoma ceils growtl bv tamc'tngRv·''! | mir- 21 | breast cancer | up | The Regulation and Function of mrR-21-F0X03 a-miR-3 4b/c Signaling in Breast Cancer. | mu- 448’ | colorectal cancer | dov n | M reused e cpressmu of fecal miR-44?S and miR1 ’v5h*3put enrly-am.gg 7>3ί·845ό43:385έ5Ζ;7/////////////: |
UUr- ((388(((((( | //83451888414884:((((((((: ((08380((((((((((((( | ((308:( | 5Εό8ίΟΟΟ3(((((((((((((((: mtcroRBA-f x zippresses /030^00:883((((((((((((: (038840444:8854883((((((((((: hepatocellular carcinoma b\ targeting ΑΚΪ2 | mir- 21 | breast cancer | up | MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. | /:35////// 885(8(((( | gastric cancer | down | mtR-449 inhibits cell proliferation and ns dcunregulated In gastric cancer |
8338///// ((3/88((((: | (000038((((((: ((08008(((((((((((( | down | FDIL$ is a novel regulatyr of epithelial i< csenctw nigl transition xuntiulhnc emit recurrence at bepatocellular iuodnoma. | mir- 21 | breast cancer | up | Combination of miR-21 with Circulating Tumor Cells Markers Improve Diagnostic Specificity of Metastatic Breast Cancer. | :(354///// 449a | /(58ci8458t448i(((((((( ((3888885((((((((((((( | 58833(: | MiR-449p functions as a /838®885884853884485(((((((((( endometrial cancer hi wgetmc *. :)< ΤΆ |
UUr- ((388(((((( | multiple mycfogta | (:38O8 | 50303083(843008((((((: induce Apoptosis aud Suppress TtUnoitgenicity (83$:f54gO5g:333(3/(385:((((((( Multiple bit Onia | mir- 21 | cervical cancer | up | Overexpression of miR-21 promotes the proliferation and migration, of cervical, cancer ceils via the inhibition of PTEN. | 83!· 449a | 50805888385((8 5:38848533(((((((((( | down | microRNA-449a finKtiora //^:8(348584(8003333(((((( gastnc adenocarcinoma by //t8853888:O:3(((((((((((((((((( |
137
WO 2017/132552
PCT/US2017/015417
ktiiuEEEt | kiiBtiO^tiOiiNEEE·: | $MiRM3EO •/BiBEti^OBftikEECEE x^tiKtibidBik^ljEEEEEEX/ downreaulallng ERMl A | nsir- 23 | cervical carcinoma | up | MicroRNA-21 promotes cell prolif eration and down-regulates the expression of programmed cell death 4 (PDCD4) iriHeLa cervical carcinoma cells. | ZiiuEEE | E^^ON^RhEEE·: | Jig? g | mtR“444u Regulates Chemosei'SHwiR to Cispfcmaby Targeting EG^iRfki?iE4hd:Btiti2tnfEEtx •fg'<M t oils | |
yntirEEE: | non-omafl cell lung ^Ο^^εεεεεεεε | Jpwft | ntioroRNA-do 7 functions as a tumor suppiessur in tiumau uou-sroalJ cel! lima cancer bv targeting Sj.C? ?A!K | 21 | cholangio- carctnoma | up | MicroRNA-23 is cverexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. | ΖίόΐΕΕΕ 44ba | gastric cancer | down | miR Uro anJ rDRo m |
mu- | /EiNfkiBN^EiEEE·: | rgiR-13 7 suppresses sell growth in uvanan rancer h\ /B^$tft^:AB5t|E:EEEEx/E | nsir- 23 | cholangro- carcrnoma | up | PTEN arid PDCD4 are bona fide targets of microR.NA-21 in human cholangiocarcinoma. | mu- | ghobbtiorga | Jig? g | MiR-4JEa evens tunrorsw^pressive funePous in xkaiO-^tidktetiohja-k^tZEEx targeting Myc -associated EaREiifj^itiiPiSkEEEEEEE: | |
xiikEE:X:X | E^dti^^tiSEEEEEEE xiMteinaiptiyEkE/EEx | MicroRNA-13 7 promoter methylation fc& associated :xyidi:paurof:overall:sarvivai:·:· hi panctiis with squamous cot' cnrcuivroa of the head aid t.p..k | mir- 21 | cholangiocarcinoma | up | miR-21 Targets 1.5-PGDH and Promotes Cholangiocarcinoma Growth. | XinifXXX: 44tia | lung cancer | ddwn | Combthiftg tttioroRNA449a/b whh a NDAC inhibitor lias a sy nergistk effect Jit growth arrest in | |
i!!U- | meN melanoma | Epigeaepcs. uacreRNAss. and cnrcrovgcncsis MbbB^ti^BdlEbfEEEEE xrogiatiPPikkxxxxxxxxxxxxEE | nsir- 23 | cholangro- carcrnoma | up | miR-21 Inliibitiou Reduces Liver Fibrosis and Prevents Tumor Development by inducing Apoptosis of CD24+ Progenitor Cells. | mu- | EltihgEk^^EEEE: | Jig? g | MfcreRNA“449a inhibits ceil growth in fung career E^diOiB^ifeh^EEEEkE iterteodk'g RNA nuclear kkNtiiRiiBkkkxEEEEEEEE:: | |
knyiEX/X/ | anaplastic thyroid EidiEreO^EEEEE^E | Jpwft | bA«n ?gi rooi oMitR 138 is associated with ig- eievpreasreu f human tcionjero^rpA or λ uansenpiase prorem in human aaapiasuo thyroid carcinoma pell lines | 21 | colon cancer | down | miR-21. and miR-145 cooperation in regulation of colon cancer stem cells. | ΖίόΐΕΕΕ 44ba | neuroblastoma | down | ran. re R M -ratun troi E^^:^^f:Sii^^^di:ih:EEE nemobiaatetna through mdu?mg roil dtnerenuatron and cell rock amrex: |
XtiiteEX/X: Bllll | EdbidhteEEEEEEEE:: iy mphOcylte 0kuti^Uk////:X:X:X:X:X: | dv'V‘0 | rouRyd 3K and *424 control palmitoylaf iOG -dependant CD'E' mediated c eil death by tauetme ucy 1 protein throeateraae* 1 and λ tit chronic !v mpbncv tic !·::! grok·. | tuir- 23 | colorectal cancer | up | Expression of raiR-2.1, tuiR-31, miR-96 and miR-135h is correlated with the clinical parameters of colorectal cancer. | xbiiix:xx 44tia | EkdhEsk^REeiixEE E!dhgE:khEerE:xEE: | Jig? g | MfemRMA-449a is Dc-wtuegufateri io Noi·Small Cell Luna Cancer and inhibits Migration and invasion bv Targeting c- |
!0K- | c!u-mic E^Edij^hdii^EEEEE xkB:^itidEEEEEX/E: | kddteiK | RGR-ABLZGATAl/rgfR138 ttuntcticuiHv BpitirihateEid-iBkXEEEEEE •:deukeinogeaesispfcluonic·:·:·:· K<} eipid leukemia | mrr- 21 | colorectal cancer | up | MiR-21 regulates biological behavior through the PTEN/Pl-3 K/Akt signaling pathway in human colorectal cancer cells. | um- 449a | itoti-smab cel] EldtigiBB^iNNNN | drove | EhftP^:O^^5dEEEEtE ayppressox Non-sroali Cell MEtikg-G^OkXXXXXXXXEEE: |
kktiiEkyX | roka-ectal cancer | Edprokx | Down-regulation offtiiR138 promotes oolorecfal dtre-dy rargetige | 21 | colorectal cancer | up | MicroRNA. expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. | ΖίόΐΕΕΕ 44ba | Etiti$ti^fe$kkxEE: | down | Χ:&Κ&ΐ^ EddtiitiEghlp|d:tiEEEE o&feo&arcyma and promotes ceil apoptosis bv targeting IK I 2 |
138
WO 2017/132552
PCT/US2017/015417
2/ΐ4«2/2/2/: 2/0/22/2/ | 22Ο&ίθ!2/2222222/ 220022/2022222 earcrnoma | 2/222222 | Downregalarion oiruBN 1 :8 Snstams NF-'?B Acth ataan and Rronsates ////Li6i4/R6ft/:Fo6/r6ait6i4rii/2/2/2 xEsophageakSqnamouadsell·:· 2020022222222222222:/ | mir2 J | colorectal cancer | up | Circulating Exosomai microRNAs as Bioroarksrs of Colon. Cancer. | /:/222/2/2/:/ ///0/2/// | ovaiiau cancer | dov n | MKrnRMA“d49a rcdiuet, cell snn'jvai and enhances ///2i2^2Bnrih44o24/$/$/$/$/$/$/$/:/ /2602214^/2^22222222222:/ ///864332666146164 2?222222222 NOTCH] in ovarian eariucr ..ells. |
$/ritf/r$/$$$ /202/2/2/ | gastric cancer | 2/0222 | MicroRNA profiling of human gastric- cancer. | mir- 21 | colorectal cancer | up | Detection of miR-92a and miR21 in stool samples as potential screening bioroarksrs for colorectal cancer and polyps. | :/|ϊ/π£$2;2 //®22 | prostate cancer | ///43344/// | uaR-4d9a targets HDAC-1 and induces growth anest 2/26020446642/2/2/2/2/2/2/ |
ίϋΐι- /202/22// | 2/&6htf/4iH/:422k2:2/222 220022/2022222 earcrnoma | 2/222222 | 20000002202222 rmasron and promotes apoptosis id head and neck squaw us bell oarotoctma ///664/16348/2/2/2/2/2/2/2/2/2/2/2/2/ | mir- 21 | colorectal cancer | up | Correlation of over-expressions of miR-21 and Notch-] in human colorectal cancer with clinical stages | mu- ///0/2/// | p...St !·.«. - .i'-cl | dov n | 22200224002222222/ dependent seif eyefe arrest and senescence in prostate ///iNkah/cbllk/////////////////////////////////////////// |
$/hhb-/:/$/$ 2/02222 | head and heck :/:2qiteSoy2/$Si/i/:/:/:/:/2/2/: /26466/1604^222222222 | 2/202/: | Bpie Of uinroRNA-f38 s$ ///a/p6t/2h6i4i//643466//////////////////////////// $2000020002222: neck sguaumus ceil 46468:464662/2/2/2/2/2/2/2/2/2/2/ | mir- 21 | colorectal cancer | up | increased expression of mi.croRNA2land its association with chemotherapeutic response in human colorectal cancer. | /:ί4ίί$/:/$/ /:/0//2/ | htitg cancer | down | Combining microR/NA449a/b with, a EfDAC inhibitor lias a $y neigistic effect on growth arrest tn 2/1/4426424842/2/2/2/2/2/2/2/2/2/2/ |
$/ritf/r$/$$$ /202/2/2/ | head and neck squamous ceO 22666i/424te222222222 | down | Doy.ii regulation of RlioC by mxroKi A Ckustrit* in de-actn anon of PAN, Sroat.d f rkiU?) smnafmp pathway in head aod heck ///$q’844i6'86/:66ii:6/666ii/i64/i62/2/ | mir- 21 | colorectal cancer | up | MicroRNA-21 controls hTERT via 35TEN in human colorectal cancer cell proliferation. | :/ίϊ/π£$2/2 4ί·ρο | ////4636434611/666/2/2/:/ /61360446642/2/242 | 6424442 | ////Do/22:/rgg4]246/r6of:4iiR$/2/2/ 45'Ό promoted non-small cell lung cancer growth. |
$4$ύ$/$/:/$ 2/0/222/ | hepuU^v-dhila}· ////246614614-42/2/2/2/2/2/2 | down | bBh-Hy induces«. ri! uoh* anostby targeting CyOtth $0222002200222222: 22202022222222222222:/ | tuir- 21 | colorectal cancer | Up | Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells | /:/hiif$/:/$: 45ria | hepatvvihflftt· caremoma | ///d/bteh//// | mrcroEN targets DNA inetfcxltonsferase 3a 2/i/b/44p4i62O622222222222/: /20^422222222222222222 |
///iiu/E/:/:/:/:/:/ /20/2/22 | /2irihg/6a6o642222222: | down | $k22$teg2O2O£222222222: tuKroRMA-f T «.du-c radivseysmcauvritt. lung 222Ο/222222222222222222 | mir- 21 | colorectal carcinoma | up | Altered levels of the ouco·· microRNA 21 and the tumorsupressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemcradtolkerapy. | :/ίϊ/π£$2/2 45db- /244//// | breast cancel’ | 6422442 | Targeting HER3 with iniR4$b- vp suppress breu*i /264466466ίί66366ίΐί86/43364222222 |
:/:/^2/:/:/:/:/: 2/02222 | naso-phar,ngeal ////24661461442/2/2/2/2/2/2 | down | MuM suppressed nasCtphaiy ugeal can. j no ora growth and fumortgeiesrs by targeting-he CCNDi 2rib20022/2/2/2/2/2/2/2/2/2/2; | tuir- 21 | diffuse large B-ceil lymphoma | Up | inhibition of mrR-21 Induces Biological and. Behavioral Alterations in Diffuse Large BCell Lymphoma. | /:/hiif$/:/$: /:/0/22// | bladder cancer | dan n | nuB-4xi iribibbs rmasmn an»3 proliferation of bladder carwei In regala-mgEMT |
$/ήη/τ$/$$$ $08//////////// | ηοη-sniaB cell iuna 2/^02222222222222 | down | MiR-138 iiiiiihits Tumor 2/Gi20O*O/20222222222:/ Repression of EZH2 wi 2022200202022222/ I'aituir | mir- 21 | endometrial cancer | up | Highly increased maspin expression corresponds with upregulation of miR-21 in endometrial cancer: a preliminary report. | /0/2/2/ | /$όΡ3όί6ό666/$/$/$/$/$ | /2©Ο4/^/βρίρ6Β222222222/ Colorectal Cavernoma Cells via Rxnvuregulaiipn of | |
nar- /202222 | ;2iteO2$222&&O/: 2/2022222222222222 | 2:222222 | ///riaR2f3§/riiO22222222222/: probRrauon he targetmg v phCtSphojftoSitfde'ifcpendaru ptotebi kinase- i Ci/r$hyhOriari/2sU/:hihg2/2/2/2/: cancer ceOs. | mii- 21 | esophageal cancer | up | The expression of mlR-21 and miR-375 predict prognosis of esophageal cancer. | mn- :/0/2//2/ | esophageal /26436436424/2/2/2/2/2 | down | MNvi ·»: .if<-44] 'm N. Broing.yN Rehw u-r A the Rsnpf^gna] Csj'ornoma OH 2ί2ί/^Β^22222222222222/2/2 |
139
WO 2017/132552
PCT/US2017/015417
):Βί«8/:))): | nou-shjaB cell Jaag /)8ti8i))////////////)//):)) | i/dkOi | Prognostic potential of micioRNA-d '8 and ns target mRWA TDK 1 m sera ::fiji:pgiieiltg:wkhnOft-:i-ftinll·:·:·: );ygk:hii^)^hkSk)))))))))))))))); | niir- 21 | esophageal cancer | up | [’Diagnostic values of salivary versus and plasma microRNA21 for early esophageal cancer]. | ):Rui9)))) )|?|)))) | ))088)))))))))))))): | doo n | MiRMA-4>l plat s a role a? tumor oppressor ro human ///^Od/oNB)))))))))))))))))))))) |
71θίή////// | oral squamous cell ]3riNik0kN///////////:]] | dc-wo | Altered tevels offtttR-21 miR-l25h-?\mtR-ljA miR-i55. miR-lS-h and nuRG'Gmoral yiuan<ou< cel! carcimunu anti );dSS$Nkii$ii/kitk)))))))))))))))); NiftteopafhoJogiC’ri )tehkfii9te«9fi9k)))))))))))))))))) | mir- 21 | esophageal cancer | up | Alteration of miRNA. Expression Correlates with. Lifestyle. Social and Environmental Determinants in Esophageal Carcinoma. | 7mif7:::7: :))0)))) | ]00|||)))))): | down | MicroRNA miR-451 ]]3$R8r^tiNe^888))))))))))))): PDfGAKT pathway tinongh CAB-38 in human /•giidb^)))))))))))))))))))))))))))): |
:/ίϊϋΝ///// | ovarian cancer | //tRO): | MicroRNA-138 suppresses <a ansi' cancel tell nu asic-ii •:af<d:inelastasiskytacgeling·:·:· | mir- 21 | esophageal squamous cell carcinoma | up | mtR-2 ί Do wn-Regulatio n Suppresses Cell Growth, invasion and Induces Cell Apoptosis by Targeting EASE, TtMP3. and RECK Genes in Esophageal Carcinoma | 7mif7:::7: :))0)))) | hepamoeilular cammoma | down | MicioRNA-4-Sl regulates activating transcription factor? 2 expression and /pibifek^ ])irif^tibh8))))))))))))))))))))))) |
/8088/))8)0))))): ίίΟ/^^ΤΤ)):))))))) | ))OO | Duwnregalatton of n«R1 v IS ae Xh isfcd s 'll Ov «(expression of human /•tefeiikid-kk'Vftr^//////:))))))) Uai'Svriplase p· olein in human anaplastic fliyroid carcinoma ceB tinea. | niir- 21 | esophageal squamous cell carcinoma | up | Expression of niicroRNAs in squamous ceii carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers foi'HNSCC and ESCC. | mn- :)/0)))): | ))O8b$8OR:)))) cammnroa | doo n | //^O^STOiOiGhti))))))))): Hepatocellular Carcinoma through Direct Suppression //bi :S&)T))))))))))))))))))))))))) -, | |
illll | carcinoma ceil senescence· Iw targeting E2U2 and is dowtuegdaicd In tinman /:hiftdP0ftiii^c3;^|////////:))) )te3k!80!^))))))))))))):)))))))))) | 21 | squamous ceil carcinoma | up | proliferation and inhibits apoptosis in Ecai09 via activating ERK1/2/MAPK pathway | iin | ))0)0))8)))))))))) | nnnoi suppmssm nf human hepatoma cell growth and T:i:ktGkisii6jti9999999999999999999999999C | |||
:/18119/7:7: | renal cleateeh )3riNik0kN/////////////: | down | MiE-l Bi suppresses expression ofhyporia- ύ^ίίί^ίΕίίέ^φΐίίίϋί:'?;:·:^:!^::::::::::::: IN m clear ceil renal cell )tetik)mPtitp^§^83B)))))))): | rair- 21 | esophageal squamous ceii carcinoma | Up | Relationship between altered expression levels ofMiRZl, MIP.143, M1RI45, and MiR205 and clinicopathologic features of esophageal squamous cell carcinoma | ybtiiN///: :)/0)))): | 91808/8889::)))))))) adenocarcinoma | :/8>88):] | ))Ag^i^lbri:bf:]]]]]]]]]]]]]]]]]]: ]]r^iri(^i8dri8/lh]]]]]]]]]]]]]]] docetaxel resistant human lung adettevatxinnma «.ells is linked with dy srcgulatmu of pjiR-45 1A>Myp* Sunk iwrad- 51 signaling. |
UU1- i|8|))))) | ]/s)hati]9eB:8)88888 )088))))))))))))))))) | /BpO) | MuioRNA-Mh Regulate» DNA Damage Response in Small Cell Lung Danger Cells!» DuectR Targeting ):8^))))))))))))))))))))))))1)) | mii- 21 | esophageal squamous cell carcinoma | up | Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell. Carcinoma. | //kuiy//// )111)))) | iiasu-plotp ngeal eatunuma | down | ]:8*Βθ8ί]«3ίιδΒ9όέΠ]]]]]]])]] growth and invasion by tergettug MB7 and is associated with surer' al m nasophan ngeal carcinoma. |
:]:ftBi9])))) ίί^ί))))) | coicu-ecfal cancer | dOwft | Regulation Of RAPiB by •MaiR-TaPatippiasseabuman:·:· A-aipiaitdig-aicktpkiagteHo/:)) /^tiferiitidit))))))))))))))))))))) | 21 | esophageal squamous cell carcinoma | up | Circulating microRNAs in. plasma of patients with oesophageal squamous cell carcinoma. | ):88())))) )|S:j))))) | GOn-SbiaBcell //li/tiig/OpkeOi/:/:/:/:/:/:/:/:/ | down | C turn ai evaluation of nnoroRNA expression profiling in non small cell /)idhg/h)iirebf)))))))))))))))))))))) |
7011)/8//// | colorectal cancer | down | Gene module based reaulalor Inference identify mg miR-1 ;O as a )::iitik0t58^i838<:8:))))))))))): colorectal cancer. | mii- 21 | esophageal squamous cell carcinoma | up | Down-Regulation of PTEN Expression Modulated by Dvsreguiated miR-21 Contributes to the Progression of Esophageal Cancer. | 7011(797: :)Βΐ))))) | //npk)5kihB:$Sii:))))) ]]l0hg:iteOrT))))))) | SiSOAk)] | ::MiereRNA:-:4-5d:fnnetions·:·:·:·:· ::/^:d:iii^):^^^^PG!8):///// hnnian non-small coll lung cancer by targeting ma- :/9eiNe3:j^tNk:/i:4///////////////: /)(/^^)88))))))))))))))))))))): |
140
WO 2017/132552
PCT/US2017/015417
7ί2«733333 :(2:22(((((( | ((¢77732312:2:2:2:2:2:2:: 33227222233(((((((((((((: | >®3 | Regulation of RAF ί B by tuiR-B* xttppressea human colorectal c ammonia ceil 9:3pii3i3!bh39:::::::::::::::::::::::::::::::::: | mir- 21 | esophageal squamous cell carcinoma | down | Serum inicroRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. | 733737: :((i?7((((( | (3722030(((2 lung «.am-er | Juv n | ((3h7:72272332:7b2(((((:((((((( fupv<4j«.i puR\(*um m non-small cell lung cancer |
:::7213::4:4: 33373333 | 2;gf7O:2:2:2:2:2:2:2:2:2 | 37333 | MiR-!98iiibrntteMc:-i J xfm mt md Po enua -1 'ΆΙ/ Vh -*d Αχρίο i tt (;3i7272i2((((((((((((((((((((((((( | mir- 21 | esophageal squamous cell carcinoma | up | Clinical impact of serum exosomal microRNA-23 as a clinical, biomarker in human, esophageal squamous cell carcinoma. | :::3514:4:4 (3332((: | osteosarcoma | down | 1 untor- mppresStepFffea^ 3322:20323333322.323333333333: ((^2322722(223((((((((((((((((((( |
33373333 | 273770^ 3733(((((2( ((27337372(((((((((((( | dyu n | 71« mkryRNA. miR-139 •:saippl«S£«S:£neiastas3a!Qd·:·:·:· ((7r3333i7772(((((((((((((((((; hepatocellular earcuiotua by dcw'u-tegulatingRLohnass: ? | inir- 21 | gastric cancer | up | Oxidative Stress Upregulates FDCD4 Expression in Patients with Gastric Cancer via miR-23. | (:337333: (122((((( | (37372313737((((( | d«w n | MiR-451 inhibits cell 3:2(2(0:222(2377(22:2^3333333: urgUmc · NCL Ϊ* -η d <5 assoclatetf whit prognosis Of Osteosarcoma patients |
:::7213::4:4: 33333333 | 2338ρ73ό2έϊ7322:2:2:2:2: carcinoma | 37333 | Eterepreasion of <-14-5 Caused by MioroRN.A-159 1:^273(37:32232:7:7:7:7:7:7:7:: (322:332272722227((((((((((((: metastasis of liuujan hepatocellular earcuiotua | mir- 21 | gastric cancer | up | microRNA-21 promotes tumor proliferation, and invasion in gastric cancer by targeting FTEN. | :::3514:4:4 (122((((( | osteosarcoma | dou ti | ((82(22(272(2232(:322233:333333333 receptor homolcg-l by mici-oRNA-451 represses 33tkp3f2l32i:2itOb3f:333333333333; osteosarcoma ceils· |
722273333: 33333333 | ((77773322^77722((((((( ((¢233333(((((((((((7( | down | (;b73237:3g3332:f22(((((((( prohfetufion and invasion oi fccqaio<€llnfar«.ateim>ma tltm.ngb the λΎΝΙ/ΓΌΜ 3W23333333333333333333333333333 | rnir- 21 | gastric cancer | up | Evaluation of MicroRNA Expression Patteni of Gastric Adenocarcrnoraa Associated with Socioeconomic, Environmental and Lifestyle Factors in Northwestern Hungary. | 3:3373333 (ί027 | ::irypo:-pliafyilgeal:· squamous cell cutetonma | 723333; | 3ί2272(3222223ί:ί7222(2((((((: ((2232(877(22(222(2^:07((:(333 j-Mam b\xplkuvngeui squamous •'ell ν.υν«.Λη<η (^7722372233(2((033333333333 expressly η steriatute |
:::^124:4:4: 11113 | coi<4ecial cancer | ((232((( | MtefoKNA expression profiles in Imutan colorectal (32228273332:3282((((((((((((( motautases. | 21 | gastric cancer | up | MicroRNA-21 inhibits Serpinil, a gene with novel tumour suppressive effects in gastric cancer. | 73373:7: 4?? | esophageal ((¢77(722:(((((((((((33 | 7337((7 | Differential expression, of nnRN ks tr- esophageal ;(323222377i72((((((((((((((((((((( -· |
272273237 | uiwratKftt and tu\ asmt. of (22322727:32^222^27((((((((( dowtuegrianng AMIR anti (:3iOO(((((((((((((((((((((7 | 21 | up | cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homoiog. | (0222 | 452 Promotes Stem-Like Traits and Tumongentcify ;(3ί3('33233((((((((((((((((((((((( | |||||
722323733: i | :33222127123213333333333: | down | intR-1 '<9-5« suppresses tat-cef vSU migration and invasion tlneogli targeting 2EBI and ZEB? tnGBM | mir- 21 | gastric cancer | up | miR.-?. 1 plays a pivotal role m gastric cancer pathogenesis and progression. | 42734::4: :(2232((( | hepamoelhrlar cammoraa | 721((((( | Mm roRE 1 k-15 2 promotes (;77nt0rig$msii-:ib3333333333333333 ((2222£2222:2i22(82i2i22222(((((: by large· mg «λ vlm dependant kinase iuiftbiior IH |
3:332333333 i | 272773227373((((((2 ((2733732s(((((((((((((: | ((73377 | 732333332:32333373737:: epititeuai-ujesettcity mal batuuiiou. migration and ha asfbft of bepauxefbiiai carcinoma cells by 33t2i2s2:tig:2EBL3id:2EB?333 | inir- 21 | gastric cancer | up | miR-2l Is a Promising Novel Biomarker for Lymph Node Metastasis m Patients with Gastric Cancer | 7313733: 2222((((( | (:372^2222((((((((( :(:772222(((((((((((((: | d«w n | Differentiate xp-essiyn of miRNAs m esophageal ((022277322((((((((((((((((((((( |
:::23394:4: 33733333 | breast cancer | ((232((( | Examining estrogen regnhtioo of cancer stem cells through multicolor | 2Ϊ | gastric cancer | up | Stromal miR-23 is more important than miR-23 of tumour cells for the progression of gastric cancer. | 933:-94:: 454 | 737323323233333 | down | miR-454 is down-regulated in osteosarcomas and ::snpp£esses:c«ll:prohfeiation·:·: and invasion bv diieetlv |
ί
WO 2017/132552
PCT/US2017/015417
())912/2292497224)))))))))))))))( | |||||||||||
!0Κ- /09///) | esophageal cancer | :(4(9(3(: | Dmiu-Regulatrou, nf unR(40 Induces FMT and Promotes Invasion hy ()9/9999099/))))))))))))) ):929719/29)9/2//2:))))))))))) | mii- 21 | gastric cancer | up | Circulating microRNAs in plasma of patients with gastric cancers. | 4/2r4555: 45 < | :(:(9792(262622((((((((((((( | down | MrcroRNA-4^5 jp.lnbiu pruineratmn and ww aston oftolc-rectal cancer by )))9797729:90(9-7772-))))))))))) oncogene *ernjoobieonme- |
:)229))))) ))09())))) | nyti-snajil cell iuna :))22//2)))))))))))))))))( | )90(// | Peripheral Bipod miR-328 E· prossron us δ Potyniial hmmarkerfm the EarR Diagnosis oi' NSCLC. | mir- 21 | gastric cancer | up | Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential hiomaikeis for gastric cancer detection. | /β// /0//// | 55i222g7i2i2455555555: ))2992/99))))))))) | ):0))))) | ):(9/22297922799799///)))))): ::mosrno-miR-:455:-:$p:edi2ng:·:·: promotes melanoma growth :5:222:2i27^7d2i2:55555555555555555: |
):222))))): ))O)))))) | ))29222911:/sE:l22gZ) ))/22//2:))))))))))))))))) | )2/22:( | rniR-140 Suppresses Tumor Gmw dt and Metasrastfe of )(9/2/9/92:/5/92/22/))))))): Cancer by Targeting Insulto-Like Growth Factor 4(29997/24555555555555555555555 | mir- 21 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. | 5:22155555 )9999)/ /0//// | )97/2226222222())) | dewy £' | MmmRNA 47>3 inhibits Prostate < aucer v.roo th through (remtivationol the AMson FandL or :)9ΐ/(ώ629992972792/)))))))))) (5:292722ό:ί£ί22δ2955555555555555: |
(5222455555 /909/ | :(:(έ292$29:5555555555555: | ()0()))) | MteroRNA expression profiling reveals the ))9797/9297992292))))))))): ()9/2(722iO/9272())))))))))))))( 529i/2/2/i/:5555555555555555555555 | 2Ϊ | gastric cancer | up | Prognostic impact of c irculating miR-21 in the plasma of patients with gastric carcinoma. | :5ίύίΐ4555: 4782- /0//// | JriP-ainsBcnU rung cancel· | down | tniR~4?h? -3p Inhibited )θ2/|ΐ797ί)/999992//////) Cancer growh viaUSTM |
):222))))): 146-3(3· | )))22/2/92)))))))))))))) | ))0/// | identification of miR-ldp. 3p as a marker associated with poor prognosis in spina! chordoma | mir- 21 | glioblastoma | up | Heterogeneous Nuclear Ribonucleoprotein C1/C2 Controls the Metastatic Potential of Glioblastoma by Regulating PDCD4. | :(:22155555 /09(//(( | ):221/9927999/2: | dewy £’ | ()Ε279/277922(2972δ/7ίέ())))))) eueigetrea can premutc carete r progre saaon |
(:(229((((((((((( 14b-?p | cosorectai cancer | down | inh.bittor or νΛίυί\’-Β cat >*r «' ell no, a· and invasive potential by miR-140-:'p mediated supptassiortofSniadi and 5:2/9^045555555555555555555555 | tnir- 21 | glioblastoma | Up | Sulforapbar.e enhances temozoiomide-induced apoptosis due to downregulation of miR.2Ϊ via Wnt/beta-catenin signaling in glioblastoma. | 5:22i4455 483- )99/))(/ | adrenal cortica! carcinoma | /0//)/ | ::)Th9h2}2(d972i227R:NA(4:4:4:4: (4»2/ϊ6(^2ΐ9ΐ/222ί925555555555555: :(:p22O2229il9^55555555555555555 adrenocortical oaicmcma·. |
):222))))): 146-5(3· | ((22/272/27761/2))))))))( ()/9/9299))))))))))))) | dyw 11 | MicroRNA -1 -id-dp suppresses tumor growth are! metastasis by targeting drLLiatqH^ w JiepsioceUuhr carcinoma. | mir- 21 | glioblastoma | up | MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma muitiforme. | 5:mii45555 4b3- ()0//// | ))2979///&297)/Z) ))9292229)))))))))( | /01// | Overoxpressipii pfnaR4*G-5pGp cooperate to inhibit mouse liverfibrosis )2992^/2/992/299/9)//)))): :(721722121/99:02519))):::55555555 (57/22/2/27/(772225:)))))))))))))))) |
4222455555 /909/ | :5(02/9//95555555555: | :)9/92(: | MtcroRVA-Li-Ljp Soppmsses tumor growth and metastasis by -argetii'g ()99399i9:979929992)))))))) Mpat^eehnlar carcinoma. | mir- 21 | glioblastoma | up | PD'CF-B-mediated downregulation of miR- 21: ne w insights into PDGF signaling in glioblastoma. | :57/24555: )91//)) /0//// | adrenal cortical 4(9912299555555555: | /0)))/) | mtEvd'^nndi ro-48 - 3 idem-died as Piedrc tor cd ()T//9)O/27t2/9:777))))))))))))))( Adreuooortieal Cancer. |
:(:229:::::::5: /(Ol/// | )(2722262(/277222()))))))( | dyw 11 | ::E-.^pression:of:irayroRNAs:·:·:· to die I nue oi Pattern* j rh Bladder r ancet | mir- 21 | glioblastoma | up | Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status | :5221/::::::: /09/// /0//// | adrenal cotlicui ))92212299)))))))))( | /0/)// | (:(:Tl7/:7272:2£:7722r2PtNA:(:(:(:(:(:(:(:(: ))2279/2ΐ72ί27772)99))))))))))))) ()99)O229^r22f)))))))))))))))))( atfrenneonua! carcinoma- |
142
WO 2017/132552
PCT/US2017/015417
81966///8 ;;|5|55;5 | 8Ρί^9899ό998//////8 | 5B555 | < ircuhnng mroioRi LAs ra scrura ίΐυ\ε18ΐΛηΛ8ΛΓζ for patterns with bladder /Aaitetir?://///////////////////////// | mir- 21 | glioblastoma | up | Expression of 19 inicroRNAs in glioblastoma and comparison with other brain neoplasia of grades Ϊ-ΪΪΙ. | /:986//// 493- 5||;55555 | glioblastoma | dm? n | MtR-4$5-4p suppresses-the proliferation of glroma veils vta directly targeting |
9836///// ;;|B555:5 | bro^t '«roer | /05/// | Direet targeting of See/3a bv mtR 3' Os influences cancer veil secrename an·! promotes metastatic /:98^8 w59ti893:3////////////////// | mir- 21 | glioblastoma | up | Co-delivery of as-roiR-23 and5FU by poiyiamidoamine) dendrimer attenuates human glioma cell growth in vitro. | 985169/8 /80/69/ 5BLLL | //3185^8:////////////8 | down | MiR-48 3-?p suppresses the xprotifeiartonufglipmaaeiH:·:· ma duet fb .aroetto? 500555555555555555555555555555 |
3:19185:///] BB^/^ | esophageal cancer | 5BI55 | K<iR-2oria/miR-i41 and miR-vti? upregulation roaght be afesoc-iaieti witit horatone re ep or , te ro and prognosis m endtimetnal caiklnomas. | mir- 21 | glioblastoma | up | MicroRNA-21 Promotes Glioblastoma Tumorigenesis by Down-regulating Insulin-like Growdi Factor-binding Protein-3 (IGFBP3). | 5105555: ;||5|5 | 900300555555 | 5055 55 | 4R3-Ap/3p cooperate to inhibit mou&e iwerftbrotia 50930006000555 :/ΟΟιΟ·Β5Βϊ·/16////////////; /:Oi6gh8i6iaic6///////////////// |
9836///// i|B;5;55 | gastric cancer | 93988/ | Down-regijlatmu of mtR* 141«. gastric caneerandns involvement in keli growth | mir- 21 | glioblastoma | up | Downregulation of Pricri4 by mir-21 facilitates glioblastoma proliferation in vivo. | 965169/3 484- | • uRn 'ra· er | dow n | MrcroRNA-mlahtis proltieration and invasion ofcolc-roctal canker by ;05000B005555555 oncogene oprujeAhieourae:/9i9f9i8ki88^6/////////////////// |
8896////// BBI56 | gastric canter | down | iiaR-i-H suppresses pioltieretion and moaftn of ga,rnuvan\rv8!abv 88ii8bgrifsj^:i5!Z^kii:t:/8888888888::::::::::: | mir- 21 | glioblastoma | up | MiR-21 up-regulation mediates glioblastoma cancel stem cells apoptosis and proliferation by targeting FAS3.G. | 8896///: 5505555 Bill | //188055^31355555 5ti98ra3ro9:///8:8:8: | 50555 | ;055005500&5555555 5O5^9i396555555555555555 atfenosvbransferase kA ewpressmn ro bepumveibdir //caroinoma//////////////////////// |
98369//// 5055555 | gastric cancer | //3986: | The downreguintion of imR-2tiv 141 ρη.·ιθυΐΛζ ZEE Ϊ/2 expression and gastric caucerpiogivsslon. | mir- 21 | glioblastoma | up | MicroRNA 2.1 promotes glioma invasion hy targeting matrix metalloproteinase regulators | 965169/3 48S 5BLLL | beput-roNlnlar :/03193166:/8:8:8:8: | dow n | (nvulveraent of mtR'-iSc- ;56336;O356i6i6i3i3555555555555 carcinoma progression 3diO5O:^^^/////////3 |
31986////3 55115:55: | gastric cancer | dtWvO | MicroRNA-i 41 inhibits tumor growdi and motas-usis in gasiH., vancer by directly targeting •transcriptional c^-acticamt 550BB03005i00555555 | roir- 21 | glioblastoma | down | MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drag temozolomide. | 8986/89 5305555 | 8^0pf6g99i///////// 85096///////////:// | droc n | izil'ferential expression of miRMAs in esophageal 90003005555555555555555555^ |
991- 5505555 | ;/8^ύΐύ9όίθ8//////// :/^9180858//////////8:8 | :53988/ | ;/tiaR5i3:8Stii4p8^:tii9:88// growth anti metastasis of HCC celts by targeting /^O/////////////////////////////: | raii- 21 | glioblastoma | up | Delivery of aiiti-micioR.NA-21 antisense-oligodeoxy nucleotide using amphiphilic peptides for glioblastoma gene therapy. | :/696:///: 5;5B;5555 | //00:///////////// | 50555 | //8nl036OiO5O/?8:////3 5005505000555555 multiple NE-?13-iiegative :/:?$^0:00:5/3///////:////3 |
31986/393 ;53B;55555: | bepameefinlar y^OOiO/////////////: | dtWvO | mroroRElAN-U inhibits oti! Idohieiauon and tov isrot. and promotes apoptosis bj targeting hppaloey te liepamccBular carcinoma tells | roir- 21 | glioblastoma | Up | MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma ceils. | /:19869// 5305555 Bill | :3r6i903bl89i988:/5 | droc n | Coropuiatmual anti in v nm Investigation of mtPNA- 5G366 00:5086:8:55555555: 3^903505055555555555; 803939160500-655:5:5:5: 50000005555555555555555 |
99Γ- 5505555 | 38^^898iOkkkkk :/^9180858//////////3:3 | 53988/ | MieroRNA-’?,01-amth «ι Hepatocellular Carcinoma 5|3θΒΒΒθΒθ5;5555 5T^n^983////////////////////// | raii- 21 | head and neck cancer | up | MicroRNA alterations in head and neck squamous cell carcinoma. | mn- /606/// 5055555 | hepatocellular :399850056666 | down | MicroRNA-4S8-$pv w bicb i/iktiOOeiOhiB^h////////////: hepatocellular carcinoma, suppresses tumor growth. h> targeting PlKARl |
143
WO 2017/132552
PCT/US2017/015417
5(1(333588888 2//1(((/ | ((ϊ//έ:/3ό8ίό4(((((((((((; 22//9/2/28222222222 | (/9/(9( | iniR-2to Inhibits lung udeROoarcinpmu cell nuasron and metastasis by ((i3ig/8t/:/22?^G2fe2((((((( | mir- 21 | head and neck cancer | up | [Expression of tuir-21 and mir375 m latyngeal squamous celt carcinoma] | 58/385888: (///2((( (//(((((( | 21////9//9/2228(2 | «tov n | Dowfiiogubuori of utiR«. s-vp or .ibi *sta unm. progression and metastasis ::byfargothigprypmfi>rigef!io·:·: ARHO^d m lung cancer |
53.01155:5:(: 2(02222 | (pishg/t/:(((((((((((((; (Οί/ό//((((((((((((( | 2//222 | MicnaENA-Tdv family members differentially •MOgnUtemoipl-niogtcal·:·:·:·:·:·:·: (([81/2/22/82/2:///2//(((((((: melanoma >.eB mvaston | mir- 23 | bead and neck squamous cell carcinoma | up | Clusterin Is a 'Gene-Specific Target of microRNA-23 in Head and Neck Squamous Ceii Carcinoma. | 5//8555: 2///8(((: Bill | gastric cancer | dbwn | Eptgeijefic Silencing of miR-ad;i- 5p Reactivates the ((/35588538818:^98/539858((((((((( SMARCDi toPiomore i Ickcoitavfer pylon- 5iai33E59 535/285((((((((((((((((( :5/;5r/i8l33//d53i5:5:5:5:5:5:5:5:5:5 |
(:(2583(-(:(:(:(:(:( (//22222 | ntesencby mat ((0///:(((((((((((((((((( | :(:2982/:: | MuroRNA INpresstun (;/ί$//όί(ϊηΚΑρ9δ/2(((((((((((: 2/22/2/^2822822822822822822 | mir- 21 | head and neck squamous cell, carcinoma | up | Co-targeting of multiple microRNAs on factor-inkibiting hypoxia-inducible factor iRTH) gene for the pathogenesis of head and neck carcinomas. | (:32/8(((( (/9/8888: I/2222 | hep <f\. dintar 5/3feih08k/(((((((((( | 2//2228 | unk-ta' '-3p ktodatam. Cell Growth and Epithelial to Meseochynial Transition 2/fK/p/t/22//!/i888(((((((((((( ((•//8/ΐ////(/3//2://888888888888 «pent g i-ndopl jspu (22/9/98//38/80//:888((((((((((((: inteitneritate remp3ffnynf Protein 3 iERGiCU. |
:::/885:::::5:: 2//22222 | oen-StoaBcell.hiOg ((/8//(((((((((((((((((( | 2//52(8 | High expression of serum 88/880;//2/:/8/ί/2:/ί2/82888:8 2011c: associated n ith peyr (:/1/2/22/2///2/222(///888( | mir- 23 | bead and neck squamous ceii carcinoma | up | Low-level, expression of mi.croB.NAs let-d and miR-205 are prognostic markers of head and neck squamous celt carcinoma. | ΟίηΤίΟ???: 851238-8888 (ill | btadder cancer | dbwn | MicroRNA e-.presston Signatures of bladder cancer 22/((93/89://:////(((((((((((((((( ((9/9/2/28/988888888888888888888888 |
(:/888((((( 2//22222 | nyii-snajd cell lung 2/9/922222222222228( | 2//222 | Mki»RNA-i4i promotes ((t/2(/2//ie/////(/f///2:8(((( small cell tone cancer cell; by regulating expression of 2|®|^|//2OI^I/2228 | rnir- 21 | bead and neck squamous cell carcinoma | up | Expression of microRNAs in squamous celt carcinoma of human head and neck and the esophagus; miR-205 and miR-2.1 are specific markers forHNSCC and ESCC. | 58333((((( 49B- 2//2222 | bladder «.aricei | 8(2///(: | Mke5&MA-4'?U-Sp lidiibife proliferation of bladder curium by tameting * Eos |
:55/85555: 2//22222 | uotwsinaB coi! king //2/2:(((((((((((((((((: | (://222 | (:Ml/2/R:N'A8:!/:/:/:/88888888888 5/is82/8fe$8//:/22/2?22j//888: v^s^janwaeellyaiehionK}:·: u«o id·, no ΛνίΡυΐ n ni tK lung elmieal anabsis vf ((8/5:/3383/22((((((((((((((((((((( | tnir- 23 | hepato-cellular carcinoma | up | Role of raicroRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet, in C57BL/6 mice. | :5tt88t65:5 8512/5(((: 1111 | cetyueai cancer | 58////(( | ((//22/rO^28//((((((((((((( Suppresses cervical earner cell growth by tameting 2/|^||||||||||((2(2( |
liar- 2//22222 | osteosarcoma | 2/2222( | Tmuor-Suppressing Effects 2/i<//R8f228r/2/2/82/((:888888 Osteosarcoma. | mir- 21 | hepato-cellular carcinoma | up | MietoRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. | mu- 2/2/222 | 2///9/88/8/2///2( | 2//8222 | 2(009/^ processed Rom die keratin 19 gene and up-regulated tn metastatic hepatoblastoma |
88/85585: 2//22222 | 5//8////222(((((((( | down | A mtR-?dR microRNA cluster as prognostic •Muaikemnadvanoedtovaiian:·: (/38///(((((((((((((((((((((((((((( | tnir- 23 | hepato-cellular carcinoma | up | MicroRNA-?.1 promotes ceil proliferation in human hepatocellular carcinoma partly by targeting HEPNl. | :5tt88t65:5 2/2/88888 | bladder cancer | Jou n | Tnnxwr suppressor micrnR 14 ,«taebrerease :: coll moRlltv: and nugmctolt::: ability in human bladder ((/3/9/2(/3////(((((((((((((((((( downregttlatteg RhoC and 1-/1)4 |
!UK- 2//22222 | ((/2/233/(/9//9/8((((((( | 2//222 | Differential microRNA eypresstuii signatures and 53//3//c///c:iii/((((((((((((((( assycialiyt· with Tavyl | mii- 21 | hepato-cellular carcinoma | up | •Circulating microRNAs, niiR21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. | m·:- 2//2222 | .5'il.itai. 88939/8/9//8888888888 | HP | MicroRNA expression in A< 'tH-proJixmgpUnitarv tontors. up -regulation of nncroRN-A-122 and-dbo in |
144
WO 2017/132552
PCT/US2017/015417
resistance in ovarian cancer jBdfeBBBBBBBBBBBBBBBi: | pituitary carcinomas. | ||||||||||
UUf· | pancieattc vanect | 3:ddO:: | 8MitOBBB^BB88888888:8:8 pangreatto cancer inhibtred •:flie:ceUpf«lifemtien:3Ed:·:·:·:·:·:· ii'?sivfiU dnretb | mir- 21 | hepato-cellular carcinoma | down | Expression of serum intR-J 6, let-7f, and miR-2! rn patients with hepatocellular carcinoma and their clinical significances. | 8ku9883 | breast cancer | down | B^WB:^BB8^riiSssa8&e383:3: progression or breast camrer tn vitro by targeting CXCR4 throughlbe Wnributa-eutotun signaling |
3toib8383 ΒϊΒΒΒΒ | niit | A study of melee ulur signals deregulating «usinaicb repair genes bi prostate cancer compare J to 8^bj^bpfoOi838383838383 :::il'3p^pi:a$!98:<::::::::::::::::::::::::::::::::::::::: | mir- 21 | hepato-cellular carcinoma | up | Anti-iniR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation. | 8191888:3 499 | cure real cancer | 3^88B | ::MicuuRNA>A9:4:p»>ntt>tes·:·:·:·:· 38έΒΒ83ΐίΒ^Β-8ί:ΒΒΒΒΒΒΒΒΒ omitfetatmt. duoucb tire regnfatrcnoi 1·Η-\ | |
3rii88883:3 | renal cell carcinoma | dv'VO | 3MiCri3l8NA4BbiB3838383:3: ctownregcdatecl in human renal cell carcinoma and regelates coll auivix al by targciingflKAiB | mir- 21 | hepato-cellular carcinoma | Up | Expression of raicroRNAs, miR21. miR-31, miR.-12.2. miR-145, miR-146a, miR-20(!e, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its progno | 31918883: | • . . · ^r | 8BBBB8 | nuRAi»>4 ss an independent prognostic factor and promotes cell migration and X!b8^W&^B^^^BX:8:888 cancel bx directb targeting BO^BBBBBBBBBBBBBBii |
3rii88883:3 | 30^:^1^88011383:3:3 8^8819019^3838383:3: | dv'VO | <tenome*%ide roieroRNA expression profiling in renal cell carcinoma: sigoifnantriOHn regyla-Oii of mtR-143 and ini.R-2t.KR, | mir- 21 | hepato-cellular carcinoma | up | Dehydroepiandrosteroneinduces miR-21 transcription in HepG2. cells through estrogen receptor ? and androgen receptor. | 31918883: | 8^3^8831838383: squamous coll 8^8c890i9B38383:3 | 3iOih:3 | 8:;3b8e-^idhtidhbbb5iRs49B83:3 8i819&itS:G^.i:G9!i8diB8B83:3: invasion and induces Cell Apoptosis by Targeting xGigfeBBBhhBTiiikBBBBBBB Transmembrane i4 ike tn Esopbagnal Squamous Ceil BGdfcibb9idBB3838383838383 |
3rii88883:3 ίίΒ?ΒΒΒ | 3bife^9sShg^8888:8:8 | BBBbB:; | jiaR-34? regulates the tianorigemcny ofbmuan breast cancer stent ceils :·:·ΐΐΛϊ>[ί3ί·ΐ4ΐΐΟ0ηί!»Η!η3ΐ:%3ΝΤ:·: signaling pariroav | mir- 21 | hepato-cellular carcinoma | up | miR-2.1 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by inducing Apoptosis of CD24+ Progenitor Celts. | 31918883: TOBBi | gastric cancer | 3iOih:3 | miR-494 acts as an antiumocene tn gustne carcinoma by targeting c · 3to3p3838383838383838383:38 |
3ΐί9ϊ383:3 | acute iymplrobiastto | down | MicroRN.A-i42-3p inhibits : :eull preliigratierenilmman::: 8ΒΒΒιΒ^ί3όέΟιΒΒΒΒΒ88 kukemsabv targeting the MU -Al -vvixnpen? | mir- 21 | hepato-cellular carcinoma | up | miR-2.1 promotes migration and invasionby the miR-21-PDCD4AP-1 feedback loop in human hepatocellular carcinoma. | 3ί9ί888·3 499 | yg:iOiha|BBBBBB | iOBB8 | iOiu/Uig mdmuon-jnehat. jbie miR-994 promotes gliyma evil wuasron through bGBR srabiireatmn bv targeting 3Bj9i^tRfe^OiBBBBB3838 |
Uilf- ί4-2Τρ | 83038 | MiR-142- ψ functions as a Bt9b59bsbppf^B>B^BBBBB88 ΐ3Γ?ν'·ηρ ί Di 3 AfK <Ρ and Lgr5 tn coloneanebt | mir- 21 | hepato-cellular carcinoma | up | Expression of serum exosomal inicroRNA-21 in human hepatocellular carcinoma | 8bui$:3:3 | hepatocellular | I’Bll | Μί32”4$4 within art oncug^nn MrercRNA megaciustor regulates Gl/S 88ri^i^b:ib:^$f8888888888 tomoiigenesis through uppiesxren, nf MtA | |
3ΐηί08883 | 8g}i0blaStoiba8838383 | down | Ffiretc-l m.tR-i42--pon tin M2 macreptiage and tbeiapoutre eff-^aev against murine glioblastoma. | mir- 21 | hepato-cellular carcinoma | up | Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma. | 3ί9ί888·3 499 | hepatocellular 8:csl9m0i&i:383:383 | iOBB8 | MicmRNA-4b4 is a master epigenetic regulator of 83r^hipl^a98ajtoh883838383:3 suppressor mioroRNAs by BtBBBcbhBOBfet-BBBBBBBB translocation J m mvasive |
145
WO 2017/132552
PCT/US2017/015417
/):22(636/(806636(66/))))))))) ))3366(6856/(6585/)))))))))))))) | |||||||||||
/:/285:/:/:/:/:/ | h^paUrtUlhtlar eareiroma | /)366/6/: | Evfb roR\*-l D-'p >t re* ///522WZ0jz2i)6-35/i)Z))))))))))): suppresses the nrigranon /)6688666666)66))))))))))))))))/ hepateceUnlar carcinoma CtiiS | mir- 21 | hepato-celhilar carcinoma | up | miR-21 expression predicts prognosis in hepatocellular carcinoma. | /:/55/-/:/:/:/: AN | hep <P\. 'finbr /)665(6/25()))))))))) | ):((6)))):) | miR-494 promotes oef! proluefation, nugianpn and /(2(68866)/663)(068668)))))))) /)08(86(6)(666(3638)(6))))))))) hepatocellular carctr^roa 636:50(560e256z6z6z6z6z6z |
!Wi· i4W | /)066(03)))))))))))): /)(868(886(3))))))))))))) | /)3666) | nueioRNA expression ))ρτ606)66(88έ506836ζ66: mlRU9 as a prognostic marker and pathogenetic hjv'Olbx tOIgetn-g<DxA nt mantle O! 6 tnyhyma | mii- 21 | hepato-celhilar carcinoma | up | MicroRMA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKTZERK pathways. | /:/155)):/: 494 | nor-small cell ////(636/66(33))))))))/ | )68))))) | Expression;and cluneal evrtlewcc of »aR-4‘N and z3)E:(58i:(6/368)3(3((53(/))))))) (1586/63(565/6/6/6/6/6/6/6/6/6/6/:/ |
/06/:/:/:/:/:/ ))BIBz) | OOi'-SnxdicOlliuOg )/386866)))))))))))))))))) | )/86))))) | /MiR -14 2-?p represses (//115)2:(686688/2(65(6)))))):) irdOlion through )3666686663)66636()(6))))) non- anafi celt lung cancer | mir- 21 | hepato-cellular carcinoma | up | indole-3 -carbinol inhibits tumorigenicity of hepatocellular carcinoma cells via snppression of microRNA-21 and upregulation of phosphatase and tensin homoiog. | /)(55))): 494 | ///h0n)5h52/$siziz))))) ////286/688666))))))))/ | /)(68))))) | TuuK.i·- derrc ed mid oRNA 494 promotes angiogenesis /(8(/2/2662/26/86((3662))))))))): :)/(68686))))))))))))))))))))))))))))/ |
i!!U- 142-lp | osteosarcoma | ))8683) | MiR-l44-6p Euncnona as a E u'enual 1 ureur -t-ppreysor jriHfjnan Q&tensareojna h> ///T3(65O:66633/(///////////////////////// | mir- 21 | hypo-pharyngeal squamous cell carcinoma | up | Altered Expression of miR-23 and PTEN in Unman l.aryngeai and Hypopharyngeal Squamous Cell Carcinomas. | »!«· )6(68))))) | •S3· caucer | dm? n. | miR-494 represses ilOXAR1 express-urn and inhibits ceil proliferation in (/2(6(/636(38/6/6/6/6/6/6/6/6/6/6/6/: |
/05/:/:/:/:/:/ Bill) | dear veil renal ceil /(6383586/6/6/6/6/6/6/6/6/ | //32///////// | Ixpkrrct met i«\AtnRNA regulatory ttetwod. 53(8861)68((8868(666))))))))): /(66(62(82(38/81663()))))))))))) generation sequeoewig /0603660(8656/6/6/6/6/6 | mir- 21 | kidney cancer | up | miR-21 downregulated TCF2J to inhibit KiSSl in renal cancer. | /:/55/-/:/:/:/: AN | ovarian cancer | down | Differential tmcmRNZA expression Signatures and ///86(6 /5 8655363(6/))))))))))))))) association with Taxed resistance· in ox arum cancel ..ells. |
•UK- )/832)86/) | ////666/686666)))))))))))) | down | Uncovering grow Ehsuppresaree MictoRNAs in /)(888536336)))))))))))))))))))))/ | mii- 21 | laryngeal carcinoma | up | Regulation of the ceil cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. | /(266/6/6 494 | pancreatic ductal aderiv-carcinoma | )/2266)/ | |
mu- | mall iympbnma | (||:| | Oreiexpression of msRI4>$p and nuR-liA «; gastn? mncosa^assomated lymphoid tissue (MALT)· k mpl-yma resistant lo JiJreN/K vf 0« 665d5ti2256z6z6z6z6z6z6z6z6z6z6 | mir- 21 | laryngeal squamous cell carcinoma | up | Downregulation of miR-21 modulates Ras expression to promote apoptosis and suppress invasion of Laryngeal squamous cell carcinoma. | »!«· 49> | /)2(8(26668666))))))/ | //8/3/////) | miR-fVf r* upi emulated by tl^WNrbreas vinecr stem cells and promote* oncogouosls and h>po\b /((885(66636(6)))))))))))))))))))) /)2852(62(2286)3()25)))))))))) coditerui and REDD I |
/:/265:/:/:/:/:/ ))BIB) | /(2(62256556/6/6/6/6/6/ /)/00655)))))))))))): | down | nticioRNA expression ::pn>iiio:andidont!f!ention:o£·:· nuR-49 as apregnostu marker anti paihogeneue factor by targeting €f>K<> nt mantle veil it tnyhyma | mir- 21 | laryngeal squamous ceil carcinoma | up | Altered Expression of rniR-21 and PTEN in Human Laryngeal and Hypopharyngeal Squamous Ceil Carcinomas | )868)))/) | ///86(83(5:/86/:5/(652835:/:/:/:/:/:/:/: Jiausttmrtb' Targeting Bnr-itt Brets ( | ||
:/:50/:/:/:/:/: J42-5p | (88528856856/6/6/6/6/ | down | MiereENA signamrea associate with pathogenesis nod progression, of osteosarcoma. | mir- 21 | liver cancer | up | microRNA 21 -mediated suppression of Sproutyl by Pokemon affects liver cancer ceil growth and proliferation. | :/:524/:/:/:/ ):888))))/ | /)236635)))))))))6/)) | Jnn n | Mu reRl 1LA tthtbre> )/65(^5266/33/)))))))))))))))() gltobtestoina mnirifonne cells b\ downregulatrng |
146
WO 2017/132552
PCT/US2017/015417
n Gm dependent | |||||||||||
!0Κ- (BBBBBiii | ((Μ^όΒ?ή!ί^Β(((((((: | :(BdO( | MtcroRNA-M? as a tumor suppressor for bladder (BOBB(((((((((((((((((((((((((((: | mii- 21 | lung cancer | up | Evaluation of dynamic change of serum miR-2 l and miR-24 in pre - and post-operative lung carcinoma patients. | :(ftoto(((: (iBBBB | hepatocellular BBtBiihpb'BBBBBB | (:*!B(((((: | (BB?toiBBiBBfeOO((((((((((: ((O^htohB((((((((((((:(((((((((( adenosybransferase LA expression in hepafycellykr $Ο;ίίώί(ώ(ΒΒΒΒΒΒΒΒΒΒ:((: |
:(hyf::((((( BiBBBBi( | bladder cancer | down | MicroRNA -Id j tone tie ns us a tumor suppiossor in kumuti bladder cancer T24 (O&N((((((((((((((((((((((((((((( | 21 | lung cancer | up | Differential MicroRNAs Expression in Serum of Patients with Lung Cancer, Pulmonary Tuberculosis, and Pneumonia. | (:toif(:((0 (BBB(((( | adrenal conical ((oaipmpBBBBBBB | down | The role c-f nitcroRNLA deregulation in the pathogenesis of atfieuoeomeal careumina |
:(fbito((((( | bladder canter | down | Replacement treatment with microRNA-143 and to? induvSA Anergieiiv mfubbion of the growth of human. bladder cancer ceils by regulating fT3R/ALt and KLkPK signaling pathways | mii- 21 | lung cancer | up | Exoression and significance of miRNA-21 andBTG2 in lung cancer. | :(bto((((( (B|B(((( | breast cancel’ | iOBBB | Analysts of MiR iV5and MiR-42? expression leguiattot; and role m breast bbbb^bbbbbbbbbbbbbbb |
:(itof-:((((( (BBlBBB | breast cancer | (B$b:B( | 4Μί?θΝΑ(Ι42ΒΒΒΒΒΒΒΒ( downregulated in bieast tai\er and regulates DN k itteito ftrattsferases 3A m breast vancet cells. | 21 | malignant melanoma | up | mi.croRNA-21 is upregulated in malianaut melanoma and influences apoptosis of melanocyiic cells. | :(toif:-:(((: (BBBBB | cervical cancer | down | MiCroRNA-Ef? is a potential prognostic marker m human cer.ioai cancer ΟΒθΒ·ΒΒΒΒΒΒΒθΒ((((:( snpprea A«r to mrgetrnj the tosubo-like growth factor 1 5ίΟό^0Ε((((((((:(((((((((((((((((: |
(:Eiff8:((((: (BB^BBB | cervua! cancer | down | miR-l-to is duwnmgnfaKd in cmritoancer and promotes apoptosis and : cinbibits: tumor formatioa by:: (BdOiBB:B0BBBBBBBBB | tuir- 21 | malignant melanoma | up | MiR-2J enhances melanoma invasiveness via inhibition of tissue inhibitor of metaiioproteinases 3 expression: in vivo effects of MiR-21 inhibitor. | (:itbi((((( BOBBi | • . v . · vr | dm? n | MKtoREto-'-to7 and hulator xlsvt'ttpUi db mmfim ((B(Of?iBLohhc^B((((((((((((((( ((h^idBaBBBBBBBBBBBBB? |
:(hub(((((: BbIII | colon cancer | dyw n | (:Th.d;£VidLlinCtol^A?(i:4SB:(: K-Ras axis m coton cancel, | mir- 21 | multiple myeloma | up | integrative analysis of differential miRNA and functional study of miR-2J by seed-targeting inhibition in multiple myeloma ceils in response to berberine. | :(hui:(((:( (BBBBB | (:g^OROtdi;BBB$B( | :(B|B| | zMioroRNAtoriSaf-dbufabn·:·: act svuenpshcaiiy mmiubit ((B^iBfBBhiB^BBB(((((((((((((((( (BBO^BB(((((((:BBBBBBBB |
:(bdto((((( (BBlBBB | :(:fto^:Sh0C^:(((((((((( | (BOB: | miltofd j overeapressfon impairs growth. cf human vetou carui'cn'u xenograft? «ι nucc w rib induction of apoptosis arxf inhibition: of (OiBsriiitob((((((((((((((((((((( | mir- 21 | naso-pliaryngeal carcinoma | up | Activation of miR-2.1 by SLAT? induces Proliferation and Suppresses Apoptosis in Nasopharyngeal Carcinoma by Targeting PTEN Gene. | :(b5lto(((: (BBBBB | cbloreotai cancer | (0((((( | Miito-lb“ promotes metastasis of eoioiecial (;id!ubBmh((((((((((((((((((((((((( |
!0K- bobbb | (BOB | Forced expression ofTmE- f'r'tvptvS Ν: Nv Mac and pf.to'p”? signaling m Concert with miR -1-15 m gait tumors of Αρο·,Μήϊ> :(buip(:((((((((((:((((((((((((((((((: | mii- 21 | non-small ceil lung cancer | up | High expression of serum miR21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. | :(ftoto(((: 49 7 | wdorectai cancer | down | AbctuRNA-40? targets msulm-iiko grow dt factor I receptor and ha> a mumnr suppressive roie in human (:ίρΐρίΒ(^ΒΒί^ΒΒΒΒΒΒΒΒί( |
147
WO 2017/132552
PCT/US2017/015417
42ΐ3«44555: 25052444 | 55533i33334332555555555: | 243332324 | 54f533332ti43iii332b32:34i4i45555: H3 auri tuiRM 45 and predicted target preterits AM5, ERK5. K-RAS. and ERS-1 are differentially expressed nt proximal and 25^4333343:3555555555555555555555 | mir2 J | uon-small cell lung cancer | up | Clinical evaluation of microRNA expression profiling in non small cell lung cancer | 54344 55555 522-05555: | 2505040323424 | J<re n | 5:3h3232t33O5b43343555555555555: suppressor uncreE NAA*’ modulates gastric cancer 403200000000544444444: invasion by repressing 250^55555555555555555555555555555: |
52232123555555 ίΐβ | :2:ό33332ό33ίϊ3ί·2:2:2:2:2:2:2:2:2:2:2 | down | Mki»RNA-i43 reduces viability and increases scnsbwiiv tp Mhiuronracil 52232^05300332255555555555 colorectal cancer cods | mir- 21 | non-small cell lung cancer | up | Downregulation of microRNA 21 expression restrains nonsmall cell lung cancer ceil proliferation and migration through upregulation of programmed ceil death 4. | 522343445: | 2Ο22222 | th pox-a injured miR -97 decreases ghouia cell OcPzltixitV Ό ΉΑλ 2:2:j:33ti3ihg2;f03320O244 4 4 4 4 4 4 4 44 | |
5^231355555 | coloreetai cancer | 2 2 2 2 β22 | Association of imcfORNA expression with iraeiossicihie instability 5^3023300432525555555555: | mir- 21 | non-small cell lung cancer | up | identification of plasma mi.croRNA-21 as abiomarker for early detection and chemosensitivity of non-small cell lung cancer. | :2ύϊίίί;::2:2:2:2 525042555 | hepatocellular caretuema | dPwn | Checkpoint kinase J ts negatively regulated by 2433θ3θ232003θ3θ23444 253334333^552555555555555555555555: -, |
5:2lGO23t3233O4:i335555555555: vNufk'Bvan reM | 21 | cancer | up | promotes radiation-resistance of non-small cell lung; cancer. | 497 is associated with poor prognosis in renal cancer. | ||||||
252t3ti455555: | 2534300004255: | 25233232324 | Down-regulation <jfERA$ti'deiactm.g miRNA-HJ predicts poor prognosis but 2523tit5reSpC'33232022iO:5555555: targeted agents in colorectal 2 2 2 33433555555555555555555555555555: | mir- 23 | non-small cell lung cancer | up | Prognostic significance of serum miRNA-2i expression in human non-small cell lung cancer | 24434444444 404555 | 2253b35333iti:i2335555: 44iit433O43342444444 | dewy n | 25^334ti3g34Oti24i23B425 5 5 5 5: 49? piomotes tumor growth 5:343333333333i3233255555555555: targeting MOGF in rtonsreaii cell lung cancer |
2:233232:2:2:202 420424242 | cnicreciai cancer | 2 2 2 2 3332342 | RREB) repressed miR1 i VI modulates ERa 9 tinwniegublioit of aatinplc 5:303425555555555555555555555555: | mir- 21 | non-small cell lung; cancer | up | Let-7g; and miR.-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features. | 2:2l34fi-2:2:2:2: 404555 | ovarian cancer | riowu | MicroRNAA*>7 inlubitinn of Pvarian eahecr cell migration and invasion through lofgvtfnc of $h 1 AD spe wf.e h ' uhiqnmu 42p233i33£3432ti55555555555555555 |
!UK- 440424242 | colarectal cancer | 24333342 | Mic-mRNA-fti? inhibits 553003000555555555555: ungiogeuoiuend soasitmes cfcaniosensitivkv to dxahplatin in < 'do· ectal 2533333425555555555555555555555555 | mir- 21 | non-small cell lung cancer | up | Overexpression or miR-2 3 promotes proliferation and reduces apoptosis in non-small cell lung cancer]. | 253454555: 00444 | ovarian cancer | dawn | MicroRNA-40? suppresses angiogenesis b> largeung i if jr vrdml tied grewif 242ί233ρ3^ά335ι2ι0ίθ244444444444 MAPK/BRK pathways ht :5ti33fi3h35433325 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5: |
4:2333424444: 55θ|5| | coioieeial cancer | dyn n | Tito regulation of Tyll-hke reecptoriby miR-i43 suppre ^es die nn asiun and nmrmcaivi asmat of human colprectal 2:20ar0i:rt0hib:33ii3-:::::2:2:2:2:2:2:2:2:2:2:2:2:2:2 | mir- 23 | non-small cell lung cancer | up | MiR-21 suppresses the anticancer activities of curcumm by targeting PTEN gene in human non-small cell lung cancer A549 ceils. | tgpifUttt 250444 | 252pkti433ti3555555555: 4433O34444444444444 | dewy n | :-MiR:-39:?:di>wnfeauiat3ri·:·:·:·:·: 25^i43ifct4i33i05ti!325 5 5 5 5 5 5 5 5 5 5 5 5 5 5 maticnaiky mpaum-atr cancer arei associates with 25232iO3Og333s5555555555555555 |
2:233232:2:2:202 550424242 | 2500305555555555555: esreinoiha | :222 3 333222 | Evin reR\* A } «pet., DNA tooth} I transferases ?A tit colorectal cancer. | mir- 21 | non-small cell lung; cancer | up | Use of Uurninex xMAP beadbased suspension, array for detecting microRNA in NSCLC tissues and its clinical application. | 2:244j4!$2:2:2:2: 40444 | pancreatic 24230024444444444444 | down | 552f334ii3sJik02g^302f03321552: rseeptorOGF-iR) as a target of MiR-fy7 and 55ρί33·ί3ίδθ32θέί32555555555 associated rati; ΪΝΜ stage oipanereatie cancer. |
148
WO 2017/132552
PCT/US2017/015417
65536/6/6 6/6224646 | 63263222444646464 6225255666666666 | 62556 | Altered le' ei> el rite οη.νπ nucroRNA N and fee lumor-suptessor udoroRNAs 143 arid 145 in ad' oared rectal canter indicate successful :2532235566:6:6:6:6:6:6:6:6:6: /:6555525252623////////////: | nsir- 21 | non-small cell lung cancer | up | Alteration in Mir-2 l/PTEN expression modulates gefitmib resistance in non-small cell lung cancer. | 6536464 622/646 | prostate ..imret | dow n | MrercRMA-^b·’ Suppresses Proliferation and induces Apoptosis m Prostate /453563:54^66/6/6/6/6/6/6/6/6/6 |
ns»· 226:6:6: | 6/22562656565656: :62555655:6:6:6:6:6:6:/ | 6255:/ | [Effect of maoroRNA/U? 62225266232623464646464/ proliferation in colonic 6652262^566666666666666: | nsir- 21 | non-small cell lung cancer | up | Prognostic value of mature mjcroR.NA-21 and microRNA205 overexpression ic. non-small cell lung cancer by quantitative real-time RT-PCR. | mu- 62246/4 | colorectal cancer | dov n | 6633/5403653246464646/ :/:/436435/5α.6435/:5/6/6/6/6/6/6/6 coiofectal cancers and na 4/623^3^33464646464646 |
C/fetfe////////// 8/1:338/8/:/:/: | ertdomeirial cancer | //235/: | Down -regulation of miR i 45 and miR -J 43 might be associated with DNA nielhj Itraosletase 'B overevpressmn and parse prognosis in endometrioid /:62355255////////////////:////// | mir- 21 | con-small cell lung cancer | up | Reduction of Plasma MicrcRNA-21 is Associated with Chemotherapeutic Response in Patients with Nonsmall ('ell Lung Cancer. | :/355/://// 6/0464 | ovarian cancer | down | ! ' ft } ////§55ί5?4έδ56/55533652/6/6/6/6 Expression and Human Cancer Growth dtiongh 4^32330334646464646/6 |
/:/555:/:/:/:/:/ 6:2|6:6:6 | esophageal cancer | 63346/6 | Differential expression of hiiRMAs in esophageal /5238552355/6/6/6/6/6/6/6/6/6/6 | mir- 21 | non-small cell lung cancer | up | MicroRNA-21 (ro.iR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Ge-in City, China. | //65:8////: 406/66 | ov arian cancer | dow n | ΜίΡ-WS Rgrfaieti TOW expression and mhtbited die pfeltferadon of human 6464654/624634/66364/6/6///////////// |
mu- 6/6224646 | esophageal cancer | ///52464 | 42222265/222666/6:/6 Expres&fep. Correlates with Lifestyle noetai and /4263/2532652464646464646 4Dgt633i653i6/i/5/6/6/6/6/6/6/6/6/ Esophageal Carcinoma | nsir- 21 | oral cancer | up | MicioRNA-21 Promotes Oral Cancer Invasion via the Wnt/beta-Catenin Pathway by Targeting DEK2. | mu- ///5546/6 1111 | colorectal cancer | up | 66230^^ promotes cellular invasion and tumor metastasis in colorectal cancer by ////t5f3535g:/F2X33:53d:/:/:/:/:/:/:/:/:/:/ /220464646464646464646 |
:/5556:6:/ 4/6626464 | esophageal /52365i65S:66ii/6:6:6:6: 632633 554/4/4/44464 | •Jpwft | RltcroS-NA -143 fane tio ns as 4 tumor suppressor in human esophageal squamous call carcinoma | 21 | oral squamous cell carcinoma | up | Relationship between rnicroRNA expression levels and histopathological features of dysplasia in oral leukoplakia. | 6551/6/6// -feha- /|26466 | oral squama us cell vare-noma | down | The association between uaR-kfea polymorphism and oral squamous .ell |
:/355:::::::::: 2||66| | gastric cancer | down | ^involve-meP-foTmiR^id^in·:·:· ersphtm resistance of gastric cancer celts via taru' mp h fe f R and ΒΠ ' | mir- 21 | oral squamous cell carcinoma | up | Altered levels of miR-21, miRl25b-2*, iniR-134, miR-155, nuR-184, and miR-205 in oral squamous cell carcinoma and association wife. clinicopathoiogical characteristics. | //555////: 66236/6/ | gastric cancer | 6356/6/6 | Mn;re&NA-5fe; sustains ηυ feurexter B ndo-remi and tudtrees gastric cancer cell proliferation and resistance to apoptosis |
:/5556///: 226666 | gastric cancer | •Jpwft | [Expression of imR-l 14 arud miR-145 pad their ::f[inetiefialstudv:ifi:gaslae·:·:·:·: 66/5652532446464646464646 | 21 | cstec-sarcoma | up | identification of Serum. MicroRNA-21 as a Biomarker for Chemosensitivity and Prognosis in Human Osteosarcoma. | ///555//////// dvh | hepaiarelhiter 4/32635 2 546464/4/ | 6356/6/6 | /MieroRNA~5rib as a xpotaitiahdiagnosfee-mniker:·:· ///366/565534636254/4/4/4/4/4/4// ///2263 3 3 34/4/4/4/4/4/4/4/4/4/4/4/ |
6553666/ /|/22/6/6/6 | 53262:62666:56565/ | 632565 | /4E46hi236/6/6i3l2i6R3A/6/6/: /4326562342/55225324/4/4/4/// Gastric Arienucarcteoma /4Α2562ί®2562'5///6/6/6/6/6/6/6 436626665053666/6/6/6/6/6/6/6/ | mir- 21 | cstec-sarcoma | up | MicroRNA-21 is involved in osteosarcoma cell invasion and migration | 55355/6/ | 42355343332464 4/32625 25464/464/ | 43/1666 | :MicroR/NA-:-5hi:promofes:·:·::·: 4/50352424623246464646 62052/252236464646464// |
149
WO 2017/132552
PCT/US2017/015417
2:^322333383323233222222222222( 22f/i898/3888838222222222222 Northwestern HuttgSiy | |||||||||||
(:(8/5-(:(:(:(:(:( 2288222222 | gastric cancer | //889/( | MnroRNA-M' A-ppreute, gastftc cancerceii growth and induces apo-pto-sisby 208338O88222222222222222 | mir- 21 | osteo-sarcoma | up | A three-plasma miRNA signature serves as novel bioinarkers for osteosarcoma. | (:(38(-(:(:(:(: 2(80222 2|3222222 | hep <tov tibibr //88/8588/////////( | 238/2//// | :(83/383859/388/8/8/////////: CYLD egression and :pi7fnetes:eenprolif?mtron:·:·:·: tn human hepafovcllubu (/:978/8//99/(//////////////////////: |
:(:(t5lf/(:(:(:(:(: 228|22222 | 22^8883882222222222( | dyu it | tfiiR-143 inhibits glj cub ate and depletes sternness of glioblastoma stem-like cdte | inir- 21 | ovarian cancer | up | The inhibition of iniR-21 promotes apoptosis and chemosensifivity rn ovarian cancer. | /:(818//// | colon vancei | OOte £’ | ::iniubittoii:ofaiiropiiagv:aud:·:·: tumor growth m colon cancer by nuE-5bz. |
•ηκ· 228122222 | (2:giro38222222222222222222 | down | •MUiRxiAkiuhibitSskuoiysk·:·:· and depletes alcmne&a of glioblastoma item-like .;dh· | mir- 21 | pancreatic cancer | up | MicroRNA-21 is overexpressed rn pancreatic cancer and a potential predictor of survival. | (:(//77(:(:(:(: 502- (18222222 | breast cancel’ | 2(98382( | 22859855895358298588522222: «3 breast cancer \ ta downregulation of TEAFz. |
mu- 2288222222 | 2298388/38322222222( (288/95/382222222222222 | 2232832 | //3Ο382/98 9 8 922222222222222 prmtten .on-no to\ wmi hi tepabxtdfoiaf esntnc.ma (((¢3/3(38893/383338//8/(8/(: (22^85(:98/888//3////////////// | mir- 21 | pancreatic cancer | up | MicroRNA-21 modulates biological functions of pancreatic cancer ceils including their proliferation, invasion and chernoresistance. | mu- | breast cancer | up | MiR-idf inhibited cell proliferation ofhnman breast cancer ceils by Suppressing CCNDl :(:(7977έ9ΐό8:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( |
/:8/8/:///( | //5/8/988//////:///////( 2238828382222222222222( | //3383/ | MkibENz\-i43 targets 225358582/88(99.529385933222( (2^88/3(8(/288/88322222222222 | mir- 21 | pancreatic ductal adeno-carcinyma | up | MiR-21 upregulation induced by promoter zone histone acetylation is associated with chernoresistance to gemcitabine and enhanced malignancy of pancreatic cancer ceils. | /(/hi////// (/:505(////: | chion vabt er | down | MtR454 <fA-Mttii3teti (2^05:8955358999822222222222( 2299988395(858995222222222222222: 288853858222222222222222222222( |
mu- 22232222222 | na&o-pltmyngeaJ 2288/95832222222222222 | 2232832 | 2:8//538583(98889898222222 and pathway alterations m m-sopl wrt ral ·ηοην* | mir- 21 | pancreatic ductal adeno-carcinoma | up | Micr oRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. | mu- | 229855589888222222 | dov n | MIR-5t?3 regulates ciapbtm .vmMau e Λ urnm A-sn cancer ceil fines b> targeting IGFiR andBCL.5. |
(//5/8///// 2/8822222 | naso-pliaiyngeal (28885832222222222222 | Jdteft | Identification of rosE -14 4 (288(593988(5888359582222: nasoplian ngeal carcinoma 2(838388880822222222222 /8/33/8s8h/33b338322222222222 | 21 | pancreatic ductal adenocarcinoma | up | Modulation of FoxOl expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. | /:/9/8//// | gasttte cancer | down | microRNA-51B inhibits gastric cancer cell growth (2(3833859 5 95/239/222222222222222( mesemhy mat transition |
mu- 228122222 | tiou-srnati ceil bag 2233/823222222222222222222 | 2232832 | »aR-14J mluhtts veil proliferation by targeting nmopfiagy-related ?13 in non-Siontl cell lung cancer /(1^380882222222222222222222 | mir- 21 | pancreatic ductal adeno-carcinoma | up | Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (FDCD4) in pancreatic ductal adenocarcinoma. | mu- | glioblastoma | dote n | MicroRNA-5b' acts as a /(95985:88588538222222222222 pbobte Avma tor imUfiple andfuu'pr etroctv bv :(:(t(5ig5iil(lg: $333 /:8/////////////// |
/:338:////: //232222222 | non-smalt ceil brag 229 8 3 8 222222222222222222 | Jdteft | roiR-145 inhibits NSCLC cell gryu th and metastasis 28839395393555385/2222222222222 | 21 | pancreatic ductal adenocarcinoma | up | interplay of miR-21 and FoxOl modulates growth of pancreatic ductal adenocarcinoma. | :(:/9/8//// | hepatic cthiiar 228888882222222222 | down | MiOroENA-?ti3 inhibits die 2258288998589(882222222222222 downmgnlabtig oycliti LG and E2FJ hi liepatooellular (/:/88//7fiU/(//////////////////////: |
mu- 228122222 | osteosarcoma | 2232832 | nacroRNA-14', dmutregulated rn osteosarcoma, prompted apvRtvSte and | mir- 21 | pancreatic ductal adeno-carcinoma | up | Association of tnicroRNA-21 expression with its targets, PDCD4 and T0V1E3, in | mu- | 22958858898522222 2238888822222222: | dote n | Epigenetic silencing ot Mt mRNA- / menial i AM Au\pres«nm mnon- |
150
WO 2017/132552
PCT/US2017/015417
suppresses luitiorigerocio by. targeting £LR2. | pancreatic ductal adenocarcinoma | small cell lung cancer ceil | |||||||||
roir- ζΒ///// | osteosarcoma | :(:00( | 9(:A:4fede4pfes//:tiiiRKA((((((( Signature serves as novel :(OOOOO4(((((((((((((((( 9(/ί///3/·3/ί3.:((((((((((((((((((( | mir- 21 | pancreatic ductal adeno -carcinoma | up | MiR-2 i, mifi-34a, miR-W8 and miR.-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. | (://r5(((: 5f) t | ((3r/l/4/4a44id4/((((: cab oareirmmo | down | Gcitviucwide Aud' Ά ••ahxaiv MufoRN As for Detection os Oral Cancer, |
54441455444: | pancreatic dttv'al atieiKi-earemyma | down | ;(/^g(§/;ii3/h//;(((((((((((( (040000/4(((((((((((5 Xenograft Growth via DCtKl -Dependent :5RO/rO5h4.5:5:5:5:5:5:5:5:5:5:5: | rnir- 21 | pancreatic ductal adeno-carcincma | up | MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraeoitiielial. neoplasm.. | xlfep?::::::: ((4//5((( | xOsGOSd/p/ititttV? | 5///|t::: | MieryRNA-dtk; acts as a 9(4443/4/3}4//3Sti /4/:4((((((((((: osteosarcoma by targeting //4||B///////////////// |
roir- iiB///// | 500/500:(((((( | :(3//445 | naR-14' turerfetes wvh ER9M signaling. arxf abrogates prostate cancer progression ir mme | mir- 21 | pancreatic ductal adeno-carcinoma | up | MicroRMA-21 in Pancreatic Ductai Adenocarcinoma RumorAssociated Fibroblasts Promotes Metastasis. | mu- 5f) t | ovarian cancer | ZB/ZZZ | MicroRNAs overexpressed nt ^anmAt cells are associated with cbeinoiesistance. |
54///(5:5 5:1543:5555 | prostate cancer | down | miR-d-B gXcrouiSvs prostate career cells proliferation and migration anti enhances thgiraeostib-ky to 5/0000/04(4(((((((((( Sjppf'zMOOOtH R-i‘ | mir- 21 | papillary thyroid carcinoma | up | Expression of miRNAs rn Papillary Thyroid Carcinomas is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients. | (:4//5:((( 5- <4 | h>po-phai>ugeal squamous*, nil :(5//:4/ό44ί/((((((((( | don n | ntieroRN A*?Of inhibits csnt?r ceb prohfetadprt m targeting CBE.6 io. ::hypapia}iyrigeai:sqaamous:·:·:·: 9(ί//3/3/3/43·(((((((((((((((((( |
(045:((((: ZBZ/Z/Z | prostale cancer | dyw n | Microf.NA-!43 inhibits veil migration and invasion by targeting matrix tt' dbprottiouro 1 mt 5/ί/^ΐ3ί/:(4/4ί/Ρ4:5:5:5:5:5:5:5:5:5 | mir- 21 | papillary thyroid carcinoma | up | MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4. | , :::fnir:>:::::::: | hy pypbaiy ugeal squamous cell :(/433/43//:((((((((( | dow t· | 9(43δ//3/ί/3δ//ί9((((((((((((: associated with poor prognosis in high-grade 9(/4/:/4359((((((((((((((((((((((((((: |
(3///(((5 53:53:5555 | prostate cancer | down | 'the tumor-suppressive tumroRNA-d -ί-3/U 5 duster inhibits ceb migration and Invasion by targeting GGLMl mpmoiate .an^er | mir- 21 | prostate cancer | up | MicroRNA-2.1 inhibits p57Kip2 expression in prostate cancer. | 54/41555: $t;o | gastric cancer | (:///:/(: | ?4rercRilA-^ti6 inhibits gastnc cancer proltferaiioo. and invasion by directly 9((/9r9^//////919((((((((((((((((((: |
:0/5(((( | ienai ceb carcinoma | down | 'Die titinor-SoppresSive mioroRNA-l 43 / hl $ c fester targets he\oktnase-2 in renal veil earaiumua | rair- 21 | prostate cancer | up | A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia | 4:444/((((( /////// | hepatocellular 5:54ΐύί/θϊί43555555: | down | MiR«$tki suppresses proliferation of hepatoma cells through targeting YAr /IB^9?^il//////////// |
roir- (|ZZ/4/Z | 9(bi/4d5//d/4//:((((((( | ((3//44(: | naR-IN meguiatimt mvfeaset, bladder -anuer cNi proddciatronbv targeting BZB2 and roauia· mg Wat signaling | mir- 21 | renal ceil carcinoma | up | miR-21 downreguiaied TCF21 to inhibit KISS! in renal cancer. | 4:434/5444 505 | nasopharyngeal 9(//43/3/3:((((((((( | down | MiR-dtiE suppresses tumor proliferation and invasion b\ targNqjpbOKGl m nasPplKuyngcal camrooroa |
5444445555: /B//Z/Z | :(:OO^k/((((((((((((( csrcwOdta | ((3//4/: | EdnroANAAl-l A-ppn*sse, eteiangiecaicinama ceb ^pioiifeiationandunvasion:·:·:·:·: ti<mugh tmpetmg platelet (/3///ti3/f/ii//(((((((((((((((: < NAlhy dmfasc ismotro ih | mir- 21 | renal ceil carcinoma | up | MicroRNA-21 is overexpressed in renal cell, carcinoma. | :(43/5(((: 4///4((( | oral squamous ceb camino ms | down | MmroRNA-Yro sopy-m aos growth and metastasis of (itiihftiidti/itia/fei/iiiiiiiiiiii: carcinoma via targeting 595//5:///5595959595959595959595959 |
ί
WO 2017/132552
PCT/US2017/015417
difiuAddd ;|BI;I; | /S5 | nenastusts otgazm caarcr /P^B^totididididididididididd/d | mir- 21 | renal cell carcinoma | up | MicrcRNA-21 (miR-21) posttranscnptionally riownregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. | 5&ftd:5d | renal clear cell carcinoma | do? n | MtR-i-On re (tow b-rcettlared 3ib;|BftO;;i;0^0;d;d;d;d;d carcinoma and inbihttoceft gip w th and metastasis 'in d;;friij^iiiigdF^?p^|;dddddddd:dddddd; | |
dnarad/d; ;IB|;|; | hepatocellular | dOwtl | nuR-14-ί suppresses the •:pfelii?r3H«n:3Hd:tHet3Slask:·:· of bcpatoecllular careitinuia by targeting £21-3 | 21 | renal ceil carcinoma | up | The ciinicai ut ility of miR- 21 as a diagnostic and prognostic marker for renal cell carcinoma. | dtbftd/d: 5vb | renal dear ceil TraiSmBBTTTTT | down | CofTCctiom MiR-506 is : Dy wn-Reayiatod: in Glyar:::: <eh Renal Cell Carcinoma and inhibits Cell Growth 3ώ:|||ώδ/Ο;$;ϊ33;3;3;3;3;3;3; dThr^ifftfigBftO^dddddddddddddd; |
dribtkddd; ;;;;O|;|; | :dhfog:BBsd:d:d:d:d/:d: | ddOfe | /OyfB/liO Proltferaftori and Induces ApoptoSS are: Autophagy in Lung Canter C oils fc? ϋ>^^έ£!^:^ί!ί$Α^;ϋ:ϋ:ϋ:ϋ:ϋ:ϋ:ϋ | mir- 21 | retino-biastoma | up | Seed-targeting; anti-nuR-23 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways. | dABirsd/rc: dW/dd ll||; | kidoev «.ftocer | down | idPOirfrcatrcnM mik^o 3p stjd mtR-?09-3p that am associated with ceil ::irrcasion:arid:mignutmii:and:·:·:· nn oh eft η· die apoptosis nf renal <ell carcinoma |
iiin | 3^0 | veil prcltferatt^tv nagrafinn :/^ddB^kfiB:d:d:d:d:d:d:d/d: usaophary ngeal carcinoma through rcprcssior. of ;BT0dddddddd^ | 21 | carcinoma | up | Profiles in Cervical Cancer. | 5vQ- llll | Jpantl miR-5;''9“'p that arc nn aston and reagraticui and mvolvecl in die apoptosis of lynal cell carcinoma | |||
dbiibdddd ;|BI;I; | d:6^BBIo|hd:d:d:d:d | down | 'the downregulation of ttuk-1 14 re asSOdauxl wfh the grow fh and invasion yf osfeosatcoma ceils through fits regulation of IAGLN dCdiB^hdididididididididid/d;: | mir- 21-3n | hepato-cellular carcinoma | down | MicroRNA-2 l-3p, a berberineinduced miRNA, directly downregulafes human methionine adenosyltransferases 2 A and 2B and inhibits hepatoma celi growth. | :OU:d:d 5ft9- ;lill | dr^^dcelld:d:d:d:d:d camtooma | /dbtoftd | fvircroRHA*^* -p inhibits camar ceft prohferatton and nnKtahon U targeting thy na togen-aclivaieri protein kinase kinase kinase 8 ;dBBBB:i8;BblO;d;:;d;d;d; dcarctftoma//////////////////////// |
dridtkd/d; ;I;B|;|; | osteosarcoma | ddOfe | Mb rreR\ A A 4-1 A-ppmssez osteosarcoma grc-w th and ittotastasts by targeting R0CK.1 and R0CK2. | mir- 2l-5p | clear celi renal celi cancer | up | Expionng the miRNA-roRNA regulatory network in clear ceil renal ceil carcinomas by nextgeneration sequencing expression profiles. | diOd:d: d:;$0t£d:d llll | d:fdtd/^ft3d:d:d:d:d: 3Β&θθ5:5:5:5:5 | riow a | Tumor snppressn e miR?09-5ρ contributes to cell migration pfolftermc-o and ddLiiiBiriB^hiBdddddddddddddddddddddddd |
dnarad/d; ;IB|;|; | pancreatic ductal | dOwtl | XMDK-92 inhibits Xenograft f jrcnflt \ ta DCLKI-Dependent | 21-5p | rectal cancer | up | Overexpression of m.iR.-23 -5p as a predictive marker for complete tumor regression to neoadjuvant chemo radiotherapy in rectal cancer patients. | dtbftddd: Bill;/; | breast cancer | Oil; | MicrokNA Mbprcmxue cell and fcumoi growth by largetmopeiOMrexloMni tn >:;bjr0^h;Briii.ii^;ddddddddddddddd:dddd; |
d:hiii:d:d:d | d^BBBOB:5:5d5 | Bldhd | Dyreu-regulafiyn ofntiR144 promotes thvreid earner e-l w\ reiob bv targeting ZEB andZEB’ | mir- 210 | adrenal conical carcinoma | up | The role of rnicroRNA deregulation rn the pathogenesis of adrenocortical carcinoma | dfthfddd: ;|ΒΪΙ | 3lPhg:BB®f:d:d:d:d | Oil; | miR-AidO promotes tomyr ercw dt m lung varied bv ;:;t^BiO;r;Ob;d;d;d;d;dT |
UUf- ;I;B|;|; | BB^BhO^bkdddd | ddsdO; | L^^i^ijp/t^Ad^h^Uhdddddddddddd::::::::: Proliferation and Invasion T^d^^iaiw^BHfefeldddddddddd 3E^^$^rcddd;d;d;d;d;d;d;d;d;d;d | mir- 210 | bladder cancer | up | Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. | mn- bBii | bnu' aderrecarctnoma | down | mfR-οΠ and nitreA267 dihhibioOld^ adenocarcinoma call proliferation by targeting |
152
WO 2017/132552
PCT/US2017/015417
$$«$:$$$ $£:£?$:$:$: | ;:bii£b^:$$£$££$:$:$ | $d£$£$ | MrcroRNA-143 farteiKWKs as n tumor suppressor ra human bladder cancer TM $||£$$$$$$$$$$$$$$$$$$$ | roir- 230 | colorectal cancer | up | Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. | $$£$:$$ 512- :$$$:$ | £ri£$£ritad:$£l:l$:$:$ lung vftticer | dm? n | inhibition of RAG1-GEF DOCK ; bv roiR*?12-3p Cbftif ilxttas to suppression of metastasis in non-srnail cell lung cancer. |
$:ϋ$ίϊ$$:$$ B^lll | bladder cancer | down | Replacement ii-eatiuem 14$ induces synergistic inhibition of the growth of human Madder •'imerc^ib by regulating fT$K$Akt and Kf APR signaling patl-w a> s | mir- 230 | esophageal cancer | up | Differential expression of miRNAs in esophageal cancer tissue. | $mtf$:::$: 513b | gastric cancer | dbwn | Hpftgulauon m u ok * 3 -b inhibits cell proliferation £hftgr$m$$ih$p$p$$£;£$$ apoptosis by targeting high tadbthh pronp-bcH 3 profeut tn gastric cftn?ei |
$££$$$$: | Madder cancer | $d$$i$ | secs”, a target gene cl jnicroRNA-145. regulates tnierfefOt· -5 mchx trot· $:i$p£g$^iA$$i$C!eg££$$: | mir- 230 | esophageal squamous cell carcinoma | down -1 | MiR-210 expression reverses radioresistance of stem-like cells of oesophageal squamous cell carcinoma. | $££r$:$$ | breast cancer | down | Re stera'ro»«. ί nvR -51M expression Induces cell apoptosis in bladder cancer ::::£/£Π:ίϊίί·ίό$£$$$$$$$$$$$$$$$$$$$$$$$; -, |
Bllll | microR'dAs m bladder | 230 | squamous cell carcinoma | cell proliferation through targeting fibroblast growth factor receptor-like 31FGFRLI). | Bill | cixa-dpahnatco the NSkdependent NT- fipxtbp-u in colorectal cancer | |||||
$£:£?$:$:$: | ;:bli£b^:$$£$££$:$:$ | $d£$£$ | iniR-H? inhibits invasion <4 bliddereanver \lbfev £ta$$t£$:$£$$££££££:$:$ | roir- 230 | esophageal squamous cell carcinoma | down | The Role of MicroRNA-210 in Esophageal Squamous Cell Carcinoma. | mu- BOil | et-ophacea: squammizve'd :$$£$£$£:$:$:$:$:$ | dm? n | $ri£.R4Si£b:$:$iA£4£££££::$ regulated. and :n\ oh ed ra ceil proliferation and invasion by targeting $R£pi$$£e$pi$^g$;££:$$$ squamous .ell ^arcuentet |
$££$$$$: £BI|I | Madder cancer | Jcwn | nuR-11<induces t asp as? $^pgpd$$£t^:££££££$:$:$ independent cell death m uroriteha· -. unem ell lac, w ith targeting ni' an expmssion signature $prg$$$pi££b^dd$£££:$:$ $$£$$;$:$:$:$:$:$:$:$:$:$:$:$:$$ | 230 | gastric cancer | down | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPf!4lE,3. | $$£$$$: 5i<>d | hepatOxtelhilar $:$£$ mb££$:$:$:$:$: | down | MicrokNA 5 fod targets MKm? and suppicsses veil growthtnthe bepatevehuUr k vuvroct. a cell lux >C c*> |
$££$$$$: £BI|I | breast cancer | Jcwn | tf£R-U5 participates with TP53 In a death-promoting regubloty loop and targets estrogen receptor-alpha in bnokta broixiv-u .writs | 230 | glioblastoma | up | Acute hypoxia induces upregulation of microRNA-210 expression in glioblastoma spheroids. | $$£$$$: 5i<>d | hepatOxtelhilar $:$£$ mb££$:$:$:$:$: | Oil; | in hepatocellular eamtootoa itdR-?l$d Is up-regulated :::&O£$^£|$h:£it$££$:$:$: rargefs CDKB3 A$p21. 1 ·! N H >’l 'UP |
UUr- BSlII | $bi£^i££££$£$$:$$$ | $:£$$$ | $:Μ®$£$£$ι$ι;$£££$££$$: ft.rteuteenesis and grcu th bv N-RASandVEGf | mii- 230 | glioma | up | MicroRNA-2 30 overexpression predicts poorer prognosis in gli.oma patients. | mu- ΒΒΪΙ | osteosarcoma | down | Cl'GF increases matrix nteraliuproteraasex $£χρ$^δϊό£:3η£:£££££££££ $pb$$h$ht$: £$£$$$$:$:$:$: himoi metastasis in human osteosarcoma through dowmregnhnrag miR*? 1 yd. |
$:££$:$$$ /££?£££ | :$£$£$£$$$$$$$$$$$ | $££$£$ | ttuR- 15 * c core xuou u< the blood of breast career $^£$i$£££££££££££$$$ | mir- 230 | glioma | up | MiR-210 up-regulation inhibits proliferation and induces apoptosis in glioma celts bytargeting SIN3A. | $$£-:$:$ ΒίΙΪΙ | $b£adgp££ri!$£$$$ | dm? n | MiR-5 ibd represses $ό$£$ί££$ίώ$£$5£.$££££££ proliferation and enhances $0iSpt£tt$i$i£Od£££££$:$: cyroto.-doity in vitro b? |
153
WO 2017/132552
PCT/US2017/015417
/(3388388880(((((((((((((((((( | |||||||||||
!UK- 53/8188888/ | 53388:0860(((((7((( | (808(: | ituR-l·** inhibits breast career \il cmwth ihit-uph 3^00555555555555555535( | mir- 2.10 | hepato-cellular carcinoma | up | Effects of knockdown of miR210 in combination with ionizing radiation on. human hepatoma xenograft in nude mice. | /:383//// 52da | hepatocellular /(:88848538:888888888 | down | .MicroRNA-2i;< and ft«cn.«RNA-?2?,a inhibit (//ό848θ38848338/88/(((((((((((: downieguiatina E2F2 in hepatocellular carcinoma. |
7:1013/777/ 55/8|88885 | ctrjcai cancer | Jaw ft | be«3'^jisiK3 of ///p'4$l3RNA$i83:3/(((((((((((((( sss'Niated wnli aagjessr. e 50888508880(38585((((((((: prognosis in human cervical cancer | 210 | hepato-cellular carcinoma | up | Hypoxia-inducible microRNA 210 augments the metastatic potential of tumor cells fey targeting vacuole membrane protein Ϊ rn hepatocellular carcinoma. | /(3)43/((( 52ba- 1111 | iJOn-ShisRcell //1/^13683/3/7////// | down | The microRNA -52da-jp /(i/3i3t8i$/^5iff548888((((((((:888 apoptosis and metastasis by targeting MAP 'K2 ui imi'c si” ill veil limp •'imer |
!UK- 55/8188888/ | 50088888808(((((((: | ((3838;( | Ghtetfewricoid regulation of a novel tllA ib-p* ** ((3iiO:388:80803(((((((((((((( (;iOd08i83000:80(:(((((( ((30888(08088388(((((((((( cert real cancel cells | mir- 210 | kidney cancer | up | miR-210 is a target of hypoxiarnducrbie factors I and 2 in renal cancer, regulates ESCU and correlates with good prognosis. | 83!· 52db | hepatocellular /(:88848538:888888888 | down | MiR-520b suppresses proliferation of hepatoma •'ells through, targeting •cnelgvgn translocation 1 5·/|έ$33/Οΐ388888888888888888 |
$333((((( | chondm-saicohK’ | dowh | The Epigenetic Regulation of EOXv fey miR-145 rn Hawaii f iiondm*arcoina | mir- 210 | lung cancer | up | MiR.-210 promotes a hypoxic phenotype and increases radioiesistance in human lung cancer cell lines | (:333(((( $08((( | breast cancer | 8/3888888/ | The niioroENzXs miR-3 73 and miR-5 2.3. promote /(8488^4/3358483:88388888888888 ;(iZ8i43838(((((((((((((((((((((((: |
/(3)13((((( 5/4/8858888 | ι»1«η cancer | dpw π | Forced expression of miR3/fepre*s' tKK and phX/p?2 signaling in v^’vp pnhnuR-rif4 m gnttumoiS ofApcfMirp (:3)483/(((((((((((((((((((((((((((((: | inir- 210 | malignant melanoma | up | Comparative analysis of melanoma deregulated miRNAs rn the medaka and Xiphopliorus pigment ceil cancer models. | ////3)43(((( 52Vc- 53855885 | gastric cancer | 58/188888 | MicroRNA profiling of Unman gastric cancer. |
73X37:77: 58/8188888/ | 5000803(((((((((( | :(8$3:8(: | Tumor suppressors mifb- ((00ri0300$(0i((((((((:( predicted target proteins AR H T 7 K R* *l<P IR M arc differentially e v.pm zsM m pm· umaf and 7θδί0Χθό37:7:7:7:7:7:7:7:7:7:7 | 210 | malignant melanoma | up | MicrcRNA-15b represents an. independent prognostic parameter and is correlated with tumor ceil proliferation and apoptosis in malignant melanoma. | ///3)43(((( 523c- 1111 | ///884880333133(((( ////588548/888(((((((((: | down | MiOroRN.A--?2t)c-3p ////ihSife/i5/8333/0083i38i////////////////// :-carcinoma ceRpipkfeianen ·: ·: /(838/4383845338865^/(((((((((( ltd κκί ji votf pp-'pms's bv tarpum-p gb puau- < |
IUU- /(/4/88888888 | 5088ί:858Ο;(((((((((( | $83003883(8000((((((((( covperatmn in regulation of colon. cancer stem cells | mir- 210 | osteo-sarcoma | up | Prognostic evaluation of microRNA-2ii! expression in pediatric osteosarcoma. | mu- 5233- $38888885 | /:/:885483/888538/((((: | Jup n | MicroRNA 52;kj-ip mh-hitz jftztru vaucer «.eh proldemtton, migipoptt. ////and/55535483/85//8888888888888888/ d^uureguUtme EphA2 ;(W4843d8(((((((((((((((((((((((: | |
////3)13////////// /(8/88(((((( | colon cancer | dpw it | Ratativo tmnor suppressor (;3θ5488308588:88Ο(((((((: cancer cell gmwdt Ip targeting urtcogene friend leukemia viPas totegratmn 1 /:8$ite7////////7:7:7:7:7:7:7:7:7:7:7 | inir- 210 | ovarian cancer | up | miR-210, a modulator of hypoxia-induced epitheliaitnesenchymai transition in ovanan cancer cell | 73)11/7:7:7 50188 | 58888i888&3388((((: ((883/48 848 8888888888/ | 58188888 | MieroRNA-52ttg induces ephhehal-mesenchviual nansmon and promotes mtagiSiS N Ιΐρρ.4Λν Ί/iuW carcinoma bv targeting ((00((((((((((((((((((/(((((((( |
:03::7:7: $5/8188888/ | 500080(((((((((( | (:3(888(: | MiR-if* direuR target? p705t>Ki in. cancer celts 10 ((Ο858(588ί88888(04:8ΐ:ί8(((((: sitgiogenesis. | mir- 210 | renal ceil carcinoma | up | MiR-210 expression rn tumor tissue and in. vitro effects of its silencing in renal cell carcinoma. | /:/3)43(((( //Ζρ^·:/::/:: IB | lucr cai.ccr | /88388888 | MiR*5?<Gp HnbaneeMhe Migration and invaamn of Li' er Cancer Cells fee |
154
WO 2017/132552
PCT/US2017/015417
45/il040405 00:050000 | «rtwievtai -.auvet | 0O000 | 3:/4040///40/://4044:0:0:0:0:0: nueroPNA-i'-A ftzsctokrfe? wtih ty mph jrctde metastasis /1 Oorecial cancer. | mir- 210 | renal clear cell carcinoma | up | Overexpression of miR-210, a downstream target of 1-( [f I ?, causes centre-some amplification in renal carcinoma ceils. | 0/04000: 52frh | 55/4///0///0//555555 | 000005 | COX-2 Elevates OucogenicnuR'-oibb mBreast Cancer 555/055^/555/011////0455555555555555555555555555 |
:::0/3::4:4 000:0:0 | cuinreciai cancer | 7:0003 | Assoctattoit nt' microRNA ;5;030/000i//5Kfr&5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5 340/00////://///ii//)))))) 0/ta/4/4/:0/i0//05/t44444444:0:0: 4://///////iOO0000000000 | mir- 210 | renal clear cell carcinoma | up | miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. | 4:/)110444: 00004 | ncm-smah ve‘d lung cancer | down | R-, dowuregntaung KuN! n«5R.-52/b Suppresses nousmall ceil lung cancer. |
oar 0O0000 | edloreUai cancer | down | E' alaatiou of microPNAs2Va. Q2a and 45 tn νοίυηχκΒ carctnuma as candidate dtagocstre markers: An Egy pttan pilot 4;/s/O00000000000040000404 | mir- 210 | renal clear cell carcinoma | up | Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. | 4:///44444 532- 404000 | 35////0///055555333335 54ί0ι5/ίΖ//5ί//5454545453 | 0005050 | 555540/^/1////55//55^51/51^3555555555555555555 rumor supprossorgeue expreszu-u «. «.mamous 555/4/513/41//555555555555555555555555555555555555555555555555 |
40/4::74 00:050:0:0: | co tareetai cancer | 4/044/4 | MicroENzk signatures: 33O//bi/040/i:id/33444444444 colorectal cancer? | mir- 210-- 3p | glioblastoma | up -1 | Hypoxic: signature of microRNAs in glioblastoma: insights from small R.NA deep sequencing. | :::mif77:2 510. 515555 | 0/0////0555555555555 eamtooma | down | MrcrcRMA expression in ovarian carektortta and its 555065/5/!/it//50400:0:0:0:04:0:0:0: vhmvopnrljnlugrcal |
0O0000 | ceii toigration and invasion in ti^utp v-writt ·η human colorectal cancer 3:////444444444444444444444444444444: | 211 | negative regulator of CDC25B expression, inhibits triplenegative breast cancer cells' growth and migration. | 532- 400:0:0 | investigation ol miRNACcfc Regulationz tn Faihogenesis miRNA 5 5 5 5Mi5t/i0S5:S//i/g/454 4 4 4 4 4 4 4 4 4 4 4 4 4 4 | ||||||
4//46::7:4: 00:050000 | «riwreetai ^aucer | down | <drdntete microRN A 000000/0000/000000: colorectal cancer $\ sfemafu icview ptviiiinc iend'es-uta e\o'rtincnti· 7//iidati0/57?57?57?57?::::7:::::7 | mir- 211 | colorectal cancer | up | MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor C33D5. ' | :5:/4/7::::::: 000050 | pamreatn. dtrctal adenocarcinoma | 000004 | Circuiaiing MicroRNAs in 55500041/5//5^/04//55^30/55555555555555555 Oncogene Transgenic Rats With Pancreatic bircral 550///0/001///^004:0:0:0:0:0: |
inu- 00:000000 | 53/6/040/0/005000 | :0/04//0 | 5:RR^/i//O/^0/4/O000:00 143/145 modulates KRAS 4:/0gO0/^4i00/000:00000000 dowmegedatton ef multiple 40/O/4444444444444444444444444444 | mir231 | liepato-cellular carcinoma | down | rniR-211 suppresses hepatocellular carcinoma by downregulating SATB2 | mu- 542- Bill; | 0£//O50/0O050555 | duv n | 55θ0ί/ΟΟΟθ404005404 suppresses cell growth of gasiric cancer ceils via targeting onectgeoe aslrocxte-elevated gene-I |
4/04407:44 00:050000 | cniureetai cancer | down | MicreENA-i-15 inhibits 30i0/0/0:g/j//fr:/0d444444444444: metas-asrs nu'-'lorettal vatxerby -argent's.iasv£i- 00400000400000004000:000000 | mir- 231 | malignant melanoma | down | The regulation of mrRNA-211 expression and its role in melanoma ceii invasiveness. | 7/4/7::::::: 5-13 | 555/h//5/i/45//i5 5 5 5 5 5 5 5 5 5 5 5 555 5555///00055555555555555545555555555 | dote n | MrcrcRBA-^iv ztoprevses endctmefrrnt cancer cuxogeuterb y -a targeting FaK and TWIST 1 |
70/07:03 | 55έ0·44ΟίΖ00:0:0:0:0:0:0 530/4/005:0:0:0:0:0:0: | down | ·:· Altered· :!uvels:of:tite:onoo-:·:·:·: microRNA 21 at-/ Ute 40//i//0///i/4///4444444444:0:0:4 mrcrnRBAs f-l; and 5 -15 in advanced rectal cancer 40//ι//ί/5έ////έ/ί//0444444:0:0: 550/^////0555555555555555555555 chcmoradiotbcrapy, | mir- 211 | malignant melanoma | down | Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. | 5:5//445:5:5:5: 000005 | gastric cancer | 0005050 | Oncogenic miR-Sid is an important hfoiecuiar Target 44/5ί50/Ο004ΐ0/0/440:0:0:0:0:0:0: |
155
WO 2017/132552
PCT/US2017/015417
iOR/RRi RiRjRRR | cmdotuetual cancer | llll | yRtpRy^dlOffRRRRRRRRR: microBNA-lTS promotes $Btffkrekiii^$rife^:kRRRRRR ::repressina:0GT4:iriiirin'4H·:·:· /kfjkrikiiki^RRRRRRRRRR::: adeimoaremomn cells | mir211 | malignant melanoma | down | Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. | :RmiR:R: 545 | RltihgyptipiRRRRR | dm? n | MtercRMA-A45 Suppresses RR^ii|jrO^ORR^RRRRRR Tat geting C% .kr< Dl and CDR4 m Lung Cancer RCki|||RRl|RRRRRRRRi |
RiRill | endometrial ratk'er | dOwft | Down-regulation CtfjntRIdS antj naP-if·. natiU ye aos'xntted v tilt D’sA ntetbvitransferase 3B Ov erexpressiort and worse progoosis in endometrioid /ktilkikditidSRRRRRRRRRRR | 211 | malignant melanoma | down | Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors | /•titir/:/:?: | colorectal cancer | down | E ’.traoeliular metabolic ::-enei:getres:can:premc;te:·:·:·:·:·:·:·:· kOi^lfktiik^tRhRRRR:R::R |
yimR///// BR5RRR | /•^sp^likkSdlCRRRRR: //^dtikSpykRsiRRRRR kbaikmOf^RRRRRR::· | tidon/iR: | yikiRGRSRiOhkRRRRRRR:: phOhferatiOit and tox asiOn of esophageal squamous veil ^arcUAiwa hi puti by | mir- 212 | colorectal cancer | down. | Genetic: and Epigenetic Downregulation of MicroRNA -212 Promotes Colorectal Tumor Metastasis via Dysregulation of MnSOD | cmifC?/· 5'M | T(^OiRR:RRRRR myelogenous CigkfeimgRRRR/R | down | Downregulation of loiR-Sl. oxR 15* and mtR jft chronic uwchord leukemia RBiRRRRRRRRRRRiRRRR |
/•ikite///// iiin | k^@kri^pliRRRRRR: squamous ceO Ri^teik^iR^RRRR/RR: | down | E'qluatmg'hciruR ri'2b arc! tulR-l 45 expression tii formalin-ftyod paraffinw e INI at J' e <1 esophageal squamous cell /ktiteiRdijidE/RRRRRRRRRRR | mir- 212 | gastric cancer | down | miR-212 is downregulated and suppresses niethyl-CpG-binding pro tem MeCP2 in human gastric | /•kuRRR :|k|RR | III! | MicreRNA-5bb activates EGFR signaling and its uihihmuit senatrees gitolylastejna cells to kbik^liigidkybRRRRRRRRRR | |
yffitiR::::::::: | esophageal t^gykiRiiy^RykRRRR:: kbaikmOf^RRRRRR::· | down | mtR-145 miltel33anr.d R^iRR|5lR|ihipRRRRR:RR Suppressive miRNAs target F-R'Nl ur esophageal squamous cell vancinmua | mir- 212 | gastric cancer | down -1 | Down-regulation of nuR-212 expression by DNA hypermethylation in human gastric cancer cells. | yfftte:/::::: ilRlRR | lung •'amer | MremRHA-^Tti promotes /•IkiigRdfGiibkSTTTTTTT/T: pf-vbferati··»» dir corah targeting tumor suppressor iBS/////////////::::::: | |
iiin | squamous ceO Ri^teik^iR^RRRR/RR: | RklRR; | altered expression lev els of MiR? f. Miff l-i 3, MiffBS. and MtR BA and cJmreopafhoJogio features of esophageal squamous /:pkilRte/«kktiitiRRRRRR:RR::: | 212 | carcinoma | Retinoblastoma Binding Protem 2 is Overexpressed in Hepatocellular Carcinoma and Negatively Regulated by miR- | BBlR | llRR? | uans.rrpuvtialh supprcssec ROWRikRiRll^kRRRRRi ovarian cancer progression. | ||
RiRill | esopfegoai ksqkqkiORRiiRRRR:: •/^iuiktetiRRRRiRR·: | dOwft | MicroRNA -14 j hone tie os as a tumor suppressor la Imman esophageal squamous cell earemoma | 212 | non-small cell lung cancer | down | miR-212 increases tumor necrosis factor-related apoptosis-rnduerng ligand sensitivity in non-small ceil lung cancer by targeting the antiaooptotic orotein PED | /•iyir/TT | :Wti!LCR:/ Craii:k:ibk:itiRR:RR·: | tkfRRR | /Α·ρρή$Ιρίί?χΡ^ρίηρχχ/ό·ό· uri&NAs as a potential diagnostic timl lot carb stage renal οοΰ carcinoma. |
!UK- RBill | kgdsOR^^R:RRRR | :|RR*G | h-RR-H5. iraE-B m and :RkiR|/||iiih|RRRRRRRR: proliferation migration, invasion gad tall cycle progression 'da tareeting Nikhtef^rehf^triRSRRiriR:: $^tffd/i^ppkRRRRRRRRR: | mir- 212 | non-small ceil lung cancer | up | MiR-212 displays Tumor Promoting properties in NSCLC Cells and targets the Hedgehog Pathway Receptor PTCH1. | mu- 57 ; | CktiiiigitikRRRRR:: RiitelhbjtiRtRRRR::· | down | unR-5’3 regulates melanoma progression by targeting the melanoma coll //^iibtiPh/kk-tsR4lRRRRRR:R: |
RiRR/RR: | ygyskrekiktiSRR:RRR | RdoR-iR | [Expression of nnR-l-G and nuR-145 and their intximnal mtdy tn gastra. | mir- 212 | non-small cell long cancer | up | Sy naptic acety [cholinesterase targeted by microRNA-212 functions as a tumor suppressor in non-smaii cell lung cancer. | :/iriiR:R/: Bill | breast cancer | d«w n | Novel oncogenic function of mesoderm dm cloptuern RO^i^iRitih|kgRRRR:R::R regulation h> MtR-?7.i-3p Ik Madder cqncer cell liras |
156
WO 2017/132552
PCT/US2017/015417
ZfouEEE: ElASEEE | Egti^l^toti^EEEEE: | NEODK a nrocel target of roiR-tilU wcreasestfie iiuashenessof Z^idbiksi0maZXZ:7:X:X:X:X:X:X:X | tuir- 212 | osteo-sarcoma | down | MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion bv down -regulation ofSox4. | NmEEE Bill; | E^dO^kfEEEE: EidOtiZEEEEEE: | dm? n | miRNAs in esophageal xiMhEebasskeEEEEEEEE | |
ZtiiiiE:://? CB|ll | pltotiiaituina | Edtitehx | bumimnal protilmg vf xtikediktifBfejBBAiZZxZE: identifies MkroRNzks essential for ghouia Zpfoi^ikfititikZxZxZxZxZxZxZ | mir- 212 | ovarian cancer | down | MiR-212 everts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. | kfokEE:: 574- 1111; | hep <P\. tiinbr E^tifoihpintiEEEEE | ;e|;:;ee | 7B?tW:fo|foRNAEEEEEEE :Bl^sfodfotifo64idh^tifkEEE Ehk|BBIbtilhp0tehfi|:EE marker for detecting liver xpOiitig^EEEEEEEEEEE: |
ZfotiExox: CBIll | Egilti^ZEEEEEZE | don it | M£D£>!C a novel target of Zi.itiOtotiti^itiCEEEE ZllBl^fofoAEEEEEEE | utir- 212 | pancreatic cancer | up | miR-13 2 and iuiR-212 are increased in pancreatic cancer and targe: the retinoblastoma tumor suppressor | Bill | EfolOfoOttilEaiktib;: | d«w n | mtfo-5?4- 5p negatb eb ;;;ΒέΙ^έ;|ΟΙΙΙΙΙΙ;Ι;Ι expression to suppress entoreotai ^ancerbver muma-J·,. |
H!H- ElASEEE | enema | Mi··'- :4^ uxlucca ADAk:17 xpcessiuR and inhibits ui Giro migration and invasion of ghoma xOglkkxZxZxZxZxZxZxZxZEEx | tuir- 212 | pancreatic ductal adeno-carcinoroa | up | miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-!. | mu- | Z^OEkitihb-EE: | up | 4:MrofoROItiiRlmg:ti£EEE bmouo gazm. ^anror | |
0foiiE0:0:: BBIil; | ZglitehEEEEEEEEEx | down | P< K Rl a novel target of miR-145. promotes glioma xOgtitidEatiddkxZxZxZxZxEEE | tuir- 212 | prostate cancer | down | A potential regulatory loop between Lin28B:miR?2J.2 in androgen-independent prostate cancer. | 0bitiE::0: ;IBII iill | bladder cancer | ZddAhE | MroroRNA-'Mto φ Inhibits ::P0|ijOb;itil|^b:EEE Canter Cells by Taraetrng ;;IBhb:fotiEEEEEBEE:E |
/•ηυίΕχ/Χ/ CBIll | ygitofotiZEEEEEE | dOwft | nuR-l l< kdubifsMigratton Stem Cells &* Targeatig iZ^Bl^lEEEEEEEEEEEEE | 212- 3p | glioblastoma | down | MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3. | ;lBll Bill | ogifobbafomatEEE | Oil; | miRNA roraroarrax reveals spevtiM expression tn the glioblastoma patients. |
xbuiE:X/:X Bllll | E^d«^^EEEEEE4 | down | MiR-145 modulates multiple components uf the lusulwt-bkc growth favtni paths a to hepatj rohda. /kdfokfohS///////////////////·?·?: | mir- 214 | bladder cancer | down | MicroRNA-214 Suppresses Oncogenesis and Exerts impact on Prognosis by Targeting PDRGJ in Bladder Cancer. | xbnEEE s- | E^lwhbtjtdbitiEEE:: | kdbPihE | EhnR4$77:fobrbbEEEEEEE::E glioblastoma tumor growth \ ta ihe Wi,i signaling B^O^|:;EEEEEEEE |
!UK- cBIII | E^tifhtifok:EEEEEE | BhO:· | luiR-id*' suppresses ceil ire η.,ΐνΰ «> heparo xilular carcinoma cells miR-l-l? ^B^BIOBIIIIII | mir- 214 | cervical cancer | down | MiR-214 reduces cell survival and enhances crsplatin-inriuceri cytotoxicity via down-regulation of Bcl212 in cervical cancer cells. | :::tiurE:X:: 45R2E44 iiii; | hepatoceRular EstoteiridfoAEEEEE | down | Bfo^'efo.tidridfEEEEE hepatocellular carcinoma by targeting CDKl and OI|:;EEEEEEEE:E |
/•ηυίΕχ/Χ/ CBIll | heputcNeliulhr Ei^ii^^ZEEEEEE | d£5Wft | EMtcfofoNA:M5Zd77777777777777 promising biy marker for hepatocellular carcinoma |||||||||||||:|:|:; | 214 | cervical cancer | down | MicrcRNA-2 3 4 suppresses growth and invasiveness of cervical cancer cells hy targeting UDP-N-acetyl-?-Dgalaciosamine:polypeptide Macetylgalaetosaminyhransferase | 5§4 | EgkdbaZEEEEE/E | down | MiOroRNA-584 functions as a tiunoi suppressor and •argots PTTGltR mghyroa |
0foiiE0:0:: BBIil; | hepatocellular Z^tetinPia^ZxZxZxEE: | down | bbeitoRNA-tif* suppress tepatooeifolat Earemoma by targeting ScSl anti its ::duwr<Streant:AktStgaalif!§:;·:·:·: | tuir- 214 | cervical squamous cell carcinoma | down | Down-regulation of mrR-124/214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. | ΧΐΡίΕΕΕ W- 111! | cervical cancer | |·;||Ε | MroroRNA-*>b Promotes Cervical Cancer Ceil Growth otti invasion by ETbr^tfo^:Bi|iEEEEE^ |
xiitiEZEE: | ZheptitscelhtiaiEEEEx | dc-wo | MleroRNA-id? inhibits : cell protifomtron by directR :: targeting ADAM f ‘1 m liepaiooeilniar carcinoma. | mir- 214 | colon cancer | down | mkroRNA-21.4 functions as a tumor suppressor in human colon cancer via the suppression of ADP-ribosyiation factor-like protein 2. | ZbifoE'X: fo'b- ;||;|; | hepatocellular X:CafEm0idpX:X:X:X:X: | ;O;I| | MicroRNA-5b0-5p regulates proliferation and hepUKKelhdar careitiorua cells bv targeting TGR-? |
157
WO 2017/132552
PCT/US2017/015417
/Olllllllllll/I/ | |||||||||||
(42/2-(44444 /99|//(/ | iuputuivlhilnr earelucraa | (4//99(4 | INpresstutt oi mi WuRNA.,. 4/22θ9:/5(/7ϊΟΐ9522ΐ?7θ//:4( 552/^9ί/ΐ9^2£9θί57ί/Ο·4:555 uflR-82kmtR 222. are! tuiR-M? nt patimtis •a ith fcepatoce Jbatar earcuionxi or umhepstrc ::<Ιΐθΐ3β21003ίΰΓΛΚ>δ:&Κ(1ίΐ£::: 5(/972795444444444444444:::5555555555: | mir2 bi | esophageal squamous coll carcinoma | down | MicroRNA-98 and microRNA214 post-transcriptionally regulate enhancer of zesle homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma | :((9/334444 ///9/// Bill | hep <b\. ribilar :(:(/2/2329333/:(:(:(:(:(:(:(:(:(:( | down | Grpwthpf Hep62 C ells Ha (:(D2C32/$2:2£:S:i:/QA(i9:(:(:(:(:(:(:(:(:(: t ypiesswm and itJnhmvU :52||/:(W92O27///:(:(:(:(:(:(:(:(:(:(:(:( |
:::2298::::::::: | kidney cancer | down | MicroRMzvbt? Targeisihe 55Μ272Β/ρ722ί2$2372332/ί:79:(:(:(: and is Suppressed m Renal <911 Carcinoma PatrenU | mir- 214 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. | 5(705(35 5s-g | epic-rectal cancer | /99/(/(/ | Hp-regulattort pi miR -588 correlates with tumor progression and poor prognosis in patients nitli «dpreetal ^aucer |
•UK· i/Olll | 3:H2S2929iS2:3:3:3:3:3::: | down | MiR-1-15 functions as a 4497/2/29/////72/:055544(:(:(:(:(:(:( directly turgoring baskm. deaceiybse ? in. liver 8822o22:83555555555555555555555555: | mir- 214 | gastric cancer | up | Down-regulated miRNA-214 induces a cell cycle Gl arrest in gastric cancer cells by upregulating the PTEN protein. | 5(7329(:(:(:(: Bill | zastm νίκοα | 4|||5 | 4(Μ|23/Κί·ΪΑ4ρ32ΙΙί3ί3§:9£4444444 human gastric cancer |
:::22244::::4:: (/01//(/ | (:(!22g(29222i8:(:(:(:(:(:(:(:(:(:(:(: earelucraa | :4//92:4 | ::::R/2/77//292i/9/229(:(:(:(:(:(:(:(:(: Suppressor miR-1 35 inhibits cancefcell growth (47232///292/9/27/72/272:(:(:(:(:(:(: pariewta u tilt epidermal 5:^9222O//l2////29t2954(:(:(:(:(:(: muianon | mir2 bi | gastric cancer | up | Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. | :57/738555( | :8:/ΐ/όθ5554(444444444: | (43:9(4444(( | miK-NG promotes glioma cell growth v& Wot/bera- (:(:997/23/:^2929892:::::::::::::::::::::::::: inhibiting wTFl and /|||^B||l|l|l|//( |
SUU* //95(/(/(/ | :(:(2i2g:2d0204(:(:(:(:(:(:(:(:(:(:(:( :4(/2//32/7//7(((((((((((((((((((((((44 | :4(//9(/(4 | MiR-145 inhibits co!) prphfcmtipnof luanao king /(2θΟΟΙΟ/ΐ2/0ΙΙΙΙΙ :433722ί32/:/:θ:ΐί^4222:44444444444 /OO///////////////////////// | mir- 214 | gastric cancer | up | Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis. | mn- (((//2((((((((( | chonkma | duv n | ' l«vf'R 5 A <' Sold microRNA-Uu regulate chordoma malignancy by targeting iB<3rEJ?_ Bcl-xL 4:(/i7d(MEL(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( |
32928:3:3 :/09(///( | :(:2i2g:(Si!/20:4(:(:(:(:(:(:(:(:(:(:(:( :(:(82//22072-2:(:(:(:(:(:(:(:(:(:(:(:(:(: | down | mreroRBA-i A mppressea 4:(R/i(g(29o/oc89l2r22:9i2244:444444 : uaiiaima aelipiuliferenof!;::: by targetHigiXT4. | mir- 214 | glioma | up | Associations between the Expression of micro-RNA 2.14 and clinicopathologic parameters of glioma. | i:9ilr8:4ii (((/(12((((((((( | hepare· relhilnr careracraa | :5992(2(:(: | Downregulation of m:R610 promotes proliferation and turev«ge£Ufb and actuate* Wre'beia-.atorftu :423/2/29/:39227/29(:(:(:(:(:(:(:(:(:(:(:(:(: ·»·.,' μ. «.’·».:#·♦ ... » 'ί t |
mu- :/O$/:/:/: | :(((ϊ222:/9/2ό4(:(:(:(:(:(:(:(:(:(:(:( (42/3/32/7//:44((((((((((((((((((44 | 59/72/2 | fpiahiu lung adenocaronjuma stem ceOs prolikraimn bv tarpettng | mir- 214 | hepato-cellular carcinoma | down | identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. | mn- /ii/i | /79//9/2///////:/ | duv n | miR-610 suppresses bang cat vet cvB prohknumt nt d invasion tareetuig 4/IBll(l(l(l(l(l(l(l(//l( |
(43211(8(4444 (/01//(/ | :(57292(2922223:3:3:3:3:3 (4/27272/222/4(:(2(2(/(/(2 | JpWft | MtR- if? regulates efrtcer ytem-like properties and cpithehahto-njeseneitt mai /9/299/24////2//444444444443/ nd-'t-^varetnomn-nuinuinu cells | 214 | hepato-cellular carcinoma | up | MicrcRNA-214 regulates the acquired resistance lo gefitinib via the ΡΊΈΝ/ΑΚ.Τ pathway in EGER-mutant cell lines. | 3:727333333 /iii/ | hepaioreiiular 4//2327/2339(:(:(:(:(:(:(:(:(:(: | down | bitR-rii 2 suppresses the im asw e-metastatk cascade (479(2///3///9/72/:444444444444444( (4/27/3397/944444444444444((((((((((((((((44 |
158
WO 2017/132552
PCT/US2017/015417
/))3)3))))): )))43)))8/) | 98θΟΐΟ/:/:/:/:/:/:/:/:/:/:/:/ | /)3388): | ):88833(0888:88)))/))))))): snppresan e MicroRNAs in ///888:3330)))))))))))))))))))))) | mir- 214 | hepato-cellular carcinoma | down | mu- | papillary thyroid carcinoma | dov n | integrated auah ses uf uncroRNA and mRNA expiessron profiles m aggressive papillary thyroid :933to3i93338/8/8/8/8/8/8/8/8/8/8/:/ | |
:::18188/:/:/:/: )0)33/3 | ]/:!8iig:Caft$Sf:/:/:/:/:/:/:/:/:/:/:/:/ | down | MicreRNA-145 inhibits tong cancer cell metastasis. | roir- 214 | hepato-cellular carcinoma | down | Downregulation of imcroPNA214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis. | :/:mi(-/:/:/:/:/ )0/3)3 | iutig cancer | down | //:/[(y/i/iRA3:8:I3tol(i/t3d/Eting:/:/:/:/:/ (m ti Ii vh roti aid Proliferation via Targeting 1^8888888888318/)38/ |
ear· | naso-pharyngeal ))))33383(3/:/:/:/:/:/:/:/:/:/:/:/:/:/ | down | •:MiavR24Ailereguto’3<jli:·:·:·:·:·:· and pathwm aberaadfis m n? to jh 3» t ?«. nf m monk. | rnir- 214 | malignant melanoma | up | Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophorus pigment cell cancer models. | :)8ti(3))): 3®33 /18/883 | ):8)833))8/3/3/3/3/3 /)3/4333(/)))))))))))))): | /)8333): | MiRNA-tii^ 4p iu£\'ivifs as a tumor suppressor at pancreatic ductal atieixroamtooroa by 8343^3330^2;/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ |
/OG/:/:/:/:/:/ )))03/3/) | nasopbrny ngeal earetooroa | /)8388) | nulM-t* inhibits mvusion and roetastaSJS by drrecdy targeting Stnad? in nasophao ngeal cancer | mir- 2M | multiple myeloma | down | Restoration of raiR-214 expression reduces growth of myeloma cells through a positive regulation of P53 and inhibition of DNA replication. | /:/351(9:/:/:/: 3(883/3/) 18888 | pancreatic ductal ::atie}xt-:cam35oma·:· | dow n | /:]h3R9rif8(S3:3/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: epigertetroally inactivate·! anti functions as a tumor /3333(3$ 88:33 patk/repik)/)))))) ductal adenocarcinoma. |
9(3((9:/:/:/:/:/ /3))|33/3/ | nasoplraryngeal /)33)888))8):/:/:/:/:/:/:/:/:/:/:/:/: | down | :///M®i)idS:/inSibiii$/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: metastasis by targeting )033833έ880Οΐ88)))/)))))): prexsc lit nis^ph-remgeal )03)3830/)))))))))))))))))))))): | 214 | nasopharyngeal carcinoma | up | miR-21.4 promotes tumorigenesis by targeting laciotiansferrin in nasopharyngeal carcinoma. | /:/35((:-/:/:/:/: )/)/)8333 )|833| | pancreatic ductal atierro-earornyrna | down | Correction: M iRNA-<. 15-$p ))33)3(388 833/833)93))))))))) /)83btii^)33m:8ii38(9333))))): Duotai Atfenocaremumahv /tThl^/tliF^/SfeiS::/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
mu- :8:43888 | /)898(0^8838/888/ | /)3388): | NEDObs. a novel target of tr<8M4\ increase» tfte )008380883))))))))))))))): | mir- 214 | uaso-pharyrigeal carcinoma | up | Knockdown of miR-214 Pro motes Apoptosis and inhibits Ceii Proliferation in | mu- )033/) | /)88))(8:/8338())))): | 388883 | )8383)RNA)33(iilni3:3f)))))))/ butOu<u gaxriv vanrer |
!UK- /:/:08/8/ | )088t88008): /)03339)))))))))))))))))))/ | )8388) | Lew rniR-b4> silenced by DNA methvfatron promotes NSCLC cell proliferation migration and invasion by ))t383iiO:i333i0/:i)/))))))))))))): | mir- 214 | osteo-sareoma | up | Upregulated expression of inicroRMA-214 is linked to tumor progression and adv erse prognosis in pediatric osteosarcoma. | /)38(3))): 3838/33) | gastric cancer | down | ):/383)8383)838888)0)/3/3/: n’2 in gastric cancer promotes cellular invasion ))toi8)3/r30(:3)^a83»3b9))/38): targeting INGi gene |
/:/:13(3/:/:/:/:/:/ /:/:08/8/ | non-small cell tong 3/)3)3)()))))))))))))))))) | down | iu(RNA-(4? intobiteiton- /))3)8)8/)883)/83)3)(833)))) (proliferation 8 targeting c- 08888888888888883/ | 214 | ovarian cancer | up | Micrc-RNAs and ovarian canc er: the stale of ail and perspectives of clinical research. | ):35((9/:/:/:/ | ////glipmp:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | down | tniR--tv?2 Suppresses ::proiifemtioreinvaston:and:·:·:·:· 3333f3ti93333itii)()i88/)))))))): targeting activating transci-iptron factor 2 in •dk<·::-.· velU |
!UK- /:/:08/8/ | /)0380330838): /)0838/))://))))))))))))): | )8388) | t xe »· · i. routes \M bead-fca&etf snspcn»u<ti array for detecting microRNA in NSCLC ))8839/))33/)3)8)8)3)))))))))): /)3/Οίέθ33))))))))))))))))))))))) | mir- 214 | pancreatic cancer | down | Dvsregulation of miR-l5a and miR-214 in human pancreatic cancer. | nm- ti?4 | rolme-tal •.arnet | down | Decreased expression of mreruRNAtof4 is associated wtih tixttOf ))38333)488438890()))))))))))) prognosis in patier-is with itoioreetal cancer |
/:/888:/:/:/:/:/ | nyri-snajil cell luna /)0838/))://))))))))))))): | down | MiR to4 attoas a n-e-astasis suppressor hy targeting roetadherm in 8)3333039338/8/8/8/8/8/8/8/8/8/8 | rnir- 214 | pancreatic cancer | up | Dy sregulalion of miR- 15a and miP.-214 in human panc reatic cancer. | :)3ti(9))): //Ο))))/ | gpstik carreer | /:/8333): | Dywn-regtiiaied miR-92? suppresses itwasioii and metastasis nf gastric vancet lp targeimg ILK |
:/:/13(3/:/:/:/:/: :/:/0/:8/:8 | :/:/npn)3l/Oi/33U/:3ikg:3: 8338333/)/)))))))))))))))) | dyw n | Low miR-145 expression lev el is associated w 8b ))08/O8808iO3))))))))))))) cto'ferentiation and poor | mir- 214 | primary cits lymphomas | down | Differential micro-RNA. expression in primary CNS and nodal diffuse large B-cell lymphomas | yritiiy/:/:/:/ | /):8833888)838))))) ))883)898(8))))))))8 | d«w n | ::n3R-:-62Ssoppre&ses:tomour·:·: mrerafteP awtittAUsrowto wgeimg t· ,P?RPl«, tepaiccctlular carcinoma |
159
WO 2017/132552
PCT/US2017/015417
prognosis in uoti-smaB cell ;5ίθ6636θ6555555555555555555555: | |||||||||||
uur- | /6ό6666682Η:ί666// 55666666555555555555555555 | 5505555: | EertimmiR-ii^a-^p. huR- 5506396:0650005555555555 drag nostro biotnaikeis in iKm-snmll cell lung yaacer | mii- 215 | cervical cancer | up | MicroRNA-215 is a potential prognostic marker for cervical cancer. | /:636//// | uorosinaB cell 55656668055555555; | down | 36665d868i886O6f389;9;9;9/ cimnlabirg miRAO 1-:p and miR-625* as blood-based markers for discriminating malignant front benign lung 86363666////////////////////////// |
6666363686)6650855 60668605555555555555 | down | MiR-145 inhibits oral squamous c ell ^aiympma iQN · ; veil gro λ <Ab< targNmg 'A!>c and Cdkf· | rnii- 215 | colon cancer | down | Prognostic significance of iniR215 in colon cancer. | 36868/3 /666//// | //^6061866665555555 | 5055555 | naPNkmitioatrny reveals specific expression in 6» ;/p65566386i565663;6f5555555555555 pfiobianoma patients | |
/:666/////: 5:3:36:///// | /666633666608555 56;866i666i8;5555555555555 | 550665 | Downregulation ofwuR- ;5;O668O5666O36i8;;5555;55: squamous ceB carcinomas and itscliitroal sigoifkanoe | mir- 215 | colorectal cancer | down | Association of inicroRNA expression with iriicrosatellite instability status in colorectal adenocarcinoma | /:666//// 96276/// | ;;;6686i8;O6655555; 5505805555555555 | dow n | MieroRNA-o2 7 Mediates the Epigenetic Mechanisms ofA nauunD to Supprero 3Pi6;i06ti66;$B;R6686;///////: Colorectal Garner Ceil and Grow lb of Xenograft //Τ666):6ί;:6ί:Μ6ίέ///////////////// |
:/636////// | 36636/336368/3////// | down | microRNA -145 inhibits osleosmt oina cell proliferation and invasion by targeting MRR1 | tnir- 215 | colorectal cancer | down. | identification and functional screening of inicroRNAs highly deregulated in colorectal cancer. | 8686///: 505555 ;||55555; | prostate cancer | dtiWR | Circulatory mR-628-5p is downregulated In prostate 55O86666668i6;55555555555555555 |
/:886/////: 55055555 | 8686853668616655555555 | dyn it | ;/;68R8i36368St6///////////////: ;586ί3666ίέ66ί33666;555555555555 probDnatton and m\ a?ron in targeting ROCK f | mir- 215 | colorectal cancer | down | inicroRNA-192, -194 and -215 aie frequently downregulated in colorectal cancer. | 8666//// bob | /:66866656363865 | ;O;55555 | MiemRNA-οόΡ is a prognostic marker for pnron ® wi bvNjfrosd ..diigu |
uur- 551155555 | ;566O5O63665555;555: | 5:36665 | hbuoRNA-U* target* vascular endotbeBai grow tb factor and inbihns jnvasioo 3666564^8686886/////////////// osleosait oina cells | mii- 215 | gastric cancer | up | MicroRNA-192 and -215 are upregulaied in human gastric cancer invivc and suppress ALCAM expression in. vitro. | mu- 50555: | hepatocellular 550/568665555555555 | up | miR-tiVi Ovotexprossroii tit Iron .xHldtft nrovroma //3383618636^863166^///////////: ;3C$f66!6i88;38fh;8i6b39;3;////// 3Fei66i6i86i//////////////////////: |
:/636///// 556055555 | ovarian cancer | ;/:3966/; | MiR-145 is dowurognlated inbiH<.abc<\aitau caroroi and modulates cell growth and im acion bv taieetmg p7QS&K 1 arid MIX f. | mir- 215 | gastric cancer | up | MiR-2 15 modulates gastric cancer cell proliferation hy targeting RBI. | 96169///: 505555 | lung «.aro-er | down | /86695/668661666///89898989 proliiemtionby fargsttiig /5Gi6S2;i663665 666555555555555555 maintains the apopiotic balance by targeting multiple modulators in human lung cancer A549 |
:/636///// 556055555 | ovarian cancer | ;/:3966/; | Mrcro-RNAs and ovanan earner the stale of art and perspectives yf clinical ;566O66;5555;55555555555555555555: | mir- 215 | gastric cancer | up | MiR-2.15/192 participates in gastric cancer progression. | 96569///: 505555 | pancreatic ;3έ66666;////////////// | down | Upregulation of mfR-1504 and nuR-tGb Induces 9;^j^^^jtg:;uji;^tfeii$aii<5555555; Cancer Cells bv laigetiug /iG^iR///////////////////////////: |
:/866:////: 55636555555 | :/605666665055555555 | dyn it | nuR-145 inhibits tumor growth and metastasis by targeting metadhemt in high-grade serous o\ anan /8806066/////////////////////// | mir- 215 | hepato-cellular carcinoma | up | Serum inicroRNA characterization identifies miRS85-5p as a potential marker for detecting liver pathologies. | 9666::5:::: bob | renal clear cell 55Ο56Ο5555555555 | 5;|6 5555; | Up-regulation of nuR- o3ti 5/m;6i!^8®;6O86ti5555555555 carcinoma is associated with lower overall surv ival. |
160
WO 2017/132552
PCT/US2017/015417
(;(;9ί227;(;(;(;(;( 22793((77( | ((0220400(33333333 | ((2203: | nriR-14>> targeting tughnNilre, gtinp V t® > (70θΟ2ό0ΐ2(ί$2θ33333333: patten· ontiome tnoxanat· 3:7773003333333333333333333333: | nsir- 216a | hepato-cellular carcinoma | up | Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepato can: iuo aenesis. | :229(2(((: | oral squamous <eJl «.arunoma | duo n | •reomnevtde StraR vl 8af.yuuv M.eroPMksior ;(;(Oo29;^^^2(Bi22(22(2(2(^ |
4ίϋίϊ4444: ((((775(((((((((((( | ovafieir cancer | down | MiCfoRNA-145 Function as a C ell Growth Repressor by Directly Targeting oMveiuBuwa» Ovam» 3:270723(333333333333333333333333: | mir- 216a | hepato-cellular carcinoma | up | MiR.-216a/217-induced epithelial- mesenchy mai transition targets PTEN and SMAD? to promote drug resistance and recurrence of liver cancer. | /494444 ((75(7((((((((( | hepatocellular carcinoma | down | Primare-specific micipRNA-63? inhibns ;;;;29ti(9O22794;222(;(;(;(;(;(;(;(;(;(;(;(;(;(;(;(; hepafovclhibu coreureroa ;(97;9492^Ο719792(222222222((; transducer and activator off transcription. 3 signaling |
42714))))) 72327272 | pancreatic cancer | 332703: | Evin roRNA-l J* rappressa., ceil proliferation, invasion and migration. in pancreatic «.ancer vO by raigeanii ((;^Oilll(ll7||((;(;7;7; | mir- 216a | pancreatic cancer | down | iExpression of uuR-216a rn pancreatic cancer and its clinical significance]. | )7)144)): 638 | breast cancer | dour | miR-tAK mediated 3(27g9292ip9(99BR(O9(((((((((( affects DNA repair and sonsifivtn to UV and cisplatin in triple negative |
7229772222; (107777 | pancreatic dewa! 30031040033333 | down | 3;(Ο^23223ί(Ο79(3(33333333333; (3BOi7O30023333333333333 Xenograft < tiowtfc x ra (((^i$|^JOO22222(2(2(2(32 ;)99s7999i529222222222222222222222 | mir- 216a | pancreatic cancer | down | MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2. | 2229232222 (0((7(7 | toioiecta! rare-ei | (27(0422(2 | MrcioRNA-tUg inhibits cell proliferation, invasion mdretexlnexvti! λ 4b\ targeting tefraspanbt ί it· ((fetibaffcpfpi^ct^;))))))))))))))) ;(;9a77i2U22U))))):222222222222222222; |
4922274))4 7202((((: | (3320337033333333333: 3300220333333333333 | down | Differentia: ruicix>*RNA expression in prinaaty CMS (:727137ρ77θ^228(^7ιθ(Β2((: 77073092023333333333333333 | mir- 216b | breast cancer | down | Regulation of the R2X7R by rnicroRNA··?, 16b in human breast cancer. | 29(942222 o.JS | gastric cancel- | 779(49(( | mtP-038 Suppresses Cell )T9i;iife29tiP72;i9;(992l2i222222222 Caraerbj Targeting 8p2 |
403144)44 7232(((((( | prostate cancer | dtmn | The functional significance of rnicroRNA-i 45 in (3:002(290233333333333333333 | 216b | nasc-pharyngeal carcinoma | down | miR-2I6b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. | )7)1232222 63b | gastrte cancer | down | MicroRNA profiling of (;2t72tO999ti(i7;792i797(222222222; |
::033::3::::: (10(777 | 7(0200ii0:((((((( | down | Restoration of naR-l-A expios&xon trap-presses «rail proliferation migration and iiwaxu-n tn prostate ^aneer fi^kiorgefinRRSCTii))))))))))) | mir- 216b | naso-piiaryngeal carcinoma | down | tmiR-2I6h suppresses ceil proliferation and invasion by targeting PKG? in nasophary ngeal carcinoma cells!. | 2229232222 (0((7(7 | 7;29aiig29229222222222; ;(;(2i27292i99i922222;(22;( | ((0(((7(7 | nnR-038 promotes melanoma ruetastasife and prefects melanoma ceils ;(97ρ27;799977727999;(;(;(;(;(;(;(;(;(;(;(;(;( ))9t799s9gy)))))))))))))))))))))))) |
!ΟΙΓ· 7232(((((( | 402000723733333 | 33292227 | $0(9^07293073333333333 regnlated gv DMA mntby lotion and p53 gene mefalrati in prostate carreer. | mir- 217 | breast cancer | up | MiR-217 Promotes Tumor Proliferation in Breast Cancer via Targeting DACHl. | )229444: Apr | bladder cancer | 2^((7(2( | Cticniatirig rmcreRMAs in s-raim not cl hmmarhers for patients with bladder 4:9a477i944)))))))))))))))))))))))): |
4922274))4 7202((((: | pmotate cancer | down | 'the ttnnor-stippressive minroRNA-l i-3/l-i 5 cluster : inhabits ceil: naarntton and: >: ni'-asionby targeting G0BM1 in presrate cancer | mir- 217 | gastric cancer | down | rnicroRNA-217 inhibits tumor progression and metastasis by downreguialiug EZH2 and predicts favorable prognosis in gastric cancer. | /99444) 0-42.0· 1111 | prostate cancer | dO'.X It | Regulation of Expression of )^ep;2y^7f0997))))))))))))))))): Hy dioxviase {DOtiKo the Enzyme Thai Catalyitea die Activation ofeJBdA. by twR - 33 Op and mtR-o-i 25p in Rrosfare Cancer Calls |
!UK- 7232(((((( | 7020007233:((((( | 727(0(3 | 3:i(taO29(:22297272(O33333333: androgen receptor tn prostate cancer cells and correlates fo prostate cancer (3:i9(0g7p7t7(33333333333333333333333 | mii- 217 | hepato-cellular carcinoma | up | MiR-2 l6a/217-rnduced epithelial-mesenchymal transition targets ΡΊΈΝ and SMAD7 to promote drug resistance and recurrence of liver cancer. | nm- ((9(1(7((((((((( | (;(;9272(27fi292t5924((((; ceil caromoujs | down | CvPvU’vwrev tud' nf -altvarv MuroRNAMor Detection of Oral Cancer, |
161
WO 2017/132552
PCT/US2017/015417
6/3868)))6/ /):(/47)))))) | ))5231)5((:66(8(23(23:/ | ))(5566 | The twiirir-fetipprcasiva mleroFNANAVUSchtxrer targets hexokrease-? 5 ))562(6:8((:68(0625)8))))))))) | tuir- 217 | hepato-cellular carcinoma | down | miR-217 inhibits invasion of hepatocellular carcinoma ceils through direct suppression oi' | ):526/))) )/685/))/) | ostcoyarcruna | don n | miRNA-bg* suppresses 6/3653666665623((6686868686 /)/02266558)))))))))))))))))))) dywnregubbng fibroblast growth factor 2 iF-GFl) |
4/2410/4/4/4 6/(:62686/6 | renal cell carcinoma | dowo | intR-l-l? functions as tumor suppressor and targets (wo unecvgeues. A.N0RT2 and )/00(13856(5(68(1))))))))))/ /)6668(2366(88888888888888888888888: | mir217 | lung cancer | down | MicroR.NA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. | /)235))): ):685/)):/) | ///5252215/)))))))):/) caromoma | down | Downregulated miR-Kto in dear cell renal carcinoma ton dated w r-h amour metastasis by targeting die am one binding protein |
n:u- /):(/47)))))) | uveal melanoma | ))6656) | MicroRNA 145 mm play an. important role in uv eal melanoma ceil growth h* potential!* targeting kaolin ///566256$86si555)))))))))))) | tair- 217 | osteo-sarcoma | down | MicroRNA-217 regulates WASP'S expression and suppresses tumor growth and metastasis in osteosarcoma. | mu- /)365/////8 | /)233((5:23(26()))))/ | up | MrcrcRMA-oort targe is (ted ro pron-Ne gazrre terteef tumoifgenrcity |
:)225:/:/:/:/:/ ί 40 9 | /:/:!26g:86685)))))))))))) | ))6452): | MiRNA-idob promotes kmg cancer ceils apoptosis tiuough targeting STATSa | mir217 | osteo-sarcoma | down | The microRNA-217 functions as a tumor suppressor and is frequently downregulated in human osteosarcoma. | 423/54/4/ ///661/8//// | //3325666666///////// | 80/6/6/ | MrcroRNA-θ^Ο expression at glioma is associated with prognosis of patients. |
/)588)))4 /:/:1/4254:4: | breast cancer | down | Evpfession of mmroRNA1-5 suppresses NF -kappaB adixitv with reduction of metastatic poteniial :n breast *ancer cells. | 217 | pancreatic ductal adenocarcinoma | down | MicrcRNAs as diagnostic markets for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm | /)55))))) 668/3/8///// | heparoteihiiaf ))3658525/))))))))): | 6636/6/6 | T frotui3i:0J<l ί tR 4 i countered w tilt dyw u- /)2(31((3266(3(8(06:862/////////////// /)3(62(65(6624))))))))))))))))))) hepatdeelhtter carcinoma |
n:u- ))(886:))): | )/353((:62366(:)))))))))/ | ))6656) | Cbnrcsl signilkatwcoi milNf-tba in gasroe cancer )6853)))))))))))))))))))))))))))))) | mir- 217 | pancreatic ductal adenocarcinoma | down | MiR-23, miR-34a, miR-198 and miR-217 as diagnostic and prognostic bioraarkers For chronic pancreatitis and pancreatic ductal adenocarcinoma. | mu- | /)/6(38686(3(:)))))))): sqnantuircveh /):5(5(6325//////////////////// | don n | Mir-&5> up-rogulation suppress?., «.eh m*uisronbv wgeimcp.bnturv bm.nr* trensfbnmog gene-1 it::-eaopl!hgnal:Sipamo.U&:teil·:·:·:·:· /):285ii553/))))))))))))))))))))))): |
4:528:)))4 /:/:1/458/4/4/ | :)/485558)))))))))))))4 myelogenous ))56((655:))))))))))))))/ | down | ApoptomrRs expmssioh modulated l>y BC/R-AfiL is bnked k t MLprcgiessrou and fmathmb resistance- | 217 | pancreatic ductal adeno-carcinoma | down | The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. | /:/52/-/4/4 /)688)/)//) | ovarian canter | down | Differomial mieroRNA ::exp£eS5a0n5gtiatt>roS:nHd:·:·:·:·:· :826285266343(/3(2)))))))))))))))/ /)33(/3((6288/24584:363(/)))))))) resistance in ox arian cancer ..ΐ’ίί:.............................. |
!0Κ- ))(836)))) | /://682((6:632366:)))))))): | 6266/6/6 | uuRNA-224 promotes ; .sn .rc ni'Nvi 3rd mntastasts by targatutg 4i2i5pi-::588(538r:44:4:4:4:4:4:4 /)^3438)))))))))))))))))))))))): | mir- 218 | bladder cancer | down | MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1. | /:/52/4/4/: ///665/8/)// | ///2(5/3(3///////////////////////////// | down | UiiR-bS^ ijilubity glioma ntaxuigetresis through repressionofRMPFlA |
):5(5:)))): /:/:1/458/4/4/ | gastric cancer | down | Ckmcai stgntib'Siic? or :il2R-:-i2ba:iQ:gSStrie:eaf!Sei:·:·:· )6858/)))))))))))))))))))))))))))))/ | 218 | breast cancer | down | Silencing of miRNA-218 promotes migration and invasion of breast cancer via Siit2 -Robo I pathway. | ):526/))) | heparoteihiiaf ////36(66565)))))))))) | 66866)6 | MiR-dS? promotes ///682(3((462685/8()))))))))))))))) hepatocellular carcinoma bv tatuetmg tronsihrcnt-bkc eohaotef protero 1 through NF-4B pmhwavs |
!0Κ- ))(836)))) | /)285((623(08))))))): | ):6652)/ | riucioRNA-14ba targets the 1 f *clladhe*:onmoiecn:e ///55/83565356/162))))))))))))): metastatic potential of )//36586(66(666))))))))))))))))))) | mir- 218 | cervical cancer | down | Circulating micioRNA-218 was reduced in cervical cancer and correlated with tumor invasion | mn- ///668686 | 63(23/66(23(/8///////////// | down | Mir-^iin iy dnwmcgulated in lung cancer patients and is ropJateinenr mbifcus iuog tumorigenesis bv targeting MDM2~p$3 unoraendu |
162
WO 2017/132552
PCT/US2017/015417
2/66ίι26/2222/ ////6/464///////// | /28462626/6446622 2 2222222/ | ////^////////// | hiicroRNA-UEa inhibits G pro'eir-v^upi^d re.. yormediated activation of NF ///64a6i24B264/4/66g62ii6g22222222222: CaRDP! and GCRSS m gastric cancer | tuir- 218 | cervical cancer | down | MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictcr in cervical cancer. | 2/64642/4 ίΛΊ | /2/648266//6/422666/////////// | duv n | Tumor-suppressive mir-AA gene induce* mitotic catastrophe growth arrest m human gastric cancer cells |
6660222$ /$1/4426/$/$/ | gastric cancer | Jim ft | MreroKNA -idiia is clOwnlegalgteri it1 gastiK carnet and regulates cell proliferation and apoptosis | 218 | cervical squamous cell carcinoma | down | Tumor suppressive microRNA218 inhibits cancer ceil migration and invasion by targeting f ocal adhesion pathways in cervical squamous cell carcinoma. | i-i>3 | 226666662421/6426/2266//64422222222 CXGRA in grioblaaioroa | ||
/:/224/4/:/:/:/:/:/ 4/1/02/22 | 2/420422222222222222222/ | /2:46244/2 | Ma.roRNA-fep'3 inhibits glioma development by 24304:482^44/41/222222222222222: | mir- 218 | chorio -carcinoma | down | MicroRNA-218 inhibits the proliferation of human choriocarcinoma JEG-3 cell line by targeting Fbxw8. | 2:264$/:/:/:/ PtG | brag «.atver | 46/64/4/4 | MtcruRNA-oh s tarceta TGFBJ and regulates lung cancer proliferation. |
42166422222 ////6/4642222: | ////Sep4t626ai!/6i46/2222222 //204462442222222222222: | 22462442: | Expression. of microRNAs miR-?.i. miR.-.N mF.-12 3, wiR--i45, naR-l-TOa, miR2V0c. miR-221. miR-222, and ituR-UN :n patient* with hepatocellular carcinoma or inirobepatre cclinUnginoarcifrorflanHdaiS·:·:· 2:/4410/222222222222222222222222222: | mir- 218 | colorectal cancer | down | MicroR.NA-218 Inhibits Cell Cycle Progression and Promotes Apoptosis in Colon Cancer by Dowuregiilaiing B/Mil Polycomb Ring Finger Oncogene. | /22144/222: Ob 3 | naso-phajyngeal eamtnoroa | /0////////4 | ///4itRl62i3/://a/22ii6O6iA//////////////// ///446862266/2222222222222222222222222: /hs$is^^/fe^^i^hhhhhhhhhhhhhi promotes rite proliferation and tutiiotigenesis of nasepltaryngeal carorooma |
26664242/: /$2/4424$/$/ | henate-ceiiuter /2/6426664i664/////////////////////222 | doun | SjnefgtSUc effect of MiR·:·:14:θ3·η·ύ!ηΚ€·:3β(1·?δΙηχ4·Η8Ε·:·:· 2//44/6:6682660246/2222222222///////// /26424424424/644622222222222222222 | 218 | colorectal cancer | down | Decreased expression of miR218 is associated with poor prognosis m patients with colorectal cancer. | ///661222222 | hepatprolhiiaf 2264662662642222222222 | /0/22222 | MicroRNA* regulate ////4246646646622222222222222222222222 aderjosyhmrisferase IA c\or sivitit hcpF* ckdu 42162666662442222222222222222222222: |
H!H- 222:46642222: | 2266664)266ίί6ΐ2ί6/////////////// 4o<4440642222/4/4/4 | 2244644//: | microRNA- 2 AG inhibits *at cr? ' jx<.s.ab> dPivr<regj:lating VEG}' through dual pathway a in $/iiep42666i/i66466a60460244/:/$/$ | tuir- 218 | esophageal cancer | down | Serum microRNA-218 is a potential biomarker For esophageal cancer. | mu- /266/8/2222/ | /I:6i4l//6ti644i0/ite////////// <eli carcinoma | duv n | ‘j«roit<cuidc Stndv vl 9nf.\uitt M.eruRNestor 0' Mrot of on· t am'. |
/22446422222 22646/42222: | bepato*ceib>K«· //:/64644462442222222222222: | 204222 | ////Sfplih/htiplbRN/A//////////////////////////// characterization identifies miR-bg5-Sp as a potential marker lot detecting river /221422042642222222222222222222222 | mir- 218 | esophageal squamous cell carcinoma | Up | miR-218 suppresses tumor growth and enhances the chemcsensitivily of esophageal squamous cell carcinoma to crsuiatin. | 461662222/ 2/64/5///////// | ////6211062/046662////////////:/: | 2/04222 | ///G64n26t6l/6ji/4lder2y4d22222222 miR-ή?? regulates tumor /24ripi2i/6$626.2RB226/62644:22222222 2/66141664646646646.222222222222222/ |
////O|2| | expression by miR-l-iOa in /2/iri6ii/6/46686/6/6ii6/22222222222//////// | 218 | esophageal squamous cell caremoma | down | MicroRNA-218 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma cells by targeting BMIl | ///65/5///////// | ISII | :Hi9:RromotesGEamaiSell·:·:·: invasion hv Deriving itttR- 66454///////////////////////////4 | |||
!UK- /:/40///////// | /2/424228666422222222222222 22000642/////////////////// | 22662662/ | Altered exptessroit A aefe Ή rob coRN As :n melanoma: onuixoBfetadv a candcproapoptoiteaotivitynt:·:· 4/600/20 | mir- 218 | gastric cancer | down | Plasma microRNAs, miR-223, miR-21 and nuR-218, as novel potential bio markers for gastric cancer detection. | mn- /:/6/7/5/$/:/$ | hepatocellular /2/4466666616/222222222/ | down | Downregulation of n rodMiRA promotes migration abd ////461/44662466641264662222222222222 hepatocellular carcinoma evils luoicl Afe* GA .’t :k ?5A stgnafmg $p4ih444/$/$/$/$/$/$/$/$/$/$/$/$/$/ |
163
WO 2017/132552
PCT/US2017/015417
:(Βηί¥((((( AlAriaAA: | uoo-sinali ceil hag ΒΟέίΒΒΒΒΒΒΒΒΒ | ((OBB | niiR-toba inhibits eel] gtowrit, ceil oiigtouon and induces apoptosis in oon::siHaUeert:hing:eaf£cer cells·; ·:·: | mir- 218 | gastric cancer | down | Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. | i(BBiB(((: (BBBBB | ((h0h(8BBBB4if((((( hmg cancer | O|(B | ft-reguhtmu N miKas..vp ooittnbuiei. tv tumor (BtoB^^B(OBBBBBBBB( development by targeting pro-iurnyrigenicGPRd? in noit-smaR cell ftmg cancer. |
8ftyfB:8:8 ttfdSayyy | non-small cell lung BBBB^BBBBBBBBB(: | down | ((MictoRBBBi-BBBBBBBBBt p>2nR R>- peiytivrphridix (B^htOBBB(B((((((((((((((((( snu-epiibdia. ta noo-smab eeii long cattoef in the Chinese popuiaiiou | 218 | gastric cancer | down | MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic mtraperitoneai chemotherapy and increases chemosensitivity to cisplatin. | (:ίρΐϋ7(3 | breast caooer | down | MicroRNA--? inhibit ::epkltelrah-to:-raesenyhyfnal·:·:·:· transition and metastasis of breast cancer ceda via targeting FAR expression |
:0b::?:?:: BOBBB | Nl: hind (•cBiBsBBBBBBBBB·:· | B^(BB | Kemwnuitof?^^p msP- (BABtoiBaBiB>(iB^BB;BBBB:((( dtag nc-SttO biomaikeiS in non-Sinali eeii hmg cancer | mir- 218 | gastric cancer | down | Thermo-chemotherapy induced miR-218 upregulation inhibits the invasion, of gastric cancer via targeting Gh2 and E-cadheriu. | (:BiB(B(( | ma! cancer | down | metastasis and invasion through targeting iocal adhesion kinase in cervical (:Giikdf((((((((((((((((((((((((((((: |
8ftyfB:8:8 ttfdSayyy | Oral squatncms celt ((iBBBf^B^BBBBBB8 | BBBBB( | miR-Uba enhances (he oncogeiikity of oral varemouiah' uoncountant targeting vi the IRAK i. TR.AFband NUMB genes. | 218 | gastric cancer | down | Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation, in gastric cancer | (:ίρΐϋ7(3 | colorectal cancer | down | miR-7 inhibits colorectal xearrcereeilpnaiifenatioiivgnd:·:· ((m^id^BBBBBi^B(fe(((((((((((( torpettog NRl *, 2 |
Ii!U- •AAhaAA: | paacreatic cancer | ((BOB | Cfitual significance of nditof-K5a in gastric cancer (B4^BBBBBBBBBBBBBBBi( | mir- 218 | gastric cancer | down | I’Reduced expression of miR-2 IS and its significance in. gastric cancer j. | mu-· | epubebid ovarian cancer | dm? n | BBhmtoiBpBOBBBBBBBBi( microRNA screens identify mtR-iV^areypiiaimg proliferation and apoptosis in epithelial ’· gnan van^er (0(((((((((((((((((((((((((((((((: |
8ftyfB:8:8 ttfdSayyy | pancreatic cancer | dawn | mjR-14bs suppresses (4iitaBsBBBi^BBB^BB((((((((: (BB?BOBBB((((((((((((((((((((( | 218 | gastrointestinal, stromal tumor | down | MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT. ’ ' | (:ίρΐϋ7(3 | gastric cancer | down | MicroRNA--? functions as y^i:pihBBB^BsBB((((((((:BBB microRNA io gastric cancer bv tan'bnpmziimriv ' plow tb faoimM receptor |
:(Bni¥((((( tobbb | (BO&B(BBBO4((( ((caiBBBBBBBBBBB8 | ((BOB | MieroRNA-H&a taigets (:ΒϊΟ^:(ΒίΒ^ΒίΒΐΒ((((((((((: pspdiarv thyroid tnutnr development | mir- 218 | glioma | down | Expression of microRNA-218 and its clinicopathoiogical and prognostic significance in human glioma cases. | mu-‘ | ((OBiOBBB(((((( | dm? it | microRNA-? mdabita die epidermal arm? th TaU m ((to^^Bh8d(thByBBBBBBBBi pathway and is dow 0legulated in glioblastoma. |
$ΟΒ:(((( :81:46^:(((: | prootaie cancer | down | ifiiR*}-Ena fttikimos as a ΑώρόΒΒΐΒί^ΒΒ:ΒΒΒΒΒΒ:((: •:prostate:eaf!cerbv:tgisetirig:·:· eiiiiiiiiiiiBB | tuir- 218 | glioma | down | MicroRNA-218 Inhibits Glioma invasion, Migration. Proliferation and Cancer Stemlike Cell Self-renewal by Targeting the Polycomb Group Gene Bmil. | :(BtB(B:(: | ρΌΛί>ΗζΚΐη3 | dm? it | :0Bi^ife;^^:0B¥BBBBB:((((((( (BhtiBj^BBBiBBBBBBBBBBB ygi^idstBBki(^(((((((:BBBB ypphiparrsoB:BBBB^BB(((((((( |
8ΒίίίΒ:8·8 tobbb | tpjpBBBBBBBB((((((( | (:B(iBB(: | (:tShhraM(BgBBtO4BBB((((((( n«R“i4ba in gastric cancel (B4^BBBBBBBBBBBBBBBi( | mir- 218 | head and neck squamous cell carcinoma | down | Tumor suppressive rnicroRNA218 inhibits cancer cell migration and invasion through targeting iaminin-332 in head and neck squamous cell carcinoma. | ««j: | (:ghp^pBb:hBi((((((( | d«w n | ::nKR£-5infdhitS:gltO'blasiOrr>a:: ίΡ\Ίι'η' smwhwv^R mtoiferiitg with the ::0|BOBBBBBBBBBB(: 3R^BS0S0i:R4BOBB((((: |
Cihif-?:?:? BOBBB | renal cell eairancttna | BBBBB( | Gaihnmylated albumin wBv ι i, -oWA i-Eu which is increased iii human renal cell | 218 | hepato-cellular carcinoma | down | miR-2 J. 8 modulate hepatocellular carcinoma cell, proliferation through rTEN/AKT/r[3K pathway and | (:ίρΐϋ7(3 | ((giipIriaNNNNNNN: | down | MieroRNA-sensith e Oi'Coivd? measles viruses ίοι trawm-specifre vectcu |
164
WO 2017/132552
PCT/US2017/015417
2/5/0/0222222222222222( | HoxAlO. | ||||||||||
!0H- 29/5/222 2:2/22222 | ((£9/000888888888 | (:9O/8: | The clinical ucntftcatxe of dGivr<regMlei!<wiuf nur-l2d?p. Grir-ddua-5p, roir-I?5~ 5p and nik-Sk'-Sp m gastric cancer 5/5/58/98i5383(888888888888888888: | mir- 218 | hepafo-celhilar carcinoma | down | Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET | (:/3/922(( | ((5-508/599(:((((((((((( | down | MicroRNA-? difecdv \regtas rnAdir-ifrre gm-uth factor 1 receptor to inhibit oelhilai prowh and glucose ((/8/35b58838/://(58i/9/i/3((((:888 |
3/38998888: ((0/222 | 2/55009/20/22: (02////8((((((((((((: | 20222 | A 4 MicroRNA siana· me can d«ciinanpte prima-c lymphomas frent anaplastic earetnouraa m tby mid ndo·.·' M-reass. | mir- 218 | hepato-cellular carcinoma | down | MicroRNA-2 IS and microRNA.520a inhibit cel! proliferation by dowriregulating E2F2 in hepatocellular carcinoma. | 8:/5889(:( | ((5/558/5/1391592228 ((8/58/08/58:::::::::::::::(: | :(//588(: | ((581/3358/3//8(8//5898888888888: gio n di and metastasis by targeting the ?13K'AKT p j'hu j> m hepanx tafnire |
!0H- 290222 | 2/850/5/5/89222222 | 889O/8i | (($209(3/900:5/8/08(88 bibb Fenns a Feertoaeb Loop f ΰ ί oh tbit die NF - -6 (0008055/9000(( ST AT 3 -£>riv eu L guc yr |:f//5Qt5pCS5:|:|:|:|:|:|:|:|5:::5: | mir- 218 | lung cancer | down | MicroRMA-2 IS is deleted and downregulated in lung squamous cell carcinoma. | mn- | hepatocellular 22/558/58/5222222( | down | Downregulation of nuR-’ npreoulates < ulbn .’CUL5>iofaciluareGi/S 88i25&5ti//5/2^/83/8(((((((((((: hepatocellular carcinoma ((858398888888888888888888888888888888: |
(:/5/98888: ((0/222 | breast cancer | down | Expression Ctf GiicreRNA- ::i:4t(SUppreSSes:NF:-AappaB:·:·: activity writ reduction of metastatic potential rn brew canxr roll* | mir- 218 | lung cancer | down | MiRNA-218, a new regulator of HMGB1. suppresses cell migration and invasion in nonsmall cell lung cancer. | 8:/5893(:( | hepatocellular ((£3/5/ό8838(((((((((( | down | MicroRNA-7 arrests cell ((5/58/(53:^88^8/5///88(:8888888 directly targeting fTCNEi m human hepatocellular .;;·η;5«<:< cd:·· |
!0H- 290222 | esophagealcancer | 20292 | Ttanseripbonal regulation (:/f:Oi29i/O/5823/2O2((:888: LAr? itt esophageal career (/08/((((((((((((((((((((((((((((((( | mir- 218 | lung squamous cell carcinoma | down | MicroRNA-218 is deleted and downregulated in lung squamous cell carcrnorna. | mn- | ((5/855/8/92:88888888 | np | (^ff//:l//58/55:t5/8/(((((((((( tnurerigemstabv activating ((5/Ry75h358igh:U:(((((((((((((((( tas/FRkASt ta Ήν λ (2589888/8^/85288/iB353((((((((((((: trauscriphottal repressor taS&iWeveveveV |
:·:· 8:3/b5:5:: | 2000/222222222 | ((0222 | (^0/208/89/0/59:((((((((((((( migration and redoeetf 9:0/02/5/8/588/5/5/8(((((((( 5θθ/:ΟΟΟθ5<<<:::::::::5:::: | 218 | melanoma | microRNA-218 and its potential functions by targeting CiP2A and BJVlll genes m melanoma. | ((93/3/8((((((((((((((( | 90999 | grewt.it and nreasroh through nreregulaPon of nnR-7 in pancreatic cancer iolU | ||
SUU* 14frb | (:53/5/9(((((((((((((((((( | 8://0(: | niuroRMA-l-iob inhibits glioma ceii migration and mt a KGibc targeting 2|O/2222222222t2222282 | mir- 218 | naso-pharyngeal cancer | down | MiR-2 IS suppresses nasopharyngeal cancer progression through downregulation of survivin and the SL1T2-R0B01 pathway. | mu-' | ((fe//95//(((((((((((: carcinoma | 909(99 | idcnttficanonof nuR-’as an oncogene in renal etai 3;/355h/83/(((((((((((((((((((((((( |
8:/58898888: ((0/222 | ((5^/58/8/:(((((((((((((: ((589/8/ 88/(((((((((((((: | down | Altered expression of selected imtroRN’As in melanoma autiptulderam e and proapoplotic acre, re» of 20/O3022222222222222 | mir- 218 | ora! cancer | down. | The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT pliosphoiylation in orai cancer. | 5teii5:::5: | glioblastoma | down | (AiiR57/$p(j&(freq//ntly(((((((( (/5//8/^5/59(/8888888888888888 ((58i^l3/t//5i((((((((((((((((((((( mrcrovascutature and :(89/i//55/te5/5/(((((((((((((((( 3:///5ί/5ίί5///ΐ5;(((((((((((((((((; proi/eraboi' U tgreeting 20//22222222228222222222 |
8:/58898888: ((0/222 | ooo-SGKdlccllluog 20/022222222222( | down | OrCoJatnig reicro-RNA expression profiles in ear/ stage nonsmall ceil lung | mir- 218 | osteo-sarcoma | down. | miRNA-21.8 inhibits Osteosarcoma Ceii Migration and invasion by Down- | 5teii5:::5: :::((0(((: | glioblastoma | down | fttiPNA iGicmartay revotas specific expression in the ((5/885/5338/15/5://888888888888: |
165
WO 2017/132552
PCT/US2017/015417
43663024455555555555555555555555552 | regulating of TIAM1, MMP2 and MMP9. | glioblastoma patients | |||||||||
UUf- 6:305554 | oral squamous ectf 44633336345555555555552 | 30233 | itaR-Uda enhances the oncogenicity cf oral carcinoma by co beomuaot targeting yf the BkAKl, TRAFb and MUMS genes | mii- 218 | pancreatic ductal adeno-carcinoma | down | Enhancer of Zeste Homolog 2 Silences miR-218 in Human Pancreatic Ductal Adenocarcinoma Cells by inducing Formation of Heterochio matin. | 655632644 2|O36 | 323013533 4444444444 24:3^5666332444444444 | down | 2 2 2kftRN4036p2233i3662444444444: melanoma cell migration 446632ihy 6606244444444444444444444: |
6230626444 224035555 | papillary fhyrokj 446d33'3 3355555555555552 | 1111 | MxtoRNa, atah sis as a ::pOtent£ai:diagI10SiieidOt:for·:·: papillary tbvreiti 43633606455555555555555555555552 | mii- 218 | prestale cancer | down | Tumor-suppressive nkcreRNA218 inhibits cancer cell migration and invasion via targeting of LASPI in prostate cancer. | 5333332 | 2406333644444444444 | mediated epigenetic silencing οί 24:206360625355555555555555555552 lankelnogeneStS in acute ufyelytd leukemia} | |
463336444 82063644: | 2:26633634:320336:6:2:2 236iti2^5ii'ii2iiaii2;2323232323232 | 242033: | MicroRNA signature distinguishes the degree ol aggressE eoess c-l' papt8ar> th; redd carek-yuia | tuir- 218 | prostate cancer | down | microR.NA-218 inhibits prostate cancer cell growth and promotes apoptosis hy repressing TPD52 expression. | 326tit8232:2 533355552 | breast earner | do·? n | miE-??.n mbibns mreor invasion andratgratrenin breast cancer hy targeting |
8:602-28282:2 4320233 | papillmy thyroid earerocma | 63355552 | Progt-cstic impircaticnsof nkR-Tfob Svpresston and 44I3OOO60OO55555644 24335363:33363:55555555555555 63O626626i624444444444444444444446 | 218 | renal, cell carcinoma | down | MicrcRNA-218 Inhibits Cell. Migration and. Invasion in Renal. Cell Carcinoma Through Targeting Caveolin-2 Involved rn Focal Adhesion Pathway. | 4:3634444 536324444 | coteremai caixer | 63355555 | Έ \ aluaiiot' of nttR- 72ri prognostic significance in. patients with colorectal 553366624444444444444444444444444444 |
2 2 2 2633233: :·:· ί:66<3:·:·:·:·: | papillary thyroid 24363333624 4 4 4 4 4 4 4 4 4 4 4 4 | 33|33 | ::E*J>fesstOH:of«afchiAp:tfi:·:·:·:·: 24353Ο53232ΟΟ62224444444444444 O.rcunurens is AssvCiated •Λ nh BEAR h hitaiton and CJinrctfpathohagteal Features in Chinese 2 2 2 3502333333333333333 | mir- 218 | renal clear cell carcinoma | down | miRNA profiling foi cleat cell renal cell carcinoma: biomarker discovery and identif ication cf potential controls and consequences of miRNA dysregulation. | 32ύύί83232 250332 | nasopi-aryiigeal 4433334635555555552 | ;2;3|3| | MiR-744 functions as a 4365506536^532::355555555555555 nasopitary ngeai osretuorea progression arxf metasbuis vta transcriptional co&trol 36^0^0^35555555555555555555 |
24236264233 303423: | primary th> retd 2 2 2 2i66i{6i6362333333: | 3033: | A T-hficroRWA signature van (haeiiiinnpie prirea-v iympJiomas Bern anaplastic carcinomas in thy mid Areloov -atears. | mir- 219- -P | glioblastoma | down. | miR-2l9-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in Glioblastoma. | :2:ihtf-:3282 53363444 | mng cancer | down | 24Th02N66ef 2005154444444444; :Deo£eases:ti£e:Fivkfeia!icr£·:·:·: and Migration nf Human 24336334636632366633355555552 :24τ6ί36366403(ό64444444444444444 |
UUf- 30333 | renal cell carcinoma | 30332 | i'arhare? Jared albumin stimulates imcioBNA-iTb. phrefus Hk.rea«ri tn buoxut renal cell 2:286ί60Ρίϋά2:2:282828282828282:2828282 | mk- 219- 5p | glioma | down | miR-219-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in Glioblastoma. | mir- 248364444: | 4:26f63563666i36444: | down | .. ·· N A · <. Kv\ Madiatni for InJiibrihtg Growth. Migrsrion and 242i2h6605ii4i3F31y0fE0t62422222222222 Treated Prostate Cancer |
2:2363:233 4303552 333133 | 2:2:6606602433333; eareircrea | :43033 | MreroRNA-'!.iAb*sp nthrhEs die grc-wdi of gallbladder carcinoma by targeting epideitual grew th 22:2fe63h26i66p33433333333: | mir- 219- 5p | hepato-celhilar carcinoma | down | MiR-219-5p inhibits hepatocellular carcinoma cell, proliferation by targeting glypican-3. | 246366442 | osteosarcoma | 4233244444 | MiorcENA-hq?. promote* osteosarcoma cell preidersficu' by tprgetmg 532664444444444444444444444444444444 |
4:2633233: xObb?·:·:·:·: 44634444444: | gllo-hlasioma | dyw it | MiR- i4ek~5p suppresses EGFR expression and reduces re vitro reigrafren and im a?ren oi glioma | mir- 219- 5p | papillary thyroid carcinoma | down | miR-213-5 p Modulates Cell Growth of Papillary Thyroid Carcinoma by Targeting Estrogen Receptor ? | 66044444 Bill | breast cancer | dewy n | |
•ηκ· 223333555 3532333: | 433633555555555555555555 | down | 22;2h6R6i626b4532i6bihii62444444444 620005000505555555552 BA^Rh 'tfgeuru | mii- 22 | breast cancer | down | A regulatory loop involving miR-22, SpL and c-Myc modulates CDJ47 expression in | 2426632444: 87' | 4430333335555552 | 52333352 | 2 2 2 2Μ£ΚΝΑ2τ2872$2ίι6η62ΐί624444444444 24:β366 100260 24444444444444444444: 44366033666366635555555555555 |
166
WO 2017/132552
PCT/US2017/015417
breast cancer invasion and metastasis. | \RO tasfsbi ς uppreosjnc 3tbh:E8prebi9h:bf3838383838 8OBBBBBBBBBBB:8B88 | ||||||||||
UUr- 8:80888 | papiBarx tfoioaf 8^ci80b59BBBBBB8 | 8BB888: | 800i8d9008:0F:88:8:8 rouroRHA andmRMA expression profiles re aggressive papillary lltvroid: : 383^0088888888:38383 | mit- 22 | breast cancer | down | miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. | 8iror838: h7A | breast cancer | down | MicroRNA-b '4 inhibits cell proliferation and induces apoptosis in human breas· voncei bv targeting 8ci^8BBBBBBBBB88:8:8:8: |
8:mii8383: i-toy- 088888 | papiBaty thyroid 80qi8mB^88883838 | 80888 | MtR- Hofc-Sp promotes metastasis arid indaccs epidrelial-meaetielix mal transition hi tin trod cancer bv fargerotg ZNRRh | 22 | colon cancer | down | MicroRNA-22 regulates hypoxia signaling in colon cancer cells. | 3bfir83:3 8^888 | gastric earner | down | 3:miR3S?4Tg9ibh5:0clf38383:3: ::proiifei«tion;nHgiad»riand·:·:· ::illv^ron:tiQ.Vagll33fgUt£!Qg·:·:·:·: aqyaportti-3 hi gasttlcL enn-oer |
899183:38 :·:8:4δΐ34·:·:·: 83988888 | papillary thyroid 8CCi8ih3rii988883838 | 8011 | KlicroRNA tiiiR-iOb-Sp transducuro: of TCTA' by repressing SMAD4 in. 39iv9):i9:cdhcb9838383838383 | mir- 22 | colon cancer | down | MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimjgratory and gene regulatoiy effects in. colon cancer ceils. | 8991888: BBBl | 8g3$iOB00888 | doxy £' | 89n&:B?B:£O9Oi98B8888:8 8ίρ93ι88Β89ί8^8ί:Β8ΒΒΒ:8:88 inhibuinu angiogenesis dirougb. STAT.WEGF-A pathway m gastric cancer. |
3b9b8383 808888 | 3bfe^fsS0g9t:888:888 | down | <tfoba: tuicroRNA Jex e! regulation of FGFR-drtven Ceif-cvtJo protein network 3:ibbro^BsBr:8iBBBBBBBB8 | mir- 22. | colon cancer | down | rniRMA-22 suppresses colon cancer cell migration and Invasion, by inhibiting the expression of T-cell lymphoma invasion and metastasis I and matrix metalloproteinase* 2. and 9 | 3199383: 8£W8:8 | 89^000383: squamous cbll 889fek9> 99:888888: | don n | Rrmonr-suppresrive mmroRMA-b7-l tonrohotes to ceil proliferation through •Ufgetma of laytone deacetylase J iu head anti neck *qnamons cell carcwnroa |
UUr- B^BBB | 89^09^0888888 | 80ll | Mtc-roRNA profiling of human gasttrc «.artcer | mit- 22 | colorectal cancer | down | Clinical significance of miR-22 expression in patients with colorectal cancer. | mu- | hepatocellular 800808:8:8:8:8 | down | Dp-regulation of nuR-87 7 irahrcedbv pamvnxel mhibit* hepatocellular carcinoma cell proliferation though targeting FOXMl |
8888:88838 8:08888 | oral squatnous etft carcinoma | 3999-93 | Genome» nJe Study Of Sain are AJmroRNAs for Detection of Oral Cancel’ | 22 | esophageal squamous cell carcinoma | down | increased miRNA-22 expression sensitizes esophageal squamous cell carcinoma to irradiation. | 8b9f83:3 1177 | oral squamous trebcarcuratna | down | CtivhtvJde M iv* Af aaliv ary JvlicroRMzks for Detection of Oral Cancer. |
39998383 3830:3:3 | 3b^908ftO^388:888: | 3dO8:·: | .A regulatory Circuit of miR-USa/l?? and DNM'Fl 8988iddhiab9^i8^B8888888:8: 8triitBibfOt8bbpB^bbi8b8::3 sngrogene*!* through Β.ίΡ- 3iR98riOi38383838383;383 | mir- 22. | esophageal squamous cell carcinoma | down | miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion. | 3999838 8888 | hepatocellular carctooma | 80888 | Serum mmroRNA choracteriratron Jrientiftes 8haBi8^|::5p989B89ihii!3B88: ntatket for deiuctrog Bx er 88OBW9£888888888:8:8:8:8: |
HJU- J48a | cemcal squamous cell earomoma | 8d89B8 | 3MiOBB89d:tfeRBBBBBB8 83^08^09:03888888838 JovoregtonaJ *tagmg and survival following surgery •:f»r:OSt>phageafaaro£Q0ma::·:·:·:· | mir- 22. | gastric cancer | down | miR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. | mu- XV5- iln | 898900008:8 | dev n | MicroRNA nifR-Sb5-5p target z (id J nnd M( M* actn ate* p*3 and mhsbrt* proliferation and sure tv ai |
39998383 38303:3: | 8O8d0ria:88838383 | BBBBB:; | bbcroRNA expressron profiling reveals file 3biroihOW8A9BBBBBBB8 88jBB8h9i388BBBBBBB3:383: | mir- 22. | gastric cancer | down | microRMA-22 acts as a metastasis suppressor by targeting meladiteiiri in gastric cancer. | 3998838 8^08:8 iill | thxrotd varcrer | 309:9:3 | MrR-bSoAp regulates <eJJ proliferation and migration, and is dysregulated tn familial nroroneriufian tBx trod cancer, |
167
WO 2017/132552
PCT/US2017/015417
59t9fj44359((( Hha | irokftectai -ancot | 9(/3433:( | (://·:/9ϊ3///43/ί343^((((((((((( apoptosis by targeting Bel2 to colorectal career | mir- 22 | gastric cancer | down | miR-22 is down-regulated in gastric cancer, and its overexpression inhibits celi migration and invasionvia targeting transcription factor Spl. | 59/44459((( few- /Bzzz | 9(//4/91./3/9(((((((((((9 carcinoma | duo n | MicroRMA miR-S86-5p inhibit* apoptosis by drovnregulating Bax expression 9(/4//49///(333/5/4((((((((((((((: ((¢3/9433///93^(((((((((((((((((: |
:9:1111/-:55555 /BB/// | gastric cancer | down | The role of miR-MKaia 9(///34/////3/9(((((((((((((((((: | 22 | gastric cancer | down | Reduced expression of miR-22. in gastric cancer is related to chnicopathologic characteristics or patient prognosis. | (:4/4459((( UU2a | cofereetai cancer | (;BZZ3 | miR-S02a regulated PPP2R2A expression and prcincfcdved proliferation ol human colorectal Omer telU |
H!H- | 9(///44/93//3339((((((((: | /BII | »nR-148a pmumtesl cell pro'tfen .on by '<r ‘curt p2.7 w gastric cancer ceils. | mir- 22 | hepato-cellular carcinoma | down | microRNA-22, downreguiaied m hepatocellular carcinoma and correlated with prognosis, suppresses ceil proliferation and tumourigenicitv. | mu | csophaoea: squantuiizve'd 9(5//4/443/(((((((((( | up | ?a lu mRMA-Q prmt-ntes tumor metastasis via repressing E-catiherin in esophageal squamous cell 9 9 9 933434444441/(((((((((((((((((((((((( |
9:94//5:9:9:9:9 9549///(((5 | gastric cancer | 95/0909/9( | [Impact of mtR-118a on die proliferation of gastric cgrciiromaMKN/:' cells and its meciiniiismj | rair- 22. | hepato-cellular carcinoma | down | MicroRNA-22 expression in hepatocellular carcinoma and its correlation with ezrin protein. | m.ii-7 | gastric adenocaitiiooma | down | 9(9Reg3i3t4sZZ4W9((((((((((((((( transcription factor 9NFtiappaBi by n-xroRNA h 95!ti;/////9//^44/595959595959595 atfettocaroinonta. |
59/3459(595 | gastric canter | down | MicroRNA- i4$a suppresses tumor ceO invasion and metastasis by doworegtiaiing ROCK 1 to 9(^Oi/9:3/i//9fi((((((((((((((((((: | rnir- 22 | lung cancer | down | Tumor suppressor miR-22 suppresses lung cancer cell progression through posttranscriptional regulation of ErbB3. | mir-3 | zartuv stimo | (9/90//5 | ::Dpwn-:foat>iated:m£p;-:$:and·:·:· nuR-433 tit human gastiic 9(/3/9/43///(((((((((((((((((((((((( |
9:94//:95959 //Bzzz | gastric cancer | 9(:3///( | 9:9:Μί/4/ϊ/Ζ/(ΐ3/39:/9:9:9:9:9:9:9:9:9:9:9:9: (/3/3/3///(((((((((((((((((((((( hypermetbyhtion and 999443/4//1/99//43(913913(^999999999999999999999999 medwlmrosieiase 1 in ga>tm. cancer | mir- 22 | medulio-biastoma | down | MiR-22 is Frequently Downregulated in Medulloblastomas, and Inhibits Celi Proliferation via the Novel Target PAPST1. | (:43/4/ 9 9 9 9 | gastnu ..anger | dow n | Aberrant bv penoethvlat .on of oftR-Ogvn^s ingvStir 99(c/i33Z9(((((((((((((((((((((((((((: |
590343((((( ((1///9(((99 | gastric cancer | down | :naciCiRNA:-:14S-as.nppiPSS0S·: huraai et tin. -tn ci «λΌ inetasiast; hv re'enwitg ephhehabto-rocsenchy mai 99944/4ιδ/4/44(((((((((((((((((((((((( | rnir- 22 | non-small cell lung cancer | -j up | Circulating miR-22. mrR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. | mir-3 | zartuv stimo | (9/90//5 | ::Development:ofanovel:·:·:·:·:·:·:· 9(://543ZNA(/r3ti/i55((((((((((: 9(3/39r/39r9/i/f/4(/3iZ-Z33(((((( chip a>*as to iJeniiiv epigeneficaily regulated 95lm340RNA3(55959595959595959595 |
9:94/4/99999999999 95/4//9((5 | gastric cancer | down | MiRM-lM :s Joam regulated in gastric cancer. •:|argotsMlviit7:aQdindicatos·: tumor in\ asw eness and 5//34(4/3//3//(((((((((((((((((9 | tuir- 22. | osteo-sarcoma | down | miR-22 inhibits osteosarcoma cell proliferation and migration, by targeting HMGB1 and inhibiting HMGBl-mediated autophagy. | 9(//0999 | gastric cancer | Jon n | mjcraRNA*9 Supprass^s die Proliferation. Invasion and Metastasis yf Gastric Cancer Cells through Targeting Ct elm 01 and L Enl |
:9:9/44/9:9:9:9:9: 148a | 9(g//44344/4/34/3/((((((: :/39/3/3/9((((((((((((((((( | 9(9/343/( | 999·/ίί&9/ΚΝΑ9:9ΐ9·/ίίΐ94/9;9;9;9;9;9;9;9;9;9;9;9; tiequeittlv dorat-ieguiated m gasttu ..sneer and acts as a tumor Suppre-z-orby : irlabrtmg colirpielderatioii;:: | mir- 22 | osteo-sarcoma | down | Downregulation of miR-22 acts as an unfavorable prognostic biornarker in osteosarcoma. | (:4/44(39(( | 5//44/39:///34(59(5 | dost i' | Epigenetic silencing of rorLNA“‘it>..otralated with prantutei-proximai ( pt ί stand hxpem.ethv btion to gastix ^ancoi an tiro and 9 9 9 91909443 359((((((((((((((((((((((((((9 |
168
WO 2017/132552
PCT/US2017/015417
////t/0.Ug///////8 148a | 42225126523444444444/ | 425464 | microRNA-USa is a [•rognosuc otioomi/R 'Diet Targets MKR. andBJM to 4363335/25252524464646/ ΑρνρΚ ι ri GhoMns oma | mir- 22 | t-cell lymphoma | down | rniRNA-22 suppresses colon cancer cell migration and invasion, by inhibiting the expression of T-cell lymphoma invasion and metastasis 1 and matrix metalloproteinases 2 and 9 | 463556 | /46662344444444444444 | 4256/64 | iP.vreasede vprerami. of mrcmRMA-OpreJj u«, an unfavorable prognosis in 662526/3352/444444444444444444/ -1 |
4/3566/6// | /82425525552/:/:/:/:/:/:/: ///465234464444444444444/ | suppresses die eprllielialη·Λ amvfcvinal traiiaPoii and metastasis of liepaforaa coRshv targeting Meh'-r-ftit ///$2122636:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | 220a | carcinoma | MicroRNAs for Detection of Oral Cancer. | 46544444 | ewpiessron of CBX7 m ///26562/32356244444444444444444 | ||||
/:/352/:::::::::: :/:/655://////// | ////58234525256/:/:/:/:/:/:/:/ ////42552253:/:/:/:/:/:/:/:/:/:/:/:/:/: | :/:/562:5:/: | microRMA-l-i&a inhibits hepatooellulat carcinoma veil rn> asrui’ b\ targeting spfciugustne- 1-phosphate /:/565226:6:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | mir- 221 | anaplastic thyroid carcinoma | up | A 4-MicrcRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears. | re.ii-9 | 4615^44444/4/4/4/ | 46346/6/ | The ( RER auk-*' uegat-xe feedback mira.-rc atti\ coordinates the migration and proliferation of glioma ///3325///////////////////////////////////////////////////////////// |
/:/25/2/:/:/:/:/:/ 4:62424:4:/ | naso-pharyngeal ////46523234444444444444/ | down | •::Siieiloiag:(jfiraRbiA>:14Ba·:·:·:· by fe pvf»vfn2ttren activates the mtegrrm mediated signaling pathway 4/5/26550326524444444444444 66656565-/44444444444444444444444 | mir- 221 | bladder cancer | up | Micro -RNA profiling in kidney and bladder cancers. | mrr-9 | 43666546233646/ 62653352/444444444 | 465666 | Up-regulation of miR-9 O'.pressmw preduate ////3562524444444444444444444444444 ohnicopadKdqgikal features 4263/346f/35g556i6/in//////////////////// patten-s wr-h hepdfev'Httite' ://4ίί5ί/ίώ/ι46·/////////////////////////////////////////////// |
:/:/552/////////// 6/60/6/6 | non-oftiftll ceil lung /4262646464646464646 | dOwft | Decreased miEMzvrfea s ·:·n»seoiaίed:·Λίtί·l·i5cf£ipίϊ·aode:·:· metastasis anti poor clinical outconies and fnueuons as a rappreas^r M ntmor metastasis m non-small ceil e/idii/g/iahiteri:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | 221 | bladder cancer | up | MicrcRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. | mir-v | 4/lari/tigeSl////////////////////// 4/5666565463464 /43653352/444444444 | 652666 | MleroRNA--^ as a novel prognostic biomarker in human laryngeal squamous ////32/3653232/444444444444444444 |
/:/552/:/:/:/:/:/ :/:/655://////// | oou-smsll cel! bang ////426656/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | down | SerumnuR-15?. nuR-USa ft5R-U8b and miR-71 as new el bromarkers m nonsmall coil ta»g umcer ///$6ΐ5$ίί2ί2/6/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | niir- 221 | breast cancer | Up | TRPS J targeting by miR221/222 promotes the epithelialto-mesenchymal transition in breast cancer. | /:/635:5//// | yriftiigmint:/:/:/:/:/:/:/:/:/:/ melanoma | :/:5646/:/: | MicrnRMA-9 up-regrilfttes //O2d/52i2/t232256444444444444 ////m6i2ii5i6//43/3?8?fe5/////////////////// 6326322635622644444444/44444/ ////5431333//////////////////////////////////////////////// |
/:/252/:/:/:/:/:/ 42/242464 | nyri-snujil <5*11 lung ////22366646464646464 | down | MIc-ioRNa- i4$a <j,\,resi>' ipdl viral fo n<sxU'vlrt real trapsitwn bv tfttummp R< K Rl m oot.* small cell lung cancer celts. | mir- 221 | breast cancer | up | From microR.NA functions to rnicroRNA therapeutics: Novel targets and novel dings in breast cancer research and treatment (Review) | mrr-9 | nasy-pkaq ngeal /43653352/444444444 | 663256 | uaR-b targets CXCPA and ftnietrows as «potential 4/5656262633263444444444444 nasophary ngeftl eareiooraa |
UUl- 6/6242464 | oral squamous ceil ////46556564444444444444/ | 426324 | •Qenomowide Study of Sa'tivan MiWuRNAzior Detection of Oral Cancer | mil- 223 | breast cancer | up | nuR-221/222 promotes S-phase entry' and cellular migration in control of basal-like breast cancer. | 655344/ | non-small cell 6556/6262354444444 | 4 6 5 44444 | Up-regulation of miR-8 expression aa a poor piOgnostiO biomsfkef in patten-s wnh non small veil ////iing/idttegi///////////////////////////////////////////// |
:/:/555/:/:/:/:/: 6/60/6/6 | Ovarian cancer | /:/3553/:/ | Altered expression of miR- ////i/55/222/ft52/5/25$/2'8/:/:/:/:/:/:/:/:/:/ ::ovaiafi:eaf£ceris:reiate4:-tu·:·:·: ///36565^265635444444444444444 | 221 | colon carcinoma | up | iMicrcRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKNlC/p57 expression). | mir-v | 455!866645d/t3/:/:/:/:/ tell varenieuia | down | MicroRNA-^ inhibit file proliferation of oral 636523363264265353344444/ /432653/462536342//////////////////////// expressmnN ( \·ΛΡI dre Wnylaeia-carenin slanallng palltn ay. |
169
WO 2017/132552
PCT/US2017/015417
:/357///// Bha | (29595839358922222222 | 2235932 | /89557(50/3355/85835:////( migration and invasion of Ovarian cancereehs via targeting sphiagystiiy- 1phospi-ate receptor i | nsir- 221 | colorectal cancer | up | MicroRNA-221 inhibits CDKNJ C/p57 expression in human colorectai c arcinoma. | 2(953322 | osteosarcoma | (29322222 | (238535(5838:89(922222222222222( prognose bionxuker in patients with osteosarcoma. |
/:(ta7/(////( (/(835(//// | pancreatic cancer | down | MiR -l-Jha regulates the growth anti apc-ptc-sis m (29958595/839585558/////////// targeting CCK8R and Bel- | mir- 221 | colorectai cancer | up | iMi.croENA-221 controls CDKN1GP57 expression in human colorectal carcinoma]. | texit-'l | roanno cancer | down | MicroRNA-*' mhibn: ovarian cancer cefi growth 22888888:8885839 52 98(022222 (28389892222222222222222222222222( |
•17f· 228882222( | pancreatic dgv'7 22393258939372222( | down | Knyckdynnof uiiyroRNA-21 inhibits proliferation and increases cell death b> iargei-rngprogramn-ed celt death 7 tEDED-l) m (29953:595/3285895222222222222222 adenocarcinoma. | mii- 221 | colorectal cancer | up | MicroRNA-221 promotes colorectai cancer cell invasion and metastasis by targeting RECK. | mir-9 | oxa·-an vixrcei | 2(/3995 | :(((Μί(;(7ΕΝΑ(7(97(3733/////// itiroorrgenesis and mediates®cPXtMA 'OClzplA.dJlt. primary epithelial Ovarian ((((0738(795//////////////////////: |
(/7l9?://// (25(38(2222 | pancreatic ductal (238£3238tt558322222 | dpun | MicroRNA -I-ilia is ctOwn- (299835/9538295888222222222222: 2(59597882935/95222222222222222 adendeareuiouias and regulates ceil sutvivalby taiPetmgf LXBR | 221 | esophageal cancer | up | Alteration of miRNA Expression Correlates with Lifestyle, Social and Environmental Determinants in Esophageal Carcinoma. | roir-v | uveal melanoma | down | MiCroRNA-b Suppresses uveal Melanyina cell migration aodtp.'.asmn 2:29838958938585222222222222 :(((p3t7558(////////////////////////// |
(:(7/7:(:(:(:(:( 22888(2222 | pancieatu dnmal adeno-carcinonia | (/:5985(/ | Mb roRNAs a® tiutenosuv markers far pancreatic ductal adeaccatcinonta anti (2859885885598997382222222 inttaepifiteital neoplasp.i. | mir- 223 | follrcular thyroid carcinoma | up | Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. | (:(77(-(:(:(:(: 233222222 | colorectal cancer | 298(2//// | :(:Α3975998(9ί35798ΝΑ(((((((( (2(3353588878922222222222222222 micro afeiluem tahil.t' 22575325529575778(22////////// adenocarcinoma. |
(:(:7/7:(:(:(:(:( (25(0(2222 | Chiorectal cancer | dpun | MicroRNA-I-hib •:SUppi7SSes:cefi:glVWihbv·:·:·:·:· tarcetntg xhNevt stokminG re xptor it. lOiorMa: ...nuci | 221 | gastric cancer | up | miP.NA--223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPE4ll,3. | /:73///// 233222222 | gastoc cancer | 2(8822222: | (MiCioRNA-R? promotes gasiiit ^aiicei cell proliferation and invasion 2:883882857972872522222222: |
»:«·- :/(03//// | (:95858:58/555:////////( | :/3583/ | 2:Mi5583O/338958222222222222 frooueiitiv dowit-regnlated m gastttc cancer anti acts as a ntbxir Supprosscuby : inhibiting yeiipiylderafiyn:: | nsir- 221 | gastric cancer | up | increased Expression of MicroRNA-221 in gastric cancer and its clinical significance | mu- 29822222(2 | (258258258958522222( | (29822222 | miRNA-223 promotes ct tin. varwet tm aarot and metastasis bv targeting /(3333338δ338(////////:///// (/:^3335(:(///////////////////////: |
:(:7ί7(:(:(:(:(: :/(03//// | bepato-cte {inter ((:(73593/3-8(////////////: | down | /895880/889:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( expre siot. is do.teased it. (29999388583/388858822222 229852889835/85(8852222222222222 (28835838222222222222222222222222 | tnir- 221 | gastric cancer | up | Deregulated microRNAs rn gastric cancer tissue-derived mesenchymal stem cells: novel bioinarkers and a mechanism for gastric cancer. | (/757(:(:(:(: (/58//////: | (//7837/////(///////( /(33333/:////////// | (29522222( | The rork-l pub matron S up-teguiated in some 2288889898388999222222222222222: (2(88(5989358558838:893(////////( induced- hy N-inye m sortie hedgehog-treated cerebellar wo:a: jrocusxor:· |
071- 22888(2222 | 2(33398855822222222 2287339782222222222222( | 293892( | Mir US* vinp.vsccs^.'i! probferaiion and invasion k< hepatocellular ?aroitni< >a by ia.gpnngWiy’Tt'by.ava-eiau padiwav | mir- 223 | gastrointestinal stromal tumor | down | Down-regulation of miR-221 and rojR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. | mu- 283222222 | 2238338238582222: | (2/8995 | MYCN-regtttated iniRNA9? nduhtis sevretmn N the (:3h3f(s3h73tii(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( DKiADbF MDKVmi ((((htaiiy3595i8ina((((((((((((((((((((((((((((((((((((( |
170
WO 2017/132552
PCT/US2017/015417
$:t££$£/£ 148b | $££££O$$£££££/£ | /££$£$ | $$$0·ΝΑ$ίθ£££££££; suppresses hepatk career stem cell by targeting £r$di£p££$l££££££££££: | mir- 221 | gastrointestinal stromal tumor | down | Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma. a case report with KIT and PDGFRA mutational analysis and miR2.21/222 expression profile | $$£$///: :|££££; | $£££$£££££££$$ £$$¢££££$££/: | l|$/| | /:|l|||O^:|||||::£:: pvprswprasaetl inhuman pancreatic cancer and ::mvolvedin:hsinvasivcnpss:·:·: paittpliy ' ia suppression of £££$£££££/$£ |
$££$$//// | noii-snujil cell lung $$£θ£££££££££;/ | down | mrR-14Sb function^ as a tumor &uppressnr itt nonsmail eel: lung career by targeting carctaxremhrypnte /:£ii£gc£:l'Ci£^///////////////:$: | rnir- 221 | glioma | up | MioroRNA-221 targeting PI3K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma. | $££$//$ | acute pionn etovUk £$£$$£$££££: | IBII | inlupitipti of MicroRNA £$$£$/iii$b$££$££££:£ :|$£$$£d£:$:H£$8£££$:$: Acute Proroyekteyfie /:Tb£k^ni8//////////////////////:$: |
/:££$$///: B;0£$ | rtun-zmail Nil tunc $£$$¢££££££$////// | $£$££$ | Seram miR* 152. miR*H8a. n£R-14Kb. and miR-zl as novel bio mark era m uon$$$£B£$$l£^ £a£s$f££££ $£$$£m$££££££££££/£ | mir- 223 | glioma | up | MiR-221/22.2 promote human glioma cell invasion and angiogenesis by targeting TIMP2. | $£$£$// | b*celllvmphama | $££////$ | MicroRNA miR*3 ’-op is Ovetexpressed in pancreatic cancer associated with a £ρ$ί£ί£$$$$££££££££: £i£y$$$:£t£d£$$$££$££ omitierotmt uidiroaron |
$££$££/ | non-smail cell lung $$£θ£££££££££;/ | down | :-Miei»Ri4A-:i4§b:£S:do<VH-:·:·:· regulated itt non-smail cell Imp iw er and a,\rtu 4 '4 with poor Survival. | rnir- 223 | glioma | up | Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip 1 in vitro and in vivo | $££$//$ | breast cancel’ | $£££££ | ::Ciieuiating:mroroRNA-:-92a·:·:· arid takroRMA-23 x rroxel uiirontally invasive hiontarkers f or primary /$$$$$$$££££££/$$///$ |
/:££$$///: Β;ό$£ | ox arian ?atk4f | ££$££: | increased e\pres>ion uf $$£R$$£$$;£y$£ta££££$£ tarcinonto and its Binmai ;$$£i$Cd£3£££££££££££ | mir- 223 | glioma | up | MiR-223 and raiR-222 target PUMA to induce cell survival in glioblastoma. | $£$$$// a2a | breast cancer | dow n | MtcroRNA expression proxies tn human fcremh canterctbs after luuhrfractiyn and sinale-dose radiahon trealmeut |
/:££$$///: ££0££; | /£vaite££ari£$£$/£: | ££$:££ | Increased exprosskni of miR 14Rbrn ox a· ran earemoma and its clinical :$i££ii$tahd£££££££££££: | 221 | glioma | up | Uptake by human glioma ceil lines and biological effects of a peptide-nucleic acids targeting miR-22 i. | $£$£/// ||||$ | breast caooer | down | Downregulation of mtR92a is associated w itb aggressive breast cancer features and increased tumour macrophage $:ibihi$a0b/////////////////////:$: |
!UK- Β;ό$£ | •parkieatk «.anus | /£$£$/: | $£aR$l4:^:ftditam$::8$££/$: $£!$0£έ£$ί£$^:$££££/£ pancreatic cancer by targeting aMRK?T | mit- 223 | hepato-celluiar carcinoma | up | MiR-22i controls cijKNlC/pS? and CD3s.N!l3/p27 expression in human hepatocellular carcinoma. | /:£$$$// a2a | breast carc-Atoma | III/// | MtR-93 enhances angiogenesis and ntetaafa>is bv targeting 3-z'TS? |
$£££$//// | paocreatic cancer | down | $Mi££RNA/:i££b:8£d£££/£ nrorokNA 1<2 texdvste $£$θ£$££ί$$;£^ή$£$££ tiro ugh sopprossion of DNA mcthyRransfemse-l gene in pancreatic career <.o!· itn.'s | mir- 221 | hepato-celluiar carcinoma | up | Role of raicroRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. | $$£$//$ 92 a | cervical cancer | ;Β·|///// | ηυΡ-9?.η is unregulated in £$$£$!/£8£$£$d££££$/£: ::promotes:ceil:pn>lrfeia!ipii·:·:·:· pud invasion by targeting i^lBlllllllllilil |
!UK- £Biii | $£$^i£££$$£$£££: | /££$£$ | MktoRNA-i49 taigeio <ίίϊ 1 ro suppress mregrtr signaling and breast cancer $£t$a$iite-$£££££££££££: | mit- 223 | hepato-celluiar carcinoma | up | miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through ΡΊΈΝ and TIMF3 downregulation. | ran- «2a. | Juditagm- £$$$ό$£/££££ | llll | $££O;?$££bj£tei £££££££ $$$$^££££££££££$£// choiangyxarcinonta as downstream taraei and It-P/Stat3 a& ypstraaro £$if$£bb£££££££££/////$/ |
WO 2017/132552
PCT/US2017/015417
dftjuAddd ;;IBl;l; | wRoiectai varreer | Mrero··NA 149 Supptesse* >, oioreeti· ( 3m Ή Ni Migration and Invasion by dEnrkilga3/Bb:3:d:d:d:d:d:d:d:d:d: d::fftiiBdreftt30idEd3tbt:d:d:d:d:d:: ;:;|^|||A|A|A|A|3| | mir- 221 | hepato-cellular carcinoma | up | Expression of microRNAs, miR21, tniE-31, nuR-122. miR-145, miR-146a. miR-20(!e. miR-221, iniR-222, and iniR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoraa and its progno | dftuiddd: | colorectal cancer | llll | hire mRNA signature; coieu-ecfaleoacerc | |
;;IBl;l; | d:^^aG^!^bd:d:d:d:: | dbftkOO^B^TBtOdddd; proliferation and <oB cvfte pfogies ion through the targeting of ZBTB2 tn human gastric cancer. | mir- 221 | hepato-cellular carcinoma | up | Micr oRNAs in Hepatobiliary and Pancreatic Cancers. | mu- | colorectal cancer | t:p | Deteftmu of »aR-9'2aaod unR-21 m siOvl samples as potential screening biooxuLers for colorectal ;dirahdSf ^W^/ddddddddd | |
dimfe/d:/: 149 | 3:glBBiOl|d4d4d4: | dd-byhc | miR-128 and iniR-J-N :Bi^B^:|dd:d:d:d:d:d:d:d:d:d:d: Β^^^^^^^?53333353 iemozolonude by RaptBn 'dfa ed t v rere 'toft remodefurg m glioblastoma | mir- 221 | hepato-cellular carcinoma | up | increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. | drairdod: 92 a | colorectal cancer | ;0;|T; | Overcvpression oi' mik-92a fde^iiib^iaf^dB'itibAyfiiBridddddddddd d;^^^«s:O^hdid;d;d;d;d;d; prognosis in patients will: • tdoretoil vumier |
;;IBl;l; | :d^OWB;Bi|d4d4d carcinoma | The associaaon between genetic polymorphism and die processing efficiency oi mik-l-B/affpctsthe ' prognosis yf palieuis v«i|h trend and rreeb squamous cN! carcm.vma | mir- 221 | liver cancer | up | Bioinformatics analysis identifies raiR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties. | mu- | colorectal cancer | t:p | hKcmRNA-Q2a functions as an Crncogene in Colorectal Cancer by fd-E^t^fiB^^dE^sifiddddddddddddddddd -, | |
iiiii | /Wmito^d:d:d:d:d:d:d | epnhehft-roe»erretf\ mat nasophan ηρΛθί varcmoma coifs | 221 | melanoma | up | HOXB7/PBX2 complex induces apoptosis in melanoma through the nuR-22i&222-c-EOS pathway | Oil; | proifliug of eftoiiated culonoev res isoiured bum feces for colorectal cancer //^dibebib^////////////////////////: | |||
dbftfdddd; Bllll | Nil forto dOBGddddddddddd | Cdpitod | :/toiB:itB::OfeB3OB:d:d:d:d d:SO|f;|i:|tolgidBBfd4d4 Cells EMT by Targeting dgOiiiddidddddddT | mir- 22i | non-small ceil lung cancer | down | Circulating micro-RNA expression profiles in early stage nonsmall ceil lung cancer. | diOd:d: ti?a | esophageal :d^toitoiRto8iid:d:d carcinoma | di?l;/d;d | mreroRNA-92a promotes i> mpb node metastasis of T&^b;8^&bg$^;;;d;d;d;d;d;d; /:;s0;i^ih0u$;0rdLc;aib;rito;riia;:;:;:;:;:; |
dtiOd/d ΒίίΙΙ | 3^n!i/3Bft;d;d;d3d3/d /!&ukOriUj|dd:d:d:d:d:d:/ | 3^|333 | SsTATi A Novel'larger of miR-idU arid miR-223 Is ddiEjN^fc^^jridti^ddddddddddddddddd: dRibiiiOmhbilL Transformed and ATI. Ceils. | 221 | non-small ceil lung cancer | up | MicroRNA-221 promotes human non-small ceil lung cancer cell H460 growth. | dbftf'dyd IBII | esophageal dkhidfhbraa:d:d:d:d:d | Oil; | |
!UK- ;l;?ill | db^fBii^d/ddddd: | lldd | nuR-did pron-ofes human breast vancet growth and malignant behavior by targylmg file pro-apoptolre purirrergiy P2X? recyptpr | mii- 22i | non-small cell lung cancer | up | mrR-22l&222 regulate TRAIL resistance and enhance tumorigenicity through ΡΊΈΝ and TIMES downregulation. | »551!- ti?a | hepatocellular :diraffth0itoft:d:d:d:d:d | np | J>ereuniaiivriui nuR-Rla eipressmn js mtplKutoJ m hepatocellular carcinoma |
dtiOd/d ΒίίΙΙ | breast eancer | 3^|:|3 | mik-142 regulates the tumyngyun·^ of banian breast cancer s|ym ceils through tire canonical WNT signaiina pathway. | 221 | oral squamous cell carcinoma | up | miR-22 land miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. | dbftf'dyd IBII | d:hifig:0aifbef:d:d:d:d: | Oil; | A poly eisttofttc rcften>RMz\ o> erexpresseft rn human lunu valuers ami euhurree> ;ditaiiwhih^ti^;d;d;d;d;d;d;d;d |
172
WO 2017/132552
PCT/US2017/015417
4334/(((4 880888888 | /(4hib33i45ii/i544(((((: tvu Lut-nik· | 8808884 | 4/Q333//8335534/4/4/4/4/4 sighificanne vi pelhrtaraud ///3333433ii33g:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ iukoR-NA iA>ia€hic«flv Zip ίΐ'ρΐ'ίχ^ tic Leukemia 4;8555Ο;4;4;4;4;4;4;4;4;4;4;4;4;4 | mir- 221 | osteo-sarcoma | up | MicroR.NA-221 Induces Cell Survival and Cisplatin Resi st an ce th ro ugh PISKZAkt Pathway in Human Osteosarcoma. | 4334/((( 4088888 | /41385/588558/4/4/4/4 | 8888884/ | Apupmsts mducriou by antisense vBgontreleotides against nBE -1.7 -5p and mlR-2da in king cancers 0\c expressing miR 17-P2 |
/(5(34/(((4 ((0/88848 | chronic m> n<£>genoas k5-.e:ida | down | Down-reg'riafmu ofmiRItiaincitfocnk myeloid leukemia CP'·* veils increases USiU-mediared ///553g33i/8/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | 221 | ovarian cancer | up | Micrc-RNAs anti ovarian canc er: the stale of art and perspectives of clinical research. | /(533(((( 804/88 | ((1353/555443((((((4 | 4/04/4/ | MioroRNA miR-17-5 p is Overexpressed m pancreatic cancer, associated with a poor prognosis, and involved 3 oanpefcell pmltferariou and invasion. |
/:/343:/:/:/7/ ((0888888 | eoiorevia! cancel· | 88088888 | Circulating Eso>outai microRNAs as Biomprkers ///43/00/333384:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | mir- 221 | pancreatic cancer | up | Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, o2?(kiul), p57(kio2), and PUMA. ' | /(533(((( 40848 | msttgnaoi /48383034544/4/4/4/ | 43844/4/ | Altered v\pm o-iou nt /43155543:33558^5:35:/:/:/:/:/:/:/ melanoma amiprohtemM e ::attdpKSapOptt>tk:aetiviiy:oi7:· /4:j53i/^i^48^S444444444444444:/:/:/:/:/:/: -1 |
/7050^3)^541/(((((((((((( aquafaoas ceO 533554335/5/545454 | 4:8888bi8535l8534/4/4/4/4/4/4// esophageal s^uaitivuz ve8 •cammomn via targeting the 480800/1088448848 | 221 | up | cancer progression through the regulation of matrix metalloproteinases. | 8855884 | /43338833444444/ | 80848 | mediates oliemoresisnhioe and enhances promt growth in mantle cell lymphoma \ ia RISK/ ART pathw ay | |||
:/:3134/7/:/:/: 3888433: | ga?tn> v.meur | 8888884 | MuM^d promotes gastric cancer proliferation by negatively regulating the pru-apoptodc gene EGR2. | reir- 221 | pancreatic cancer | Up | /Metformin Causes Cl-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 UpRegulation in Pancreatic Cancer Ceils. | 4337/((( 92 a | osteosarcoma | 488448// | /4U3533533z534z4z4z4z4z4z4z4z micmRNA.-l7-92 cluster associates w dh < amor progress ton and prugnosia /(3)/4344453535(/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
in«- 3888433: | 483333334:4:4:4:47 :43.33535:4:4:4:4:4:4::: | 343/ | Altered miR-l 43 and rein.Mo ”spresstvrizre 4/jk3O5^i/836/8/4/4/4/4/4/4/4/4 tnonottacteaf celts for diagnosis <3non small celt 4133453534/4/4/4/4/4/4/4/4/4/4 | mir- 221 | papillary thyroid carcinoma | up | Expression of miRNAs in Papillary Thyroid Carcinomas Is Associated with BRAF Mutation and Clinicopathological Features in Chinese Patients. | mu- 8883884 | /48353154585/4/4/4/: | 8088888 | The relR-92h funcrireis as a potential oncugene by tnrgeiing on KreadG m 4^^00/8888888888888888888 |
/(5(34((((( 4:8883 33 | 4&8j3433$544:4:4:4:4 | 88088888 | ntiR-150 promotes the •zpre-iigratmureHdiHEgratrefi:·:·:· of lung causer celts by targedug SRC kinase 48^58θ5/:085ί5ί:/84444444 | 221 | papillary thyroid carcinoma | up | Integrated analyses of microRNA. and mRNA. expressioti profiles in aggressive papillary thyroid carcinoma. | :/:533:/:/:/:/ 40/8888 | 4385:354/4/4/4/4/4/4/: | 4088888 | MiR-RkbkhibitOi /(p333i43/^re53:443/(((((((((( apoptosis via targeting DKL' and bloJang the W nsbeta-ca tenin signaling •unhwav |
!UK- 4:858333 | /4353338R:4:4:4:4:4:4: 4335883844:4:4:4:4:4 | 43334 | tracroRNA expression prvid1 md td ί fu ·οη Λΐ miR-29 as a pmgoostn: /(33i3533^/R43i4^535ikZ(((((( fav'Oibs targeting <Dka in mantle cell ivmpfcoma. | mii- 221 | papillary' thyroid carcinoma | up | MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. | ren- «?b | non-small cell /48188/8555844/4/4/4/: | np | MiR-92b regulates the cell growth uTpintto chetnosensitivriy of A549 non small cell lung cancer ceil hue and target PTEN |
73337:/:/:/: 5888433: | nyu-smail cell tuna ((¢45453(((((((((((((((((: | 80884 | Increased expression of :///r5aC3R4i43d30:/tS/:/:/:/:/:/:/:/:/:/:/:/:/:/: /(43450553333^3(((((((((( pr-ognusis m oon-sinall vNl h-m< cancer | mir- 221 | papillary' thyroid carcinoma | up | In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma. | :/:/3l37/:/:/:/ 88B888/ | ////88388311/453:/:/:/:/:/ /4l88g:588488/4/4/4/4 | /808884 | ////33t45i5Zr45i:53R/(55bZ((((((((( suppresses nonsmalicell lime vat.*er veils gtooth and motility bv targeting (00(((((((((((((((((((((((((((( |
173
WO 2017/132552
PCT/US2017/015417
65t53.U05)))6 0000:04 | 0p0000/OOtai45454 adeixy-careittatoa | :0/0004 | A Decrease tn ttuR- i 30 Regidates the Malignancy ol Pancreatic Cancer by Tareeting e -Myb and 000^4444054545454545454555050545 | mir- 221 | papillary thyroid carcinoma | up | in vivo imaging of miR-221 biogenesis in papillary thyroid carcinoma | 45///4545 60046454 | 5)500165654/605345)))))) | dm? n | •'htu.il siurftftvan.e J nn<tioRMA’93 downregulation tn human 3053/6350/65(24535353535353535353535: |
35ίΟ535353 40:0/0:0:0: | colorectal cancer | 4004005 | MicnaRNA expression profiles in hubisn colorectal cancels with In. or 40000/0445050505050505050505 | mir- 2.21 | prostate cancer | up | MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of :1EC’[1>2 and RABI A. | 5-5105454 | colorectal cancer | 00/05050 | Association of fttiCroBN A 555/506//10/55/5/16555555555555555555555555555555555 5 5 5 5r5ra05r/$6t/U5ti/:5t5r!$i4b5i/t3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5)61/6/51//53/6/3451/65))))))))))))5 adenoraremonta. |
•UK· 0®040 | pancreaik: cancer | down | 5 5 5 ^01///1//3/55/0/1105-55155/6 5 5 5 5 5 5 ar<ri ttiiR-M” induces Apoptosis in Pancreatic Cancer CeBsbv Targeting 5:5:Γ€3^^5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5 | mii- 221 | prostate cancer | down | Downregulation of miR-221, 30d, and -15a contributes io pathogenesis of prostate cancer by targeting Bmi-1. | 5:5//40454 4/305:5054 | ))661//0)/5))))))))): 5)///1/45//)5))))))))) | )5/6//50 | )Ο0ί4/5ΝΑ4ί6))/6/ί4//))))))) 5)/31/030//666/3435))))))))))))))): dev etepmert v :< A nid'eta- 55556///0//(/0/555555555555555555555555555555555 35/ekO5gti0ng)53535353535353535 |
5:5/053535 05/4004 | coiorecte! cancer | 540/50/5:5 | MtR-icO-sp Suppresses Coiofeefal Cancer CeB Migration and lovasicn through Targeting MUC1 | mir- 223 | squamous carcinoma | up | Unique MicroRNA Expression Profiles in Cervical Cancer | 4/)/4545:5 4/304045 | ))0/d6/)6t//!535))))): 555:6/0//655))))))))))))) | )400))))): | :NA Suppresses muB-Rttib025 Cluster Expression through. Downregtdaticn cf 55:5l4//iS)3/35/60/5li/)))))))))))))) rtolB'eraiton and induces Apoptosis inJitmtauEMC' |
0:000400:0 | 5:5:·4/}4Μό30όί!0!ίίί5:5:5:5:5:5:5:5 63/33//05)))))))))))0 | Mputatna cell uiigrattun and invasion bv targeting 4^041040404040404040505 | 221 | up | miR-222, both overexpiessed in human thyroid papillary carcinomas, regulate p27Kipi protein levels and cell cvcle. | 4/3050545: | 60/60505 | nuvtvRNA-tii inhibits rite pmltferaticn andprouxaec apoptosG of A 1752 gfioma ·<”··:............................. | |||
5:5/053535 004000 | pancreatic cancer | 540/0/5:5 | 33fE0O4//O4M^O0405 prolifietaiioti and promoted apoptosis bi pancreatic 5)4/603()00400)))))))))))))))))))5 | mir223 * | gastric cancer | up | MicroRNA profiling of human gastric cancer. | 5:5/liri5353 tit | i/gOrik////////); | 4006405) | itiiEWA promotes ceii profifeiatioit in gfiomas 5556:/(6///5650654/64/56/55555555555555555555 M31-?A14 signaling 5:5/606/35353535353535353535353535: |
4004:4:: 005004040 | 5);0TOf5tO5 5 5 ;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5 myelogenous 0/0000505054545404 | On | Dcwn-iegoiaficn ofmiRItlainehronk rriyelpid leukemia CP34+ cells m ret tiv-Uiv1·* ):/4/ί)45ί4/3/)))))))))))))))))))))) | 222 | anaplastic thyvoid carcinoma | up | A. 4-Mi.croRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology' smears. | 5:5//-5:535: 4/444445 | bead aod beck ))36063/6/6500105)))5 5)/3(40(60/05)))))))) | 60/60)6 | Increased expression of 5)6///035(656/030506)/6/5)))) poor prognosis; in head and ))603///0/6/(3/2)24/5)))))))))))) 5):6/64iitei536ii))))))))))))))))))))))): |
SUU· 1510 | 400003004000504050 | 5:51:5:5:5:5:5 | MkroRNA-i:A'n-3p ts rfowriregubted inhuman osteosarcoma and repnhbes 555/6/5/1/1//06///5///55555555555555555555 35/6/(6/503353535353535353535:5353535 | mir- 222 | bladder cancer | up | increased expression of miR-222 is associated with poorprognosis rn bladder cancer. | mu- 510440:0 | 5)5/3//54/455/34/5)))) squamous ceil 5)56/001/6//5))))))))) | OH; | •'muprchenn' e MicioRNA omfcling tat head and (.trek spttat.'Ct.s 'eil |
356//35353 40:0|000 | :55500/:0305:510:00/:055:555:555: 460501/04545454454545 | 0005040 | Circulating microRNA 5 5 5 θί5’///5/0//ί////04545454545:5 •:brouutlkeisfpf:diagHOSlSuf:·: 45/400 4/0 5//(05))))))))))))))) 5:56/4)/(3/(65)))))))))))))))))))))): | mir- 222 | breast cancer | Up | Analysis of serum genome-wide microRNAs for breast cancer detection. | 5:5)05:5:5): | 5)5:0O£6Zi56565635555555 squamous v ell ))260/60//05))))))4 | 00/060) | MicmRNA-93 regulates cy efin 62 expression and plays an oncogenic rote in laryngeal squamous cell :5:53/5(314/(4/)))))))))))))))))))))))) |
35η6ο5-53535· 40:01040: | breast earner | down | A legublQf* cuemt of rniR-iafca/iS? and D5NMT1 5)/(5536//0//6///53/))))))))))))): transformation and tumor angiogenesis through JGF- 40//0/45454545454545450545 | mii- 222 | breast cancer | up | miR-221/222 promotes S-phase entry and cellular migration in control of basal-like br east cancer | 5:5(6ri$535O 3/i»5353535 | ripso-fkaix ngeal 5Οό5ί(ό/ίό3/65Ο5Ο5Ο5Ο5:5 | 60606 | MiciuRNAAG promotes cell growth arid in' usiyri in nasopltatytigeal carcinoma bs targeting disabled )5560/36/04)52)555))))))))))))))))))))) |
174
WO 2017/132552
PCT/US2017/015417
4:3919-44444: ////Β?////// | ewdometnal cancer | //999(9/ | Z/irilR//^ sttpprcssuf mi WvRNA that (:(32(9322//|'22(B29(:(:(:(:(:(:(:(:(:(:(:(:( kypermetlq latlon in endometrial cancer. | mir- 222 | breast cancer | up | TRPS1 targeting by miR221/222 promotes the epithelialto -mesenchymal. transition in breast cancer. | 4:39336:444 (I!///! | (/(/h9b//h91i(/9i(l(:(((:(:((( hmg vancer | ZOZZ/ZZ | Expression of nuR-2!A, iniE-PL and :mRN2.9as Rofemial BroOKukeisfor Detection of Early Stage 'TVK-Sfiud Kung Canter |
$19316:4444: //BI/////5 | gastric cancer | dowO | m3R-l52. suppresses gostree canrerveil prdarfpttnn and motiiib bv targeting (Oil!!!!/!!/!!!/// | mir- 222 | chondfo-sarcoma | down | Analysis of mic roRNAs expressions in chondrosarcoma. | 4:ίΡίί$:444 /Bl/I | hepatocellular coretooroa | down | :(:(M3R48(6S(iii39h3iS(444444444444444 hepatocellular carcinoma growΊι and correlares with prognosis of hepatocellular careruoma patients. |
UK- Bill/// | gaslro-inlestiual //623929/////////////(/(/( | down | (/(Bt/oBI/is!t2((((((((((((((((((((((( frequent!} down-regnlated re gastric cancer and aus as a .urnor upprtsscn b> inltibiting cell OroJiienatlon. | mir- 222 | chordoma | down | MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. | 4(9933:444: /$!!/! | prostate cancer | //999/(/ | ::MicroRNA:-O4:y:sappfesSO&:·:·:· prostate cancer roigtanon and mission bv regulating (/(BB!!!!!!!!!!!//! |
(:/393(6:4444 BB///// | phobia ironia | ::(:229(2:(: | MtR-:s 2 hw mo-ns as u turner suppressor In .glioblastoma stem cells hy targeting Koppel-like /27//229:((((((((((((((((((((((((((((((((((((((((((((((((((((( | mir- 222 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. | (:(99:46(:(:(: //99(((((((( | bepubvreilnlar :4(Z99ih03&9(444444444 | dem u | mediated Repression of oiiR-Pdl. Enhances Lysine iKy-Spechk Demethylase op t yptessmu in 1 lepuronnt (/(3/9:19/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/(/( |
:::222/::::::::: Bill! | (/912222////////////////// | down | (:(MiR;(i$2(:gl(lt|:(r2iR:T:3(5S:(:(:(:(:(:(:(:( reduce glioma celt tm avion vWd aogtog^n^MSMikk· - :/99B/O!//:/:/:/:/:/:/:/:/:/:(: | mir- 222 | gastric cancer | up | increased miR-222 inH. pyloriassociated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. | (:(999(:(:(:(: 842 | 449$opf!agP9444444444 squamous ceil carcinoma | //!///// | nuR-O-K promotes cancer sieiu oelMike traits In esophageal sqttamnm cell /Ζ/?.99399θ!^ activation of wnbfcetacatemn signalling uathw ay |
4:39336:4444: //BI/////: | oou-small cel! bang :(:(/22222(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: | down | MiereRNA·*:?? targets ADAM17 to Suppress (/(|i!!(p(r29r(/292i/((((((((((((((((((((( | rair- 222 | gastric cancer | Up | Deregulated microRNAs rn gastric cancer tissue-derived mesenchymal stem ceiis: novel biomarkers and a mechanism for gastric cancer. | 4:3998(444 /Bl/I | cervical cancer | ////1///// | sroyel htfvrops <red mrgets 4((.9:(h9B!t:4:i9(hUi/999:(:(:(:(:(:(:(:(:(: cervical cancer cells |
822268:8: Biiii | nyn-snujli cgli bang //222/22(/////////////////( | down | Serum miR-152, miR-biSa, niiR-l88b, andnuE-21 na novel biomarkers ui «Ληstuall cell hrog cancer :45Οί:6όί93ί9(444444444444444444444444 | mir- 222 | gastric cancer | up | Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer | (:(999(:(:(:(: | coiouectai | //!///// | MiciuRNA-05 promotes :/(///33/0^8799779(9933/(/(/(/(/(/(/(/(/(/(/ targets sorting. Nemn : in :/(/99999/91/79/99/(/(/(/(/(/(/(/(/(/(/(/(/(/(/ 44όδ99ήθ 309444444444444444444444444 |
!UK- ////7/////////////// | (:(222it22:222622(:(:(:(:(:(:(:( | :(:229(2((( | Altered ecptessroiW ro:R15 2 and mfR-Ubain ovariat. carteef is related to (:(9SU(:pl933fpi(9t3933(444444444444444 | mii- 222 | gastric cancer | up | Ϊ^Ϊ-222Λ''0ΕΪ4,ΎΑΪ’-ΤΕΑΪ>Ϊ regulator/ loop promotes proliferation and invasion of gastric cancer cells. | (49916444: 85 | (:(:99ίθ99θίύΙ(((((((((((((((((((((: ((((/99(19999(((((((((((((((((((( | /B/l/z | MicroRNA-$'5 promotes cell probferaticTO and •nrgets sofdng Nevin 1«. (/(9/1999(9/193/993:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: (:(:93:993399/9/:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: |
(:(9999(:(:(:(:(: ////3//1/////( | pancreatic cancer | down | MtcroRNA-bibb and MBiCioRNAxl-i^^reactivate:·:·:·:· Z/tgip/i/Zd:^ (4tlaOUghS0pprSSSi60:Of44444444 DNA roetbvbransferaseN gene mpaucreaficeaucor (:(2g2:inie$::(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | 222 | gastrc-mtestinal. stromal tumor | down | Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tuinois. | :430946:44( //9/:/:/: | oor.-Sbislicell 44i(9tlg(e3i3iC:9i444444444 | ///!/////////// | MiR-85 induces ::proiifeiation:nrid:ohemo:-:0:£·:·:· admiesistance titi'-'ugii directly targeting ootttng nev.nl <$Ν\Γ. mn«n* small cell lung caooer. |
7S
WO 2017/132552
PCT/US2017/015417
^ititikRR/ | /hR^tRhiRiRRRRRR | //iRkRR: | Md'-U' mhibitevptibehtiη.Λ x'fkfcvifiei tranxttoiibv targeting raetatiherin in MRtkkRkRdRROkRRRRRR | mir- 222 | gastro-intestinal stromal tumor | down | Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma, a case report with KIT and PDGFRA mutational analysis and miR2257222 expression profile | RmiR:R: ilOiRi | RikbRSdhdiRRRRR: | don n | /ThRitOfR^RRtiiRRRRRR tepukh' z the pm-hler nmn and migration of human RikkRddbkrkkRiiRkRRRRRRR Rtdi^irag/AkikRRRRRRRRR: |
cikiRR/R RORRR | Rgli^BkkRRRRRRR: | down | MkiuRNA-153 is tumor suppressive in ghobbstiunu /RttoR-teiiRRRRRRRRRRRR::: | mir- 222 | glioblastoma | down | Expression of 19 microRNAs in glioblastoma and comparison w ith other brain neoplasia or grades I-III | cknRRR /RRRRR | Madder ^aucei | 1!B1I | MicreRNA (expression signatures ofbladtier eancer rev eNed be Jeep scHixjxjn·.· |
SUU* Rk^RRR | /hORR'MhilkRRRR·: RRiteitibRRRRRRRR::: | R^ll | Micro··NA-i\? pret-rete wnt'beta-caremn activation nt hcpatocniluiar carcinoma through Supprasskth of i/lOikRRRRRRRRRRRRi | mir- 222 | glioma | up | Co-suppression of mrR-221/222 cluster suppresses human glioma ceil growth by targeting p27k:ipl. in vitro and in vivo. | mu- :|RRRR | bladder cancer | tip | ' rrtbetic but targeting miiUib3-9MS? cluster crniiR-Glii inhibit growth and migration ami induce apoptosis inbladder RcakdbRRiilRRRRRRRRRR:R:: |
ChuBR/R: RjRSRRR | cihjjgcaksBRRRRRR | down | Suppression of ART e-pressmnby miR 153 ^Oli^RikORfiWRRRRR·: vtiotte mhtn.vU’cW | 222 | glioma | up | MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. | iBRRRR | breast cancer | cO/rr | Unregulated miR-9u CiRiiOR^tiRiRikRdfbRRRR:: Rd0tobi:0gb^bkRRRRRRRR:R: transcriptional factor |
/iriK:://: R^RRR | ίΐυβ-,η»1ί reli furre /•CteiRdRRRRRRiRRR:: | /RRRlR: | MtR-l'M rahjb.Aritign«rtn and iovasinn of human tmnsmall-cell lung cancer by targeting aDAMIO. | mir- 222 | glioma | up | MiR.-2.2l/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2. | xMlrA::::: /Brrrr | breast cancer | BiBR/R | •miR*90 promotes turner ptubieratiutt and «waston by targeting RECK m /htei^fCSkcB//:?:?:?:?:?:?:?:?:?: |
ybitiR::::::::: BRsrrr | /RRsORiteotoRRRRR:: | diWvO | MicJOKNA-153 inhibits /:kBR^4iRtik^/S^RRRRRR:R ?piRi^RhiRRakdtikiR^mkRR by targeting. TGF-'G. | tnir- 222 | hepato-cellular carcinoma | up | GNAJ5 inhibits tumor ceil migration and invasion and is post-transcriptionaliy regulated by miR-222 in hepatocellular carcinoma. | •RkiRRR | 7chfphicRRR?RRR myelogenous R!gkR$RtiRR:RRRR: | ;OR;R | Donn-regulayonof raiRliia kt Phrenic myeloid leukemia GD 34+ cells me teases USE 2 mediated Rbkii:kfbRtRkRRRRRRRR:RR: |
tiRnRR//// BOBBB | /kkgitekR^ikRRR/R: | down | MicroRNA I“3 fjuv..nib as a tumor suppressor by teraeriug SET? and &EfG ra ovarian cancer cells | mir- 222 | hepato-cellular carcinoma | up | P.ole of microRNA.-155 al early stages of bepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice | cknRRR /RRRRR | culoievtu! vd»c<r | 1!B1I | Expression of miR-M, miR-31 v ittiR-9* and uuR155b is vurrelared with the ebntcal parameters of :/bWf^Dl:R^(^k7/:::7:7:7:7:7::: |
UUf- R^RRR | /RMRtiteptikO//:::::::::: | /WRR/ | ftpiegclarren nf mil -J 4 > prouxife^ce'd prehieratiuit via dOwnreguiafkth of the PTEN tumor suppressor gene in l-un-an prostate /rOR/RRRRRRRRRRRRRR: | mir- 222 | hepato-cellular carcinoma | up | miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through ΡΊΈΝ and TIMP3 downregulation. | :0147:7 /Brrrr | otibiectai cancer | O^RR | MicroRNAA'b promotes RbR^jrdik^btibRRRRRRRR: colorectal cancer cells and Israels tumor protein p?3 ndm-bie najep p-otern t, forkltead bos protem 01 (IBbraiUmdFOXObi |
citiiiR////: BllBBB | RRiiRiiR-toliRRtCdRRR: | RtikR-iR | miR-154 suppresses colorectal cancer cell growth and motility by /•kaBRiR^RRORRRRRRcRR | mir- 222 | hepato-cellular carcinoma | up | Expression of microRNAs, miR21, miP.-3L miR-122, miR-145, mlR-J46a. raiR-20(!c, raiR-221, miR-222. and miR-22.3 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its progno | yRuRRR BRRRR | C^d^ktiggdRRRRR r^Orrrrrrrr | 7Ο777 | /RRR:RR;ptRRpteRRRRRRRR creltietatrei. and -hemo or radioresistauee by downregulating RFC! ra R^dM^slkkORRRRRRR:/ |
176
WO 2017/132552
PCT/US2017/015417
36ί69//39 559055555 | uoo-smaB ceil Jaag :903655555555555555555 | 553366:/ | miR-154 suppresses nonsmall celi lung cnrecer growth in vitro and in vivo. | mir- 222 | hepato-cellular carcinoma | up | Micr oRNAs in Hepatobiliary and Pancreatic Cancers. | 3669//// 5055555; | :3860655555555555555 | ;O;55555 | The· utiR-f 8'?/PA'lli2 8G^69O^66//////////9;9; Oxidative Apoptosis and 9^6000^9655555555555555 Chemotherapy in Ghomas |
/:6668////: 550555555 | prostate cancer | dowh | miR- 15-i inbihros prostate career cell probi'erawonb>- ;;Β||Β^ΙβΙΙΙΙΐ5ΐ | mir- 222 | hepaio-cellular carcinoma | up | Expression of senim mioroRNAs (miR-222. roiR181, miR-216) inhuman hepatocellular carcinoma and its clinical significance]. | 366839:: | 3g:iO66y9tttttty9;9; | 3033333; | mtR -On KBPl/W rtvbeiacafenin regulator, Cfrounry promotes ghontq grow tit |
UUf· Biin | ;$όΦ86;ΟΟ6ί555555555 55Ri&O6;55555555555555; | 5055555 | Pharmacological targeting of ituh-K^ va the bBiizDS-acnvataig etroyme tnlahdoi KR N B'V tPevonediStati ro ELT5 ITD acute rny elaid 96963666////////////////////////: | rnii- 222 | malignant melanoma | up | The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-22i&222-c-FOS ’ pathway | 36639///: 586//////: | 9&36OOi463;9;95; :36030333333333: | 5055555; | OnconaR naR-Uti and miR) 82 promote -eU omitferotron rodmvazun through Otgetii'g ephrmAA 3:1686069^866//////////////// 9:9060333333333333333333333333 |
9686939/ 55055:555; | anaplastic latge-ccB //^6^6005555555555555 | 5505555 | vmrogenc. role c<f miR - 1 *4 3696680868^0 881///////// fimpltomn lacking the | 222 | non-small ceil lung cancer | up | miR-22l&222 regulate TRAIL resistance and enhance tumorigenicity through PTEM and TJMP3 downregulation. | /:669///// 586555555 | hepafixitihriaf ;;5966;68 661////////// | 5093333 | W ot'beta -Cateron activates MrR ihLUtw 1ST expression m bepymcetiglai varoutuma |
3686·/////; 551155555 | bladder cancer | 5505555 | ;/ί2όίί8!6ίί06;066ί9θ3;555555 E vprc*smt. of Micro·· NA14-.jp Rfjifder^-u ro-’ro’d 966&Ο&55555555555555555555555; | rnii- 222 | non-small cell lung cancer | up | Use of Luminex xMAP beadbased suspension array for detecting microRNA in NSCLC tissues and its clinical application. | 36639///: 586//////: | 55966369963189///// :36030333333333: | 505551 | 9;99thi8f668;6666R/36;////////// e-.pressmurodiKe; cell 9:060030333333333333333 Hrtnopen.n.v of NepG2 //&ripr69:6ih/c6i6/;///////////////// |
96669//// 55055:555; | bladder cancer | 5055555 | Mb roRN A-l4< Fmi..Pt<s bladder carnet growth by repressrog die turner 3939609^00555955555555 | mir- 222 | oral squamous cell carcinoma | up | miR-221 and miR-222. expression increased the growth and tumorigenesis of oral carcinoma cells. | 96569///: 586////// | noii-sujaB vNd 55066055555555: | dow 0 | h '.press-on M ronrokN Atit. ami its potential functions hy targeting FOXOu hi non-small cell //1666966939//////////////////////: |
9686///// 550555555 | bladder cancer | dpwn | Evpfession of mmroRNAs in the Urine ofLatienis ith Bladder r aacei | 222 | pancreatic cancer | up | miR-221,'222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. | :5669/5555 586555555 | ovarian cancer | 5055555 | The upregulation of Signal iransdnoei and activator of IMS uplul ‘ ^upvPdett //60&0B8;Oi555555555555 mrere.PN pr.ymorex ovarian cancer ceB proliferation by targeting 1 wad box O 3 wora //936663996169///////////////////// |
3666-///// 550555555 | breast cancer | 5055555 | Clinical sigi'ifitm'oo of MicoRNA-i$5 expression ;/696668389386ί/3863655555555 | rnii- 222 | papiiiaiy thyroid carcinoma | up | Integrated analyses of inicroRNA and mP.NA expression profiles in aggressive papillary thyroid carcinoma. | 362888 3ijg9:;//// | ox a^m· ^aricei | 505551 | 9;EiM66ti681;693ti6i^A9////;9; expression signatures and 550O69O09555555555555555; usx«wj'!«nynf. Giro! resisfaoc·1 ro ox ana* caro-ei 9:961839////////////////////////////: |
/:686////3 550555555 | 30000////////// | 5505555; | Auafi sis of unR-?h? and troR-l$5 exprosskro in. the ;/Οθ6θΟΟΟ?5;55555555 9600/////////////////////////3 | roir- 222 | papillary thyroid carcinoma | up | MicroRNA analysis as a potential diagnostic tool, for pap;lla:y thyroid carcinoma. | 3663:3:/ | ;/83636868:555555555; //?6i86655555555555555 | JOP it | mjRNA*9ti suppresses KRAS and firoctroret as a tumor suppressor gene in pancreatic caiieer. |
9686/89/ 55055:555; | breast cancer | 5505555; | P’FSJIdml ip fe’Nih* miR-155 expression and //ro8;O8;OO?^i:555555555555; | 222 | papillary thyroid carcinoma | up | MicroRNA. signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. | /:6696/// 58 6555555 | prostate cancer | 5055555 | tniR-96 promotes cell 5|^j99O3|3B55555555:555555;5 clonogenicity by liowt·legulatip.g oi'EGNCB m |
177
WO 2017/132552
PCT/US2017/015417
6(863((686368686868686868) | ///656588:763((6/8(466)))))))))) | ||||||||||
!Uir- 6/8/736666 | /:/25(036746))))))))): | 6/6466/6 | MroioRNA-fi·^ fuiivfiuus a, spot \,pwRjp br'is' cancer by targeting the /)32845(6462868864864)))))))): 6(33638836663636666666666) | mh- 222 | papdiaiy thyroid carcinoma | up | Circulating microRNA profiles as potential bioraarkers for diagnosis of papillary' thyroid carcinoma. | /:/245/:/:/:/: /)64/))))): | :/:/357685/(:367(()))): | /)46/6/66 | ]]:·)ίύ23Γ3((6885/:3(686888))))))))): ia*ror-‘; promotes prostate bone metastasis through induction of mteroRNA -90 and activation of the tnTOR :/:3684565/))))))))))))))))))))))))) |
•/•245/·/·/·/·/· 6/80/686 | breast cancer | 664/666 | wiR-l55 drives teiomore fragility k ifumnn breast otuicorbi targedtig TREE | mir- 222 | papiilaiy thyroid carcinoma | up | Expression of miRNAs in Papillary Thyroid Carcinomas is Associated with BRAE Mutation and (Tioicopathoiogical Features in Chinese Patients. | ):/255/:/:/: :/:5}/:::::::::::: | prostate cancer | 6646668 | nnR.-lS3-9O-l.f2 cluster is o> eiexpressed inpiostate tissue and regulates zinc homeostasis in prostate· cells. |
!Uir- /68/7486/6/ | /)25(666367(6/))))))))): | 664/666 | MreiuRNA-l?^ regulates edi sur* :v al, grow tb. and tfcentoSfcOSUivitj’ by targeting lAdXGisa tnbreasf ////78575)))))))))))))))))))))))))))): | mh- 222 | thyroid carcinoma | up | MicroRNAs (miR)-223 and rniR.-2.22, both overexpressed in human thy raid papillary carcinomas, regulate p27Kipl protein levels and ceil cvcle. | ran- N.-^p | teWtcUi *an*ret | down | Mil· <·. V u-η..:».vs teifulutr grow th and is associated with poor /](2(565)i6//c355(38!))))))))))) ////3558i/p4ire55))))))))))))))))): |
/:/55-/:/:/:/:/:/ /68/7486/6/ | breast cancer | 6/648/86 | Rote ol nncroPNA: >5 2 -155.-197 sod -225 as )/586886882:252584/388388)))))) /)3(5(226/358368882 76//////////////// ):/55652)))))))))))))))))))))))))): | 222- 3p | endometrial cancer | up | /:/55-/:/:/:/: /)66/)))))) | )6(686668663(8686/ | down | Breast cancer-specific /]5R4it)5p5(2i86/))))))))))))) mediated by ioiRNA response eieuteuis M let-* /):648:48468/22)))))))))))))))))))): | |
BB/6/6/6 | /6646/66 | siguifivatiee of nuR-175 lit human primary hreoz /58863(6868686868686868686 | 223 | leukemia | microRNA-223 comprise an autoregulatorv negative feedback loop in acute myeloid leukemia. | /1(/6/6/6/ | 60086868686 /):(8(7(6345)))))))):/) | /)58(55(2(2))))))))))))))))))))) /)2547683863((6356/)))))))))))): carcinoma. a nun-invasive carcinoma, and is not correlated with pro gnosis | |||
/:/55-/:/:/:/:/:/ /68/74 86/6/ | cervical cancer | /88486/6 | Mii-175 promotes cervical e-sncer ceil proliferation tlnp ugh suppression of its target gene LKEi | 223 | bladder cancer | up | Micrc-RNA. profiling in kidney and bladder cancers. | /:/55-/:/:/:/: /)66/)))))) | colon cancer | down | tet-7 mteroRNA functions /]p2/8]6$8®O8/8(4'584/)))))))))) suppressor m iruman volon :/)724767/778875)))))))))))))))))))) |
:/:ffiin-/:/:/:/:/: 6/80/686 | /)0150215)))))))))))))))) ///13683888(/463))))))))))) /)866^2366))))))))))))): | 6/646/68 | Signal Transducer and Acti'-gtor of Transcrip-tion3 induces MicroRNA-J55 ):£O336688/(2/486235/))))))))/ E.ymphoey tic Leukemia | rair- | chronic lymphocytic leukemia | down. | MicroRNA-223 expression is uniformly down-regulated inB celi lymphoproliferative disorders and is associated with poor survival in patien ts wi th chronic lymphocytic leukemia | )025//))): 686/6/6/6/ | esophageal /)8(8(88(86/(88668) ))38((836886)))))))))) | down | Rote of mteroRNA let-7 ///2485ff3675)£i4i5)76)i4/))))): squamous teli 66388(630868686868686868 |
i!!U- 63476//6/6 | /:/72557////////////////////////////////// /):25/688/6(86683))))))))): ))tei56223))))))))))))))) | ))2563): | Downregulation of uuR-' 1 ttiiM < mdniP^t^tt chronic m> eioid leukemia | mir- 223 | chronic lymphocytic leukemia | down | [’Expression of microRNA-223 and its clinical value in B lymphoproliferative disorders]. | mu * 6866//6/6/ | /)8(78858(8())))))))) squumuirete'd /)685320123)))))))))) | Jem n | /:/52355(044/687())))))))))))) uncrcRMA-2Ll positranscriptionally regulate ::enhaneer:of:zesto: homoiog:·:·:·: 2 and inhibit migration and /)724(2ι76/5(84ι8863/8)))))))))))) esophageal squamous cell /:/:74512045/3/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
i!!U- 63476//6/6 | cleat ceil renal cell /):(626668)))))))))))))))): | nireroRNA-ίΜ <,ikn*atg /)(84834(/65868(88834824/))))) migration and toduoes ::apOptOSis-2yup£0gu5iing:·:·::·: BACK I in renal cancer | mir- 223 | colorectal cancer | up | Association of microRN A expression with microsatellite instability status in colorectal, adenocarcinoma. | mu * 6866//6/6/ | /)8676858(3())))))))) squumuirete'd /)68512523)))))))))) | Jem n | Expression of circulating unercRNA-2ba and iet-”a in esophageal squamous /)6(8((8568665))///////////////////////////////// |
WO 2017/132552
PCT/US2017/015417
(ZZOZZZZZZZZZZZZZZZZZZ/: | |||||||||||
!UK- ((BZ/z/z | (9C95lti595/5£5i(9(((((((((9 | 9/ZZ//9/ | 9:9iO^/3i/3:Z343//Z9(((((((((( expressron ol n»3M*A w colon caiKOr and serum cgn.inoen3>ryotnc antigen level and us contribution to recurrence and metastasis (:9343333(((((((((((((((((((((((((( | mir- 2.23 | colorectal cancer | up | •Circulating Exosomal rnicroRMAs as Biomarkers of Colon Cancer. | gastric cancer | /B//(/ | MictoRNA profiling of human gastric cancer | |
99995/549((((: ZOZ/ZZ | 493/435/54/1:95/5/559((((9 | zBIl | (ΒΖ/5Ζ545/θ595ί(/9/9/9((((((((( nucroRNA-l promo Ms the migration artel invasion of colorectal cancer cells through the eguialrot'tif ciandin-l expression. | inir- 223 | colorectal cancer | op | MicioRNA-223 functions as an oncogene in human colorectal cancer cells. | (:93/459((( ZB//// | g:n-m'· | dow t· | xGvefexpreSSfefiXjfRiciR·:·:·:·:·:·: inhibits ceO invasion m pf.on-a · ell hue* through upreduladonofrorR og |
:::3/35:5:5: 9/BZ/z/z | Cutaneous f-ceil 999453/43343/99999999999999999999999999 | //Β/// | 9 9 9 9§ΤΑΪ5/4443ί/ΐ539(((((((((((((( expression ofoocogemc ((3/4/9(i959$9lZ/Z3/Z/3/Z /://// cell b nipliorna. | 223 | colorectal cancer | up | Overexpression of miR.-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. | 9:9mir9-9595 /5/9(((((( | 9999//14033551144135:99999999 9 9 9 93/5445/45/(((((((((: | down | 9 9 9 ^or0IW53Z9(((((((((((((((((: 9 9 9 9i9fe^5t/B!4-3Z9(0/459(((((((((((((( 9(^5/55/3445942/5//45.9((((((((((((: |
50X0:5:5:5 //B//// | titiiuse iaige D-ceil 9(94/34/433439((((((((((((: | /////ί/ | Coordinated expression of 9 9 9 9r5434/R9i/A(94/29/54l9((((((((((( predicted target gcn.es nt (BBZZB/ZZ/3/Z//////// tv ntplro·::·.·. | rair- | colorectal cancer | up | C/EBP-z-activated microRNA223 promotes tumour growth through targeting RASA1 in human colorectal cancer. | 9(44345(((: ZB/Z/Z | lung Cancel· | down | Reduced expmssioo of Dicer· associated with pour progiiusit; rn lung cancer (9gaife54Z9(((((((((((((((((((((((((( |
!UK- zB/zzz | cntiomeftiai cancer | ZZB/ZZ | 9(A9^i/433339if 4//593(((((((((: receptor anti raiP. 5A5 in endpmetnjl*^nA.'r* s> nergiStic antiproliferative effects ofanti-niiP.-i55 and 9(Β/333/(3/:/ΖΒ39ί53ί/4((((((9 (:5/5505:159((((((((((((((((((((( | mir- 223 | endometrial cancer | down | MiR-223 suppresses endometrial carcinoma cells proliferation by targeting tCF-JR | mn- ZBZ/Z/ | ((554/9/5439349(((((((9 | down | : u-‘ t ^Ic\ ne' p? it AV xh 1' levels 'm rargefmg ed NIRf mti χ ropti-s-rox 'he cmw rh Of A8-IS lung cantor cells |
BB/Z/Z | 9(:59//ί/39/39((((((((((((( | Z;B/Z;Z | 9(33/435^//5^/3///////9/9 nuc*.mmJ mth flic aggressive malignant 999^45433593/34/454/3./349((((((: 9(93/5445/45/((((((((((((((((((((((( | 223 | carcinoma | up | in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1. | ZB//// | tet-7 mictoRNAs inhuman inug cancers in association 9999/445953039155559999999999999999999999999999999999999 postoperative sutiiv ai. | ||
:::3/35:5:5: zBz/zz | gastric cancer | 9(:3/3939( | mieroRNA-M5 is tiowraeguiatedio gastric vai -c’fe ai d in. 3. ed in 9(5/ii99/43/Bi/Z///////////// | mir- 223 | esophageal cancer | down | Differential expression of miRNAs in esophageal cancer tissue. | 9:9felr5595 (90/((/ | ujdllgnaoi 99993Z4/5sfe/(((((((((: | down | uiiR-VS suppresses 99995/955554//(54540//9(((((((((( 9(4Βί5/^Ζ:ΖΖ/^/ΖΖΖ/Ζ/Ζ/Ζ/Ζ( feedbavh loop w nh its tagged gene £1.-6. |
99995/549((((: ZZiz/zZ | 999//344395/35/9((((((((9 | dow 11 | (9D5935O4!/443Z:3f /9/9/9/9(((( nu roRNA }·* -neck, no* cel· growth and invasion by targeting vim c m. human gastric caremoma cells | inir- 223 | esophageal squamous cell carcinoma | up | Clinical significance of serum miR-223, miR-25 arid miR-375 m patients with esophageal squamous ceil carcinoma | :9101195:9:959 ZB//// | na$o-piracy ugeal ((3/1/45533//9///9/ | dow t· | MigroRNA let-2 suppresses na&opharyngeal carcinoma veil umlticiatmt hroneb tiownrepoDtmc e-hb*. |
//BZ/ZZ | 59//43/999999999999999999999999999999999(9 | :99Zli59rZi4W5i9.iS99iZd5939fes 9 9 9 9 9 9 9 Olinina Cell Prahicration 53i39iii3/4e3tiZiiioh9:oZ59595959:9 ΖβΖ/((((((((((((((((((((((5/5 | mir- 223 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. | mu- /BZ/ZiZ | 9(:33/45513/4/45/99999999 | dow n | 9:9935//28899^555599999999999999999999999999999999 9(55545/4544395139/559((((((((((((( enhances M7C9N fevds via 9 9 9 9feZ2(4dpi44^Si5fe9((((((((((((((: |
179
WO 2017/132552
PCT/US2017/015417
3083:34 BBbbb | B^iOBBBBBBBBBB | eiexpresOn of n-mmRNA-M? pOuts poof prognosis in gboma 8B^i^^BBBBBBBBBB:BBB | mir- 225 | gastric cancer | up | MicioRNA-223 functions as an oncogene in human gastric cancer bv targeting FBXW7/hCdc4. | 30843: ilBBBB | ovaiiati cancer | dm? n | EZH2-xpeciffc microRNA9 'mh.bifzfui.an oxvtfd». 8θΒθΟί:8θ43434343:3:3 proliferation«'4 regnlating the pRh E2F pathway | |
3ϊίϋύ4343 B^BBB | bepaip-eelbiiar 8(dtoihBh438383:3:3:3 | BBBB(B | Roie of tnictoRNA-l55 ai 4^O:SWBsBBB4:4:4:4:4:4:4 iKpatucarcinogenesis induced by cbhlm.cdeficient and omroo aciddefined diet mOTEO Oh^BBBBBBBBBBBBBBB | tnir- 225 | gastric cancer | up | Plasma microRNAs, miR-22.3. miR-21 anti miR-2lE, as novel potential biomarkers for gastric cancer detection. | 3ΐρίί8:34 | pancreatic ductal ndengi-carcinoma | dbwn | ief -7 MicroRNA transfer in. paocfeafic cancer-dem-ed cells inhibits in ·, Rip ceil proliferation but fails to alter rumor progression. |
4hO343: BiBBBB4 | h^patvvNlhO eaiOoma | B^BB;; | [ENpres Λυη and sumv ai predicts ο of niteroRNA - 4:iB54iiS$pBB8gibiE3B((((:4:4:: caminpnia after liver BiBiiBBiBfW^BBBBBBBBBB | mir- 223 | gastric cancer | up | MicroRNA profiling of human gastric cancer. | 408:34 3OBBB | biadtfer cancer | down | uneroRNA-'toa robtbmog cell prolderstien nugt atran and invasion hy targeting fibroblast growtiifactyr BiO^bBBBt(bi^hBBBBBBi BOddfBBBBBBBBBBBBBB: |
3ίΡιί343:3 iiin | 4Ϊ&00088484848 | BBBlI | ?<3F-?i acts through miR,f>5tc dcwn-rogniate jpk i\[ npn.nx.bi’j epithelial -meseneliy uiaJ transition and caooer stem 3cgR:pkgiip^4BBBB4:4:4:4:4: | mir- 223 | glioblastoma | up | microRNA-223 promotes the growth and invasion of glioblastoma cells by targeting tumor suppressor P.AX6. | 4fhii845: 9$ a | Odtki vUKeei | :OO? | nacroRNA-bVa acts as a down-regelated in htadder fO^gBcBBBBBBBBBBBBB: |
308434: B^BBB | 4!Bhg:Oh0434343:3:3 8(dtoihBh438383:3:3:3 | BBB:BB; | ΡΛ ?ηηίοιι?{Λζ'η\?Εΐ' «fmtR-155 in serutn from yhoB^OOOOhBBBB? 3B8riBiB(BBBBBBBB4:4:4:4:4 | tuir- 225 | hepato-cellular carcinoma | Up | Circulating microRNAs, miR2.1. miR-122. and miR-223. in patients with hepatocellular carcinoma or chronic hepatitis. | 308:34 99 a | breast tomer | 4iOh4 | MiR-Oa antitumor antn it> tn human breast cancer cells tiupnah targeting of |
410114343: BiB|BB4 | 8iOOk034343:3:3 | BBBBBi: | Dnierenfial MkipRN/vs Expression in Serum of Panetits with Luug Cancel·. E-uhunnnrv Έ uheroutosis. (:gf^(BB^i3^Pig(((((((:4:4:4:4:4 | 223 | hepato-cellular carcinoma | down | [Role of mi.croRNA-223 and its target gene oncogene c-myc in hepatocellular carcinoma pathogenesis.] | 4mif434: 4OBB4 | cervical cancer | riowe | miR uha at,-· .-Ms mbitot cervical cancer ceii proliferation and invasion bv targeting mTOR signnfuig pathway. |
mu- B^BBB | 4tohB4O6BBB:BBBi | EI88 | inhibition of Enpo uainduced roiR-155 ι?ΟΐΛζθηί.η^'« b\vA\f 4OgBO4BfO4343434343 | mir- 223 | hepato-cellular carcinoma | down | Expression of microRNAs, miR21, miR-33, miR-122, miR-145, iniR-146a. raiR-20’ic, raiR-221, tniR-222. and miR-223 in patients with hepatocellular carcinoma or iutrahepatic cholangiocarcinoma and its progno | mu- $'8y | cep i_:j· 3O$mBBBBBBBB | dm? n | nuR“9p inhibits cervical carvumroa veil pmhfcratmu by targeting TRtEi?. |
3:tmi8:3:8: Bllll | 4iOB06B:BBBBB: | BBB|| | 4M@34;55:ii:ihiMtkiilBB4:4:4:4 sewsriivitv of lung cancer eeiia m entpidiin via negatw e regulation of Apaf i exp-essrpn | mir- 223 | hepato-cellular carcinoma | down | Sulfatide Epigenetically Regulates miR-223 and Promotes the Migration of Human. Hepatocellular Carcinoma Cells. | 408:34 $'8y | Op£iiagO:4:4(34: squamous veil BOOOBBbBB | d«W £' | 3MrofpRNA3'>9k‘¥S&(((((:4:4:4: pmroNes apo-ptuata bv rargeimc nitORm firman espfdtageal squamous cell 4000108:43434343434343 |
308834: B^BBB | 4OigO8343434343 40i00(3434343:3 | dv'vO | MicmRNA-i55 targets the 4^TgenhdipShmaa43434343 melanoma cell lines | tuir- 225 | kidney cancer | up | Expression of miR-223 in clear cell renal ceii carcinoma and its significance]. | 308:34 89 a | gastric cancer | ;OBB4 | nuRNA*? 2' promotes gastric cancer tovasici. and metastasis by rargetmu 4?OOsOdfObiBBBBB4848 (B^BBiBBBBBBBBBBBBBBi |
180
WO 2017/132552
PCT/US2017/015417
):/tb35))))) )1855858 | 5808888555555555 588858335558585858 | 5888388) | )3338/:338333885:/:/:/:/:/:/:/:/:/ selected microRNAs in melanoma antiproliferative and oroapoptotic aoti' rtv of 83033538888888858888) | tnir- 225 | lung cancer | down | miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclindeoendent kinase 2. | :)33))/)) 388/8535 | /):888538888883))):/) carcinoma | dnv n | ?a lu roRNA-’Na inhibit* hepatocellular carcinoma growtit and correlates with :pl0gnosis:of:patiot(rsxyi(li:·:·:·:·: ))898833988358/83(9393855) |
/:/3(3:/:/:/:/:/ )))81))33/ | malt lymphoma | 88385)8 | Overs-.presston of turR 142-5p and miR-155 in gastric mneosa-assoeiaied brovKro. -an-e-MAl A lymphoma tesistant to ////l3s35'p338385ti:/:/:/:/:/:/:/:/:/:/:/:/: :/3(8di5atidit)c:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | 223 | mantle ceil lymphoma | down | MicroRNA-223 expression is uniformly down-regulated inB cell lymphoproliferative disorders and rs associated with poor survival in patients with, chronic lymphocytic leukemia. | ///11/////// | ))(3339888))))))))/:) | ))838(83855555555555555555 hepaiovarcmogenesiy reveals that tuiR-l 0«} and RI.KI dySregulatiCit is an early event moiruaioed alyng tumor oroaresaion | |
:/:/313-/:/:/:/:/: )80/3/3) | ////0333:09)!:/:/:/:/:/:/:/:/:/:/:/:/:/ ly tupliOmh | /88858/8/ | microRNA exptessron profile and Identif matron of miR-2c us a prognostic marker and pathogenetic factor φ targeting LOR ti m mantle cel! ti tuphnroa | mir- 223 | mantle cell lymphoma | down | [Expression of microRNA-223 and its clinical value in B lymphoproliferative disorders]. | yiphe/:/:/:/: | :/:/1358:89883))/))))))) csrotunma | down | Clime Significance of nutroR 14 poacxfo^ -rot :/)1553383)l3tg))))))))))))))))))) adenocarcinoma. |
mu- /3388/33/3 | naso-plreiyrtgeal /):3.33833:))))))))))))) | /8011 | M·· - :u'-usUk.!'·»^ E MPf £·Ν4 conti-ibides tu tikfsossd fttisoplafvr.gtal ear mono dl n-ohtemtion 533)8tig3t553))))))))))))))/)))) | tnir- 223 | uaso-pharyrigeal cancer | down | Circulating miR-Ι 7, miR-20a, miR-29c. and miR-223 Combined as Non-lnvasive Biomarkers in Nasopharyngeal Carcinoma. | mn- ):888/)):/) | mesenchymal ))83383858585858) | dnv n | MicroRNA Expression Profiles :n 1·· nposi’s ////S93938)))))))))))))))))))))))))) |
:/:335/:/:/:/:/: ))8883/3/3 | nasu-phar,ngeo( ////333933:/:/:/:/:/:/:/:/:/:/:/:/:/: | /)05)5) | Uprognlatron of MiR-J 55 )/3:8838008055555555/5 emcinoma is partly driven by LME’i and LMHA and dowruegiriatea a negafn e prognuSti' marker /)3MJD8a)/)))))))))))))))))))))))) | rcir- 223 | naso-pharyngeat carcinoma | down | MiR-223 targeting MAH3 suppresses proliferation and migration of nasopharyngeal carcinoma cells. | :)33)))): | top-ywll ed /):133939898))))))/:) | ):(8583/:) | /):0^18335888/3/)))))))))))))) ////8$3/8(8/g39fp8:3l9/:/:/:/:/:/:/:/:/:/:/:/:/: promotes proliferation,, migration arid invasion in non-small ce8 btng cancer A?4‘> and Bl?‘N edis |
/:/3((-/:/:/:/:/:/ ))8583/3/3/ | nun-aitall tel: lone ))833835))))))))))))))) | /:/:338/) | Circulating micro-RNA expresstun profiles tn early stage nonsmalt sell tong /38358555555555555555555) | mir- 223 | splenic marginal zone lymphoma | down | MicroRNA-223 expression is uniformly down-regulated in 13 cell lymphoproliferative disorders and is associated with poor survival in patients with chronic Ivmphocvtic leukemia. | ):888())))) 5888)))): | non-small «.ell /)833/88958855555/ | dow n | miR-99a suppresses the metastasis of human nonst'oall cell lung caocer cells by targeting AKTl signaling pathway, |
/)355)))))) ίίΐιι | /)p385ti888588888ti58 ))838(338/5)))))))))))/ | 8011 | Mici»RNA-i55 inyrai ):8388333/89388553335858/ Ov ereypteasKftt ΙΛν^!η·ΐ'·«η «t>}progoAztte :/:^88831)/)))))))))))))))))))))))): | mir- 223 | splenic marginal zone lymphoma | down | [Expression of microRNA-223 and its clinical value inB lymphoproliferative disorders’!. | 58885))): | ))983883585858585) | 5885551 | {?<3 promotes cell invasion ])889:^93i8938)55)85)85858) endbeim e\pres»ron m pancreatic cancer cells by regulptinn mammal·#' Largct of raparovcin. |
/:/3(3:/:/:/:/:/ /38583)33/ | o«i squanrous cell /)3338838/8/))))))))): | 88385)8 | Upregulation, of o potential :pro:gnosPobtomamen:rniR:-:·:· ))8^5883888888883))))))))))))) /)3858383558/888883883)))))):) with oral squamous cell tnrJnonto. | 223- 3p | prostate cancer | up | MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. | /:/13(/-/:/:/:/: 58885358 | cervical cancer | down | unR opa and -‘Ms inhib-f cervical cancer ceii :piol£foration:andinvastoii:·:·:·:·: bv taioetmg niTOK signaling patitway. |
!0Κ- 8/8583/3/3/ | /):38838/833())/5/))): | 83/38/) | MuwRNA-s^t a t»' ci suppressor of ovarian <a<\vr mroating cell» tba· /)G(g338^^i)))))))))))))))))) | mir- 224 | breast cancer | up | MicroRMA-224 targets RK1/P to control ceil invasion and expression of metastasis genes in human breast cancer cells. | mu- 58885858 | ^erv ma: /)88853335358585) | down | /)98:08:833593/98393585858 carcmumu cN! pm-Bierotiun by targeting'FRB3? |
ί
WO 2017/132552
PCT/US2017/015417
ZitiuExZx: BBlil; | Unregulated miR-J 55 m EOiji^M'B'BlZZEEEE Chrcinoma Promotes ZYdhiShi^^ Targeting aPC and Aetii atrog λ\ nt/beraCaiotun Signaling | mir- 224 | cervical cancer | up | Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. | NhtGEE dOdd; | E^bObdbfEEEE EddOfEEEEEEE | llll | miRNAs in esophageal 4iMhEebassheiEEEEEE4E | ||
4buiE:EE; iiin | :;proOIBk^i:EE:E: | 1111 | A stiidy of motec nlar signals deregulating mismatch repair gene» in prostate eattoef compared to /:BkO:ffeOfeEEEEEEEE: Zibp^ldSrefEEEEEEEEEE:: | mir- 224 | colorectal cancer | up | Up-regulation of miR-224 promotes cancer cell proliferation and invasion and predicts relapse of colorectal cancer. | ZmlAEE BB^I | :ylihig:$dhpiiEy:y:y:;: | ddbkihE | nncroRNA-PVb pels as a tumor suppressor in tiousioft'd oellbrng vftoeerbv dteetily iargototg bhrobiasf gm u th factor recopto 15. |
xitifcE:::::::: ZiBlII | tecral cancer | zOll | The qaftotitatire analysis by stem-loop real-time PCx revealed the mreioRNAMa. ipacroRNA-t>5 and roictoBNAMdbc ox ere xpreesmn in human colorectal cancer. | mir- 224 | colorectal cancer | up | Mciecularbioinarkers and classification models in the evaluation of the prognosis of colorectal cancer. | ZinifEx? Ζ|Ϋ|:| | h-ceB lymphoma | ;0|:| | MiciORNA miR-P-SprS overomressed in pancreatic cpruen ass'\ dted w r> h a Puni oroenreu mA mvobedre •ai’vprocll prubieraiiuit and invasion |
:Etf3:fS:E:E::: B;5l|| | Z^^^safeelltEEE:: earewoma | B||E | nuPNA profiting lor Near -cfem dl care imrea biomarbor dlsoovery and identification of potential witivls and coriscqacp.ve; | mir- | colorectal cancer | down | MicroRNA-224 suppresses colorectal cancer cell migration hy targeting Cdc42. | dfeifyyy: e|;eee | breast varemoma | IIeez | όΜΐθ3Υ^Β?έΕΕΕΕΕΕ::Ε angiogenesis and metastasis by largstmgLzkTS’. |
4buiE:EE; iiin | ESdbdbDbSEEEZE E^iu^^EEEEEEZ | |||| | Uiiiqne MicroRNA, Expression rrefdet; tri | mir- 224 | colorectal cancer | up | The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. | ZmlAEE ;;;ill;| | colorectal ^amet | llll | MietpRNA expression proidhtg of exfoliated eoionoro us isolated from feces for colorectal cancer |
:Etf3:fS:E:E::: | gastric cancer | ZdptehZ | IV ektneal stgiuiresmre ol dPivrrcgnlatioovf ms r- 124?p. mir-146a-5p, roir-155-5p and mir-dk'-Sp rn gastric cancer Zfbi^OhbiteSreEiEEEEEEEE:: | mir- 224 | colorectal cancer | up | mi.croRNA-224 Promotes Cell Proliferation and Tumor Growth in Human Colorectal Cancer by Repressing PHLPPl and PHLPP2. | dfeiAdd: C|:|:|: | esophageal E^dhiOkBlEE: camiooeoft | IIeez | |
:::bury:::::::::: eB^eez | breast cancer | down | :MiR:-i$aisuf!dere^pressod·:·:· and inhibit» the evil ro Ά bv targeting CYME! m dbteblEiirkdtEEEEE | mir- 224 | gastric cancer | up | Effect of antisense miR-224 on gastric cancer cell proliferation arid apoptosis]. | ymiryEd ;;;ill;| | :yiihig:$dhpiiEy:y:y:;: | llll | EMfoipRNAdidREf A:$p:iS::EE: overexpressed In pancreatic, caauets. a seriated w rth a BB^fo^i^ill^dEEEEEE involved in cancer cell proliferation and ire asiyn |
xfoteEX:::::: ZiBlII | •.mufti oaremuina | down | MiR E ka and milt A f. induce autophagy and «.ti ui e «4 er rosci no 11 of Catnplotitecdn | mir- 224 | glioma | Up | Upregulation of microRNA-224 confers a poor prognosis in glioma patients. | ZbiitE:::::: Ζ|Ϋ|:| | EhbigE^^EEEE | |·Ι|| | A pubxiarromc mreroRNA Ον C' expressed w Irumpn EbbBWhfefoii^EEEEEEEE |
:::bury:::::::::: B^lll | X:tihfoiuiX:X:X:X:X:X:X:X:X | down | Aberrant mreroRNA expression in Chinese p4K.lt« .ubJllvilc JvmnfeocvtK len-remis. | mir- 224 | hepato-cellular carcinoma | up | Transcriptional regulation of miR-224 upregulated inhuman HCCs by NF?B inflammatory pathways. | ymiryEd d|l|:| | :yiihig:$dhpiiEy:y:y:;: | llll | Apoptosis htductiyn by prrtisense oliaontjcleotidos ZUktob^EiOl^lfeABEEEE: miR-Miw, limp •'«reere ovete’.pressing mtR- 17--92 |
182
WO 2017/132552
PCT/US2017/015417
:86τ66-:88888 64046/6 | ///6h86m6////////////////////////////////// i> utpbocy he ;2feitk62i2i424222222222222i | 6/44686:2 | ///^0^606406464/4////// proee zsiito conuthnt z to do wnmguiaticm of MiR:/:/|/5/40:ΐ61/6ΐ1ΐ/66ί6/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: b roph,X} in; feukenus | tuir- 224 | hepato-cellular carcinoma | up | Androgen pathway stimulates microRNA-216a transcriptionto suppress the tumor suppressor in lung cancer-1 gene in early hepato c arc iuo genesis. | :26468222/ 6446464 | //26868866/666/////////////////// h mphoma | 40464 | The wihNA-iV' G duarcr mediates eheumresiste.nee and enhances tumor growth in mantle cell 1} mpi-oma > to PT x, ALT pafhw ro /8:66886666882:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
/ΝύΒ^:/:/:/:/:/ | /22112624222:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: 2:^/6616422:46////////////////////// /2i6626O8:22222222222222/ | .Jfinft | Burna microRNA genes pre Requeu'd} located at fragile sites and genomic regrons involved u> vaaeecs | 224 | hepato-cellular carcinoma | up | MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. | :264628222/ 4444646 | osteosarcoma | 4444444 | Upregulation of mrcroRN 5 P Ά duster associates w rth tumor progression arxf prognosis ::::ΐ6:6δ266366ό886&:::::/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
mu- 64046/6 | doom.. i> ropboc? ye 2:fe2xk2ii642:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | :2/64266/2 | 2//6aR425266d//68Pil4464ll46///// upoptosis hv targetyjg 4ΟΟ2222222222222222222222222222/ | tuir- 224 | hepato-cellular carcinoma | up | tniR-224 promotes cell migration and invasion by modulating p-PAK.4 and MMP-9 via targeting HOXD10 in human, hepatocellular carcinoma. | mu- 6/0464 | b-eelJ lymphoma | up | MicroRNA miR-l7-$pis overe\pressetf in paneroatie catteef, assoe-ated with a /8pe06/p80^b8ki822:3ii62/888:/:/:/:/:/:/:/:/: :/8rrN/6l8/6d:i6:/666668^/612/:/:/:/:/:/:/:/:/ proliferation and invasion |
/ΝύΒ^:/:/:/:/:/ | coica-ecial eoncer | dim ft | ’ftfu o/GitR 19$ cyrrcdates with lymph node metustaois and pv-n progonvtiWi coivigviat .;·.·η·.ι .· | 224 | hepato-cellular carcinoma | up | MicroRNA-224 upregulation and AKT activation synergisticallv predict, poor prognosis inpatients with hepatocellular carcinoma. | :264628222/ 44488/4/4/ | breast carcinoma | 4444444 | MjR-<G enhances ::ang!»gene£4s:andmetaatas6·:·:· 8864448θ444Αί4ί628/8///////////////// |
»!«- 64046/6 | esophageal cancer | /64S646/ | DiSercndal expression of nuRNAzin esopbao'i! 2486664404622222222222222222222/ | tuir- 224 | hepato-cellular carcinoma | up | Serum microRN A characterization identities miR8H5-5p as a potential marker for detecting liver pathologies. | mu- 2/844/4////// | troloroclal cancer | up | MuroRNA exptessron profiimg of exfoliated toiooo. y to, ixdntetf iron, feces for colorectal cancer //82662662662:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ |
:/:/6i8f5/:/:/:/:/: 64046/6 | ///6i6g/e86641:/:/:/:/:/:/:/:/:/:/:/:/ | duWO | 1 ftstoite deacon-la as inhibitor triehestatin A fncipases the expression of DfeozOuR-fNMM via /2/i4bO446/66448O/i244^:2222 :/:4488:646664:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | mir- 224 | meningioma | up | MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma. | :/:/16815:/:/:/:/ 6844/4/4// | esophageal squamous cell 8864648666:26/888882888: | 441/444 | |
mu- /1044/4/6/ | /266426262^28266////////////// | /11/6 | miR-15aNv-l enhances /266ίί64ίί166ΐ^6/44ι82^11111111: dtiferotuiation ofleukenuc cebs nod ts op-regulated h> $^46144644?$:$:$:$:$:$:$:$:$$:: | tuir- 224 | non-small cell lung cancer | down | Decreased microRNA-224 and its clinical significance in nonsmall cell lung cancer patients. | mu- 6844/4/4// | /8/i468666i6/668/8888888 | 4446/64 | ApohuaiKMJk mtcioRNA /868668662/6/^8658682:26/////////////////// ox ere\pros*ed wi human lung cancers and enhances ::::26ίί:Ρΐ6:6ί6ί6626085:5:5:5:5::::::::::: |
:/:/^226/:/:/:/:/: 64046/6 | //:/66416162482616612222222 | 4/4446/6/ | MroroRNA-ioa promotes rteurohtestoma nugratien by fa-genug levysrou Ηύΐί,Βκ tst'iHa π 1 protein oith Razed neritf* Klj and regtilntrop fttfhv Otetallnprotetijnse V $62466$8ί616:$:$:$:$:$:$:$::::::::::::::::: | mir- 224 | prostate cancer | down | MicroRNA-224 inhibits progression of human, prostate cancer by downregulating TR1B1. | :/:/16815:/:/:/:/ 68444/4// | ////6866/646066///////////////// | 441/444 | Apoptosis mducuon by onusense ohgontteleouries against miR-l?-5p and nuR-20a in lung cancers ov ereyptessmg mrK 17-02 |
:/:/62226/:/:/:/:/: 64046/6 | yoiwsumll cel! hang 6/66664642222222621111111 | duWO | MicroRNA-ioa induces cell apoptosis and inhibits metastasis by targeting BCL2L2 «ί non-small sell /2/146^6/646462222222222222222222222 | mir- 224 | prostate cancer | down | Tumour-suppressive mrcroRNA224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. | :/:/16815:/:/:/:/ 68444/4// | ////6866/646066///////////////// | 441/444 | MicroRNA miPN“Apig overevpressed in pancreatic car wen w\ Uted w n h a poor prognosis., and rrtvolveef tn uuicerceh prohietanuii and invasion |
183
WO 2017/132552
PCT/US2017/015417
(:85535:((((: :(9/95858 | panereatie cancer | 3/8//( | J>5 sregnladnu of rniR-l 5a and rtuR - 214 :n human pancreatic career. | mir- 224 | prostate cancer | down | MicroR.NA-224 and its target CAM3sK2 synergistically Influence tumor progression and patient prognosis in prostate cancer. | (:/588(((( :(9//222 | 8////5/8/582885( h tuphoma | 8////8 | The md'NA-17' >2 flustuf nxdtates cbomoresistance and enhances tumor growth hi mantle cell b mpi-oma . m PT x ALT pathw to ((59385559/((((((((((((((((((((((((: |
ΜύίΒ:::::::::: 505555 | pancreatic canctr | 3//5888 | Dysfegulattoit bf faiR -15a arud f;5R-2;4 in humari ((505/95/5:59595/(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | 224- 5p | ovarian cancer | up | Expression of reiR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma. | :::£ϊί£:;::::::: 255/222 | osteosarcoma | :(5/9((((( | TipregulaiiOG «f mreroRN k P 'C cluster associates w rtb tumor progression and prognosis ::::i5:S5teSSafc/5&::::::::::::::::::::::::::::::::: |
inu- 59/95858 | (:25555/5/89///585/222( adeim-carcinoroa | 8/8/8(: | (:(5/R28/5O5/88i555/((((((((((( pmuicnvteo and epithelial ta taesench> real y-anstyon 8:55:0552/90:9528/9(((((((((:2: adenocarcinoma bj down- (5900//5:^/528(((((((((((:(((( | mir- 2278 | chronic myelogenous leukemia | down | Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted !,miR-2278!' as a tumor suppressor for regain of chemotherapeutic rmatimb response due to target! | mu- (:95/((((: | b-cell lyrnpboina | up | MicroRNA nnR-i-?pl& overeypressetf in pancreatic canker, associated with a (5ρ$ό£ρ//92/8/(55/:(((((((((((: 3:5535/8/ 35(5355585:585(((((((( proliferation and invasion |
(:38355:5:5: 8(8/8(((((( | (/855/88:8/8/5/58288 | down | Downregulation of rniR221, -Rki and-f5a «.mureur'« o-pa imon'«t, of prostata eancat by (:(33(f9ta85^(fe:55(-I(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | rnir- 23a | bladder cancer | up | Micro-RNA profiling in kidney and bladder cancers. | 585955(5 50858 | vbreastcartanctma:·:· | 50555 | ((MiR(-93(585i558558((((((((((((( angtogenesrs and meia^taois b\ tarcnmpl AiS' |
(:/5/(:::::::::: 2://52222 | :(90/895/2((((((((((((: ((0058/222222222 | :(:995//(:( | tr<8M5a and ttuR^fa are implicated m <ell uv^lc 555/08/595:/:0(((((((((((((: dependent manner and are frequently deleted yr downregulated in non-small cell (:/585:5550(((((((((((((((((((((: | reir- 23a | breast cancer | up | c-MYf regulated nuR-23a~242~27a cluster promotes mammary carcinoma ceii invasion and hepatic metastasis by targeting Sprouty2. | ifelN:::::::: 59//588 | colorectai cancer | (999(((((( | MicmRNA expression :(9/88//8/9/8///8/((((((((( cotottooytes isolated from feces for colorectal cancer 8/888558//5858582858585858: |
ιηιι- 88//5858 | ((9/89259((((((((((((((((( h, inpboey he ((0/5/52222222222 | 8/8/8(: | (:22/1/8/8/8(/89/8889/8/588: apoptosis b> iargatuig 2/052222222222222222222; | mir- 23a | colon carcinoma | up | [Expression and clinical significance of miR-23a and metastasis suppressor I in colon carcinoma]. | mu- (:95/((((: | ((5959//59558:8(:8(( ξψΚηϊΙυΠ,υΟΰ 88//8/8//(((((((((( | 5/95585 | |
uur- 508585 | (:(:£5r5855(((((((((((((((((((((((((((((((((( hmphncyttc 5/30//5((((((((((((((( | (:(:5952/(( | (;De5/;ti5e:/Mi5SHA:((((((((((: processing contributes to downregulation of MbR- ((£5/555(885 ¢585855((((((((((((((( bropltoovric tenUuna | mir- 23a | colorectal cancer | up | •Circulating Exo so mul microRNAs as Biomarkers of Colon Cancer. | :::885rk:::::: 59//588 | ((52/5:8/8/9/(((((((( | 85/(((((: | MicroRNA ubR-1 ?-3p is ox ere\pres>ed rn pancreatic cancer associated with a 8p555///5/i/58i/88333333338 involved in eanceroefl oreittetatren andimnstuii |
ΙΪΡι/Ι::::::·: /£//2/22 | colorectal cancer | down | Downregulation of rniR105 correlates whit i> mp3 node metastasis and poor prognosis in colorectal cancer | rnir- 23a | gastric adenocarcinoma | up | MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MCrC803 and downreguiates interleutdn-6 recentor. | 585955(5 22//882 | 8//888 | A polycistronic microRNA ((¢855//8/^88:^1895(((((((((: overckpresseri m banian inng oancere and enhances | |
!Uir- 508585 | (((5885551(((((((((((((((((( | 2:5952/(:( | (;μ8ϊ/8/8(58/:92//89/2(((((((( reJuc gituinacN! ireaaun and angiogenesis vto NRR- 25(539:0^92222222222222 | mir- 23a | gastric adenocarcinoma | up | miR-23a targets interferon regulatory factor I and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. | mn- 895/888 | ((52/5:8/8/92:8(:8(:8: | up | Apoptosis indtKituii to tonmense rthoouxlemtdn, against rn.tR- iMp and rinP,-20a in long vanceis overexpresshig miR.-17-92 |
184
WO 2017/132552
PCT/US2017/015417
:):)t9u4):):):): ((()70(7(7((( | ;(7OiO77i9i;(;(;(;(;(;(;(;(;( (;(27(f7i4)i:(7;(;(;(;(;(;(;(;(;(;(;(;(;(; | 3;d977;(; | ;;;ϋ9772έ7ί2ίθ7;37:(;(;(;(;(;(;(;(;(;(;(;(;( tt9crbRNA-J<h by hepatitis 5)4))97844)98739045)22222222222 ifepatoeeilular oareinpraa 2;pr7i(ii97i77i2(727(222222222222222; iuvosx brausfera&e 2- ;(;(ΰίθ9^(;0^9;ΐΐ(;(;(;(;(;(;(;(;(;(;(;(;(;(;(; cxpresUon | nsir- 23a | gastric cancer | up | MiR-23a in Amplified I9pi3.i3 foci Targets Metaltothionein 2A and Promotes Growth in Gastric Cancer Cells. | 2;7u7(;(;(;(; :2)^7(:(:()()( | )()(473394981(1()()()()()()()()()( !y mphotna | (07(7(7 | The t.uhNA-17'4 duaivf mediates chemoresistance and enhances i.umor growth in rnantie call ly rnpiraina . ra PT tv ALT pafTw uy )()(3733893reh()()()()()()()()()()()()()()()()()()()()()()()()( |
mu- 77^^777777 | :»!WO:m.er | 7d977;(; | Hiatune dcaceti bras inhibitor trieboiratin A increases the expression of Diei^j9«iR-J5a/id-i via HDAC3 in non-small call 77i2O77O7;7;7222222222222222 | nsir- 23a | gastric cancer | up | Upregulation of mieroRNA23a/b promotes tumor progression and confers poor prognosis in patients with gastric: cancer. | mu- :2;^7(;(:(;(;( | oateorarcorna | up | )()(!)j^^i3btid44f)()()()()()()()()()()()()()()()()( miereRMA-1742 cluster associates with tumor progression and prognosis :):)37)054όδύ£ό779ί·):):):):):):):):):):):):):):):):) |
77947:7:7 (((07(7(7 | 77®7gti3f7;7;7;7;7;7;7;7 );(2ite(i977227;(;(;(;(;(;(;(;(;(;(;(;(;(; | (707(7( | MictoKNA -l$fc represeraa ^anindepeudetocpfognosfie·:·:·:· pararoetci and 1* vnuebtcd 2;(7(h7(h2(702(99722222222222222222; proliferation and apopto>i> to malignant inebooioa | 23a | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPE!4 IE,3. | ))794)))): 7(0)(7()( | b-cell lymphoma | ((0(7(222 | MicroRNA roiR-l?-?p is pverexpressefi rn pancreatic cancer, associated with a poor prognosis, and motiedra car. er«.9! prehDrafreu and invasion |
):)994):):):):):) 7707(7777; | )9447341879299))))))) | ((((7^((((((((((( | tt9R-l5a/'iM enhances retiootc aonl-mediated differentiation of feuhetoic cells and is up-regulated by 777279277έ7ί2;7;7;7;7;7;722222222 | mir- | glioma | up | Targeting microRNA-23a to inhibit glioma cell invasion via HOXDIO. | ))7514)))): 22472)2(2) | breast varcmoma | 70)))()()() | Miprat «uhanvos angiogenesis and metastasis by targeting Lz\TS2. |
)599433333) 7(07777 | to og-re cancer | Jon n | MtR-?9fc andtrnR-lNa regulate vbei'to'iierapy (;(«}36Ϊ^έ^;(^!3^ώΪ!^ί3(:(:(:(:(:(:(:(:(:(:(:(:(:( mcranchyifial transition in bnutan tongue cancer cetis cf^ciargsttoR :87912)))))))))))))) | 23a | hepato-cellular carcinoma | up | Stat3-mediated activation of miR-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregutating G6PC and PGCi? | ))794))): 7;O77(;( | colorectal cancer | ((0(7(222 | MicroRNA expression profiling of exfoliated rolunocytes irabted from, feces for colorectal cancer )()(39(t898i9g)()()()()()()()()()()()()()()()()()()()()()()()()( |
»94 fo | bfatfder cancer | )5899(4)) | MteroRVA-lb inhibits ()(Bbd904C989e(i()()()()()()()()()()()()()()()()()( Proliferation by Targeting 7^O07;7;722222222222222222 | mir- 23a | laryngeal cancer | up | High mrcroRNA-23a expression m latyngeai squamous celt carcinoma is associated with poor natient prognosis. | ):)7514):))): ()(0(7(7( | esophagea! )()(3075999(981(1()()()()()( earetocroa | 70)))()()() | |
749(7)3(77) | ):7is^t;99897i(;))))))))): | down | Downregulation of the tuinor-Sappresscr GifR-16 27(77 7i8^ri07bO728ti(222;(22;(; onco-genu Mgtiafing contrihuiea to breast cancer 7θ8θ7ώί222222222222222;722222 | mir- 23a | nenro-bbstoma | up | M)icroRNA-23a promotes neuroblastoma ceil metastasis by targeting CDH1. | ):9984):)) (70777 | )):i(t(t8g:98h8b4)))))))): | ()(^((((((((((( | A pubrasitoGic mreroRVA )(7ύ7ί97))89^2)77·2772:752))))))))))))))) 0\ e· expressed m Imuran lung cancera and enhances ()()7(7fi)({9^i(ifejr)7E77(r3()()()()()()()()()()()()()()()() |
)5)994)17)))) | :;)72s9$2;$s7c;7i)))))))))): | ):797)7:2 | (2θθ7ρθί77;97(;(;(;(;(;(;(;(;(;(;(;(;(;( iracroENA-lb declines (29όί07Ο2>77722(22222222222222 pnahfciat-btt ate: todures apyptesis in Iranian bieast 279737):783272222222222222222222222 | mir- 23a | osteo-sarcoma | down | miR-23a suppresses proliferation of osteosarcoma cells by targeting SAd'Es 3. | )))7933))):) 70(7(7) | ))(l(i37g(i33i73s3()()()()()()()()( | (0(7(7((( | Apoptosis induction by antisense obgonaUeondes against uuE-l ’-‘ψ and 358ii)fe774b9937g)098c8rf5):):):):):): 0\e· exptessing reiR 12-42 |
):77931722 | cervical caGtiootoa | 32397¾) | ;)7O2)f;53:71t787.0)f;92222222222 ;(;2ii7(t7;790i^5O773t555:222222 ::eu'Tianoe:<benioranattb:it>·:·:·:·:·: ;(;tif(7h(i97^5b7O22(222222222222; | 23a | osteo-sarcoma | down | MLR-23a Functions as a Tumor Suppressor in Osteosarcoma. | ))793)-)))): 70)7(7( | ))i)9ng)0ai5C0r))))))))) | (0(777; | MicroRNA r.iiR-l?-?p is Overexptpssetl m pancreatic )()(ίί^97)8^8έΐ7Ϊ8Ϊί()7337)7()()()()()( )()·3999^397ί9772)3ι79)()()()()()()()()()()()() moherirt. car. er«.9! prehDrafreu and invasion |
185
WO 2017/132552
PCT/US2017/015417
/38598/9/2( | 229 8 59 89/2222222222222222( ί> ropbocy ηο //tei3333/////://///////( | 2233332: | 2:80559308022222222222 proce zsttic conrohnt* z to tip woregulation of MiR(/((1(7/4(3115 35737(/:///////////// h mphyv? tic fedkious | mir- 23a | prostate cancer | down | Downregulation of microRNA. 23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway. | :/37/////( 22955(2222 | (2(358599(9855222222222 R tnphoma | (25822222( | The nuhNA-lV' 3 Nuswr •mediates ehemoresistanee and enhances tumor growth in mantle cell h mpiromy . iu R x, ALT pafhw uy (/753737(////////////////////:(:(:(: |
(:(7t7lti(((( | /97717////////////////// myelogenona /28855583222222222222222 | doun | ApoptomtRs expros sioo modulaleti by BCR-ASL is talked B t MLprogiessmu and imannih resistance | 23b | bladder cancer | up | Micro- RNA. profiling in kidney and bladder cancels. | ::77-:::-: 225982222: | osteosarcoma | 2(5592//// | Tiproguiatioo «f navfoRN A P '3 cluster associates w iti- tumor progression -and prognosis (:(:8:θδ3θδί7787(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: |
2(5883922 | cnlorectal cancer | 2233392: | Association of microRNA (232738888299822222222222222222 ftikrosaiolltte· instability (((381398393338-:(////////////: (2988888883838/222222222222222 | mir- 23b | bladder cancer | down | MicioRNA-23b functions as a tumor suppressor by regulating Zebl in bladder cancer. | mu- (288(2222 | b-ceti lytnpbnina | up | MicroRNA mfR-l-?pi& overeypressetf in pancreatic cancer, associated with a (((ροό57335877/:3ί8(((((((((((((((((((((((( (((783893(3/((715/83(915(/(/(/(/(/(/(/(/( proliferation anti invasion |
:/75838// | coiofectal cancer | doun | bA«n mro rooi criAtR 105cyrreiaies uith lymph node metastasis and pv-n prognosis in eok.reuaJ -;-.·η.ι ·· | 23b | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPEI4IE3. | (:(77(-(:(:(:(: 2138222(2 | breast caremoma | 2(559 22222: | MiR-03 enham.es ::angmgenesis:and-metastasis:·:· 288/5853858888338222222222222 |
2(5883922 | colorectai caneer | 2233392: | microRNA-fb represses «.Nurwdvnt 2(85585828(85553:55922222222222222 regulating the pS/Nstroiiin signaling patitwav | mir- 23b | gastric cancer | up | Upregulation of microRNA2.3a/b promotes tumor progression and confers poor prognosis in patients with gastric: cancer. | mu- (288(2222 | colorectal cancer | up | Mu mRNA eyptession profiting of exfoliated ί,οίηηο. y fe, txdatetf iron, feces for colorectal cancer (((738571g/((((((((((((((((((((((((((((((((((((/(/(/(/(/(/( |
/:35833// | <o!oreetai ^ancer | down | Pmuna·* MouikPUvoi MicroRNA -lo Expression (295^0880989188(8888888888 /:53793//////////////////////://// | tnir- 23b | gastric cancer | down | The reciprocal regulation loop of Notch? pathway and tniR -23b in controlling gastric carcinogenesis. | (/585/(///: 2t;a | esophageal squamous cell 229885935832222222222 | (25822222( | |
:(((7ΐ8ί8(/: | esophageal (28855:855885(5:88///////// 2295855355 8 2222222222222( | 229822222 | Expression of naeroRNAs •MnaquanioupxyEyurcineina:·:· of human head and neck arid the esopbaeus unR- 2898(8955(853/35(833222222222222 (((7®99n(5i383338///////////: HNSCC and EEOC | 23b | glioma | down | miRNA expression profiling in migrating glioblastoma ceils: regulation of cell migration and invasion by miR-23b via targeting of Eyk2. | (:(77(-(:(:(:(: 2138222(2 | ((((h7g(0a7/7////////: | 2(559 22222: | MicroRNA roiR-J?-?p is Civerexpmsseti m pancreatic cancer, associated with a /393888998898888 958888888888888 mokedtn ten etvti! proliferation and invasion. |
/35888// | /389988//////////////////( | down | MicroRNA-i6 inhibits glioma ceil gro u dt and (29988988853999(222222222222222 suppression of SCL2 ami (2883(93958833858922222222222222 >'£ J7MMP9 signaling pathw.i·. | tnir- 23b | ovarian cancer | up | MicroRNAs overexpressed in ovarian ALDHJ -positive ceils are associated with chernoresistance. | (/855/(///: 2t;a | (/9858(888835(//////// | (25822222( | A puRmstroroc muroRNA /25873823588582892/13/222222222 0\ e· expressed «· irumun (2/19983888332938/337789222( (29855/359 8 8 88559 32222222222222222 |
uur- ίυ | 2(98093(737222888888 Squcunvu z v?!l (/(339338///////////:// | 228 822222 | Bxpres&ion of microRNAs in SqKarnvKz vNd oarcinvina of In-man head and oeek you thy esophagus naR2ti5 ami iniR-21 am specific markers for /338333/838(9939/(///////////: | mir- 25b | prostate cancer | down | nuR-23b represses protooncogene Src kinase and functions as methylationsilenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. | nm- 2(33822222 | 22888:885559522222222: | np | Apoptosis mdtuavri bv uUnnense *itootakJeouJe, against rotR- P-5p and naP,-2t)u m long vanceis oveiexpresshig unR- P-90 |
186
WO 2017/132552
PCT/US2017/015417
25522244 | /452223/522213/4444444/ 2345322534444444444444/ | :4/62524 | < ireulamig mictoRi JAs at, ///2663622626226444444444444444444 JiepsiOceUulaf carcinoma. | mir- | breast cancer | up | Association between mir-24 and mir-378 in formalin-fixed paraffin-embedded. tissues of breast cancer. | ////522/////// 4522/4444 | 44022/225444444444 re tupboma | 22542/2/ | The miRNA-17' D charer •mediates ehcmoresistauee and enhances tumor gfowffc hi mantle cell b mpi-ouia . fU Ρτ x, ALT palhw uy ///jR/twhtmte//////////////////////////////////////////////// |
///ουη-ίο/:/:/ | hepatc-eelntiar 636332662:4444444444444 | dim it | Expression of serum intR////i/ti6i6i::624/2i63:5iR-:/2/i///i/h/////////// patrenrc v nit hcpaiocelfelat earctnoma and thewchmeai sct-iV.-jt:.. ox | 24 | breast carcinoma | up | MicroRNA. iniR-24 Enhances Tumor Invasion and Metastasis by Targeting PTRM9 and PTPRF to Promote EGF Signaling. | /:/mir/-/:/:/:/: //162/4444 | osteosarcoma | 4/22/66666 | 'Upregulaiioo of mrereRN v P 'D tlustei associates w ith tumor progression and prognosis /:/:5:o5^OSafi5h&:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
4536354 | san ureal 2345 5 2 2 5 34444444444444/ | /6654444 | 4/553225022/5253/44444444/ rv\m and promotes ceil inoiiiib in human iaryitgeal carcinoma cell nan MEp·’. | mir- | gastric cancer | down | Tumor suppressor mrR-24 restrains gastric cancer progression, by downregulating RegIV. | mu- 2222/4444 | b-cell lymphoma | up | MicroRNA miR-l-$pi& ovurexpressed in paaurearte cancer, associated with a 3/ρο·5ρ2532·5ΐ2/·5η3///////////////////////// //:/ΐ;5ίίθ5^1/ί3//(^3έ5/έ$ίί///////////////// proliferation and invasion |
///ουη-ίο/:/:/ | 6:&3£Ρ4$5564444:6:6:6 6363662662:4444444444444 | dim it | Quercetin Decreases ///5ί26366/·2/Β6266352444444444 Mediated b\ Dp Regulation ni irreroRNA nuR-lo in Lung Adenocarcinoma /:/Α232/ύϊ!:ίδ/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | 24 | glioma | up | ///533//////// /12542/// | breast catcwtoma | 4/22/66666 | MiR-<*3 enharees ::ang!»genesis:andmetastesis:·:· /622/535322/2325266666666666/ | |
mir-to | rtun-attail rel! haw 6:25262:44444444444444444/ | /:/:3636/:/ | Downregulation of miRDb promotes grow th and motdiix by targei-mg NOGF ///5626626366/6266/63 6 2444444444 ///is/fkiei/seiB//////////////////////////////////////////// | mir- 24 | hepato-cellular carcinoma | up | ’,ficroRNA-24 Modulates Aflatoxin BI -R elated Hepatocellular Carcinoma Prognosis and Tumoagenesis. | ///3666/////// a2a | colorectal cancer | /622/66666 | MrcmFNA expre? aon /4235222/2522222523666666666/ enhonocy tes isolated from feces for colorectal cancer //Siteim/ite////////////////////////////////////////////////// |
///ουη-ίο/:/:/ | 05te0-5steoma | dim it | Mtcro/RNA signatures associate p rib pathogenesis aud progression of | 24 | hepato-cellular carcinoma | up | miR-24 promotes the proliferation and invasion of HCC cells by targeting S0X7. | ///533//////// /1626666/ | esophageal 2/3235232/22244444/ 4422325524444444444 | 4/22/66666 | |
/433264225266244444444 | down | reiR-lii inhibits cell probfctaiionhx targeting ///53265/6itri/i&3/26f5//////////////////// MEK ID-ERkhD. parity as in.esteesamoma | mir- 24 | laryngeal squamous cell carcinoma | down | miR-24 functions as a tumor suppressor in Hep2 laiyngeal carcinoma cells partly through down-regulation of the S3 00A8 protein. | ///2ηΕ$/8/ 6/625//////// | ylhiigtepnc/ei:/:/:/:/:/:/:/:/:/ | 42566666 | A polycistronic rnicroRNA /232552//53353235666666666/ overexpressed inhuman bmg cancers and enhances :/:/c32/25i:i5tet5h:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | |
nuf-iB | purexeattc dreral atfeno-t'areinonta | /:/:3656/:/ | hixroRNAs Targeting ffepogenes Are DownRegulated in/jPancreafic Malignant Transformation ////fidhfSghigh//Tnitt0/32////////////////// | mir- 24 | lung cancer | up | Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and. post-operative lung carcinoma patients. | ///235/////// a2a | 3;b5g5252;Z;Z;Z;Z;Z;Z;Z;z | 4/224/666// | Apoptosis mdrerem in u<ntrcense rtlmorareleottd<*, against mtR- i*Mp and unP,-A)o in lung vanceis oveievyresshig miR-17-92 |
///ουη-ίο/:/:/ | pandtety thxrcai /4363662662:4444444444444 | dim it | Integrated analyses of ////ή'4ί:ι/ο535/35/2/ι2.55/////////////// expression profiles in ugunrcsix e papdiarx thx raid //226656266//4444444444444444444444/ | 24 | naso-pharyngeal carcinoma | up | [Clinical significan ce of plasma miR-24 dysregulation in nasopharyngeal carcinoma]. | ///533//////// /1254444 | yi&hgZShpeefeiyi/i/i/i/i/i | 4/22/66666 | MicroRNA niiR-1 7-5p is Overexpressetl in pancreatic /20332224/232223355252/66666/ 4522223223256222666666666666 reoRedm tan erv'fi pjoltfcrshot· and imasicm |
!Uir- h. | renal ceil carcinoma | 46244444 | Deregulated mivioRNA-ie a., an ore ogeoe in renal cell ///26356666/////////////////////////////////////////////// | mir- 24 | non-small cell lung cancer | up | Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small, cell lung cancer. | mu- u?a | mantle cell lymphoma | up | IbemiRNA-f7 '^λ cluster media.es «.heirere a., rare' and enhances tub»ί gro wth in mantte cell lympfcofto \ la ΡΠίζ/ΑΚΤ pathy, ay CacirejfUure:::::::::::::::::::::::::::::::::::::::::::::::: |
187
WO 2017/132552
PCT/US2017/015417
663000$:$:$:$$$$$ 66060306666666:6: | 63306 | uiiR-J5a and uiiR-Jb are imphcatcd «1 coif w tie regulation in aRb::4epefdera:Qm«ef:aad:are:::: frequently deleted01 down regulated us ηοη-smalf cell 24023330064444444444444444444444 | mir- | non-small cell lung cancer | up | Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small ceil lung cancer. | 40304444 43304444 | osteosarcoma | 633304 | 24:ΐ6303ώ33333355555555555555552 micreRMA-17-92 cluster associates wafc tumor progression and prognosis $ΐ2ί6ό50όδύ£ό330$2$2$2$2$2:2$2$2$2 | |
623066644 603666 | 66600466666666666: b mpliocytic 63000366666666:6: | down | Defecto e DRQSKA piuces® cutnnbulcs to downregulation ni kbR44046046350036:44444444444444: kmphoqviie teukemto. | mir- 24 | oral squamous cell caremoma | up | miR-24 up-regulation in oral carcinoma: positive association from clinical and in vitro analysis | 630066 40304444 29b- :036666 | breast cancel’ | $330344 | inl-srned > onation ru miB 29 e\ore sum suoptesses breast «.ftocer progression by targeting th? mefastasis Sukteptlblllty gene kndcb |
2:20132:28282 601555552 | $00066666666666 $030303044444444444 $1003306666666664: | :4:003:4 | t«8M5 and unRti 6 induce apoptosis by targeting 4:|Ο55555555555555555555555555555 | mir- 24 | oral squamous cell carcinoma | up | Gecomewide Study of Salivary MicroRNAs for Detection of Oral Cancer. | luntu- :2ύί·ίίί$:$2$2 243904444: 1141 | breast cancer | down | inherited t anaimn to uuk* 27;i expression suppresses breast caocer progression, by targeting the oxtiastasis 6002001000060033644^ |
$6066:6$ 6233355552 | 420jjg;63h$6?4:4444444444: | Jdwft | Histone deaceiylascs inhibitor trrciioslatin A uurcases the expression of Ε)Βη?/ιηιΚ4*όν1Μ ua HDACS moon-small celt 61000303444444444444444444444: | 24 | osteo-sarcoma | down | MicrcKNA-24 inhibits osteosarcoma cell proliferation both in vitro and in vivo by targeting Ε,ΡΑΑΤ?. |
188
WO 2017/132552
PCT/US2017/015417
Table 3. Complete list of tumor suppressive raiRNAs and their relationship to cancer.
£ausro | fliilt | Euf. | asE | is® | £ausor | CsasfjNr | : &¥(k | |||||||
mir- | 8:39889:88:: | rair-127 | hepatocellular | down | maBgnaui | /55889$/ | mir-218 | gastric cancer | down | mtr-^Ah | Jm.nre | ::199035//9 | ||
83:0:3:3:: | 390189:939 | carcinoma | 3ίηήΐ3ηό3ί39$9/ | ::!9$9:9:9$9 | bmpbpvxtic | d////////////: | ||||||||
3:fibg$:M8: 80558 8880888 $08889 | liiii | leukemia | Illii | |||||||||||
9ϋΐ8880θ88ί5893939: | 39093:3:3: | mrr-127 | hepatocellular | down | 9:98.998:593939: | $5ό598583ί:8ό1ϊ:: | /590359/ | mir-218 | gastric cancer | down | nur-Ub | oudomreirial | 898999$:$ | |
carcinoma | Inna van'er | ::19:9:93939 | 9:353855555 adeotreamrop <·»:* | 1111111 | ||||||||||
9185^55 | brean w<nm· | 3:398893:3:: | rair-127- ’P | glioblastoma | down | 3:89r8j953939:9: | warm «.aocer | ::19:58558:: | mir-218 | gastric cancer | down | mtr-^Ah | gastric cancer | /199033//9 |
8fei89k£^89r888888: | 89893:8:8: | mrr-127- | osteosarcoma | down | nur-l>5-dp | 958559389885: | : down | mir-218 | gastric cancer | down | nur-Ub | beparoceBafai | ::55859:5:: | |
3p | B98:89898 | varcmnma | ::ί:$5$5$5$5 | |||||||||||
$£88559:9 | citoudiosurcoma | 899889888 | mir-1271 | gastric cancer | down | :889981:598:9:9:9:: | 88588885558889 | • down | mir-218 | gastric carreer | down | mir-3Ab | iungeaiKor | :^358898 |
$15538:9:9 | colorectal cancer | $3993939 | mir-1.2 3 | hepatocellular | down | $3953593939:9 | :53888893939 | ::1::::58595: | mir-218 | gastric cancer | down | nur-d49 | ηοη-sroall cell | • down |
carcinoma | :9035·ίύδ185$:$:$ | ti/9393939 | iungeaiKor | /1//55555: | ||||||||||
ki*“3 | $¢90389^39393939: | down | mrr-1271 | oral squamous | down | 9:939-:1:539:9393 | $oiironio$9$9$9 | ::199033:3: | mir-218 | gastrointestinal | down | twirsUb | osteosarcoma | 89do89$// |
8800008888: | cell carcinoma | b nrphoC} nt | /1958888 | stromal tumor | 5:9:////////9 | |||||||||
:/03101110 Ηίρ:///////////: | leukemia | /-://///////// | ! | |||||||||||
ki*“3 | gastnc cancer | down | mrr-128 | glroblastoma | down | 9:939-:1:539:9393 | $oiironio$9$9$9 | 8990339:: | mir-218 | glioma | down | twirsUb | $o38riah$9$9$/ | 89do89$// |
b nrphoC} nt leukemia | d///////////: | :58j88B$9$9$9 | 8888888 | |||||||||||
ki*“3 | gastrrc cancer | down | mrr-128 | glroblastoma | down | 9:939-:1:539:9393 | $oiironio$9$9$9 | ::199033/9 | mir-218 | glioma | down | twirsUb | $o38riah$9$9$/ | 89do89$// |
b nrphoC} nt leukemia | d///////////: | diSroBibh^///// | 8888888 | |||||||||||
ki*“3 | gastrrc cancer | down | mrr-128 | glroblastoma | down | 9:939-:1:539:9393 | $o&ronio$9$9$9 | ::199033/9 | mir-218 | head and neck | down | twirsUb | parrereatrc | 89do89$// |
b nrphoC} nt | squamous cell | 9ό888^8$9$9$9 | 5://////////9 | |||||||||||
$}3&emi89$9$/ | ! | carcinoma | ! | |||||||||||
k i* '·» | gastrrc cancer | down | mrr-128 | glroma | down | 9:989:1:5593939: | colorectal | ::1995339:: | mir-218 | hepatocellular | down | 99889db939 | parrereatrc | 89do99$// |
xCnHCef://///////: | carcinoma | /:08585/////////: | /!/////////:/// | |||||||||||
l·........... | ||||||||||||||
ieL-’:t | gastric carreer | :/dGWh////: | mir-128 | glioma | down | //ΐήηνίΡίύ://///// | OidhgreaUCer:///: | ! down | mir-218 | hepatocellular | down | mtt-34b | /:papBia39://///: | ! down |
5:9:9:9:9:/9 | carcinoma | $5iyi-oid9$9$9$ | ||||||||||||
varcmnma | : | |||||||||||||
ieL-’:t | gastric carreer | 8:3988988:8 | mir-128 | glioma | down | 9:355:1599:9:9:9:: | uou-sroaB octi | ::5:5885:5 | mir-218 | hepatocellular | down | mtt-34b | :::55553:5::55: | /59033//9 |
tang carreer | /!9$9$9$/9 | carcinoma | :/98885:9:9:9:9:/ | ii//9d9d9d9 | ||||||||||
91585893/ | 8g!isma88888888888· | 3:9893:8:8: | mir-128 | glioma | down | ::::hu8/138:///////: | pan^ieatic | ::1//5555//: | mir-218 | lung cancer | down | unrA-tb | /:5398555555 | • down |
:908998539993:3 | 933158553////: | /555555/ | ||||||||||||
9:1089539: | nasopharyngeal | 39893339 | mir-128 | glioma | down | 9:98.9:15393939: | pancreatic | ::59083/9 | mir-218 | lung cancer | down | mir-j-to | breast cancer | 89do89:93 |
9Ο3ίθίή8389$9$9:9$9 | 339883989898:8 ::adeu<3earcit>o·:·: $b39$9$9$9$/9 | d///////////: | i!:$9$9$9$9 | |||||||||||
31583839/ | 9399:9939 | mir-128 | glioma | down | $3955553939:9 | ;5ro5afe$9$9/$ | /ί55855;5 | mir-218 | lung squamous | down | ||||
:539£ρ&:88ί$9:9$9$9: | 9:ό88888$9$9$:$ | 89393939: | c ell carcinoma | 5:9:////////9 |
189
WO 2017/132552
PCT/US2017/015417
£$£$££ | $££$$$$$££££: | £$$£££ | mir-128 | head and neck squamous ceil carcinoma | down | ££i$£££££££ | $ sipiampii£ 7:7:7:7 £$$£$$££££:: | donn | mir-218 | malignant melanoma | down | ni«-$4v | $$£$:$£$££; | :$$$£:$$ |
pancreatic ductal •sdcr.oearcluoma | /:$$£££ | mir-128 | meningioma | down | mu-l^b | ££$£$£££££$$ b nipbckx tie $:i££k$iii£$:$:$:$:: | donn | mir-218 | nasopharyngeal cancer | down | mlr-34c | <?IU ·.. IvmphOvvtk leu! omi-.· | down | |
l£L-':l | iemdkcli $£$ί$$£:£$:$:$:$:$: | /:$$£££ | mir-128 | prostate cancer | down | mu-l^b | ££$£$£££££$$ b nipbckx ue $:i££k$iii£$:$:$:$:: | donn | mir-218 | oral cancer | down | mlr-34c | vMop. cativet | down |
breast cancer | /:$$£££ | mir-128 | prostate cancer | down | mu-l^b | :$£$$$!$:$:$:$:: $$$£$::$:$:$:$:$: | donn | mir-218 | osteosarcoma | down | m«-34c | $$dri£i£$$£$ $$$$!$:$:$:$:$:$ | down | |
$$$t£$££$£;:££££ | 3p | carcinoma | adenocarcinoma | $$£$£££:£:£: | ||||||||||
:$le£7£-l$: | colon cancer | $d0$a$$$ | inir-1280 | bladder cancer | down | //$£:$$$:$:$:$: | hepatocellular $££$t$$£$££$ | down | mir-218 | prostate cancer | down | mir-j-ie | gastric eancer | $$$££$ |
$$£$$£:: | esophageal :$$$$$£$$:$$$$ earctnotua | $dfl$£$$$ | rair-1280 | malignant melanoma | down | $$$j£h$:$:$$$ | tunc van ter | $:£$$:$ | mir-218 | prostate cancer | down | mro-idc | lung cancer | :$$££:$$ |
$$£$$$: | esophageal :$$$$$£$$:$$$$ earctnotua | $dfl$£$$$ | rair-1285 | renal cell carcinoma | down | $$$j£h$:$:$$$ | otoucvan e·· | $:£$$:$ | mir-218 | renal cell carcinoma | down | mro-idc | lung cancer | :$$££:$$ |
$$£$$$: | $£b£$cc$i$£:$:$$$ :$£$i$h$$$$$$$$$: | $dfl$£$$$ | rair-128a | medulloblasto ma | down | $$$1$$:$$$$$ | bladder cancer | $:£$$:$ | mir-218 | renal clear ceil carcinoma | down | mro-idc | :$$£$$£:$$$$ melanoma | :$$££:$$ |
:$Ιθί-$8$£/ | $$£$$$$$7:7:7:7:7 | $$$£:7:7 | mir-129 | breast cancer | down | $$$$:::$:$:$:$: | oteatl career | down | mir-219- 5p | glioblastoma | down | nyr-'-K | nasnpharyngc alcaminnnta | $£θ£$$$ |
$ί$ΐ£;0$$$$7:7$7$7: | mir-129 | coioreclai cancer | down | :$£&$:$$$$$$$$ | $£$£$$£$£$$ | down | mir-219- 5p | glioma | down | ttii -‘-ra | osteosarcoma | £$$££$ | ||
$$£?;$ί$: | $$£££$$$$$:$:$$$ | $£$$$$$ | mir-129 | glioblastoma | down | $$$££$$$$$$7 | $£$$$:$:$$$$$ $££$t$$£$£££ | $:££$$:$ | mir-2 3 95P | hepatocellular carcinoma | down | jnir-34c | osteosarcoma | dowri |
ί.'-*-! | nasopharyngeal carcinoma | down | mrr-129 | non-small cell lung cancer | down | $$$$$$$$$:7: | :$$!$$$:$$$$$$ lymphocytic $$$£$:£$:$:$:$: | :$$£'£:$: | mir-219- 5p | papillary thyroid carcinoma | down | nuw.;4c | $$£$$$$$$$$ $$$£:£:$:$:$:$: | $:£$£$$$ |
:$lo£7$l:$ | neurobiastoma | $$$$$:$ | mir-129- -.‘P | gastric cancer | down | $$$$:$:$:$:$:$ | $$$£$$:$:$:$:$$ myelogenous $$$£$:£$:$:$:$: | $:$$£:$: | mir-22 | breast cancer | down | «yr-tax | $dy£u8$$$$$$$ :$$£$£$£$:$:$: | $:do$£$:$ |
pancreatic >hutal eJentx an. moron | down | mrr-129- 2-3p | gastric cancer | down | :$$$$$$$:$:$$ | colorectal $$$$££££££ | :$$£'£:$: | mir-22 | breast cancer | down | nuw.;4c | $$$$£$:$:$$$ :$$$i$:$:$:$:$:$: | $:£$£$$$ | |
let -'>-2 | b-eas1 <»{>»;« | $$$£££ | mir-129- 3p | gastric cancer | down | $:£&$:$$$$$$$$ | $$$$$!$$$$:$: $$$£$::$:$:$:$:$: | down | mir-22 | colon cancer | down | uiir-34c | $$$$$$$$$$$ $$$$$£££££ | $$£££$ |
broi'OtnoinaJveohr $$$$££$:$:$:$:$:$:$ | $do$n$$$ | mir-129- 3p | renal cell carcinoma | down | £bii$i£:$:$$$$$ | cotnreetai $££C$££££££ | dOwri | mir-22 | colon cancer | down | jnir-34c | $$£a£$$$$$$$$ $£$£££$£$$$$ | dowri | |
1ίί*73*?. | $¢¢$££$$£$$$$::7: | down | mrr-129- 5p | gastric cancer | down | :$$$$$$$:$:$$ | colorectal $£$$£$:$:$$$$$ | :$$£'£:$: | mir-22 | color, cancer | down | nuw.:4c* | $£££$£$$:$:$$$ | $:£$£$$$ |
$$£$$$ | /£$£$$$$:$:$$$$$ $$$$££$$£££$: earcraotoa | :$$$£:$:$: | mir-129- 5p | gastric cancer | down | :$$$$$:$:$:$:$: | /$$£$:$:$:$:$$$ | donn | mir-22 | colorectal cancer | down | m«-34c- $££$$$$$$:7: | $$$$$$$$$$$$ | :$$$£:$$ |
let-’:l-2 | $$£$$$££££$:$ $$$$££$$£££$: earcraotoa | £$$£££ | mir-129- 5p | liepatoeelluiar carcinoma | down | nm-Jo | liepatoccliulaf £$$£$$£££::£: | donn | mir-22 | esophageal squamous cell carcinoma | down | mu-B'l - $££:$:$$$$$$ | non-smail cell brag cancer | down |
190
WO 2017/132552
PCT/US2017/015417
4O;W4 | hepat^veUuiar | inir-129- 5P | laryngeal squamous ceil carcinoma | ! down | 44353-354444444444 | l,euatoreeiluk»f 4534535504444444: | down | mir-22 | esophageal squamous cell carcinoma | down | 44554-3554444 3:5^3:3:3:3:3:3 | vnlorcclaJ ! 4:55544444444444444!; | down | |||
ieL-’:t-2 | 4:354454444 | iuir-129- 5P | medulla^ thyroid carcinoma | ! down | mu-ft· | lane adenocarcino ma | down | mir-22 | gastrrc cancer | down | η:η-:·Μ - 3:553:3:3:3:3:3 | gastric cancer | 3; | down | ||
ieL-’:t-2 | 4:354454444 | inir-129- 5P | ovarian cancer | ! down | mu-ft· | nou-stuaJJ cell lung earner | down | mir-22 | gastrrc cancer | down | mir-353 | head aud neck squamous cell | 3; | down | ||
ieL-’:t-2 | 4:354454444 | uiir-1291 | renal cell carcinoma | ! down | mu-ft· | osteosarcoma | down | mir-22 | gastrrc cancer | down | Η:ΰ-:·<·.· | cnlon cancel | /:; | down | ||
3(ei-5a-5;: | •MlUSOptiaryngceal:·:·:·:·:·:· 45545515:044444444 | 450455545 | mir-1294 | esophageal squamous cell carcinoma | ! down | //535/15////////// | :::p4topraigpigii:::::: | 4355454 | mir-22 | gastric cancer | down | mir-355 | Itepavx ellolai 455554555^4444: | /:; | down | |
295b-3p | cancer | ;<dirct^·:·:·:·:·:·:·:·:·:·:·:·:· adenoearcitm 415544444444444 | carcinoma | /:; | ||||||||||||
4O;W4 | pancreatic ductal adefiuearciooiua | 4:354454444 | rair-1296 | prostate cancer | ! down | 4:35i4Jb/;44444444 | 43535555444444444 3^^^1^:33333333333 ^utrcm-u. ·η | down | mir-22 | hepatocellular carcinoma | down | mir-365 | uou-sraaU cell Jana cancel | 3; | down | |
breast cancer | 4:354454444 | inir-1297 | lung adenocarcino ma | ! down | 4:35i4Jb/;44444444 | //ssibapinbn:///////; 3i^ihbihd:::3:3:3: | down | mir-22 | lung cancer | down | mir-3b>b- 355355555 | rctmoblasmm 454444444444444444 | 3; | down | ||
!;: | : bronchioloalveolar: : 45gi5ih054545454545 | 44334454444 | inir-1307 | colorectal cancer | ! down | //155435:/1//////// | 53hiphi53:3:3:333 Jv mpbocv tn, 4;i5t3<3b4i5444444 | down | mir-22 | medulloblastoma | down | 45314352444 | sas-Urc A-ance· | 3; | :35354444: | |
455455;555455444444; | 44334454444 | inir-I30a | breast cancer | ! down | //155415:/1//////// | 53hiphi53:3:3:333 Jv mpbocv tn, leukemia | down | mir-22 | osteosarcoma | down | 4;53i437&444 | 4big£iO455;55 4335455444444444 | 3; | :35554444 | ||
44555554 | 4555555345444454:45; earciuoiua | 44334454444 | inir-130a | endometrial cancer | ! down | iChai/liS/i///////: | lung cancer | down | mir-22 | osteosarcoma | down | 4;53i437&444 | 4Ιί.5ρ51555ΐΙ5ί51 caremuma | 3; | :35554444: | |
45554535454444:4545; 55045555541454:4: earciuoiua | 44334454444 | mir-130a | hepatocellular carcinoma | ! down | :4hihyi§/iy3g:45 | 53hiphi53:3:3:333 Jv mpbocv tn, leukemia | down | mir-22 | t-cell lymphoma | down | 4;53i437&444 | larv ngeal squamous cell carcinoma | :35554444: | |||
44555554 | 44g44|54b&;4;444444444 | 44334454444 | inir-130b | colorectal cancer | ! down | :4hihyi§/2/:4:4:4: | 53hiphi53:3:3:333 Jv mpbocv tn, leukemia | down | mir-220a | oral squamous cell carcinoma | down | 4;53i437&444 | 40444444444444^ squamous tell carcinoma | .-I- | :35554444: | |
44555554 | 44334454444 | inir-130b | endometrial cancer | ! down | :4hihyi§/2/:4:4:4: | 53hiphi53:3:3:333 Jv mpbocv tn, leukemia | down | mir-221 | gastrointestinal stromal tumor | down | 415314372///// | 453151331//////// 4335455444444444 | :35554444: | |||
44555554 | 44334454444 | inir-I30b | hepatocellular carcinoma | ! down | :4hihyi§/2/:4:4:4: | lung cancer | down | mir-221 | gastrointestinal stromal tumor | down | 45314372///// | ;;;|i.gpgiP45i|pJ5r; caremuma | .-I- | :35554444: | ||
yhlttgoaitoep?:?:?:?:?/ | 4^0455444 | mir-1.30b | ovarian cancer | ! down | CCBitiy/i:?:;:;:;:;:;:;:;:;:;:; | acute iUyelOid //1555^555///////// | down | mir-221 | non-snaali cell lung cancer | down | 55555:53545; | colon cancer | ::l: | down | ||
ki*“3*3 | uasophanngeaf 453ίέί55450£44444444; | down | nur-l30b | papillary thyroid carcinoma | ! down | :3:^:133:3:3:3:3: | :3Oighdgi3:3:3:3: melanoma | 3iid6ft3 | mir-221 | prostate cancer | down | nurc.:7I | norasntail ccJJ lung (. ,Wti | /:; | down | |
ki*“3*3 | ueurohlasroma | down | nur-l30b | prostate cancer | ! down | 5^5/45/53////// | hreast earner | 3iid6ft3 | mir-222 | chondrosarcoma | down | nurc.:7I | panvfpatrc 40055343434 | 3; | down |
ί
WO 2017/132552
PCT/US2017/015417
433-3/3( | pancreatic ductal adenorearrelooma | 44535444 | mir-132 | breast cancer | down | 6/4534:354:6//////// | ((¢444554:6/(((((((/ (555445/(///////////////////// | down | mir-222 | chordoma | down | ioir-3 74 a | /(375456554544/(( | :/:/5634:/:/:/: |
/(IdO?/?/; 7357/7/7/7/ | /(43453:654554:4:4:4: | 45535444 | mir-132 | colorectal cancer | down | ///:3331:7/(54:/:/:/:/:/:/ | nyn-smalicpll ((355454565////(((: | :45434:6/ | mir-222 | gastrointestinal stromal tumor | down | (//5^33735((/ | (/35343444444( /(444545/(/((((((((( | down |
/(73(33?/? | 4 u-pitoblpstk (:3(ife53uhZ(((((((((((((: | /434/33/(((( | mi.r-132 | iiver cancer | down | ((-33^13(4/4/4 | acute my eic-id (/3454545/(/((((((( | down | mir-222 | gastrointestinal stromal tumor | down | /(7336325(((6 | cervical ::s<paamo.u&:eell·:·: varetttoma | (5435/((( |
43353:((( | breast cattreer | /434/33/(((( | mi.r-132 | osteosarcoma | down | ((-33^134/4/(4 | breast cancer | down | mir-222 | glioblastoma | down | /(7336325(((7 | colorectal (/34543/(/(((((((((/ | (5435/((( |
(453/3/7/7 | breaz ...merer | /(45/5/5/:/:/:/:/ | mir-132 | osteosarcoma | down | ((45/4/1/454:/:/:/:/:/:/:/ | ((03453/((((((((((/ lymphocytic leukemia | /:/4535///// | mir-223 | acute myeloid leukemia | down | vNorx tai (24575(((((((((((( | /(5434:/:/:/: | |
(54((53(((: | breaz v .merer | /(454/5/(((( | mir-132 | pancreatic carcinoma | down | ((45/4/1:444:/:/:/:/:/:/:/ | ((03453/((((((((((/ lymphocytic leukemia | /:/4555///// | mir-223 | chrome lymphocytic leukemia | down | colorectal (24574(((((((((((( | /(5534:/:/:/: | |
(54((54/(((: | bronchioloalveolar /(4533453((((((((((((: | /(454/5/:/:/:/:/ | rair-133a | bladder cancer | down | ((45/4/1:444:/:/:/:/:/:/:/ | oastm vancrer | /:/4555///// | mir-223 | chrome lymphocytic leukemia | down | esophageal (24574(((((((((((( | /(4534:/:/:/: | |
(54((54/(((: | Cvlon cattcer | /(454/5/:/:/:/:/ | rair-133a | bladder cancer | down | ((4531/545/((((((/ | ((3343/:/:/:/:/:/:/:/:/:/:/:/ | /:/4555///// | mir-223 | endometrial cancer | down | esophageal (24574(((((((((((( | /(4534:/:/:/: | |
C:-!: | x/e^fi’W^:/:/:/:/:/:/:/:/:/:/:/ squamous ceB /(543(3433/(((((((((((( | /:/5634:/:/:/:/: | mrr-l33a | breast cancer | down | :/:/54355/45/:/:/:/:/:/:/: | nrri oquamous -.eBvatcmomu | down | mir-223 | esophageal cancer | down | 75437/(27/7/ | :::s45454544:Z7Z7Z: xptoxms trelf 'arerntthra | :/4735/:/7/ |
ic:-:: | :::ό54ρ3673Ζ?Ζ?Ζ:Ζ?Ζ?Ζ?Ζ (/4^5303:643/((((((( /(54335)53/(((((((((((( | /:/5634:/:/:/:/: | mrr-l33a | coiorectal cancer | down | ::::543454/5/5/:/:/:/:/: | /:/3353/:/:/:/:/:/:/:/:/:/7/ | down | mir-223 | hepatocellular carcinoma | down | 75437Z(?Z7Z7Z | :::s45454544:Z7Z7Z: squamous cell carcinoma | :/4735/:/7/ |
3!-:: | :::010/6:/6504/:/:/:/:/:/:/:/ | /:/5634:/:/:/:/: | mrr-l33a | coiorectal cancer | down | ::::533:4434434:/:/:/:/: | :::iiqnss535z565Z7Z ((354/4545456//////// | down | mir-223 | hepatocellular carcinoma | down | :/:5437/(7/7/7/ | :::s45454544:Z7Z7Z: xptoxms trelf •'arctn.oma | :/4735/:/7/ |
3!-:: | ::0^:/5404:/:/:/:/:/:/:/ | /:/5634:/:/:/:/: | mrr-l33a | coiorectal cancer | down | :/:/5447/^/5:4/53:/:/:/:/: | /:/3353:/:/:/:/:/:/:/:/:/7/ | down | mir-223 | hepatocellular carcinoma | down | :/:5437/(77/7/ | gastnc vap.vt't | :/4735/:/7/ |
43353/((( | gastric ear-reef | /(/3433//////// | ink-133 a | coiorectal cancer | down | 4;n«3t$/i/O7;/;/;/ | non-small cell 7345543/3//((((( | down | mir-223 | lung cancer | down | /(7336325(/((( | gastric Cancer | (5435/((( |
/(3353((4 | ?54θ6$547/3ζ((((((( Z(453i5453(((((((((((? | (:/453/5///////// | mir-1333 | colorectal cancer | down | mir-181a-5p | bepanxelhiiar /(2433323(((((((/ | (:453/5/:/:/ | mir-223 | mantle cell lymphoma | down | :/:555375/(((: | gaz« tat e·* | dowb |
ki*“b | /(335/44565)/((((((((((( | down | mrr-l33a | esophageal squamous cell carcinoma | down | /;/;n«r-/3/45/7777/ | (:3343/((((((((((: lymphocytic /:/55555555:/:/:/:/:/:/:/7/ | :/:/5444:/:/: | mir-223 | mantle ceil lymphoma | down | ttur*.:7* | gastric carxer | /:/4735/:/:/:/ |
3!-:: | /:/:53/3/5456)3////////////////////// | :/:/5634///////// | mrr-133a | esophageal squamous cell carcinoma | down | :/:/543/^/445/:/:/:/:/:/:/: | (/5575/45/(((((((((7 lymphocytic /:/55545h55?/:/?/?/?/ | :/:/5454///// | mir-223 | nasopharyngeal cancer | down | uur- '< | 755444((((((((((( | /:/4535/:/:/:/ |
3!-:: | /:/:53/3/5456)3((((((((((( | :/:/5634///////// | mrr-133a | gastric cancer | down | :/:/544354/5/:/:/:/:/:/:/: | ///54445/(((((((((((: odettocarcino ma | :/:/5454///// | mir-223 | nasopharyngeal carcinoma | down | uur- '< | head arid neck zjuauxms cell .n.mo-u;- | /:/4535/:/:/:/ |
3!-:: | 45343456/45454545 4443453544444444/ | :65434///////// | mrr-133a | gastric cancer | down | ((543/^545/((((((: | /(:54445/545354:/: | down | mir-223 | splenic marginal zone lymphoma | down | m-w- '< | bepamceBafai varemoma | /:/4535/://(: |
43354(((( | nasopharyngeal 4453344444444444: | //(3434//(((/ | mir-133a | gastric cancer | down | ////l/raill/S/fb/:/:/:/:/:/:/: | /(33436/(((((((((/ | down | mir-223 | splenic marginal zone lymphoma | down | ///7753325:/:/:/:/ | 45555354545444 7£5rei55h3c7Z7Z7Z: | //5434:6/// |
/(3353((4 | tteuroblastoma | ((4535///////// | mir-1333 | gastric cancer | down | (()331/813(((((7 | glioma | dOwtt | mir-224 | colorectal cancer | down | :/:555375/(((/ | hsytrteai /(44454344545/(/ carcinoma | dowb |
192
WO 2017/132552
PCT/US2017/015417
/(Ο·//// | pancreatic ductal arienocarciooroa | /:9/(9//:/:( | mir-133a | head and neck squamous ceii carcinoma | ! down | :(:(9ί«/Βί9:/:/:/:( | /((9/(/99//////////: | dorat | mir-224 | non-small cell lung cancer | down | mlr-3 'j | rctsopharv nge al carcinoma | (:/(/09/333: |
!CL-'b | renal cleat ceii :((//3/3/999:(:(:(:(:(:(:(:(:(:(:(:(: | /:9/(9//:/:( | mir-133a | head and neck squamous ceii carcinoma | ! down | (:(:-9«(t/-:9i?(:i:G:(:(:(:(:(:(:( | «ou-snrall cell bang carreer | dorat | mir-224 | prostate cancer | down | mirk ;· | uoiKriuail cell b.mg carreer | (:/:/09/((((((( |
!CL-'c | avtile ruvciotd :(((1////3/3/(:(:(:(:(:(:(:(:(:(:(:(:(:(: | /:9/(/(//:/:( | mir-133a | hepatocellular carcinoma | ! down | :(:(9/939/99/:/:( | /((9999//////////: | dorat | mir-224 | prostate cancer | down | mirk ;· | oral cancer | (:/:/09/((((((( |
pronnehx? n. knkemia | squamous cell carcinoma | /:(39:7/29923((((((((((( | ||||||||||||
lung cancer | myelogenous leukemia | (:(299//97(////: | ||||||||||||
(((//1/3//3//((((((((((((((((((((((((( | //39:3//9923/(/(/ | |||||||||||||
:(:te9Ic:(:(:(:( | colon cancer | :(:(209/3333: | ink-133 a | ovarian cancer | ! down | :(:(9y9l(M(9 $5p(((:(: | astrocy toma | down | mir-233 | osteosarcoma | down | ((((9192353(((((((( | pancreatic :(:/Z9/9(////////3 | ((/3d$939333 |
:((^//:/:/ | esophageal :(:S/y//5/y/(09i3(:(:(:(:(:(:(:(: :::/33/19/396:(::::::::::::::::::::::: | :(:(9/(9/(:(:(:(:( | rair-J33a | pancreatic cancer | ! down | :/9/9^19/:/:/:(: | (((g3:/99(:(:(:(:(:(:(:(:(:(:(: | 3(//3//(:(:( | mirk 3 a | prostate cancer | down | mark 75 | parereatre 3(3/99/333333333 | 3/:((1099333: |
la-V | esophageal :(:S/y/93/y/(09i3(:(:(:(:(:(:(:(: :::/33/l9/9ia:::::::::::::::::::::::(: | :(:(9/9/(:(:(:(:( | rair-J33a | renal cell carcinoma | ! down | :/9/9^19/:/:/:(: | neuroblastoma | 3(//3//(:(3 | mir-23b | biadder cancer | down | mark 75 | pancreatic ?an.nroms | ((1(((/29/333: |
la-V | (:(9/p/tf!SS!(iiii//((((((((((((((( :(:////3/999:(:(:(:(:(:(:(:(:(:(:(:(: | :(((9/9/(:(:(:(:( | rair-J33a- | prostate cancer | ! down | :/9/9^19/:/:/:(: | nnrosroaB cell bang carreer | 3(//3//(:(3 | mir-23b | gastric cancer | down | mark 75 | pancreatic (:(9/92/(:(:(:(:(:(:(:(:(:( adenooarenro 3/3933333333333333 | ((1(((/29/333: |
kikR | hepatoceilular (:(/y9:39/9ia(:(:(:(:(:(:(:(:(:(:(:(:( | down | mir-l33a- 2 | prostate cancer | ! down | (:(:/99(1(8(:1:/:(:(:(:(:(:(:( | ::(:9997(:(:(:(:(:(:(:(:(:(:(:( | :(:/99/:(:(: | mir-23b | glioma | down | (:(/2///5(:(:(:(:(: | pan^reatro :399193333333333: adynyearcino 3:(92(3333333333333: | 3/(/2(99333 |
(lilll | (:((lij(fig:0a909i:(:(:(:(:(:(:(:(:(:(:( | :(:d$99(:(:(:(:( | mir-133b | biadder cancer | down | :/99/1^//:(:(:(:(:(:(:( | giro ms | down | mir-23b | prostate cancer | down | /:3995/9////: | squaorems varcuKmia | ! down |
kikk | (:(i3i9g:/9/9//:(:(:(:(:(:(:(:(:(:(:( | down | mrr-l33b | coiorectal cancer | ! down | (:(:/99(1(8(:1:/:(:(:(:(:(:(:( | norreamailceii tong <an?er | :(:/99/:(:(: | mir-24 | gastric cancer | down | mirk 76a | chord tosareo (396(3333333333333: | 3/(/2(99333 |
!cl-'c | 2/9//999ΖΖΖΖΖΖΖΖΖΖΖ | /:9/(9//:/:( | mir-133b | esophageal squamous ceii carcinoma | ! down | rou-182 | ca-.riu adeno. u<rew.A ma | dorat | mir-24 | laiyngeal squamous ceil carcinoma | down | mirk 79a | glioblastoma | (:/:/09/((((((( |
!cl-'c | nasuplun rigeai :((//3/3/999:(:(:(:(:(:(:(:(:(:(:(:(: | /:9/(9//:/:( | mir-133b | gastric cancer | ! down | rou-182 | v: hre .. b.-vt | dorat | mir-24 | osteosarcoma | down | mirk 79a | hepatocellular carcrnoma | (:/:/09/((((((( |
(((/93/39/39/((((((((((((((((((((((((( | rueiartoroa | |||||||||||||
:(:te9Ic:(:(:(:( | neuroblastoma | :(:(/099:(:(:(:(: | mk-l33b | gastric cancer | ! down | /:-99^9/:/:/(/ | :(:(392/1(:(:(:(:(:(:(:(:(:(:(:(:(:( (:((992399/(////// | down | mir-25 | colon cancer | down | --76(. | malignant mylaitoiua | ((/332939333 |
:((^//:/:/ | noo-smali «.NI :(:(i99g($9/c//(:(:(:(:(:(:(:(:(:(:(: | :(:(9/9/(/(:(:( | rair-133b | gastric cancer | ! down | mtrGkl^p | :(:(993!(:ό9ΐ:(:(:(:(:(:(:(:(: :(:(0/93391393333333 | 3(//3//(:(3 | mir-25 | prostate cancer | down | vsrevsarcuma | 3/:((10993:33: | |
k:-c | pancreatic ductal ?dm.rxammoma | ://99(9((((((((( | mrr-l33b | rung cancer | ! down | ///997(/2//:/:/:(: | breast cancel | down | mir-26a | acute myeloid leukemia | down | nur- | o*te*>4.arcoutt« | /1(///793(/// |
193
WO 2017/132552
PCT/US2017/015417
62006504 | prostate cancer | 553303555; | mir-133b | prostate cancer | down | 443301323446555: | Sidney cancer | ;:5533005; | mir-26a | bladder cancer | down | uitt-377 | hepatocellular caremoma | 440ό002;2;2;2 |
603000:44444: | 63603444: | endometrial cancer | down | 2300202103:232323282 | breast cancer | 2:220502024 | mir-26a | breast cancer | down | $2rghhl:$2l3a02$2$2$ 200262626266666 caremoma | down | |||
600655: | renal clear cell 66000055555555564 | 443303446 | mir-134 | hepatocellular carcinoma | down | 44h301S;3;;44444444 | gastric cancer | 0;036634; | mir-26a | breast cancer | down | $03063066 | 403000015555555; 2403330244444444444 | down |
630664 | breast cancer | 44330444: | inir-l35a | pancreatic ductal adenocareino ma | down | $08013044444444 | gastric cancer | 2:24206436222 | mir-263 | breast cancer | down | mir-j?# | colorectal 4023035324444444444: | 4:600404255 |
66000065555555564 | cancer | osteosarcoma | myelogenous leukemia | |||||||||||
6063555; | :::C0O:600606$2$2$2$2:2 | ::0p0I:i::::::: | mir-135a | renal cell carcinoma | down | :::0κί8ΐδ;3::::::::::::::::: | : xetinobla&toinq | :1:833008 | mir-26a | gastric cancer | down | ;403003044;4 | gastric cancer | down |
606066 | :40600044444444444: 48200060605044444444 ;46ΟιίώΟ444444444444: | 443303444; | inir-l35a- 5p | clear cell renal cell cancer | down | 6000046444444 | :4;3i030555555555: | 2:020626642 | mir-263 | hepatocellular carcinoma | down | mir-j?# | naSripbary ng? 6000300120000055; | 4:600402444 |
6060555 | :40600044444444444: 430350330044444444 4304400444444444444: | 443300444 | mir-l 36 | chondrosarco ma | down | 600030 44444444 | :4;3i030455555555; | 2:240660222 | mir-263 | hepatocellular carcinoma | down | mir-j?# | 00000300044444440 246300000440555 | 4:600402444 |
6060555 | 63046303034444444: 4304350643:0044444444 4300443444444444444: | 443303444; | mir-l 36 | glioblastoma | down | 600030 44444444 | 6;30iig3a0$4444; melanoma | 2:240660222 | mir-263 | hepatocellular carcinoma | down | mir-378a- | colorectal 240305044444444444; | 4:600402444 |
5;O6056; | hepatocellular car-ciooma | down | mrr-136 | glroma | down | $0001806644444 | neuroblastoma | 54436004 | mir-263 | hepatocellular carcinoma | down | mir-? 78a- 46064444444444 | colorectal 240500044444444444; | 24000402444 |
606066 | 60300004444444444 | :43303:444 | rair-136 | oral squamous cell caremoma | down | $33013044444444 | nouroblastonta | :1:403008 | mir-26a | hepatocellular carcinoma | down | 6030050444; | breast cancer | 2;2;03002;2;2;2 |
Li-! | lung cancer | :::&30':U$2$ | mir-137 | anaplastic astrocytoma | down | mlr-i8d | : :non-small:call· 44i3h3;33ti60:444; | :1806008 | mir-26a | hepatocellular carcinoma | down | mir-Bbi | breast ewer | down |
6063664 | kutg cancer | 443303444; | mir-137 | colorectal cancer | down | 6;3u01856$44444; | breast cancer | 444360634 | mir-263 | hepatocellular carcinoma | down | 24086:6814444 | ;2;}0h2g;2;2;2;2;2;2;2;2;2;2;2;2;2;2; 4800600001:3100244: 240:04444444444444444 | 4000402444 |
606066 | nasopharyngeal 436000446555555555 | 443303444; | mir-137 | colorectal cancer | down | 6;3u01856$44444; | breast cancer | 202066464; | mir-263 | lung cancer | down | mir-38.2 | C teCscitioma | 5000402555 |
606064: | 400000304444444 | :43303:444 | mir-137 | gastric cancer | down | 633013044444444 | esophageal 6;3303066063; Cipteriteiba:;:;:;:;:;: | :64630344 | mir-26a | malignant melanoma | down | mtn-38? | uxteusurewma | down |
606064: | 40003044444444444 | :43303:444 | mir-137 | glioblastoma | down | ;$330l3$$4444444 | uastre cancer | ::4463034: | mir-26a | oral squamous cell carcinoma | down | mtn-383 | breast cancer | 2405002444 |
teA'd | pancreatic ductal aJer.ixarcmumu | 443303:444 | mir-137 | glioblastoma | down | mu- lb< | ;4;3i0304;55555555 | ί down | mir-26a | osteosarcoma | down | nur- '8' | 0006400 0555555504 | 55650405552 |
606066 | 63000060555; adewcarctuotua | down | mir-137 | glioblastoma | down | 55005^544444444: | hepatocellular: ;;030f3603;55555 | : down | mir-26a | papillary thyroid carcinoma | down | mir-335 | 24gli0i0044444444444 | 24000404255 |
606366; | ;2;2re;0al;2cs}i2;2;2;2;2;2;2;2;2;2;2;2;2;2; :46oO03555555555555; | 443303444; | mir-137 | glioblastoma | down | ;$ύ0$ΐ;8;544;444444 | malignant 443013330055555: | 44463004: | mir-26a | primary thyroid lymphoma | down | jnrr-383 | glioma | dowh |
le !>7ii | breast cancer | down | mir-137 | glioblastoma | down | 6;!00l8;0666644 | $;0!0344444444444; carcinoma | 2:2;2;d6wh2;2 | mir-263 | prostate cancer | down | m8w?8 j | meduliohiask 2;2m04444444444444;2;2;2 | 24000402222222 |
194
WO 2017/132552
PCT/US2017/015417
)5510))60)))) | brouchloldalveoiar 5)403)360666660 4 0 46 | ):0000/0))) | mir-137 | glioma | down | ))65ai6i5k/))))))))5 | veil htng earner | dorat | mir-26a | prostate cancer | down | mtr-a’CS | osteosareonta | 5)5/0500/45)5 |
carcinoma | ))/)/456/53)0)5)))))5 | vSji))))))))))) | 5)0//03()))))))))))) | |||||||||||
0:00/0:4: | esophageal 5:53/y/35t0US5:ic56l(:5:5:5:5:5:5:5:5 capemoma | 555/03/555555555 | mir-137 | hepatocellular carcinoma | down | 0://6:63605050505: | prostate 5)))6(/:656050505)))))) | down | mir-26b | breast cancer | down | mir-W- ):035)))))))))): | colorectal )56//606)))))))))))5 | )305330)) |
600/6:6: | esophageal 5:53/y/35t0US5:ic56l(:5:5:5:5:5:5:5:5 capemoma | 46/)6/65655 | mir-137 | multiple myeloma | down | n«j'-iS8-5p | hepoK-cellutar 5)))6(0)/66/65))))))) | down | mir-26b | breast cancer | down | mir-W- ):0535)))))))))): | gastric Cancer | 5)/06635))) |
5;53ί)40)))) | hepatocellular 5)05/)41/06/35)))))))))))) | 46/)6/65655 | mir-137 | neuroblastom a | down | n«j'-iS8-5p | prostate 5)503/406666666666666 | down | mir-26b | colorectal cancer | down | mir-W- ):03))))))))))) | gastric Cancer | 65/06635))) |
5)10))005)))5 | lung vftocer | 55)//66/5545)5 | mir-137 | noo-stnall cel! lung cancer | down | 5555/)/415//55555555555555555 | bladder cancer | 5)://3/55555 | mir-26h | giioma | down | 453/435/95455)5 )1^0404040 | 555(/635))))))))))))): adenocarcino 5:5630:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5 | 5)//3/555)) |
)00000)))) | lung vftocer | 55)//66/5545)5 | mir-137 | ovarian cancer | down | 5555//351585/554555555555)5 | 5555 0/15/0/1)))))))) ////Ο))))))))))): | 5)://3355555 | mir-26h | hepatocellular carcinoma | down | 55556/3/113455555 )05)))))))))) | 555063///5455555555555555555 5550/30/65))))))))))) | 5)//3/5))) |
5)/4///6/6/0))))))))))) | 5)/000)))): | mir-137 | uveal melanoma | down | n«r· (fcb | 5):5/(//060(/)))))))) melanoma | down | mit-26b | lung cancer | down | «bine capper | 66/0330)) | ||
600/60) | tiusypiuuxpgeal 5)6/(4//6//65)))))))))))) | 5)6/)6/))))5 | mir-138 | anaplastic thyroid carcinoma | down | 5555)//415/35))))))): | 55)/660600/3666)))5 | down | mir-26b | non-small ceii lung cancer | down | mir-4 id | 5)05//))))))))))))))) )36f///(636560i6)5 varcutdiita | 5)5//66/)))5 |
mir-138 | chronic lymphocytic leukemia | down | 5555)//415/35))))))): | ))6//0006))))))0 506/360604040404 | down | mir-26b | oral squamous cell carcinoma | down | mir-4 id | 5)36/63066604045: )56//606)))))))))))5 | )5/066/5))) | |||
000/00) | )553//////6/-45/6/6/)))): vyi-ciuxaremoiMa:·:·:·:·:· | ))6/)6/))))5 | mir-138 | chronic myelogenous leukemia | down | 5555//531//)))))))): | /ladder’ cancer’ | down | mir-26b | osteosarcoma | down | 5)50/5(4/551535))) | 5)463///5)))))))))) )56//606))))))))))): | )5/066/5))) |
tnir-138 | colorectal cancer | down | 5555//531//)))))))): | /ladder’ cancer’ | down | mir-26b | osteosarcoma | down | mir-422a | 5)60(6660365)))))): (/////i))))))))))): | )5/066/5))) | |||
5)10))005)))5 | 5 5 5 5/41^6/60651-565))))))) 5)00///64545555555555555555555 | 5)//50545)5 | mir-138 | esophageal squamous ceii carcinoma | down | mir~ld2 | colon cancer | 45/O/545 | mir-26h | prostate cancer | down | ink-Wo | hepatocellular caret no ma | down |
0O?O) | breast cancer | 5)//50545)5 | mir-138 | head and neck squamous ceii carcinoma | down | mir~ld2 | colorectal 540/03050505)05)0 | 45/O/545 | mir-27a | acute leukemia | down | mir-dki | 555403/03155555555555555555555 5550/305/5355555555555455555)5 | down |
)0000/00) | bronebioioalviniar 55566//(/////5555555555555555555555555 | 55)//66/45455 | mir-138 | head and neck squamous ceii carcinoma | down | :0i633i/?:0:0:0:0: | 55)0/0633)050505) 540/03))))))))))4 | 5)://3355555 | mir-27a | colorectal cancer | down | 45/43402/54545 | 5554/(4/3555555555555555555555 bmpbOotic leukemia | down |
)0000/00) | Ονίοη cancer | 5555//66/5)))) | tnir-138 | head and neck squamous ceii carcinoma | down | :0i633i/?:0:0:0:0: | 5)06/300 555 4 4 55555 )5 Ovanan cancer | 5)://3355555 | mir-27a | esophageal squamous ceil carcinoma | down | 45643402/4545 | νΛίοΡ Ά'Γ | down |
)0000/00) | esophageal 5 5 5 6//60////5///5))))))): :5:6/i4i/6/i6:::5:5:5:5:5:5:5:5:5:5:5: | 5555//66/5)))) | tnir-138 | hepatocellular carcinoma | down | :0i633i/?:0:0:0:0: | (arte van rer | 5)://3355555 | mir-27a | esophageal squamous ceil carcinoma | down | 45643402/4545 | epJometrtai 555C//0/655555555555555555555555 | down |
)0000/00) | esophageal 555///6/4///5///5:5)))))): :5:6/i6i!46/46:::5:5:5:5:5:5:5:5:5:5:5: | 5555//66/5)))) | tnir-138 | lung cancer | down | mirG'Uta | 5)06/60054545455)5 Ovanan cancer | 5)://3355555 | mir-27a | giioma | down | 45643402/4545 | hepatocellular caret no ms | 5555//3/5555555 |
)0000/00) | 5 5 5 h///f/6/0(///5))))))) 55566/65(//1//)))))))))))): | 5555//66/5)))) | tnir-138 | nasopharynge al carcinoma | down | nnr-i'Uta'Ap | breast cancer | 5)://3355555 | mir-27a | non-smalt cell lung cancer | down | 45643402/4545 | vsievsareoma | 5555//33))): |
195
WO 2017/132552
PCT/US2017/015417
/Ββζ | ΪΖΟΪΟ/Ζ/:/:/:/// | /888/8((((9 | mir-138 | non-small cell lung cancer | ! down | ((/54/1/35(3/9((: | ((4/5/:/5/5/5(((((: | dorat | nsir-27a | small cell lung cancer | down | »>«-424- (:988(((((((((((: | hepatocellular caremouia | 99((980//89999999 |
lung cancer | ((/55/95/9(((((((((((9 | squamous cell carcinoma | ||||||||||||
lung cancer | lung cancer | 9(/35///9((((((((( | ||||||||||||
/:14/24/4(( | nasopltafyngeal 9(/34/i854459(((((((((((( | 9993488((((: | mir-138 | oral squamous cell carcinoma | ί down | 9(9/54/19995/99999999999999 | hepatocellular ::;:£ύίρ1ηρ9κί3;:;:;:;:;:;:;:; | dowji | mir-2S-3p | colorectal cancer | down | mir-42.8 | breast cancer | 99199993/9589((( |
9991//219-919/ | :::h3ik3b}iZ4/:Z3:9:9:9:9:9:9:9 | 9(//4//999999(9 | rair-138 | ovarian cancer | ! down | 9999:/1891/3/99999999999999 | waUgnaui 99999/8414444483(((((((: | 9(:35889(( | mir-28-5p | colorectal cancer | down | mire-129 | νΛ1θΓ · rov't | 99i9(9809w989999999 |
!C:*i-l | pancreatic ductal ader-ixaremomu | :9(5/9/9/9(((( | mir-138 | papillary thyroid carcinoma | ! down | mu- 19 | 9/859/8/9/881/95/1/(( 9(488/9/5/5/5(((((: | down | mir-2S-5p | renal cell carcinoma | down | itur-42·: | (//1/4//154(((((: carcinoma | (1/88/98(((9 |
!C:-i-2 | 9(145094585//((((((((( | :9(5/9/9/9(((( | mir-138 | renal cell carcinoma | ! down | mu- 19 | primary cns lymphomas | down | mir-29a | acute myeloid leukemia | down | itur-42·: | gastnc vanccr | (1/88/8(((9 |
/444(2//9( | : bronchioloalveolar: : 9(/84/4859/559(((((((((((( | 9(//(49/((((: | mir-138 | renal clear cell carcinoma | ! down J- | ((45/4:1(4499999999999999999 | 999/345//54/8(((((((9 9(:/555/89((((((((((( | down | mir-29a | cervical squamous ceil carcinoma | down | mir-4'29 | ham ad 'um «euro 9(858(((((((((((((( | (19(93///989((( -.- |
lung cancer | 9(/555/89((((((((((( | (/58584(((((((((: | ||||||||||||
let-7f-2 | esophageal (/9/85/4585955419(((((((9 (9/54/1/5545:(((((((((((( | 9(3/9/9/999999(9 | mir-139 | colorectal cancer | ! down | 9 9 9 954538459(((((((( | gastric cancer | down | mir-29a | gastric cancer | down | 9:988831289:9:9:9:9 | non-small celt lung canepr | ! down |
let-7f-2 | esophageal :9:5///545/8//18:((((((: 999/44/1/554/9(((((((((((( | 9(3/9/9/999999(9 | mir-139 | colorectal cancer | ! down | 9999541859/59(((((((( | gastnc cancer | 999938989899(9 | mir-29a | gastric cancer | down | 999858419/9999999999 | 99//589(((((((((((9 squamous cell carcinoma | 9919999349/44(((: |
let-7f-2 | 9 9 9 9/3ί^ί$5/!9ί441·48((((((( (95/5/4//4//((((((((((((: | 99(3//9/999999(9 | mir-139 | colorectal carcinoma | ! down | 99995/85/599999999999999(9 | lung earner | 99993895899999 | mir-29a | gastric cancer | down | 99985841939999999999 | osteosarcoma | 991999934/8(((: |
ic:-”!-? | 9(91/9//9/0/0//999999999999999999999 | down | mrr-139 | glioma | ! down | 9 9 9 91(5/-91:995 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 | osteosarcoma | ((559/9899999 | mir-29a | gastric cancer | down | /4/4/89^/// | 9990/883899999999999999999 9(/85///9((((((((( | (/985/89999999 |
iO | (99//4/9/5//5/9((((((((((9 | //////((((ί | mir-139 | hepatocellular carcinoma | ! down | 585/-/9/3((((((((: | :999 3dr/5359(((((((((( 9(/9558/84((((((((((( xuromm. a | dorat | nsir-29a | head arid neck squamous ceil carcinoma | down | 9(85/-429((((: | 9(///95359(((((((( (://8///(((((((((9 | 9:/(80//959999999 |
iO | (99//4/9/5//5/9((((((((((9 | ///(//((((ί | mir-139 | hepatocellular carcinoma | ! down | 9(:/5/-9i9/3((((((((9 | 9(33448849((((((((((( 9(/9553/84((((((((((( xuromm. a | dorat | nsir-29a | hepatocellular carcinoma | down | 9(85/-429((((: | renal eel] carcmoma | 9:/(80//959999999 |
/444(2//(( | KasupimM'geal 9(/54///5///9(((((((((((( | 9(//(//((((9 | mir-139 | hepatocellular carcinoma | ! down | 999945/51/3((((((((: | bladder cancel’ | down | mir-29a | hepatocellular carcinoma | down | mir-432 | 9(///8859(((((((( (:55858/(((((((((: | 9919(93///89((( |
let-7f-2 | neuroblastoma | 9993//9/999999999 | mir-139- 5P | colorectal cancer | ! down | toir~J95 | breast cancer | down | mir-29a | hepatocellular carcinoma | down | jnrr-433 | gastric cancer | ! down |
let^f,? | pancreatic .hural adenocarcinoma | down | mrr-139- 5p | glioblastoma | ! down | 9999//5-9/99599(((((((: | breast earner | ((5/9/899999 | mir-29a | hepatocellular carcinoma | down | mir-431 | gastric earner | (/9889889((( |
///0/9/ | breast cancer | 9(:/54/59(((( | mir-139- 5P | hepatocellular carcinoma | ! down | 9(:/5/-919/399999999999999999 | breast cancer | dorat | iisir-29a | mantle cell lymphoma | down | ttire-4 ;3 | hepatocellular caremouia | 991999980//959999999 |
Li-:: | chr/a/yc/ii///;???????? | y/o/’:/????: | mir-140 | esophageal cancer | ! down | :::://83/5:::::::::::::::: | COlMe kite:::::::::::::::::::::: ((4/54885//8/9((((: leukemia | 9:95/988:9:9: | rnir-29a | mesenchymal cancer | down | inir-dc? | Iwei vancei | ! doyai |
196
WO 2017/132552
PCT/US2017/015417
bronchioloalveolar /RdBihbM^RRRRRR: | 43070:3 | mir-140 | non-small cell lung cancer | down | RhmklRRRRRR | RdikdhmRRRRR:: b mpho«.v no /•fetikkhiiR://////// | dowu | mir-29a | monocytic leukemia | down | niir-4 '3 | /RBRRRRRRRR squamous cell /RdjRidbMkRRR: | RdpBiiR/: | |
bt-'a | /RpOR^^RRRR/R | 4d0hriR3 | mir-140- 5p | colorectal cancer | down | m«-rj5 | /RhiROdiRRRR 75Rh4RRRRRRR4 | dowu | mir-29a | neuroblastoma | down | mir-44>S | hepatocellular oarcra.uuta | down |
^O^kRshRpMiRRRR /RdteihbifiBRRRRRR: | 5p | carcinoma | Rd^dkR:RRR::R | lung cancer | /RdiakRhBRRR· | |||||||||
^O^kRshRpMiRRRR /RdteihbifiBRRRRRR: | 5p | Rd^dkR:RRR::R | cell carcinoma | /rO^rrrrr/r | ||||||||||
gastric career | R^PBiRR: | mir-141 | bladder cancer | down | 4:ήκΒ1#5444/74 | RgSPplkikdMRRR: : ·: SipjaiflOllS: CS ί I ·: ·: · carcinoma | RdpR-rR· | mir-29a- 3p | gastric cancer | down | gastric cancer | down | ||
/RdBmdtodRRRiRRR | lymphocytic leukemia | /rO^RRRRR/R | ||||||||||||
/RdBmdtodRRRiRRR | 4^jt«pRRRRR4 adertocarcuiu BhdRRRRRRRR | |||||||||||||
:^Μ?§ί^ήθ&ί::::::::::::::::::::: | C^pR’iR??: | mir-141 | gastric cancer | down | ::::hkri:dR5:::::::::::::::: | :::ghRhB:C:C:C:C:C? | cddR-fR: | mir-29b | esophageal squamous ceil carcinoma | down | mir-4-t9a | gastric cancer | down | |
7iOR:74 | :^Μ?§ί^ήθ&ί::::::::::::::::::::: | C^pR’iR??: | mir-141 | gastric cancer | down | RhiuRlRJRRRR; | ^hepatocellular·:·:· RPdkrhpkiRRRR:: | RdPRiR: | mir-29b | gastric cancer | down | mir-449n | gastric cancer | down |
RIssrbr/ | lung cancer | RdPBRR/ | mir-141 | hepatocellular carcinoma | down | RpkB^BRRRR | hepatocellular Rp^ihpMk:RRR: | //dpRiR: | mir-29b | gastric cancer | down | twir-Uba | glioblastoma | 7dpBPR4 |
nasopteuyngeal /RdBihbM^RRRRRR: | /ffflteriR·: | rair-141 | hepatocellular carcinoma | down | :4u«R3RrRRRR | hepafoceiinlm· carcinoma | Rdpkhc | rair-29b | glioblastoma | down | mdr-l'+ba | RtohgRRtkeRRR: | RdbRbR4 | |
!e- . | ueuroblasroma | :::dpO:7:: | mir-141 | hepatocellular carcinoma | down | mu- Rrc | brag career | down | mir-29b | lung adenocarcinoma | down | ir<if-44Qa | hu;g e-anoer | SdokRt:::?:: |
RIssrbr/ | pancreatte ductal xadcfaxarcmoitia:·:·:·:·:· | RdPRiRR:: | mir-141 | lung adenocarcino ma | down | RkpBi§BRRRR | hrag cancer | down | mir-29b | mantle ceil lymphoma | down | twir-Uba | neurobiasterit i/SRRRRRRRRRi | 7dOBRR4 |
:/|BR/RR; | mir-141 | mesenchymal cancer | down | Rnni-dRSRRRR· | /R'RBRhihtiRsUR/ RMhgRdiRsR:RR: | down | mir-29b | monocytic leukemia | down | mir-4-iria | ^ksBRikaii/ipllR siphgRdrRgRRR: | RdPRiRR· | ||
:RgR^RR: | breaz xuucwr | /ffflteriR·: | rair-141 | osteosarcoma | down | :4u«R3RrRRRR | mow-small cei! Rlp^RpiRBRRR | Rdpkhc | rair-29b | non-small celt lung cancer | down | mdr-l'+ba | won-small cell clniikRkRabRR/ | down |
k-l | 7hibhchlMdaiyS0JdiR: carcinoma | RdoBiRR: | mir-141 | ovarian cancer | down | mu- iti* | //hpriBiiBiiReliR: 4lOR03RR44 | RddBrR· | mir-29b | non-small cell lung cancer | down | ir<if-44Qa | osteosarcoma | RdokhRR |
b: · | :BbOR^^R:RRRRi | down | mir-141 | pancreatic cancer | down | Rnni-dRSRRRR: | RpSisPOphtR/R | down | mir-29b | non-small cell lung cancer | down | mir-4-iria | /R4k«gkRRRRR /RdhpBRRiRRR·: | RdPRiRR: |
7teR?iRR· | esophageal /RqRaMphRPptiRRRR /RdteihbiiiaRRRRRR: | xdoteiR// | rair-141 | renal cell carcinoma | down | rair-F?5 | osteosarcoma | down | rair-29b | osteosarcoma | down | jnrr-449ti | prostate 70SiiC:0i7:7:7:7:7:7: | dowir |
7i$R?RR4 | esophageal /RqRaMphRPptiRRRR /RdteihbiiiaRRRRRR: | sdoteiRc/ | rair-141 | renal clear cell carcinoma | down | rair-F?5 | RpapiiipBRRR/R: RkBikidRR:RR::R carcinoma | down | rair-29b | prostate cancer | down | 70SiiC:0i7:7:7:7:7:7: | ||
7i$R?RR4 | cb^jaipppbRkRRRR/ N-aBmdhBRRRRRRi | 4d$wn7R | mir-142- 3p | acute lymphoblastic leukemia | down | rair-F?5-?p | hepatocellular RPdrSmMhRRRR:: | down | rair-29b-l | gastric cancer | down | jnrr-449b | lung (. oncer | dowir |
197
WO 2017/132552
PCT/US2017/015417
265/6iiii | hcpatmeibikn /)886(8396/2/6/)))))))) | /)/866/5//))/ | mir-142- 3p | colon cancer | down | ))666(698/)))))): | /)6616/66()))))))) /)/636/79/)))))))))//) | dowtt | mir-29b-3 | head and neck squamous cell carcinoma | down | mir-4^0 | uou-sroah cell hmg cancer | ///2866))): |
iCL-’i | 6588520868686868 | ):8655/////// | mir-142- 3p | glioblastoma | down | mu-rj7 | esophageal ////63686////////////////////// | dowtt | mir-29b-3 | hepatocellular carcinoma | down | /)5(69926/)): | hepatocellular carcinoma | down |
3p | carcinoma | carcinoma | :/:/3jt:/:/:/:/:/:/:/:/:/:/:/: | |||||||||||
/)15)79/))) | kmg cancer | ///8656///////// | mir-142- 3p | mantle celi lymphoma | down | ////6850)))))))): | hepatocellular /)257(8668/)))))//) | down | mir-29b-l | hepatocellular carcinoma | down | /)(569/71////////// | ybiaddpr;/;/;/;/;/;/;/;/;/;/; //68665////))))))))): | )2698/)]] |
8695/:/):/] | nasopharyngeal :)285(6853::::::::::::::::::::::::: | /28866/6/)) | rair-142- 3p | osteosarcoma | down | ///85665/)))))))/ | ))665(6))))))))) ///588666/))//////) | /)965/)) | mir-29b-l | mesenchymal cancer | down | :/:/5(58/3(/):/:/:/: | teforv tai carcinoma | /:/8266/////// |
k:-i | ueurohtasioma | :/:2856///////// | mir-142- 5p | lung cancel | down | mu-19 * | /)/52((6/))))))))))): leiomyoma | down | mir-29b1 -5p | mesenchymal cancer | down | ):66/688())))) | )667/863668(/))))): varcmwma | /)2652))): |
/)(5)7(/]]]] | eva ·4ΐ· catwei | ////2656/////// | mir-142- 5p | mantle celi lymphoma | down | ////856(266/)))))): | :/:/65p88l:/:/:/:/:/:/:/:/:/:/:/: /)/686889//////////////////// •..ονη,οί, ,a | down | mir-29b-2 | gastric cancer | down | tnir-451 | ///g(585))))))))))) | )2656))): |
):5465))) | ):636755522622)))): aderaxarciooiua | ////2656/////// | mir-142- 5p | osteosarcoma | down | ////856(28)))))))): | ///89652(6()))))))) )83686//////////////////////// | down | mir-29b-2 | head and neck squamous ceil carcinoma | down | tnir-451 | ///g(585))))))))))) | /)2666))): |
/)(56(/)))) | Wdjei tdHcei | ////2656/////// | mir-143 | bladder cancer | down | ////856(28)))))))): | :: hepatoeeliulaf::: /)8866668)))))))/ | down | mir-29b-2 | hepatocellular carcinoma | down | tnir-451 | /)1685665(6(86)/ :/:fi6rc5265:/:/:/:/:/:/: | /)2666))): |
:)2254))): | biadder cancer | ))6656/)))) | mir-143 | bladder cancer | down | ////8864(8/)))))))) | long tanner | down | mir-29b-2 | hepatocellular carcinoma | down | /)886960)))) | hepatocellular /)66851666))))))) | down |
/:/666(/)))) | :)2568656:)))))))))))): | down | mir-143 | bladder cancer | down | /:/:886(9/8///////////////// | /]:ρ68(6((2))))))): ))665/)))))))))))) | ):2298)): | mir-29b-2 | hepatocellular carcinoma | down | /:/2868/7(//]]]] | hepatocellular /)6852585////////))) | /)2652/////// |
nm-l | )68856253:8))))))))))) | )/8656//))/ | mir-143 | breast cancer | down | ////656(/698////////////// | /)6866668665))): ):53)))))))))))))))): | down | mir-29b-2 | mesenchymal cancer | down | i!:u-4<l | lunc adenocarcino J__9................ | down |
)/5(6())))/ | colorectal uuioer | )/8656//))/ | mir-143 | cervical cancer | down | ////656(/698////////////// | hepatocellular /):63(7(668))))))): | down | mir-29c | bladder cancer | down | /)5(69/6(/)))): | uasuphary uge at caretnuma | ):2666))): |
:)2254))): | /)266(85666(:))))))))))) sqaatnoaa tell /)256(6658/)))))))))))) | /)2856/))//) | mir-143 | colon cancer | down | ////886(286))))):/) | ^hepatocellular·:·:· //)686(668))))))): | /)2666)): | mir-29c | esophageal squamous ceil carcinoma | down | ):68698())))) | nyti-smali cell ///(656/2666(/))))) | down |
:)2252]]]] | gastite cancer | ////d$56/)))) | mir-143 | colon cancer | down | roir~45a | bepayxoituiar ////626(6(68))))))): | dOwft | mir-29c | gastric cancer | down | /)886940)))) | uon-smaU cell /)56588(066//):)) | down |
):6258:)))) | /)635(268:654))))))): )68225386:666)/))))))/ ///885(8625)))))))))))): | ////8652)))): | mir-143 | colon cancer | down | ////53606////////////// | hepatocellular carcinoma | ):2858///// | mi r- 2 9c | gastric cancer | down | /)28665(/)))): | ncm-sreaii cell lung c ancer | )2696)]] |
):2258:)))) | head and neck ///888-55286:666)////////////// ///885(8625)))))))))))): | down | mir-143 | coion cancer | down | ////5(6(/966///////////// | xidrex camw | /)2256///// | mir-29c | gastric cancer | down | /:/2863/7(/)/////// | osteosarcoma | /)2662/////// |
):2258:)))) | hepatocellular· •carcinoma | down | mir-143 | coion cancer | down | ////5(6(9/66///////////// | noroxmailcel! long tamer | /)2256///// | mir-29c | gastric cancer | down | /:/2863/7(/)/////// | osteosarcoma | /)2662/////// |
:)588:2()))): | ///58866488265//////////////// | /):8654)))) | mir-143 | colorectal cancer | down | :/:/656(/698))))))) | ovarian cancer | down | mir-29c | gastric cancer | down | /)5(694(///:/:/:/: | /:/065983(2653////// | ):2856))): |
:::22i±2:::::::: | lung cancer | ::2p56:/:/:/:/ | colorectal cancer | down | ::566(9/66::::::::::: | ovarian cancer | /:8966:/:/: | mir-29c | gastric cancer | down | ::58696(6:::::: | 5 pnphary nge /)6(/66666568/]]]] /)6852585////////))) | down |
198
WO 2017/132552
PCT/US2017/015417
:(6ί«8ϊ((((: | uasopton tigeal (6616666(66((((((((((( | 6860((((: | mir-143 | colorectal cancer | down | :(66686666(((((: | (6660860(6(( ly mphomas | down | mir-29c | gastnc cancer | down | (0086(((8 | (0160((((((((((( | :0063:3 |
3606066(((((((((3 | cancer | glioma | (06666((((((((((( | |||||||||||
4ίήίί41343 | osteosarcoma | 4:&Ο(((3 | mir-143 | colorectal cancer | down | iun-f99a-5p | ((gltoh6(((((((((((( | down | mi r-2 9c | head and neck squamous cell carcinoma | down | tnir-4 ?4 | 0 teCranoma | 06666(( |
4ίήίί41343 | (66(^6666((((((((((((: (60660(((((((((((( | 4:&Ο(((3 | mir-143 | colorectal cancer | down | iun-f99a-5p | kidney Cancer | down | mi r-29c | hepatocellular carcinoma | down | 4iuir-4:55((((( | colon cancer | (66668(( |
361163434 :(666((((((: | brean | 4dOB(((( | mir-143 | colorectal carcinoma | down | unr-l'W3p | uStrosaRG. >a | 3660:3: | mir-29c | hepatocellular carcinoma | down | mim47? to •*P | (:060(((((((((( 3060((((((((((4 | (:6666(((: |
rorc- :(666:(((((( | (00600((((((((( | (:66666((( | mir-143 | colorectal carcinoma | down | mif-ltebt-ip | osteosarcoma | down | mir-29c | hepatocellular carcinoma | down | roir-4'S?- | (066860(068 lung cancer | ((6666(((i |
3:08:8:8::: ΒΟΒΒΒ: | venroal ccnunqma | ((660(((8 | mir-143 | colorectal carcinoma | down | nar-l99a-3p | ((66666600((3 | down | mir-29c | hepatocellular carcinoma | down | mir-4$3 | (£6Ϊ666Ο6((((((( (060(((((((((((( | (006((( |
308:3:3::: :(666((((((: | chondrosarcoma | 3:d$teh343 | mir-143 | endometrial cancer | down | mir-tatoa-Sp | 33papihO((((((((( 33iiB;:teiB:((((((((((: carom.oma | dOwn | mir-29c | hepatocellular carcinoma | down | jnir-'tk?- 6O||6((66 | glioblastoma | down |
308::3:3:: :(666((((((: | chondrosarcoma | 3:d$teh343 | mir-143 | esophageal squamous ceil carcinoma | down | mir-tatoa-Sp | renal cell (Lar8ih66:66(((((((: | dOwn | mir-29c | hepatocellular carcinoma | down | jnir-'tk?- 6O||6((66 | giro ma | down |
8niii8(484 :(666((((((: | Cotati cancer | 3:d$teh343 | mir-143 | gastric cancer | down | Uiir-tatoa-ip | cotorectai 46666666((((((((8( | dOwn | mir-29c | lung cancer | down | jnir-484 | colon cancer | down |
!>4Γ- 8:083:38 | ciu.cef | down | mrr-143 | gastric cancer | down | mm-lripa-sp | hepatocellular carcinoma | ((66666:3 | mir-29c | mantle ceil lymphoma | down | (066063:3 (:Bh(:(((((((((( | hepatocellular (00006666 | :(6066:((( |
mu- (666((((((: | colorectal cancer | 6860((((: | mir-143 | gastric cancer | down | ((66686660((( | hepatocellular ((66666086(((((( | down | mir-29c | mesenchymal cancer | down | (000(((8 | esophageal 3Ohi3tei3(((((((((( | down |
:(666(6(((( | sqaatooas veii 4ChtCih0ri^84343434: | 46000((((((8 | cancer | (0((((((((((6 | (6((((((((((((((((((: | |||||||||
:::mito4:4:4 :(666((((((: | (666666066(((((((((( sqaatooas veii 4ChtCih0ri^84343434: | :(66666((( | mir-143 | glioma | down | ::::piii4i&Sli::::::::::::: | :::C:i:lpn6C:hiCmlO:::::: 60((((((((((((((((: | 4^BB:4: | mir-29c | nasopharyngeal carcinoma | down | nur-dho- ((0(:(((((((((( | l-epatooeilnlar (66ΟΌ8ί((((((( | down |
308:3((3 :(666((((((: | 8:gh0hi3$tai0h84343:3 | 3:d$teh343 | mir-143 | hepatocellular carcinoma | down | mir-tatob | ((^0066((((((( 33iiB;:teiB:((((((((((: carcinoma | dOwn | mir-29c | ηοη-smali cell iung cancer | down | mtr-48o- ((0(:(((((((((( | lung c ancm | down |
3:03:383: :(666((((((: | 8066666660((((((( (6066* 666((((((((((3 | :(6666(((( | mir-143 | malignant melanoma | down | 3::hiii3|B6li((((((( | xhepahxelluiai·:·:· (£000((((((8 | ((666(66( | mir-29c | pancreatic cancer | down | mir-490- (0((((((((((8 | gastnc cancer | down |
4^0434: 3:0((((((: | hepatoceilular carctuomn | down | mrr-143 | nasopharynge ai carcinoma | down | ((60004343 | hepatocellular carcinoma | ((66666(( | mir-300 | breast cancer | down | nur-49<to (:Bh(((((((((:(( | :(h|O886(((((((((( 88086:((((((((((: | :(6066:((( |
ίϋΐι- (666((((((: | mescncln mat (666666((((((((((((((((( | (ΒΟΒ(((( | mir-143 | nasopharynge al carcinoma | down | :4tou3i;O((((((( | pm*iate :(666666(((((((((((( | down | mir-300 | head and neck squamous ceil carcinoma | down | :0004((( ((5^(((((((((((: | ^0680:(((((((((( :(686666(((((((((((: | ((6866(((: |
ίϋΐι- (666((((((: | fioo-sinaH ceO (:6-606660(((((((((( | (ΒΟΒ(((( | mir-143 | non-small cell iung cancer | down | ((8086606(4 | breast cancer | down | mir-301a | endometrial cancer | down | (0008((4 35188((((((((3 | ce:\j.al :(686666(((((((((((: | ((6066(((: |
::034:::::::/:: (6666((((( | :»ial:squa«ieeaeeh:: :(666600((((((((((((: | :::duB:h:4:4 | mir-143 | non-small cell lung cancer | down | ηώ-1<κ%-5ρ | ::hepahxelluiai'·:·: «.arcumma | 4d0W:rt::::: | mir-301b | endometrial cancer | down | :;(00(4343(4 (06666((((((((((( | down | |
(:0:(((((( ((0((((((: | osteosarcoma | 4:&Ο(((3 | mir-143 | osteosarcoma | down | mn--l^9h-?p | mecluiiobiasta 3:0:(((((((((((((((( | down | mir-302a | colon cancer | down | 1411--4¾ | breast cancer | (6666(8( |
199
WO 2017/132552
PCT/US2017/015417
/:(74/////( //87/((((///( | ovarian cancel | 47895///( | mir-143 | osteosarcoma | down | 9(358587585884/ | mesenchymal (/399939//////////// | down | mir-302a | prostate cancer | down | /(889577////( | esophageal aqnantotts celt (/47737////// | //3995///: |
u:u- //87/((((///( | ovarian carcinoma | 4785555( | mir-143 | pancreatic ductal adenocarcino ma | down | //39579379////( | breast cancer | down | mir-302b | esophageal squamous ceil carcinoma | down | /(889577///// | gastric cancer | down |
(:(:57:(:(:(:(:(: 80888888 | prostate ^tixer | down | mrr-143 | prostate | down | (/77895/////// | hfatlder cancer | //35859// | mir-3 i)2b | gastric adenocarcinoma | down | nurcfh-' | 7 «.an e·· | //59599(/// |
u:u- //8(7/(/////( | bladder cancer | //35895///( | mir-143 | prostate cancer | down | //3957999/////// | breast cancer | down | mir-302b | hepatocellular carcinoma | down | /(889577////( | or ana:: /23379////////// | down |
8178388 | cancer | //355555555575/ (/7(//////////////// | carcinoma | :(:7θ835(:(:(:(:(:(:(:(:(:(:(:(: ad kciko | ||||||||||
u:u- /|7//////( | vcrcual uaivtnutiia | //35895///( | mir-143 | prostate cancer | down | //3957999/////// | //3955559//////////// adewocarcuta //7////////////////: | down | mir-302c | hepatocellular carcinoma | down | niri-4‘G | ................ breast cancer | //5395///: |
(/(74/////( //87(4((((((((( | tkoia£'grc\.arcmo 8:308(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: | down | mir-143 | renal ceil carcinoma | down | (/(37279/////// | (838957///////////: | dov.n | mir-30a | breast cancer | down | mir-495 | (838857/////////// | 8(53895(/// |
(:((07((((((((((( 9(0((383( | Cotati cancer | //373///( | mir-144 | bladder cancer | down | (895538598599999/( | mir-30a | breast cancer | down | (/377/(///////// (83589879////////// carcnivma | down | |||
(:((07:(:(:(:(:(: 83(788(3(:( | cotan cancer | //377/(( | mir-144 | choiangiocarc ino ma | down | (83398559559///////( | mir-30a | breast cancer | down | nik-4«7 | breast cancer | down | ||
(:(37:(:(:(:(:(: 8(878(3(3(: | statteef | down | mir-144 | gastric cancer | down | (:(:9397393(//////: | hepatneefiutar carcinoma | //95859// | mir-SOa | breast cancer | down | mirc-lb“ | cervical (/055535/////////// | //99599(/// |
η:ιι- 83(93(3(3(3( | er7roct«al cancer | 8/39989///( | mir-144 | hepatocellular carcinoma | down | //3957999/////// | bepatooelluiar carcinoma | down | mir-SOa | chondrosarcoma | down | η:ιι·-4*Γ· | vNorechd /274545555555( | down |
:::(ή'7?:::::::::: (897398(8 | endonKfrial cancer | ::37:n:(:(:(: | mir-144 | lung cancer | down | mir-ltittp | :(:(95^(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: (/399995988898//// (/:7(//////////////// | (:(377:( | mir-SOa | colorectai carcinoma | down | :::(h'4(rt4(37:::::::::: | ::9(p858798(:(:(:(:(:(:(: (/555558///////////: | doyvn |
(887 398(8 | 823557555:8588//////// (/433/77(//////////// | carcinoma | ||||||||||||
(:(38(3(:(:(:(:(:(: (897 398(8 | gastric caneer | (839(9:9:/// | mir-144 | osteosarcoma | down | mir-ltittp | ioesene rt> mpi //839898//////////// | //99889// | mir-SOa | non-small ceil lung cancer | down | /((33(947////( | lippaloceilnlin· (/5337597//////: | doyvn |
(/:74/////( 8(379(9(9(: | gastric cancer | (/(3079// | ink-144 | nancreatic ductal adenocarcino ma | down | //97297(//////: | neuroblastoma | down | mir-SOa | non-small ceil lung cancer | down | (/(7:(492(//// | kidnev canter | :/99599///( |
(837 338(8 | gastric cancer | lungcaacor | ||||||||||||
:(:(97((((((((((( 8(373(3(3(: | gastric cancer | /(733/:// | mir-144 | uveai melanoma | down | ((((9397393(((((((((((((( | pancreatic (8:389898(//////////// ::aden<yeaECtl>p·:·:·:·: :/7(//////////////// | //359/5// | mir-SOa | renal cell carcinoma | down | ((((33752(///: | /(75955//////////( 899957///////////: | :/59599///( |
(:(37:(:(:(:(:(: 83(7(9(9(9( | (((g!(7(i3Sta99(:(:(:(:(:(:(:(:(:( | :(((17:9(:(:(:( | mir-145 | bladder cancer | down | (835985598859///////( | mir-SOa- 3p | colorectal cancer | down | mk-47 | (/0747/://////// (:(0380(7(:(:(:(:(:(:(:(:(:(:( | down |
200
WO 2017/132552
PCT/US2017/015417
(:5/8-(((((( ;(383/222222; | 3:/0/5///333333333: | :(:5/82/2222: | mir-145 | bladder cancer | ! down | 8(82/88032888888; | asirecy toma | ;£(5/88838; | mir-30a- 5p | hepatocellular carcinoma | down | (:/52888:’8'(2888; | pancreatic (5555/5(((((((((: | 5(/0552(( |
£//22222222 | (/52/5/5/((((((((((((: | 5p | ;(8/8i/8/333333333 | |||||||||||
55584(((((: :(2//((((8 | hepatoceikdar (59252/52/52:22222222222 | :(55555((((: | mif-145 | bladder cancer | ! down | ((5//:2805((((((( | breast cancer | (1255885(: | mir-SOa- ?P | gastric cancer | down | ¢55/4497/((( | cp58$t3t/iiiiiiii :(/5/5/2(((((((((: | £28/55;((( |
¢5585:4444 :(8//:((((( | (;//j2/9595i:/2(:((((((; 535//50:(((((((((((: | ((5fl82/((((: | mir-145 | biadder cancer | ! down | ((35/(822/5((((((( | breast cancer | ;£2dpwu8 | mir-3 Ob | colorectai cancer | down | (:8//82/(9/((((( | «.-fore tai (55/8/5((((((((8 | £(585(882( |
!0Κ- (:9//((((8 | 2/5/5(5/52/55/2222222 carcinoma | ((/52/5((((: | mir-145 | bladder cancer | ! down | ((/33/28/5/((((((( | cttolaugiocarcl 2:5/25/(((((((((((: | ί down | mir-3 Ob | esophageal cancer | down | (:/88///323333 | *· arian ;(555/58;((((((((( | £(5/33/333; |
55585((((( £;O;£;£;£; | :(55//2/5/5/5/(((((((: ;(c/i8mh/85;(((((((((((( | ((5/2//:(((( | mir-145 | breast cancer | ! down | iiar-20Ub | esophageal squamous ceil vudvtttot. .a | ί down | mir- 3 Ob | gastric cancer | down | mir-49<i | /5/55/8322222222 :(/5/5//(((((((((: | £;;//58;((( |
:(:ΐ5ί/(((((( /18/5/5 | :(5/5/555555((((((((((: | 55/82/8288; | mir-145 | breast cancer | ! down | iiar-20Ub | naslix vancoi | ! down | mir- 3 Ob | non-small ceii lung cancer | down | mir-ittoa- (://(((((((((((: | (///((((((((((((ί squamous cell ufth.tttoma | £;;//58;((( |
55585((((( 32//85(8 | :(2///:5/5/532(((((((((( | ((5/28/2222: | mir-145 | breast cancer | ! down | uar-20Ub | ((gi/385/222222222; | ! down | mir- 3 Ob | prostate cancer | down | mir-5P2 | (5/15/(55/8/8(: | £;;//58;((( |
¢55524444: £8//222228 | ¢555825557444444444444 (://52/5/ί5/((((((((((((: | cdowcy? | mir-145 | breast cancer | ! down | nrir-Tribb | glioma | /(;;dow;5;( | mir-30c | acute myeloid leukemia | down | mir-$52- ££££££££££33 | breast cancer | • down |
¢555222 (:9//(22222 | naaopltarengeaf (55/5858558((((((((((( | down | mir-145 | cer/rcai cancer | ! down | :(:/5/22/5/((((((( | 2/158/3/(((((((((: | (12555(58: | mir-3 Ok | endometrial cancer | down | tuiwdfE | talon can tar | £2do558(( |
am· (:2//(((((( | non-srmtil ceO 2:/35/:55/5//((((((((((( | :(:5/28/2222: | mir-145 | cervical cancer | ! down | 2235/8/5/52(((((( | hepatocellular carcinoma | ;£(5/88838; | mir-30c | endometrial cancer | down | m«-5b3 | gastric cancer | £(/05/(((: |
(:55/::(::(::: £8//222222 | (^/5/(5/2/22/5222((((((: (:/-22/5/5/522(((((((((( | ((/52/222222 | mir-145 | chondrosarco ma | ! down | mir- Irittb | ¢^£¢¢¢¢¢¢¢¢: adeuoearcmo ;(:i/5;(((((((((((((( | (/:/58/5::: | mir-3 Oc | non-small ceii lung cancer | down | mar | gastric cancer | ί doy.u |
38//383:8 | (;5/t8c/8(((((((((( | lung cancer | ||||||||||||
(:/5/(((((: :(8//((((3 | o var-art carcinoma | (2552/5:(((( | mir-145 | coion cancer | ! down | ((55/:2/5/((((((( | ::nasapbS£yftge·: :·:·3ΐ·!*:ΰΪΡ:1βΡίβ3:·:·: | (15558855 | mir- 3 Oc | renal cell carcinoma | down | ¢55/://3((((( | hepatocellular carcinoma | £25055((8 |
¢558544444 :(8//:((((( | pancreatic cancer | ((5fl28/:(((( | mir-145 | colon cancer | ! down | ((35288282/5:((((((: | ovarian cancer | £85/88/8 | mir-30c-l | prostate cancer | down | imw5ri3 | nou-smu'd cell Jung cancer | £(/85/5(( |
!0Κ- :(8//:((((( | papillary thgwia :(/52/25/25/((((((((((((: | :::/ρ22·5:£:£: | mir-145 | coion cancer | ! down | ::::/33/58/5/::::::::::::: | :::p5/or//885:;:;:;:;:;: 25/21/32444444444 adeno· ,υηη- 253744444444444444: | ! down | mir-3uc-2 | prostate cancer | down | ¢/5//5/:::::::::::: | -ml squamous ceil carcinoma | 5280//2:2 |
mu- :(8//:((((( | papillary thyroid 2:5/252/522/((((((((((((: | (:5/28/:(((( | mir-145 | colorectai cancer | ! down | :(:33/3/288/5:((((((: | predate /:/5//5/(((((((((( | £55/83/8 | mir-30d | non-small cell lung cancer | down | m«-5b3 | osteosarcoma | £4/05/244 |
:::53/::::::::::: 88//8883 | :::/l:5s2/t/::C/r25/2(y:y:y | :::/p22’:d:y:y: | mir-145 | colorectai cancer | ! down | nur-lribb | :::p5o/taie::::::::::::::::: ((¢/58/3(((((((((( | (/(/55(5:( | mir-3 Od | prostate cancer | down | inir-Njd | k pophaw nge (595/5/5/35/(( | ! doy.u |
! | 855581/5:/35:2((( | 5(((((((((((( | ||||||||||||
η:ιι- :(8//33333: | retinoblastoma | :(:5/28/2222: | mir-145 | colorectai cancer | ! down | 2233/82/5/5((((((( | tongue cancer | ;£(5/88Z2; | mir-30d | prostate cancer | down | bypopitatyngc at squamous Cyin:·:·:·:·:·:·:·:·:·:·:·:·:·: | £(/05/(((: | |
! | caritnoma | 5:222225 | ||||||||||||
tbif- 338/8933333 | gaatnc cancer | down | mir-145 | colorectal cancer | ! down | 22/5/28/5/((((((( | bfatfdor cancer | ί........... (/(down?: | mir-3 Od | renal cell carcinoma | down | ;(/5///5;(((( | gastric earner | £;://33/333; |
201
WO 2017/132552
PCT/US2017/015417
5/885-))5/)) /51/855/))5) | heparovedular /)8385585(88))))))))))):) | 3883953/ | mir-145 | colorectal cancer | down | 5/838-058585) | breast cancer | )1/838339/8/ | mir-30d- 5P | non-small celt lung cancer | down | hepatocellular carcinoma | ))9895))): | |
9θ||3 | cancer | /33395:)5/)))))5 | myelogenous leukemia | alcaiciwoma | ||||||||||
5:80555: | yen real squamous )3551)59553585588))))))/) | cancer | /)585893859/988/5 carcinoma | |||||||||||
/)338)))))5 5:50555: | /)8888385885855/5/)))) | /):39/8:835: | mir-145 | colorectal carcinoma | down | mlr-GbPe | /)398559598/55/)) /)8988833/3/3/3/3/ | )1))89888):) | mii'-SOe- 5p | non-small ceil lung cancer | down | war 5t«? | 5((3313184()))))5 ί|Ο/5/5/5/5/5/5/5 carcinoma | dov.n |
5:30555: | cancer | ί|Ο/5/5/5/5/5/5/5 carcinoma | ||||||||||||
/)338)))))5 5:50555: | /)999)5389/88955555: 5958833839555/)))))5) | /)39/8:855: | mir-145 | esophageal squamous cell carcinoma | down | mlr-GbPe | gastric cancer | )1))89888):) | mir-31 | breast cancer | down | mrr-dtiS- 7:353::7:7:7:7:7 | lidnoy cancer | dov.n |
:/8893858 | ):5833839/5/5/5/5/5/5/ | squamous cell carcinoma | : ·: sqtnniioua: oe ί 1 · carotnoma | ):/353:)))))))))) | ||||||||||
:)3587:)))5 5:8035)) :)3(:))))))): | clear’ ceil renal cell /)8888388/8/8/8/8/8/8/8/) | /)39/8:855: | mir-145 | esophageal squamous cell carcinoma | down | mlr- Itate | ::hopahxollula*·· earewoma | /5)/89888):) | mii-31 | chronic myelogenous leukemia | down | nar 5tm- :::-353:)))))))))) | ):/3833511)))))))): /)5889339939/)))))) | dov.n |
•:-mar-:-:·:·:·:·:·: :50535)) | :/:8893/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ pronnelocj tie /)938533))))))))))5/)) | ::3p/5’:4:/:/7 | mir-145 | esophageal squamous cell carcinoma | down | mlr- Itate | ::hopahxollula*·· ])993i8839))))5 | /5)/89888):) | mir-31 | gastric cancer | down | nar 5tro- 1?58/||||| | ):/3833511)))))))): /)59898998(/)))))) | dov.n |
•:-mar-:-:·:·:·:·:·: /805)5)5 | :::3:9885551)38/7/7/7/7/ | ::3p/5’:4:/:/7 | mir-145 | gastric cancer | down | mlr- Itate | /:/9548/7/7/7/7/:/7:7 ::adenoearcrno·:·: /):(88/)))))))))))))) | /:17:8988:8:/7 | mir-31 | glioblastoma | down | /)3985:1/1)))) | )/858855))))))/)5)) adcnycarclrro ):(98/))))))))))))))): | dov.n |
:/:33:-/:/:/:/:/:/ 305/555 | :::3:339/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | 535/395)) | mir-145 | gastric cancer | down | /)38198839535) | mir-31 | glioblastoma | down | miro? 12,- )/98)/)5/5/5/5/ | non-small celt /)1589895889)/5)) | dowit | ||
/:/3(3:/:/:/:/:/: 5/0555/5 | :/:/gi33a/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | /)3538))): | mir-145 | glioblastoma | down | ))3832898))/)5)) | malignant melanoma | )))/8838)5 | mir-31 | liver cancer | down | :/:/883:9/83/8/): | gastric cancer | )9999)/)) |
:/:33)/:/:/:/:/:/ /55585/555 | 53383))))))))))))5)/)) | /)3839/))) | mir-145 | glioblastoma | down | rolr-?tii)c | malignatn melanoma | )1/):89339/)) | mir-31 | malignant melanoma | down | mir-5l7a· | breast caocer | /)8593))): |
:::3437:::::7 /805/555 | head and necl·- )353858535388)))))))) /)883(89(98/)))))))))))) | ::3p3:i:i?:7: | mir-145 | glioma | down | mlr-dtiPe | mesencin mal /)8983855/3/5/5/5/ | /:17:9388:8:/7 | mir-31 | malignant melanoma | down | mir-3 l&a- 7:3537:7:7:7:7:: | 7(01333:89::7:7:7: /)5588958585858) | dov.n |
m<r- /808/555 | he#· and necl·- )358858585388/))))))): /)883(89(88/)))))))))))) | ::3p3:i:i?:7: | mir-145 | glioma | down | mlr-dtiPe | ovarian cancer | /:17:9888:8:/7 | mir-31 | meoulloblastom a | down | ::3a85:lS37: | esophageal /)589898853/9833)) carcinoma | dov.n |
nan /80855/8 | :393/9500/7/7/:/:/:/ /)8939388995))))))))))) | ::3p3:i:i?:7: | mir-145 | glioma | down | mlr-dtiPe | ovarian cancer | /:17/9888:/7 | mir-31 | prostate cancer | down | mar-319d | liOpatoeeilalar /)588889588))))))) | dov.n |
/:/3(37/7/7 8/088/85 | prostate carcinoma | 53833)5) | mir-145 | glioma | down | n«r-.230c | pancreatic /):888593/)))))))))) adewoearomo 593)))))))))))5/)) | )))/8838)5 | mir-31 | prostate cancer | down | mir-5 | 0 teOtakoma | :)99859/))) |
:80858/8 | carcinoma | earewoma | 3p | /)588895)))))))))):) | ||||||||||
):3(3/))))) 8/08888/ | )33983))))))))))))))))/ myelogeno-us | 538335)) | mir-145 | hepatocellular carcinoma | down | n«r-.230c | rettal clear cell :)388888985))/5) | )))/8833)5 | mir-31893p | glioblastoma | down | mir-dltia | hepatocellular carcinoma | :)99859/))) |
202
WO 2017/132552
PCT/US2017/015417
9:6)666666:3333333333333; | ||||||||||||||
gastric cancer | carcinoma | 33^65666685555555 | lung cancer | /8p/////////// | tong cancer | |||||||||
:5686999999 58:0:55555 | bteaai cancer | 9866:65555: | mir-145 | hepatocellular carcinoma | down | n<h 86 | hepotcgellidar /8^00:9999999 | dowh | mir-32 | non-small ceil lung cancer | down | mjr-526h | hepatocellular carcinoma | 560885:55 |
/:666////// 5105393 | gastnc cancer | 55608:5555 | mir-145 | hepatocellular carcinoma | down | unre?b?.-4p | 5506.8036:9999999 :980665835555555: | 558668:33 | mir-32 | oral squamous c ell carcinoma | down | 0-521» 30:3333333333 | 1. \vat>x eltol u carcinoma | :5668/6:555 |
!UK- 551033333 | bladder cancer | :96666:9999 | mir-145 | hepatocellular carcinoma | down | 5568066660333 | down | mir-32 | osteosarcoma | down | uk •'2t«d- | gastric carnet | :5:8066999: | |
96s69:9:9: 33BB3333 | pancreatic cancer | 5:8063333; | mir-145 | kidney cancer | down | 9966628699999999: | :3660:668555555555 56000:5555555 | down | mir-320 | colon cancer | down | mir-5Ob | :36008^:60:3 bw.g cauvot | 38668:333 |
3666:3:3::: 55036555 :::36:::::9:9:9 | gastric cancer | 556966:3335 | mir-145 | liver cancer | down | 0--283 | bladder cancer | dCwtt | mir-320 | glioblastoma | down | jnlr-$32.- | :36660603333333 | dowh |
3686939:9 550333333; | breast cancer | 556966:3333 | mir-145 | lung adenocarcino ma | down | 0-/283 | bladder cancer | dCwtt | mir-320 | glioma | down | jnlr-$32.- | retmohlastom :38:333333333333333333 | dowh |
3686939:9 550333333; | breast cancer | 556966:3333 | mir-145 | lung adenocarcino ma | down | 0-/283 | 553Ο;68ί;9999999999 536860 555555555555 | dcwtt | mir-320 | osteosarcoma | down | hik--54/2.- :0:9999999999: | gau« cat | dowh |
50699999; 550333333; | gastite cancer | 556966:3333 | mir-145 | lung adenocarcino ma | down | 0-/283 | 553Ο;68ί;9999999999 :36860:3333333333: | dcwtt | mir-320a | colon cancer | down | hur-54 3 | endometrial :/0616:0:////////// | dowh |
/06:///// 550333333; | 9:^8033333333333333333 | 556966:5555 | mir-145 | lung adenocarcino ma | down | 0-/283 | colorectal :5:6800:9999999999: | 558668:99 | mir-320a | colorectal cancer | down | jnrr-54-5 | lung (. ,Wti | dowh |
96869:9:9:: 550333333; | 9:6^669956836:999999: :::6666:666333333333333: | 556966:5555 | mir-145 | lung adenocarcino ma | down | 0-/283 | esophageal ::ade»<jeaECit>0·:·:·:·: :50:5555555555555555 | 55868-65:3 | mir-320a | colorectal cancer | down | jnrr-551a | :50016106319999999: :/00:56//////////// | dowh |
36869393: 550333333; | 969]O395Oti5;9;99;9; 9663066999999999999: | 556966:5555 | mir-145 | lung cancer | down | 0-/283 | esophageal :56066:33333333333: | 55868-65:3 | mir-320a | colorectal cancer | down | 5:8668885555 | 6016065555555555 nty otogenous leukemia | dowh |
36869393: 550333333; | 5:6^068568365555555 96ΟΟ66333333333333: | 556966:5555 | mir-145 | lung cancer | down | 0-/263 | esophageal :56086:33333333333: | 558666:99 | mir-320a | glioblastoma | down | 5:6680555/: | mabgnar-i melanoma | dowh |
!UK- 5305:33333 | hepatoeeilnlar earelnoma | down | mrr-145 | nasopharynge al carcinoma | down | 9:66626)39999999: | esophageal AjUidfiuKS ΟΛΙϊ | 3:6868:55 | mir-320a | nasopharyngeal carcinoma | down | «•6-574-- | breast cancer | :9:8668:999 |
!UK- 330555555: | hepatocellular earelnoma | 5588689:333 | mir-145 | nasopharynge al carcinoma | down | nur-263 | esophageal squamous ceil | 5:6668:33 | mir-320c | bladder cancer | down | 3:6686:74:3555 | 96658h8668;99999: :966606699999999999 | :5:8666333: |
!UK- 330555555: | hepatocellular carcinoma | 598666:3333 | mir-145 | nasopharynge al carcinoma | down | nur-263 | ::56185656333333333333 | 5:6668:33 | mir-323- 5p | oial squamous cel: carcinoma | down | nuf-^yq- :/8p://////////: | 366105606333333: :966606699999999999 | :5:8666333: |
:5886:33333 530555:333 | 56^006053333333: :36000:333333333333 | 5:86669:555 | mir-145 | neuroblaslom a | down | 9966628399999999: | : ·: hepatocellular: ·: ·: 96000:9999999 | down | mir-324- 3p | nasopliaiyngeal carcinoma | down | mir-576- 5:8:655555555555 | SSSiOiSSSSi 366660833333333333: | 98668:999 |
96668939: 550333333; | 96ep6$3e566363939:; :569660356333333333333: | /6068:///: | mir-145 | non-small cell lung cancer | down | Ο-/2.63 | kidney cancer | dcwtt | roir-324·· 3p | nasopharyngeal carcinoma | down | 5:66605555 | glioblastoma | dowh |
9686:939: 550555555: | rivetcancer | down | mrr-145 | non-small cell lung cancer | down | :5:66626539999999: | 6ϊΟΌθ555555555 squahions cell :568656 656 85555555: | 3:6668:55 | mir-326 | chronic myelogenous leukemia | down | :56866623:5:9 9:8699999999999 | hepatocellular :96668609999999 | :3:8668:333 |
203
WO 2017/132552
PCT/US2017/015417
/6555/66666/ 6/3066666/ | $55550535$;$;$;$;/ | /43235/6666 | mir-145 | riou-siriall cell I lung cancer ί | down | ////353213//6666666/ | 46552/25222566666/ | donu | mir-326 | glioblastoma | down | 6/552506666/ | ///2445425////////////////// | //1////50/3/2/////// |
122« | gastric career | lung cancer ! | glioma | 6/554///////////////////// | ///25241244455///////// | |||||||||
/:/554566666/ 17.2;» | gastrointestinal /4252525)//////////////////////////////// | /$5535///////// | mir-145 | non-small cell ί lung cancer ! | down | rmi-cOA | malignant /)/4321252452/))))))) | down | mir-326 | glioma | down | ndr-fib# | obordwma | i/l/i/idc/wri/i/i/i; |
tjCife::::::::: i??> | $55055534325//666666/ /3231552/5///////////////////////// | ))5542 56666/ | mir-145 | oral squamous ! cell carcinoma ί | down | mm-7b3 | malignant ////32/152533/////////////// | ////2535///// | mir-32.fi | glioma | down | $5i258;25;4444 | i. vv.% eiitii u carcinoma | )1/)/553626666 |
USH- i?.2a | /6550222052/6666666 uareiooma | 6555/26666/ | mir-145 | oral squamous ί cell carcinoma ! | down | /6/52325566666666 | /4/53525245//////////////// melanoma | down | mir-328 | colorectal cancer | down | /45255/45///////// | Jana cancel | //i66355/5666/ |
4/55566666/ 2β66666 | /653052525/124//////////////// /6253320666666666666 | 443255///////// | mir-145 | osteosarcoma 1 | down | ////253555///////////////// | 4//2434g25m//////////////// /)/4052452/))))))) | down | mir-328 | gastric cancer | down | uiir-fi 12 | 6/5255422/2142454 caremuina | //1////52452/////// |
:::/5556::/::::::: | bladder career | ))354226666/ | mir-145 | osteosarcoma | down | mir--7.b3 | pancreatic ))252252/)))))))))))/ | down | mir-378 | glioma | down | jnir-ol? | papilraiy /)424/4243))))))))) | ! dowh |
///555//////////// | $55ί3ί$δ5Ο·3/////////////// 4/5245425245///////////////////////// | $/3542266/)) | mir-145 | osteosarcoma | down | mir--7.b3 | 453535///////////////////// ))252252/)))))))))))/ | down | mir-329 | gastric cancer | down | jnrr-o l-i | lung c aflCti | ! dowh |
/:/555/:/:/:/:/:/: ////0///////////// | 4/253235 456666666666666 $5555552253//////////////////// | down | mir-145 | ovarian cancer ί | down | /:/:525/55///////////////// | ;$ρ3233/6666666666 ))525522)))))))))))) | ////53/33///// | mir-329 | oral squamous cell carcinoma | down | miwfil^- ////55/////////////////////// | pareream. /)053525////////////////// | //1////35425/////// |
nai- 440666666/ | breast cancer | 463255//666/ | mir-145 | ovarian cancer ί | down | nnr->’'· | itahdomyosar ////2252/6666666666666 | donu | mir-330 | glioblastoma | down | nab' ic· /6/55)))))))))))/ | pancreatic ///55343:///////////////////// adenocarcino mi | //ί////5ό524/////// |
iltif- ////0///////////// | breast cancer | down | mir-145 | ovarian cancer ί | down | ////525/55/66666666 | r...................... squamous vuuvttten .a | ////5335/:/:/ | mir-330 | prostate cancer | down | miwfil^- /:/)5.5/:/:/:/:/:/:/:/:/:/:/:/ | parereatu /)d4:2452/))))))))) adooocareiry> <·»:* | //16635425/////// |
$555-:/:/:/:/:/:/ ////0///////////// | brean vunewr | :/63255///////// | mir-145 | ovarian cancer ! | down | ////25335:/:/:/:/:/:/:/:/: | jftstra v ancon | ////3555///// | mir-330 | prostate cancer | down | miui-27 | gastric cancer | //1///5555/////// |
!UH- ////0///////////// | ///520/525225/66666666 | /45352/6666 | mir-145 | ovarian cancer ί | down | /6/52352566666666 | )/5424342/66666666666 | down | mir-3313P | gastric cancer | down | mtr-'Di | )/5442542/))))))))/ | //1443555/////// |
///553//////////// ////0///////////// | b-cas1 vOKcei | 4//3255//666/ | mir-145 | pancreatic ί cancer ί | down | ////25/32/22///////////////// | 4424345253//////////////// /)/4055452/))))))) | down | mir-331- 3p | glioblastoma | down | tiiir-275 | /)2542456525))))) ///525252666666666/ | //1////32425/////// |
/:/555/:/:/:/:/:/: ////0///////////// | breast cancer | $:d$5;5/:/:/:/:/ | mir-145 | pancreatic ductal ί adenocarcino ί ma ! | down | mir--73i | rasophaty age 4//25255/235365///////// | dowft | mir-3313p | prostate cancer | down | jnir-oH | gastric cancer | ! dowh |
///553/////////// ////0///////////// | b-cas1 vOKcei | 4//3255//666/ | mir-145 | primary ens ί lymphomas ί | down | ////25/32/32///////////////// | ))254252455/254266 ////5425/525252/))))) | down | mir-331- 3p | prostate cancer | down | tiiir-275 | 6/55254252142454 carcinoma | //1////32425/////// |
///555//////////// ////0///////////// | cervical squamous $220230536666666 | 46d$55///////// | mir-145 | prostate cancer ί | down | mir--73i | nou-small cell lung cancer | dowft | mir-33 5 | adrenal cortical carcinoma | down | jnir-o??^ | ocn-small ceil luus. career | ! dowh |
/:/553:/:/:/:/:/: ////0///////////// | «.OretJ career | down | mir-145 | prostate ί cancer | down | /:/:525/55/:/:///////////// | otaeosoreoma | ////5355/:/:/ | mir-33 5 | breast cancer | down | miM?'7 | :/:5245245))))))))/ adenocarcino mi | //1////35425/////// |
/://553:/:/:/:/:/: ////0///////////// | eOretJ career | down | mir-145 | prostate ί cancer | down | /:/:525/55/:/:///////////// | renal dear cell careir-oma | ////5355/$/ | mir-33 5 | breast cancer | down | miwfi?8- ///55/////////////////////// | ):22556210/6666666/ ///525252////////////////// | //1////35425/////// |
iUll* /6555/66//6/// | colorectal cancer | 463255//666/ | mir-145 | prostate ! cancer ί | down | 66353245///////////////// | leiUtoblaAvtua | down | mir-33 5 | breast cancer | down | mir-6 'V | lung cancer | 6^)35362)))/ |
204
WO 2017/132552
PCT/US2017/015417
ZimriEEE | colorectal cancer | BOlEE | mir-145 | prostate cancer | ! down | mu-X4- ip | beoatix,eliular ;B^hpdik::EEE | down | mir-335 | cervical cancer | down | uiri-6 hi | pancreatic ::E8hbbi::EEEE: | :!ΕέίόΑ·ίΐ5:Ε |
carcinoma | Eb^dtEEEEEE: | squamous ceil carcinonta | ||||||||||||
4puEE:EE | ZtibbAEE | mir-145 | renal cell carcinoma | down | mlr-diM-Sp | gastric cancer | EdbfohE; | mir-335 | hepatocellular carcinoma | down | iiur-007 | Itepatoc ellnlcn Baiaitohid:EE | down | |
ΖηυΙΕΕΕό | cOforextal cancel | 9d0iE?j:EE | mir-145 | uveai melanoma | ! down | nar-2ri4-5p | xpaptBariEEEEE thy roid «. mat m< a | down | mir-335 | hepatocellular carcinoma | down | mir-638 | breast cancer | ;iEd$whE0 |
ΖηυΙΕΕΕό | cOforeetal cancel | 9d0iE?j:EE | inif-1469 | lung cancer | ! down | Ehtii:20:5:EEEE | bladder cancer | down | mir-335 | mesenchymal cancer | down | mir-638 | colorectal ΖέΡΡΟέίΖΕΕΕΕ | ;iEd$whE0 |
0&iriE:::::0: | esophageal cancer | EdotehEE: | rair-546a | breast cancer | l down | EbtiriXgEEEE: | breast cancer | EdhririE: | mir-335 | neuroblastoma | down | ifiir-i-18 | gastric cancer | :i:0d0Wh4E |
UUf· | :B^O;O^4i:EEEE | BbKREE | nur-146a | breast cancer | ! down | mu- itA | breast cancer | down | mir-335 | non-small cell lung cancer | down | nur-^s. | gastrtc cancer | |
ZfoiiEEEZ | gOStlX cancel | ZtidtehEE | tnir-146a | chronic myelogenous leukemia | ! down | Ehnb:2h$:EEEE | EbfobSEbO^i-EE | down | mir-335 | osteosarcoma | down | niir-iA2a- BlEEEEE: | Zpfo$thtg:EEEZ BdhbEiEEEEZ | ^EdofoitZE |
ZfoiiEEEZ | gOStlX cancel | ZddtetiEE | tnir-146a | gastric cancer | ! down | Ehnb:2h$:EEEE | EPhddritetridlcEE B^I^EEEEEE | down | mir-335 | ovarian cancer | down | niir-iAw | B^EEEEEE: s<fnamuu& cell carctttunta | ^EdofoitZE |
tnir-146a | gastric cancer | ! down | Ehnb:2h$:EEEE | gostix vancer | down | mir-335 | ovarian cancer | down | tui' | osteosarcoma | ^EdofohZE | |||
ZititeE::::::::: | Z^hdbfoiibfokEEEE:: | EdotehEE; | mir-1463 | gastric cancer | down | mir--2b5 | Eglidb^EEEEEZ | EdhmhE; | mir-335 | pancreatic· cancer | down | jnir-o4t< | cfohabpgliEEE ciidnome | :!:0d0WiU:0: |
!>4f- | cgbpfehtEEEEEEEE | down | mrr-146a | glroma | ! down | EhPisTGEEEEE | Bi'bh^EEEEEE | Edbbh:E | mir-335 | primary gallbladder | down | nuMr-k | esophageal squamous ceil Ciiduome | :|dflriri::E: |
!>4f- | :Bifofo|:E::EEEEE:E | down | mrr-146a | hepatocellular carcinoma | ! down | EhPiOlEEEE | head and neck squamous cell | Edbbh:E | mir-335 | renal clear cell carcinoma | down | nuMr-k | BthridhEEEE: BObtZEEEE | |:dbriri::E: |
UUf· | 9gbh^EEEEEEEE | BbKREE | nur-146a | hepatocellular carcinoma | ! down | mu-2V5 | hepauxctiulat carcinoma | Εέίό9Α:Ε | mir-335- 5p | gastric cancer | down | xrer-^% | 4^idhid:EEEE: | |
EB4EEE: | hepatocellular Bhterhbhte:EEEEEE | BOIee | mir-146a | hepatocellular carcinoma | ! down | EbftriXSEEEE: | bepatoceliular B^ihbihkEEE:: | down | mir-337 | pancreatic ductal adenocarcinoma | down | lung, cancer | :|Bb;h9E | |
ypiifEEE:: | Zti^ibB^foiEEEE: ZSbfoibtikSEEEEEE: | ZdbbAEE | mir-146a | lung cancer | down | mlr- Iho | kidnro cartel | yddfort::?: | mii-338 | gastric cancer | down | nur -ow- | gastric cancer | down |
hepatocellular B-ifofohfoaEEEEEE; | down | mrr-146a | malignant melanoma | ! down | EhPisTGEEEEE | lan ngeal squamous coll AtikihdriidcEEE | Edbbh:E | mir-338 | oral squamous cell carcinoma | down | tWP4. ' | glioblastoma | •lEdflW'XEE; | |
Zhiife::::::::::: | medulloblastoma | down | mrr-146a | non-small cell lung cancer | ! down | EhPisTGEEEEE | Ei^ligiidhlEEEE melanoma | Edbbh:E | mir-338- 3p | colorectal cancer | down | nuMo8 | ::E^:EEEEEE: xf'janxms cell vOicuroma | •lEdflW'XEE; |
Zhiife::::::::::: | nasophanngeaf Bdfofoh&aEEEEEE; | down | mrr-146a | non-small cell lung cancer | ! down | EhPisTGEEEEE | Ei^ligiidhlEEEE melanoma | Edbbh:E | mir-338- 3p | colorectal carcinoma | down | ;Of^l?;EE | hepatocellular | •lEdflW'XEE; |
neuroblastoma | BOIee | mir-146a | pancreatic cancer | ! down | rou-X' | :Ebikihhhitk:EEE: melanoma | down | mir-338- 3p | gastric cancer | down | mil-' | breast cancer |
205
WO 2017/132552
PCT/US2017/015417
2:)949)22222 )2(5)4322222 | rjon-smail «.eO )()(i(O(7O94()()()()()()()()()() | 7:8244)()()()) | uiir-146a | pancreatic cancer | down | ()()8ft37(253s()()()()()()()()( | preraute )()(999977)2:)2:)2:)2:):):):): | down | mir-338- 3p | gastric cancer | down | ()()4557722222222 | )()84738)93()()()()()()()()()( 2:89898722222222222 | 227377222: | |
7(0777)7 | ()(7757:33 8 8 83:2)222222222 | papillary thyroid carcinoma | :)44432222222222: )()89974()()()()()()()()()()()()( | 3p | )()798869)()()()()()()()()()()( | ||||||||||
7)0777)7 | ))(43(4:79824)()()()()()()()()()()( | cancer | ):):p20S8i28)22)))))))))))))))) )()89974)()()()()()()()()()()()( | 3p | carcinoma | 2)(4748)()()()()()()()()()( | |||||||||
7(0()7)7)7 | ()(843454)222222222222 | cancer | ()(8398432222222222: )()89974)()()()()()()()()()()()( | 3p | carcinoma | ||||||||||
)24339))))))))):) 7)0)7777 | osteosarcoma | )2)9048)2))):)) | inif-l46a- 5p | gastric cancer | down | 2229440)5)2)))))))))))))) | prostate 228447()()()()()()()()()()()() | down | mir-338- 3p | hepatocellular carcinoma | down | 2:)9839/)2222222: | glioblastoma | 2)339)99222) | |
:):)434):):):):):) 7)0777(7 | osteosarcoma | 228944):):):): | rair-146b | breast cancer | down | 22574455)22222222 | 22879)442222222222 )2)999777)22222222222: | 22454)22 | mi r-3 3 Stop | liver cancer | down | 2)4554)2222222 | glioblastoma | )2)77757222: | |
!UK- ((((0(((((((((((() | ovarran cancer | :)4848)()()()() | mrr-l46b | breast cancer | down — | mir- 2ri< | )()(4892)8913()()()()()()()()() vu<re«>ra. .a | down | mir-338- 3p | neuroblastoma | down | uar-7 | glioblastoma | ):)7854)222 — | |
7)0)7777 | /:221:9937498:):):):):):):):) )()(8475447222:)2:):): | 3p | lung cancer | ||||||||||||
):)344:):):):):): (374333(3 | prostate cancer | ;/:8$4)4:):):):) | mir-I46b | malianant melanoma | down | Gun-kriti | breast cancer | down | mir-339·· 5p | breast cancer | down | ||||
):)994:):):):):): ί?-.-.ρ | vstroet ivina | down | mrr-l46b | non-small ceil lung cancer | down | )2)9942(04)2222222: | dear cell renal cell cancer | ))))9843322: | mir-333 | hepatocellular carcinoma | down | )))977-9)2222222: | fcepatoceBnfar (((45457943(3(3 | )27854)222 | |
mu- ΙΝΑρ | bladder cancer | :):8244)()()()( | rnir-146b- 5P | gallbladder carcinoma | down | )()89298773722)()()()()()()( )()(999777)2:)2:)2:)2:):):):): | down | nsir-33a | lung cancer | down | mil-' | hepatocellular carcinoma | down | ||
·:·ϊΐϋ4:·:·:·:·:·: u«i> | gastric career | ytieAn////: | mir-l46b- 5p | glioblastoma | down | nur-krih | gastric cancer | ):)994:9:):): | mir-33a | malignant melanoma | down | /:33978/:///////: | Itepaiot eilnlai )()87545949)222222 | down | |
):)994:):):):):): 7111) | )t)gSs389)))))))))))))))))))))))))))))))))) | )2)98)48)2)))))) | ini.f-l46b- 5p | glioma | down | 222442)04)2222222) | gastric cancer | down | mir-33b | breast cancer | down | ()(433(48432)22 | glioblastoma | 2)339)99222) | |
:):434):):):):):) 7)7777)777 | pa&sreario cancer | 2289(44)22))) | rair-14 | breast cancer | down | mrokrio | jftstra cancer | )2454)22 | mir-33b | osteosarcoma | down | ιη«·-?-5η | glioblastoma | )2)73757222: | |
USH- 7:3)07))))))) | $304////////////////// h npf.chbzu )244381922222222222222 | ):)9848::///: | mrr-14? | orai squamous cell carcinoma | down | :):)44820)4):):):):):):):) | :/g3Siri8)?8n878):):) | down | mir-340 | glioblastoma | down | :):33779/47:):):): | rnaagnafil )()4743)949()()()()()()( | /454):):/) | |
USH- ()()3(24()()()()() | epithelial ovarian ()(2(8)428)()()()()()()()()()()()()()()()()( | ):)9848::///: | mrr-l48a | breast cancer | down | :):)44820)4):):):):):):):) | fcepauxebulat «.arutretun | down | mrr-340 | glioblastoma | down | :):35779/)257):):):): | acute m> eiom icukeuna | /454):):/) | |
:):)994):):):):):) 7)04777 | ()(41(483842324()()()()()()()()()( | ()()92574)()()()( | mir-148a | cervical squamous cell carcinoma | down | 22294220:922222222: | : ·: hepatocellular: ·: ·: >/C:afCin0ift3///////: | down | mir-340 | non-small ceil lung cancer | down | mir-flti | )()7474(43439()()( | )()(73779)()()() | |
7(ίΒ7)7)7)( | mir-148a | colorectal cancer | down | ))))294:2)0)9))))))))))))))))) | )()144944)()()()()()()()()( 2)(744477777722)7: v vui a | down | mir-340 | osteosarcoma | down | mir-'??!:’ | lung cancer | //477///: | |||
):)994:):):):):): 7(3(0((7(7) | oral squamous cell )))43489739)()()()()()()()()()()()() | )2)9848)))))):)) | mir-l48a | gastric cancer | down | 22294:2)0:9))))))))))))))))) | malignant )()(447777772222222: | down | mir-342 | promyeiocytic leukemia | down | ))))9839/952222: | 2)4)509)22222222) ()(897985()()()()()()()()()()() | 2)33o99222) | |
:):)994):):):):):) 7(307(77 | breast cancer | )2)9848)))))):)) | mir-l48a | gastric cancer | down | 22294:2)0:4)2222222) | mecloiiobiasfc )2:49)2222222222222222 | down | mir-342 | colorectal. cancer | down | n.ji-l'7· | breast cancer | 2)33o99222) | |
:):434):):):):):) )(((07777) | breaa vutnccr | 2289)44)22))) | 1.)4-148,3 | gastric cancer | down | mrokrio | oral squamous ceil csictootoa | )2454)22 | mir-342 | glioblastoma | down | intr-873 | glioblastoma | down |
206
WO 2017/132552
PCT/US2017/015417
8:462688888/ 8408/888 | colorectal uuicer | /646446/64:/ | mir-148a | gastric cancer | down | 8866544488/88888/ | acute nu elotd ///404566/88:8////////// | down | mir-342- 3p | cervical cancer | down | /8862248:/(/4////////// | /86666480466888 | 886644888: |
^arvurotua | 3p | lung cancer | ||||||||||||
////6666/88888 4404464: 85588888888 | gastric cancer | :/656446666: | mir-148a | gastric cancer | down | nar-2ba | malignant /:8645105646/8888888 | 5owA | mir-345 | colorectal cancer | down | nm 4*7-1 | gastric cancer | 8/46486/888 |
////6686666668 4404464: 85588888888 | 8:6όη$666ίί1/645/6666666: ;6i66g/i/6665r/66666666666 | 88506$;$/: | mir-148a | gastrciiitestlna 1 cancer | down | :/:/56642/6/:/:/:/:/:/:/:/:/:/: | colon carper | 5owA | mir-34a | b-ceil lymphoma | down | ltU}4*7-! | head and neck ::$ipanio.u&:eell·:·: vatettromn | 8/46486/888 |
////6686666666 4404464: 85588888888 | 8:6όη$666ίί1/645/6666666: ;6i66g/i/6665r/66666666666 | :/856866$/:/$ | mir-148a | hepatocellular carcinoma | down | :/:/56642/6/:/:/:/:/:/:/:/:/:/: | esophageal /6545455664:4488: tmu a | dowA | mir-34a | bladder cancer | down | rtui | hepatocellular carctitoma | 8/46486/888 |
////6686666666 8/40446/6 6064646/ | breast cancer | /856866$/$/: | mir-148a | hepatocellular carcinoma | down | :/:/56642/6/:/:/:/:/:/:/:/:/:/: | glrohtestotns | dowA | mir-34a | breast cancer | down | rtui | 8/60///8888888888888 :-:;XpanXiU&:eell·:·: vatettromn | 8/46486/888 |
////6686666666 440446/6 $08868/:/:/:/ | glioblastoma | /856866$/:/:/: | mir-148a | nascpharynge al carcinoma | down | :/:/56642/6/:/:/:/:/:/:/:/:/:/: | hepatCfCelhiter /88:0606646/8888888 | dowA | mir-34a | breast cancer | down | rtur-h&S- 8:148:8888888888 | neurobiaSfOrit /84888888888888888888/ | 8/46486/888 |
$06$/$/$/:/ 440446/6 $08868/6/:/ | 6:6666660645/6666666: ;6i66g/i/6666r/66666666666 | :/856866:/:/:/:/: | mir-148a | non-small cell lung cancer | down | ndi-Ί-νρ | hepatocellular /88:/0606646/8888888 | 88540888: | mir-34a | breast cancer | down | mir-libb- 8:5:.6/////////////////////// | th> mid cancer | 8/46486/888 |
$:O6$$:$:$ 440646/6 | bladder cancer | :/856866:/:/:/:/: | mir-148a | non-small cell lung cancer | down | :/:/566:266888:/:/:/:/:/: | esophageal squamous cell :/866080808888888: | 88540888: | mir-34a | breast cancer | down | mir-libb- 8:/5588888888888: | cervical ://4654164526/88:8////// | 8/46486/888 |
$:O6$$:$:$ 440646/6 | bladder cancer | :/856866:/:/:/:/: | mir-148a | non-small cell lung cancer | down | :/:/566:266888:/:/:/:/:/: | :/8608850646/88888: /8082606000/88 :/866080808888888: | 88540888: | mir-34a | breast cancer | down | 8:546:68888888: | /80446/88888888888 846666666654888 ///8658888888888888888 | 8/46486/888 |
$:O6$$:$:$ 440646/6 | breast cancer | :/856866:/:/:/:/: | mir-148a | oral squamous cell carcinoma | down | :/:/566:266888:/:/:/:/:/: | esophageal squamous cell :/866080808888888: | 88540888: | mir-34a | cervical carcinoma | down | 8:546:68888888: | gastric Cancer | 8/46486/888 |
$:O6$$:$:$ 440646/6 | breast cancer | :/856866:/:/:/:/: | mir-148a | ovarian cancer | down | :/:/566:266888:/:/:/:/:/: | gastric cancer | 88540888: | mir-34a | chordoma | down | 8:546:68888888: | gastric Cancer | 8/46486/888 |
$086/:/:/:/:/:/ ///406////////// | breaz ^uicer | ////46446/:/:/:/:/ | rair-J4Ha | ovarian cancer | down | /80604:/:/:/:/:/:/:/:8/ | breast cancer | /8:4688/5///// | n)ir-34a | choriocarcinoma | down | 8//4588-6/8888888 | gastric cancer | ////6644888: |
006/646 | :::b/l:6aSt:/iO446/$/$/$/$/ | yOO:/:/:/:/: | mir-148a | pancreatic cancer | down | xfuOli:;:;:;:;:;:;:;:;: | ::h^pato<tellular·:·: «.arutrotun | /:/4665:/:/: | mir-3 4a | choriocarcinoma | down | SjJitsSiSiSS | :::^tS:t/r6::/466cei:/:/: | down |
:::ύ/Ο$$:$:$ 440646/6 | breast cancer | :/856866:/:/:/:/: | mir-148a | pancreatic ductal adenocareino ma | down | 885Ο426688888888: | malignant /:84861666646/8888888 | dowA | mir-34a | colon cancer | down | 8:/446:68888888: | gastric Cancer | 8/46486/888 |
006/646 | 6/02454068/66666666/ /06006/646464646 | ductal adenocareino ma | tue-lanoroa | roelarroma | ||||||||||
64ό6/464 | $046060464646/ | /6460448/ | mir-148a | pancreatic ductal adenocareino ma | down | mu-31! | /826065O208888888/ melanoma | down | tuir-34a | colorectal cancer | down | mil-'-' | uasophart uge al caretnoroa | down |
!Utf- 66856666666 | ////g6a/t46/:/$/$/$/$/$/$/$/$ | down | Jtur-I48b | colorectal cancer | down | ////566-2/66/////////////:/:/ | ////501204668888888: tuelanoroa | 886408888: | mir-34a | colorectal cancer | down | ////54468888888: | oral *quanjous ceil caremoma | /846485/////// |
207
WO 2017/132552
PCT/US2017/015417
$85933333: 12?b | bopatovoOular 358914888333333333333: | 8599939$ | mir-148b | gastric cancel | ! down | $5ί«88ί3$:$:$8$ | 3855308:88$:$:$ :$5O8b8$8$:$8$: | down | mir-34a | colorectal cancer | down | $959 933333333 | 5d55rj58:8:88$8 $33585:8888$ | 3334098:333 |
ion | $88988888ί3$33333333 | carcinoma | cancer | melanoma | ||||||||||
9958:3:3:3 | hepatocellular £8“ί8ί9Φ55888:$9$9 | 35095939 | mir-l48b | hepatocellular carcinoma | ! down | 3358881833:333333 | gastric cancer | down | mir-34a | esophageal squamous cell carcinoma | down | mb'-92a | breast cancer | 3ί333595$33 |
99583:3:3 | hepatocellular £898ί9Φ55888:$9$9 | 35898393 | mir-l48b | liver cancer | ! down | 3358881833:333333 | hepatocellular vtiStViftriffth/////// | down | mir-34a | gastric cancer | down | mb'-92a | breast cancer | 3ί333595$33 |
3398:39$: 39958:3338 | $985i89885:i89$33333: 3988ίΐ48 85:333333333333 | 35995393 | mir-J48b | noo-small ceil lung cancer | ! down | 8:8895188888:: | non-small ceil 81585838ί5ί59$9 | 88595:9: | mir-34a | gastric cancer | down | $9599283333: | breast cancer | 833ddwq333: |
UUr- ίΐόίϊί | 99(9^393:95988398 carcinoma | 85855939 | mir-148b | non-small cell lung cancer | ! down | tur-ele | osteosarcoma | down | mir-34a | gastric cancer | down | :39884833833: | colon carreer | 3:89894:333 |
$9583:9$: 3908338 | 3555g59i8888888; 99859385888:3939 | 95898393 | mir-148b | non-small cell lung cancer | ! down | 85888888888: | Ovarian cancel’ | down | mir-34a | gastric cancer | down | mirk 3 | 5$Pld885th$:88 earcHturna | 31:34888:38: |
9999$:$:$ 12:·!' | 9j55iig555t:9:9:9:9:939 3555591558883:393 | 388959$9 | mir-J.4Sb | pancreatic cancer | down | tnir--212 | 859088888:8:8 33549033433333333 | down | mir-34a | gastric cancer | down | v4ICUtoQia | ||
9958$:$:$ ::9033333 | oral SquaifivKS 8*8 3935:8988888888: | down | mrr-148b | pancreatic cancer | ! down | nuredl 99p | ghoh!n*:oma | 3:5585:8: | mir-34a | gastric cancer | down | mir-945 | $9O59$$$8$: 90585858888$ | ::!33d395$33 |
am· 12?b | i5555ij959l558393:3 | 58599393 | mit-149 | breas: cancer | ! down | mu-214 | bladder cancer | down | mir-34a | glioblastoma | down | mu-'-'dl | hepatocellular caremoma | 384558:333 |
ion | cancer | 8559:58$8$8$8$:: | ||||||||||||
99583:3:3 ϊΟίΒίϊί | Oshi ten uWcl | 35898383 | mir-149 | gastric cancer | ! down | nur-214 | 8359088888: 85^888$8$:$8$: | down | mir-34a | glioblastoma | down | 55yr-8q$5$9 | ηοη-sroaii cell lung c pacer | 3ί33»1555$33 |
$5993939 39958:3338 | ovarian carreer | 35995393 | rair-149 | gliobiastoma | ! down | 0((1-21 i | $:088k5h$9$9$9: 885O5858|88 carcinoma | 88595$:: | mir-34a | glioma | down | $85999:38:3 | pancreatic $c8495$3333333: | /:338858:333 |
$5983939 398583338 | bladder carreer | 35395393 | rair-149 | bead and neck squamous ceil carcinoma | ! down | 8588818838:83: | roton 'aireer | 88595$:: | mir-34a | glioma | down | mtr-9<9?p | vAforx tai $335888888$8$ | /5458433:3 |
$5983939 398583338 | brenz tracer | 35395393 | rair-149 | noo-small ceil lung cancer | ! down | 0((1-21 i | 389888941/33333: squamous cel: carcinoma | 88595$:: | mir-34a | glioma | down | $55998$$$$ | breast cancer | /:335898:333 |
am- 8^85333338 | 3885)99593388888:: | 85593393 | mir-150 | chronic myelogenous leukemia | ! down | mu-214 | hepatocellular 839<88898888$8 | down | mir-34a | head and neck squamous ceil carcinoma | down | 8559983838 | brouciaoioalv $5088:8:88$:$:$ 8858:98484333; | 3ί:34ό88:333 |
$5983939 8^85333338 | Culor cancer | 35395393 | mir-550 | esophageal squamous ceil carcinoma | ! down | 0((1-21 i | hepatocellular 8398i8898888$8 | 885953:: | mir-34a | hepatocellular carcinoma | down | $85998$8$8 | vNor · rover | /:335888:333 |
mu- 3985333338 | 3835)99593388888:: | 85595393 | mir-150 | mantle cell iympboraa | ! down | :mv-2l4 | hepatocellular 8398i8898888$8 | down | mir-34a | hepatocellular carcinoma | down | 855998888 | esophageal squamous cell 8855318559888 | 3:3:4ό58$33 |
mu* 8^85333338 | coloructai carreer | 85595393 | mii-150 | pancreatic ductal adenocarcino ma | ! down | :mv-2l4 | $484855ό333$33333: $58899533833333: | down | mir-34a | hepatocellular carcinoma | down | 855998888 | esophageal squamous cell 889995593883 | 3:3:4ό58$33 |
9958$:$:$ bObbb: | «rokreviJ carreer | down | mrr-150* | pancreatic cancer | ! down | 85888188888: | 8555όθ99$$8$ //cr8599$333333333; | 335899:33 | mir-34a | hepatocellular carcinoma | down | 958858888: | esophageal Xfuanrems celt vuicuioma | :::33dq95$33 |
208
WO 2017/132552
PCT/US2017/015417
3:292333333 /ZB//ZZZZZ | colorectal carreer | /9/29//// | mir-150- 5P | colorectal cancer | ! down | Ζ/Ζ/ίΖ-ΖΟΖ/Ζ/Ζ/ΖΖ | ZZ/n/ZOOZZ/ZZ 2 mpbomas | down | mir-34a | hepatocellular carcinoma | down | /33939/ZZZZZZ | /Βί/ί///////////: | 3/39292/33(: |
/Β!///// | 5p | carcinoma | /9///3/0//2( | |||||||||||
(3229333333 //Β!////// | esophageal cancer | :(:(9993333: | ink-150- 5p | pancreatic cancer | ! down | ((((/OBZ//////// | /(201906133333333: 4//6/2/9///////////: | down | mir-3 4a | malignant melanoma | down | roir-88 | lung cancer | ((1(((9222(333 |
4:292-444444 /(Β////// | esophageal (309090(3333333: 4:992ϊ9φ&ί2:::4:444444444: | 3((99/(3333 | rair-151 | chronic myelogenous leukemia | ! down | (3:2991:5:(:(:(:(:(:(:(:(: | 3(:0/23021(33333333 :(:(2/9/9(33333333333: | down | mirk 4a | malignant melanoma | down | :((3393933333333 | lung cancer | 3/((d0w2333: |
:(:292444444 /ZB//://:/ | gastnc carreer | 3((99/(3333 | mir-152 | breast cancer | ! down | (3:2/993(5:(:(:(:(:(:(:(:(: | 339/23021(33333333 :(((2/9/2/(33333333333: | down | mirk 4a | malignant melanoma | down | :((3393933333333 | lung cancer | 3/((d0w2333: |
nur- Ζ/Β!/:/:/: | Z(Z/62pZ/Z/9229ZZZZZZZ: | //29-/////: | mrr-152 | endometrial cancer | ! down | 3//Z299B/(//////: | 3////22/332///////: /Ζ/ΖΖΖΖ/ΖΖΖΖΖΖΖΖ | down | mirk 4a | malignant melanoma | down | /^29/(/2////: | malignant tueiatmroa | (ZiZ/d/Z/Z/ZZ// |
:((2929(33333 Ζ/Β/ΖΖ/ΖΖΖΖ | gastric carreer | /9/Z/Z//ZZZ | ink-152 | gastric cancer | ! down | 44ήϊη$2(1:66(444444: | /(//2//62^2/2// //26/2/9///////////: | down | mirk 4a | neuroblastoma | down | mir-8h | ng&opha·} nge al carcinoma | Z(i(Z(Zd222(Z(Z(Z( |
::(29244444: ((((Β!/:/:/ | gastric cancer | :(:d$92:4444 | mir-152 | gastrointestina i cancer | down | mlrk.ltib | breast cancer | down | mir-34a | neuroblastoma | down | ////////////// | ||
(4929(44444: Ζ/Β/Ζ//ΖΖΖ | gaatrro cancer | down | mrr-152 | glioblastoma | ! down | (:((9/393:2/(333333: | nasopban nge ai carcinoma | 339/3333: | mirk 4a | non-small ceil lung cancer | down | (3Z/239&333333: | :((93(2939(33333333 :(:062///(:(:(:(:(:(:(:(:(: | 3/32992(333 |
ίϋΐι- /(Β//(/(/(( | hopat^veiJular 2Z//29/22Z2ZZZZZZZZZZZ/: | /9/Z/ZZZZZZZ | mir-152 | glioma | ! down | mtrkMr | na&opltarvnge ai carcurtvma | down | mir-34a | non-small celt lung cancer | down | 23/33/62////// | pancroapc ZOO////////// adenocarcm.o ma | (:/((9292:(:(:(: |
!>,«- (/0(/(/(/( | hepatocellular carcinoma | down | mrr-152 | non-small cell lung cancer | ! down | mif-il? | r...................... gastric cancer | 339/3333: | mirk 4a | oral cancer | down | mrr^ria | Z/hl/dd/Z/Z/Z/ZZ/ /2//999////// | (ZlZ/d/Z/ZZ/ZZ |
ίϋΐι- Ζ/Β/ΖΖΖΖΖΖΖ | Z(Z9j29g92t///////////// lucoortrelmtua | /9/Z/ZZZZZZZ | mir-152 | non-small cell lung cancer | ! down | Z/ZZZOZiZZZZZZZZZ | hepatocellular //////ί////////: | down | mir-34a | osteosarcoma | down | mirk‘hr | /39093//(/3 3269692(33333333: | ((/((9992((((((( |
3:929:33333: ((((Ο////// | /^/9/6///2/29///////: ZZZl2/g(2/2///ZZZZZ/ZZZ/Z | //922/9///: | mir-152 | ovarian cancer | ! down | ::::222(2:ί9::::::::::::::: | :::/3η§(2Ο?ί(44444 | (:(9/332: | mirk 4a | osteosarcoma | down | ::;222-$2a:::::::::: | ::breast: carreer·: | ! down |
(492944444: (/0(/(/(/( | ttoit-zttetil ceil 3(0^999(33333333333 | down | mrr-152 | pancreatic cancer | ! down | /:99Ζι93Ζ/Ζ//////// | osteosarcoma | down | mirk 4a | osteosarcoma | down | mrr^ria | cervical :((06/9//(33333333: | 3/(2999(333 |
499944444 /(0/(/(/(( | 3(2//0/9936/3333333 /ZiZOZOZOZ/Z/Z/Z/Z/ | 3((/92/(3333 | mir-153 | breast cancer | ! down | i!!f-?l * | uSt'usaroAt. .a | (3://39( | mirk 4a | ovarian cancer | down | :((33939336(:(:(:(:( | :((099(1/23(((((((((((((((( carcinoma | ((1((((9/92((((:(: |
nur- (:((0(/(/(/( | :(:Z92OZ92ii>:(A69(4444444 ZZZO!/02iZZZZZZZZZZZZ | :430-2:(444: | mir-153 | glioblastoma | ! down | 4493293:/44444444 | (4Ρ69ρΟ2(4444444 (:(:dl(2i/2:(:(:(:(:(:(:(:(:(:(:(:( adeuocarctuo ma | down | mirk 4a | ovarran cancer | down | :(:22ί68Ζ97:4444: | esophageal squamous cell carcinoma | 4/(2q99(444 |
ίϋΐι- /ΖΟ/Ζ/Ζ// | non-small cell /ΖίΖθ9/92/2ΖΖΖΖΖΖΖΖΖ/: | /:2/Z/Z/Z//// | mir-153 | lung cancer | ! down | mu-217 | pancreatic Ζ^//////////////: odenocarcino 4339/3333333333333333: | down | mir-34a | pancreatic cancer | down | markka, | hepatocellular carcinoma | (:/:(9292:(:(:(: |
(492944444: ζ/Οζ/ζ/ζ/ζ | oral SquarfivKa οΛίΐ 3(20///3633(3333333333 | down | mrr-153 | non-small cell lung cancer | ! down | /:99Ζι93Ζ/Ζ//////// | pancreatic ΖΖζοό/ΖΖΖΖΖΖΖΖ/Ζ adeftctearelno (3:22(3333333333333333 | 339/339( | mirk 4a | pancreatrc cancer | down | mrr^ria | hepatocellular carclrtoma | 3/(29(29(333 |
4:99944444 /ΖΟ/Ζ/Ζ// | osteosarcoma | ((((/92/(3333 | mir-153 | osteosarcoma | down | (3:2i993(S(33333333 | bladder cancer | (:(://9':9: | mir-34a | prostate cancer | down | iBKkWS | /39/9/////////// adentrearomo 3:22(3333333333333: | ((:((((6092333: |
209
WO 2017/132552
PCT/US2017/015417
:/4356////// :454544:4:4 | 4:4006(3544444444 | 4:365634444; | inir-153 | ovarian cancer | down | 4455363534444;4444 | breast cancer | down | mir-34a | prostate cancer | down | niu-9'% | mescncba mai /636634///////////: | /:606444/// |
40444444 | aJcuocatcinoma | cancer | /43344666/////4444444 | lung cancer | ||||||||||
i/liO///// 4454644444: | 45e®|:6544444444444444: 453i6i3344444444444444; | //36565://// | inif-154 | non-small celi lung cancer | down | //336:268////////; | //6636?666;/////////: //633666444444444444 | down | mir-34a | renal cell carcinoma | down | /;556:S5a///6 | non-smail ceft /:(611^5644665///// | 436(65444; |
65635///// 40444444 | smaB cell Jung 4535566///////////////// | //56565://// | rair-154 | prostate cancer | down | ;/:333/265://////// | //03466/43////////// 4;Ο544ΟΟίΙ;4 //655535533///////: | //ddiyb//; | mir-34a | renal cell carcinoma | down | 646(33956//// | von real /556634/////////6/ | //636/34/// |
65635///// 4Ο544444 | non-small •.eO 54i4g4356654:4:4:4:4:/ | //56565://// | rair-J 55 | bladder cancer | down | //456621:6/://///// | ..hofHXvircU'··' //433////////////////: | //5555/:/ | mir-34a | renal cell carcinoma | down | 645(33555//// | /56(64646////////// caret no ms | //636/34/// |
UUr- 44044444: | 4^4640664444444: | 44664634444: | mrr-155 | chronic myelogenous leukemia | down | nur-ilS | //6513436461444///// 44633663444444444444 | down | mir-34a | retinoblastoma | down | 4:5633734444 | Jang c-anccr | 4456(56444; |
UUr- 4404444444 | ;4543334535456444;44444: | 44654654444 | mrr-155 | gastric cancer | down | nur-ilS | //6513636461444///// 44633665444444444444 | down | mir-34a | uveal melanoma | down | mmu-mlr- 2W-?p | :/636654454566/// | 4456(56444; |
:/4354://:4 44044444: | b-eas1 vdKcei | //36563//// | mir-155 | gastric cancer | down | //1316:263://////// | esophageal 45366544444//////// | down | mir-34a- -P | colorectal cancer | down | mmo-mir-- 2‘>b-5p | /546664:546566444: | /35644444 |
:::435-:-::::::::/: 440444444 | gastita cancer | yftow//// | mir-155 | malignant melanoma | down | ;/:6ί366ΐ;5;//////// | esbplxgeat //3a6443;r4to66;66ll/// //655556536///////: | down | mir-34b | breast cancer | down | ink-la 3b | ;/(463ΐ56?1:;///////: ;/6663i5365i4444444 | down //635444444 6143556/// |
mir-34b | breast cancer | down | ί«κ-25& | ga,t« thr «*·* | down |
210
WO 2017/132552
PCT/US2017/015417
Table 4. List of examples of oncogenic miRNA relationships to cancer.
!»i< | Cuta-teC | <WftXS· | Retefetroc· | ||||||||
iet*7a | colorectal $£$$£££££::£ | $$$$$:7 | Crrontanog Kaoromal mrorc-RNAs as Bfomari-ers c-3 $££$£$ah$:$£££££££££::£ | nur- 393h | malignant melanoma | up | rniR.-J93b Regulates Md-1 m Melanoma. | rair-22? | glioblastoma | $....... | mi rouRN A*? 2 5 promote, th* growth aod invasion c-f ghyblastontp cells by targeting tumor ssgapressoi PAAb |
$$£$£££ | $££$$££:££££; $£$$$££££££: carcinoma | /:$:$:$:$: | Circulating nucroRNA ££$$$ $:$$ρ££1££££££$$ biomatkeia for diagamars of papillarv fin, mid oammoma | mil-194 | pancreatic ductal adenocarcinom a | up | Upregulation of miR-itM contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. | mil-223 | hepatocellular carcinoma | UP | Circulating u-icroRNAs. nuR23, ηι®.-ι22χ and miR-223., in patients with hepat^celhilar carcinoma or cbror-ic ht puuds |
esophageal sduaiaous celt $£$£$££££££ | U.S | MioroRMA-tbQ promo-i.es t ngr nr jf md « v vsron through toanimatteu target of mpninycut in esophageal souamyns cell cacmoma | mil-3 95 | neuroblastoma | up | nuR-loa/lb-l enhances retinoic acid-mediated differentiation of leukemic celis and is up-regulated by retinoic acid. | mi:-22:· | kidney cancer | np | iikpressinu of miR-223 in Otero ri! moa! ell v <4 wot s < and its signiftcancaj | |
$£ίί$Ο:£: | gastric cancer | $$$$$$ | mb.N A -223 promotes gastric cancer tavOsiOb anct i k U4a>i h' afgr tii a umor ;$$j$h$££:RR$£i£3£££££/£ | mir-195- 5p | osteosarcoma | up | identification of a plasma four-roicroRNA panel as potential noniuvasive biomarker for osteosarcoma. | mu-2233p | prostate cancer | up | Abb d 3 3 tsroe’ing RHP f' promotes rite hroiogicat behavior yf prostate cancer |
$taitai£e!l:$:$:$:$:$ $$$$£$££££ | $$$:$$$ | Gvorexpressior- of iiramPRAi p«?±.cU an mdm rouble prognrou ra :$$$$:$$i$$£££££££$ | mir-196a | breast cancer | up | MicroRNA-3 9t>a post·· transcriptionaliy upreguiales the UBE2C proto-oncogene and promotes ceil proliferation m. breast cancer. | mir-224 | breast caocer | up | MicroRNA-224- targets RK1R ό cpnlrol «,eb in. ac-ron and expro* sror ui roetasn rouet' in human breast cancer ceils | |
esophageal $$$£££££££: | U.S | $$$;$$££$£$$£££:£££ rotRNAs in esophageal nanvpr $ίί$$££$$$$$$$$$$$$$$$$$$$:$ | mir-396a | cervical cancer | up | MicroRMA-19ba promotes cervical cancer proliferation through the regulation of HQ AO J at'dp27)Kipl Ί | mu-224 | ceroieal cancer | np | Uprcuukifivn yf mixtuRVA221 ssaoovtatad ns-th aggressive progression anct Poor progne-s· 4 in tarn-an cep-leal cancer. | |
mir-b23 | colorectal /:$£$£££££££: | /££:$$$$ | HR3 v rxAcltargc'vi mbiii 3, pla> s a Suppressive rc-le in yolyreclal cancer fax itro | mir-396a | colorectal cancer | up | Upregulation of raicroRNAI9ba and microRHA-fubb cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal earner | mm-224 | s. ok rev <! mror | up | Up-regnlancro of mtR-224 promotes cancer eeli •:-pi-ol!fe-r-aiipn:-audTnvasion:ai-id:·:·: predicis relapse yf coloieetal cancer, |
roir-ffU | oolomctal | $$$:$$$ | h b rouPN A*b< - Prro. .pies Colorovtal Cancer bv Targetrag Tumor Suppressor | itur-396a | esophageal adenocarcinom a | up | MscroRNAs in Barrett’s esophagus and esophageal adenocarcinoma. | roir-22-f | colorectal cancer | up | Mulevptar bmroarkers and viassibeatton rood-ris in tiro evaluation c-f the prognosis c-f eolyreylal cancer |
mir-ld3 | gastric cancer | $££:7:7:7: | mb VA-223 promotes gastric cancer ipvasioo anct i k U4a>i h' arg’- tit a umor ;$$i$h$££:RR$£i£3£££££/£ | mir-396a | gastric cancer | up | MiR-19ba Is Up-regulated in Gastric cancer and Promotes Cell proliferation by Downregulating u2 7ki*ol. | illtr-’J-l | • . v ’ vf | up | ibe.ritaua! and btologi tel sigi-iiKai-teofbUR ’2-i expiessten incyloroetal cancel metastasis |
$$£££££$: ItlSa-Sp | bladder career | $$£$$$ | hitcrobNA profilmg in kidnro ai'C bladder xaixeis | mir-196a | gastrointestinal stromal turner | up | Upregulation of mxLR- tuba and HOTAIR Drive Malignant Character in Gastrointestinal Stromal Tiunois. | mir-224 | colorectal cancer | up | n«eroRNA--2?4 Promotes Cell frolifeiariun and Tuu-yr Growth ra Ehnrara Colorectal Cancel ta Repressing PUiPRl andPlHPR? |
211
WO 2017/132552
PCT/US2017/015417
mm-Rtfra | $334243555555555 /35455444444444( | (454((((((: | /(:35445334:4433534:24344((: i-'f-am vOtoreaaUaocer and /($s/$5233:5ig4i/4k/5423(((((((((: | mir-196a | glioblastoma | up | MiR-196a exerts its oncogenic effect in glioblastoma multiforme by inhibition of I?B? both rn vitro and in vivo. | (/3554523444 | 55Ο233424555555 | 44325555 | fRffeci of antisense ntiR-224 on gastric cancer cett prol-fcration and apppfpsisj |
mir-ldoa | coiorectal /(554554((((((((((((( | 4:454(:4:4 | Candidate owtipRNz' biomarkers tn butban cokrecial cancer. Systematic reuew pioftbriv studies and e\pentncnii! Aabriutti”!. | mir-196a | head and. neck squamous cell carcinoma | up | MicroRNA.-196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance. | mri-TM | $3333(((((((((((((( | /5442555555 | Upregulation of nttefoRNA · 224 conf ers a poor prognosis $334232(34434355555555555555555/ |
•zKlifvilXsq:·: | $$34343243555555/ (:5454554(((((((((((: | <P | TSA Suppresses niiR-ihhbA x t lister^xu*·' surei through Pop rtregulannn of MYC andlnhiirits Pipliferauprt and induces Apoptosis in Human EMC | mir-196a | non-small cell lung cancer | up | MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting H0XA.5. | /42254225(((/ | ////333334:32455555/ 4//55453533/5555555555 | $43555555/ | /(/32324/422323-6344/34223/555/ miR-224 irpregulxtednt /(/2433/322235323/5555555555/ nfiammaiory paihwavs |
mir-ldoa | gastric cancer | ((44(((((( | Circulating microRNAs in plasma cf pauems with $^344423433355555555555555555555/ | mir-196a | pancreatic cancer | up | MiR-196a Promotes Pancreatic Cancer Progression by Targeting Nuclear Factor Kappa-B(nhibitor Alpha. | jp.ii-224 | hepatocellular carcinoma | $442555555 | Androgen pathway stimulates microRN A 2 Ina transcription /($0234433/443/34432555555555555/ aufgwessot tn iungcawoer-l 55O25243345555555555555555555555/ bepatpcarcirtogenesls. |
mm-Rtfra | XJS{«·; -UiXCi | u.i | /(:5/54330/5354455:454((((((((: human gazm. cancer | tnir-196a | pancreatic ductal adenocarcinom a | up | MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. | mu-244 | 4//h353555l335/55555 carcinoma | up | MicioRNAGAt <> ου· regulated in hrepatecefiuiur re mm afl’r.uphv'tu'n'i :/:/322/2533442:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ |
mm-Hk-a | gastric cancer | /:24((((((: | nuP-lUba is fireque-irtR unregulated in gastric cancer andinfeibos die extnnsic apoploUe pathway by ((33244442322/////////////////////////////////////////// | mir-196a | squamous carcinoma | up | Unique MicroRNA Expression Profiles in Cervical Cancer. | mtr-22-l | hepatvKlhdar caremoma | ($3/(((((( | ttiuR*? N promoted vO'd migration and invasion by modulating p-PAK.4 and MMr-9 \ ta targeting /(43223423/442322((((((((((((((( bepatOvNiuiar eno.ifiuma |
mm-Rtfra | gastnc canter | (:24:4(:4(: | /(:34/554545/454453/:454:4:4:4:4:4:/: /(4i54454525:44445(24/45454:/:/:/:/:/:/:/:/ ptasma vi patients with :(g5542$/$555i453?3/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | tnir- 196a* | gastric cancer | up | MicroRNA profiling of human gastric cancer. | 5/43322555 | 4453535551335/55555 ((33545555 3 5555555555/ | 44335/3 | MicroENA-224 upregulation /(:33/332/34224422((((((((((((((( ®Ai\.r<ttAte$v 3··χΚίΡ0ΛΓ progrtesis in patients with hepatec vlluUr carcinoma. |
mm-Hk-a | gastric cancer | (:24((((((: | nisP-ddba cvnfers ci^ttatm resistance bv regulating RTEN/Akt pafhwaj in gastric (245545/5533444444/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | mir- 196a 1 | glioblastoma | up | MiRNA-196 is unregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. | illtr-’J-l | /(:535305015555/((((( caremoma | ($3/(((((( | ((3234222222/((((((((((((((((: clxreactt-ifzstion identifies niiR-R85-$p as· a potential nradrer for detecting liver 32232222/((((((((((((((((((((((((: |
nur- Cx-a | gasUte vgneei | ((454(:4:4 | MicipRNA-k>6a targets ΤΓΜΓ2 tv regulate inv asipn and luctaslasife of gastric /(245545/444444444444444444444444444444 | mir- 196a··! | oral cancer | up | OncomiR-i 96 promotes an invasive phenoty pe in oral cancer through the NME4JNK-TIMPI-MMP signaling pathway. | $33(0555/ | ((525343335/5555555/ | 443235/ | Mk-oRNA 22a ta-gcsERGd $33/2343344324244344343445555 progressions of menitigiorta |
nur-ttida | ovanan cancer | up | ;(i2ite3355:O33W/:444444444/ expression signatures and cett type -specific associauprt wuli Taxol resistance in ovarian /:/:2^/1025/25:/2/^550(/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | mir- I96a-l | oral squamous cell carcinoma | up | miR-196a Overexpression and miR-196a2 Gene Polymorphism Are Prognostic Predictors of Oral Carcinomas. | um-.:24- 4||/45555555; | ovarian cancer | up | ·. \ .< 5 · sK tea -s associated with the anginal cisplatin ire istatx? 01 ovarian papillary serous carcinoma. |
212
WO 2017/132552
PCT/US2017/015417
4:2l28«824444444 032500000 | gusto wer | 020002004 | Circulating microRNAs in plasma of payouts with 24260010500062610:44444444444444444444: | tnir- 196a-2 | glioblastoma | up | MiRNA-2196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. | 323ui4228002 | bladder cancer | 2;205|5| | Mjcro-RNA pmrilmg m kidney and bladder sneers |
gfbiNgcgcg: 0:00:0000 | οιλϊκ v-n.cer | 24602444444 | Μι τυΡΝ A prefiltug of human gasure cancer | mir- l96a-2 | oral cancer | lip | OncomiR-196 promotes an invasive phenotype in oral cancer through the NME4 JNK-TIMr 1 -M2MP signaling pathway. | tum-Bit | breast cancer | 05500020 | e-MNG regulated miE?BoBB2.'-27a cluster promotes mauuoarv caremoma cell invariun and hepatic metastasis b\ :2t^0e2tihg2tip2rflii2t554.:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2: |
:::0003:3:3:3 06000000 | gastric cancer | up | 44R335303ti52«i23?8550i2444444444444: circulating mhR-21 tu the plasma of payouts with 242680ri62$8OO0s424 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4: | mir- l96a-2 | oral squamous cell carcinoma | up | miR-196a Overexpiession and miR-196a2 Gene Polymorphism Are Prognostic Predictors of Oral Carcinomas. | 240018230444: | colon carcmnuia | E\cro sum and chmcal significance oindR-Ba and avikWiz A-ppressnr Ϊ m 4460502528605:6^444444444444444444: | |
gfbiNgcgcg: 440044444: | 3gfi0004:44444444444 | 24002222222222222 | Gem u-regnUito» vi nuP Jti!6b suppresses the growth 026f 212310203:^05 02044605-244444444444 | mir- I96a-5p | gastric cancer | lip | Clinical significance of upregulation of mi.r-l96a-5p in gastric cancer and enriched KEGG pathway analysis of target genes. | tum-Bit | cPtoreotai cancer | 05500002 | Cirenlaimg INnsotua! muroRBsn Fiu'iiViW 440;5OO£O00:04244444444444444444 |
4::000:4444444 220360822222: | head anti neck 240086000:000:444 carcinoma | 240P2444444 | ( oreprelumsrce MicroRNA ::profilklg:foi:head:an4nee:k:·:·:·:·:·: sqnane'u* -cli ^aren<pn<a> | n8r- 196b | colorectal cancer | up | Upregulation of microRNA196a aud microRNA-196b cooperatively correlate with aggressive progression and unfavorable prognosis in patients with colorectal cancer. | mir-.Ba | adenocarcinoma | 00020020 | MicreRNA-2?n promotes the 23gl:02d'2th20i:g8$tri02:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2: 443505Oi0i50h^206ti:h550 42 0 24 4 4 4 MGCKO? and tfo-wnregtdntes ynerieakiO-6 receptor |
2:004-832222: :00:044444 | hepatocellular 2460680000244444444 | 05600002 | Over-expression of itttR-idGh promotes colt migratyxt and metastasis in hepatocellular carcinoma lz< activating ep.triehd*mes't. bvn.al transition precess | mir- 196b | esophageal cancer | up | Differential expression of miRNAs in esophageal cancer tissue. | mu·-Ba | 4O06444444444444444: adertnonreinoroa | 0000002 | miR-Bra targets interferon 242r5^8?0i6i52:i65i0262i24565244444444444 2426^5^5i32355‘ii804444444444444444: preirieutmu and pachtaxoiindttceri apoptosis in gastire jdu xz.rcm .juj ^cUs |
4:008:4444444 0:0400444 | 43008103011010:2444 vareitWKua | !1.5 | U preguiatrnn nf microRNA!bb is ass-rcrarej whit pour prognosis :n hepatocellular 4460rei60m0424444444444444444444444444 | tnir- 196b | gastric cancer | up | Transcriptional regulation of miR-J96b by ETS2 in gastric cancercells | mu-2ui | pasutc cauvcr | np | MdNBa m Amplified Bp:: I'! net Targets MetallcthtonemdA and Frcunoios Grow tb m Gastric 2 2 2Ga866i2G35$244444444444444444444444: |
30082222222: :00:044444 | 430>06g06k244444444: 24606802600424444444 | 2:00444444: | MtRBB-b promotes ^eli proliferation vta targeting R£i in laryngeal carctnoitis | mir- 196b | gastric cancer | up | Epigenetic regulation of miRI96h expression in gastric cancer. | mir-’Pa | gastric cancer | 2404444444 | Upregpfiatren vf mrerPR NA* Ba/b pre tuples tumor progression and confers poor prognosis in paherds with 2 2 25^002:68060264444444444444444444444: |
5ΟΙΙ5 | 828OSsssss carcinoma | 0000202 | the tumor suppressor RUNX2 mlarvngea! caremcono colls. | 196b | up | glioblastoma but not in anaplastic astrocytoma and has prognostic significance. | 02002000 | 443i8i05023i0288i5828hti444444444444444 wtiWbfo urpetbremu·^ suppressor EPBB! ; | |||
4:008:4444444 0:000004 | meduliobiusto 240044444444444444444: | a.5 | miR-bAb ii oaercvpiesscti tn toedti!Ri8n;uupas aud mom strict h uni INI\ | tnir- 196b | glioblastoma | up | Upregulation of nuR-196b confers a poor prognosis in glioblastoma patients via inducing a proliferative phenotype. | mu-2ui | gimtirn | np | I nsetiug tiivPREl^Gto iribifwi photon edi tn\ asmu 4:5i50^:^:E3iS04444444444444444444444 |
213
WO 2017/132552
PCT/US2017/015417
(:94545-(((((((( /Βό/ζ/ζ | (985/14598/((((((((((( xftrc«w>tra | /5//((((( | MuroRMA im n8 cuienf re a roetaatatfe non-frrectfening pituitary earcmcma | tnir- 196b | oral cancer | up | OncomiR-*96 promotes an mvasive phenotype m oral cancer through the ΝΜΞ4JNK-TIMP1-9MMP signaling pathway. | (99/54/2859((( | 9(3/8/4/8/114/84/((((( curetuotua | /B///;/ | Stat '-mediated acir, alien of :tuR-23a suppresses gnteoneogenesis in. ((h3/8t3534i9/i835984/i3588/9h9/9(((( dywraegmiatingG'PC and 43840/9/9/9/9(/9(/9(/9(/9(/9(/9/9/9/ |
99995/88/85((9 | 9(gl4o8489(((((((((((( | 9(3/9(((((( | Mt mRX-v Ihbb zp ''V' f glioma himtxigeiisis by 9/i^88i^9;^!^i8;&4/88(;9(((((( suppressor genes. | mir- 196b | oral squamous ceil carcinoma | up | miR-196a Overexpression and miR-196a2 Gene Polymorphism Are Prognostic Predictors of Oral Carcinomas. | mir-25a | ary Jigeal cancer | /9///9/// | Hmb nucroRN k Na opresston m Igiy j-seal cquamoiUvod uaroinomat* asroetateri reith poor patten: ρ:ί!··ηοχο |
/48439187((( | xustnc -Uixet | U·· | MuroRMA-ib’ promotes proliferation of gastric cuncet cHbfr· are^ttn? svslm /9/^53^^^8/^99^////////// | mir-3 97 | breast cancer | up | Role of microRNAs -29b-2. 155, -3 97 anti-205 as diagnostic biomarkers in serum, of breast cancer females. | mii-2'u | 9(:8/84/84/^484/8((((( | ijp | MtcroRNA-2 fepromores neuroblastoma ceil inetastasis 9995594888585598:913819899999999999999999999999999999999 |
(983848/((( | gastric cancer | /Β/;/// | MkrcRWA-lri?, an oncogene mkipRMzk that regulates >/ί^ϊ488ίί8/Ηϊ98;88ίϊ^8ί94ί9£849///9:9:9:9:9:9:9:9:9:9:9 9(984/45588/90 £·ί · R1 ir gis.i-ic xtixen | mir-397 | follicular thyroid carcinoma | up | A. limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. | mre-Mb | bidder cancer | /3//9/// | 999 145c8(RXA39fefii55948(((((((((: kidney and bladder caocers. |
imr- i»7 | /9/8///9/ | miPNA-223 prymyles gastrk 9(59/3/58/8/5/4/895589(((((((((((((( reetavtasts by targeting mumr (958/0/58988///^3((((((((((((( | mir-197 | lung cancer | up | Differential MicroRNAs Expression in Serum of Patients with9Lung Cancer, Pulmonary Tuberculosis, and Pneumonia | mir-23b | ((/^44:8(/8//3/9(((((9 | /511// | mtRMA_-22S promotes gastric ((b8ffe388355i589583((((((((((((((( 5«*tiMVbin argetwotpn^r suppressor ΕΡΒΊϋ ; | |
:9:9888/879:9:9:9 | jftztru «.anoer | 9(3/9(((((( | 9(5/4ZW!59ti8/98i:98'8i33R9N9A(9((( 10” reduces proliferation m bun.auga tnv can?e: cells!» targeting the IrtmscriptipK (:i8/t/89B/?B///////9/9/9/9/9/9/9 | nur-198 | pancreatic ductal adenocarcinom a | up | MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biom.ar9ti.ers for chronic pancreatitis and pancreatic ductal adenocarcinoma. | lum-Bh | gastrin cancer | /9/3///;/ | 9 9 9 9i9435'^8ti889fl4(84fei8RM9A(9(((( N a/h preufiviev tumor progression and confers poor prognosis in paifenfs y«5h ((gO48(584338(((((((((((((((((((((( |
9(588(4448(((: | 9(/54/8(519558554((9 | /Β//// | MkiyRXA-10a targets <HL1 arid pioroote» vcli grow rh, 9(48i4Z/8/8(/8/9/5858r3838(((((((: human cervical cancer cells. | mir-199a | gastric cancer | up | miR-199a regulates the tumor suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. | mir-23b | oxa··#' vdKcei | /O/ZZZ | MicroRNAs O'-erevpressed in re ansn ALPH1-positive xblls 9/:fe88/5;889e^9t.84<^:9583t^9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9: ((8585338585859((((((((((((((((((( |
/358:188((( | gastric career | /3/9(((((( | p.uRMA expression prolife in primary gastric cancers and patreri fy mph uode meiastases redieafcs tJjei naR.-ltka plays a 9(4/4/9 33/r9rB8/45Si8if34/9((((((((((: pnmnry Ka&fnvreuxe· ly :9(4/84/8:859/84(((((((((((((((((((((((: | mir- 199a-3p | esophageal adenocarcinom a | up | MicroRMA 223 is Upregulated in the Multistep Progression of Barrett’s Esophagus and. Modulates Sensitivity to Chemotherapy by Targeting PARR·. | /85/2/((((( | 9(54/8449358/84((((((( | O///;/ | Aos'rofairotibero ecu rar-24 anti roar U'g mibimaltu-rixed paraffin-embedded tusues of 9999845884984808449999999999999999999999999999999999999999999999 |
9:9388588(((: | 9(/8/84/88/((((((((9 (9/53///((((((((((((( | 9//3///9/ | 9 9 9 9Mi34/RXA(i88:i8((((((((((((((((: oven?xpre&se8 in human 9(/5/84/588858//83/3((((((((((((9 im aR cl in n, w.v aso-cpcss partially via suppression of 9/4/89433^4:88/89:9(((((((((((((((( | mir- 199a-3p | gastric cancer | up | MiR-199a-3p promotes gastric cancer progression by targeting ZHX1. | (:44//8/9((((9 | breast carcinoma | /Ozzzz | •:MiyroRXA:miR-:;24:Ef!itan<ys·:·:·: ((3/543(^/^885(853((((((((((((((( Metastasis Ire Targeting /3BB/9/B9ZBZZ///Z/Z/Z/Z9 Promote 9BGF Signaling |
999(35885(9((: | Xidd'. * am'. | (:95/((((((: | MumRl 1 A-lrib promores migration and invasion through KLF4 and BOxDXS m hunan bladder vancei | mir- 199a-3p | osteosarcoma | up | identification of a plasma four-microRNA panel as potential neninvasive biornarker for osteosarcoma. | :9:388(//9((((: | 99998/0//8999999999999999999999999999999 | 9((849999999999999 | 999/3439-928999^8815:8899113999999999999999999999999999 prohrerationand tn\ asfen of 9 9 9 9gi9i08i39B/9B:7i94(88938(((((((((((: 9 9 9 985844ί85/75ίτ3998:8448ίί4ί84(((((((((( |
214
WO 2017/132552
PCT/US2017/015417
breast cancel | )43/)))))): | Exosome-mediated txanafei of miRUPb promotes cel! Mh aston tii bmasf cancer | mir- 199a-5p | esophageal adenocarcinom a | up | MicroRNA 223 is Unregulated in the (vluitistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARPi. | 65/333/66666 | 5)5/3330/0(131/(55))))) carcinoma | 63/666663 | MrcioRNA-24 Modulates 5)^34(343(3443^303))))))))))))) Hepatocefiular ( memoma ^PfognosisandTumprigunesis:·:·:· | |
4//4-30/44 | 5)/010(03/())))))))) 5)034//())))))))))))): | 5)305)))))) | 50501/(0/0(305)))))))))))))))) 5)4/(4/0(/030/)0)/0))))))))))): invasive role fit colorectal cancer through enhanced 5:5:04:5/43^/04:75:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5 | nyr- 199a-5p | gastric cancer | up | Up-regulated miP,-199a-5p in gastric cancer functions as an oncogene and targets kloiho. | ):/3452/5555555555 | tiepafOxAitiiiar ))0/6636/33))))))))))5 | 5555336666665 | rniR-M promotes the 5)3(0iif3r:/30/)/353:(04 001/((5/(5:)))5 tiff «.tab'· <argvtiP4 -OV |
43/(405)0 | esophageal 5)0/00)))))))))))4 | U«< | MiofoRNA-ibb promotes i i'pr m re md n \ vs.on :5:5(/4/0/(( 5Ki)E3:5i3 5//(0.3/:5:5:5:5:5:5:5:5: esoptegeal cancer ceil tines | mir- J99b-3p | esophageal adenocarcinom a | up | MicroRNA 223 is Upregulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARPi. | mu-24 | 5):133/5/4(/6/6666666666 | op | Pialuatmuof ❖ oamte vfcance of serum mill-2 Ϊ and miR-·?^ mpm- and post-opotatite lung carcinoma patients. |
555:0/010:5:5: | gastri’. vSt'Cer | 5)305)))))) | 5 5 5 5 0(000053(0(/01//:/41/)))))))))) no asron dir ouch RimC-aKT )3/003//533/(0/0504))))))))))))) targeuug !K(>3>lf,in gaxtrre .Muvr. | nyr- 199b-5p | papillary tiiyroid carcinoma | up | Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma. | ):/30523))))) | tiasopharyngerd 5;5;/536έ(66346ί3;5;5;5;5;5;5;5;5;5;5; | 65336666665 | pTifif at ignifnaute B plasma miR-24 dysregitlaltan 664(5(33(300066666666666666666 :)531/0(/0(/3/:))))))))))))))))))))))))5 |
)553/(405)0 | gaxtne earner | U«< | 5):(2(13305314/0(/3(/66666666666666666 ytgntfuante ol nuRMbb expression tn gastric :5:/30(/0(/45)))))))))))))))))))))))))) | mil-19a | lymphoma | up | MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer ceil proliferation and invasion. | mu-24 | 5555/3(/3/335/3/666666 lung «.oncer | tip | )550’p53t(3(i3(363:33((O236666666666 prupto'esccl· vmkfemtim. m iutretwgN* 1 'nnwri'l :5:5003640433430:))))))))))))))))))) |
5 5 5 50:30(05)) | gbobiastoma | 5)305)))))) | Oncogenic effecis of tiriR-dbh 5)i05gii/‘0i/30(/35$400/:00(-4)5)))))5 | mar-19a | bladder cancer | up | miR-19a acts as an oncogenic microRNA and is upregulated m bladder cancer. | ):/30523))))) | uor'-smsBcbU :5:5153(3:4/(34(5:5:5:5:5:5:5:5:5: | 65336666665 | Circulating naR >2 rufP-Ί and miR-34a as novel predictive (immature to 5)/336/((340363/43/666666666666666665 • hrmmf’UjpA mu-barted non small teilhing canter. |
555Ο4Ο555555 | gbobiastoma | tip | Expression of 19 microRNAs 5)3/5/0(0/(/30θ5{/3θ/))))))))))))))) comparison with ether brain 5)0/03(30(/3050//0/0505(((65)))))))): | mir-19a | breast cancer | up | MicroRNA expression profiles in human breast canc er cells after muitifracticn and single-dose radiation treatment. | ):33(552/:5:5:5:5:5 | 555:3(/l566f/333365:5:5:5:5:5 cell carcuxtoxs | msR-24 up-iegylatioti m nml • vmumma puS-terc association from crimeal and 5)304(((0:0/544030:))))))))))))))))))): | |
55550:30(3))) | 555/((0(//5555555555555555555555555 | 5)305)))))) | MjcroRN A (dh induces glioma ceii impsivK 4y 5)533/4(/6566^5/^^6543)3(6535))))))) uRAR expression via )365/6/403/5))))))))))))))))))))))))))) | mar-19a | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis by targeting LA.TS2. | ):/30523))))) | oral squamous cull tere-noma | 65336666665 | Genomewide Study of Salivary MicroRNAs for Dplecliot’ oPOral Cancer |
5)50430(05)) | : :fc?patoeelhiiar::: 5)0/Οι3/ί05)))))))) | m | nuR-lOy is ov erexpresspd in (icparocoiiuiar carcinoma and ptuipuies <eil proliferation migration and ittvssmn 5 5 5 5((4/4/4(04453/0/((35)))))): 66/03))))))))))))))))))))))))))))))) | mir-19a | cervical cancer | up | MicroRNA-19a and -19b reguiate cervical carcinoma cell proliferation and invasion by targeting CUL5. | •S3·.·. ||............................ | )3(03334/033:)))))) | 663366661 | ))033^5(4g33(^533K)))))))))))) 2 (a -24-2~2a cbisfer promotes tmammaix carcinoma cell invasion and hepatic metastasis b> 555434/((0/)4/(0/0(4))))))))))))))))) |
215
WO 2017/132552
PCT/US2017/015417
97777333 | 37554574775333 ^arcwwntui | 8454888888: | MicroRMA-ttib promo-i.es t npr ί» jp mti a v vs.oa :(((759iig5((c7^77k((S33ia4((///:(: bepaOtelhikp carcinoma 477i5(888888888888888888888888888888888: | mil-19a | cholangiocarci noma | up | miR-17-92 cluster promotes cholangiocarcinoma growth’ evidence for PTEN as downstream target and IL6/Stat3 as upstream activator. | /:(tiute2(4:-//// 11449595 | (3(555958(53 5 9 943333333 | 975(887 | UflRNA-24- promotes veil (377577755(557:754955888888888 apoptosis in hitinanbraast cntrceibv tametm£p2''i.tipi |
/((mircdtih/// | king cancer | (87888888( | mterc-P.NA otiR -J. Ok /((ί75775(ΐ®755δ:7ίϊ(:(:(:(:(:(:(:(:(:(:(:( 8855574458858585538997:787888888 apoproaia nt won woatl cell funovan’-ertN w t rotite | mir- 39a | colorectal cancer | up | MicroRNA. expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening | mti-2-4- ;|75;5;5355 | (:(533:47(//////////////( | 9(999999: | miR-titi-3p and mtR-Ga-dp promote ceil proliferation in gnomacpllsMa coope'ytrce 33597474543557^7:4//////////////// |
/(timr/dtifi/// | ngsopharsagea 35(45757573333333 | .<p | Over-expression of ntiR-ltib 8(45058575775497554578853 88875857(98855387(85858888888888( | mir- 19a | esophageal squamous cell carcinoma | up | m-·- 2? | (3(45785573(3333333333 | 57(9(89(8 | (((((hyR/-2($((pibi(rt0(t9$($Sti(///////////: pmldetation ba targeting h 1 Ί tn I'tOiXte. en rc at eammoma KeLa cells :. | |
9777888 | mtsopbaivngea f earcmotua | in* | miR-ibb rrornotefe Migration (355985 7 7 7 5 53 7 88888888888888888888 Nasopharyngeal Carcinoma | mil-19a | gastric cancer | up | MicroRMA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. | mu-2' | colorectal cancer | HP | Association of roicfoRMA eypressmt. with ntrcro^mfhio instability stains to colorectal :(3(7(7ό3(77 47:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: |
:/777::/:: | non-small ceil kmg cancer | (/7(////// | /:(7:7(5(57(57:/(1(7(///////////// (85785845577857(7988888888888: proliferation. and promotes apoptosis in non-small cell htog cancer tNSCLCt cells. | mir-l9a | gastric cancer | up | miR-J 9a Promotes Cell Growth and Tumorigenesis through Targeting S0CS1 in Gastric Cancer. | 8(777^3(((((((( | critoractai cancer | (87(:(:(:(:(:(:( | The e\prc>>:ou nt mtR-?c is orcroas'dm jterc ?bairc'. and >s a$x«'i3:ed uitL patient (35757958(33333333333333333333333333( |
(/ny(r-(li)b(//( | upn-smah celt (3449585944:958888888 | (/7(////// | AhcroPNA-dtih indicates a 8855948988577598554585844999(///( cell lung cancer and targets E- 88997778888888888888888888888888888 | mir-19a | gastric cancer | up | MiP.-19a'b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor (MXDJ | :/77/2(5(////( | endometrial 3379598:888888888888888 | 3(97888888 | T$$ A Suppresses iniR- itiob 03 2d Chisie· Expression through Dow mogubtion M (3(577:9745755588888888888888888 Proliferation and induces Apoptc-Ste in Human EMC |
:(:777/// | (/78(777///////( | up | Oncogenic function and eafiv (8(573587577774(55//////////// miRNzvLib in oral cancer as identified by microRNA /75757/(///////////////////:///////( | mir-19a | gastric cancer | up | MiR-19a promotes epithelialmesenchymal transition through ΡΙ3Κ/.ΑΚΪ pathway in gastric cancer. | mj!-.?·· | esophageal (35547755579555333 carcinoma | MkmRNA-25 promotes veil migration anti w.\ asm?l jn esophageal squamous toll (:(:03ίόΜ0(τ9^(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: | |
(((77(0fi(((((( | pancreatic (89558578888888888888 | (/7(////// | ((((MtaroRNA/(lfih(i$((((((((((((((((((((((((((((((((( Overexpiessed <n pancreatic earner. promotes its W\ 4Si\ «.mss Vid uffCilkx :/:5'ti55d/77(:57574i7(/////////// | mir-19a | gastric cancer | up | MiP.-19a promotes epithelialmesenchymal transition through PI3K/AKT pathway in gastric cancer. | :/(77/2(5(////( | //esdphjsgsaF//////://: 33545959955:8855(/////( (3(45785373(3333333333 | 87(888888 | Ciimcai significance of somm miR-223, KiiR-25 arid miR- 339579777577757333333333333333 esophageal squamous cell //0797075/////////////////////////// |
(((777/// | 877997988888888: (85555558888888888888 | up | ((((k(ti$i4RN-7/(i9(5(i$(//////////////// over-expressed tn pancreatic (8(539535888888888888888888888888888888: | mil-19a | glioma | up | miR-19a and miR-19b Overexpression in Gliomas. | ....... | 3(539899885999(45(88888: | 975(5(53 | itaRN A 22' prQMO'fc}. £<.>trrc (3:4575559794975(547333333333333333( metastasis 'ra targeting ttura-r suppressor 1·:Ή·ΐ H.5 |
(8777888 | pancreatic 594 7 7 53333333333333 adenocarctncyn | up | 33450703445747377535558 sure-vd <rod •'teroorcsisian.te ((((53(733775(777/////////////// (:(:ad75?77itpitig:.(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | mir-19a | glioma | up | MicroRNA-19a promotes glioma cell growth by repressing LRIGL | mj!-.?·· | gastric cancer | up | WiP e'piv.Hvw'. rcurc Uv'r^vksp.owti rati inottlifv bv targeting REC K |
/:777(//: | pan», ream (((377(///////////// adcoocareircoro. 8(588888888888888888888 | /:7//////: | mierc-PNA-lilh enhances paooteatic cancer ceil invasion by Suppressing TirdO e vpression and promoting EOF and TGF-'? //57όή3/(///////////////////////://///( | mil-19a | lung cancer | up | Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR·· 20a in lung cancers overexpressmg miR-17-92. | 8;595?53333; | gastric cancer | (/7(////// | MicroPNA-25 promotes gastric cancer migration, Ihv asioo and proliferation by directly targeting transducer ofERBB2.1 and correlates //7rite7749tiiNi7teZZZZZZZZZZZZZZZZ |
216
WO 2017/132552
PCT/US2017/015417
):5(6)))))):/) 9539999/ | ):66(6(6756)))))))) /)646788))))))))99/ | :486)))))): | MuroRNA expression profiles ip human evlorectal cancels wtili liver nretaxtases | mil-3 9a | lung cancer | up | MicroRNA miR-l7-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer ceil proliferation and invasion. | ):58699)))): | /)(5565))))))))))))):/) | ///(5999 | roiR-i'v promotes ghoma ced proliferation bv iaroeunp 90Oi5999999999999):9 |
/:/(56/))))))) 9539:999 | esophageal /)60566/66)): carcmrona | :)99:)))))) | miR -5 (77 promotes cell ////48/6756/46/5866/))))))))))))))))): esophageal squamous cell cart mom·.· | mi r- 19a | lung cancer | up | A pclycistfonic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation | ):(5625/))))/ | head ami oecb. ///84685686/661(/))))): /):78(65658///////////////////// | /)(5999/ | Comprehensive MicroRNA p.vffoi g fvr 1 cad ar a r e squamous eed carcinomas |
ί!!11-ΐ 22 | ):668669(519/:(9 * are rooroa | !b‘ | Circulating nucroRNAs, miR21, intR-i2?. ami miR-223. tn patients with hepatocellular carcinoma ar chrcmic /)696899)))))))))))))))))))))))))))) | mil-3 9a | mantle cell lymphoma | up | The miRNA-17792 cluster mediates cherooresistance and enhances tumor growth, in mantle cell lymphoma via ΡΙ3Ε/ΑΚΪ pathway activation. | mu-2' | /)5685666(06)))//) carcinoma | Up | Nprceulamro of mnauRNAΆλχ wires wiih s^urcai® to hepatocellular carcinoma. |
mir-122 | baparotellular /(661/565(9)))))))) | ///99///////////// | E ’.press-on of mxrokNzvs, niiR-21, miR-31. reiR-12'2, miR-14?. luiR-Uba. nuR’ ' rctR-’Ί uiP^> rod nt.R-223 moments with hcpahxalhiisr carcinoma or /)458(9(5((9/)))))))))))))))))))))))/ cholaugieearcinoma and Us /)0988))))))///////////////////////////////////////////////// | mar-19a | medulloblasto ma | up | The miR-17/92 poiycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. | ):(5625////////// | ocn -small cell :/:(5(6:^86/:5-/:/:/:/:/:/:/:/:/: | /)(5999/ | DaurmeguladCn cf uR 2* ::modu!ates:non-:pmiailceli:bing·:·: eumet veils h\ targeting /)69599)))))))))))))))))))))))))))))) |
reif-12'2 | /)898958655(/) carcmrona | ////99/))))) | Ep. gtarelre regulation of nuP 122 bv PihAR' and hepatitis /)^)5(50/9(6(626(6)999999/) hepronchtiSni·· <rcitmn.a ..I SR | mir-19a | neuroblastoma | up | MYCN-reguialed microRNAs repress estrogen receptoralpha (ESR1) expression and neuronai differentiation in human neuro b lastoma. | ):(8(((28/)))): | ////66668(81(/664))))): /)(688966679///////////////// | /0999/ | nuR 2^ targets the modulator of apoptosis 1 gene robing ))786(66/)))))))))))))))))))))))))))))): |
mircb?2 | (/56989))))))))))) carcmama | /)99///////////// | k d •'roPN A e xpre® aoo it. ])A9596p5566rig /9695(6))))))/ tumors, up-regulation of ////65(62M9) (22/569 (923/16/)))): phuharv earcinomas | mir-l9a | non-small cell lung cancer | lip | Seram miR-J9a expression correlates with worse prognosis of patients with non-small ceil lung cancer. | /:/(6595/:/:/:/:/: | ovarian cancer | /0999/ | MtR-M regulates apuprossa by targeting Bim ro human /]5'/8656/c8hc76////////////////////////////////////////// |
mir-122 | renal clear cell /)66i/565(9)))))))) | /)99/)))))) | nuRN a pr«f .Jjng mt clear cell renal celi careirroma.' hiommhei disvoven and idermfieatmt* of potential controls .rod rorcequentesN :/:/5iR55k:d6SiSgylr560::/:/:/:/:/:/:/:/:/:/:/: | mar-19a | osteosarcoma | up | Upregulation of microRNA17 -92 cluster associates with tumor progression and prognosis in osteosarcoma. | ):(5625))))) | ovarian canter | /)(5999/ | MiR-25 promates Cvanart /)68666(/89565866)665))))))))): routihp b' targe tine EAT*12 |
UUf- 12.2K | hepatocellular carcinoma | Up | tuiR-1228 promotes the proldcratiun and itmtastasts oi hepatoma cells through a p53 fyro aid feedback loop | mir-19b | lymphoma | up | MicroRNA tniR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | mn-.:··· | small cell lung /):986866///////////////////////////// | up | MieroRMA-2> regulates small ))5(966593657)59)/))))))))))))) deveioproauf and ceil cycle /)859(^5^86^6/6/6/6/))))))))): |
9(929999/ | )):/6699:((((((999 | 968999/ | nuti'cRiMs as Biontarheix of /)665(694675)))))))))))))))))))))) | mir-19b | breast cancer | up | MicroRNA expression profiles in human breast cancer cells after muhifraction and single-dose radiation treatment. | ///(8(((568)///// | iiKdangioA.aremp /:/:88(/))))))))))))))))))) | /39/////// | Mre-oRNA 2t a promotes t hedantpovare uioma grow1 h b\ a.tn atme Xateoni |
217
WO 2017/132552
PCT/US2017/015417
6563-6:6:6:6: 1233 | /66(51366/:5555: ^arcinhttta | 40444444: | 660iO:WOu64(666l465556444 ruaptmzre implicat tens of serum ntiR.- :/5233/(666164//////////////////////// | mil-3 9b | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis by targeting LATS2. | :/56(/266///: | //66666444434443444/ | 4044644 | MrcroRNA-2*a Pranietes 66li(56f 55654^ /2A65i6666656:53/|56(56by////// Enyctlv Targeting Protabitin |
:::36(6:::::::::::::/: 4415(4444444: | colorectal 45601555555 | :/56ΖΖΖΖΖΖ | Ctrctttariog KariRtatai mntroRNAs as Bjornaritars of /660600///////////////666/ | nur-l9b | cervical cancer | up | MicroRNA-19a and -19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. | mlr-2aa | ovarian cancer | :/66:444444 | MtR-?' < pmi’Nre« ov imm caik or proldbratro 0 and //(ώ665565656//////////////////////: |
mir-dx-ia | 600401444444 /006564444/444 | 4064444 | mmroRNA expression profile : andideniifteatron <θίηΤΕ-25: ·: ·: ·:· as a prygiKistre marker an J paritogenetN fa*tor5\ targeting CORP m mantle cell jvmp:.um:i | mir-39b | cholangiocarci no ma | up | miR-17-92 cluster promotes cholaugiocarcinoina growth, evidence for PTEN as downstream target and 1L6/Stat3 as upstream activator. | mm-2ob | htadfier cancer | 4:66444444: | 6 55666/5266:6(56(166:63////://///: kidney and bladder canc ers |
6563-//////// /50644444 | XJS{«·; -JiXCi | :m | 6309400055660444444444: t it aog?z m tat^r | mil-3 9b | colorectal cancer | up | MicroRNA expression profiling of exfoliated colonocvtes isolated from, feces for colorectal cancer screening. | nm -2u | breast cancer | Up | 446/59092(0(66:(6^ 2ta-24-2-2“3 cluster promotes mammary carcinoma coll invasion and hepatic metastasis by targeting Sprculvx, |
ndr-lTSa | bmast cancer | /O:////// | N6oroRNA-d25ainfluences breast cancel' Stern cells by rargebne leukemia rni.rb nnrv factor receptor which regulates ihe hippo signaling //665666:::::::::::::::::::::::::::::::::::::::::::::::/:::::::: | mdr-19b | esophageal squamous ceil carcinoma | up | m(r-27a | colorectal cancer | 655644444 | Novel m jriemo for «.urcutmn and bosy.ellic acid induced vhemopno, euimn riuoagh regntatmn or naR- * ta and iniR*?“a rn ovlorectai ..amer | |
636(6///////: 44106()444 | notttama'J coif hang cancer | /O:////// | Seram in:K-l 2oa-op. mlR- 5ϊθ4θΟΟθ6664444344454 diagnostic bio markers in nohsrttali cell kjrig vancei | itur-l9b | gastric cancer | up | MiR-l9a/b modulate the metastasis of gastric cancer ceils by targeting the tumour suppressor MXD1. | /:36(6276/// | esophageal //263(62544444444444444: | :/66:444444 | //:9(((s(56(ta9666336ri665(//////// iniRMAs m. esophageal cancer //ti^ne///////////////////////////////// |
/:566://///// //Ο/:////// | a».uto mvekwri /:(4666666///////// | /O/////6 | intOM2Sfc promotes piOltferaiJOn of human acme nn elyid leukemia cells by targeting Bakl h | mil-3 9b | gastric cancer | up | MicroRNA-l9a/b regulates multidrug resistance in human gastric cancer cells by targetina PTEN. | mir-2“a | //g^iric///////////////: adenocArcmnma | :/((6:////// | Mr -oRNA-it -nm js an oJkOgem hi gastric •::aderaxnrcinoma:by:targetina::·:·:·: /5(6(66((5(///////////////////////////: |
:/ί3ίί6://////6 4406444444: | 6630666/////// /566269///////////// | /O:////// | MfcroRNA expression //p65l(6g656:55O05444444444: dtignosric bmlRvriUvm //665366//////////////////////////////: | mdr-19b | glioma | up | miR-19a and miR-1.9b Overexpression in Gliomas. | m(r-27a | gasttte cancer | 655644444 | Boun-regoladOo of miR N’a //66^6/6((65((5(6(^6(65664655// drag resistance of gastric /:96566(56(((/////////::::::::::::::::::::::::::::::::: |
/:666::::::::::::::: 4432264444444 | gasUR vancei | 666464444 | naPNA >23 piymyesgasiiK 56666(:6(0(664044444444444444: metariasts ™ <· ugctmc 'umur 6:5:ΟΟΟΟΟιθ444444444444: | mir-19b | lung cancer | up | A polycistronic mrcroP-NA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. | 66652255/ | :/5^(((6:565269////// | :46|444| | //66O5(65(65(66;56i5664444;4444 gastim s-aiwc! cell metas·asmb\ mduuita cprdieJral-t^inesenchy mai transition. |
UUr- 506:6:6: | gastric cancer | up | iv£sR-G5b promotes cell migration and mrasiun by targeting 3?PP1CA-Rb signal pathways rn gastric cai\.en resulting in a py«r prognosis | mir-19b | lung cancer | up | Apoptosis induction by antisense oligonucleotides against miR-l-5p and miR20a in lung cancers overexpressing miR-17-92. | mir-2··! | hepatocellular :4:4632(6655/////44444: | up | /;M3R32266i655(6(444/////////////; bepatOvOSutar cammuma «.ell 4:5(life|ii665(i^6l4444444444444 suppression cTris target gene //66(66((6 55:5(5696(6(65444444444: activated receptor T |
:/566///////: 4432264444444 | glioblastoma | 40444444 | mrP.-i>?b promotes call ptvlrfer«iUvr he d'le.ttv 44(006:066364444344464443: gbnbtaauma siein..e!Rwith. tow expression levels of mix - | mir-39b | lung cancer | up | MicroRNA miR-l7-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and | 6566223///: | //:3(56566(:///////////: //03(0(60(66:////////// | 4:56444444: | jMioroRNA-27a promotes proliferatron and suppresses tpooe i>bv mrctwgPlT x in fan ngeal carcinoma. |
218
WO 2017/132552
PCT/US2017/015417
B?BBBBBBBBBBBBBBBB77 | invasion. | ||||||||||
4tiili474747 | 7gti0toR77:7:7:777 | 7:tip747:7 | RB!:R7i25k7MiibkSRRRRRR747 CcuyiexirN 3 ami Tm motes 4GlreMRQtoB:tbRRRRRRRR:74 | mir-l9b | mantle cell lymphoma | up | The nuRNA-17792 cluster mediates chemoresistance anti enhances tumor growth in mantle cell lymphoma via P13K/AKT pathway activation. | wtir-2?a | liver canuef | 7^7777; | Adtpo*e nxsue-seereted mtR?7o promotes liver cancer by tareteiing FQX01 m obese Ri^i7^^iRTTTTTTTTTT7:7:7 |
4tiaG74747 | 73titiitiiiTTT7:777 | UP | ivisR-i 25b expression affects BhROii^Okd^RRRRRRR apoptosis of human gtioraa reibbx ar£^ttoABoit | mir-19b | medulloblasto ma | up | The miR-17/92 polycistron rs up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-my c in sonic hedgehog-treated cerebellar neural precursors. | mir-2'·! | osteosarcoma | ::17:7:: | Dncrmxti. and vrerrju tic potentials of nucioRNA-27a 4itipsteds^d0B3774747474747:7 |
7hBitoMpOkd77 | 4tip:7474 | MioroRNA--i25b is a novel negative regulator of p$3 | mir-l9b | osteosarcoma | up | Upregulation of microRNA17-92 cluster associates with tumor progression and prognosis in osteosarcoma | 7buB27ii:77 | 4bRtotitoGPrikR47:7: | 7^||7 | MieioRNA-27a Promotes Prolifeiattom Migration and 4&·ίΑί^ Osteosarcoma Colls | |
7tii«747474 | 7gtolROi3titiS74 ooh carcinoma | U-‘ | [Expression and clinical significance of plasma microRN.A -J 25b level in. patterns wtih oral squonyms veii «.atompioa- | mir-2O0a | breast cancer | up | Direct targeting of Sec23a by iniR.-2.O0s influences cancer cell secretome and. promotes metastatic c olo ni zatio n. | mi:-2j | ovarian cancer | ijp | Chicoacnm MtctoRNA-27a is u fu<rget lor Cenuemm 7:G7pri3BGkh4ei:C^ii377777777 |
7iiib747474 | pre-state causer | 77747777 | Widespread deregulation of mitroRRM P*preSSton at | mir-200a | breast cancer | up | MicroRNA-200a Promotes Ancikis Resistance anti Metastasis by Targeting YAP1 in Human Breast Cancer. | 71ρίι4273:74 | ovarian. cancer | W333R | MlotoFNAs c-verevpressed m RtirRbsOiB^ibiii^RRRRRRRR Rbi^tiidto^idtid3RRRRRRRR47: |
7ikito74747 BiBlBBBB^ | 7pid$ttitgR3h$SR:7 | 707777 | R0pC;pimkiraR3iR$pRRRRR7:74 RRjppi^teRRi^.M^:ikRR747: modnlan. ρ5 t-d^mLntand p5 Mndepcnd-rai spdptusts in 7^1Ρδώ1ή:4ΪΡόέί34747474747474: | mir-200a | esophageal adenocarcinom a | up | Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma | 4toii$2^d7:7 | pancreatic cancer | ^BBBBB | 7GBnSirkbdhlftbiiRGrki47474747 Growth and In? asion riimuah kegnlaram 01 MtR-2“a itPancreatic < an rer Cells |
4htiG74747 iiBBBBBB | raese nchymai RcapteRRRRRRR: | 74777777 | mtR*?'* Acts a., 3 Dxch ra .ar jmis rcParent' 4feito6pBtipRB5toi4R2RRRRR:7 mRNA from Degradation by 3β?333333 | mir-2O0a | esophageal cancer | up | Differential expression of miRNAs in esophageal cancer tissue | 4toli7O:74 | 70^:^117:7:74747: Riratelh0Bd:7:7:7:7:7: | 7^7777; | 4:^lG2RRRBri7dtekRRll74747:7:7 proliferation ami merasm*:* ra renal eeihiarouKraia |
7tiyf477777 | /RptoraRklRR/RR 4PakipkRRR:RRR | 47tP4747: | MteroRN A exptoSsrc-o ::protilesin:b-nraa!Q:Cplorectal:·:·:·:·: cancers with liver metastases. | mir-200a | esophageal cancer | up | miR--200a/miR-14l and. miR205 upregulation might be associated with hormone receptor status and prognosis in endometrial carcinomas. | i<nr-2?a | 7B-ksm0aR7474747 77kftti43k&7777777 | 7^47777 | 4UmqkRMtCtol^A7474747:747 Expression Profiles in |
mir-12b | gdsinc career | 74477774 | 7§E7B^O^:wiabdRRR474 SOX2 expression and contribute* to gasme catoit-pgenpsis | mir-200a | malignant melanoma | up | MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. | 3bti?42O7: BBBBBBB | 7$O&7777777777 | OBBB^ | miR-24-3p anti rnlR-27y-?p promote coli proliferation tit giu-ma cNls v :a coopentti Λ 4;iOl^^h::3f:^^iG777777777·: |
219
WO 2017/132552
PCT/US2017/015417
mir-lzti | 59259288995222228) tusiiswxra | :)338))))):) | tromparanvc auahoiaoi tuelatrema deregulated nriPNAs in the roadaLa and Xtplmphoms piarnynt cell :/)CahCS5iti>8S!())))))))))))))))))))): | mir-200a | non-small cell tong cancer | up | MiR-200a enhances the migrations of A549 and SKMES-1 cells by regulating the expression of TSPAN1. | ):52255858)):) | /)888588/553885))))/:) | 52285553 | na.R-27 promotes bwuan gastric cancer cell metastasis bv inducing epithettai to - ))i/rk8595835338i3/5593595555352222222222: |
///ffiifJS?/:/:/: | /)08/000))) call carcinoma | /298/222222 | DOwnrei’tiladdftdftoiR IN toduPes siigfdgfcrtesls and iymphangiogenesis by actri auew of VfSfjF-A tn oral 889985522222222222222222222222222222 | mir-2O0a | ovarian cancer | up | Upregulation of microRNA200a associates with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer. | /)2005)) | 0899))))))))))))))) | :)229))))):) | PApressron and ton troll ol 8/θ8θ258/ΐ2θ20285)))))2) |
rott-Jzti- )::58)))))))))) | acute troeloid lettkeroia | ;m | U pregulatioa nf microRNA te-<pjs tyedtial. drug resistance to Cytarabine and pont prognoate in AML :/)patigri35/)))))))))))))))))))))))))))): | tnir- 200b | breast cancer | up | Direct targeting of Sec23a by miR.-200s influences cancer cell secretome and promotes met astatic colo niz at io n. | rot:-2b | giroma | Up | MieroEN A-2 'b mlubtte ••pre? expression and promotes coll invasion to :/:388/328/58535/3933/2222222222222222 |
7/1.07/7/7:7: 1 Oh | /)805:50)))))))): ///cO/thOd/:/:/:/:/:/:/:/:/ | 598/222222 | GOsteto etownregedates oncp-miR -L-tiOb and inhibits ::AVHt-:signaiiirrs::£n:-renal: cancer:·: )|95|||||9||||||553 | mir- 200b | colorectal cancer | up | mi.croRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteinerich protein with Kazai motifs | /)2005)) | oral squamous cell carcinoma | 3358222223 | /:/Oiro25tewidg:/Stody/3f:/:/:/:/:/:/:/:/:/:/:/: Salivary MiciriRNAkfor Detectronof Oral Ganger |
/:/30/7/7:7/: ))3959)))))): | hepatocellular carcinoma | :):98))))):) | f pregutoied MtR-i te*· to hep rued! tter v tteitroma and ua cltfricat significance | nur- 200b | endometrial cancer | up | MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating ΊΊΜΡ2 in tinman endometrial cancercell line HEC-1A cells. | /)2828588/))) | ovarian cancer | /)38/222222 | MicroRNAs m-etexprezscd it. ovarran AE.idlf'positive veils are associated wifii /)0595595995228599))/22222222222222222 |
):/rO)))))))) 8/508/8/8/) | ):98385858292288222: carettwama | :)335)))))): | MuroRNA-too > promote* /)88958589559833/538885))))))))))/) hep nonclntinr v <re«rottd \ n dcunreguiaficr pfFOXOI | tnir- 200b | gastric cancer | up | MicroRMA-zOOb Regulates Ceil Proliferation, invasion, and Migration by Directly targeting ZEB2 in Gastric Carcinoma. | )O8O)))) iliii5 | /):4/59528i8585))))))))): ))889898222222222222222 | 52295332 | Differential e cpressrou of miRNAs it. esupl-ngasl «.aocer 5595885))))))))))))))))))))))))))))))): |
7riO7/7/:/7: ////58888))))/) | )3558388553:)))))))): :)558888))))))))))))) | ):235)))))): | miR-Gito promotes metastasis and forms a v’-siri· 'fredbKx-hvpbiti )/|eil||||||||/998 | mir- 200b | malignant melanoma | up | MicroRNA-zOO family members differentially regulate morphological plasticity and mode of melanoma ceil invasion.. | mtr-2vh- 11111 | gastric cancer | /:/529/:/:/:/:/:/:/ | MroroENAG*-*-^ mcreas* , proliferation in gastric vahetef dKQunh repression »£ Caudal ))50^/358359853825)22222222222222: |
nur-127- )33)))))))))) | alioblpstpina | ))83/222222 | hhcryRNA-G? 3p promotes «grinbi-asfoi-riacetl^miaratinii:·:·:·:·:· and invasion by targeting. the }.jR<.-x.pptexsot- n ·> Sl-pi'7 | mir-200c | breast cancer | up | Direct targeting of Sec23a by miR-200s iniiuences cancer cell secretome and promotes metastatic colonization. | mir-2sa | acute myeloid /)0382588)))))))))))) | 5995535 | mrcroRNA_-29a induces aberrant self-enewat capacity at hematopoietic provewtotv brayed I’ti tired tiroctovroen. and acute treeio'd leukemia |
UU1- 5:29082/8) | gastric cancer | up | J be role nf mieioRi JA-12 '4a m die numuigcncsis of gastric cancer: acceieiatuig cancer /)09559988595598/9358/2222222222222 /):538935535533835555858)))))))))))) targeting POXt/N, | mir-zOOc | colon cancer | up | The roles of miR-200c in colon cancer and associated molecular mechanisms. | mn-2'!·! | breast cancer | up | Nexf-generatroir sequencing ui nuoroENAz tote bread 3398855398035222222222222222222 |
220
WO 2017/132552
PCT/US2017/015417
war-J 28 | 652544666666666666666 {>· Rtphohlastic ///4002666////////////// | /)52/)))))) | )/025240/420/0066666666666 •tgnattire is associated w uh the diagnosis and progmAtS :/:/ό2225/ί2θ5ί5ΐ2ί2/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | mir-200c | colorectal cancer | up | MicroRNA-zOOc modulates epithehai-to-raeseRchymai transition <EMT) in human colorectal cancer metastasis. | )/554/-252/////) | /)342554/525554)))))//) | 635 666666 | uftcmRNA-29 negativel? regulates EMTreguiaior N- ))2iy2)42t5fe4i5r2h)bfe22///////////////////// |
mtr-f?8 | acute ittyeteu! 6/40026666666666 | ///0///////////// | fuainuxe rwtu/RNA signature is associated w ith. the diagnosis and prognosis :/:2f /52215//15252525)/7/7/7/7/7/7/7/7/ | mir-zOOc | colorectai cancer | lip | Plasma miR.-2.COc and roiR1.8a as potential biomarkers for the detection of colorectai carcinoma. | mir-Ma | critometai cancer | 6/33666666/ | mi raPN* ..\vre,a'<mpn>T'L tii stage fit colorectal cancer: Firnibtmg nuR-lha and nuRNa as promising biyiuaikeis |
mlr-lzh | Osteosarcoma | 6/33666666/ | MicreRNA-lTS promotes piplrierariui' in ysteysarcoraa cells by dowrneguiating 6110/11111111)1111 | mir-200c | colorectal cancer | up | mi.croRNA-200b and micicRNA.-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteinerich protein with Kazai motifs | imr-Na | eolorectal oancer | /633/666666 | /MieroRNA-Na promotes c-olorectal ^aiwei metastasis by regulating tnairiv metadoproLCiiiase 2 and E- |
/://524-/:/:/:/:/:/:/:/: ////43536666666 | non-amai/l celt brag cancer | ///0///////////// | CpregnkUioo pf MrR-Ί Fxaiex κΛ« '>r Small Cell Lung Cancer Tissues | mir-zOOc | endometrial cancer | lip | The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. | /:/2443^2/)//) | critoreetai cancer | 3443666666/ | /):i352i4i5tfe5/33424542RWfe//////////// Na. 92a and 1-15 m colorectal /);25f2i2542-5/32/2522i/25te////////////////////// diagnostic markers: An ///3222522545452325)//////////////////////////// |
mir-ilga | hepatocellular //25020///////6666/ | ////Ο///////////// | [miR -1 ?ha is up-regulated in ::bopatoeeiiu!ar:caiei£te-maar!ri:·:·: promote;; twmor ceil proliferation hi targeting ////fO22/////////////////////////////////////////////////////////// | mir-200c | malignant melanoma | up | MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. | mir-29fc~ 664666666666666 | breast cancer | 6/33666666/ | mternRNA 79negati\eh eguiaies EMT regfeafer N- ))234)42/2422454/24245244/)))))))))) /)/454324)))))))))))))))))))))))))))))))/ |
)/4252/))))))) /i/^?////////////// | ///4215462544424/))))) | /452666666 | tj p-regnterior. of roicroENA '$ totp nr, v\ t j\it' a z md affects die reprogramnuRg of cohort cancer ceils | mir-200c | non-small cell lung cancer | up | Expression of rnicroRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. | 6/554)2525)) t:/?/:/:/:/:/:/:/:/:/:/:/:/:/ | /)342554/525254))))))) | /633///////////// | mtereRNA-zO negativeb regulates EMTregukunr Nmye lotmuor ia breast 3/333336666666666666666666666666666666 |
:/:/53/3/:/:/:/:/:/:/:/ IN;; | esophageal squamous cell )2540225///////////////// | ///55///////////// | Mn.roRNA-l?'F' promote* esophageal squamous cell ))2531252452/22/255444245252/6666/ /)/525252452242)/66666666666666666666 | mir-200c | non-small cel: hung cancer | up | Nigh expression of serum mtR-21 and tumor miR-TOOc associated with, poor prognosis in patients with lung cancer. | mtr-?vv | breast earner | /)/23/)))))) | mn.roRMA-.z9 ncgatively /)ΐ55ι224ό5/Ε333) 45/5512424/3sT4////////// myc mteractor in breast 6622252/)))))))))))))))))))))))))))))//) |
):1222:))))))/ /11^////////////// | 12, er cancer | /6/0666666/ | ::ldent!iaeatirei:oflHiRNAs:th3t·:·: /)22252252412/2522525442546/)))))))) suppressive IXEn-FL tutfcer nan Λΐ re get u Rl ’*-*>'» i w.d'ortu. | mir-200c | ovarian cancer | up | Differential rnicroRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. | mir-2sc | /)/2526542215253/////////// ////325/525254////////////////// | /633/333 | Expression ufiuiR 29,,. naPAk aud miR-429 a* Potential Biomarkers far Detecttow of ι-ariy -Rage Non-Small Lung i.'a.Kcr. |
!UH- 333336666666 | gastric cancer | up | niiR-1Targets Claudin-18 )/43525//fe/2OO45fe))))))))))))))))) PiAliferationaud invasion, of ))432533//332253525//)))))))/////////// | mir-zOOc | ovarian cancer | up | miR-200c modulates ovarian cancer cell metastasis potential by targeting zinc: finger E-box-binding homeobox 2 (ZEB2) expression. | mir- | που-small cod /)/5425/525254)))))))//) | up | /)05224542/52542202/666666666/ expression profiles in early stage nctiismall cell lung /6/524324)))))))))))))))))))))))))))))))/ |
esophageal /)52506666666666666 | 660666666/ | Differential expression of miRNAs in o&yphageal cancer /)43^25))))))))))))))))))))))))))))))))/ | mir-200c | rectal cancer | up | The quantitative analysis by stem-loop real-time PCR revealed the microRNA-3 4a, microRNA-155 and microRNA-200c overexpression inhuman colorectal cancer. | Ο///////////// | Promotes Proliferation and ’u t ran oiOsfevvu/nreiha ))/404425/33633//666666666666666666 |
221
WO 2017/132552
PCT/US2017/015417
niir-1 'tia | ()(7399449395(:(:(:(: •.arciPOma | )2(48(8()()() | Upt egulated naR-J 'ba increase> drug revtxtonce by regufatmgRf.;MX5 and W'm signaling in Oplatiu-lreated )()(00)8033()()()()))()()()()()()()()()()()()()()()()()()()() | mir-203 | bladder cancer | up | Micro-RNA profiling in kidney and bladder cancers | ()(45538(9()() | colorectal cancer | (39(((((( | MicroRNA-3tq a promotes •nreratmt <redtmn,n.u bx torgctiGg TC8PBR2 tt· human ))()488885989898855()()()()()()()()()()()()()()()()()() |
ΧΙΡΐή)-):):):):):):):) )()(534()()()()()()( | eoloreciat )2(4348(8(8(8(8()()()( | 20)()(3()()() | MkreRMA-BOh Promotes 220r023340003:092ii5)2222 )))44890)999)0883()()()()()()()()()()()( 3947438)53)9875593585()()()()()()()()()() C-mcei | mir-203 | breast cancer | up | Anti-miR-203 Upregulates S0CS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. | 2)455488( | colorectal cancer | )()598()()()()() | MiR-ovla promotes coloreraal c.onrei reft growth atftlMi' asiytipy directly ()(44483S54S83()()()()()()()()()()()()()()()()()() |
2)559 95)222255 ίθ|888 | )()43999195222222222 (28938838(8(8(8(8()()() | <P | ))))Μ)9)399ΝΑ)-)ί5)99)Ρ399989)2222: Tutuoi Development and Is )()083595049(03833()()()()()()()()()()( Prognosis re Com rectal ( an·, i·· | mir-203 | colorectal cancer | up | Association of rnicroRNA expression with rnicrosatellite instability status in colorectal adenocarcinoma | •:UU£-:3dla·:·: | (2)45554894888(8()()( | ((((4)(1()()() | Ckprexpresred miR-3tila ornt jo-.es veh ptvfiini tvi red tm a zu n bx urgetwg Rf N\ mga ret « |
):)5595-):):):):):):):): 8(308:8:58: | esophageal squamous cell )24434)22222222 | 50)222222 | MjR-Bflh an omogentc role by repressing PTEN expire ion to renphagrei :)O)9S)9ten$)095:Oc)9!0)9i9):):):):):):):): :3890533()()()()()()()()()()()()()()()()()()()()()()()()()()()()()()( | nur-203 | esophageal cancer | up | Alteration of miRNA Expression Correlates with Lifesty le, Social and Environmental Determinants in Esophageal Carcinoma. | mirGO fa | gastric cancer | ()(4)()(3()()() | Abnormal ex pres au ui mtP3pia m gastfec -.anrer associated with prepreSS-on )()(84(4987:44842)()()()()()()()()()()()()()()( |
5:99922222222 8(308(8(8(5 | hapatorelfolar )))40059)()()()()()()()( | 2)59)322222 | fdetaitnat-on of dniofenonlk expressed nucroRNAs in )()(79)49(0448590833()()()()()()()()()() adenoma associated with type i^heogen storage disease a ))289437544)422222222222222222 ))))93839995892222222222222222222222222: | mir-203 | bypepharyngea 1 cancer | up | Effect of microRNA-203 on tumor growth in human hypophaiyngeal squamous cell carcinoma. | mir-jOla | hepaforethiiar ))))483558359()()()()()()()()()()( | )()(4)()()()()()() | imR-rolalsa Candidate Οο<,Λ8δκβ that Targe· s die Homeobox, Cette Gax in )()(1(744274438443()()()()()()()()()()( ()()82474778()()()()()()()()()()()()()()()()()()()()()()()()() |
:):5958):):):):):):):) )()(784)()()()()()()( | hepatocedinfar )280)00)22222222 | )0222255 | )2439)44444222222222222255 uKtroRMzx-i ‘refc correiatre y.fflt poor prognosis of patients rath hepatocelluht :)25399859322222222222222222222222222: | mir-203 | pancreatic adenocarcinom a | up | MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. | mh-miit | pancreatic adenocarcinoma | )259)222222 | nnRvtiBaas an NE-7B aotw atar to parrereatre ranter 84438(8(8(8(8(8(8(8(8(8(8(8(8(8(8()()()( |
:255992222222: ((ί®(((((((((( | „'·ί,.ν· | 8(0)()()()()()() | ))))9O3999AO)fi|i9g)9£)222222222: )()(7947(4O834i888:333333333333 | mir-203 | pancreatic ductal adenocarcinom a | up | Circulating MicioRNAs in Serum of Human K-tas Oncogene Transgenic Rats With Pancreatic Ductal Adenocarcinomas. | •:UU£-:3dla·:·: | pancreatic cancer | ()(4)(1()()() | ))))790:85:8:755559899)22222222222222: ()(74399:3)(89888847()()()()()()()()()()()()() proliferation bx direcrb inhibiting Rim e\prre>:cre |
Wir-f32 | )243022)2222225)5) | up | Upregulation of rntR-J U ' prexs-ontn 'mma eredux ciimoal stgitifkanre. | mir-203 | squamous carcinoma | up | Unique MicroRNA Expression Profiles in Cervical Cancer. | mi ··- ?0fa-9 | pancreatic cancer | iB)))))) | ?a IkroRNA- 'hi a- 9 promotes pancreatic cancer progression v-a {.egaoxe regulation or )2444382222222222222222222222222222 |
rohr-J ?? | 24844425)5)25): )()54033:)2222222222 | 20222222: | miR-B2 andmiR-?f? ate mcreared in pancreatic Conner >:andtargeiilie:tetino9asioma·:·:·: )()(340)47288893835()()()()()()()()()()()()()()()()() | mir-203a | renal cell carcinoma | up | miR-203a regulates proliferation, migration, and apoptosis by targeting glycogen synthase krnase-3? in human renal cell carcinoma. | :):9i3ff:):):):):):):):) )()(43()()()()()()() | )244493)2222222255 csret&oma | )259)222222 | MieroRN A-*; lb promotes reft imasirenass through •argeting TPf>3 to pancreatic ()()48398559(8848()()()()()()()()()()()()()()()()()()() |
2:9958:2222222 :):)7^4:):):):):):):) | cow κ«1 2)40059)()()()()()()()) | »p | )))A)fi43RNA2)33)S8))is)“9i883)3222222 pmurater of cervical pareinoinadeyeiopmetit :)2ΐθ90)54:9έθ94)44);););); ERE aod AKTJ pathwav-s | rnii-204 | prostate cancer | up | Mechanisms and functional consequences or PDEF protein expression loss during prostate cancer progression. | mil -382f | ()(44289883833()()()() | )(((4()()()()()()( | ))))Mii)i)9RNA))pi0ltlt9g:75)2222222222 )()(73474778)89784:33333333333)2 |
222
WO 2017/132552
PCT/US2017/015417
9:681699999999 61::86:333333 | 58686568555555555 :3668686333333333333: | :366:5:3333 | Asfeuxtaaonoi microRNA expression u rth nucrosarellnc instability stares incNoreotai 36d6h6666166683333333333333333333 | mir-204- 5p | colorectal cancer | up | miR-204-5p expression in colorecta· cancer: an autophagy-associated gene | rati-Eto- 386::::::::: | ;96Oti^65l9999999999 «.preroj bvT :5:8686686:999999999: | l-lll | t prossmuN tireml Na ro squamous ceil carcrooroa of human head anti neck anti the esophagus; miR-205 and miR21 pre sp-redre markets fix HN ff md^Cf |
roir-EU | bead and neck :908666:66866999: carcinoma | 5:86:999999 | ruiRd >1 UxtuCes yncoaeiuchy and metastasis ra bend and neck utiroraoina through targeting. wwf)N nene | mir-205 | bladder cancer | up | Micro-RNA profiling in kidney and bladder cancers. | mircoa- 11111 | 55660168999999999999999 | 5:8:333333 | Analysts nl «liR-v·! «Ρ :3^6^866:18^6668333333333333: 99866618355:99999999999999999999999999 |
iU-J ' -:j | bladdoi cap.voi | !1.5 | X!.{-i ,. v.>i, proliferation through poattransottpticroallv regulating mtEESandFOXOi ro ;90686;til888666;6ti866;9999999999: | mii-205 | breast cancer | up | Role of mrcroRNAs -29b-2. 155, -197 and-205 as diagnostic biomarkers in serum, of breast canc er females. | ;3:666d:86d;:660b;33333 «.preroj bv' :58686686:999999999: | op | E prossmuN roreml Na ro squamous ceil carcrooroa of human head anti neck anti the eSrethagu roik ’Ά andttuR21 pre spe^dre markets fix HN ff md^Cf | |
mir-l?5a | bmasf canaer | :386:333333 | torRN-'-I promO'* breast cancer tall migration and invasion bx targeting 868068666666666665556 | mir-205 | cervical cancer | up | Serum micrcRNA-205 as a novel biomarker for cervical cancer patients. | roir-jOh | medulloblastoma | :988:99999 | ;5;AinpitiRatO86i;33333333333333333 o« eiexpressrpn cf miR 20p roiR-8d anti KBDRSS' at hq'-l 2?-q2- 2>ro |
iU-J ' -:j | 5:66l6i66O555555555 :5666686555555555555: | !1.5 | MiR-i / 5a promotes growth and mv assort of vOforental cancer via metastasis 556iO6i-6d68a683ik6i;5555555555555 | mii-205 | cervical cancer | up | miR-205 Expression Promotes Cell Proliferation and Migration of Human Cervical Cancer Ceils. | 6886-5068:9 | pancreatic dtretal atfenoenroinonta | op | Circulating MicroRNAs ro cruroot ironwul -tic Cn.'ugci’c J UTOzgen.* Rns With Pancreatic Ductal 9A8666ia6iih6ih^39999999999999999: |
natr-l '5a | colorectal :9606686999999999999: | ::88333333: | Asronruh ti numRN^ expression w ith. nucrosatellite instability stores incolyrectol adenoearxnrerca | mir-205 | cervical squamous cell carcinoma | up | miRNAs expression, profiling to distinguish lung squamous cell carcinoma frorn adenocarcriioma subtypes. | n«r-Ad | heparorelinlar camrooma | 568:333333 | MioroRNA-Rkf prumutes tumor ire asicut and nretasiasts by torgputig Galphai2 m heptmvcilular c «ufPviN |
:::886:888:3 5:0669999: | :5661618668999999999 :3666686333333333333: | :586:555555 | bireroRNA expression :5;:58fiti;hg:6£;686htos633333333333: cokuocx re* isolated front feces for colorectal cancer L sacci»!»·’ | nyr-205 | endometrial cancer | up | miR-205 promotes tumor proliferation and invasion through targeting ESR.RG in endometrial carcinoma. | roirGori | 551866686666:99999999 | 5:88:33333 | Γ aka -on ot A nar x 1 at -re oi se· uni uuR 21 and uoR-2-t ro pre and post-operam c lung carcinoma patients. |
»!«1 >3a-2 | 5661660655555555: :3666686333333333333: | 5:86:555555 | MicroRNA expression profiling of exfoliated .rokooex tc, t rotated iro:n feces for colorectal cancel· 55656868166355555555555555555555555555: | mii-205 | esophageal cancer | up | Alteration of miRNA Expression Correlates with Lifestyle, Social and Environmental Determinants in Esophageal Carcinoma. | 6866-508999 | :3:8666116615886833 | :368:6:56 | 3:86818861068133333333333333333 oveiexpressren oi nuR-Eto. rotRGOd anti KHDRRS' at Sq2-l.22-q24.2j ro :::6idti8l6hla66663:7::::::::::::::::::::::::::::::: |
1 >5a-5p | gastric cancer | :566:99999: | Eegufatron ul B· .< -S?f cNS κι itreire ioadnatn mni :5;|ίθΒΒΒΙ^ΙΙΙΙΙ;55555 | mir-205 | esophageal cancer | up | miR-200a/miR.-14J and miR205 upregulation might be associated with boiinone receptor status and prognosis in endometrial carcinomas. | 5:868868:55: | ;58h8685;3333333333333: | 568:333333 | (ontring radtaticm-irtiucible nuR Orx'nrrexNroiua ell hi·, asipn tiiToygh EGFR stalxhcatiyn he d-reefiy 98686ti66;i2S85Si333333333333333333: |
:96866999999: BO5555555 | 5:6616888188:5555555: 9668686:999999999999 | 888:333333 | MktoRNA-l$5b regulates metastasis SUppresSO·· 1 expression and promote!; migration and imaann ro colorectai cancer. | mir-205 | lung cancer | up | Evaluation of dynamic change of serum tniR-21 and mi.R-24 in pie- and postoperative lung carcinoma patients. | 3;6|68: | 5581888 888686855555555555555555 atvastveness ro an orthotopic xenotransplantation model bv dtotuptrog ihe NE-7Sti?D? negative Redback kon |
223
WO 2017/132552
PCT/US2017/015417
606(6(6(66 66:08(868 | (06606(((6((( (£660((((((((((((: | 6(866((((( | idenaficarmn cl mrueRNAi 35h In Stool as a Potemiai NbttUiv asiv e Stomarkef for Colorectal Cancer and 4;(Οθ6θ3((((((((((((((:::3:3:3:3:3 | mir-205 | lung cancer | up | miR-205 regulates A549 cells proliferation by targeting PTEN. | 6foB68i868: | eeroical canter | 6(6ftR88:£iB8686iB68:8h£££££(: oncogene in eervtcai cancer. | |
3mit343434 (:8066(((((: | colorectal :(66606(((((((((((: | :(0((((((: | MicteRMA-l35h promotes catxer progression b> aouiig (666θ0ό680ίό0: £?((((: ^ι,-ugcfiic path w a' s m w>fow (£6666B((((((((((((((((((((((((((((((: | mir-205 | non-smail ceii lung cancer | up | Prognostic value of mature microRNA-21 and microR.NA-205 overexpression in non-small cell lung cancer by quantitative real-time RTPCR. | 6166666666: | rfu-rfcai ..atRter | 6866868( | MiR-·! is an independent prognostic factor aud 6686666668:88:86:6666816^6:6:6:(:(:( cercroal cancer via targeting 6(80^6686868686868686868 |
4foli434343 6806((((((( | colorectal (£8086(6((((((((( | 408484 | kb'roRNA xxpteSztvn ((ρ6Β8解·Ο00ΐύ8(:((((((((((: colonoey tes isolated from feces for colorectal capper 360660((((((((((((((((((((48484 | nur-205 | con-small cell lung cancer | lip | miR-2.05 promotes the growth, metastasis and chemoresistance of NSCLC ceils by targeting PTEN. | (:foiri8£:(((( | • £tan 'in- or | (06(666 | The tumor suppressor gene ((8ΒίΡ^6^8:ΐ66:Ρ04ύί(83ί6ί8δ1::(:(:( :(:£8^:Βίΐΐ(δρί888(6$ίδΒ(:(:(:(:(:(:(:(:(:(: (3(^8^8(6(8888888((((((((((((((((((((((((((((((((((((((((((((((((( |
4ίύίί3:3:3:3:3 ((00((((((( | 4cei0teei3l434343 (£666666(((((((((((: | 3(dp343:3 | m R 1 -fob relief* ( ai rf Progression by Targeting fouistaruure ror' AEkU fo. iR'eptefllt · 1 4» (O0iO6O06£O((((((((((4:: | mir-205 | ovarian cancer | up | The role of miP.-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion. | (:folr(3d((((( | colorectal cancer | 6(66868(8 | MicroRMA signatures novel 4Bi£hhiik6f(foiCOr(86i866(((((6(((((( 6(8686668(8(8(8(8(8(8(8(8(8(8(8(8(8(8( |
(06(((((((( (:8:856((((((( | •.rohuc.i'd (£6606(((((((((((: | U.S | IdcnhTicarionandfmictrimal zvfromupoft irf-»\Az highly iteregutetetf lit coloreetai cancer. | mir-205- 3p | non-small cell lung cancer | up | Relative expressions of mrR205-5p. miR-205-3p, and miR-21 in tissues and serum of non-small ceil lung cancer patients. | mu-to | colorectal cancer | np | !- '.^χχ,<···4^ 1 4 -2 ί · 4 roik-tos rndmiR-d Giro corteiatetl % nb the Mutt 'ai parameters of colorectal (((£h6$£(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( |
3063:3:3:3: ((006(((((: | ooioreetaf :(66606(((((((((((: | ::0343:3 | hXptosnoa vi mtR-’Ί, mtRto mtP p andnoB-foShts eonetated w tth the clinical parameters of eotereclal ((60664((((((((((((((((((((((((((((3 | mir-205- 5p | non-small ceii lung cancer | up | Relative expressions of miR205-5p, miR.-20.5-3p, and miR.-21 in tissues and serum of non-small cell lung cancer patients. | 6B8B68666: | stolettro <! nterf- | 4:88:3434 | KH-VMmn roRNA-4 6(Ο88Β666ΟίΒ6Β686868(868 colprcvtai cancer progression bv repressing its target gene |
5fonr343434 00((((((( | 60((((((: | 68C0O0B06OO66666666: sigwRcanee and laneteon ol miR-Ι tab m the occurrence anddruJ-'ptf'vi’ Ncazin·. •JvX Ci! | mir-208 | esophageal squamous cell carcinoma | up | Mir-208 promotes cell proliferation by repressing S0X6 expression in human esophageal squamous cell carcinoma | 3ί£ί£$ϊ((((( | coioreeta! ..arroei | 686((((((((((6 | identification of mkipRNA.135b m Stool a& a Potential Noronvaaive Blomarker for ( oloreetnf < m.ecr .4x1 -Vkuota,· | |
4063:3:3:3 680((((((( | 4160::0686:3:3:3: | up | MicroRNA-l tab promotes hrog cancer metastasis by regulating multiple fargete tn 4:ii:i^Oi:O6:B6fofo6>'::6rB8:::::::::::::::::: £O0(B8££££££££££686:6 | mir-20a | lymphoma | up | MicroRNA mtR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. | 3Β8ϋ8£434 | coloreetai cancer | t/Shhhhhh: | (5Gh6tab(8£hbihgie£i: 4545454545 «t*minvJ’c'OTt xro‘'NA-3f -143 and-145 expression m 60866^66686(8(8(8(8(8(8(8(8(8 |
mir--10<? | nou-i-maii ceil (Oig(O6O6((((( | 60((((((: | xUpregniatioiinifniR-ddAdn:·:·:·:·: 60068000 O0O66666 etrroct evilsprorrot' tri 13. aeiuayonhv targeting | mir-20a | breast cancer | up | Diagnostic potential of PTEN-targeting miR- 214 in the blood of breast cancer patients. | 681(6(66 | 8(68(808(8(8(8(8(8(8(8(8(8(8(8(8(8(86 | ||
nur-13’ | bladder cancer | up | hbcroRNA-l' 7 Upregulation Increases Rtedder Car ror Cell Proliferation and fovasiouhy ((ί6^έβί^:®Α^^4848484848:8 | mir-20a | breast cancer | up | MicroRNA expression profiles in human breast cancer ceiis after muiufractt.cn and single-dose radiation treatment. | mu- Ί | cotatetoat xarroet | up | As&oclatron of microRNA expraszun will mt rosirohitc instability smtus in colorectal 5:^b£8dfc:ih0(tp.6(((((((((((((((((((((((((((((((((((((( |
224
WO 2017/132552
PCT/US2017/015417
22//831/32323: | £8/8883//££££££( .areittotua | (38/((((((: | MkroRNA-te7 promoter tuedreH -on is a® ,0· tyed u ui. 2ρό5382(88οί811/5585/2:228(((((((: ::pa8etiiSvaihsqWH0US:C’K!l:·:·:·:·:· 35822233423// // 333//38//:/2:29((((((: 8:85/8((((((((((((((((((((((((((((((((( | mir-20a | breast carcinoma | up | MiR-93 enhances angiogenesis and metastasis by targeting LATS2. | 3//332//3333: | 338///23833//13333333333 33/////23333333333333333 | 3 3 3 22/2323233 | Differemiai e vpressi-u of miRNAs it. esuphagk3l«.aneer (;E^88222222222222222222222222222222222 |
tuir-l?8: | gastrr. udt'Cer | 8//8((((( | tehcroRNA prefiltog of | nur-20a | cervical cancer | up | miR-20a promotes migration and invasion by regulating TNKS2 m human cervical cancer ceils. | mir-3 i | ((es5pl8ig8888((((((( 33/22/8//238//82/33333 338/2/2852853233333333: | 33332//33333333333 | The nreogenenc role of 228582220/32:/5/8302/28 932222 biumarker in oesophageal squat. .pus tail. <υν«.-υ .a |
238522958222 (:3ρ:222222222: | (58l/8i/t8i:((((((((: (:888/32((((((((((((( | <P | ((185885RNA;5858885!5:522222222222 profiles hi bmuao colorectal ..ancetv % ith liver tnetastase> | mir-20a | cervical cancer | up | Circulating miRNA-20a and miR.NA.-203 for Screening Lymph Node Metastasis in Early Stage Cervical Cancer | 885828522222 | 33;58/5;8/93;ί2Ο;33333 338/5/2/////51/33333: cureteoma | 333//3232323 | Co-targeting of multiple 32:52152/2/32222/322 8 328 5 2 89(322222222222: ittbibumg by poxia-inducibie factor ·Ε1Εί) gene for dm pathogenesis of head and neck :;:Catei80i85te:::::::::::::::::::::::::::::::::::::::::::::::::: |
(/l5/29298((( | breast koncer | 803(33 | Examining esfregon regulation ofkancot stem v’-ifc. Ανίχί inlti vbi 222i3i3t/5/5/i5/t59 322222222222222222222: | mir-20a | cereical cancer | up | MLR-20a promotes ceivical canc er proliferation and metastasis in vitro and in vivo. | 3^83333333 | hepatocellular earemcma | 238/222222: | Expression of mu.ro RNA 4 nuP-zi m-B-D mtP i’2 nbR-d-k', niiR-i4t>a, miP.2d0c, p.uR-22RtuiR-z2z. aud iniE’zB m patients with hepatocellular cam mo ma c-r 333320/5/0 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 220^5/5/82/82/83889322/322222 (5585/52222222222222222222222222222222: |
tuir-l-to | uon-SmaU cell (85///822252((((((: | 8//8((((( | Poripheml Blood mix ·3?1ί Expression as a Potential Biotuarker for the gaily ((έ85/238//://;ί/////((((((((((((( | nur-20a | cboiangiocarci noma | up | miR l 7-92 cluster promotes cholangtocarcinoma growth: evidence for PTEN as downstream target and ELb/Siatj as upstream activator. | mir-3 i | ((hmg(((((((((((((((((( adenocarcinoma | 33332//333333333333 | MicroRNA-31 Predicts the Presence of Lymph Node Metasrases and Sun n al tn 2;E5!i5/3t/Ol2i8i59 32 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 (:(Ad8b/58t5i85i85222222222222222222: |
mit-idd- (:3/(((((((((( | (/118/3//58((((((((( | (://:(((((( | Mur-RNA -repression vreiilmp rm 'als rite 3- emit lnuuton of microRNA-^ u> 2/83^2/2023232323232323233 | mir-20a | colorectal cancer | up | MicroRNA signatures: novel biomarker for colorectai cancer? | 3//3323333333 | 338 52//82/223/51/33333: hrng «.aucer | 322/223322 | Gse of Lununea vMAP headbased suspension atruv ter dettaung u uroRNAm NSCLC tissues and its dinteal :::8/858/855(:::::::::::::::::::::::::::::::::::::::::::::::::: |
mar-ldO·- ££/8(38383 | (8/8////28((((((((( | (://((((((: | iter J* a utotf rntR-'R* p as a marker associated with poor prognosis in spina! 322/83////((((((((((((((((((((((((((( | mir-2i)a | coiorectal cancer | up | MicroRNA expression profiling of exfoliated coionocyles isolated from feces for colorectai cancer screening. | 2/P83/3323 | orai ..arkmoma | :(22/:(((((( | Kvpteiung salivar, mfR-il as a clinical hiomarker of oral 22^5/i298583858;58/8i8/i2i8322222222 |
2:8582888(((: | bladder cancer | 3//3((33 | Ciienialmg mioroRNAs in ::Seipfn;:rft>vef:bre£naiAeis£oi·:·:·:·:· ut ret ts withks-det utfluPt·’ | mir-20a | esophageal squamous cell carcinoma | up | 88583/((((: | 33:5/8938582/5:/8233333 | 3 3 3 03332323 | Dysreguiatiun yfnuR-M and itflR-3 75 expression is associated rath clinwal o’tecmusmortl t mitoma | |
55859//8( | :(8288/:2//882((((( | up | Direct targeting yf $ec2Sa by miR-20' !s tufitrences cancer ceil seeretuiite and piuifiuie®, metastatic coioniiAtiOtt | mir-20a | esophageal squamous cell carcinoma | up | Expression of circulating microRNA-zOa and let-7a in esophageai squamous cell carcinoma | 2:/88(582(((( | 3382///9/82/5:5832333: 205/95830323223 | 3333//333323233 | itflR-c 1 is up-iegufgted «· yqi piematignant epithelium and 32:58/3383/285/32832/5222222222222222222: 225888888^^ :::0i5l:kei58h/5vi§Sf :::::::::::::::::::::::::::::7: |
minl'+i | esophageui :(3/8/22((((((((((((( | (://((((((: | ριΰΐ-ΜΠη/οηΚΝ'-Ί kuduu»?il 5 upregulation might bs associated with hormone ::reeeptpf:stptas:nnd:pi:ognysis:·:·:· In endotuelilai uHciuotuas | mir-2i)a | gastric cancer | up | involvement of miR-zOa in Promoting Gastric Cancer Progression by Targeting Early Growth Response 2 (EGR2). | 228283/3323 | orai squamous cell carcinoma | :(22/:(((((( | Ktf up-mtub'es u»R*N through die C/EEx0 signal ((c8/cad82i:8:O88l/i/8828 898/22222222 |
225
WO 2017/132552
PCT/US2017/015417
$$$££$2 | $$££$£££££ roetetroroa | :£$:$:$:$: | MiofeRMA-2VQ famili toetpiroro Jfiiereptt rth regulate nrorphologtcal plasticity anil mode of //m$iisro£syi|;ih$g$0ro$$:$:$:$ | mir-20a | glioma | up | [Expression of miR-20a in human glioma tissues and its effect on the proliferation of human glioma ceils in vitrei. | $$£$£££: | pancreatic diura! atfenostareinoma | $$$$$ | Cneutatrog MicroRNAs m ecu..of Human! -ns f'ncngcncTrrm gere-c Rat: $££$$$£$$£$$$$$$$$$$$ /$$$ed$ropro^$$$$$$$$$$:$: |
mir-ldl | non-sntaii cell lung tteiteef | $$$££ | High eroresorort of seroro. miR-21 andiumor roiR~20hc :$ass£c£$ed:$tl$$oi$$$$$$$$$ $$£$$ί£ΐ£$$$£$££$$$$ $$$$$έέ£$£££££££$:$:$:$:: | mir-20a | hepatocellular carcinoma | up | MiR-20a induces Ceil Radioresistance by Activating the PTEN/PISK/Akt Signaling Pathway in Hepatocellular Carcinoma. | $$£££$:$: | prostate cancer | $$$$$$: | Screening Bromarkers of Prostate Cancer by Integrating mkroRNA. andmRNA $$$$$$£$$$$$$$$$$$$$$$$ |
$$$£££$$ | nou-smnil ceil $$:$$$:£££ | <P | /£$R$roRN$d£:i$£i:0ir$tg£ii'ig:$: $:$£$$$$$:$$$$$:$:$:$:$:: regulnttr.g expression of | mir-20a | lung cancer | up | MicroRNA miR-I7-5p is oveiexpressed in pancreatic cancer, associated w ith a poor prognosis, and involved in. cancer ceil proliferation and invasion. | $£££$$$$$: $£30$$$$ | $$$$$$$$$$$ $$tta$$$$$$$$$ | $$$$$$: | MieroRNA-312.7 promotes. £$i$$l$$$£ta$£££££££ $$$£$$$££$$$$$$$$$$$$ bepatdveihihi cmtvrnnma disrupting or IN 31 IzxRT negative regulation |
$$$$£:$: | non-sntaii cell lung tteiteef | $$£££; | //0$RO$$£$$££££$i£$ biotoarke? for progression of so.aamytta ceti carcinoma grid adewocluxuroron of tl.e long $£!$$ί:$$ί$ί£$:$$£ί$:$:$:$:: nntkrt·. | mir-20a | lung cancer | up | A. polycistronic inicroRNA cluster, mi.R- 3 7--92. is overexpiessed in human lung cancers and enhances cell proliferation. | $$£32$$:$ | acute myeloid $$£$£.$$$$$$$$$ | $$$$$:$ | MioroRNA-32 upregulation h> 1 ’Mihxdroxc'itarutafM u 1 utitai ng. clvid Kub-ttia cells leads ro Bim fatgettog arxl tnlyburon of Ars< $:i$rii££:$d£$$i5///:$:$:$:$:$:$:$: |
$$$$$$: | ™ anan cancer | lb* | $:$$te$ta££$$RO$$::$:$:$: expression signatures aud veil type-spevific assoeiatu-n % ah $ root resistance m 0\ anm- $$$$$$£$$$$$$$$$$$$$:$$ | mir-20a | lung cancer | up | Apoptosis induction by antisense oligonucleotides against raiR-l?-5p and miR20a in. lung cancers overexpressing miR-17-92. | mu-'C | colorectal cancer | ijp | 'Hie relationship between arid Jtpu <d stpt rinanro erf phosphatase and tenant hpn ologue e · presbi'Ut ·η i£$to2t8$h$2£££££££$:$:$: |
$ityf-:i£l$:$ | prostate eancer | $$$$$$ | A -study of molecular signals ducgulptnu nu mot 1 ’•patr genes at prostate earner compared to benign prostattv $:$$$8$$$££££££££$:$:::$: | nur-20a | malignant melanoma | up | .Altered expression of selected. microRNAs in melanoma: antiproliferative and proapoptoiic activity of mjRNA-J55 | roir-32 | hepatocellular $$$$££$$$$$$$ | $$£$$$ | MiR 2 5 tndu.tes cell proliferation, migration. and mv asrou n·. hepauxellulat careinomaby targeting PTEN |
roir-142 | breast cancel | :$$:$:$:$: | ίί$$$^£ίί$^$$:$ί$:$:$:$:$: tuntorigeuieity of human breast cancer stem celts $$$£ύ$$ί$Α£$$81 $$£$$$ $$$$£$$$£$$$$$$$$$$$ | mir-20a | mantle cell lymphoma | up | The miRNA-17792 cluster mediates chemoresistance and enhances tumor growth in mantle cell, lymphoma via ΡΙ3Κ/ΑΚΪ pathway activation. | $$£320$: | osteosarcoma | $$$$$ | ideu’ifieatmu N a pla&ron four-mtcroRNA panel aa $$$$i;$$£$i$$$$$$$$$$ hromarker for osteosarcoma |
roir-hfe - $$:££££$ | norosmaU celt $l$;£ $£$£$$$$ | $$:$:$:$ | MtR.-l4?-3p represses TGF'-luhroed srovh uduiotion through repression of TGF'RJ in nett-small cell $$$££$$$$$$$$$$$$$:$:$:$:$: | nur-20a | medulloblasto ma | up | The miR-l/92 polyci.st.ron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. | $$£$$$$$$ 3M< | colorectal cancer | $$£$$$ | MicroRNA -j 2bh pro brotes eolorev'pl cancer proliferation and invasion hj competing i$$$$$di$O$i$i$i$££ $$ita$R£$$$£$$$$$$$$$$$$: |
•mir-l'C- £$£$£££: | clear cell rertal cell omroer | $$:·$:$:$ | Exploring the nuRNA-ntRNA regulatory network in clear cell renal cell carckroiw hj next-generation sequencing expression profiles | mir-2Oa | nasopharyngea I cancer | up | Circulating miR-17. uuR-20a, m!R-29c, and miR-223 Combined as Noil-Invasive Biomarkers in Nasopharyngeal Carcinoma. | nuw37f. | • . c ’ vf | $$$$$$· | MicroRNA- Uo broetrons as a tumor suppressor nt cotareetai cancerby targeting the ran $£$£ΐ$1$$£ί$£$$$$$$$$$$$ |
226
WO 2017/132552
PCT/US2017/015417
mu-k2- 8::5466666 | 48545666666666666666 {>· rophoroa | 8:5488:6666 | Gvorexpros&mn oiTraR-142V «wi 1 η* - Γ < w g ror\. mucosa-associated Jyt'opfeoid tissue •’MaLTj. ly niphyma resistant io Helkybacter pxktteradtcatrcu | mir-20a | osteosarcoma | up | U pregulation of microRNA17-92 cluster associates with tumor progression and prognosis in osteosarcoma. | 64545525666 | /654555666666666666666 | 455411 | MiR- '2$ promotes glioma /6/545/8545545:485/558454466666666/ Jepehdeft· Wm-srgnshttg yaO/ttyatte ίρ:?::::::::::::::::::::::::::::::::::::::::::::::::?: |
mir-l-U | esophageal /64545586 6 66666666666/ | /6884/666666 | Eifierardial e\pm:sjAa of mF.NAs Ik esophageal canyei 841445468888/888888888888888888888888888 | mir-20a | ovarian cancer | up | miR.--2.0a promotes proliferation and invasion by targeting APE! in human ovarian cancer cells. | mir-32h | hOn-ShisRcnll $/i;iii6g/056w/$/$/$/$/: | 4554444; | KApheroi Bkod mF-F'x Expression as a Potential 6//Bi55852554i45454:545576666666666 6:Di5550kiS:55/5i5c5c6666666666666: |
mir i-G | 444555545444464/ 6445545666666666666 | <P | 668U64554466 4£i®85NA;666666666666: Exor' »w ί oraTa-e* .ub l.he*ryie, Social and Ffi\ «Pune nal DcieBrar-ardS th Esophageal Carcinoma. | mir-20a | ovarian cancer | up | Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA/B expression. | mir-330- /154444444 | :$£$qpfcag0i6i;$;$;$;$;$ /645455545445666666 curcttmma | 451/444; | •:Miy£oRNA-:-30P-0p£aactiom·:·:·:·: as an oncogene in human esophageal oaueer by targeting programmed ceil doll: 4 |
mir-fit 1 | jftztru vat.cer | /6685/666666 | ///:55$5ί8ι488554ί5654445/44:/6666666 Fxpies i<wi Pattern or Gasrr.c Adenocarcinoina Associated /;6m68i/:S4i/854c5i80i/rft56666666666666: Environmental and Lii'estv fc favOf uj Bodhw'zicrn h 8!,avav> | rtur-zOa | pituitary carcinoma | lip | MicroRNA involvemen t in. a metastatic non-functioning pituitary' carcinoma. | mirGFp 4454444444 | non-smaB vO‘d luAg cancer | 45446;4;4 | miR-'GOGp controls cel: prolFerafktoby targeting early growth response z in non-smgB-tall lung canter. |
ιρ.«-ϊ44 | nasophaiyngea 1 caromonia | tm | M.^rnp\[ A i,z p,vrtrf, ,.v.. proliferation. migranuA and im anon di t.ax*pnar> ope d carokOfoa through repression /6/555^08888/66666666////////////////////////////// | mir-20a | prostate cancer | up | nuR-zOa promotes Prostate cancer invasion and migration, through targeting AB 1.2. | mu-’G | acute myeloid 445454545544444448 | £ prcssmuN mivrol Na-v,i can be used a* a pretli.aorfur respuA*e to therapv and sun Rai in acute myeloid 6:fe454l6ka:p85i485$/66666666666666666: | |
mtr-iAa | 'uiOUvAU <· | /:/44666666: | nuF-21 anrimiR-FU enoperauan. in rogulatio 0 of colon canyer stem cells. | mir-2i)a- 5p | coiorectal cancer | up | Association of microRNA expression with, microsatellite instability status in colorectal adenocarcinoma. | mh-Ft μ 1544/4/444 | hepam xlinlnr carcinoma | /6685/666666 | From unRGS? atei miR* t $ I* tp as dtagi'C tu and piygnowm nujikera m panynts 668454:45454654548548868/66666666666 6:8a8$ih0/hG/66666666666666666666666666: |
mir-i4$ | 44548444548884464/ 644554566:/666666666 | 4/454/4/4// | Vp-iegalation of miyroRNAΪ45 associates whit i> tirpii node metastasis in colorectal /64555458888/6666666666666////////////////////////// | mir-20b | breast cancer | up | MicroRNA-20b promotes cell growth of breast cancer ceils partly via targeting phosphatase and tensin hotnologue (ΡΊΈΝ). | mir- 335 | :$h$5q45ri542q$;$;$;$;: | 451/444; | Targeting oncogenic mF.-$3? uiinbw* cm f'n at uw root of malignant, astrcvv toroa 41554444444444444444444444/ |
6:54555?/666 | endometrial ///£354458;/;/;/;/;/;/;/;/;/;/;/;/ | up | Cp-ieguiathra of microRNAΊ-k promotes dhierercrativn. by repressing iXiTi in human endometrial adenovouinonia 665455666666666666666666666666666666666/ | mir-20b | hepatocelluiar carcinoma | up | Crucial Role for Early Growth Response-1 in the Transcriptional Regulation, of miR-20b in Breast Cancer. | mir-335 | ////08544444646666 | ////T5455/55485RW66835/66666666666 expres zron ts associated wAh poor prog nos· s j a human /6/54554:666666666666666666/////////////////////////// | |
6;;mi8$l8t$666 | esophageal /6454555:44655/888 4545445455484464 | /6684/666666 | Re ί ipr sh pc “vt N eft yvyressioK lev y!s of MIR2i. roFP3, MFi4Gand 8:555-555//0888888888888888///////////////// clmmopaFoiop-n feabicts M esophageal squamous eeB | mir-21 | adrenal cortical carcinoma | up | The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. | mir-335 | /68808060/666666 | 4/544/4/4// | mtR.-z 3 5 promotes ceil piylFerahonby dimctly 88hi8555h505/m/8888888888888888888 /8/555405546:888888888888888888888/ |
mtr-iAa | 8/56444545/1/5414888 lung cancer | 6:44666666: | Senim mF-ll^a^p.mlfc* 66/i558c48545i^455445666666666666/ diagnostic biomad-.ers dinonSKiaB yell lung cancer. | mir-21 | breast cancer | up | Next-generation, sequencing os' microRNAs for breast cancer detection. | mtr-Ft?. 15/4/44444 | gastric cancer | /6685/666666 | MicroRNA profiling of 66541545/555584/53815546666666666666 |
227
WO 2017/132552
PCT/US2017/015417
mir-lAba | gastn <wker | 9tip:EEE | mrR\A-225 promotes gasrnv cancer invasion anti itetastan bv 'argetit-v untor | mir-21 | breast cancer | up | Quantitative Measurement of Serum M icroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females. | mjr-339 | Eh0te8h^tiE2iiEEE lung saucer | l-lll | Peripheral Blood miR-328 Expressmn as a Potential Etiomartter for the Early |
mir-lfoa | gastric cancer | EeEEEE | mteroRN.A-14da inhibits β protein-counted roceptor- kappa&fo targeting CARPI 0 md t OR4 8 :n gastnc -c-jp^cr | mir-21 | breast cancer | up | Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. | mm-339- | PAptoaty tfo.ro to caromoma | WEEE: | muroR 1 v Ί 'pnxhlii4 Na-El - aytppo iter-mediated radfoioTide uptake. |
mir-tifoa | 9hSp3ihifobditik:E: carcHiotna | <P | TSgttifo:fotefoRNAEEEEEE:T eharacterizatiori identifies roiK-8S>5p as apotemidl marker for detecting liver E:££rjidtk^££:iEE:E:E:E:E:E:E:E:E:E:E:E:: | mir-21 | breast cancer | up | Tissue specific expression of extracellular micro RNA in human breast cancers and normal human breast tissue in vivo. | mm-33p | :9gtipifoi9:9:9:9:9:9:9:;: | Hill | nftti rtit g ctol se ti-rcuew d v r > ERA and NOTCH pathways |
mlr-I4da | non-small cell lung csncSf | toljiEEE; | Senna roiK-1 25a-5p. miR- diagnostic bio markers in nohsmph cell long vancei | mir-21 | breast cancer | up | Differential expression of miR-21, miR-125b and rciR191 in breast cancer tissue | mir-3-l·'; | glioblastoma | |||EE | miRNA mscroaroty rcxcaB Vs ilk e\pmfSjAi mile glioblastoma patients. |
mtr-l-foa | Λη1 squamous cell carcinoma | 2rip:EEE | nwR-Baa Pid’oPvto-be OncCgOiiCUY ofotol cptirtohs^ targeting of the IRAKI. RRAF6 .and NUMB genes | mir-21 | breast cancer | up | BMP-6 inhibits microRNA21 expression in breast cancer through repressing deltaEFl andAP-l. | Ε:ίϊίίί:4Ε:Ε:Ε:Ε: | gastric cancer | :Eih:EEE | MicroRNA profiling ol TifoOf^^riEEdifoefiEEEEEE: |
mir-tifoa | 9te^feghEEEEE carcHiotna | Carbamylated albumin stimulates miereRNA-B6. which :s increased inhuman renal cell carcinoma | mir-21 | breast cancer | up | Circulating microRNA-92a and microRNA-21 as novel minimally invasive hromarkers lor primary' breast | mir-345 | EtlfotoiiiO^EE:: | uftomRNA expression kt els tixfliztipvtfok 4 rfoto'RS Eto'ifo^lNtilhOiEEEE | ||
ytiabE::::::::::::: | cdh^fefkcEEES tohyfoid:EEEEEE | UP | A 4-MivreRNA signature can discriminate primary lymphomas from anaplastic 9Ctir£m^^^ cwtogv smears. | mir-21 | breast cancer | up | Up-regulation of miR-21 by i3ER2/oeu signaling promotes cell invasion. | mir-34^ | folheniar thvreid kO<ihtoi^:EEEEE | EAli^bd/reitoi'hriti^EEEEE::: MicroRNA ss deregulated tn follicular fig roid carcinoma. | |
cnyiEEEES | esophageal 9C3tefoE:EEEEEE | StipEEE; | Tronscrintronal tegulaiiot· of imR-i-fob by CEBR?La?2 in esophageal earecereetis. | mir-21 | breast cancer | up | The Regulation and Function of miR-2 l FOXO3a-miR·· 34h/c Signaling rn Breast Cancer. | mir-3-ld | ovarian cancer | MkroRNAs mtrexpresssti m ovarian kLDHl positive cells cijeniorestsianee | |
9foiite^EEEES cfoyfoitiEEEEEE /Phiah^tteEEEE: | expression defones migiatron EdhdtiPO^bhbhfoiiikthbE Icfli tolar thyroid careinuinas | mir-21 | breast cancer | up | MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. | ω Ba | Eg^iiroptirteSEEE::: | ||||; | MuoRNA profiting of | ||
!UK- | ceil esreitmma | up | miR-Ι 4^a enhances the E0hd0g0O|:rifb^E:EEE:T^ caromorna lay concomitant targeting of tire iRAKR TRlkFo and NUMB genes | mir-21 | breast cancer | up | Combination of miR-21 with Circulating Tumor Cells Markers Improve Diagnostic Specificity of Metastatic Breast Cancer. | mu- '4·· | nou-small cell NhtogE^hkhfEEEE:: | up | CncuiafiwgnuR-22 naR-24 and miR-34a as novel prodtetw o fcforearkers to pemefrereti -based chemotherapy ·ηadvanced non small celt lung cancer. |
SmtmcEEE | SpdpiSaiyEEEEE: cfoyfoitiEEEEEE /Phiah^tteEEEE: | EeEEEE | VumRNa aivlv potential diagnostic root for paptiiarv thyroid carcinoma | mir-21 | cerAcal cancer | up | Overexpression of miR.-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN. | ymiC3ia9y: | pancreatic ductal «aderiocaminoma:·:·:· | WEEE: | IMjR-’I imR-'to miR 195 and mif 217 as diagnostic anti prognostic titornarkers for •.hronm pancreatitis and cptirfofohteE&ito^ |
228
WO 2017/132552
PCT/US2017/015417
((3d$7i22273i2623/((((((((((((((((((( | |||||||||||
/:/7732/:/:/:/:/:/:/:/: )43/05555555 | ///32/2123((((((((/(( (3432/(((((((((((( 7332323(((((((( | up | 7/ίνΚ3ρ123Α//33232376////////////////////////// distinguishes :he degree of aggressiveness of papillary /(77657$t6/2272i7i67r35555555555555555/ | mir-21 | cervical carcinoma | up | MicroRNA-21 promotes ceil prolif eration and downreguiates the expression of programmed cell death 4 (PDCD4) iuHeLa cervical carcinoma cells. | mir-Ma | papillary thyroid /(:534213223/(((((((((( | MiR-34a targets CAS I to promote -.eB prohterattonand inhibit apoptosis m papillan -hyoid vOte-noma > ra Pl tfCAkl/Bad pathway, | |
(:332:((((((() 5(20/(55555/ | ;(32/$2G(((((((((? (/34334(((((((((((( /(373233(/////////////// | 5532555555/ | Prognostic Implications of miR-ladb Expression pre· Its b'lKttwPaJRwkw Fepil’ar· /((4244342:4(043055555555555555 | mir-21 | cholangiocarci noma | up | MicroRNA-21 is overexpressed in human choiangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. | ren Na | rental cancer | /50455555/ | Tire qaar-titativ e analysis by stem-loop real time PCR revealed the microRNAGNa ((7232:^01)23/223555555555555555 /()73322 230/023555555555555555555/ ov erevcessicri m human ///$6ld)tes73i)/$6r2s)6)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/ |
:::3237:7:7:7 ((40((((((( | /(-3311343(((((/(((( (2320)555555555555 ((:/233333(((((((( | /(33/:/:/:/:/:/:/ | Express-ixt of miRNzks ui Papillary Thy ror-J Carcinomas is Associated with BRAF /(ivii237i63/32d/5555555555555555555555/ ClmiCvpaihvJouical P”amres :/33/4i:f2$i32$:/443ii$:i23?/?/?/?/?/?/?/? | nur-21 | cholangiocarci noma | up | PTEN and PDCD4 are bona fide targets of microRNA-2i in human choiangiocarcinoma. | /(433223/////// | ((23377332/(((((((((( /(/42432373///////////////////// | 5/055555; | /(73/3i373)/Mic72RNA)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/ E.\pressipi- RfoRtes to ((<$$30^222775555555555555555555 |
UUr- ((40/((((((: | urnmnx (224432/(((((((((((( /(72332373(((((((( | up | A 4-MrereRNA signature can discrimuiaie primaty lymphomas from anaplastic ////o2r3n04232/t2/4h443i3///////////////////////// ////2456/7224:2232/3((((((((((((((((((( | mir-21 | cholangiocarci noma | up | miR-2 i Targets 15-PGDH and Promotes Choiangiocarcinoma Growth. | mir- <2 | renai -.ell 442346443433/(555555555 | up | /(A3$2$t2f 37325^2377555555555555/ miRNAs a> a porenttai diagire-stte tool for early-stago renal cell carcinoma |
/:/323?/?/?/? ((40/((((((: | /(42437:622/(((((((((: (323330(((((((( | /(33/(((((( | Carhamy lured albumin stimulates microRMA-Ftb, wfavli is increased in human /(72h2i(263/2242432432(((((((((((((( | mir-21 | cholangiocarci noma | up | rniR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by inducing Apoptosis of CD24+ Progenitor Cells. | ruirGb/N 4/0/555555555/ | gastric -.rukter | 50)444444 | ’rruntt r« Autt-j P'-rM-Pp ((7332773/737273322/333555555555555 ////732332776f $732133/723326(((((( •'anus Cell*by ItMaiget Cf.-XT |
(:/237/((((((( /(232/3/3/((: | ///2327222/)5555555555 /(722433/(((((((((((( oaremaina | (:32((((((: | Integrated anab sea of ((72040343524075555555555/ e xptessmn prof TD z to ipgmrerve papttt jo thy rout /?ο6ί3ίηό3ΐ3/?/?/?/?/?/?/?/?/?/?/?/?/?/ | mir-21 | colorectal cancer | up | Expression cf miR-21, miR31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. | mil -362-405555555555 | gastric cancer | )50)555555 | ////Ai3i(2i7R(S62(6p//ii37ih77$/)/)/)/)/)/)/)/ Mreration and turusmu, nf ilumanCusirmt anrerCeBs by h> Target 082 |
/(233((((((: 1Anb-5p | ?ρ3ρ7227γ?(((((((() /(722423/(((((((((((( carcinoma | (:32((((((: | MiR-146b-dp pturaules metastasis am: induces epithclrai-meserehymal - ·ρκ&ηιοκ m ihynxd ^anccu tu ((724556343/0444(4(((((((((((((((((( | mir-21 | coiorectal cancer | up | MiR-21 regulates biological behavior through the ΡΊΈΝ/Κ-3 K/Akt signaling pathway in human colorectal cancer cells. | 7/261736277/ ΙΪ555555555 | /:/:h$38tpfi0ll6i34/////////// carcinoma | 4044)5555 | Cpreoutetmu cf raoR- 2- ψ η«κίυΜΐ'ζνΓΛΙιίΡ··<«Λΐ. md anchorage-independent (h M drrcvth uuetitig Tch2 in hepatocellular /)/232:732733)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/ |
(:/3347((((((( /(:43273((: | ///22244344((((((((((: /(722433((((((((((((: carcinoma | (:32((((((: | MicroRNA miR-143b-5p regulates signal trar&duchpn iVf-' tw teptessing SM AD I it- n retd tan e·· | mir-21 | colorectal cancer | up | MicroRNA expression profiling of exfoliated eolonocyt.es isolated from feces for colorectal cancer screening. | mil -362-- )405555555555 | ///2$68t6i:6U3t27::55555 (($32:73 273 35555555555/ | )50)555555 | MieroRNA-362 -5p promotes tniiivr grew th and me tastaz* b> targeting CYID m tcpiK vlml-tr <re ttm a |
(//34-2/3((( | gastnc career | (:32((((((: | /7:23c2?44NA3424243g/447/(((((((((: hirtufto gazru career | mir-21 | coiorectal cancer | up | Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. | mu ·*'·· | paireieattc -.artcer | 4044)5555 | ua.R-'Sv piohiote* vpUheBaltouresenclty mal transition and ii-vasicn of pancreatic d-actel adenocarcinoma cells bv targeting the Smad’-TGF- |
229
WO 2017/132552
PCT/US2017/015417
' swmdlmgpariwa' | |||||||||||
irur-GS-a | 50fc08&48$:$:::$:$: | U}' | Mi.roRMAcxore *ion profiling meal? fire putenual function of roreroR.NA -3 1 in 5388988888885;333333333333333333333333: | mir-21 | colorectal cancer | up | Detection of miR.-92a and mjR-2J in stool samples as potential screening biomarkers for colorectal cancer and polvps. | roir-369- illlli | pancreatic ductal ade-nocamtoorua | :033/ | Cmultmitg MtcioRNAs m Serum ni'Kmuan K-ras Oncogene Transgenic Rate With far·- oaU- Da- · al Adenocarcinomas. |
rora-U&a | gast«e vdt'Cer | 5^39555583 | miR -J 4Ka promoted cell vf»faiudtm b> targe ·η-ρ2’ 559:00388998889ΐ9;333333333333 | mir-21 | colorectal cancer | up | Correlation of overexpressions of mix-21 and Notch-! in human colorectal cancer with clinical stages. | mk-3?h | acute mvtfotd 33188198345555555555555 | 8055558 | ;54η589398885ήί28ΝΡ;884ΐ;5555555555; 5;p®O:888488:095555555555555555: nayroRNA profiling reveals that MtR-' >0 ta unregulated 55959;9i953855£95hi85O95;55555555 ntveloid leukemia |
irur-GS-a | glioblastoma | U}' | 33i5O;O04485:S:9;33333333:3555 Prognostic -w.evmtR fired Targets MfGo ard BtM to 3;98g9589:5?G8^:3rid3:5555355555555 Apoptosis in Chyblastoma. | mir-21 | colorectal cancer | up | increased expression of microRNA-2 land its association with chemotherapeutic response in. human colorectal cancer. | mil- | gastric carreer | up | Occm'.picx'ivoo· mu - Ά* 55959;Ο8Φΐ99^830Βί4Β55555555 ;5;O9i5t9O850ORib55555555555 contribute to the progression of gasnre camureroa |
2:19932323 35905555555 | ovarian carreer | 5^39555583 | Irrereased expression of miRI-ihb in ovarian caratooma 55999 ;888899841598g88i88948855;333 | mir-21 | colorectal cancer | up | MicroRNA-21 controls hTERT via ΡΊΈΝ in human colorectal cancer cell uroliferation. | mk-3?h | gscsttre cancer | 8085558 | Lpreacdaitonot mix T7 contributes to tlie orogressren of gas-ire carou-uma' ia 3:8894984983όί®94ί9955555555555 |
8ί5ί9$:$:$:$ 58O85;5;5;3 | 5839899555555555555 $>;9i&tf58O33$:::$: | 808:8:8 | increased expression. ofraiRI4$b m ovarian carcinoma audit*-mu >1 sicrrirotrrea | mir- 21 | colorectal cancer | up | Clinical correlations of miR21 expression in colorectal cancer patients and effects of its inhibition onDt.DJ colon cancer cells. | 3;b9$O$55 | hepatocellular 3:Camth0i39:$:$:$:$:$: | 50555555; | niR 3Ή Vdown mg-Bare, pre mRNA processing fturor 4 horoolog B !,RRRF4B) anri facilitates the iJ f/$ transition ;539:9O98:b999O88rii58355555555: ;:;carambmareeii9;3;3;3;3;3;3;3;3;3;3; |
Η)«·-ΪΨ> | nasnpbar> npea 1 cam-noma | It;. | mfR-U? promotes epuhehaltoesench> mal transition and invasion m rasepharvogeal 5589999384i;981i833333333333333333333 | mir-21 | colorectal carcinoma | up | A ltered levels of the oncomicroRNA 23 and tlie tumorsupresscr microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradio therapy | mi.-v? | 33OhOhbB9i8ri55 55e9i3e3;333333333333333 | 839555583 | C arn-uMunerton un-roRMA screens identify nhR-dOSa reguisiing proliferation ami : apoptosis ni:epi£helialeva«ail·:: ;5O888;88O53553553553555555; |
mir-IX* | 85889:9305:$:$:: | U}' | 8:SO£95&OW;£00£ 55555 mtR-150 and miR-223 Is Inv vb cd tn fbe Rroltfersrioo Ofin*LV-LTrsnsfO«'<5Od and 5^3^3333555555555555555555555 | mir-21 | diffuse large B-cell lymphoma | up | inhibition of mrR-21 induces Biological and Behavioral Alterations in Diffuse Large B-Cell Lymphoma | mi- v*x | ehonre | up | Cotrclatmti of uft-routa-3 '2 uprcgulatmtt with poor χ, jornw « Hmm fuff) |
mire 150 | breasi cancer | 50833333 | roiR-d 53' promotes human breast Cancer growth and nialiananl belraviyr bj taigeriiig fire prc-ap'pt'Ate purmcrgtc {*2λ“ teveptm | mir-21 | endometrial cancer | up | Highly increased rnaspin expression corresponds with up-regulation of miR-21 in endometrial cancer: a preliminary report. | rumD?2 | bead and neck squamous ceil 3:Camth0i39:$:$:$:$:$: | 50555558 | mtR -; 7 2 inhibits pf>2 tu bead 35999:09804019:48855555555555 330898089590548939833333333 50855355355355355353555555555 |
mir-15ri | 3999O8O85;55 | ί^ίϊίϊ: | miR-142 regulates the tumorigoiacity of hutnan breast vancor stem cells fbrough the -anotueal ΆΑΤ 53ri895^5:^59ay35555555555555555 | mir-21 | esophageal cancer | up | The expression of mix-21 and miR-375 predict prognosis of esophageal cancer | mir -3?2 | 5598959881484955555 3399898943333333333: | 505355 | Dpresiila· ron yf micioRNA172 aamroafe* with tumor progression anri prognosis in neprtc -brihr ro wro a |
230
WO 2017/132552
PCT/US2017/015417
iSiu/iiSis | :(:/36/392(:(:(:(:(:(:(:(:(:(:(:(: 9 mphoeytie (:(30//92((9((((((((((((( | :(:/333:(:(:(:(:(:(: | :(:(32326333/(239226333/(3333333333333: stgn.tfuance oi cefiular and serum ciroulatn-g υικηακΝζ'i m Chrome LtiiMhv > re Leukemia patients | mir-21 | esophageal cancer | up | [Diagnostic values of salivary versus and plasma mi.croRNA-21 for early esophageal cancer]. | rodrk'k | ((((/36//3(///6//(((((((((((((( | /9//:/(3/ | lire mtvroRNAs nuR-VM and n«R-*20epr<«mte tumour dw osioo and metastasis |
(91(65950444 | ooiorec-fat :(://9//(9(:(:(:(:(:(:(:(:(:(:(:(:( | (:((33/(:(:(:(:(:(:( | Circulating Expsoroa! microRNzks as Biomarkers of ((((963/3/(32/9/62((((((((((((((((((((((((((((((((((((((((((( | mir-21 | esophageal cancer | up | Alteration oi' miRNA Expression Correlates with Lifestyle, Social and Environmental Determinants rn Esophageal Carcinoma | :(:9/90444: | :8606:2024444444448(8 carotboroa | 3:92((((((((((((( | MioroRNAk ?3 functions as an oncogene and targets VODl geneincen ical (3:(//2/2(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( |
ssssisssi | <P | MlR-fNl promotes gastric cancer proliferation h> aegadvelv regulating the proapoptotte geoeEGR2 | mir-21 | esophageal squamous cell carcinoma | up | miR-21 Down -Regulation Suppresses Cell Growth, invasion and induces (Sell Apoptosis bv Targeting EASE. ΤΓΜΡ3, and RECK Genes in Esophageal Carcinoma. | Zi/O/Z/ZZ | :(:(693331633/3:9///33/3(3 (:((//2///(((((((((((((((((((((((((((((( | /91/3// | (:(:©hH(l-:pf:-f2r2:962:h2i(i6KNA.4444: screetv; rclentd} nuR-lbfa regulating proliferation and opoptosis in epithelial ovarian :(:(3232/3://39(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | |
mir-GA | /9/9444444444444444 adeaycarekiom (:(/(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: | (:(9/:444444 | Altered roiR -145 and mR.158 expressions In peripheral blood mononuclear cells for diagnosis of norosuiall«. el! /(9//(99969(44444444444444444444444: | mir-21 | esophageal squamous cell carcinoma | up | Expression of microRNAs in squamous ceii carcinoma of human head and neck and the esophagus’ miR-205 and miR-21. are specific markers forHNSCC andESCC. | roir-3?2 | 44es6ph3gga9:8:8:8:8: :(:///23/6//://32(((((((((( (:((//3/3/63//:(:(:(:(:(:(:(:(:(:(: | /3//(//// | Mi roRNA--7· troik 17-} (((96/33321/3/33233933/332(((((((((((((((((((((((((( regulates targe tumor ((((9329///O:26i/6i9/:2(33333333333 •Έ AT$2> and stimulates proliferation tn buroao :(566pi2966f 696/628(8(8(8(8(8(4448 |
(((0515(0(((((( | brag cancer | (:/9444444: | mrR-ΙΝ! promotes the proliferation and migration ol lung cancer cells h> targeting SRC kmase rignalhug 496/36//2(98(8(8(8(8(8(8(8(8(8(8(8(4: | mir-21 | esophageal squamous cell carcinoma | up | MicroRMA-21 promotes the proliferation and inhibits apoptosis in EcalOS via activating ERKI/2/MAPK pathway. | mtr-}} | 420922(8(8(8(8(8(8(48 ode nocaro umma | (433/:444444 | MieroRNA-ik is (((293/g936t6/(:66/:33O6(4444444444 (:(:3W!BB2/93t366(266i376333333 cancel., contnbntrug ro murengencsis |
:(:/33(/(:6////9(:(:(:(:(:(: | (((//:(:(:(:(:(:(: | mtcroRNA-}?·’ rs associated :(:3/33996//:93/////9(32:/0//(:(:(:(:( :(((/3//3i(5/333i3333/(/6////(:(:(:(:(:(:(:(:(:(:(:(: | squamous cell carcinoma | up | expression levels of MtR21, M1R143,M5R145, and MIR.205 and clinicopathologic: features of esophageal squamous cell carcinoma. | (:((//3/3/63//:(:(:(:(:(:(:(:(:(:(: | /91///3 | ((((362/03(93:2363/333333333333333333: pbrophrotz f> fnnutoro; a z an ororogetre :n hcparorelltthar :(:(66//ί/ό326:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | |||
:(:999:(:(:(:(:(:(:(:( /(BB/Z/ZZ | (((¢¢10999944444444 (((6/33//9((((((((((((((((((((((((( | (:(9/:444444 | MmroRNA exprossicro ::prorileain:hurnaQ:Coiorectal:·:·:·:·: cancers with Iwer metastmres. | mir-21 | esophageal squamous cell carcinoma | up | Expression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma. | roir-3?da | gasttte cancer | (:((3/3(((((((((((:( | mR.k 7-ia promotes cell preliferaiiom migration and tmastortlw targeting SRC fNl 812263:66626260:8:8:8:8:8(8(8:8:8 |
:(:(/9295(9(((( (((/9(((((((((((((((((((( | •••osteasarcwmrt········· | (:((9/9(((((((( | MtcroRNA-10Va-Sp is do unregulated in human osteosareoroa and regulates :(:(/633(:93//3/36312/:/29(:(:(:(:(:(:(:(:(:(:(:(:(: roremiron | mir-21 | esophageal squamous cell carcinoma | up | Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. | (:(ίήί£$4444444: | ((((69/6//3//333/((((((((((((( | Z9|ZZZ3 | (:(:3d6h33i3/6si66:6i9(pl6S366:(:(:(:(:(:(((:( fom-nkeroRNA panel as (:(963/B363993333i626i(/6((((((((((((((((((((((((((( bionrerker lot osteosareoroa |
irer-IM- (:(52::(:(:(:(:(:(:(:(:(: | (:(///33/39(:(:(:(:(:(:(:(:(:(:( (((/////ί!///////////: :(:2/9ji/2/i2(44444444 | up | Z(:(9336/36t3//(:////3RW(3333333333 :(((/93333//(//:23///3363(33333333333333: bioroarhens for dtagnosts oi papillary thyroid carcinoma. | mir-21 | esophageal squamous cell carcinoma | up | Down-Regulation of PTEN Expression Modulated hy Dysregulated miR-21. Contributes lo the Progression of Esophageal Cancer. | mir- | rton-sruall cod :(:(133//(/6///3(:(:(:(:(:(:(:(:(: | up | Claudm-l ts a novel target of uuRk ?? tn ttprasmafi-oell :(:(1(69/:66ηέ/3(4444444444444444444444444 |
i
WO 2017/132552
PCT/US2017/015417
0h8p8te30&d8f:::0: vftrettWMun | 2460244440: | MicroRMA-iB promotes WoiBteaieou; activation tti hepatocellular enreiuorra Ibioaaii suppression of 0603X00240000000000000000: | mir-21 | esophageal squamous ceil carcinoma | up | Clinical impact of serum exosomal microRNA-zJ as a clinical biomarker in human esophageal squamous cell carcinoma. | rotr-t'/ba | pancreatic diKtal atienoeominonta | 0650000 | Crrctiiatmg MteroRN Ax re cm.,<rf Human J -ns f'rpngene'Pran gerto Rat: 44555i60P6666006i:2:£366i6624 4 4 4 4 4 4 4 4 4 2 2 2A0$hog0p$r6bi6^44444444444444444: | |
426026553444: | prostate cancer | 05500002 | Upregulation of miE -1 $5 promotes celt proliferation via downregulation of tie PTEN 246532^00600060300:5556050 42 0 24 4 4 ί art. .ao prostate . w w | mir-21 | gastric cancer | up | Oxidative Stress Upregtdates PDCD4 Expression in Patients with Gastric Cancer via roiR-21. | 421564000444: | gastric oancer | 42654244444 | 2MjOioR2NA~3 77 predicts poor efintcaJ outcome of gastric 2466i626l202r^:0i66624 4 4 4 4 4 4 4 4 4 4 4 4 4 4: nm-enitetiesu lw targeting multiple tutuor-suppressor •nuts |
mu-i* | acute roveioid fetAeuna | U.i | HennavPiogtcaJ Ur^mtc vf oR*)MM!8iheNKES>SN activating anz> roe inhibito ί kQ N-tvN .RevonMfS'atjni 2 2 2 2014 T62tf2Ti52aP5te2:t65sii5ui24444444: 2 2 2 2 jb6k5h6d4444444444444444444444444444 | mir-21 | gastric cancer | up | mrcioRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. | mn-vs | acute myeloid 44ί60Ϊ0ί5ίί024 4 4 4 4 4 4 4 4 4 4: | up | Ο ere core ssroo of rmR- is frequent and reuv affect ireatroem outcomes inpatients wuh Mute η λ eionf leukemia |
giiyrefSSgy | anaplastic 0l8ig540550:0:0:0:0 J> rophoroa | TltiiaT:;:;:;:;:; | Oncogenic rote of ηυΕ.-155 in 44a656i255602i3tg5200U244444444444444: h rephoroa Jacking the ti 2 8; 44tf500i56365004444444444444444444444: | nyr-21 | gastric cancer | up | Evaluation c-f MicroRNA Expression Pattern of Gastric Adenocarcinoma Associated with Socioeconomic, Environmental and Lifestyle Factors in Northwestern Hungary. | mk-j?h | breast cancer | 025500002 | Assoeotionbotweentinr-24 and mir -57ii tn formalin-fired paraffut-erohedJed ttosues nf 246f603005060i.44444444444444444444444: |
mw>J<5 | tiidd'. varc'· | ::56:0::::::::: | Correlation of tuereuseti Expression of kborc-ENA440032 60^0i535iSg605i46h6244444: 24:0006:36444444444444444444444444444 | mit-2l | gastric cancer | up | MicroRNA-zJ inhibits Serpinil. a gene with novel tumour suppressive effects in gastric cancer. | 426560002444 | ot anon cancer | 24602444444 | kBE-.:7b as a hmmarkerfor response to anti-angiogenic treatment in ovarian cancer |
giiyrefSSgy | bladder career | 422002444444 | kfioroEN A-d55 pronx-tes bladder van tian' hty repressing the tmuor 44536605566055615:600 42 0 24 4 4 4 4 4 4 4 4 4: | nyr-21 | gastric cancer | up | MicroR.NA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein. 4 and phosphatase and tensin homolog. | mk-j?h | ovarian cancer | 025500002 | Differential microRNA «expresstoncstgnaiuresandeeh·:·:·: ripe-specific association with Tu voJ reststam. e tn ox arum 4453γ660635344262444444444444444444444 |
mw>J<5 | breast ewer | 4:0)6444444: | Clmieal npnrfreaoee ut kifeoR2NA-d55 expression in 00-63002 605504656X62444444444444: | mir-21 | gastric cancer | up | miR-21 plays a pivotal roie in gastric cancer pathogenesis and progression. | illtr-Hi | gastric cancer | 24602444444 | to .tested 'xpn.sstoiOT ntE* a?i m human gastric can-muma arc ηχ Umival 22253Sh6rdt5!ti44444444444444444444444444 |
giiyrefSSgy | breast career | :465:444444 | Analy sis of mix -205 and miR-it'S expression in the ;420160026i06060$0200600i444444444444 22:20056160.44444444444444444444444444444: | nyr-21 | gastric cancer | up | miR-2 ί is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer. | mk-421 | gastric cancer | 025500002 | MiR-42 J regulates apoptosis of BGC-‘ό2> gastric cai-v« cells by targe- -ng vuspase |
2402^6026266666000 | 0:56000:0 | 4400040:0105366455000610100244444: 0200i04 0$32:000i5s0i06660444444444 reduces TPSitiMPJ expression in MCJ--7 fcre-au ewer cedis. | mir-21 | gastric cancer | up | Stromal miR-21 is more important than miR -2 ί of tumour ceils for the progression of gastric cancer. | 2420260462214442 | 446^400450500624 4 4 4 4: | Olli: | Mn, oRN A 421 rs a new •:potentiai:diagHOS£shtonwker·:·:· wrhludvr setsuo i, <rod 446066056666656444444444444444444444 eaminoomhiy onio antigen ami ai erre troxt IB ir _a.fix 2450540624444444444444444444444444444444 | |
240060253044 | breast career | :465:444444 | MteroEN A-J55 functions as an OncomiR in breast Oancer ::by<!a<get£!Qgfhe:SUppresSOi:of:·:· ex tokree· signaling 1 getie- | nyr-21 | gastric cancer | up | Circulating microRNAs in plasma of patients with gastric cancers. | mk-421 | nasopharyngeal 2 4 20400Λίΐίί·ρ6ίίί324;2;2;2;2;2;2;2;2;2 | 025500200 | rtnE-aM u-riuccooeil proliferation and apoptosis 44i53t3i560046065536ii444444444444444 nasopharvtigeal carcreoroa via |
232
WO 2017/132552
PCT/US2017/015417
douuregntotion vi E0X04 | |||||||||||
UUf“iM | (9b9r8/59e8/80r94((( | up | turk-1 A* drw es tototuete fragihti in human breast career by targeting TRRi | mir-21 | gastric cancer | up | Plasma microRNAs, miR223, miR-21 and miR-218. as novel potential biomarkers for gastric cancer detection. | (:44/88/:49((( | 9999/3/4851484/984/9999999999 | ((G8958Z488l8/559pZ/45to49(((((((( «uppres^r m 'out hv puR -1 ’ 1 promotes probferatioo and ::QKgrettoa»ff£ee»3bfeStenw::::: | |
reio-M5 | breast eancer | :9:583:9:9:9:9: | MureRMA-15* regulates cN! surehal growth, and ::eheK10S0ilsitivky:by:taigeimg:·:· FOXCAju· beas· voneei | mir-21 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and. metastasis by targeting tumor s up pre ssor EPB 41L3. | illtr-Hl | breast career | 49/89(((((( | Gerere analv>!sanJ preliminary function study of nuR -123 in breast career |
9(;ii98i98-9i;?95Z9;9; | breast cancer | 9993/9333 | Role of miere-RMzvs -?s»b-2. - /BoBZBBBBi/////// diagnoalic hmmuikeia m reruiu of breast cancer ΙΙδ/ί/ΐδΖΤΤΤΤΤΤΤΤΤΤΤΤΤΤ: | mir-21 | gastric cancer | up | Prognostic impact of circulating miR-21 in the plasma of patients with gastnc carcinoma. | mkM2j | 9 9 9 9/38888/881389((((( ((¢88448888((((((((((: | /58/9/// | MicroRWANzd promotes ceil glvwtl and rcgul4ci C< 1 vS trareitr·’!!^ <rfgfcti«u 9(82483/4//5//588////////////9 hep dre rihitor i.ao.mum 1 |
9(9ΐ3444:49$$4(( | 484888:388/343/9( | /3/9/9/9/9 | (Expression and its clinical siomfkarree ol iwR-l>s «, human primary breast 9(5858881(9(9((((((((((((((((((((((((((99 | mir-21 | glioblastoma | up | Heterogeneous Nuclear Ribouucleopiotem C 1/C2 Controls the Metastatic Potential of Glioblastoma by Regulating PDCD4. | mil-423- BZ//|/// | 999./9185/381(((((((((((( ((5384/84/8((((((((((: | 9//8/9/// | nacroRNA-123 - Sppiornytes utivrpivgre^sivi rot modulation of AdipnR? in hoy ngeal caremoroa |
reio-M5 | vviMcnt. e·· | :9:95533:9:9: | Mtr-l*^ preurerez vcn icai career cell pforifeiarron through suppression. of rts target gene LRBl | mir-21 | glioblastoma | up | Sulforaphane enhances tem.czolomi.de-i.nduced apoptosis due to downregulation of miR-21 via Wnt/?-cateniu signaling in glioblastoma. | 99993/48/139(((((((((((((: myelogenous leukemia | 438994949(9 | Restoratuuivi ntiR-42-1 suppreSSeSBCR-ABf refivP. Util eirrizOv (9 kQ tHb 0 nua'Qub treatment | |
9(9ΐ3444:49$$4(( | 9(34/54/3(((((((((((( 9(4/984/8/8/8/9(((((: /4//8/8/8/:/:/:/:/: | /3/9/9/9/9 | 9(9^898583fe9t38/8/i9a83((((((((((: Activator of Tiau&criptiou-i Indm'rokbuuRNA-l^ 99(38/854818894443/8484849((((((((: Lymphocytic Leukemia | mir-21 | glioblastoma | up | MicroRNA-21 targets LRRF19P1 and contributes to V9M-26 resistance in glioblastoma multifcrme | ink-424 | 99989/1/95818498/5435(( | 9//8/9/// | Dyw «regulation of miR-iV5 roare-latcs wrh h mph red·, meiari jms and pouf progtms's 9994893548f58i849$3888f9((((((((((((((( |
reio-M5 | clear ceil renal xc'd cancer | in. | mreruRNAMA* silencing 9(4/8tb8/9543iifei/i/853/d(((((((( migration and induces apoptosis 4» upreguiatk- g 8ACB1 in renal cancer cells. | mir-21 | glioblastoma | up | PDGF-B-mediated downregulation of miR-21: new insights into PDGF signaling in glioblastoma. | i«tr-«4 | o\ anao career | 438994949(9 | MreroRNAz merevpressed re o\ anao A31>! 11-positive ceils 9999/3998/8/89154//(5391/999999999999999999999999999999999 /9^5to/8^^Z/////////:///: |
viferediSSvI | colon cancer | /58////9 | Correlation, between expression of m£R,-i5? in cotort cancer and scmiu ircreveu, ηυ mu iitogvP level and its contribution to recurrence aod metastasis ii/jii/i/Sti-iTTTTTTTTTTTTTT | mir-21 | glioblastoma | up | Downregulation of mlR-21 inhibits EGFP. pathway and suppresses the growth of human glioblastoma ceils independent of PTFN status | 934/8942349999 /0////// | pancreatic cancer | /3//9/// | Mi0toRN_A-42-i-5p yuppr^res hcExpu root of p. £ ml5 thereto» t nt ci |
tuir-lo* | colorectal ///8/////////://9 | //////(ί | 1. prepretotoo οί ms roRk Ai$5 promotes the migration 9(388 4i588/84r3oZ8/fei/09t5i((((((: •.aovci veils diroitcbtbe· 9(/3/84/3/84/38^88884((((((((((: ((58/i8s5i884(((((((((((((((((((((((( | mir-21 | glioblastoma | up | Expression of 19 microRNAs in glioblastoma and co mparison w ith 0 the r b rain neoplasia of grades ϊ-ίί I. | iukM25 | gastnc career | /58////9 | NR-kappa8-dcpcudent MioroRXA-42? upreguiatio 0 p-omoiKs gasniv career«,βίι growth hv targeting 35TEN /9/8/8(4/9/1//9^^ |
45/8(43954(: | 9:90αί»ίί0ή9ύδ9ΐ-:9:9:9:9:9:9: ceil b mphoma | <P | STAT5-metiiate3 expression 9(38/8/8/8/i898M8/i3S9/8(((((((: xttfanevus 3Xref! iv tupboma | mir-21 | glioblastoma | up | Co-delivery of as-rniR-21 and 5-FU by polv(amidoamme) dendrimer attenuates human | /44/8428// | breast cancer· | /5/9//// | Direct targeting of Soc25aby unR-iM-j. tufrreatecs cancer cell seeretome and promotes |
233
WO 2017/132552
PCT/US2017/015417
glioma cell growth in vitro. | ructa&taixc colcrixcatioxt | ||||||||||
xuif-i>* | ddi'uso large )330 3 6666666666666 :5:330/333)))))))) | up | C u-uduiuted e xpuresmt. of teicmP V At and prefi ueti target genes m diffuse large 5)4)0(300(00(3 03666666666666666665 | mir-21 | glioblastoma | up | MicroRNA-21 Promotes Gbobiastoma Tumorigenesis by Down -regulating Insulinlike Growth Factor-binding rrof.ein-3 (TGFBP3). | :5:30()00(5))) | wdorectal cancer | :05555555 | 5 5 5 5?0t(R5-02453500:((3(3/(0i(4)))))) remyx-st ixmrmtetorxxri cancer and evena its antiapop’Otrc fumupn tu targeting S0X2 |
cnyt-TSM/: | endctuetftal 5)00(300)))))))))))): | :)40:)))))) | Artgiofeostii ίί rcpe ί tetepfcr and uuR 155 xn endotnetnai 5))(30:03)4340433666666666666666 an ipxuldna X' e cfrc\t> wi lou-tuiM** ard W'dd' endometrial cancer ceils | mir-21 | glioblastoma | up | Downregulation of Pd.cd.4 by mir-21 facilitates glioblastoma proliferation in vivo. | rnir-429 | hepatocellular ))003((3((3)))))))))): | 65336666665 | Mr roRNA -l^Modfia^ HepamceBulpr Carcinoma ::BrogHOSisaQd:Tumorigefies3:·:·:· |
5)33033/0))))))) caretaoms | tip | ))330):0003330:03))))))))))))))) with the aggressive nisrigrtant behavior of gaiihtadder 5:5:(30t(05305)))))))))))))))))))))))))) | mir-21 | glioblastoma | up | MiR-21 up-regulation mediates gbobiastoma cancer stem ceils apoptosis and proliferation b v targeting FASLG. | mu-42'' | hepatocellular :)4033034:)))))))))) | up | Epigenetic modification of MiR*-^ promotes fcxer tumour -utniatmg ceil properties by targeting Rb b-ud-ug protein -1 | |
5)500i5-:i)?4))) | :5:g((030:)))))))))))) | :)40:)))))) | KiJCmPNk (<5Pup,,ores :5:53000(05300)0(00(400(3(0)(3:)): the Regulation of ΜΧΪ1 | mir-21 | glioblastoma | up | MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. | rnir-429 | 5:5:03(3043))))))))))) :5:53/(034(10:5:5:5))))))): | 6533666665 | MicroRWA-’Ori frm.K members differerPtalt} regulate morphological pla»LXvtiy and inode 3 meJaootua ceil invasion. |
5;5;iiiii5-:i5$?>:55;5; | :5:0((034:)))))))))))) | ):405)))))) | 5)5050/30303(0(60/6666666666666666 uiivmRNA l55piedKt>prtwr prognosis :n gfroma patterns | mir-21 | glioblastoma | up | Delivery of anti-micioRNA21 aiitiser.se- obgodeoxynucleotide using amphiphilic peptides for glioblastoma gene therapy. | ioii-42<i | )4(0330300(366666 | 643666666 | ):5303030((3(04:00)))))))))))))))) nactwRNA-429 uihihiU cad profrtersrioofry targeting p2“Rxpl«. human pm-staXw . amor .--13- |
hepatocellular :5:0433433)))))))) | U;> | Rpfcuf n 5:5:033530000)00))))))))))))))))))))) hepatctesretncgeuests induced 5)50^5(03(0330003004:50/35)))))))): anuno ac-xd-defuicd diet in | mir-21 | glioblastoma | up | MicroRNA-2 J targets a network of key tumorsuppressive pathways in. glioblastoma cells. | U’u- 63066666665 | :5:51(38:(0/40/:)))))))): | :)(3:)))))) | MicroRNA -U251 ts a primate* specific iegoisfOr of airway tell dtficieotisriOn and iuny catwinp^enesis | |
5;5;iiiii5-:i5$?>:55;5; | : :h?paloeelhi(ai:::: 5)00(0i4d43))))))))5 | ):405)))))) | 5)5(E(p3334:03(333335))))))): prediction of ruxcroRNA-io? in hupafocefitxiar carcixtoma after ixver trauspiautarion] | mir-21 | head and neck cancer | up | MicroRNA alterations in head and neck squamous cell carcinoma. | ioii-4S2 | )5/(04(30/0(:666666666 ))43(36666666666666665 | 66/3666660 | Differential e vpreasiou of miRNAs xtt e&opfcageal cancer 65434(666666666666666666666666666666666 |
5)44/3*3))) | 5)((0(/44000/))))))5 | tip | ))·ίϋΕ)?(403303(0/:(/333§;) io dvwu-rcguiaie IPS 'INPJ ))(0:3/434303603034(3()))))))))5 mesenchymcd transition and canter stem «.eii phewfi p<x | mir-21 | bead and neck cancer | up | [’Expression of mir-21 arid mir-5175 in laryngeal squamous celt carcinoma]. | mir-452 | hepatocellular 5)4303030:6666666666 | 50555555 | MieroRMA-4>2 promotes ))0334(3(3435(4))))))))))))))))))) hepaxwceiixttar carcinoma by targeting eycfrn-dependent :513(3(434((3(4^7:7:7:7:7:7:7:7 |
mir*15* | :)1033))))))))))))))) adenccareiitom. )50))))))))))))))333 | :)40:)))))) | P-nvitaridtepnoxtii. Mire Λ mfi.-l5? in serum front lung adenocarcinoma patients | mir-21 | bead and neck squamous cell carcinoma | up | Clustenn Is a Gene-Specific Target of microRNA-21 in Head and Neck Squamous Cell Carcinoma. | tuirMN^ 6336666666665 | malignant :5:53/(0340.0)))))))))): | 5)03)))))) | Reduced adenosmerio-mowne n«R -iS^.Sp. ecl.tmg promotes ))033(3 ((35343(/( 3r3)))))))))))) ):3((3334)))))))))))))))))))))))))): |
5:553/35(5555:)): | (ung csncer | 5):005)))))) | ))(50f333^;^33(W0:;:;:;:;:;:;:;:;: 5)33533305(03033(336666666)) RaiieutS u ith Lana Cancer, ihdrnwiatrc Tuberculu&tSs and ))33(33(04))))))))))))))))))))))))): | mir-21 | head and. neck squamous cell carcinoma | up | Co-targeting of multiple microRNAs on factorinhibiting i iy po xia -inducib le factor (FIH) gene for the pathogenesis of head and | mtr-riB- 11111 | adrenal cortical 5:5053330((4::5:::::::::::::::::: | ):44:666666 | Ttie rcle of mteroKNA ))030^010(30(((0(0:)))))))))))))))) •:patho:geues!Si>f:ndrenocoifieal·:·: ))04((0(43))))))))))))))))))))))))))) |
234
WO 2017/132552
PCT/US2017/015417
neck carcinomas. | |||||||||||
mircfrA | lung enneer | /)93/)))))) | tufebnuro vi fe pu aa-mdmed mtR-i?? rariioseftsitizes fepoxiv lung vainer vNB | mir-21 | head and neck squamous ceii carcinoma | up | l ow-level expression of 205 are prognostic markers of head and neck squamous celi carcinoma. | roir*48.:* | bepvi:h\.5i»lar /)(4416/488)))))))))): | 5(53636/ | Dvercxpression oi'miR*48 A spApcoqperafero mhdxt ))656765(36(/58(979:5(/////////////////////// /)(633(764(9)8987(3393:3))))))))))) stimulated HSCs m transgenic |
/)((69-366))) | /)1659786867))))))/ | up | /)98(5(55((886933388)))))))))))) sensitivity of lung eancet oeBs io oispJatsn via negarive /)/5593((6666/46456))))))))))))): :/:8)56585:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | mir-21 | head and neck squamous celi carcinoma | up | Expression of microRNAs in squamous ceii carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers forHNSCC andESCC. | iuir-48 <- /:|96/6/6363 | adrenal cortical /):78(65699)))))))))): | .................................. nuR-iy? and miR-4>?3-5p ))i8385i(6d4(/i55dt8i6(64i)))))))) /)()68(/9756866(6(63)))))))))))))))) Adrenixortical Caucer | |
)/585565]]] | ///536/)))))))))))))))/ )/9/651565)))))))) | 793/559 | Overe'qxession of roiR-lA2 5p undrciR-155 mgar-trn nnic osa assot -uted b mpboid i!*sue iMALTibmphoma KMsfao ro ('Uvfeji er /:/:661θ(ί:6(88(όΐ565/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | mir-21 | hepatocellular carcinoma | up | Role of microBNA-155 at early stages of hepatocaicinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice | mtr-d’G- Bil/555 | afireixd cortical /:/0/ή(ό5ό688/:/:/:/:/:/:/:/:/:/:/ | ):58///////////// | Hie role of mteroRNA ))88163618956(65963)))))))))))))): •:patirogenea!aof:a8renocodteui·:·: ))656t66(88))))))))))))))))))))))))))) |
mu-lv | ):5655/:67(1/)))))//) 6 mpfcoma | lb* | nuvtvRNA c *pnresiOb profile and idenfiikatwn of roiE *29 as a pregtrostte marker and patfiogeoeuc facrorby targeting CDIib «< mantle ceil /):(8656566)))))))))))))))))))))))))) | mir-21 | hepatocellular carcinoma | up | MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. | mu -EG- :1915665 | 75655666(0(/576/: carcinoma | Up | Ovetu.vprcsalon of miR-W?p/3p cooperate to inbibn mouse fiver Fibrosis h* suppressing tfieTGF-·’ s- ·ηκ·ΐ3'θί1 HSCa in nans genu. /)6666)))))))))))))))))))))))))))))))))) |
/)(563/55)))/ | rtesepharyGgea /)1/88669365)))))): | /)58/)))))) | MfR-155 ΐφ-regutetionby ////65(9()/5699/66(66(66(66/16/))))): increased uasopfeay ngeal vutowtroi. .a vdi prekferatrnn a-4 .η<·.·π:1·υη | mir-21 | hepatocellular carcinoma | up | MicroRNA-21 promotes ceil proliferation in human hepatocellular carcinoma partly by targeting HEPNl. | mir-485- ;|Ϊ565656 | hepafotelhiiar )//6866ι666/4)))))))))): | 593/6/6/6/ | MicroRNAs regulate ////6(84866(66/))))))))))))))))))))))))): adeirosv Itrawsfemse 1A e'.pressmr mfiepaioteBular .::·Γ.·ι·«ι·« |
nasqpharynjrea f earerootua | lb* | Upregulation ofbldVl55 in nasupharviipesJ cnremuinutz partly driven by ί.ΜΡ f and EMR2A and ctownregulates s negative prognostic nupker ):9995(4)))))))))))))))))))))))))))) | mir-21 | hepatocellular carcinoma | up | •Circulating microRNAs, rniR21 , miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. | mir-4*& | g:rotu:t | nidi-Pfe' osiaius NE- 'ft roll* nv ά dt®ruptro? mtihipte Nt - ?B*nep mv' teeobrcv /)(9587////////////////////////////////////////////////////////////////// | ||
///(56(/55/))) | ::Oiab Squamous·:·:·:· /)678/758(66(88/)): | ///58/)))):/) | hficroENA-155 in oral squamona coli carcmpma Ovurcxpnus&ton, Rvahzaucn. and prognostic potential | mir-21 | hepatocellular carcinoma | up | Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation. | roir-4‘R~ ;|Ϊ565656 | hepafotelhiiar )//6866ι666/4)))))))))): | 593/6/6/6/ | rt«R~NO-3p Mofiutetes Cell Grow th and Epithelial to Mesenchymal Transition of Hepatocellular Cntclnoma ))6619665:55(57((63)))))))))))))))): Endoplasmic RedCuluu. -Coigf intermediate Cympanment Pmk'w hKC < /' |
235
WO 2017/132552
PCT/US2017/015417
mti-15> | 37455455545555333 cell statcinoma | 8954888888: | L prggutetion of a potc rrtial prognostic btoraarker. nnR- 8(357770558:773333333359593 proliferation ik patients u itb 33945557495795377(///////////////( (3:50597988888888888888888888888888: | mir-21 | hepatocellular carcinoma | up | Expression of microRN As, iniR-2l. raiR-31, miR-122, miR-145. miR-146a. miR2t)0c, miR-221, miR-222. and miR-223 inpatients with hepatocellular carcinoma or intrahepaiic cholangiocarcinoma and its piogno | mii-tiy? | (333435755455553333 | 434141 | MreroENA-AC is processed from the keratin 19 gene anti up-regulated in metastatic 334399374954949588888888888888888888: |
papHlaro /455557://////////// :(:054/7775://////// | (/:45(////// | Upregnisieti ttyJM5* in Papillary Thy mid Caretiyanta Promotes Tumor Growth by 3377534433171343(//333333333333( Activating W ntG-f Ttienht //7575ί45///////////////////////////: | mir-21 | hepatocellular carcinoma | up | Dehyriroepianrirosteroneinduces miR-21 transcription in HepG2 ceils through estrogen receptor ? and androgen receptor. | roiMSC | /7595453:///////////// (/45535375/:///////// | 98348888888 | (/5553335/59734597(3(//////// (((A(i5437-p39i335(753453(//////: tumors up-regulation of ((((hki(ipR33-:4(22/d33(:353((i9/(((((((((( 8(87053:5533539588888888888888: | |
/(7771(5(5/// | (3575897(5995558/ | 5(45(888888 | A study of moiepaiar signab deregulating mismatch repair genes m prostate cancer compared to benign prostatic :(:(407747(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: | mir-21 | hepatocellular carcinoma | up | miR-21 Inhibition Reduces Liver F ibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Ceils. | mir-ltM | c-ettroai .sneer | 4311888 | MicroRNA-4tN promotes 33333593343537534539455333 throtroh tbe regufattup ul 33808888888888888888888888888888888: |
rectal esncer | (/:45(////// | The quantitative anati sis bv ((((797/777(77·/4(7·$((ρ33((((((((((((((((( revealed the nikmRNA-Sau, :(((47/777i7/i55((tir7/////////////:(: (3:5754977782559888888888888888888: overespressron in human cokuecia: comer | mir-21 | hepatocellular carcinoma | up | miR-21 promotes migration and invasion by the mrR-21PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. | (/749/9?9(/// | colorectal cancer | 98348888888 | mdriM'N is an mdependeni prognostic fxior anti promotes eeii migration and m·. askm tn colorectal cancer by drrectb targeting PTEN | |
renal clear cell (35557534333333333( | a.: | miRNA profiling for clear cell renal cell careroouta· htomarker discover, and identification of potential controls and consequences of miRNA dvsregtiiaiion | mir-21 | hepatocellular carcinoma | up | Expression of senim exosomai microRNA-21 in human hepatocellular carcinoma | 3(745/933843 | giretnn | np | iomzutg radtatron-wditcihJo msR-dW promotes ahoma veil iny astou tl rough F< tell stabitirationhy targeting 97975^3033^5333333333333333333 | |
(/nyf-(i(55///( | squanxros (34547775788888888 | (/74(////// | (((Grtt4(tte(Sita7RNA((((((((((((((((((((((((((((((( 3348744945474(7554475:444(88888888888 (387571978(774758888888888888888888: | mir-21 | hepatocellular carcinoma | up | Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma. | mir-PN | hepatircethilaf 334 995:44 3 44388888888888 | 533888888 | MtR B1 w nhit· an ontogenro MicroRNA megsohister regulate; G1 5 transition hi Ip at rumoiigeweota through ropprezsron ot Mr< |
3(344335333 | esophageal (34544548888888888888 | 8:74888888: | Difi'arentiai expression of uiiRNAs m esophageal cancel :/77ΐ7///////////////////////////////:(: | mir-21 | hepatocellular carcinoma | up | miR-21 expression predicts prognosis in hepatocellular carcinoma. | 88743959888: | (33353555343733333 33499549545588888888888 | 934191 | MjcioRN A-4‘N is a master epurewetic tegulatei ul mtittipfe tn\'asmn-snppressor nncroRNAs by targeting ten ((((pig9rtii(fi/9(r!$!(6i(hiroti(d((i9/(((((((((((((((((( invasive ίηηηηη hepataeellulm /:4(75ih57ti(3(tite7////////////////:(: |
/(tikr/dfd:/// | (31747794774(33( | 4(45(888888 | 3347(7/55748584:975599958888888888 ((((dAi(rte(ii(/d$id/5(3dmtsd(/////////// ddieieiniation M ietikeniro cells anti u up*regtt!ated by ((((ί7(ϊ0(0ϊ0(δ(0ί9/(((((((((((((((((((((((((((((((((((((((((((((( | mir-21 | hepatocellular carcinoma | up | MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through ΑΚ.Ί7ΕΚΚ. pathways. | mir-ltM | 33439935544395888888 (:(:ρ735ό(τΡ7:(:(:(:(:(:(:(:(:(:( | (389188888 | miR-tya promotes cell ^protit’eratrorp-migia'doriand·:·:·:·:·:· invasion·. and increased 3355335433555345483333333333333 hepatocellular carctboma by targeting PTEN. |
236
WO 2017/132552
PCT/US2017/015417
3:5ί3(9(:52///: | /:536365166506/: | /:3.(6/////2 | hiuraRMA-Oa prrattoes tiourohlastonui raigraiion fey targeting reversion-iGdnOiGg cystelne-rkh pipleln v.ffh Kazal motifs < RECK) and ;36565(65(i59626(633333333333://////; metafinproieinase-ft o-.pccss.on | mir-21 | hepatocellular carcinoma | up | indole-3-carbinoi inhibits tumorigenicity of hepatocellular carcinoma cells via suppression of microR.NA-21 and upregulation of phosphatase and tensin homolog. | 966(/466///: | //666/65(63(52i3://///: bmg «.racer | /339333333 | t cpressmw and chwcai eyrdeuec «t mtR-b 1 and 3;P/f759i35:666i369x6ii/06l(/l(dig//// //66(5923333333333333333333333333333333 |
956(66:52///: | pUiVitaJU·. /666259///////////// | lb' | 3:(9225:66(6926;2f :6656376:////// /566:95(0(136/66(6663////:///// //p66cf66i63/s66O///////////////// | mir-21 | hypopharyngea I squamous ceil carcinoma | up | Altered Expression of miR-21 and PTEN in Human Laryngeal and Hypopharyngeal Squamous Cell Carcinomas. | 9636/666///: | //56(625(63(52(3/////: bmg «.racer | np | •umcft-denv ed ratcioRNA1 * f prcnoo. ex «mura ran, rt. 33662·/26ΐ5((:29!ί;1566;5·4629(/////// |
656(5(55/// | malignant :364916656/6//////// | 60/6:/6 | MkroRWA-l5b represents an independent prcgtxtatic paianx-fcranri is correlated with tmtra «.eh proliferation and apoptosis m malignant m.u..!’..m·. | mir-21 | kidney cancer | up | miR-2I. downregulated TCF21 to inhibit KiSSJ. in renal cancer. | 96507/// | breast oartcer | /Ο////// | u«R -LA js upregubted bv EL2/E4? tn breast cancer stem )326((626(3l2(66i6O//////////////// o-Kpg'P' t> rad topoui resistance via downregulation ;39(/fe2666256:695;R2:f/E6;(3333333 |
6569-255:6:: | /:636366i66i53(i6://: | lb' | /:561533:66/(637636(65256/////////: tratra«. «rad-med· «cd dtSeremiatio n of leukemic cells and is up-rnguiated by //(66(662:66(6//////////////////////// | mir-21 | laryngeal carcinoma | up | Regulation of the cell cycle gene. E5TG2, by miR-2l in human laryngeal carcinoma. | mu -4:b | //h656i262ih(b2/////; carcinoma | UP | ):55i(6(O62:3256b63333333333333) //02(52(52////////////////////////// adenosv btartsfeiase J A expression In liepafocellulur /:03(0(60(62/////////////////////////// |
:::569/(5:::6/ | ' λ ph igeft squamous colt /65i:(i(i56i6//////// | 3365////// | F\pre® uoo vf mb roR\ As in squamous cad carcinoma of x ltansaa head: and neck and (lie:: : esophagus. unE-205 and lift dl are ptrenrentukcis Ira HE bit ardrKi | mir-21 | laryngeal squamous cell carcinoma | up | Downregulation of iniR-21 modulates Ras expression to promote apoptosis and suppress invasion of Laryngeal squamous ceil carcinoma. | ):66(/697/// | lOkrcv <! ra<r | /:65//////: | Mi ..)RXA-l‘>'totrtbrfft'tt act s> nergistically to toiublt colorectal cancer metastasis |
:/569-:(5////: | head anti neck squamous celt carcinoma | :/663:////// | Expression of muc-roRNAs at rakniiknsrai! mtiioinaof human bad and r.e 't. and the escpItaguS miR- 205 and ί tlP 21 <.« .pOs-dL Qkftklia hHti ί< and^Ci | mir-21 | laryngeal squamous cell carcinoma | up | Altered Expression of mdR-21 and Ρ1ΈΝ in Human Laryngeal and Hypopharyngeal Squamous Cell Carcinomas. | ;/566657))) | colorectal cancer | /339////// | WiR-49' prcfttrhcs meiasbsu ot oulorcotal earner edis ))t63h65l|r6p()326396326:33333333 |
/:569/(5////: | bryngeal /65i:(i(i56i6//////// | /:363//////: | \*j oPX-l Iwtu Λ v\n and prpi ip <. gb t iotdi v « human bn rigeai carcincrata /625;6(k:W/23://///////////////// | mir-21 | liver cancer | up | rnicroRNA 21 -mediated suppression of Sprouiyl by Pokemon affects liver cancer cell growth and proliferation. | mir-497 | ))g66365://////////////: | 269/////2 | Bv fri>\ .0 mot.· scd nuR »P<7 33662(62(62^59(^3/2233333333)://// 3362623((5i26/5(9956|:663333333333333 inhibiting apoptosts |
//:6(2:1((2:156////////: | 769//////; | //26:2(66:^3(5/66(266(:261(////////: /:265)3(6)326//////////////////////://// | mir-21 | lung cancer | up | Evaluation of dynamic change of serum miR-21 and rniR-24 in pre- and postoperative lung carcinoma patients. | /o////// | //22(69162:((652(66/969:1366(//////: ntetust 11> tu v4?rtv al vat d bv tatgraurpFDXO-l and :d>CB-i. | |||
:/555:(569// | neurobbstoiim | Up | miR-J 5:2 ί P-1 enhances reupvi' amd-n .ediat'd daiei'erttjat'iwtcf leukemk yells and k op-regulated by )/6566516:62(53://////////////////////: | mir-21 | lung cancer | up | Differential MicroRNAs Expression in Serum of Patients with Lung Cancer, Pulmonary Tuberculosis, and Pneumonia. | mir-50· | gastric cancer | up | MmroRNA-5to? sustains nnJ€atiacior-913 actuation: and induces gastnc cancer csll 3;33(2iii2(6(i6636((|(26st6(6262/// 3;2p6p2(2(5///////////////////////////: |
9(6(9/(6/6// | neuroblastoma | /:363//////: | )364(R;/l)59/3;6/2:66h65262/////////; retinoic acid-mediated ddferemdalion yf leukemic «.ells and is up-rceuiated to | mir-21 | lung cancer | up | Exnressi.cn and significance of miRNA-21 and BTG2 in lung cancer. | mlr-5tK: | ))&2ί(6ί262(!61·52/////: ///6(6(66(95:////////// | /Oi//// | MicroRWA-5vb aa a potential 33>l66665i969i69k6i:2693333333333333 //6969(626(1:6(6(/9632(62(66////////: |
237
WO 2017/132552
PCT/US2017/015417
3/553330539335353535353535) | |||||||||||
/)3889/8:7:)))) | ti rophnma | up | ))99(35933:3553:)58)83:54/)))))): λλ Wc\ur'zzedti pm· rta * cancer, associated with a poof prognosis., and invoked in cancer cel ί proliferation and ))998983)))))))))))))))))))))))))))/ | mir-21 | malignant melanoma | up | microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. | )/359r)3Q/i]:)) | hepatocellular 55533589/8998585858 | 0777 | );μ333838Ο)788)38999595))))))); !IEV replication bi targeting 8538/Ο53535353535353535353535353535/5 |
:)38933)))5 | 389583389-:85535 | ))89)))))/) | MkipRNA. expression /):939953889:5553538:958855)))))))/) /)8559535:59558/55335)))))))):))))))))) rtrolttfraetion anti single-dose /://359353(98/99·5ϊ 39399/)))))))))))))): | mir-21 | malignant melanoma | up | MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinase's 3 expression: in vivo effects of MiR-21 inhibitor. | )81 5 5 5 5 5 5 5 5 5 5 | 7:£/aigm099/7/7/7/7:7: | 5558| 5 5 5 5 5 5 | expression and prompter· cell proliferation in human bepatevNtotar eatcinuiita |
):933:5:7:)))): | )9353:))))))))))))): :/:(58)8333)))))))) | ):885)))/)) | /):33359537/:853335885/)))))))))))))))) angiogeoesis and metastaats ////855)ί939855935ι53τ88)))))))))))))) | mir-21 | multiple myeloma | up | integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma ceils in response to berberine. | ):995)055: | breast cancer | :)85))))/)) | 785ti?C<<7/ft3(88(d9ell/:/:/:/:/:/:/:/:/:/:/:/ proliferation pi hunter- breast caikCr cells b> suppressing CON’D i expression |
))i(afc:i $))))) | cholaiigiocarci 885838385/5353535353535 | up | miR i?-u2 Jysiei promotes cholangrovarcirtoma erov th ti'tletSc T0· Pf’ \ <s do w nstrearo target and ILrvStaG as upstream activ aton | mir-21 | nasopharyngea 1 carcinoma | up | Activation of miR-21 by STATS Induces 35rohferaiion and Suppresses Apoptosis m. Nasopharyngeal Carcinoma by Targeting PTEN Gene. | ):955)253/:/:/:/ | ):99853358855589)))): | 55^8555555 | ::/MioioRNAspvefexpre»sod:if£·:·:· ovarian ALDH l-po<rve colls are associated tilth dieniore t taut? |
:)9388387))))) | :/855535555/)))))))): :353598))))))))))):/) | ):858)))/)) | ktwroR'-SA expression vroftfrop Λΐ v\fcti<rod ooiohocytes rsoiated front feces foi c No· ec tai vancei /)^((9:999///////////////////////////////////////////////////// | mir-21 | non-small celt lung cancer | up | High expression of serum miR.-2.1 and tumor miR-200c associated with, poor prognosis in patients with limit cancer. | ):995)0555 | breast cancer | :)95))))/)) | MieroENA** Iti promute, cell atxl fumor growth bv targeting peroxitecloxihl tit breast 5/5/888858/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/ |
:)999^7)))): | Colorectal )):953985858585: | 539/))5/)) | Association of mteroPNA ::expiessioii:-withuiicrosateiiite:·: instability sarins in colorectal adenocarcinoma | mir-21 | non-small cell lung c ancer | up | Clinical evaluation of microRNA expression profiling in non small cell lung cancer | /)))955/))))))): 3588588/5535353 | iutig cancer | 838985858 | roiR~? i tty promotes mroor g-ro,lfc miung ..pncei 0' )^98(198/5^5336/////////////////////////////////////////// |
):999:13))))) | ):555535355):5):5): /)88839833:5:5)):5 | :)33)))))): | 8:39889855838559838575 8 5 8 5 8 585 promotes ceil proliferation, humour grow th and cell cycle progre»sion by targeting the END I tttOKaif uppteSSro gene m coiorevtal cacinoina | mir-21 | non-small cell lung cancer | up | Downregulation of microRN A-21 expression restrains non-small cell lung cancer cell proliferation and migrat ion through upregulation of programmed cell death 4. | :/:(011/:77:7:7:7 5511^288585 | /):8338559835538))))): 5989088935353535 | 5533 // 5 5 5 5 | )/399888385313839358(8189399////////// miR-5 J *>d is up-regulated by 5/55$5O58W9/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/ h> puinethy kroon trod targets cbKNlA/p2i,RTEN AKT3 /7939:939^2)/)))))))))))))))))))))))): |
:)99997)))): | esophageal 853583339885535: /)88533833)))))):/) | 539/))5/)) | mir-21 | non-small cell lung c ancer | up | identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. | mtr-?2ite | hroast cancer | /5/335///////////// | Tlie rn.teroP.NAs n(iP.->75 and rtflR-52bc promote tumour invasion anti metastasis. | |
33889/8593535 | gastric cancer | up | ]:/9ϊιέ38593555:358333338593))))))))): /:/:53059555535:535985385))))))))))) | mir-21 | non-small cell lung cancer | up | Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. | mir- 52dc-'p | gastric cancer | /1777 | /5/^38883908353(3838/59/5/5/5/5/5/5/5/5/5/5 human gastric cancer, |
238
WO 2017/132552
PCT/US2017/015417
23x1« ureer | 707777 | Overexpression oftmR-i? re gasttre ..ancons «yrebicd with proliferatio n -associated 700300^000777777 | mir-21 | non-small cell lung cancer | up | Prognostic significance of serum miRNA-21 expression in human non-smaii cell lung cancer. | 707777777 520-g | 7007067017067737 cureiuorua | OBBB^ | MicroRNA-52Vg induces epitheiiaUmesepohymai rers-iiOi and prompt 7770007600210770227702777: csteioymaby ta-genng 3S^G337377737773777373737·: | |
73033173333 | gastru. vanger | 707777 | inh&kioli of ntteroRNA - .•.jLzf2'j3'Sui*pre^e*'red·······'···'·'· pmhreuatrep moatim. vtn ci bv uxuhtiotreg UBE2C ο·.ρηρ·χ·υη | mir-21 | non-small cell lung cancer | up | L,et-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathoiogical and molecular features. | mir-525- 7BBBBBB | hveicancer | 7027777 | MtR 5?5-;pFnhan?cSthe Migration and invasion of 7Ο2207ό0ί720ίΐ6:0277777777: )λλ nreguGting ZNF so* |
3:032:333:3 | xlwma | !1.5 | identificspori and iancteonal 7r00OOO07777777777 imgroPNAs invoked to the malignant progressnon of 70033377777777777777777772 | mir-21 | non-small cell lung cancer | up | Overexpression of miR-21 promotes proliferation and reduces apoptosis in nonsmall cell lung cancer]. | mt.- | breast cancer | tip | <U\-2n^Gre-recru. puB-5?f*b tn Breast <'anecrht 7RP2A2fi:'0ii0i777777777777777 |
33073333 | 37303033333333: | 707777 | increased expression of micipRNzvP predicts poor ::pfO§r»sis:i«fcW^H:gli«nw:·:·:·:·: | mir-21 | non-small cell lung c ancer | up | MiR-21 suppresses the anticancer activities of cur cumin by targeting PTEN gene in human non-small cell lung cancer A549 cells. | mtt-532- 70777777 | 77010(0727777777 melanoma | 7777777: | Regulation of RUNX3 tumor suppreasoi gene cxpiv sion m 70022026177700r07r077777777:7 |
7BiO777 | 713^::0732777:7 | 707777 | A poly cistronio microRNA 70000002707777777: overexpresaed in human lung, cancers and enhance* eeh 7O^3cO3J777777777777777: | mir- 21 | non-small cell lung cancer | up | Use of Luminex xMAP beadbased suspension array for detecting microRNA in NSCLC tissues and its clinical application. | 77077(077: | pancreatic ductal adenocarcinoma | 4BBBBB | Circulating MicroRNAs in 33S733fe30f:G3ite33:te7B33737373 Grecpra* Tranaggoic Fata With Pancreatic Ductal :/Α7ίήί70£·50·076ίί0:::::333333333333333 |
33033133333 | ίυηρ cancer | 707777: | Apoptosis sndlKUvP. bv antuense ohgenucJeonde* 337706030^33:33703576306^3:333 2203337Og3:3d3O7777777777 ^uuxvressnwtidR U ‘C | mir-21 | non-small cell lung cancer | 13p | Alteration in Mir-2. I/P'ITN expression modulate* gefitinib resistance in nonsmaii cell lung cancer. | ruir-c-k | gastric career | 307:7:7 | Grecptuc mtR-M 1 ts ,<υ imp»·* mt Mote tiu* la. *' m 77(007270:007222733333333333333:33333: |
33033133333 | lung cancer | 707777· | MteroRNA miR-l?-5p is yvprexpressed w pancreatic causer, associated with a poor prognosis, and invoked in cancer ceil proliferation apJ 736Ονρ33777777777777777777:· | mir-21 | non-small cell lung cancer | up | Prognostic value of mature microR.NA-21 and microRNA-205 overexpression in non-small cell lung caneerby quantitative real-time R.TPCR. | U Uf | 7^0057777777777 | 7027777 | MicroRNA -5oP acto at os EGFP s-guaki'g and ns 77000i(7202h^itte2777777777777777 77Ο^Ο60002ί07077777777777777ί 33303673(0337373737373737: |
70777777 | 33303300333333: 3030306033333: | 707777 | Comparative anakaxof melanoma deregulated miRNAs in the medaha uruJ Xlphophoms pigment cell 33te07760d7033333333333333: | mir-21 | non-small cell lung c ancer | up | Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic «.espouse in Patients with Non-small Cell Luna Cancer. | mtr-5p | 7tei3gp3iFi0B777777 | 7((77777- | \ticr»RNA*57i> pro-mute* htiig OafOtiiOhia prohiototion 726770202 OF3733333333333333333 |
7702777 | 703213:077777 3070100033:333 | 707:777 | Tire miRN’A- i cluster mediates cifempres-arame and enhances tumor grow rh in mantle cell iy mphoma xta RUK/AF.T pathway :30000300:33333333333333333333333333 | mir- 21 | non-small cell lung c ancer | up | MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN. RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. | 770777277: | ov a-ran ^ancer | 3BBBBB | Upregulation of MiR~:'?2 transcriptionally suppresses 3;$^6$:4;Ο^?Β^3333333373 «uitnhures to htmian uvanan 77(06622^0262222067777777777777777: |
239
WO 2017/132552
PCT/US2017/015417
455/5ΐ7/455 | medulloblasto 46554666666666666666/ | 455///////////// | fncum 1' D Pubv-s^our /)224^2^2552252252/4/4/4/4/4/4/: /)5is2g2S$52/5/425/))))))))))))))))): medulloblastomas and /)2i524/25:b/y4is555/c/)t2/24* 252))))) hedgeb^g-ireaicd cerebellar ))2255425405/f5257/))))))))))))))4 | mir-21 | oral cancer | up | MicroRMA-21 Promotes Oral Cancer Invasion via the Wnt/z-Catenin Pathway by Targeting DKK2. | rnii-572 | /)2555/:4/25)))))))))))) carcluotua | 433/64/46 | ):)5555547555/:25555/666666666666 /):425^2/24:5654654542/)))))))))): diagnostic tool for ooriy -stage renal tell ναι,.·ηβ<η& |
nasopbaryngeo 42555244/4/4/4/4/:/ | 425/4/4/4/ | 6//0^42224222/5252274/)))))))))) Combined a> Non-lnyg^ye /)3ι45κ524455ζ5'αΖ))))))))))))))))))))): Nasoplfeiy ngsai ( oremon a | ceil carcinoma | up | rnicroRNA expression levels and histopathological features of dysplasia in. orai leukoplakia. | 633466666666/ | ))455542554666666666 | 433/4646/ | thgractermatiou identifies miR-ShS-op as a potential maikei lor detecting lt\ or /:/:β5ί55ίό5Η5):/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | ||
/:/6525-27/)))) | ustevsan.onfe | /:/55/:/:/:/:/:/:/ | t. prepurairoo te mb roRN A17-92 cluster associates with ))7ά42>25555?ί®552ζ4/555))))))))))) prognosis hr vsteysarcouia. | mir-21 | oral squamous ceil carcino ma | Up | Altered levels of nuR-21, miR-l25b-2*. mtR-134, miR155, miR -184. and miR -205 in oral squamous ceil carcinoma and association with clinicopathoiogical characteristics. | iuk-575 | gastug ^ftfjcer | 6/35666666/ | Zt^MtcteiRNA/ptefilte^NiZ)))))))))) human gastrte tancef |
6/54/563674666 :::52:/:/:/:/:/:/:/:/:/:/ | bladder varc.er | a.; | /)/Ο65570555/&ίί52/5ί/))))))))) * rdt \ <ud riidd'· a M\e.« | mii-21 | osteosarcoma | up | Identification of Serum MicroRNA-21 as a Biomarker for Chemosensitivity and Prognosis in Human Osteosarcoma. | :1^/6/4/4/4/4 | gbohbsteina | »p | mrRNA ntrcwarrav rev eals spv.tei' expres ztvP to th' )7ρ455>52/ί^:3?545 54/))))))))))))))): ghcblastoina portents |
////555:27$/////// ///Β':/:/:/:/:/:/:/:/:/:/ | breast career | /:/52/:/:/:/:/:/:/ | miR-J?-5p promotes human proas· vance· veil mig-atrnn /)525:/5552i5552p5^h))))))))))))) ////5552224/55:57^52)/:/:/:/:/:/:/:/:/:/:/:/: | nur-21 | osteosarcoma | up | MicroRNA-21 is involved in osteosarcoma cell invasion and migration. | mir-59t;- /41////////////////// | cervical cancer | 6/53////4/4/ | MicroRNA-fTri Promotes Cer. 'a-N Canter Cell Growli and Invasion by Targeting cm. 1 |
4525224/////// /:/55/4/:/:/:/:/:/:/:/: | 4/25/4///4/// | Ckonialing rinoroRNAs 5i plasma of patterns with ))55f55/2420/4te/))))))))))))))))))))/ | mir-21 | osteosarcoma | up | A three-plasma rniRNA signature serves as novel biomarkers for osteosarcoma. | mir-Nv- 6333444/46/ | ))24p452s552i4i))66/ ))455542554666666666 | 453333 | Mu-oRNA *<xMpregulates proliferation and im asron tri /)44555436252)42454^5)))))))))))): carctuotua eeiU hv targeting !Τ.ί·· ’Pl! | |
:/:52/54/74/////// /://544/:/:/:/:/:/:/:/:/: | gastric cancer | up | 7fe/55252tte/5i5?24/5Gi/)))))))))))): m tea oi/ mtR-’ f to ti plasma of patterns with )/g5iri2/45i55552i)))))))))))))))))^ | mir-21 | ovarian cancer | up | The inhibition of rniR-2 i promotes apoptosis and chemcsenshivity in ovarian cancer. | mir-592 | edlorectal cancer | Dp-regteatron of mir.-d$'2 tcu-relaies w rib tenter Ζ)ρό255445525544:52ρ5ζ))))))))))))) prognosis ia patterns v«feh edlorectal cancer | |
Z)nyr-/17/-/))7 :/:32//////////////////// | gastrr. vat-oef | /:/52/:/:/:/:/:/:/ | ))55R)77)7p/p^55!feS/))))))))))))) vr^tiiciatru b> targe ·η„ SOCShwgasiiK lumet tells | nur-21 | pancreatic cancer | up | MicroRNA-? 1 is overexpiessed in pancreatic cancer and a potential uredictor of survival. | miffed 1 | gastne cancer | 6/53/4/4/4 | MicroRNA profiling of ))424654/^5645/525242/)))))))))))): |
4525554/4 31213334 | 45^52455554/: 44/244/5555/4/4/4/4/ | 4/25/4/4/4/ | ))5552276$pi /555552/)))))))))))4 ;/)555i:4442z/472442/54///////////////////////////// hepatocellular carcmonai celts through the p.:h mitogen-octtvated protein kinase-heat shock postern 27 :/:p25ri55:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | mir-21 | pancreatic cancer | up | MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistauce. | 435/333 | grey, th via WnvA^ai^ata -pathway by inhibiting VMF/I :/:/553/43)3334326/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: |
240
WO 2017/132552
PCT/US2017/015417
8(8688617-8888 456(444:(:(:(:(:(: | 46666686616666888 varomonui | 8466(888888 | (88068608(8868(8(8(8(8(8(8( prognostic marker for itepatoceiiutar carcinomn | mir-21 | pancreatic ductal adenocarcinom a | up | MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer celts. | (:(81844(4(4(4 66868868(8 | 4620666664888888 | (((686(6(1 | MicroRNA profiling Af 88666266664666 6 6 6 6 6 488888888888: |
88668888888888 | 4hishgite£6(4(4(4(4 melanoma | 8(66(888888 | 8866666662666616466(68888888888888 (4pi0tete6(8p(88!6:8>4(4646464646 6(088886(8(8(8(8(8(8(8(8(8(8(86 | ductal adenocarcinom a | up | cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. | 681(6(66 | vro-ftv e prossmu m tiro 8:646i6664666i64666888888888888888: 4:«!Ϊό6ΐ366ί86866$62(4(4(:(:(:(:(:(:(:(:(:( | |||
4tmi4i74444 :::16:6:6:6:6:6 | roahgrtem 846666666688888888: | 4(3p44(4(4 | Altered expression of selected antfprohfemtivo and vtaSpcpKik AcUMA Of | mir-21 | pancreatic ductal adenocarcinom a | up | Modulation of FoxOl expression hy miR-2! to promote growth of pancreatic ductal adenocarcinoma. | mir-nfo | colorectal caixer | 868(6(6((8 | MicroRNA-otoi is a prognostic marker fyr pattei'ls •with oNurcctal cancer. |
86888:8686 :::86:4::::::::::::::: | pji\re;jiu 8666666888888888888: | !1.5 | (8606860868608(8(8(8(8(8(8( Enhances <bemvsensvivitt to '<*4 \Ji Epreguiafing &im.Expressioh in Pancreatic Cancer Cedis. | mir-21 | pancreatic ductal adenocarcinom. a | up | Knockdown of inicroRNA-21 inhibits proliferation and increases ceii death by targeting programmed ceii death 4 (PDCD4) in pancreatic ductal adenocarcinoma. | 668868886 | 8866626660666888888 carcmoma | .ί-R-., 'u < > ?ro\vf?5Vv..u 1 roa wt elf ii <r ^nromoma 421863526:(^^146184(4(4(4(:(:(:(:(:(:(:( 4E66836668(88t88i£66844(4(4(4(4(4 824866642648888888888888888888888888: | |
6602668 88668888888888 | 6£6Β686Β6686868 46668668888888888888 | (88(6(8((8 | 6θ8βί(β68668866(6(6(6 n\ euwe^edu piwcivmn, x uroet rosnvi tted v* rn n ueror pmgttoxW 3rd rt\ AR'd it. ctunter eeii proliferation and :4iit4aSiO6(46464646464646464: | mir-21 | pancreatic ductal adenocarcinom a | up | interplay of miR-21 and FoxOl modulates growth of pancreatic ductal adenocarcinoma | mir-PSv | :4l£32 £15314301144444 686666666668(8(8(8( | (((Bill; | Up-regulation of miR-P3v in cte κ .vii tend veil varomoma 88i4(626622682i46(2666(888888888: 88666468662666688888888888888888888 |
488867464: 80868686 | pailvtaatm 8666666888888888888: | :(:8(:(:(4:4( | 6;MfORMA6f66(84(4646464646 o\ ere ’.pressed in human 466662666666664 666888888888888: involved it; its «ivasivunuss paitialR m suppression of 44hdBti6O(i:(66h2(4(46464646t4 | mir-21 | pancreatic ductal adenocarcinom a | up | Association of microRNA-2.1 expression with its targets. PDCD4 and ΊΊΜΡ3, in pancreatic ductal adenocarcinoma. | tair-iu8 | 4mditgiteh£444444444: meiaooma | :(686:(:(4(:(:(: | miR-ο promotes melanoma metastasis and protects 8838886688(66886:866688888888888888: apoptosis and atitapbagy |
868888868: (866(888888888: | 6886866868686 668888086868 | 4668(88888 | MumRMA im nl\ euient ui a 8466264666(:666:6666664666(88888: $£86830080(84(464(444:44 | mir-21 | pancreatic ductal adenocarcinom a | up | MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. | nui-63$' | 66686866688868(8(:( | (((686(6(1 | Crreuhtnig microRNAs in serum novel biomarkers for patients wnhbiadd*r utovet’ |
mir-lSla | 630ύί£66:6:6:6:6:64 pfoiraetovvlK 8466666668888888888 | :(:68((((((((((((( | ί^ϊΤ/RAR? -tegniafsd ntfR18 la/b closter targets the ::hliriOi:SuppfesS0rRABSFlA·:·:·:· w acUvTtvn'ete <f,v 4(806666(4(4(4(4(4(4(4(4(4(4(4(4(4(: | mir-21 | pancreatic ductal adenocarcinom | up | MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. | mir-3$f! | gScSttte cancter | 8688(868 | MicroRNA-o?b targets INGA Ό promote gastric itai\.ei 888868666688682(888888888888888888888 |
6668-888B6 | 6683868886686 | »p | ::Ttarisfe«rana:gio-wthfaetoi>:?:·:· regulates the sphcre-ufttiateng stem veO-irke feature rn breast cancer through naRN A-J 81 :4636:(826^4(4(4(4(4(4(4(4(4(4(4(4(4(:( | mir-21 | pancreatic ductal adenocarcinom a | up | MicroRNA-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis. | iiOiSSiii | ginm;'· | (688(((((((((6( | ::MieroRNA>i5-5f>:expressro!Q:if£·:·:· giroira is ass^viated « nit 86626662(2(66624688888888888888 |
ί
WO 2017/132552
PCT/US2017/015417
ere xal ow-er | (///(((((Ζ | MkroRMA-lb la eufcaaoefe the ebemoresistauee of human eetv teal squamous cell carewoma to cisplutw by ((ik/5tUlg(//iSC£9-:((((((((((((((((: | mir-21 | papillary' thyroid carcinoma | up | Expression of miRNAs in Papillary Thyroid Carcinomas is Associated with BRAE Mutation and Ciinioopatiioiogicai Features in Chinese Patients. | mx-bdv | ((8/8/15859899893(((((: carclnotua | 333//8383833 | Upregulation of miR-hdO is 338/990//398/99/88388(((((((((((( ((^58ί//;9838/θ(ΐ;8/8;((((((((((: ρ· ’•'gression of hepaOceihilai ((^8518518/5(((((((((((((((((((((((((: | |
mir-lSia | cotonkancer | :(//:(((((( | miR ixiantodia.e ntotoboin (;^999982238/9//:582289/3:938998382/222 (:3985:82i3^O^3///8Wi8/(2323(((: | mir-21 | papiiiaiy lily raid carcinoma | up | MicroRNA-·?1 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed ceil death 4. | mir-d?7 | hepafo.-eth1i.3r 38///2/8222888888((( | 3333//3333333333333 | MiR-o57 promotes ;3;389/828^9^8/39i/2222222222222222222 bepat-tasilulur caremoma to targeting trenNucuwil. enhafxkr protein! through. ((89((^:^/^2((((((((/(((((((( |
(^/959/8^( | colorectal 333//8//83333333333333333333333333 | :(/8:(((((( | Mi •'tuRNA'-iSia promotes tutnorgrowtb and liver metastasis inkolOfeetoi s.<xwoi to targeting the tumor ((/89/8/0:^930:(((((((((((((((( | mir-21 | prostate cancer | lip | MicroRNA-21 inhibits p5Kip2 expression in prostate cancer. | reir-bh? | hmg «.ancer | 83//838328 | MreroRE-tA-'N· 1 targets 8;τ383ί8^;3ί28ι8(9/§ι;//3ί88;9η/8;((((((^ ;88/hos88939h8898t02;2;2;2;((((((( |
mir-lSia | gastru. vat'Oer | :(//:(((((( | teheroRNA-l &1 a pronto tes aasiiK ^pncei to aegatnuh regulating tumor suppressor 333899I/3333333333333333333333333333333333333333333333333333333333333333 | mir-21 | prostate cancer | up | .A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic | mir-dbj | nasopharyngeal 38//882/8222832222222222 | 3333//3333333333333 | MiR o'? anuoroRN1* 'Urgetmg plbWAFPCfRf n ornt.iotes the urNtteiutfot. wd ((8/91/998/8//838392222222222222222222 nasopharyngeal carcinoma |
3(898929/9:/2: | XUstflC -UiXCi | !b‘ | C-eueto pNy morptesm at (3:859/3//ί/:/98·3/ί8·/3/983232323((((( eoninbutesto gastric cancer ((4i/0/a//il8te((((((((((((((((((((((; | mir-21 | renal ceil carcinoma | up | nuR-21 downregulated TCF21 to inhibit KISS! in renal cancer. | 3(99///8/232 | ((858/15859899893(((((: carclnotua | up | (AbcioFNAsteguiato;;;;;;;;;;;;;; ((8989/98/985((((2222222222222222222222 adettosvtoansfcmsc J A expression in liepafocellulur (:catot80i85;((((((((((((((((((((((((((: |
(:(8///9/9:/(: | (:/8/98/:(((((((((((( | :://((((((: | MiRMSlo regulator bJoutl·· tumor barrier penne-abditj by targeting Kr?gpei-lske factor ¢¢£¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢¢:::: | mir-21 | renal cell carcinoma | up | MicroRNA-2 J is overexpressed in renal ceii carcinoma. | nur-ft·4 | cblvii «.ftoeer | ;(298;(((((( | Oncofetal 1 tl toderiv ed miR- ;86?8ie^iNes;/ifn0n((((((((((((((; ((889/85885830/83889/5/:3:3:3:3:3:3:3:3:3 ;(55ί855έί/8;5855έΕ8;8;8;8;2((((((((; |
mir-lhla | hepatocellular (08/8929892/22222222 | :(//:(((((( | Cp-reguiated MrcroRNA 18 la induces oaioiiKigeuesis ((98398///9//3^(///8//9/98/(((((: beparooehulur caiomoma to ((20999^220 232222222222222222222: | mir-21 | renai cell carcinoma | up | MicroRNA-21 tmiR-21) posttranscriptionaiiy downreguiates tumor suppressor PDCD4 and promotes ceii transformation, proliferation, and metastasis in renai ceil carcinoma. | tbir-875 | 8^80103((((((((((((((( | 3333//3333333333333 | Long Non-Coding RNA. IN 8 Promotes Glioma Cell tmasmuto PemiuunuR- 22 8398322222222222222222222222222222222222 |
(:(8///9/9/(: | hepaioccllitfor :(8888//898:(((((((( | (://((((((: | KivvVvbo aromatre hydrocarbon fPAK)-mediated (589/9/98998/ 38393:/8/8/8333(((((((( microRNTvi^i family pmumtcs cancer ceil rn.gr umt to tar^ ·η* Evtol k phosphatase-? regulating die actoa-OH of P58 kfAPR | mir-21 | renal cell carcinoma | up | The ciinicai utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. | nuwf)5- 31/3838383838 | ;(:8/8(s898/;88i;i;(((((: ((hriig;5au5e/(((((((2 | ;(298;(((((( | Kwo-r torn! nun Λ puP-fTte 5p contributes u> tumor progression and development by targeting pio-tumoiigenk GPR3S at non-small coil lung 325/988922222222222222222222222222222222^ |
(:(8///9/9/(: | o>tco>amoifia | (://((((((: | MuroRtlA signatures associate with pathogenesis 3(58/^9/89/0838/3((((((((((((((( ((8/t58/5885;/i/((((;32 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2: | mir-21 | retinoblastoma | up | Seed-targeting anti-tniR-21 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways. | ;(99/^39((((((: | ;882/g;8/8858((((((((( | ;(298;(((((( | KO ptooxu rc furu tuhiorigenests by actuating ((83/0/9/891^93 832 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 Ras'EPdto7· ty ι pathway dial urgvts die F < 2 tans <,<,p tvi ui 2;i/8^5(84;fe98h:2;2;2;2;2;2;2((((((((; |
242
WO 2017/132552
PCT/US2017/015417
()(7799375 | 'tete-teanronst | :)54)()()()()()() | MicroRNA 1,8 kt approves proliferation and mvauon. suppresses apoptosis of :):)0854^948(:49:):):):):):):):):):):):):):):):): | mii-21 | squamous carcinoma | up | Unique MicroRNA Expression Profiles in Cervical Cancer. | 599555555: | pancreatic «.anus | (((77((((((((((((( | Curcumin inhibits yell growth and invasion through up* 8))9)^848788787598-7):87)88888888888: OUKcreauc caneyr ceils. |
8)995987)8 | pancreatic 547995(5(585(58 | ))))4)5)5)5) | UPS Induced nnR-dhla Fre-notes Pam-rea·? C Ceil Mteratioo via Targetthg (()(499(4l9O?^l999)9)8) | roir-2]- 5p | clear cell renal ceil cancer | up | Exploring the miRNA-mRMA regulatory network in clear cell renal cell carc inomas by next-generation sequencing expression profiles. | 8)99-5)5)5)5) | 888461)475)5)5)5)5)5) $)9984995)5)5)5)5)) | 5(45(555 | idenhiipatron ui miR-~ as an 8)7757987)48698)97))))))))))))))))))))))))) )8)77987584)))))))))))))))))))))))))))))))))))))))))))))))))))))) |
$1010$)$)$)$):) (()(878788()()()()( | : :h?paioeelhila:::: )()488499())8()()()()()) | 848()()()()() | idetitiikalroa yf mkroRNA1G by genome-vy fde x u 'date as a vtrovid ph* ct wf h AM-pcn Kpru )8)444394:849):):):):):):):):):):):):):):):):):): | mii-2 i5p | rectal cancer | up | Overexpression of miR-21-5p as a predictive marker for complete tumor regression io neoadjuvant chemoradiotberapy in rectal cancer patients. | 5955(49(5() | )()999989839975 | ((4(((((( | ))(459)447)98)9989395858585: prognoyre significance m patients with colorectal )()(579678()()()()()()()()()()()()()()()()()()()()()()()()()()()()()( |
):)49:):):):):):):): ()((48788()()()()( | )877979)5)5)5)5)5) ()34959)()()()()()()()()()()() $87899787)5)5)5)5) | ):)59):):):):):):) | Expression cl nnRNA? in Papillary Thy reid Carcinomas is Associated wiikBRAF )(94797798888888888888888888888) Gativypi.tkyh.ncai feaaties 3)585)99746)4856495)5)5)5)5)5)5): | mir-210 | adrenal cortical carcinoma | up | The role of rnicroRNA deregulation in the pathogenesis of adrenocortical carcinoma. | )8998359888 | nasopharyngeal $)7394594)5)5)5)85): | 5(45(555 | MiR-TU: functions· as a proroortcogeoe in nasopharyngeal rermnonra progression and metastasis' ra * aitsciry rairal control Ά ARib-jAf' |
)))599:):):):):):):): ((1498((((((((( | )(4448)4448( | )()(4)()()()()()() | miofoRNA-lSi promotes prostate cancer ceO proliferation by regniattnp )()(1)4)958)787977978888888888888888 | mir-210 | bladder cancer | up | Sy nthetic miRNA-mo weis targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer ceils. | nur-802 | ()(99899399(5(55 | ((((45(555 | Mre · RNA Eb2 prouz te ()(775979798)86:8)()()()()()()()()()()()()()()()()() prokterottonby taro.'treg p? “ |
:):5958):):):):):):):) )()(449)()()()() | hepamcebnfar $99994)5)5)5)5) | ):4:):):):):):): | idcnttti 'atron vt microR NA* 88)88)84))4)9998889)))))))))))))))))))))))))) Svfeeoing as a ^ai piav yr kt EpU AM-positive hepatic vanret stent ceib | mii-210 | colorectal cancer | up | ilypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer | mtMK5- (19((((((((((((((((((( | hepatu toknlnr caroiooma | )84)888888 | 883599749979)8888888888888888: di&racietizauen identifies miR-45#5-$p as a potential ()()79793(9578984739888()()()()()() |
((1491)()()()( | ()(4(99)()()()()()()()()()()()() )()67978 7 98788888888) | ()(4)()()()()()() | Jtaptflaty Thyroid Caie-ittnmas is Associated with ERAF )()(4589579995888888888888888:5:5:5: Cbnicopatboiogical Features in Chinese TaUtaits. | cancer | up | miRNA.s in esophageal cancer tissue. | ()((45(5(5() | PRF2R2A expiesstoti and promoted cell proliferation of hntuan vOiurpctdl can ter reds | |||
:):5958):):):):):):):) (54(4(1(5(5 | 'It .. <. V | :)4:):):):):):): | ntroroR NAM 81 promotes prostate cancer ceil pioiifeiration by regulating DAX-1 expression. | mii-210 | glioblastoma | up | Acute hypoxia induces upregulation of microRNA210 expression in glioblastoma spheroids. | )8994)5)))5)) | $9999485)5)5)))5)) 8)594758ι8:84)88888 ()()9987899()()()()()()()()()()( | )84)888888 | Mi?roRNA-$ prorpufes tumor metastasis via repressing F- )()(9d977)t7)8797489()()()()()()()()()()()( squamous ved caromyma |
:):)49):):):):):):):) (()(875789)()()( | gast«v rem'er | ):)59):):):):):):) | MoroRNA prefibog of )))37948975488879875888888888888) | mir-230 | glioma | up | MicroRNA-210 overexpression predicts poorer prognosis in glioma yatients. | )854889))))))))))))) | 8)45)05)5)5)5)5)5)5) | 5(45(5(5() | increased expression of mkroRNA-b predicts yn anfav yraple prognosis m 84949999)5)5)5)5)5)5)5)5)5)5): |
:):)039):):):):):):):) i£la-5p | ga&tete vancei | )()(4)()()()()()() | naP.-iSia-SpEvpiessron and Effects yn Cyll Trolifyratiou ()()87)99859()4389(5()()()()()()()()()()()()()()()( | mir-210 | glioma | up | MiR-210 up-regulation inhibits proliferation and induces apoptosis in glioma cells by targeting S1N3A. | (((4555(5 | expression yf CSX? in human )()(57799()()()()()()()()()()()()()()()()()()()()()()()()()()()()()()( |
243
WO 2017/132552
PCT/US2017/015417
/^afe:::::::::/// :366:6:::::::::5: | 38816:55555555555555: yPttAtiWirt’ 3:100:555555555: | 5:81555555: | RMURAR? -regulated utiRi K la/b chivter targets the iuhx< t Suppressor RASSEl A re Acute Rromc ·βί·\ x tit ::/UH8886//////////////////////////: | mir-210 | hepatocellular carcinoma | up | Eff ects of knockdown of rniR-2.10 in combination with ionizing radiation, on human hepatoma xenograft in nude mice. | 3:85536333333 | :3:05556 33333333333333 | ::::6655555: | Hie CREB-mtR-9 p.egame reedK-A mrexre. oitr ctiordtnatos the migration atd ρ· '-Ίι8ιηί£οπ of gtiyrea ved$ |
/:&«/-://///// | breast sanest | 3:58:555555 | Transforming growdi factor-? regulates the spbere-roit£atir>g Store «toll-tike feature in breast iiXvf itiretob roil NA-H· 330586^655555555555555555555555555 | mir-210 | hepatocellular carcinoma | up | Hypoxia-in.iiucible miercRNA-2J.O augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 rn hepatocellular care inc ma | /:8165:////// | hepatocellular esnetooroa | :3556333333 | Up-teguiatioo of ntiR-'l expression predicate advanced chrucopati-ok gxal featu· es uitd poor prognosis in patients 555555453556555683555555555555555555 car.-ioon-a |
/:818://///// :56665555555 | cervical oatroer | !1.5 | 55iO8O880i6508333:5555: proliferation and redncev apoptosis by repressing ike expression of ationylyi evtiase u (AO<Ki«,eni-4l :/8660E6ii6//////////////////////// | mir-210 | kidney cancer | up | miR-210 is a targe: of hypoxia-inducible factors I and 2 in renal cancer, regulates 1SCU and correlates with good prognosis. | rets -·ι | are nueai qiMpp izv'ti :/:868086://///////: | up | MicroKNA-$' a& a trove! ptugtros’x hromariror to human laryngeal squomous 458565fo58bi6:////////////////////: |
/:818///////: 55i:si8:555555 | bspatoceaular :/0ti6£8O55555555 | ://8:////// | PolyCx cite aromatic :: liydroeatoOilfEAii 1-:- mediated·:·: npreoulauvuoi fcepatx. mioroKNA-lKi family /881818::8568811:///////////// migration by targeting MARK. phospha'ase-5. emulating the activation of p'?8 MARK. | mir-210 | lung cancer | up | MiR.-210 promotes a hypoxic phenotype and increases nadioresisiarice in human lung cancer cell lines | :/8166////// | oon-sreall coll //iikigteSRi^/////////: | :586:55555 | Up- regulation of roik -v :/6ki55:868'5 648:568535555555555555 3338343866i3:385i33:56555555555: patients with non-small cell //bin 68686::::::::::::::::::::::::::::::::::::::::::::::/: |
/:818://///// 360::55555: | ::0}atSqn3ia0US:·:·:· :/816:886550555 | ://8:////// | Relationship between niiA-foPNA expression le' els and fftsinpatiitoogica· features 396:^0£6:8:ρ8855555555555555 :/:1ό61165ί8//////////////////////// | mar-210 | malignant melanoma | up | Comparative analysis cf melanoma deregulated miRNA-s in the medaka and Xiphophorus pigment cell cancer models. | :/8166////// | osteosarcoma | :586:55555 | '•eftw·· rmR-^ as a prognostic bicren-iker in patients w idi 33ό6883635833333333333333333333333 |
/:818://///// :56685555555 | ^o'C^oarvona | 5055:5555 | MicroRNA signatures associate mth pathogenesis :38ti8OiiO868;33333:5555555555: 546888553583333333333333333:555555 | mir-210 | malignant melanoma | up | MicroRNA-15b represents an independent prognostic parameter and rs correlated with tumor ceil proliferation and apoptosis in malignant melanoma. | :58t66:55555: | :3:05553566558:33333 | ::::6655555: | MicroENA-9 pt emotes rumviigenesia and mediates sensitivity to ctsplatin tn prttnaiy epttiielird Ox artan :/6a353354£3‘6:333333333333333333333333: |
/:818://///// 38:0:555555 | ovarian cancer | ://8:////// | Micro RNA--1 til b promotes v\ar£U££vxr ei «zll growti and invasion 8 targeting :/Ra6S8://///////////////////////////: | mir-210 | osteosarcoma | up | Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. | mir-v? | colorectal cancer | 3:86555555 | Association of mtcroRNA :/63ti5563835:6863588s$6sti86:3: rosf ttitit. at η tn toferro al adenoureetiioma. |
/:486/////// :5^8165555555 | :/p88s66O8:55 | 33653:55555 | ::MicreRNA-:lSipaxpresS£On·:·:·:·: re prostate cancer tissues aud t< reflu et svf «.it'broteci ii :3titih586i6i5lh8p8titi633:5555555: •.amerctli h«roEi?-· | mir-210 | ovarian cancer | up | miR-210, a modulator of hypoxia-induced epithelialmesenchymal transition in ovanan cancer cell | /:58652///// | :::^8556355835:55555555 | 3:033333: | MicroRl'lA-92 promotes ::::g8ii63386s3:8833333333333333333 proliferation and tt.\ asroti 3355ίί345έ388^35543:6?44333333333333 |
!UK- 38033:5555: | relatublaaitiuia | up | Hypoxia-uitiueed rerR-Hlb enhances angiogenesis of retirtefclastoma cells by targeting BDCDlti arm 3356805:333333333333333333333333333: | mir-210 | renal cell carcinoma | up | MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal ceil carcinoma. | tuir-ti’ | gastiK, cancer | up | ntiRNA-22f promote* oa*iru croivennvaiictii and metastasis by targeting mmor suppressor EPB41L3. |
244
WO 2017/132552
PCT/US2017/015417
$$££$$$$$ $£$i$$$$ | $$$$$$$$$ v are literate | $$$$$$: | Identification oi ntreioRNAiKl by genome-wide sereeoing as a eritmal pla> er m EpCAM-poshho hepatic $$$0$$h$p$$$$$$$$$$$$$ | mir-210 | renal clear cell carcinoma | up | Overexpression of miR-210, a downstream target of E3IF J ?, causes centrcsome amplification in renal carcinoma cells. | $$£$$$$: | medulloblastoma | $$$$$ | Hie miR-1 N2 poh cistron ts ttp-regutared in >ooic $$$$$/ίί$$£$$$$$$$$$$$$: $$$$$ $!$$$$£$$$$$$$/ induced by N-royp in sonic hedgehog Reared ccrehcliuf rieum! previtrws |
$$$$$$$$ | $$£$$$$$$$$$: $&$$$$$$$$$:$ v are monte | $$$:$$$ | Expression of miRNAs in Rafiil*r fibroid · καινήν» b Άνχη>ο0 wnh BRAE $$$$£ $£$$$$$$$$$$$$$$$ Gmiccpatbclogkal Features in Chinese Patients. | mir-210 | renal clear cell carcinoma | up | miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. | $$£92$$$: | $$d£*b$ib££$$$: | $$$$$$ | :-MTGN-:-rogu!uted-miRNA:-k:2·:·:·: inhibits rectetion oi the tumor supprexror INCXKORF-t •DRk } to rtreti obtYro ma |
$$$:::$:$:$: $£$!$$$$ | prostate cancer | $$$:$$$ | ntteroRNA -J 81 promotes prostate cancer ceil proiiieTOttoii by regulating $i$$$£$£$m£$$$$$$$$$: | mir-210 | renal clear cell carcinoma | up | Serum. miR-210 as a potential biomarker of early clear cell renal cell carcinoma. | $$£92$$$: | pancreatic cancer | $$$$$$: | :O0i£RWi$$$$$$$$$$$$:$: $$e£$$$d££$h$$$$$$$$ pancreatic cancer and inv oh ed tn its rro aa« etiefeo partially via suppression of dir :1< AA: net* |
$$£$:$:$:$: $$O$$$ | $$$$$$$$$ v are monte | lb* | Identification ci mretoRNAiKl by genome-wide SCreeoirtg sS a erittaal pla> Or m BpCAki-poStUve hepatic $££$$£$$:$$$$$$$$$$$$$$$ | mir-210- 3p | glioblastoma | up | Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing. | mu -'Ca | avtuo proroyeiocyde leukemia | UP | tulitbmon cl MreroRNA miR92a Inhibits Ceil Proliferation $$£$$£$$£$$$$$$$$$$$$$: ProOtyeloCy tic Leukemia |
$$$$:$:$:$: $$O$$$ | $$$$$$$$$$$$ $$$$$$$$$$$$ $$$$$$$$$$$ | ·:$$$$$$: | 1 Mr'WctaU m-R\*s -ii Papillary Thyroid Carcinomas $;i£$S$$$$W:S$^£$:$:$ $O$$fa$$$$$$$$$$$$$$$:$ C tauv^patl^tagreai Fvgture* nt< bit.e,el£daent. | mir-211 | coiorectal cancer | up | MicroRNA-211 expression promotes colorectal, cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. | mtr-92a | b-oeB lymphroms | $$$:$$$ | MteroRNA iniR-1 ?-?p is cu expressed in pai.eread? $$£$$$ $$£$$:$ prognosis., mid inv oh ed tn uarocf veil proBbetauvfi and mvusicn |
$$£$:$:$:$: $$O$$$ | $$$$£$£$£$ | :$$:$:$:$: | nucroRNA-1 81 promotes $p$£$£$$b£$i:i£££££$:$:$ prolitmtronbv regniatmg RAX-l expression. | mir-212 | non-smail cell tang cancer | up | MiR-212 displays Tumor Promoting properties in NSCLC Ceils and targets the Hedgehog Pathway Receptor PTCH1. | $$£9?$:$: | bieast caromoina | $$$$$ | $$BO$$O$£i$i$i$i$i$:$: angiogenesis and metastasis $$ίθ$9$:ί$£:$$$$$$$$$$$ |
mtr-lMc | gastric cancer | $$$$$$: | Lpregntattonof MicroRNA iii ic Expression. in Gastric Cancer Tissues andPUsrog- | mir-212 | non-smail cell tang cancer | up | Synaptic acetylcholinesterase targeted by inicroRNA-2 3 2 functions as a tumor suppressor in non-small cell hma cancer. | inir-Ka | eemicai cancer | $$$:$$$ | imR-riga is ttpregulared in cenj.tai .ancer and promotes cell proliferation and invasion bv tareretingFBX^T |
nar-ihic | $$$$$d$$:$: $$££ΐ$$£$$$:$:$ | $$$:$$$ | idererfivStioa of niivfoPNA iSl by genome- wide svftentag a vHf,v4 ptav vf in EpCAM-positAn hepatic $£$£C^eib:0N:ik$$$$$$$$$$$:: | mir-212 | pancreatic cancer | up | miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor | $$£92£$$ | clKdangiOvgrenio $£$$$$$$$$$$$$:$ | $!$$$$ | miR-i ? -92 cluster promotes c hotanitiOvgFv moma grow1 h $£gi$£$£$::$$O$$$$:$:$:$:$ downstream target and EL* ti/Stafj os upstream activator. |
$$$ί£ί£$ | $$$£$£$£$$$ | Up | MicroRNA signatures associate wiiii pathogenesis $:$£$$$$$£$$$$$$$$$$$ $¢$¢$$£$$$$$$$$$$$$$$$: | mir-212 | pancreatic ductal adenocarcinom a | up | iniR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor palched-1. | $$£92£$$ | voRre.*tai vanvet | up | MicroRNA signature* novel biomarker far colorectal £$$^$££££££££££££££:$: |
245
WO 2017/132552
PCT/US2017/015417
/(/ίη/Β/ΖΖ | ZO39OZ/Z/Z/(: :(:i/BZBZ48:8:8:8(:( oarcmoma | :(///:(:(:(:(:(:(: | Exor' »·ηο vi puRN Δ s nt Papilkuv Thyroid Carcinomas Is Associated with BRAF ((((M5i2ii69(6i'!((((((((((((((((((((((((((((((((((((((((((((( Chriicopaihological Features (46h:(d/i566/Oi/6i6:4:(:(:(:(:(:(:(:(:(:(:(:(:(:( | mir-214 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor s up pre sso r EFB 41L3. | mir-i2a | colorectal cancer | /9533333/ | Defection of naR-* 2a and miR-dl in stoolsampies as potential screening bmruari ers for v^lorectal ((((639266/393(/6^32:(((((((((((((((((((((((((((((((((( |
roir-lMe | prostate oancot | (:(9/(:(:(:(:(:(:( | r.ikmRMzvlhi promotes (((/309/3/(6/96/6/://(:(:(:(:(:(:(:(:(:(:(:(:(:((((( >IvJpv href bv rc^tuarine £·AVI vVvf'.xioti | mir-214 | gastric cancer | up | Down -regulated miRNA-214 induces a cell cycle Gl arrest in gastric cancer ceiis by upregulating the PTEN protein. | roir-v?a | colorectal cancer | (:((33/((((((((((((( | l)v el? · preSSiOrt PI u uk v 2a correlates with tumor metastasis arid poor progtrosrs m patients with cok.revta! caixcr |
mir- /(BB3333333 | :((h/9/t/6/}i9i6i(((((((( ..are moron | U.I | idefittficafinn oi mretdRNAiKI by genome-wide screooing as a critacal play or to EpCAM-poslttve hepatic :(:(696/66(269666/2:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(: | mir-214 | gastric cancer | up | Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: no vel biomarkers and a mechanism for gastric cancer. | mu -'Ga | colorectal cancer | Up | MrcroRNAAfa Functions as ati (oncogene in Coiorectal Cancer hy Targeting PTEN. |
8o268(8(8(8: /(BB3333333 | hepatocellular :(:έ/ί0ϊ/(65ί2(:(:(:(:(:(:(:(:( | (:((//(:(:(:(:(:(:( | Rcdycycik aromatic bydmcSibon fFAK)-roediate3 :(((/p3/g/39t(i63i(/B299t(i6((((((((((((((((((((( mrctoRNA-l 81 iantilv promotes cirocereoh rengrafiOP hy targeting MAPK phosphatase-? regulating Ute aetoa-Ou of LiAPR | mir-214 | gastric cancer | up | Hemolysis-free plasma roiR214 as novel biomarker of gastric cancer and is correlated with distant metastasis. | (:(393669298(8 | colorectal oaneer | :(:9/:(:(:(:(:(:(: | (MioroRNA expression :(:(96632(16/:635661(5312366(:(:(:(:(:(:(:(:(:(:(:(:( eolynoeytes isolated from feces for culnreetal cancer (:((3/3//935/3333333333333333333333333333 |
82808(:(8(8(8( /(BB3333333 | 8ρ/ρί8θ:8(8(8(8(8 :(6//3/1/(:(:(:(:(:(:(:(:(:(:(:(:( (:(6266125965((((((((((((((((( | (:(99:(:(:(:(:(:(: | 1 \3r'«z'ou«.i m-F\*s ·η Papillary Thyroid Carcinomas (((i/(3B/66i9t6/((63i3/((B?6O(333:(:(:(:( ((((B9i2it69(63/i(((((((((((((((((((((((((((((((((((((((((((((: C Imiv^padrolvgtval Fkamn^ m< bronzePoiieotz | mir-214 | glroma | up | Associations between the Expression of micro-RNA 214 and clinicopathologic parameters of glioma. | markka | esophageal (((999939699:66/58(8(:( //26526522(/(/(/8/8 | (935:8(8(8: | nin.mRMA-'k.a promotes lymph node metastasis Of •::hu£nan:ospphageof:squamoup:·:·:·: ceii carcinoma via E-cadherm, |
mir- /(BB3333333 | (((9f/266f/(/2it662(((: | /2//8:8/ | mrctoRNA-l 81 promotes (((/305/30(//9//6(//:(1((((((((((((((((((((((((((((((( ptuliieranuiibv relinking DAX-l expression. | mir-214 | hepatocellular carcinoma | up | MicroRMA-2 34 regulates the acquired resistance to gef itinib via the PT'EN/AKT pathway in EGFR-mutant cell lines. | (:(33/5352/:(:(:(: | (:(:/5//99/6/1((((((((((((((:(:(: «ll'vl’ro Izv'd :(:(/96/39/3/9:(:(:(:(:(:(:(:(:(:(: | /9//:/:(:/ | |
8(656//62:8(:( | Nidd'. t aire'. | :(:99:(:(:(:(:(:(: | Aitri.pp. t..iPN A-toowers targeting roiR-ISS-Od-l&i duster or nuR-2ii! inhibit grow rb ypj mtgudmn and induce apoptosis tf. bladder 6565665021668(8(8(8(8(8(8(8(8(8(8(:( | mir-214 | malignant melanoma | up | Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphopliorus pigment ceil cancer models. | intr.923 | (:(:h9/6t0ge3i33i96(:(:(:(:(:( earethoros | (:(335:8(8(8( | Dereguiattvii oi'miR-'k-a twpm'Sj'n κ nt pit are J nt hepatocellular carcinoma ::::6/6i^Zi///i9/3333333333333333333333: |
mir-fS2 | /96922(6/068(8/ | »p | Vp-icguUiipi' of nuR-186 hy ?-eatentri wt breast cancer m.Rprestu ^nowiutv m3 tovasivertesshy targeting the /652662( /:6/393369663/33936(:(:(:(:(:(:(:(:( (:(:t9h/3666(l3feiZK::(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( | mir-214 | nasopharyngea 1 carcinoma | up | miR-214 promotes tumorigenesis by targeting iactotransferrin in nasophary ngeal carcinoma. | mir -^2a | :((1233/(6/26/3:(:(:(:(:(:(:(:(:(: | /0/(/:/ | A polycistronic microRNA ((((6B/t/6/2/ii/67//2/i/((((((((((((((((((((((((( ov ere ^pressed in imumn bine cancers aod eoliarxtes ceii (((96pi^(69t62/(((((((((((((((((((((((((((((((((((((((((((((( |
roir-GG | breast coroner | ::(99::::::(:::::: | :(:/999663όϊ63ί569ίΒΜ:3268:8:8:::8: (:::65ί/Β^^3ΒΒ/Ζ^//79/33333333 (:((0//6(5665(://52651/2516^/(:(:(:(:(:(: (((//6/66:/3/22/332:(:(:(:(:(:(:(:(:(:(:(:(:(((((((:( | mar-214 | nasopharyngea 1 carcinoma | up | Knockdown of miR-214 Promotes Apoptosis and inhibits Cell Proliferation in Nasopharyngeal Carcinoma. | roir-v?a | (:(:l26g:69266i8(8(8(:(8: | Z/93333333 | Apoptosis mcbiciior. by ardiserioe oligonucleotides against ndR-i?-5p and ndR- (:((265(Β((6/ί/(/5Β:6//(:(:(:(:(:(:(:(:(:(:(:(:(:(:(:( uv ere^pressing mtR-i”-$2 |
246
WO 2017/132552
PCT/US2017/015417
5/448884:886888 | breast cancel | /58 48/55555 | E iglicr expression of οΐκπΙθίΐηρΓΟπΜδζ as a novel btemarhar for breast /5848448/555555555555555555555555555555 | mir-214 | osteosarcoma | up | Upregulated expression of inicroRMA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. | mii-923 | /6/0/545555888888888 | //44/4/// | MicroRNA iiftR-l ’-dp is Οι '.?\3··'’χΛ wpatvreaj cancer associated w uh a poor p· .-«gnosix and rtft yE ed «· «cancoroeihpi^iiferAdonand·:·:·:·:·: /:/ilte/^i0iii/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ |
mii'-lSz | :/:C$l0ragt3l:/:/:/:/:/:/:/:/:/ adenycarckiom 454844444444444/: | /884/888888 | Enhanced mik -1X2 ti&xx option is a predre roi of poor yvcraO survival in xofe^tj· ifen* muroma n->:km·. | mir-214 | ovarian cancer | up | Micro-RNAs and. ovarian cancer: the state of art and perspectives of clinical research. | rok-v?a | ////bslighabi/;/;/;/;/;/;/;/;/;/;/; 86644408846888/888888/ | ///555/4/4/4/ | Altered C’.pressronot selected roixiyRNAs in Melanoma 6655ί5585555655555/5885686868686888:55 ·ν ktmt «3 miR 1A-1--S |
8/448888:58888 | C.lhUCAUl 45055844:44444 | a.i | nuR-H2 promotes coll pmn th and invasion b> targeting iorhheadboxF’ transcription factor in 55486468484648444468/555///////////////////////// | mir-214 | pancreatic cancer | up | Dvsregulation of mi/R.-15a and miR-214 in human pancreatic cancer. | mu -'Ba | nuuule -cu h mpiroma | 55:0/444064444442544048/55555 mediates eKniute rotarne and enhances tumor growth m mantle ceil Kmphoma ua ΡΪ3Η/ΑΚΤ pathway ///^tmk6re/fi8555555555555555555555555555 | |
mii'-lSz | :/:c$l0ragt3l666666666 4430544444444 | /645/666666 | Up-reguiaiioo of miR~lR2. expression inooiyrootel cantor tissues and its | mir-215 | cervical cancer | up | MicroRNA-21? is a potential prognostic marker for cervical cancer. | rok-v?a | osteosarcoma | ////55/4/4/4/ | Upre£tdatron ol mitroRNzv17-02 cluster associates with 55455$44:854564544588545ί888888888888 |
mif-ihl | /64580558/6666666/ 58484488/55555555555 | 4454444/ | 405458060:445054444448 special Αϊ-treh sequencebinding protein 2 to promute .roiorocia! cancer predrierotron /:/3h4/ibaO^R5:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | mir-215 | gastric cancer | up | MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression invitro. | mir-92h | 55460446440888888/ | 45144/4/ | The mF-92b unquote, us a 80440040408/8888888888 xiroeim* troSrowr m 5541444464444444465/88888888888888888888 |
////4555/8/2/////// | onloroctal ///505/666666666666: | /645:666666 | Ctrontettog n»R-1S2 is a btomarker M .roiorocia! adenocarcinoma progression | mir-215 | gastric cancer | up | MiR-215 modulates gastric cancer cell proliferation by targeting RBI. | mrcA’h | git. .11?.. | 6/55/4/4/4/ | ////?5f4R442b/8h48h8t54:544554led/:/:/:/:/ gimmacef! apcptesisvia targeting BKK3 and blocking /5848454566455846846458868888888888888/ signaling patlro a' |
mir-tR? | ///c$l0tec/t3i/;/;/;/;/;/;/;/;/; 4450544444444 | /645/666666 | RATS; and2 brcolotectal 84868488888888888888888888888888888888; | mir-215 | gastric cancer | up | MiR-215/192 participates in gastric cancer progression. | hOn-ShraRcell :/:/1/1/5^/030/:/41:/:/:/:/:/:/:/:/:/: | ////55/4/4/4/ | MiR-92b tegulareS the tab ;5:gi458654584064:855555555555555556/ cheit-rrorosni' it\ or A-49 unu small coll lung cancer cell Im.c /5O4/W4t5R8B3i46555555555555555555 | |
8/44888858888 | 58488848688888888888 /64555058844888 | :/:/55////:/:/:/:/: | increased ospirresmt. of utiRNA-1^2 in colorectal carcinoma. an independent m3 tissue spectf.c ptegnosro 0OtPf8:$:$:$:$:$:$:$:$:$:$:$:$:$:::::::::: | mir-215 | hepatocellular carcinoma | up | Serum microRNA characterization identifies miR.-88.5-5p as a potential marker for detecting liver oathoiogies. | 456445?ί444 | /6/545545555/545588888 88444444868448/8888888/ | 455444/4 | 55i46i844444444484O4248/55555555555 suppresses nonsmall cell lung Ov'tvvbsp.owtf m>l ntotlldv bv targeting EEC K |
/050/4/: | enriunw trial 455455/54448844888 | 6:55:66666: | MuroRBA-lb2 [•rontuten /4ΪιηΟ:θ5:/<θ575/'β456555555555 Targeting Traasyrtpdon EioKgaovU Fuv'Oi A Id e Λ ικ Endometrial f'armrema | mir-216a | hepatocellular caremoma | UP | A ndrogen pathway stimulates micrcRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarernogenesis. | 8/4094/5555/ | • . . · ^r | /6555:666666 | Aroremtron of rouroRBA exprorsjpn vjfh route Stellite ;5:ii4i8^688t45564848/88/548884 86448:8/ 554548555848488448468:55555555555555555 |
Kiir-182 | 45005544545 /64555058844888 | »p | /6:/fGE64;5O5545556554O8855 expression tn promote' ριΊΕΚΜνΓνηι .ztt' roost’ by targeting CAfrMl | mir-216a | hepatocellular carcinoma | up | MiR-216a/217·· induced epithelial-mesenchymal transition targets ΡΊΈΝ and SMAD7 to promote drug resistance and recurrence of liver cancer. | 6:ή4ϋ§3:8;655 | ////gkddhtetria·/;/;/;/;/;/;/;/;/; 4//4^455556/:/:/:/:/:/:/:/:/:/:/:/:/:/:/ | 4/554/4/45 | TS k Suppresses nuR ittob 9t-22 Uhrster Expression 5/44ι/ό4846ϊ484488484484886/848/5555 /64W/444i44O848/888888888888888/ Fteltferaf Ion. abd Induces Apoptosis in Hyman EMC |
247
WO 2017/132552
PCT/US2017/015417
894908:3 | ;59i894555555555555; | 598555555: | Thu ιιύΚ-18'.'2$,χ2Βί2 Cluster Regulate *9xidatfve Apoptosis and Sensitizes 55C0893^89OiOO3893333333 539199955555555555555555555555555555 | mir-217 | breast cancer | up | MiR-217 Promotes Tumor Proliferation in Breast Cancer via Targeting DACHl. | milk? | ;5:O895;5555555555555; | 8898888 | :C·' ere -pressed nucroRN A9$ inhibits the proliferation and promotes apoprosis of 33999:^99494948333333333333333 |
inir-l&2. | $99945/55555555555 | 8:898888 | in.iP.-iS2 asaprognctetre :300888:83093333333333333333: 53898989985488:0993333333333: 5590:88955555555555555555555555555555: | mir-217 | hepatocellular carcinoma | up | MiR-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver canc er | 8g88O88888888;8; | 88888883 | biiR-^S promotes sell proliferation ra gliomas 8599489995 88898^888888885 Rl <te'Ahl signaling pathway | |
889989885 | 84888998914985 -aremotna | mJ | CnconuR miRkri andituR '2prorout' edorohteruror 538890089889:05555555555555 //54^0058000:9555555555555: heuntoeeiiukii carcinoma | mir-218 | esophageal squamous cell carcinoma | up | miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. | mu -ή | ;5:h995889;49fe;55555; «tUvU'W iz-'H 559994943333333333: | up | increased expression of nuRΆ iz assocrarod withprar prognoses ra bead and necl squamous seif eareinoroa |
inir-l&2. | hepatocellular ;/ό4ή:ϊ9888;33333333 | 8888888 | \Ynyte£sf Shin acth ates MtRχΒΛό,ίκ’ expmssiooin ::hepatitoekulaf:caK-lfief!2ati'4t:·:·: proraotea cell invasion | mir-22 | non-small cell lung cancer | up | Circulating miP,.-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lane cancer. | head and neck //989Ρ99;$η955555; 559989893333333333: | 88888885 | Compraheosive MtcroRNA profumg for head and nePk squamous cell carcinomas. | |
889908:3 | 8998989999955: -aremotna | mJ | $erau,miR-H2 antlroiRft 1- ip as diagnostic and prognov- nwrker* m procntz 801^0988:18888888888888 5384909433333333333333333333333333: | mir-221 | anaplastic thyroid carcinoma | up | A 4-MicroRNA. signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears. | mu -ή | arc (rue;:! «.pxn’to Iz-'U ;3:99989a5555555555; | Up | MfcroRNAk' regulates evclinG? expression and omw or-Ad't>H role in laryngeal squamous cell :/ca9909a/////////////////////////;$ |
$9980555 | hepatocellular ;/04rei988855555555; | 5033333: | y909R9003333333333333333333: doumegulatas toerastasis 539i90O58;9988:8:9098933:5 io rnciastaste of hepatocellular /3849999833333333333333333333333333: | mir-221 | bladder cancer | up | Micro-RNA profiling in kidney and bladder cancers | intr-9? | narophtuvngeai cammoma | 5893333333 | MieroRN Ak? promotes cell ;/^99954985ϊ8984948933333333333 ::nasopb3ryr<geaicarokioiua:hy::: laureling rHahted fAi-rotegk |
ujif-ibi | 888849888848883 carcinoma | 8888888 | MtR ί'όΐ is up regulated and targeting Cebpa tu bepatoceiluiar carcinoma. | mir-221 | bladder cancer | up | MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAD... | mir-vj | 55989499949555555 ;5d89988889533333333 | 891888; | Expression of mtR 2V-. naP‘Ah and iniR-42f> a* Petcriteai Biomarkers for Detection of Karfy Stage NonxSmalf hung Cm .ter. |
itur-fbe | $94984899333333 | up | //08999088990934/:5555555 rxororo'onin era..<4 Patients with Lung Caocer. Rylmonar Tubeicuto*is. Oi'd /599988985555555555555555555555555; | mir-221 | breast cancer | up | TRPSl targeting by miR221/222 promotes the epithelial-to-naesenchymai transition in breasi cancer. | iuir-y42 | esophageal 559889884:48:855533 cammoma | /:$y//////: | nuR-‘-M2 promotes cancer 339499998888984843333333333333 esophageal squamous call carcinoma ilirough acth ai9n of Wnv? -catenin signalling 394993933333333333333333333333333333: |
uur-ibl | 89488488888888: | 8888888 | 55Ο98989Οί8:8ί533333333333333: iiikiyRNA-itC u&ibi& cell . h uw asfou hi targetrap programmed veij doath. t m human rung adeiiucaicii'-uoa cells | mir-221 | breast cancer | up | From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment (Review). | nur-U44 | con mat cancer | 89|888 | Nro ei fynt uyns an J -atgets of naR-O-te h, fcanua -en real ;58484848995333333333333333333333333: |
$9981342333: | $94:9899555555555 3:9φ98Ο855555555: | 3:033333: | Aberrant nuR-182e*pressipn promotes melanojna metastasis by represSUig FOX03 and inicTophthahiiia/394499(9498918999333333333: | mir-221 | breast cancer | up | miR-221/222 promotes Sphase entry and cellular migration in control of basallike breast cancer. | /:9998///// | • . . -r | 5493333333 | MioroRN Ak5 promotes cell proliferation and targets sorting Nmm 1 in human 8;9^99^;849ι9)94$88888888: |
248
WO 2017/132552
PCT/US2017/015417
:03060642024444444444444444444444444444 | |||||||||||
246561822444 | reabguaut 42681666344444444: | 24602444444 | Comparative analysis of 242601-5006-5:60666060 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 miRNAs in the medgka and Xipbtiphonis pigment. ceO 2 2 2 2 p8tk00:2ft0j:d0!8:444444444444444444444 | mir-221 | colon carcinoma | Up | IMicroRNA-221 promotes colon carcinoma cell proliferation in vitro by inhibiting CDKNI C/p57 expression'!. | mirAS | 4466646644444444444 2426006:5664444444444: | 5060:000 | MieroRNA-95 prontotes ceB proliferation and target sorting Nexm i m human 240di0i55530020t0rh0604:04:04:04:044 |
mir-lR2 | mesenchymal 2466004244444444444: | 42002444444 | MioroRNA--l82 drives 44i00606560606606'4424444444444: satv^macbv tatoctreg 440030660600000000000000000 | mir-221 | colorectal cancer | up | MicroRNA-221 inhibits CDKN lC/p57 expression in human colorectal carcinoma. | mil -s$ | nyu-small cell 44060250600 424 4 4 4 4 4 4: | 05600550 | MiR-95 induces proliferation aod-heroo urradrorusratwe dftougl, tluevdv tatcetreg sortingne-.ml tSWlpr ·.- t sol -h ..'!! :n·. · uxc- |
05660555 | ™ ananxwer | Micro-RNAs and ovarian v re. w the slam »1 <-rt red perspectives of clhncni :2:2reXa6h42:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2:2: | mir-221 | colorectal cancer | up | iMicroRNA-221 controls CDKNIC/P57 expression in human colorectal carcinoma] | mu | bladder cancer | Op | Mi ..AN·5 >. x .·. x .< signatures ar titndrkr canror rev ealod hy deep sequencing | |
:::606:086:2:2:2 | ovarian career | 24602444444 | Anri-MsR*) 82 reduec> Svanan cancer burden, invasion and metastasis: An 44024 021002 026002024 6006666424444: xenografts of nude mice, | mir-221 | colorectal cancer | up | 2M2icroRNA-22J promotes colorectal, cancer ceil invasion and metastasis bv targeting RECK. | roir*vf> | bladder caueer | 0060:0:04 | hynthetic mtRNA-uxtivers targeting ntiR-183-90- ia2 Ju tei cr nnR 21b mluhti growth and migration and red jvc rpoptosjs mhiaddet can xrctite |
mir-i hl | 245002066066620 | <P | The upregulation of signal «•visdi. vruid κ mrorot nwa' mn '--depot 'ei t 24:266666650646655555555555555 micreRNzvOf: promotes 445000002550000066244444444444444: proliferation bv tatoctreg furhheadbov»3 .jpuP tepur Minre: | mir-221 | esophageal cancer | up | Alteration of miRNA Expression Correlates with l ifestyle, Social and Environmental Determinants in Esophageal Carcinoma | 42166000244: | breast cancel’ | 5650000 | ::UfU«g»lgted:f!2iR:-yb:iaduees·:·:·:·: cell prolticratmn mlmman 2500565066650202020252020252020 2240h665200i66g44444444444444444444: transcriptional factor 56|OB0000000000000000005 |
05665055 | anan ^arorauma | im | hhcmRNA-182 promotes ceil 440056l6.430066020064244444444444: ?beifivres!Siu<oee bv tarptirep programmed cell death 3 44^6660i41006i02602000005i524 4 4: 2 2 2 2 έ86ι002ι2ά004444444444444444444444444 | mir-221 | follicular thyroid carcinoma | up | Differential miRNA expression defines migration and reduced apoptosis m follicular thyroid carcinomas. | mu | breast cancer | Op | nflR-bs promotes tnrant proliferation and wivasmu hy aneting RECK re br' isf 550666050000000000000000020 |
tiUJ'-lR? | 246603644444444444 24026660 424 4 4 4 4 4 4 4 4: carcinoma | 24462444444 | miR-182 targets CHLJ and controls tumor grow th and invasion ni papiliarv tB> roid : 2 2 2 8060620644444444444444444444444444: | mir-221 | gastric cancer | up | mtRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. | 2:26ir26S2:2:2:2:2: | 242862506224444444444444 440006050600444444: 246556650555555555555 | 06000020 | Doun-roguladOn ofniiR 10a m eiirorae up eloid leukemia (VN·' vJls mxunwAbbh2 mediated cell prentit |
mir-ifl | 240260666660622 | 0:00000:0 | miR-18 3 -182 < luster is oYcrexprcssed in prostate ί^?υΛ andmgtilates nm homeostasis in prostate ceils. | mir-221 | gastric cancer | up | increased Expression of MicroRNA-221 in gastric cancer and its clinical significance. | 42166000244: | i-oloievtai v«x<cei | 5650000 | Expression of iuiR-2fe miRN v ntiR-,)rt and nuR-13 ^b is currehatedwith the tireua! parameters of Culoreetal 5565686555555555555555555555555555504 |
249
WO 2017/132552
PCT/US2017/015417
)/)/i277$7/S2/)/)/( | prostate cancer | /5572)555555 | Overexpres&cd mureRNAIK2 promotes prohtfersiioo /(636/7776251237/12/33367672/////////////////// career PC-3 cells by down- /47O376ti$0O3d$$55555555555555555/ dew «stream regulated gene f )/)/fO7$0$7)))))))))))))))))))))))))))))))))))))))))))))))))))))) | mir-221 | gastric cancer | up | Deregulated microRNAs in gastnc cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. | 5/7377533()/)/)/)/ | colorectal cancer | 4453 444444 | MteroRN A-9o pren-otes the pruirierabonnr v^ter.rerel caire Or Cells and targe-S fur- Or protein p53 inducible nuclear protein 1, fyrkhead box o^cmDl tK,x Ob and )/20666)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/) |
mir-iST- $635555555555 | bladder cancer | 550555555/ | Chreygemy n3RNA-lS2-5p targets Smadd and RECK in human bladder career. | mir- 221 | glioma | up | MicroRNA-221 targeting rI3-K/Akt signaling axis induces cell proliferation and BCNU resistance in human glioblastoma | $7203$$$) | 3/2$Qpl!3g06i/:/:/:/:/:/:/:/:/:/: /()6677227/((((((((((((((( | 41144444; | (MM$33(3/re)i3372$$/$/$/$/$/$/$/$/$ prelilerattor and chemo- nr radioresistansre by doren- ////r2/^3i3fi2g)R/l/iCK(f6((((((((((((((( esophageal cancer |
/(7737$ίΐ72$;$ :::0):):):):):):):):):): | prostate gancnr | /)/)0/)/)/)/)/)/)/ | Α’ύ·'ΓυΒΝΑ'Ί8?Ό Prett<rttcs 44£ό$ί200020555555^ :/:/iOlif2/f03n:3:6:r>)6teii:/:/:/:/:/:/:/:/:/:/:/: Regulating F0XF2, RECK and MTSS1 Gene:; m Human /)/7027676)/20223)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/) | mir-221 | glioma | Up | Mil’.-221/2.22 promote human glioma cell invasion and angiogenesis bv targeting ΤΪΜΡ2. | mirebh | :/:/0423/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | )4^)444444 | The mtlb/IS/TTviK? Chaster ///S2/^6ia)te6/(/$3irikfi26)/)/)/)/)/)/)/)/)/)/)/)/)/)/) Apoptosis and Sensitizes Cells OLnemotbyrapv in $/$6733733;$/$/$/$/$/$/$/$/$/$/$/$/$/$/)/ |
5/0/$/$/$/ | signature:· ofbladcier cancer revealed by deep sequencing | up | 221/222 cluster suppresses human glioma ceil growth by targeting p27hip 1 in vitro and in vivo. | )5551)44444 | regulator errvuito promotes /(636266)/27672777.555555555555555555555/ | ||||||
/(773731)82(((: | bladder cancer | /)/)0/)/)/)/)/)/)/ | Svntfccfie miRNA -mewem targeting miR-l8T-9A-l8i cluster or in.iR.-?10 inhibit grew h and imgraUvi und tndnee apoptosis in bladder )/)/262262/23773/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/) | mir-221 | glioma | up | MiR-221 and ituR-222 target ΡΗΜΑ to induce ceil survival in glioblastoma. | /:/7376462)/)/)/)/)/ | heputtevNiuiar ;$66$2i222t$;$;$4444;$; | )4^)444444 | /(:D22673il$/:3377.2k4/6h3273!:R$/:/:/:/:/: 18 2 promote· ceil profrfersiion and invasion through, targeting /$6i67i/i/r25233/r3/b$736i2$^72i6r/$/$/$/) )/)/2376723736555555555555555555555555555 |
$$3205555555555555 | 5/0/$/$/$/ | expressron w rdi miyrosatelitte instability stated mcok.nretal /)/)626262622726726)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/ | up | lines and biological effects of a peptide-nucleic acids targeting miR-221. | /$$673732733/$/$/$/$/$/ | )555155555/ | 183/96/182 expression in hepatocellular corcmoma that □remotes «. '8 rm a /mn | ||||
mir-7 $3 | $$3767260555555555 $263622/555555555555; | )550)555555 | /$ί622$23Ο20726)/2ί$/$/$/$/$/$/$/$/ miymRNA-183 mliuman cniprectft! cancer and ns ciinicai signiftcairep. | mii-221 | hepatocellular carcinoma | up | MiR-221 controls CDKNlC/p57 and CDKNJB/p27 expression in human hepatocellular carcinoma. | 5/7372533((((( | /$h2t73i3$27l7367)/55555 ((23767237365555555555/ | 044441 | $/i2h7b7636/27:)33R$36$/$/$/$/$/$/$/ expression reduce:; iteli )/)/276736737762/36775555555555555555555 dprtpgettterty of fctepCt? /:/&263i2773t:22ii6):):):):):):):):):):):):):):):):):):):):):) |
mir* J S3 | $£376726761((((((((( /)/263622/555555555555/ | )/)/0)/)/)/)/)/)/) | Pbsma twlM8' predi xs recurrence and prognosis it. 4405ίΟ$)θΟ/θ5δ73$ί2ί)))))))))))))))))))) /$$2622$$555555555555555555555555555555 | mit-221 | hepatocellular carcinoma | up | Pole of microRNA-l55 at early stages of hepatocarcinogenesis induced by choime-deficrent and amino acid-defined diet in C57BL/6 mice | $732692((((( | o\ arum cancer | /)/776/)/)/)/)/)/)/ | 'Die· upregulation of signal transducer and activator of tianscriphun 5-dypyndenl ////2ra276RNA?(i)S2/326i////////////////////////////// micmRNA-bn promotes $/323232(263662/2377/$/$/$/$/$/$/$/$/ proliferation by targeting iorid-yad bov 03 upon leptin ////277333/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/)/ |
$0:)72)33)4/ | esopliageal $2$2$/$i$;5$555555555 | /)/0))))))))))):) | wiRNzvirG suppresses apoptosis and promotes piolderaUoi’ in ysopiidgeai ^arxeibv tatcetntg P7XD4 | mir-221 | hepatocellular carcinoma | up | miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TEMPI downregulation | mir-vh | ovarian cancer | 5/51555555/ | Differential microRNA «expiessiomsignaiuresand-yeli·:·:·: type-specific sssov niton with *i»vvl «-u t tract tnm imm ..mre.'j -ccite |
250
WO 2017/132552
PCT/US2017/015417
mil-1 S3 | esophageal squamous eolf 33753373533333333 | 8557888888: | MuroRMA-lh' promotes proltferanon and ιηνηηοη in oesophageal squamous cell carcroymaby targeting 3354555944:49979(575(79774(7/3//////( | mir-221 | hepatocellular carcinoma | up | Expression of microRNAs, miR-21. raiR-31, miR-122, miR-145. miR-146a. raiR200c, miR-221, miR-222, and miR-223 inpatients with hepatocellular carcinoma or rntrahepatic cholangiocarcinoma and its progno | 3(995/7533333 | prostate «.anus | (3(75843333 | 337547(-97:547457779(5747(88888888888: (394744475447554478888888888888888888 clonogenicity by dowhleguiatmpoi FOXOl m (359755997597594:59445/3333333333333( |
(/9745995////( | 050^///(:(:(:(:(:(: 373733(333333333333 (/0005////////: | (/Ο:////// | //555^^54/^4455///////////;//: O’.pressnon defines nttgrafiot' anti reduced apoptosis in fydivuia· liuioid ^orcmomas | nur-221 | bepatocelluiar carcinoma | up | MicroRNAs in Hepatobiliary and Pancreatic: Cancers. | mir-vh | prostate cancer | (857(888888 | Ttsrtsiormmgprowth factor-' ((((pf$735t9i-:95574749(5$57(//////////: metastasis through induction ((((pf((r0i0ipRN7577$dhd////////////:(: activation of the mTOR /57497(75/////////////////////////////: |
3(79(333333 | 88575745(5705474574753333333333 urcttternmti <nd rev? z*onU gastric cancer celts by | carcinoma | up | expression in hepatocellular carcinoma tissues and its roie in enhancing cell growth and | (851(88888 | ovcrcxpicsscd in prostate trcane arxf regulates «oc botueov en® ro pros' <t' ocha | |||||
8((5445 4454888 | (37445475333333333333( | 3(79333333( | 1 be i’Wih W/fx 2 (iustef 3(957549995154799553333333333333 Apoptosis and Soositir-os Cells iu Chenxuherapj m //Obt7b£ZZZZZZZZZZZZZZZZZZZZZZZZZZZZZ | nur-221 | liver cancer | up | Bioinibrmatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor proneities. | (347 4745788888 | gastric ..ancer | (857(888888 | (3(5947954799:54794497993333333333( human gastrh cancer |
mir-lST | bapabxtttuiaf (3775895554933333333( | (/77(////// | nur-221 | mafia nant melanoma | up | The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR221&222-C-FOS pathway. | mir-vpa | gastttc cancer | (857(888888 | twRN A 5 M prot 10 ώ ga *rtv (35944575544:595999(9449333333333333333( mu 1 tests *w argvtinctanur (375447775575(54^94(4988888888888888 | |
m«-JS3 | 397574577445479888: uarcmonta | 8:77888888: | miR-Ηϊ inhibits 'iAE-betadtndticed apoptosis in duw nregntaiiuii 01lf*t :)-1 expression k human heyatocoliutaf carciiipma :|7i5llllllllllll(8888( | mir-221 | non-small cell lung cancer | up | MicroRNA-221 promotes human non-small ceil lung cancer cell Ϊ-Ϊ460 growth. | 3(4549745333 | panoieatto «.anus | (3(75843333 | Artiag'niisin of imcmRNAprooxtiPv'3 >m <st»r 33797(4475597974544784588888888888: cadherin expression k pancreatic c prwoi cells by rc^natinenennte'nre *roct oi'raparovAit |
mir i<G | (3^979475957995333( carcinoma | 3379(888888 | ::ExpieSSioii:gnd:Signifieaiiee·:·:·:·: of MicroRNA-3 re. Hepaiocetiaiar Carcinoma. | mir-221 | non-small cell lung cancer | up | miR-221&222 regulate TRAD- resistance and enhance tumorigeiucity through PTEN and T1MP3 downregulation. | (3555574888888888888888: | (891(51( | rniRNAa in esophageal cancer (357797888888888888888888888888888888888 | |
(34475479888 | kidney cancer | Up | trfioroRNA-iX3 plays as m ·η>ηιζη<*ucB proliferation, migration and tnvasronxia targeting protein phosphatase -A. in renal //dhtadCiteiiij/:///////////////////////: | mir-221 | oral squamous cell carcinoma | up | miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma ceils. | mi:-:' | b-culi lymphoma | up | 54i7n/l?iBSOii9:l:///////( overc ’pressed ippAr’i’c cancer, assoo-Ated w td 1 a poor prognosis, and in·, ol·. ed in caovm veil proliferation and :(:mf^tbh/////////////////////////////: |
mir i<G | (3554944*95888888888 (((/&58Sl7(///////////:( (375575447 54733333333( | 3379(888888 | :(((M(ii(ipR(NA(pidfilH(ig((d£(////////:(: (35959799737^47:594794908888888888: tuedttDan tlt\rotdvat.-er ideniii'® trotinrorsoi rxdd roeiastaSJS, prognosis, and potential therapeutic targets. | mir-221 | osteosarcoma | up | MicroRNA-221 induces Cell Survival and Cisplatin Resistance through Pi3K/A.kt Pathway rn Human Osteosarcoma. | ;(((ipii:/i(4(:(:(:(:(: | breast carcinoma | (891(1(5 | MiR-hS enhances angiogenesis and metastasis 8855979574ΐ4475/Α(ί(978(3333333333333( |
i
WO 2017/132552
PCT/US2017/015417
mri-RG | 36398696363636/: /)95(569/)))))))))))) carcinoma | )658)))))): | ntdh MS regutetteNohretcel bpba* :or in papdiaiy thyroid carcinc-tna by targeting tbs programmed cell death 4 | mir-221 | ovarian cancer | up | Micro-RMAs and ovarian cancer the state oi art and perspectives of clinical research. | /)468557))): | colorectal cancer | 398636/6 | Mi roRNAcxure suro profiling vi eriohated eolonOcvteS isolated frc-m feces for colorectal cancer //S6i$6h(5g/))))))))))))))))))))))))))): |
jntr~l&? | pre-state cancer | 588/6/6/6/ | m.iR-iS3No-fS? cluster is ovete’.pressed in prostate /)5(456)99/(896(9875((9))))))))) humeo&tasis in prostate cells | mir-221 | pancreatic cancer | up | Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kipi), p57(kip2), and ΡΕΜΑ.. | ]/ro(((55/)))): | esophageal ))48699988994/)))) ////644695669///////////////////// | ):58)))))): | |
mir-1 S3 | prostate cancer | !b‘ | /66539609985695536363636/: jpteu w ' tare' ro/J>i vt rod SM ADI m. prostate Cancer | mir-221 | pancreatic cancer | up | miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. | mi:·: | 3865466865976767/ | UP | )/48665544/8654(8)68)5)))))))): Οι '.ο\3··'®λλ wparrout cancer associated with a poor /]p(0^(95i6)559ri98N65/(8)////////)) •::caucerceil:pl»hfeia!iOf!;aQd·:·:·:·:·: /:/445((693/3/3/3/3/3/3/3/3/3/3/3/3/3/:/ |
mir-lRl · 388636363) | lung tetteef | /)98/)))))) | Up-re/uiatior- of microRNA - ::iS3-:-3p:iS-:a:pOtent· prognostic·:·:·: /)/9886389(/55(5)))))))))))))))////////// adetrocarcmuma oi femate /)3835)38(56315))))))))))))))))))))))): | mir-221 | pancreatic cancer | up | Metformin Causes G1-Phase Arrest via Down-Regulation ofM/iR-221 and Enhances TRAIL Sensitivity through DR.5 Up-Regulation in Pancreatic Cancer Cells. | /)(04)/1/2))))) | ]]!5ng/5a8688/)))))))) | /)98/6/6/6/ | A pedyei&trooic mteroRNA /)9869()9^664)8968)))))))))))): uvere-xpiesscri in harrow lunq cancers and eribanee?. cell ]/5r$ii4(9fi05)))))))))))))))))))))))): |
rotr-lb-i | head anti tiaGx squamous cell /)66(64445/)))))))) | /)98/)))):/) | ( -Mai-geting of ninitmle 7084098830547676767: iOhibith-g bypovra-toductbie ////4546/(^0)6865:(54)8(8)))))))): pathogenesis of head and neck carcrooroas | mir-221 | papiilaiy thyroid carcinoma | lip | Expression of miRNAs ro Papillary Thyroid Carcinomas is .Associated w ith BRAF Mutation and Ciinicopaihological Features in Chinese Patients. | /9649))))) | bmg «.anger | 698/6/6/6/ | /:/:964:9(56(5:86569868:83////////////////////// «wsrcse Jigjpt· bro-iote again t miR J -> <p Sod miR /:/:2Q6:(53i/i8(8:369c/8i$/3/3/3/3/3/3/3/3 rotet ^ssu^fUK / 3„ |
careinuma | /)88/)))))) | Trawseripiiofialh Regulates St>\71 xte'zSioo ud Rro-jjot' z ( cl· Proufcn- -on m //]9559i/f/i6p6i8669588))))))))))) /346(318584:3/3/3/3/3/3/3/3/3/3/3/3/:/ | thyroid carcinoma | up | microRNA. and mRNA expression profiles in aggressive papillary thyroid carcinoma | /):99888969))))))))): | 691/636/ | mediates cbero^rcsistnace and enhances tumor growth in nxmriete'J iyropboroaua /]4ί5499τ/ρ6(3488))))))))))))))) /:/5i6i36h65;3/3/3/3/3/3/3/3/3/3/3/3/3/:/ | |||
3/64836:69)))/ | hepatocellular /)38684445/)))))))) | ):/55)))))): | YremRllA-fS < tthib's tell ptehferatron trod ro.va&iom and specifically targets 680400956067676767) | mir-221 | papillary thyroid carcinoma | up | MicroRNA analysis as a potential diagnostic tool for papiilaiy' thyroid carcinoma. | :/:9(9/1/4)))): | osteo sarcoma | /)668/)))))) | Uprcypiiaixro vf mscrriR NA* P v2 Jixtei as OcnfeS wdb tumor progression and u ustrosaumt-n |
mir-lhi | squ&rnous 789/69898636363 | ///98/)))))) | MjeroPNA ItiimblOStell /)8(6655:68666)688/((59858))))))) and specifically targets TNFAEP2 in Glmtua. | mir-221 | papiilaiy thyroid carcinoma | up | in vivo imaging of functional targeting of miR- 221 in papillary thyroid carcinoma. | /)(3553/84))) | b-teil lymphoma | 6/98/6/6/6/ | MicroRNA naR-17-Sp $ overexpressed in pancreatic car-ten a&so>. Oted w t- h a poo· -prognosis. and involved re • vU’v'rcvllprNri-.nmr and invasion |
/)58965:93) | bladder cancer | up | Mkro-RNA profiting ro kidney and bladder cancers. | mir-22I | papiilaiy thyroid carcinoma | up | in vivo imaging of miR-221 biogenesis in papillary thyroid carcinoma. | /)6689588))7 | breast caroirroma | up | MiR-*.·' enhances angiogenesis anti mero>tasis Κ !-.·γ:·χ::!ι·: L \Ts2 |
35896893) | gastric cancer | up | /)48466049456683/96)))))))))) human gssroo cancer | mir-22I | prostate cancer | up | MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RABlA. | /)589686)/)) | vblme-tai •.arxet | up | MiteR’U.’ p.«.ssmn profiling of evfuliated cNc-tx-ey fes isolated from, feces fc-r colorectal cancer ///66(6685((8//))))))))))))))))))))))))))) |
252
WO 2017/132552
PCT/US2017/015417
/983519584/9 | /8/8/8/3//((//(( 94/83/894444444444444 adeoocarcinom. /8(((((((((((((((((((( | //45//((/ | p.uR-iRP and ?2h Predict the Prognosis of Pancreatic Ductal Adenocarcinoma and ::Affeetiiie:Rroilf?£atlOli:aad:·:·:·:·:· Migration of 8 sneer Cells. | mir-221 | squamous carcinoma | up | Unique MicroRNA Expression Profiles in Cervical Cancer. | (9834/19//(((: | 9/8/88/8/14444444444 izv'ij ((//354/558((((((((((: | /BII/ | |
Inif-dRa | :9:4/:838048./:9:9:9:9:9:9:9:9 | /:/8//// | MicreRNA imR-P-Spis overexpressed in pancreatic u$s>-Mated wi h a Movr prognosis. and involved in career cell proliferation and im aUo« | mir-221 | thyroid carcinoma | up | MicroRNAs (mLR)-221 and mtR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kipl protein, levels and cell cycle. | retr-lha | iufig cancel· | /3//((((( | Apetl}C.iSO-»me uutreRN-i JinteiMtuR-lN'D is ::oyeiexp£esseriinbuman:hing:·:·:·: otov'tsrondvfivrevx ell :484/83^84/8//(((((((((((((((((((((9 |
/355/55// | 010:101 ximce: | :1.5 | MureR’i χ -puss.»·' profiles m human breast ((oa/cghoefi/:3838(((((((((((((((((: niultifiactioii and singlo-dose ((4//48(4θ88θ5ί/58(((((((((((((((: | mir22 5* | gastric cancer | up | MicroRNA profiling of human gastric cancer. | mu-:-'u | /5//83/8/58////(/ | up | (9/35//1/845/8^/5/8889/9/9/9/9/9 mu xi'se Nt *At i»leorid' z against imR- i 7- ?$> and naR.- 9 9 9 92/84899144885/8/5459444444444444444 oveiexoressing miR-17-82. |
Inif-dRa | 49888344444444444449 /0/888835(((((((( | /:/8//// | :9(08839343/8/58((((((((((((((((( angiogenesis and metastasis 9(/8/54858/85OB((((((((((((((i | mir-222 | anaplastic thyroid carcinoma | up | A. 4-Mi.croR.NA signature can. discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears. | retr-lha | lung cancel· | /3//((((( | 99^cr58W:34l5/f74?/4:844444444: 0\ e-vx pressed m iiancrcaoc 9459888/89/58/i:9484//484t3/95/3/(9 prognosis., and mvolved m E.?i xfx'ttprnJri'nui ind ..svasiito |
943551955444 | ciiofangiocarci //835//(////(// | :1.5 | • '.K · ' .. C’C .,..· Ι«··ι«'ν\ xioluig-rean-iijma trmvn evidence for PEEN as do w astream target and IL-- re ups un: u.avi | mir-222 | bladder cancer | up | Increased expression of miR22.2 is associated with poor prognosis in bladder cancer. | mu-:-'u | nunule .di ri mphoma | up | /9/ΐ89984/85&4θ^ mediates chvitrero ziztaree and enbance-z tumor growth in mantle ceil Kmphoma ua ΡΪ3Κ/ΑΚΤ pathway 9453855/8444444444444444444444444444 |
mir-lSa | cpton cancer | :((4/9(((((( | M9icroRXA-l Ra AtretmateS 9(08.(0/5/3(5-58/4/:358///:/ Suppiessmg the Expression of 4«\b le'to’gturasu1 Mutated in ( uloteitaf < anocr | mir-222 | breast cancer | up | .Analysis of serum genomewide microRNAs for breast cancer detection. | /nfe/W// | osteosarcoma | /://///(( | Upregularean Ol toxreRNzw 17-02 cluster associates with 44/0/:/30//0/3/8494444444444 pregureis it. AztcAztoreipa |
/355155/:( | (3/154/0////// 9(/5//8//(((((((((9/9 | //4////(( | minreRNA expression prolife uuragv iii vNufee-id career Circuiting ituR-iha and miR -20a as premising //OOO///////////////// | mir-222 | breast cancer | up | miR-221/222 promotes Sphase entry and cellular migration in control of basallike breast cancer. | (9358:1//(((: | b-cell iymphuma | /BII/ | 4:^8//8409/9^19/(//9:8494444444 oveiexpresreti tn parereattc • tocror azzOroto'dPi’itapoo· prognosis, and involved in •::cancoroeil:pi»iifeia!ionand·:·:·:·:·: 9:9889818/9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9:9 |
mir-lSa | /001048534((((((((( 9(/8//8//(((((((((9/9 | :((4/:(((((( | Plasma miR-Chttc and miR1 Ra as potential biomaikeiy :-:fortfe-:doiecii»!a:»£ooioreetai·:·:· ((//3i435i5(/(((((((((((((((((((((((( | mir-222 | breast cancer | up | TRPSJ. targeting by iniR221/222 promotes the epithelial-to-me sen: hy mai transition in breast cancer. | mir-l/ia | breast carcinoma | /://///(( | 49MiR483488883885444444444444444444 angragenesis and insriastasfe 443(4858/5/98880//444444444444444 |
mir-iRs | //84/088//((((/ ((:9/3//8((((((((((((( | /://///(( | Mkio&NA. expression 9(84/3134/383//344/38:(((((((((((: eotonocyies isolated from feces for colorectal cancer ·,υο:η··η> | mir-222 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPEs4lL3 | /88//// | profiling of exfoliated 94/3i/38/83/95/3ii/d:853/9444444: trereKr ο·«·Μΐ! iter sera mu·: | ||
itur-dRa | esophageal squamous cell /8/3/883/:(((((((( | up | mir-222 | gastric cancer | up | increased miR-222 inH. pylori-associated gastric cancer correlated with, tumor progression by promoting cancer cell proliferation and targeting RECK. | mir-l^a | esophageal /8/883//88/3/((/ caremoma | up |
253
WO 2017/132552
PCT/US2017/015417
)5:t305(:8())) | esophageal squamous cell )50(300//0))566666: | ):(3)))))): | Cbuival impact oKiivniatu.a tuiRM 8a in plasma of paueres w if h oesophageni squamous 5))(01//030303))))))))))))))))))))) | mir-222 | gastric cancer | up | Deregulated microRNAs in gastnc cancer tissue-derived mesenchymal stem cells: novel biomaikers and a mechanism for gastric cancer. | ):3(0515005))) | 5)040(40/0(0:)))))))) | 663 666666 | MtcioRNA miR-l ’-dp is Ov '.e\te'e,te wpatvrcaj cancer associated with a poor p- 'gnosis., and im <?\ ed m «cancerceifpiulkeiatiofcaQd·:·:·:·:·: 5:5fE5tG5ri3i33;:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5:5 |
t3r-18a | gastri·. vdt'tef | :))(0:)))))) | Diagnostic and prognostic 'ame 'f circulating m3 is? in the plasma ^patterns with ))0(400:0(0(/05)))))))))))))))))))))5 | mir-222 | gastric cancer | up | Circulating miR-222. in plasma and its potential diagnostic and prognostic value in gastric cancer | mir-l/ia | 5:5:30(403(0:)))))))) | 65(36666665 | A polycistronic mteroR.N.A 5)5(3$3054i^3|430/6666666666665 overcypiessud 3 human lung cancers and eshanaev ceB Pi obi'erariu.i |
65(305(:8())) | XJxtftC -Ji'tei | an | 5)0330503/0006666666666 human pa>triv cancer | mir-222 | gastric cancer | up | miR-222/VGLL4/YAJ5TEADJ regulatory loop promotes proliferation and invasion of gastric cancer cells. | 65(30000:))) | 5)5140/40535(/))))))))) | up | ):04306430(0(040/66666666666 mttznse Nt *Λΐ uviemid' z ugamat mtR.- i 7- ?p and nuR.- :5:5200:10::30(4:000(53)))))))))))))))) oveiexpressiug m3.-17-02. |
mir-d8a | gltohlnstoma | 5):0/)))))) | :5:5044)50:3000:((3))))))))))): proliferation, migration and ):50505 0030: :(0513034:))))))))))))))): gtmhlasioma ecil by targeung ))00(00306))))))))))))))))))))))))))) | mir-222 | glioma | up | Co-suppression of miR 221/222 cluster suppresses human glioma ceil growth by targeting p275hip 1 in vitro and rn vivo. | 5:5(30515(3:5:5:5: | 5:503000:0(0))))))))): ))334130366566666665 | ):40:666666 | Tlie ntiRN.A -J 7Ό1 duster mediates tbemoresistame and enhances tumen groy.th tn mantle cell iy mpbotua via I'DR/ART patbwat .Kiiv.jk.u: |
65(30(58(:))) | hmg «.oncci | an | A pwh nucioKi A duster. miR-d?*92. is overexpressed in human bmg earners and enhunceaoeil ):503((00(0(3:)))))))))))))))))))))): | mir-222 | glioma | up | MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. | 65(30000:))) | o&teosarcoma | tip | Upregulation of microRNAP*v2 chisteraSzOviatos oitb ))0/4/0:0iO(0(i/0540/)))))))))))) prognosis in OsteOzuvoins |
:5:53(4(0::5::: | bang cancer | 5:(3)))))): | Apoptosis mducuor bv anusense oligonucleotides against miR-l7-5p and iusR- 5)0000000/0066666666666666 u\ crC'.presstog miR-J”*ri2 | mir-222 | glioma | up | MiR-22 3/22.2 promote human giioma cell invasion and angiogenesis by targeting TIMP2. | )533)30))): | b-cefi lymphoma | :)((0:)))))) | MicroRNA mtRM7*?p is 0\ expressed tn lar-cread? 5)05/0(0/)03053:30()400:0:40(6665 ptegnosiSs. and involved tn re? retelfprohi'tuire ted Sip, .Jxjon |
504050: | ):3(3)00(0000: | /Ο)))))): | 5);0O34O;(O6(/6545466666666 yverespressetf tn panercairc as«re iSSj tm. 1 01 b a 'ter prognosis, and tnvoived m vittei ted prodifer^tiou gnd 5)(333(3)))))))))))))))))))))))))))) | mir-222 | hepatocellular carcinoma | up | GNAE3 inhibits tumor cell migration and invasion and is post-transcriptionally regulated by miR.-222 in. hepatocellular carcinoma. | 65(300/4666 | breast carcinoma | 663 666666 | ):540343500/0/03)))))))))))))))))) augmgeuesis and metastasis 65//)(033305()0((666666666666666 |
t3r-18a | malignant 5)3(310///)))))))): | :))(0:)))))) | ( ontparatlte unuka-S Pi 5)030305(50/006(0))))))))))) miRNAs in the niedaka and Xiphophonre pigmem cell :)00O/O(03):66666666666666666666 | ttur-222 | hepatocellular carcinoma | up | Role of micrcRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet rn C5 75BL/6 mine. | thir-l/fc | colorectal cancer | 6534666665 | MicroRNA expression 5)060ί(335θ/05Βί3ί0())))))))))))5 c-olouecytes isolated from feces for colorectal cauecr ))603(460(6666666666666666666666666666 |
nyr-18a | tuabgitaitt melanoma | UP | Aitreed v vwfCjsron of %L*.eJ nacmR NAs m meianouja. 5:5:00(060/0((0:(0:(0()))))))))))))) proapoptorie acti' tri of 66304606/506(6666665(6666666666666^ | mir-222 | hepatoceiluiar carcinoma | up | miR-221&222 regulate TRAIL resistance and enhance tumorlgenicity through PTEN and TIMP3 downregulation. | :)4005493))5 | esophageal :)400/4500040/)))))) carcinoma | up |
254
WO 2017/132552
PCT/US2017/015417
iy ntphomo | 3ri|3;E3 | /(ThiTralW mediate? chetnoressatattee anti :E$?iii^iii?^;:fiifid.$^:g^0\y3tl^5ii;333333: mantle sol! iy tophytna \tp Ρί3ϊ·?ΑΚΤ pathway Τ:^ί9ίη^Η^ΑΤ999999999999999Τ9999999: | mir-222 | hepatocellular carcinoma | up | Expression of imcroRNAs, rniR-2l. raiR-31, miR-122, miR-145. :miR-146a. miR200c, miR-22i, miR-222, and miR-223 inpatients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its progno | 3dui9i:9{59E | El^gtephptii:::::::::::::::::: | l-lll | A polymstronte microRNA ch:»t€f. roiR*17-92 is overe-roresaed in human lung :Τ^3Εϊώέίί»::^ώ^:^3£ί;ί^ίίί<$ί:έ^1ί22:::::::::::: 9£ίρί$έί^ | |
me»ht8«btezro | 3:1^:333333 | The nt84.-l”/'82 poly piatron is up-rogufoted m sonic 2tp^hsb^ radioed bv N-nwv rasonte ttedgeimg-trcateJ eereheRar pm.uc-x···» | mir-222 | hepatocellular carcinoma | 13p | MicroRNAs in Hepatobiliary and Pancreatic: Cancers. | 3(81:83:93888 | lung «.ancer | ;O|8| | antisense oligonucleotides again t mrR 1 -> <p and mtR 9:2Qp:m:fihig:0tote^9::::::::::::::::::::::::::::::: ον», re <,·.ssu^miK / 8,. | |
nasopbarynpea f narcitioma | !1.5 | p.uR-Ba promotes reaUgnaHi progression hy impainag nun.R\* htetw Μ»» nasopharyngeal carcinoma | mir-222 | hepatocellular carcinoma | up | [Expression of serum rnicroRMAs (rniR.-2.22, mrR181, miR-216) in human hepatocellular carcinoma and its clinical significance!. | 3|Ο;Ο33 | Ehitigktt^^/EEEE | tip | EMteroRO;8i«R8h?38p;is9EE89 Oi '.px/'re'1 mpamroai • <.4>v'f a^o». totednrhapw prognosis, and involved in voancorcethpitolifeiatiomand·:·:·:·:·: | |
roir-t8a | rtenrohlastoma | 33l>iti;333333 | 8 JYC N -regutete d mic roRNAs repress estrogen receptoralpha iFSRI) expression and t totetaf miiefwpatet ·η 9|8θ3θ*ΙΜΐΙΟ;3;3 | mir-222 | malm nacl melanoma | up | The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR221&222-C-FOS pathway. | roir-ltifc | mantle csU :9i^l^iphtte:9:9:939: | The uiiRNz\-i7?p? duster mediates U'omyre&islaove and enhances tumor growth ro mantte toll h mphoroa' ia PUK/AR l’p3i!Wv3v actuation. | |
nur-ISa | now-small colt hang cancer | up | Peripheral Blood mrR-32h E\pte?»:wn as a Potential Diagnosia of NSf.Lf. | mir-222 | nou-small cell lung cancer | up | tniR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and ΪΙΜΡ3 downregulation. | 9imrii9h93 | osteosarcoma | :O/99 | Upregulation Af torero! NA17-82 cluster associates whh tumor progression and 2£ipgiid$O3^ |
roir-t8a | OSteOStifCdtna | 33l>iA;333333 | Upregulation of mtcroRNA ιΛ-3'2 Justei associates wnh prognosis in osteosarcoma | mir-222 | non.-small cell, lung cancer | up | Use of Luminex xMAP beadbased suspension array for detecting microRNA in NSCLC tissues and its clinical application. | mir-2tia | b-oelt lymphoma | MkrnRNA nuR-17-Sp ,5 overexpressed in pancroatk citiivets. a»tretoted v nit a poor progresis. and involved tn • mtotiitoRprokKratet and invasion | |
nur-t8a | pancreatic 9οήίίέΕί999999999 | tip | i hw cl diagnosis, x attic nt cireahving mtR-: ha :n plasma of patients wkhpannreatic 8&ώ^ί889999999999999999999999999999: | mir-222 | oral squamous cell carcinoma | up | miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. | 91841928339: | breast carcinoma | :O/99 | yhhR^tehlihiie^TTTTTTTTT angiogenesis and nteta>tdssa :3l|ri3^edri^:|W§|EEEEEE(3 |
/phhsteAtiEEEEE 9dn8ipf5555598:898 adenycarckiom 333:393939393939 | 33ίφ333333: | ^mtoitomc MmroRNAs m 3;:§$^iii:6fEFifsfidi^?i:;E|:-^g3333333333 Oixqgene Transgenic Ra-s 5-^ifoghrite^ | mir-222 | pancreatic cancer | up | miR -221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. | ronr-h >3 | • . . ^r | :0:83:3:: | MicroRNA expresvum 3pii|diti^^ eolyuocytes isolated from feces for colorectal cantor Tj>£fri£Ej;w^;TUTUTUTUTUTUTUTU999: | |
mir-tba | 9pfo$tAiSE8ii$Si:9: | ::MlorofoNA:-:l&a:iS:clevgted:in:·:·: prostate voncei ana promyes T;fijtjfiyTi^^^j^:iifttejf4^foh33h3h3h3T3 srpptes z« o 8 3 <« v t ro •md in vup | mir-222 | papillary thyroid carcinoma | up | integrated analyses of microRNA. and mRNA. expression profiles in aggressive papillary' thyroid carcinoma | uur-2i!a | x^Qphtigepl:::::::::::::::::::: 9$g8groOE:^|8;8;8 Ei^hmh^EEEEE: | 99^^999999 |
255
WO 2017/132552
PCT/US2017/015417
520598535/ | breast cancel | 525855555 | ))05809)2885/85/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/5/ upregulated in breast cancer and modidates genes m.vohed ))i8/888/:98gi8t(88)))))))))))))))))): | mii-222 | papiliaiy thyroid carcinoma | up | MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. | )/98828858 | 850588588585858 | 5598 85555 | MicroRNA inrR-l ’-dp is Οι 'mrro'1 wparoreui cancer associated with a poor p· gnosis,, and nw oh ed m •::canceroeil:pi»iifeia!iona£td·:·:·:·:·: (8(88828::(:(:(:(:(:(:(:(:(:(:(:(:(:::::: |
:)98(5))))))): 5555Ο55353535 | teparocdtoiar 5888585/985/9353535 | ):)(9///////////// | ):UpyReg8iatioh)of)))))))))))));)))) MkroRNA-1 Wp Plays a Ryle HU ..ctsctlRrh-l lla< Induces invnbn Resistance tn ))ίίή9599ί5$8538Φ8ί5899))))))))))) :3:G8f089O/333333333333333333333333: | mir-222 | papillary tityroid carcinoma | up | MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. | roir-’oa | ))lprtg:(aho8f)))))))( | 5/5/98585/585/5 | A polycistrohic teteroPNA ^)/519998/9^/593239////////////////////////// yverexpiessetl in bainan lung cancers and eribunce* cell tepteiiWNteh)))))))))))))))))))))))): |
5/59335898))) | bronsi career | ):89)))))): | thfferemml expression of mtR-N mtR- I2$b and n«R- ))28:829:έ(88(3/(8895$599έ89/))))): | mir-222 | papillary thyroid carcinoma | 13p | Circulating microRNA profiles as potential biomarkers for diagnosis of papillary' thyroid carcinoma. | roir-20a | hmg cancer | 5)985)))))) | ))995/83088)89((8(98:38)))))))))): antisense oligonucleotides again t miR J <p and miR 332Qp:ih:fi(iigteph(^s3333333333333333 υ\«Λϋ '’V.xSU^mtK t % |
:)98(/999)): | bteasf earner | ):99///////////// | 219990805/89835)5385/5/5/5/5/5/5/5/5/5/ ::pfOU10tOS:£lKglUt£On:!li:breasi:·:·:·: caixcr thronch complex reputation of i<rf -nphJing in hypo, ie nite fete rtv ifo nnterif. | mir-222 | papillary tityroid carcinoma | up | Expression of miRNAs in Papillary Tityroid Carcinomas Is Associated with BRAE Mutation and Ciinicopathological Features in Chinese Patients. | roir-’oa | mantle csU ))ΐ99ί·9588988//////////////////// | /5/593///////////// | The miRN-v-pm? Jh ttj mediates Uteroyresrstairae and enhances tumor growth m mantle xil h mphomn' ia );Ρ9κ/Ζ.ΑΙ5238·Ν88'·58////////////////////////////// a.twatioi·. |
5/598(5895/)); | colornctal )8885555))))))))))))) | ):89)))))): | miR-l'?-! promotes innxtrigerreste Pf human cotoreevai cancer through )/2^gOting/;C5B5B88)/)))))))))))))))) | mir-222 | thyroid carcinoma | up | MicroRNAs (miR.)-22l and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kipl protein levels and cell cycle. | roir-W | osteosarcoma | 5/59855/5555 | Upregulation of mreroRNA17-92 cluster associates with tumor progression and 898598829/(85593955828899)/5/5/5/5/5/5 |
):98(/999)): | ):(0l0te(t3l))))))))) 388ί5ΐ(ι98ι9)))))))) | ):89///////////// | MIcroPNA-Rti contelates γ,ΐίΐι poor prognosis of coloieciai carcinoma and pirn s multiple roles b*, targeting tusire tulnhiior nf :::&888·8β898ΐδύ2:)/:/:/:/:/:/:/:/:/:/:/:/:/:/::::: | mir-222·· 3p | endometrial cancer | up | mir-v>a | b-cell lytupfcoma | /5/593///////////// | MicroRNA nuP-17-Sp ,5 oveiexpressed in pancreatk caixere a»croii»ted v rdt a poor ):88258928)/9585(595582989/285/5/5/5/5/5/5 • rox'tixIlprokKrarot and invasion | |
598(3859355 | ):0oi8i(959))))))))) cnrcm.omu | up | MicroRNA-ΓΗ correlates ))999/885(/85598828/88/5/5/5/5/5/5/5/5/5/5/ cotorectai cateirptra and 5$958 /8588(885(8352/ 58585855585 targetmc rustic irinbtrot of metallppioiease 2 | mir-223 | bladder cancer | up | Micro-RNA profiling in kidney and bladder cancers. | :)98())129/)): | breast caroriioma | :0777:7 | ):819993)292898(9/))))))))))))))))): nngmgeneste atwl metastasis ))ί853·592ί2998Α/τ98))))))))))))))) |
8899299/)) | g3Steh vUncei | 55985555555 | ithPNA >23 pioioo-esgustiK 3/(8iic:8858i3^883/8(t8)))))))))))))): metastasis™ <·trgetinc mmor /)5(:/388555595599985985////////////////////////: | mir-223 | colorectal cancer | up | Association of microRNA expression with microsateliite instability status in colorectal adenocarcinoma | 5598/555555 | profiling of exfoliated ))592825259282/29252(82598825/5/5/5/5/5/5/5 hreraKr ora-Mu! mtr seen .tine | ||
5/59885895/5/5/5 | hepatocellular cnrcm.omu | up | HypouietliylatKftt of the miR191 incus causes high expression of nut-lvi and promotes 'be epithelial to I’leaeneiry mpl ίρκμίοκ in hepatocellular carcinoma. | mir-223 | colorectal cancer | up | Circulating Exosomal microRNAs as Biomarkets of Colon Cancer. | ///98()829/5/5/5 | esophageal ))589595888585ι/ί//////////// carcinoma | up |
256
WO 2017/132552
PCT/US2017/015417
/:569-7/6(/222 | raLcraarcunja | /966//////: | MicroRMA-RPa-Ap is dew nregnlatedm human osteosarcoma and regulates /6|96226fe(6/!66:666////////2//// //(156(6666222:::::::::::::::::::::::::::::::::::::::::::::/:: | mir-223 | colorectal cancer | up | MicroRMA-223 functions as an oncogene in human colorectal cancer cells. | mii-S2a | 2355666666622/2/2/2 | 9959///// | A poiyeishnnic micro-RNA ebreter. miR-f 7-92 is overe-.pressed m human lung 2256(62(6:666:6(666(:6921(////////: //6(61(^51((66222222222222222222222222: |
2/2(6(9159222: | osteosarcoma | 2962///// | VumRN ' 151 pt a re> es ////όί9έό2692/6(66/66(1ί·2222222222222222 pf'-diieiatmnby fargo-mg checkpoint binase 2, | mir-223 | colorectal cancer | up | Overexpression of miR-225 correlates with tumor metastasis and poor prognosis inpatients with colorectal cancer | mii-‘t2a | lung cancer | /:65/222222 | Apoptosis induction by antisense- oitgetnx leotrdes /26/56((65/655//(/1/266616(56-222/: //566/6(/0/6609/222222222222222 o« erexpre® xt.g t. uh -3 ? |
256665(///: | 2((662(6662////////: /6566962/////////// | <P | 22(262(6RN(9-79(:2{5662(t26//////:: pancreatic vaoeer pmgreasmu bv targeting USPl ii. | mir-223 | colorectal cancer | up | C/EBP- ? -ac trv ated nu.croRNA.-223 promotes tumour growth through targeting RASA1 in human colorectal cancer. | ///((6(/536222/ | 9611/// | ///69(6(6697-26:665.99223621622222222: yverexpiesscd in pancreatic cat. \.r assoc-akd w uh 3 poor prognoses and mv oiv ed in caocercoll proliferation and ///(66^(6622222222222222222222222222222: | |
n6r~iA2 | gastric cancer | 996/////9 | MicroRMA-lb? and -215 arc upreguiated in human gastric cancer in' mo and suppress ALCAM expression tn vhro· | mir-223 | esophageal adenocarcinom a | up | MicroRNA. 223 is Upreguiated in the Muitistep Progression of Barnett's Esophagus and Modulates Sensitivity to Chemotherapy bv Tareeting PARPi. | ///56((936222: | 2/(56566/666222222222: //05566(6////////// | /:65/222222 | Hie miRNA -J ?7p > cktatar mediates themorosistamo and enhances tomoi growth m manrie ceO > inphotua via PBR/ART pathway .Kiiv.nkn: |
9569-79229: | XJsI«C -UiXCI | lb* | Riasnja η<ΒΜ22 at:d miR- :/799/:66/66ta66666226i:///////////: htomarkers for the eariy detactio 0 of distant metastasis ////6f 666(69/:666266/22222222222222222: | mir-223 | esophageal squamous cell carcinoma | up | Clinical significance of serum miR-223, miR-25 and miR375 m patients with esophageal squamous cell carcinoma. | mu -'Ua | osteosarcoma | up | Upregulation of micr-oRNAP-v? cluster aszn.t3ies with 2265fta5/5(65(56569266l//////ZZZZZ: prognosis «< osteOzovNUna |
2/66965(5//2/ | gastric cancer | 26692222: | MtR-?iVi97partK!patcs in gastnc «.aGcer progression | mir-223 | gastric cancer | up | miRNA-223 promotes gastric cancer invasion and. metastasis by targeting tumor suppressor EPB41L3. | ||||
mir-lb? | pancreatic 265|6(/////////////: aJeoraauiwttu /:/6/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/:/: | /:66//////: | RiagnOtau arid hroiogicai Siarnfi^ance pfmieiuRNAP2 in pancreatic dttefal :/26666666(6(66(66/222222222222222222: | mir-223 | gastric cancer | up | MicroRNA-223 functions as an onc ogene in human gastric cancer by' targeting FBXW7/hCdc4. | ||||
////666/2222222: (9>a->p | ///(666(/666/222222222/ careirirana | ////56///////////// | 22(9:6662(626(66629652:///////////: miRNAs as a potential diagnostic tool foi carb -stage renal celt carcinoma | mir-223 | gastric cancer | up | Plasma microRNAs. miR·· 223, miR-21 and miR.-23S, as novel potential biomarkers for gastric cancer detection | ||||
///569(/2222222 BBI////I | ///§9(6(66/222222222222 | »p | 22691R2 953625(6(66(65/969(222222222 proliferation by fargeihtg nttad ' ta i-ntt-at- pltaitta | mir-223 | gastric cancer | up | MicroRNA profiling of human gastric cancer. |
257
WO 2017/132552
PCT/US2017/015417 fable 5. Summary of microRNA/MMP Jinked interactions in cancer.
lei··? | ·········+ | S3S3F 'ί> ρΐ- ,>Λ<ί fΛ<*<·ί :«·>&·>:«$> | Cell proliferation and migration | ||||
let-? | 1 | ΜΜΡ-14. nKKl/2 activation | I Pancreatic nuctai | NA | ERkl/z activation, 1 GE-βΙ | ||
ί adenocarcinoma | sisnaiing | ||||||
let-7 | 1 | F ocal adhesion kinase (FAK), | I Glioblastoma | Migration and invasion | AKI' and ERK | ||
1 | AKT, ERK, MMP-2 and MMP-9 | I | |||||
mix-9 | ί | MMP-2, MMP-9 aud VEGFA | ! Uveal melanoma | Migration and invasion | NF-κΒΙ signaling | ||
miR-9 | 1 | MMP-14 | ! Neuroblastoma | Invasion, metastasis, and | - | ||
1 | | | aneioeenesis | |||||
miR-lOb | ί | MMr-9, E-cadberin and vimentin | 4------------------------------------- l Nasopharyngeal carcinoma | Proliferation, migration. | - | ||
1 | ί cells | invasion | |||||
miR-lOb | ί | MMP-14 aud uPAR | • Glioma | Cell invasiveness | |||
miR-lub | 1 | MMP-2, EGFR. | ! Glioblastoma muhifonne | Apoptosis invasion and migration | EGFR pathways | ||
miR-15b | 1 | MMP-3 | ί Glioma | Cell invasiveness | MEK-ERK pathway | ||
miR-17 | 1 | MMP-3 | ί Hepatocellular carcinoma | Migration and invasion | p-AKT | ||
miR-21 | 1 | RECK, MMP-9 | i Prostate cancer | NA | - | ||
mix-21 | 1 | Phospho-c-Jun. MMP-2, MMP-9 | ! Hepatocellular carcinoma | Migration and invasion | |||
miR-21 | 1 | RECK, MMP-2 | ! Glioma | Apoptosis, migration, and invasiveness | - | ||
miR- 21 | ί | MMP-2, EGFR. | ί Glioblastoma muhifomie | A.poptosis invasion and migration | EGFR pathways | ||
miR-26a | 1 | MMP-2 | ! Lung cancer | Migration, invasion and | AKT phosphorylation | ||
1 | l | metastasis | |||||
miR-29b | I | MMP-2 | ί Colon cancer | Migration | - | ||
miR-29b | ί | MMP-2 | ! Hepatocellular carcinoma | Tumor angiogenesis, invasion, aud metastasis | VEGFR-2-signaling | ||
miR-29b | 1 | MMP-2, Mcl-1, COLIA1, and COL4A1 | ! Prostate cancer | invasion and metastasis | |||
miR-29c | ! | MMP-2 | ί Nerve sheath tumours | Ceil invasion and migration | - | ||
miR-30d | S0CS1, phospho-STAT3. MMP2 aud MMP-9 | ! Prostate cancer | Proliferation and invasion | STAT3 signalling | |||
miR-34a | 1 | Fra-l,p53 MMP-ί and MMP-9 | i Colon cancer | Migration and invasion | - | ||
miR-92a | 1 | MMP-2 and -9 | ! Lung cancer | Migration, and invasion | STAT3 signaling | ||
mix-101 | 1 | Enhancer of zeste homolog 2 (EZH2), CDH1 and MMP-2 | ! Lung cancer | Cell invasiveness | |||
miR-lOob | 1 | MMP-2 | ! Breast cancer | Migration and invasion | ERK signaling cascade | ||
miR-125b | 1 | MMr-2 and MMr-9 | l Glioblastoma | Invasion | - | ||
miR-133 | ί | MMP-14 | i Lung cancer | (tel: proliferation, migration and invasion | - | ||
miR-138 | 1 | RhoC, MMP-2 and MMP-9 | ! Cliolangiocarciuoma | Proliferation, migration and invasion | p-ERK signaling | ||
miR-139 | ί | IGF-IR and MMP-2 | ! Colorectal cancer | Migration, invasion and metastasis | IGF-IR/MEK/ERK signaling | ||
mix-143 | 1 | MMP-13 | ! Prostate cancer | Migration, and invasion | |||
mix-143 | ί | MMP-2 and MMP-9 | ! Pancreatic cancer | Migration and invasion | |||
miR-143 | 1 | MMP-13 | ί Osteosarcoma | Cell invasiveness | - |
258
WO 2017/132552
PCT/US2017/015417
iBKOBS A | &#>&*»* | ||||
miR-145 | ί Etsl. MMP-1 and-9 | • Gastric cancer | invasion, metastasis, and amnoaenesis | ||
miR-146a | : MMP-1. uPA, and uPAR | ! Brain cancer | Migration, invasion and metastasis | - | |
miR-146a | ! MMP-16 | i Colon cancer | Invasion | - | |
miR-149 | ί MMP-2 and CyclinDl | • Glioma | Proliferation and invasion | AKT signaling | |
miR-152 | t MMP-3 | ! Glioma | Ceil invasiveness | MEK-ERK pathway | |
miR-181b | ! MMP-2 and MMP-9 | ! Hepatocellular carcinomas | Migration and invasion | TGF-13. Smad signaling | |
miR-182 | ί MMP-9. PECK | ί Breast cancer | ceil invasion and colo ny formation ability | - | |
miP-l96b | ! Viraentin, MMP-2 and MMP-9 | i 'Gastric cancer | Migration and invasion | - | |
miR-205 | ί MMP-9 andRobol | • Glioblastoma | Proliferation, migration, and invasion | ERK phosphorylation | |
miR-206 | ί MMP-2 and MMP-9 | ! Breast cancer | Invasion and migration | - | |
miR-211 | ! MMP-9 | ! Glioblastoma inultiforme | Cell invasion and migration | - | |
miR-218 | ! LEF1, MMP-2, -7 and-9 | ! Glioblastoma rnultiforme | Invasion | - | |
miR-218 | ! MMP-9 | i 'Gliomas | Ceil invasiveness | JKK-p/ΝΡ'-κΒ pathway | |
miR-224 | ! MMP-9 v ia targeting HOXD10 | ! Human hepatocellular ! carcinoma | Migration, and invasion | ||
miR-338-3p | ί SMC· and MMP-9 | ί Hepatocellular carcinoma | Invasion and metastasis | - | |
miR-340 | : MMP-2 and MMP-9 | ί Breast cancer | Tumor cell growth, migration, and invasion | - | |
miR-430 | ! EP_K, MMP-2 and MMP-9 | ! Bladder cancer | Proliferation, migration and colony formation ablilitv | ||
miR-451 | f Akts, CvciinDl, MMP-2, MMP-9 ! and Bcl-2 | ! Glioblastoma | Proliferation, invasion and apoptosrs | P(33G'AKT signaling | |
miR-49I | ! MMr-9 | ! Hepatocellular carcinoma | Migration | - | |
miR-49l-5p | ! MMP-9 | i 'Glioblastoma rnultiforme | Invasion | - | |
miRNA-590-3p | ! PI3K, Akt, MMP -2 and MMP -9 | ! Bladder cancer | Proliferation, migration, and c olo ny -fo rmation | ΡΪ3Κ. Akt signaling | |
miR-874 | i MMP-2 and -9, Aquaporin-3 | ! Human gastric cancer | Cell migration and invasion assays and in vivo tumorigenicity | ||
miR-874 | ''f'MMP-tand’SA | ! Non-small cell lung cancer | Tumor cell invasiveness and in vivo tumor growth | - | |
miR-885-5p | ! MMr-9 | ί Glioblastoma rnultiforme | Invasion | - |
259
WO 2017/132552
PCT/US2017/015417 fable 6. Target proteases and cancers associated with their overexpression.
tWk | 1«ί,'»ϊί»Μ | ||
I General | Intracellular, lyscsomes | ί Most | |
ί Cathepsin K | Extracellular, bone | ί Breast | |
Cysteine Cathepsins | ! Cathepsin B | Extracellular and pericellular under pathological conditions | ! Breast, cervix, colon, colorectal, gastric, head and ! neck, river, lung, melanoma, ovarian, pancreatic, prostate, thyroid |
• Cathepsin L | ! Breast, colorectal | ||
Aspartic Cathepsins | i Cathepsin E | Endosomal structures, ER, Golgi | i Cervical, gastric, lung, pancreas adenocarcinomas |
• Cathepsin D | Lysoscroe | Breast, colorectal, ovarian | |
! General | Intracellular, secreted | ! Most | |
I iiKi | ! | ||
Kallikreins (hK) | i PSA(hK3) | Prostate, ovarian | |
i hKl9 | i Colon, ovarian, pancreatic, head and neck | ||
! hK15 | i Ovarian, prostate | ||
Serine Proteases | ! uPA. uPAR. | Membrane. Pericellular | ! Cervical, colorectal, gastric, prostate |
Caspases ί | Intracellular ί | ||
! General | Extracellular | ! Most | |
I MMP-1. -8,-13 | ! Breast | ||
MMPs | ί MMP-2.-9 | Breast, colorectal, lung, malignant gliomas. ! ovarian | |
! MMP-14 | Membrane | ! Breast | |
ADAM ί | Extracellular ί |
260
WO 2017/132552
PCT/US2017/015417
Table 7. List of selected oncogenes associated with human malignancy
! ABL1 (ABLl | 9q34.1 | Chronic myeloid leukemia | see tyrosine kinase Abelson murine leukemia protein |
I ABL2 ! (ABLL,ARG) | Iq24-q25 | acute myeloid leukemia | Member of the tyrosine kinase family. Important for synapse assembly and remodeling |
ί AKAP13 (HT31, ! LBC BK.X) | 35q24-q25 | breast cancer | Blast crisis oncogene |
! ΑΒΑΠ | Xpli.4-pl3.2 | angioimmunoblastic lymphadenopatliy with dysproteinemia | Serine/threonine kinase |
I ARHGEF5 (ΊΊΜ) | 7q33-q35 | Breast cancer | Codes for protein that controls cyioskeletal organization through regulation of small GDI3-binding proteins |
I ATF1 | 32qi3 | ATF1/EWS fusion gene associated with malignant melanoma or soft parrs (MMSP) ATFJ/F1JS with histiocytoma. | ('odes for cAM35-dependent transcription factor-?. |
! AXL | l9qJ3.J-q?3.2 | Chronic myelogenous leukemia | transforming gene to acute leukemia |
! BCL2 | !Sq21.3 | Burkiti lymohoma, follicular lymphoma | Mediator of apoptosis. Translocation is marker of poorer therapeutic response |
! BRAF (BRAF·, ! RAFBi; | 7q34 | Hairy ceii leukemia, Malignant melanoma, thyroid papillary cancer, thyroid anaplastic carcinoma, bowel cancer, adenocarcinoma of lung, non-Hogkins lymphoma | see proto-oncogenes |
I BRCAl | 17q2i | Hereditary breast-ovarian cancer syndrome. Familial Breast cancer, Papillary serous carcinoma of the peritoneum (PSCP), Prostate cancer | see BRCAl. |
! BRCA2(FANCD1) | !3ql2.3 | Familial Breast cancer, prostate cancer, pancreatic cancer | see BRCA2 |
! BRIPl | !7q22.2 | Ovarian cancer, breast cancer | BRCAl interacting protein C-terminai heiicase 1 which is important in normal double-strand break repair |
1 CBL(CBL2) | 31q23 .3 | see proto-oncogenes | |
ί CSFiR(CSF-!, ! FMS, MCSF) | 5q33.2-q33.3 | Type M4 acute myeloblastic leukemia and chronic myelomonocytic leukemia | Codes for colony-stimulating factor-? receptor, otherwise known as macrophage colony-stimulating factor |
! DAPK1 (DAPK) | 9q34.1 | Bladder cancer | Codes for death-associated protein kinase a positive mediators of apoptosis induced by gammainterferon. |
! DEK(D6S231E) | 6p23 | DEK/NUP214(DEK.'CAN) fusiongene associated with acute myeloid leukemia | ('odes for DNA binding protein involved in transcriptional regulation and signal transduction as a component of the splicing complex that remains associated with spliced exons. |
261
WO 2017/132552
PCT/US2017/015417
DUSP6 (MKP3,PYST1) | 12q22-q23 | Non-small cell lung cancer, pancreatic cancer | Codes for member of mitogenactivated protein (MAP) kinase family and has key role in cellular signal transduction |
EGF | see proto-oncogenes | ||
EGFR (ERBB, ERBB1) | see proto-oncogenes | ||
ERBB3 (HER3) | 3 2q 13 | Non-small cell lung cancer | elevated ERBB3 mRNA levels in breast cancer |
ERG | see proto-oncogenes | ||
ETSi | see proto -oncogenes | ||
ETS2 | Acute myeloid leukemia | Codes for a transcription factor | |
EWSR1 (EWS, ES, PNE.) | 22ql2 | EWS/ERG in Ewing sarcoma, esthesioueuroblastoma EWS/FEV fusion gene in Ewing sarcoma, EWS/ZNE278 in small round cell sarcoma, EWS/3113 inEwmg sarcoma , r/wS/ATF I in malignant melanoma of soft parts(MMSP EWS/WTl in desmoplastic small round cell tumor | Ewing sarcoma breakpoint 1 gene |
EES (EES) | 35q26 I | Fi cell lymphoma, acute promyelocytic leukemia, bladder carcinoma, lung cancer, breast cancer, colon cancer, neuroblastoma, pre-B lymphocyte neoplasm, plasmacytoma, multiple myeloma, T cell lymphoma, sarcoma | Codes for a tyrosine-specific protein kinase with a role in regulating immune response |
FGF4 (ESTF1, KEGF) | 13ql3 | Stomach cancer, kaposi sarcoma | A fibroblast growth factor Important in limb development. |
FGFR1 | see proto -oncogenes | ||
EGERTOP (FOP) | 6a27 | FGFRl/EGERiOPz fusion gene in non-Hodgkin lymphoma | |
EL. CM | I7pl 1.2 | Renal cancer, bowel cancer | see FFCN |
FOS (c-fos) | 14q24.3 | see proto-oncogenes | |
FRAPI | see tumor suppressors | ||
jiys/na._____________ | I6pl 1.2 | see proto-oncogenes | |
E1RAS | 3ίρί5.5 | see proto-oncogenes. | |
GLU | 12ql3.2-ql3.3 | Glioma, myxoid liuosarccma, saiivarv gland tumor | Codes for a Kruppe! (Kr) zinc: finger protein |
GLI2 | 2qi4 | Glioma | Codes for a Kruppel (Kr) zinc finger protein |
GPC3 | Xq26 | Germ cell cancer, Hepatocellular cancer | see GRC3 |
HER2 (ERBB2, TKR1, NEC) | 17q21.1 | Breast cancer, lung cancer | see FIER2. Targeted by Trastuzumab. |
HGF (SE) | 7q21.1 | Prostate cancer, renal cancer | Codes for hepatocyte growth factor (liepatopoietin A, scatter factor) which is upregulated in many malignancies |
262
WO 2017/132552
PCT/US2017/015417
IRF4 (LSIRF, ί MUM1) | 6p25 -p23 | fi-cell lymphoma, B-cell leukemia, Multiple myeloma | Codes for an interferon regulatory factor essential for lymphocy te function | -- |
! JUNE | 19pJ3.2 | see proto-oncogenes | ||
! KIT(SCFRl | 4ql2 | Gastrointestinal stromal tumor (GlSTs), mast ceil leukemia, mastocytosis, seminoma and dysgermiuoma | Transmembrane tyrosine kinase receptor for stem cell factor (SCFR) is required for haeraatopoiesrs, melanogenesis and gametcgenesis. Mutations cause piebaldism. | |
I KRAS2 (RASK2) | 32pl2 1 | see proto-oncogenes. | ||
! LCK. | lp:;5-p34.3 | Non-snail ceil lung cancer, Neuroblastoma, nonHodgkin tvmphoma | codes for lymphocyte specific protein tyrosine kinase | |
ί LCO | 2qi4-q21 | Hepatocellular carcinoma | ||
i MAP3K8(TPL2, ί COT. EST) | 10pll.2 | Ewings sarcoma, adenocarcinoma of lung, thyroid carcinoma | Codes for a serine-threonine protein kinase. | |
I MCF2(DBL) | Xq27 | Breast cancer | Codes for a GDE’-GTP exchange f actor that modulates the activity of small GtPases of the Rho family | |
I MDM2 | 32ql4 :5-ql5 | Multiple | MDM2 acts as a major regulator of the tumor suppressor p53 by targeting its destmction. Direct association, of p53 with the protein MDM2 results in ubiquitiiiation arid subsequent, degradation ofp53 | |
I METjHGFR. ί RCCP2) | 7u31 | see proto-oncogenes | ||
! MLE tvue genes | see proto -oncogenes | |||
I MMD | 17q | Non small cell lung cancer, hepatocellular carcinoma, colon cancer | Godes for monocyte to macrophage differentiation associated protein. | |
ί MOS (MSV) | 8qll | Burkitt lymphoma, acute myeiobiastic leukemia | Function in man unknown. Above associations indirect but analogous gene to Moloney murine sarcoma vims. | |
! MRAS (RRAS3) | 3q22. 3 | Activated in many tumors | Godes for a RA S GTP-binding protein membrane-anchored, intracellular signal transducer | |
ί MSN Ape genes | see proto-oncogenes | |||
I MYB(AMV) | 6q22 | Alterations found in more than a third of human solid tumor lines | Encodes for proteins critical to hematopoietic ceil proliferation and development | |
I MYC | 8q?.4.12-q24 13 | Burkitt lymphoma Over expression in many malignancies, possibly associated with angiogenic, invasive promoting properties in excess. | A transcription factor that promotes ceil proliferation | |
I MYCL1 (L.MYC) | Ip34.3 | Small ceil lung cancer, adenocarcinoma of lung, neuroblastoma | ||
: MYCN | 2p24.3 | Neuroblastomas | Overlaps with NMYC aud is transcribed from opposite DNA. strand |
263
WO 2017/132552
PCT/US2017/015417
NCOA4 (ET.El. ARA?··, PTC3) | WqJE.2 | Prostate cancer | Interacts with the androgen receptor in presence oi dihydrotestosterone |
NF I type genes | see tumor suppressors | ||
NMYC | 2p24 | Neurob lastomas. re finch las to nm | Overlaps with MYCN and is transcribed from opposite DNA strand. Probably a DMA-binding protein. |
NRAS | lpl3.2 | see proto-oncogenes. | |
NTRK1 (TRIG, TRKA) | Iq2!.-q22 | see proto -oncogenes. | |
NEJP214 (CAN, D9S46E) | 9q34 1 | NUP2E4/T)FK fusion gene associated with acute myetoiu leukemia, NUP2J4/ABL1 associated with Tcef.1 acute lymphoblastic leukemia (T-ALL). | Codes for nucleoporio component of the vertebrate nuclear pore complex.. |
ovc | 9p24 | Ovarian adenocarcinoma | Abnormal in about 40% ovarian adenocarcinoma |
TP53 (P53) | 17pl3.1 | see tumor suppressors | |
PALB2 | 16pi2 | Breast cancer | see PALB2 |
PAX3 (HUP2) STAT1 | 2q3J | Alveolar rhabdomyosarcoma | Transcriptions factor, causes some forms of Waardenburg syndrome and regulates RET. |
PDGFB (SIS') | see proto-oncogenes | ||
PEM genes | see proto-oncogenes | ||
PML (MYL) | 15q22 | see tumour suppressors | |
PMS (PMSL) genes | see tumour suppressors | ||
PPM1D (WtPi) | 17q22-q23 | Breast cancer, Osteosarcoma | Codes for a serine/tbreonice protein phosphatase that attenuates apoptosis and facilitates transformation oi' primary ceils in cooperation withRAS |
PTEN (MMAC1) | 10q23 .31 | see tumor suppressors | |
PVT1 | Iicj24 | Burkitt lymphoma | |
RAF1 (CRAP) | 3p25 | Stomach cancer, renal cancer, glioblastoma, laryngeal cancer | A_ regulator of endothelial ceil survival during angiogenesis. Activated RAT counteracts apoptosis by suppressing the activation of mammalian sterile 20like kinase (MST2 ). |
RES] (P.B) | 3 3ql4 l-ql4 .2 | Retinoblastoma, osteogenic sarcoma, small ceil carcinoma of lung, bladder cancer | see RBI |
RET | 10qil.2 | Multiple endocrine neoplasia type 2a and 2b and Medullary thyroid carcinoma | see RET |
RRAS2 (TC2D | 1 lpter-p 15.5 | Teratocarcmoma. ovarian cancer | Single point mutation activates its oncogene potential |
ROS1 (ROS, MCF3) | 6u22 | Glioblastoma and probably others | ROS3/FIG fusion protein is a tyrosine kinase found in astrocvloma |
SMAD type genes | see tumor suppressors |
264
WO 2017/132552
PCT/US2017/015417
SMARCBl (SNE‘5, IN) I) | CX'ftY t 22ql 1 | see tumor suppressors | -- | |
SMURF· | 7q2l.3-q3l.J | Pancreatic cancer | Codes for a HECT domain E3 ubiquitin ligase that regulates tumor celt plasticity and motility through degradation of RhoA | |
SRC (AVS) | 20ql2-qi3 | hepatic metastatic bowel cancer, colon cancer, leukemia | Intracellular communication regulator protein Mutations are activating, transforming, tumorigenic, and metastasis-promo ting | |
STAT I | 2q32.2-q32.3 | Non-small ceil lung cancer | see STAT3 | |
STAT3 | 17q2T | Epithelial canc ers | Codes signal protein that induces cell transformation through a combined inhib ition of apoptosis and cell-cyc le activation | |
STA.T5 | 17qll .2 | Permissive for a wide range of malignancies | Codes signal protein that induces cell transformation through a combined inhibition of apoptosis and c ell-cycle activation | |
TDGF1 (CRGF) | 3p23-p2l | teratecarcinoma | Probably codes for signaling protein for mesoderm, development | |
TGFBR2 | 3p22 | see proto-oncogenes | ||
THRA (ERBA, | see proto-oncogenes | |||
TFG (TRKT3) | 3qll-qi2 | Papillary thyroid carcinoma | Chimeric oncogene withNTRKl proto-oncogene | |
Τΐϊ'Ι (TRIM24. TIFIA) | 7q32-q34 | Fusion genes associated with papiliaiy thyroid carcinoma and myleoproliferative disorder | Codes for transcriptional intermediary factor I | |
TMC (TN, HXB) | 9q33 | Neurofibromatosis type I , Pancreatic cancer | seeTNC | |
TRK | 3q2i-q22 | see proto-oncogenes | ||
7USC3 | 8p22 | see tumor suppressors | ||
USP6 (TRE2.) | 17pJ3 | Multiple cancel’s | Codes for a ubiquitin-specific protease found onlv in primates | |
WNTI (INTI) | 32ql2-ql3 | see proto-oncogenes | ||
WT1 | llpl.3 | Wilms tumour, over expressed in breast aud lung cancer, myeiodysplastic syndrome and acute myeloid leukemia | A zinc finger DNA-binding protein acting as a transcriptional activator or repressor depending on intracellular context | |
VEIL | 3p26-p25 | see tumor suppressors |
265
WO 2017/132552
PCT/US2017/015417
Table 8. Tumor suppresor miRs that are downregulated in specific cancer types
&»<<> t toxo | lst-7a-i | ::::::::::::::::::::::::::::::::::: mir-103 | mir-125b | &$$£££££££ let-7a-l | lei-?b | fW/xwty·· | SsSiSisssi | ||||||||
mir-i | ier-7g-5p | mir-193b | mir-143 | mir-1297 | let-7d | lst-7i | mir-101 | let-7a-3p | |||||||
mir-101 | mir-100 | le;-7a | mir-145 | let-7a-2 | mir-130a | mir-338 | mir-145 | lst-7a-2 | mir-141 | mir-101 | mir-218 | mir-iOO | ir.ir-1181 | let-7c | mir-183 |
mir-ilSO | mir-101 | εΐ-'’a-l | mrr-17-Sp | lst-7a-3 | mir-130b | mar-lSa | mii-1826 | let-7a-3 | mir-145 | mir-125b | mir-34a | mir-124 | mir-124 | mir-100 | mir-204 |
mir-1236 | mir-lOba | let-7a-2 | mii-203 | ls1-7b | mil-134 | n;ir-15b | rair-199a | let-7b | mir-16 | mir-1280 | mir-375 | mi.r-125b | mir-1247 | mir-101 | .............. |
mir-PJ-Sp | mir-124 | !.Bt-7a-3 | mir-214 | let-7c | mir-143 | mii-16 | mir-J99a- 3p | 1.S1.-7,; | otlr-200a | mir-143 | mir-494 | mir-129-5n | rr«r..l33a | mii-105 | mir-365b- 3p |
rair-12.5b | mir-l?.4a | iet-7b | mii-218 | 1.1-4.-7,1 | mir-145 | mir-16-1 | mir-203 | let-7d | m.ir-200b | mir-146a | mir-JOO | mi.r-130b | mir-141 | mir-124 | mir-4S6-3p |
mii-126 | n-.ir-125a | lst-7c | mir-335 | let-7e | :rdr--152 | irtir-J 6-l--3p | mir-205 | Is1-7e | mir-200c | mir-146b | mir-124 | mir-135a | :rdi-i45 | mir-128 | mir-532-5p |
roir-1280 | mir-i25a- 5p | !e!--7cl | rair-342-3p | Ie1-7f-l | mir-205 | mir-16-2 | mir-497 | iet-7f | mir-29b | :r,ii--l55 | mir-1250 | mir-137 | mir-146a | mir-1296 | |
mir-153a | mir-125b | let-7e | mir-372 | let-?f-2 | mir-223 | mir-18 la | mir-508-3p | l“t-7f-l | mir-3 81 | mir-l? | mir-125b | mir-i 38 | rr.ir-148a | mir-13 Ob | |
mir-i33b | mir-127-3p | iei-7f-l | mir-424 | I.Et-7g | mir-301a | mir-l81b | mir-5C9-5p | let-7r-2 | mir-409-3p | mir-3 84 | mir-126 | mir-141 | mir-148b | mir-l33a-i | |
mir-141 | mir-128 | lct-7f-2 | mii-491-5p | 1st-?» | mir-301b | mir-195 | lst-7a | M-7g | mir-429 | inir-185 | mir-1271 | mir-145 | mir-150* | mir-133a-2 | |
mir-H3 | mir-129 | mir-497 | mir-100 | mir-30c | mir-223 | ist-7d | ist-7i | mir-451 | mir-ixb | mir-136 | mir-148a | mu-150-5p | mir-133b | ||
mir-144 | rmr~i36 | iet-7i | mir-101 | mir-34a | mir-29b | rair-106a* | mii-193b | mir-138 | 01).1-152 | mir-135a | |||||
mir-145 | mir-137 | mir-100 | mir-99a | mir-126 | mir-3 4 c | mir-34b | mir-126 | mir-100 | mir-99a | mir-200c | mir-145 | mir-i55 | rnir-15a | mir-143 | |
roir-155 | mir--339--5p | mir-107 | mir-99b | mir-142-3p | mir-424 | ,.4,---4. | mir-1285 | mir-101 | 7a-1 | mir-203 | mir-147 | mir-155 | mir-198 | mir-145 | |
mir-142-3n | mir-lOa | mir-100 | mir-449a | mir-424 | mir-129-3p | i“t-7a-2 | mir-204 | mir-148a | mir-i99a | mir-205 | mir-346a | ||||
nik-iSa | mir-143 | mir-lOb | mir-101 | mir-145 | mir-543 | inii-lOa | mir-1291 | mir-122 | ier-'?a-3 | mir-205 | mir-181a | mir-200a | mir-214 | mii-154 | |
mir-192 | mir-145 | mir-122 | mir-15a | mir-192 | mir-34b | mir-146a | mir-133a | mir-122a | let-7b | mir-206 | mir-206 | mir-200b | mir-216a | mir-15a | |
mir-195 | “i6b“H 5P | mir-124 | mir-16 | mir-200c | mir-150 | mk-135a | mir-1236 | ter-?c | mir-20a | mir-220a | mir-200c | imr-29c | mii-187 | ||
„E9it?P23 | mir-149 | mir-1258 | JSfcaS | mir-2,1 | mir-138 | mir-124 | .iSCst | mii-211 | ..“irMa | 01).1-212 | mir-335 | mir-188-5p | |||
nii.r-200b | Piii-i52 | mir-125a- Jp | toir-886-5p | rmr-214 | mir-155 | i:ii:-!41 | mir-125b | i.Bt-7e | mir-218 | roir-26b | rap-335 | ..iSiiZii | mii-199b | ||
mir-200c | •r,ir-153 | :r,ii-!25b | mir-J06a | mii-215 | mir-2278 | mir-143 | mir-126 | iet-7f-l | nfc-26i | mir-29a | mir-54a | mii-34h | mir-200b | ||
mir-203 | mir-195 | mir-126 | mii-124 | roir-22 | mir-26a | mir-182-5p | mir-127 | isi-7f-2 | mir-31 | mir-32 | mir-34b | mdr-Sdc | irur-203 | ||
mir-205 | mir-148a | mir-30s | mir-2C0a | mir-1271 | i=I-7g | mir-33a | mir-323-5p | mir-34c | mir-373 | mir-205 | |||||
mir-214 | rpar-2!2-3p | mii-129 | mi.-29a | niir-302a | mir-3 | mir-218 | rpar-128-3p | let-7i | ;nir-34a | mir-329 | mir-409-3p | mir-375 | mir-212 | ||
mir-218 | mir-219-5p | mir-130a | mir-375 | mir-320 | mir-326 | mir-28-5p | mir-129-5p | mir-l | mir-34c | mir-338 | mir-411 | mu-410 | mii-218 | ||
mir-231; | rmr-222 | mir-320a | mir-564 | mir-30a | mir-130a | mii-376a | mir-370 | oar-429 | mir-497 | mir-221 | |||||
mir-26a | m.lr-29b | mir-133a | mir-34a | mii-27a | mir-30c | mir-130b | mir-133b | mir-376,; | mir-410 | mrr-432 | mii-615-5,; | mii-224 | |||
roir-29c | mir-34c | let-7b | mir-30d | mir-135a | mir-158 | mir-573 | mir-429 | mir-449a | mii-630 | arir-23a | |||||
mir-320c | mir-3189- | mir-145 | mir-365 | mir-J24a | mir-3 4 a | mir-134 | mir-142-5p | mir-7-5„ | mir-433 | mir-494 | rrdr-96 | mir-23b | |||
roir-34a | mir-320 | mir-146a | mir-373 | mi.-142---,, | mir-378 | mir-137 | mir-144 | mir-9 | mir-499a- 5p | mir-497 | mir-132 | mir-25 | |||
mir-320a | mir-l46b | mir-424 | ier-7c | mir-429 | mir-158 | m.ir-1469 | mir-98 | mir-503 | mir-498 | ier-7a | mir~26a | ||||
mir-409-3p | mir-326 | mir-147 | mir-429 | mir-l 7 | mii-509-5p | mii-139 | mir-146a | mir-506 | mir-519d | lct-7a-i |
266
WO 2017/132552
PCT/US2017/015417
mii-429 | IBB | ::::::::::::::::::::::::::::::::::: EftSiyafcWftfc:::: | i&xwK&«SiR·:·: < X #.<x > <· ..... mir-20a | giielll | ..... | mir-632 | mar-655 | lct-7a-2 | ίέΟ&ίβί | ||||||
mir-148a | mrr-455 | mir-646 | mir-139-5p | mir-29b | |||||||||||
mir-451 | mir-331-3a | mir-149 | mir-484 | mir-2aa | mir-133'o | mir-140-5r> | mrr-15a | mir-646 | mir-9 | iei-'?a-3 | mir-302a | ||||
mir-490-5p | mii-340 | mir-152 | mir-502 | m.ir-30c | le1-7b | mir-141 | mir-1.5b | mir-668 | mir-98 | let-7b | μίϊϋτο? | ||||
mir-493 | mir-342 | mir-] 53 | mir-503 | mir-720 | let-7c | mir-i42-3p | mir-16-1 | mir-877 | mir-101 | lst-7c | mir-30b | ||||
mir-576-3,, | mir-34a | mir-15a | rorr-93 | mir-107 | mir-200c | mir-143 | mir-16-2 | mir-9 | mir-632-5p | !e!-7il | iriir-30c-l | ||||
mir-376a | mir-98 | mir-342 | mir-204 | mir-144 | mir-182 | mir-124a | let-7e | mir-30c-2 | |||||||
mir-449a | mir-17-5p | mir-186 | mir-34a | mir-335 | mir-145 | mir-192 | mir-192 | iei-7f-l | mir-30d | ||||||
mir-483-5p | mir-lBia | mir-30a-5p | mir-202 | mir-377 | mir-i46a | mir-193a- 3p | mir-193a | let-7f-2 | mir-30. | ||||||
mir-503 | rnir-1826 | mir-627 | mir-142-Sp | mir-506 | mir-148a | mir-194 | mir-7 | iet^g | |||||||
m.ir-577 | mir-183 | Iet-7a | m.ir-29c | mi.r-l48b | mir-195 | let-7i | mii-330 | ||||||||
mir-063 | mir-185 | mir-ί | mir-145 | mrr-150-5p | mrr-198 | mir-126 | mir-331-3p | ||||||||
mir-195 | roir-124 | mir-l 93b | mir-15b | mir-203 | mir-l 35a | mir-34a | |||||||||
mir-7-5p | mir-193a- 3p | mir-125a | mir-199a | raa-if, | mir.-2!7 | mir-143 | mir-34b | ||||||||
mir-873 | mir-195 | roir-129 | mir-214 | mir-lS]a- 5p | mir-218 | mir-144 | iriir-34c | ||||||||
[et-7a | mir-199b- | mir-1295b- 5p | mir-22 | mir-185 | mir-l 59 | mir-374b | |||||||||
l“t-7f | mir-19a-3n | mir-130? | mir-137 | krar-188-5jj | mir-223 | mir-16 | mir-449a | ||||||||
mir-i07 | mir-200a | mir-15 Ob | mir-197 | mir-i93b | mr-26a | mir-20'3a | mir-4723- 5p | ||||||||
mir-122 | rnir-200b | mii-177 | mrr-195 | mrr-26b | mir-200b | mir-49? | |||||||||
mir-124-Sp | mir-200c | nar-ma | mir-195-5p | mir-29c | rnir-200c | mir-62S-5p | |||||||||
mir-139 | mir-205 | mir-133b | mrr-19? | rmr-33a | mir-21? | mir-642a- 5p | |||||||||
„5iS7?A6a | mir-206 | mi.r-i.98 | oiir-34a | mir-218 | mii-765 | ||||||||||
mir-I46b | mir-211 | mir-138 | roir-199a | mir-34b | mir-337 | mir-940 | |||||||||
mir-15b | mir-216b | roir-139 | mir-199a- 5p | mir-34c | mir-494 | ||||||||||
mir-'f, | mir-218 | mir-139-5p | mir-199b | mir-365 | mir-98 | ||||||||||
mir-181a | mir-22 | mir-i49-5p | mir-199b- 5p | mir-449a | |||||||||||
mir-iSla-l | mir-26a | mir-148a | n,ir-200a | mir-449b | |||||||||||
rnir-181a-2 | rnir-26b | mii-148b | mir-200'o | rnir-486-5p | |||||||||||
mir-181b | mir-300 | mrr-149 | mir-200c | mir-545 | |||||||||||
mir-iSlb-l | jS* | mir-150-5p | mir-202 | mir-610 | |||||||||||
mir-18Jb-2 | roir-154 | mir-203 | mir-614 | ||||||||||||
mir-iSlc | mir-335 | mir-iSa | mir-204-3p | mir-630 | |||||||||||
mir-lSM | mir-339-5p | mir-i5b | mir-205 | mir-660 | |||||||||||
mir-<84 | mir-33b | mir-16 | mir-206 | mir-7515 | |||||||||||
mir-185 | 5!i:?4a | fett· | ..151221 | mar-9500 |
267
WO 2017/132552
PCT/US2017/015417
&X<>> ; ί >,c#» cteXO O. | {ϊ;«·ί«>χ·>κ·:·:·:·:· | ||||||||||||
mir-199a- ! 3p ! mir-34b | mir-191 | mir-21 | ! | ||||||||||
mir-200a | mir-34c | mo-193a- 5p | mir-21-3p | mir-99b | 1 | |||||||||
mir-200b ! mir-374a | mir-194 | mir-211 | mir-133a | ! | |||||||||
mir-203 ί mir-j'N | mii-195 | mir-212 | let-7a | ! | |||||||||
mii-204 ! mir-381 | mir-196a | mir-214 | mii-IOO | ! | |||||||||
rr.ir-205 ! mir-383 | mil-198 | mir-217 | :rdr-106a | ||||||||||
mb--2i8 I mi)--425 | mir-199a- 5p | mil-218 | )110--107 | ί | |||||||||
mir-23b ! mir-429 | mil-203 | mir-219-5p | mir-124 | ||||||||||
! inir-4S0bniir-26b ί 3p | roir-204-5p | mii-22 | mir-125a- | ||||||||||
mir-27a ! mir-494 | mil-206 | mir-227 | mir-125a- 5u | ! | |||||||||
mir-29c | mir-495 | mir-212 | mir-26a | mir-126 | ! | |||||||||
mir-32S ! mir-497 | mir-218 | mir-26b | mir-126* | ! | |||||||||
mir-34c-3n ί mir-502-5p | mii-224 | mir-29a | mir-129 | ! | |||||||||
oiir-34c-5p ! mir-517a | .JSSAiAH-- | mir-29b-i | aiii-l37 | ! | |||||||||
rriir-375 mir.-574.-3p | mii-26b | mir-29b-2 | mir-140 | ||||||||||
Π’.ϋ--383 ί 010--638 | roir-27a | mir-29c | 01()-143 | ! | |||||||||
mir-451 ! rnir-7 | mir-2S-3p | mir-302b | mir-146b | ||||||||||
mir-452 ! mir-720 | mii-28-5a | mir-302c | mir-148a | ! | |||||||||
mir-495 ! mir-873 | mir-29b | mir-30a | mir-14Sb | ! | |||||||||
mir-584 ! mir-874 | mir-30a-3p | „E9iE7?2l-2P... | mir-i49 | ! | |||||||||
iinr-622 ί oii)--92a | roir-30b | mir-335 | 01()--152 | ! | |||||||||
mir-656 ! mir-98 | mil-328 | mir-338-3p | mir-154 | ||||||||||
mir-98 ί mir-99a | mir-338-3p | mir-33a | mir-155 | ! | |||||||||
! mrmi-miimir-124-3p ! 290-3n | mir-342 | mir-34a | mir-E7-5p | ! | |||||||||
rnir-181b- j inmu-mir- 5p ί 290-5p | mir-345 | mir-34b | mir-181a-l | ! | |||||||||
mir-20C'b ! | mir-34a-5p | mir-365 | mir-i81a-2 | ! | |||||||||
mir-3189- j -;P ! | Πιπ-3ό1-5ρ | mir-370 | mir-181b | ! | |||||||||
mir-375 | mir-372 | mir-181b-l | ! | ||||||||||
! | niir-378 | mir-375 | mir-iSlb-2, | ! | |||||||||
! | roir-378aJjl____________ | mir-376a | mir-18b; | ! | |||||||||
! | mir-378aJip.____________ | rmr-377 | mir-iSld | ! | |||||||||
roir-409-3p | mii-422a | )110--184 | ! | ||||||||||
! | mii-422a | roir-424 | mir-186 |
268
WO 2017/132552
PCT/US2017/015417
&»<<>> ; ί Υί» orixo O. | fc&GlW.·*. | ||||||||||||
! | mir-4487 | ηώ-424-Sp | mir-193b | ! | |||||||||
! | mii-483 | mir-433 | mir-199a | ! | |||||||||
! | mir-497 | mil-4458 | mii-204 | ! | |||||||||
! | mir-498 | mir-448 | mir-212 | ||||||||||
! | mir-518a3,: | mir-450a | mir-22 J | ί | |||||||||
! | mii -55 j a | mir-451 | mir-224 | ||||||||||
mir-574-5p | mir-4S5-5n | mir-27a | ! | ||||||||||
! | mir-625 | mir-486-5p | mir-27b | ! | |||||||||
! | mii-638 | mir-497 | mir-29a | ί | |||||||||
! | roir-7 | mir-503 | oitr-jOa | ! | |||||||||
! | iiiir-96-Sy | mir-506 | mir-30b | ! | |||||||||
mir-202-3p | mir-519d | mir-30c | ! | ||||||||||
! | mir-30a | mir-520a | mir-30d | ||||||||||
! | mir-451 | mir-520b | mir-30d-5n | ί | |||||||||
! | mir-520i> 3p | mir-30e-5p | ! | ||||||||||
! | mir-5S2-5D | rnir-32 | ί | ||||||||||
! | mir-59G-5p | mil-335 | ! | ||||||||||
! | mir-610 | rnir-338-3y | ! | ||||||||||
mir-612 | mir-340 | ! | |||||||||||
! | mir-625 | mir-342-3p | |||||||||||
mir-637 | mir-361-3n | ί | |||||||||||
! | mir-373 | ! | |||||||||||
! | roir-7 | mir-375 | ί | ||||||||||
! | mir-877 | mil-4500 | ! | ||||||||||
! | rair-940 | mir-4782- „22_____________ | ! | ||||||||||
mir-94] | mir-497 | ! | |||||||||||
! | mir-98 | mir-503 | ! | ||||||||||
mir-99a | mir-5 12-3d | ί | |||||||||||
! | mir-i32 | mir-520a- 3n | ! | ||||||||||
! | mir-31 | mir-526b | ί | ||||||||||
! | mir-625 * | ! | |||||||||||
! | ! |
269
WO 2017/132552
PCT/US2017/015417
Claims (97)
- CLAIMS:1. A recombinant oncolytic virus comprising one or more copies of one or more tumorsuppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication.
- 2. The oncolytic virus of claim 1, wherein the virus is a herpes simplex virus, an adenovirus, a polio virus, a vaccinia virus, a measles virus, a vesicular stomatitis virus, an orthomyxovirus, a parvovirus, a maraba virus or a coxsackievirus.
- 3. The oncolytic virus of claim 1 or 2, wherein the virus is a herpes simplex virus and wherein the one or more viral genes required for viral replication is selected from the group consisting of UL1, UL5, UL6, UL7, UL8, UL9, UL11, UL12, UL14, UL15, LJL17, UL18, UL19, UL20,1.4.22. UL25, UI..26, UL26.5, UL.27, UL28, UL29, UL30, UL31, UL32, UI..33, UL34, UL35, UI.,36, UL.37, 1.4.38. UL39, UL40, UL42, UL48, 14.49. UL52, UL53, UL54, ICPO, ICP4, ICP22, ICP27, ICP47, gamma-34.5, US3, US4, USS, US6, US7, USS, US9, LJS10, US11, and US 12.
- 4. The oncolytic virus of any of claims 1-3, wherein the tumor-suppressive miR target sequence is a target sequence for a miR selected from Table 3,
- 5. The oncolytic virus of any of claims 1 -4, wherein the one or more tumor-suppressive miR target sequences is incorporated into the 5’ untranslated region (UTR) or 3’ UTR of the one or more viral genes required for viral replication.
- 6. The oncolytic virus of any of claims 1-5, wherein replication of the virus is reduced or attenuated in a first cell compared to replication of the virus in a second cell.
- 7. The oncolytic virus of claim 6, wherein the first cell has an increased expression of a tumor-suppressive miR capable of binding to the one or more tumor-suppressive miR target sequences compared to the expression of the tumor-suppressive miR in the second cell.270WO 2017/132552PCT/US2017/015417
- 8. The oncolytic virus of claim 7, wherein the expression level of the tumor-suppressive miR m the first cell is at least 5% greater than the expression level of the tumor-suppressive miR in the second cell.
- 9. The oncolytic virus of claim 6, wherein the first cell is a non-cancerous cell.
- 10. The oncolytic virus of claim 6, wherein the second cell has a reduced expression of a tumor-suppressive miR capable of binding to the one or more tumor-suppressive miR target sequences compared to the expression of the tumor-suppressive miR in the first cell.
- 11. The oncolytic virus of claim 10, wherein the expression level of the tumor-suppressive miR in the second cell is at least 5% less than the expression level of the tumor-suppressive miR in the first cell.
- 12. The oncolytic virus of claim 6, wherein the second cell is a cancerous cell.
- 13. The oncolytic virus of any of claims 1-12, comprising tumor-suppressive miR target sequences for miR-124, miR-451a, miR-143-3p, and miR-559.
- 14. The oncolytic virus of claim 13, for treating pancreatic, lung, and/or colon cancer.
- 15. The oncolytic virus of any of claims 1-12, comprising tumor-suppressive miR target sequences for miR-124, miR-451, miR-143-3p, miR-1, and miR-559.
- 16. The oncolytic virus of any of claims 1-12, comprising tumor-suppressive miR target sequences for miR-124, miR-451, miR-145-5p, and miR-559.
- 17. The oncolytic virus of claim 15 and/or 16, for treating a tumor derived from any type of cancer.271WO 2017/132552PCT/US2017/015417
- 18. The oncolytic virus of any of claims 1-12, comprising tumor-suppressive miR target sequences for miR-205p, miR-141-5p, miR-31-5p, and miR-124.
- 19. The oncolytic virus of any of claims 1-18, wherein the tumor-suppressive miR target sequences are inserted into the ICP4, ICP27, UL19, and/or UL30 locus.
- 20. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-136-3p, miR-432-5p, miR-l-3p, miR-127-3p, miR-3795p, miR-493-5p, miR-223-5p, miR-223-5p, miR-136-5p, miR-451a, miR-487b~3p, miR-370-3p, miR-410-3p, miR-431-3p, miR-4485-3p, miR-4485-5p, miR-127-5p, miR-409-3p, miR-338-3p, miR-559, miR-4II-5p, miR-133a-5p, miR-143-3p, miR-376b-3p, miR-758-3p, miR-1, miR-101 miR-1180, miR-1236, miR-124-3p, miR-125b, miR-126, miR-1280, miR-133a, miR-133b, miR 141, miR-143, miR-144, miR-145, miR-155, miR-16, miR-18a, miR-192, miR-195, miR-200a, miR-200b, miR-200c, miR-203, miR-205, miR-214, miR-218, miR-23b, miR-26a, miR-29c, miR-320c, miR-34a, miR-370, miR-409-3p, miR-429, miR-451b, miR-490-5p, miR-493, miR576-3p, and/or miR-99a.
- 21. The oncolytic virus of claim 20 for treating bladder cancer.
- 22. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive iniR target sequence is a target sequence for nuR-1251-5p, miR-2I9a-5p, miR-219a-2-3p, miR-124-3p, miR-448, miR-I38-2-3p, miR-490-5p, miR-129-l-3p, miR-1264, miR-3943, miR-490-3p, miR383-5p, miR-133b, miR-129-2-3p, miR-128-2-5p, miR-133a-3p, miR-129-5p, miR-l-3p, nuR885-3p, miR-124-5p, miR-759, miR-7158-3p, miR-770-5p, miR-135a-5p, miR-885-5p, let-7g5p, miR-100, miR-101, miR-106a, miR-124, miR-124a, miR-125a, miR-125a-5p, miR-125b, miR-127-3p, miR-128, miR-129, miR-136, miR-137, miR-139-5p, miR-142-3p, miR-143, miR145, miR-146b-5p, miR-149, miR-152, imR-153, miR-195, miR-21, miR-212-3p, miR-219-5p, miR-222, miR-29b, miR-31, miR-3189-3p, miR-320, miR-320a, miR-326, miR-330, miR-3313p, miR-340, miR-342, miR-34a, miR-376a, miR-449a, miR-483-5p, miR-503, miR-577, miR663, miR-7, miR-7-5p, miR-873, let-7a, let-7f, nnR-107, miR-122, miR-124-5p, miR-139, miR146a, miR-146b, miR-15b, miR-16, miR-181a, miR-18la-1, miR-18 la-2, miR-181b, miR-181b·777WO 2017/132552PCT/US2017/0154171, miR-181b-2, miR-181c, miR-181d, miR-184, miR-185, miR-199a-3p, miR-200a, miR-200b, miR-203, miR-204, miR-205, miR-218, miR-23b, miR-26b, miR-27a, miR-29c, miR-328, miR34c-3p, miR-34c-5p, miR-375, miR-383, miR-451, miR-452, miR-495, miR-584, miR-622, miR-656, miR-98, miR-124-3p, miR-181b-5p, miR-200b, and/or miR-3189-3p.
- 23. The oncolytic virus of claim 22 for treating brain cancer.
- 24. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-10b-5p, miR- Ι 26-3p, miR-145-3p, miR-451 a, miR- 199b5p, miR-5683, miR-3195, miR-3182, miR-1271-5p, miR-204-5p, miR-409-5p, miR-136-5p, miR-514a-5p, miR-559, miR-483-3p, miR-l-3p, miR-6080, miR-144-3p, miR-10b-3p, miR6130, miR-6089, miR-203b~5p, miR-4266, miR-4327, miR-5694, miR-193b, let-7a, let-7a-l, let7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-l, let-7f-2, let-7g, let-7i, miR-100, miR-107, miR-lOa, miR-lOb, miR-122, miR-124, miR-1258, miR-125a-5p, miR-125b, miR-126, miR-127, miR-129, miR-130a, miR-132, miR-133a, miR-143, miR-145, miR-146a, miR-146b, miR-147, miR-148a, miR-149, miR-152, miR-153, miR-15a, miR-16, miR-17-5p, miR-181a, miR-1826, miR-183, miR-185, miR-191, miR-193a-3p, miR-195, miR-199b-5p, miR-19a-3p, miR-200a, miR-200b, miR-200c, miR-205, miR-206, miR-211, miR-216b, miR-218, miR-22, miR-26a, miR-26b, miR-300, miR-30a, miR-31, miR-335, miR-339-5p, miR-33b, miR-34a, miR-34b, miR-34c, miR-374a, miR-379, miR-381, miR-383, miR-425, miR-429, miR-450b-3p, miR-494, miR-495, miR-497, miR-502-5p, miR-517a, miR-574-3p, miR-638, miR-7, miR-720, miR-873, miR-874, miR-92a, miR-98, miR-99a, mmu-miR-290-3p, and/or mmu-miR-290-5p.
- 25. The oncolytic virus of claim 24 for treating breast cancer.
- 26. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-143, miR-145, miR-17-5p, miR-203, miR-214, miR-218, miR-335, miR-342-3p, miR-372, miR-424, miR-491-5p, miR-497, miR-7, miR-99a, miR-99b, miR-100, miR-101, miR-15a, miR-16, miR-34a, miR-886-5p, miR-106a, miR-124, miR-148a, miR-29a, and/or miR-375.273WO 2017/132552PCT/US2017/015417
- 27. The oncolytic virus of claim 26 for treating cervical cancer.
- 28. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-133a-5p, miR-490-5p, miR-124-3p, miR-137, miR-6553p, miR-376c-3p, miR-369-5p, miR-490-3p, miR-432-5p, miR-487b-3p, miR-342-3p, miR-2233p, miR-136-3p, miR-136~3p, miR-143-5p, miR-l-3p, miR-214-3p, miR-143-3p, miR-199a-3p, miR-199b-3p, miR-451a, miR-127-3p, miR-133a-3p, miR-145~5p, miR-145-3p, miR-199a-5p, let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f-l, let-7f-2, let-7g, let-7i, miR-100, miR-101, miR-126, miR-142-3p, miR-143, miR-145, miR-192, miR-200c, miR-21, miR-214, miR-215, mi.R-22, miR-25, miR-302a, miR-320, miR-320a, miR-34a, miR-34c, miR-365, miR373, miR-424, miR-429, miR-455, miR-484, miR-502, miR-503, miR-93, miR-98, miR-186, miR-30a-5p, miR-627, let-7a, miR-1, miR-124, miR-125a, miR-129, miR-1295b-3p, miR-1307, miR-130b, miR-132, miR-133a, miR-133b, miR-137, miR-138, miR-139, miR-139-5p, miR140-5p, miR-148a, miR-148b, miR-149, miR-150~5p, miR-154, miR-15a, miR-15b, miR-16, miR-18a, miR-191, miR-193a-5p, miR-194, miR-195, miR-196a, miR-198, miR-199a-5p, miR203, miR-204-5p, miR-206, miR-212, miR-218, miR-224, miR-24-3p, miR-26b, miR-27a, miR28-3p, miR-28-5p, miR-29b, miR-30a-3p, miR-30b, miR-328, miR-338-3p, miR-342, miR-345, miR-34a-5p, miR-361-5p, miR-375, miR-378, miR-378a-3p, miR-378a-5p, miR-409-3p, miR422a, miR-4487, miR-483, miR-497, miR-498, miR-518a-3p, miR-551a, miR-574-5p, miR-625 miR-638, miR-7, miR-96-5p, miR-202-3p, miR-30a, and/or miR-451.
- 29. The oncolytic virus of claim 28 for treating colon or colorectal cancer.
- 30. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-101, miR-130a, nuR-130b, miR-134, miR-143, miR-145, miR-152, miR-205, miR-223, miR-301a, miR-301b, miR-30c, miR-34a, miR-34c, miR-424, miR-449a, miR-543, and/or miR-34b inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 31. The oncolytic virus of claim 30 for treating endometrial cancer.274WO 2017/132552PCT/US2017/015417
- 32. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for nuR-125b, miR-138, miR-15a, miR-15b, miR-16, miR-16-1, miR-16-l-3p, miR-16-2, miR-181a, nuR-lSlb, miR-195, miR-223, miR-29b, miR-34b, miR34c, miR-424, miR-lOa, miR-146a, miR-150, miR-151, miR-155, miR-2278, miR-26a, miR-30e, miR-31, miR-326, miR-564, miR-27a, let-7b, miR~124a, miR-142-3p, let-7c, miR-17, miR-20a, miR-29a, miR-30c, miR-720, miR-107, miR-342, nnR-34a, miR-202, miR-142-5p, miR-29c, miR-145, miR-193b, miR~199a, miR-214, miR-22, miR-137, and/or miR-197 inserted into the 5’ UTR or 3 ’ UTR of one or more viral genes required for viral replication.
- 33. The oncolytic virus of claim 32 for treating hematologic cancer.
- 34. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-1, miR-145, miR-1826, niiR-199a, miR-199a-3p, miR203, miR-205, miR-497, miR-508-3p, miR-509-3p, let-7a, let-7d, miR-106a*, miR-126, miR1285, miR-129-3p, miR-1291, miR-133a, miR-135a, miR-138, miR-141, miR-143, miR-182-5p, miR-200a, miR-218, miR-28-5p, miR-30a, miR-30c, miR-30d, miR-34a, miR-378, miR-429, miR-509-5p, miR-646, miR-133b, let-7b, let-7c, miR-200c, miR-204, miR-335, miR-377, and/or miR-506 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 35. The oncolytic virus of claim 34 for treating kidney cancer.
- 36. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive nuR target sequence is a target sequence for let-7a-l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f, let-7f-l, let-7f-2, let-7g, let-7i, miR-1, miR-100, miR-101, miR-105, miR-122, miR-122a, miR1236, miR-124, miR-125b, miR-126, miR-127, miR-1271, miR-128-3p, miR-129-5p, miR-130a, miR-130b, miR-133a, miR-134, miR-137, miR-138, miR-139, miR-139-5p, miR-140-5p, miR141, miR-142-3p, miR-143, miR-144, miR-145, miR-146a, miR-148a, miR-148b, miR-150-5p, miR-15b, miR-16, miR-181a-5p, miR-185, miR-188-5p, miR-193b, miR-195, miR-195-5p, miR197, miR-198, miR-199a, miR-199a-5p, miR-199b, miR-199b-5p, miR-200a, miR-200b, miR200c, miR-202, miR-203, miR-204-3p, miR-205, miR-206, miR-20a, miR-21, miR-21-3p, miRWO 2017/132552PCT/US2017/015417211, miR-212, miR-214, miR-217, miR-218, miR-219-5p, miR-22, miR-223, miR-26a, miR26b, miR-29a, miR-29b-l, miR-29b-2, miR-29c, miR-302b, miR-302c, miR-30a, miR-30a-3p, miR-335, miR-338-3p, miR-33a, miR-34a, miR-34b, miR-365, miR-370, miR-372, miR-375, miR-376a, miR-377, miR-422a, miR-424, miR-424-5p, miR-433, miR-4458, miR-448, miR450a, miR-451, miR-485-5p, miR-486-5p, miR-497, miR-503, miR-506, miR-519d, miR-520a, miR-520b, miR-520c-3p, miR-582-5p, miR-590-5p, miR-610, miR-612, miR-625, nuR-637, miR-675, miR-7, miR-877, miR-940, miR-941, miR-98, miR-99a, miR-132, and/or miR-31 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 37. The oncolytic virus of claim 36 for treating liver cancer.
- 38. The oncolytic virus of claim 37, wherein the liver cancer is hepatocellular carcinoma.
- 39. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-143-3p, miR-126-3p, miR-126-5p, miR-1266-3p, miR6130, miR-6080, miR-51 l-5p, mIR-143-5p, miR-223-5p, miR-Ι 99b-5p, miR-199a-3p, miR199b-3p, miR-451a, miR-142-5p, miR-144, miR-150-5p, miR-142-3p, miR-214-3p, miR-2145p, miR-Ι 99a-5p, miR-145-3p, miR-145-5p, miR-1297, miR-141, miR-145, miR-16, miR-200a, miR-200b, miR-200c, miR-29b, miR-381, miR-409-3p, mIR-429, miR-451, miR-511, miR-99a, let-7a-l, iet-7a-2, let-7a-3, let-7b, iet-7c, let-7d, let-7e, iet-7f-l, let-7f-2, let-7g, let-7i, miR-1, miR-101, miR-133b, miR-138, miR-142-5p, miR-144, miR-1469, miR-146a, miR-153, miR-15a miR-15b, miR-16-1, miR-Ι6-2, miR-182, miR-192, miR-193a-3p, miR-194, miR-195, miR-198, miR-203, miR-217, miR-218, miR-22, miR-223, miR-26a, miR-26b, miR-29c, miR-33a, miR34a, miR-34b, miR-34c, miR-365, miR-449a, miR-449b, miR-486-5p, miR-545, miR-610, miR614, miR-630, miR-660, miR-7515, miR-9500, miR-98, miR-99b, miR-133a, let-7a, miR-100, miR-106a, miR-107, miR-124, miR-125a-3p, miR-125a-5p, miR-126, miR-126*, miR-129, miR 137, miR-140, miR-143, miR-146b, miR-148a, miR-148b, miR-149, miR-152, miR-154, miR155, miR-17-5p, miR-181a-l, miR-181a-2, miR-181b, miR-181b-l, miR-181b-2, miR-181c, miR-181d, miR-184, miR-186, miR-193b, miR-199a, miR-204, miR-212, miR-221, miR-224, miR-27a, miR-27b, miR-29a, miR-30a, miR-30b, miR-30c, miR-30d, miR-30d-5p, miR-30e-5p, miR-32, miR-335, miR-338-3p, miR-340, miR-342-3p, miR-361-3p, miR-373, miR-375, miR276WO 2017/132552PCT/US2017/0154174500, miR-4782-3p, miR-497, miR-503, miR-512-3p, miR-520a-3p, miR-526b, miR-625*, and/or miR-96 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 40. The oncolytic virus of claim 39 for treating lung cancer.
- 41. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for let-7b, niiR-101, miR-125b, miR-1280, miR-143, miR-146a, miR-146b, miR-155, miR-17, miR-184, miR-185, miR-18b, miR-193b, miR-200c, miR-203, miR-204, miR-205, miR-206, miR-20a, miR-211, miR-218, miR-26a, miR-31, miR-33a, miR34a, miR-34c, miR-376a, miR-376c, miR-573, miR-7-5p, miR-9, and/or miR-98 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 42. The oncolytic virus of claim 41 for treating melanoma.
- 43. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for let-7d, miR-218, miR-34a, miR-375, miR-494, miR-100, miR124, miR-1250, miR-125b, miR-126, miR-1271, miR-136, miR-138, miR-145, miR-147, miR148a, miR-181a, miR-206, miR-220a, miR-26a, miR-26b, miR-29a, miR-32, miR-323-5p, miR329, miR-338, miR-370, miR-410, miR-429, miR-433, miR-499a-5p, miR-503, miR-506, miR632, miR-646, miR-668, nuR-877, and/or miR-9 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 44. The oncolytic virus of claim 43 for treating oral cancer.
- 45. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for let-7i, miR-100, miR-124, miR-125b, miR-129-5p, miR-130b, miR-133a, miR-137, miR-138, miR-141, miR-145, miR-148a, miR-152, miR-153, miR-155, miR-199a, miR-200a, miR-200b, miR-200c, miR-212, miR-335, miR-34a, miR-34b, miR-34c, nuR-409-3p, miR-411, miR-429, nuR-432, miR-449a, miR-494, miR-497, miR-498, miR-519d,WO 2017/132552PCT/US2017/015417 miR-655, miR-9, miR-98, miR-101, miR-532-5p, miR-124a, miR-192, miR-193a, and/or miR-7 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 46. The oncolytic virus of claim 45 for treating ovarian cancer.
- 47. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-216a-5p, miR-802, miR-217, miR-145-3p, miR-143-3p, miR-451a, miR-375, miR-214-3p, miR-216b-3p, miR-432-5p, miR-216a-3p, miR-199b-5p, miR199a-5p, miR-136-3p, miR-216b-5p, miR-136-5p, miR-145-5p, miR-127-3p, miR-199a-3p, miR-199b-3p, miR-559, miR-129-2-3p, miR-4507, miR-l~3p, miR-148a-3p, miR-101, miR1181, miR-124, miR-1247, miR-133a, miR-141, miR-145, miR-146a. miR-148a, miR-148b, miR-150*, miR-150-5p, miR-152, miR-15a, miR-198, miR-203, miR-214, miR-216a, miR-29c, miR-335, miR-34a, miR-34b, miR-34c, miR-373, miR-375, miR-410, miR-497, miR-615-5p, miR-630, miR-96, miR-132, let-7a, let-7a~l, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-7e, let-7f1, let-7f-2, let-7g, let-7i, miR-126, miR-135a, miR-143, miR-144, miR-150, miR-16, miR-200a, miR-200b, miR-200c, miR-217, miR-218, miR-337, miR-494, and/or miR-98 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 48. The oncolytic virus of claim 47 for treating pancreatic cancer.
- 49. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive nuR target sequence is a target sequence for let-7a-3p, let-7c, miR-100, miR-101, miR-105, miR-124, miR128, miR-1296, miR-130b, miR-133a-l, miR-133a-2, miR-133b, miR-135a, miR-143, tniR-145, miR-146a, miR-154, miR-15a, miR-187, miR-188-5p, miR-199b, miR-200b, miR-203, miR-205, miR-212, miR-218, miR-221, miR-224, miR-23a, miR-23b, miR-25, miR-26a, nuR-26b, miR29b, miR-302a, miR-30a, miR-30b, miR-30c-l, miR-30c-2, miR-30d, miR-30e, miR-31, miR330, miR-331 -3p, miR-34a, miR-34b, miR-34c, miR-374b, miR-449a, miR-4723-5p, miR-497, miR-628-5p, miR-642a-5p, miR-765, and/or miR-940 inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 50. The oncolytic virus of claim 49 for treating prostate cancer.WO 2017/132552PCT/US2017/015417
- 51. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-101, miR-183, miR-204, miR-34a, miR-365b-3p, miR486-3p, and/or miR-532-5p inserted into the 5’ UTR or 3’ UTR of one or more viral genes required for viral replication.
- 52. The oncolytic virus of claim 51 for treating retinoblastoma.
- 53. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-143-3p, miR-133b, miR-1264, miR-448, miR-1298-5p, miR-490-5p, miR-I38-2-3p, miR-144-3p, miR-144-5p, miR-150-5p, miR-129-1-3p, miR-559, miR-l-3-p, miR-143-5p, miR-223-3p, miR-3943, miR-338-3p, miR-124-3p, miR-219a-5p, miR219a-2-3p, miR-451a, miR-142-5p, miR-Ι33a-3p, miR-145-5p, and/or miR-145-3p.
- 54. The oncolytic virus of claim 53 for treating glioblastoma.
- 55. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-143-3p, miR-223-3p, miR-6080, miR-208b-3p, miR-206, miR-133a-5p, miR-133b, miR-199a-5p, miR-199b-5p, miR-145-3p, miR-145-5p, miR-150-5p, miR-142-3p, miR-144-3p, miR-144-5p, miR-338-3p, miR-214-3p, miR-559, miR-133a-3p, miR l-3p, miR-126-3p, miR-142-5p, miR-451a, miR-199a-3p, and/or miR-199b-3p.
- 56. The oncolytic virus of claim 55 for treating head and neck cancer.
- 57. The oncolytic virus of any of claims 1-12, wherein the tumor-suppressive miR target sequence is a target sequence for miR-133b, miR-208b-3p, miR-6130, miR-141-5p, miR-31-3p, miR-1293, miR-129-2-3p, miR-129-5p, miR-124-3p, miR-219a-5p, miR-219a-2-3p, miR-4903p, miR-488-3p, miR-935, miR-124-5p, miR-122-3p, miR-122-5p, miR-l-3p, miR-133a-3p, miR-375, miR-141-3p, miR-31-5p, miR-205-5p, miR-200c-3p, and/or miR-203a-3p.
- 58. The oncolytic virus of claim 57 for treating a Schwannoma.279WO 2017/132552PCT/US2017/015417
- 59. A recombinant oncolytic virus comprising one or more of:(a) one or more tumor-suppressive micro-RNA (miR) target sequences inserted into a locus of one or more viral genes required for viral replication;(b) one or more polynucleotides encoding one or more proteins or oligonucleotides, wherein the proteins or oligonucleotides reduce the expression or inhibit the function of a miR, a gene, or a ΊΊΜΡ;(c) at least one protease-activated antibody; and/or (d) a polynucleotide encoding at least one protease activated antibody.
- 60. The oncolytic virus of claim 59, wherein the miR of (b) is an oncogenic miR or a microenvironment remodeling miR.
- 61. The oncolytic virus of claim 60, wherein the oncogenic miR is selected from the miRs listed in Table 4,
- 62. The oncolytic virus of claim 59, wherein the gene of (b) is an oncogenic gene.
- 63. The oncolytic virus of claim 62, wherein the oncogenic gene is selected from the genes listed in Table 7.
- 64. The oncolytic virus of claim 60, wherein the microenvironment remodeling miR is selected from the miRs listed in Table 5.
- 65. The oncolytic virus of claim 59, wherein the ΊΊΜΡ of (b) is selected from ΊΊΜΡ1, ΊΊΜΡ2, TIMP3 and ΊΊΜΡ4.
- 66. The oncolytic virus of claim 59, wherein the oligonucleotide of (b) is an shRN A or a decoy oligonucleotide.280WO 2017/132552PCT/US2017/015417
- 67. The oncolytic virus of claim 59, wherein the protein of (b) is a nuclease, a bispecific Tcell engager (BiTE), an anti-immunosuppressive protein, or an immunogenic antigen.
- 68. The oncolytic virus of claim 67, wherein the nuclease is selected from a Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR)-associated endonuclease, a zincfinger nuclease (ZFN) or a Transcription activator-like effector nuclease (TALEN).
- 69. The oncolytic virus of claim 68, wherein the CRISPR-associated endonuclease is selected from SpCas9, SpCas9-HFl, SpCas9-HF2, SpCas9-HF3, SpCas9-HF4, SaCas9, FnCpf, FnCas9, eSpCas9, C2C1, C2C3, Cpfl, Casl, CaslB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, CaslO, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, CsxI6, CsaX, Csx3, Csxl, Csxl5, Csfi, Csf2, Csfi, and ('ski
- 70. The oncolytic virus of claim 69, further comprising a heterologous polynucleotide encoding an tracr-RNA (trRNA) and a crispr-RNA (crRNA), wherein the crRNA is targeted to a genomic DNA sequence encoding a miR or a ΊΊΜΡ and wherein the trRNA facilitates binding and activation of a CRISPR-associated endonuclease
- 71. The oncolytic virus of claim 67, wherein the anti-immunosuppressive protein is an antiregulatory T-cell (Treg) protein or an anti-myeloid-derived suppressor cell (MDSC) protein.
- 72. The oncolytic virus of claim 67, wherein the anti-immunosuppressive protein is a VHHderived blocker or a VHH-derived BiTE.
- 73. The oncolytic virus of claim 59, wherein the protein of (b) induces an anti-tumor immune response.
- 74. The oncolytic virus of claim 73, wherein the protein is selected from EpCAM, folate, ΙΡΝβ, anti-CTLA-4, anti-PDl, A2A, anti-FGF2, anti-FGFR/FGFR2b, anti-SEMA4D, CCL5, CD137, CD200, CD38, CD44, CSF-1R, CXCL10, CXCL13, endothelin B Receptor, IL-12, IL281WO 2017/132552PCT/US2017/01541715, IL-2, IL-21, IL-35, ISRE7, LFA-1, NG2 (also known as SPEG4), a SMAD protein, STING,TGFp, andVCAMl.
- 75. The oncolytic virus of claim 59, wherein the at least one protease-activated antibody of (c) or (d) is incorporated into a viral glycoprotein envelope.
- 76. The oncolytic virus of claim 59 or 75, wherein the protease-activated antibody is activated by a protease selected from a cysteine cathepsin, an aspartic cathepsin, a kaliikrein (hK), a serine protease, a caspase, a matrix metalloproteinase (MMP), and a disintegrin metalloproteinase (ADAM).
- 77. The oncolytic virus of claim 76, wherein the protease is selected from cathepsin K, cathepsin B, cathepsin L, cathepsin E, cathepsin D, hKl, PSA (hK3), hKIO, hK15, uPA, uPAR, MMP-i, MM P-2. MMP-3, MMP-7, MMP-8, MMP-9. MMP-10, MMP-! 1, MMP-i 2. MMP-I 3, MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-I9, MMP-20, MMP-21, MMP-23A, MMP-25 B. MMP-24, MMP-25, MMP-26, MMP-27, MMP-28, or a protease listed in Table 6.
- 78. The oncolytic virus of claim 59 or 75, wherein the protease-activated antibody binds to a protein expressed more highly by a cancer cell or in a cancer microenvironment than by a noncancer ceil or in a non-cancer microenvironment.
- 79. The oncolytic virus of claim 78, wherein the protease-activated antibody binds NKG2D, c-met, HGFR, CDS, heparan sulfate, VSPG4 (also known as NG2), EGFR, EGFRvIII, CD 133, CXCR4, carcinoembryonic antigen (CEA), CLC-3, annexin II, human transferrin receptor, or
- 80. The oncolytic virus of any of claims 59-79, wherein the miR target sequence of (a), the one or more polynucleotides of (b), and/or or the one or more polynucleotides of (d) is inserted into a gene locus of the viral genome.282WO 2017/132552PCT/US2017/015417
- 81. The oncolytic virus of claim 80, wherein the virus is a herpes simplex virus and wherein the at least one polynucleotide is inserted into or between one or more viral gene loci selected from the group consisting of the internal repeat joint region (comprising one copy each of the diploid genes ICPO, ICP34.5, LAT, ICP4, and the ICP47 promoter), ICPO, LAT, UL1, UL5, 14.6. UL7, 14.8. (4.9. (4.11. UL12, UL14, UL15, (44 7. (4.18. UL19, UL20, 14.22. (4.25. UL26, UL26.5, UL27, UL28, UL29, 14.30. 14.31. UL32, UL33, UL34, UL35, UL36, UL37, 14.38. UL39, UL40, (4.42. (4.48. 14.49. UL52, UL53, (4.54. ICPO, ICP4, ICP22, ICP27, ICP47, gamma-34.5, US3, US4, USS, US6, US7, US8, US9, US10, US11, and US12.
- 82. A nucleic acid molecule encoding the oncolytic virus of any of the preceding claims.
- 83. A viral stock comprising the oncolytic virus of any of claims 1-81.
- 84. A composition comprising the oncolyti c virus of any of claims 1-81 and a pharmaceutically-acceptable carrier.
- 85. A method of killing a cancerous cell, comprising exposing the cancerous cell to the oncolytic virus of any of claims 1-81 or compositions thereof under conditions sufficient for the oncolytic virus to infect and replicate within said cancerous cell, and wherein replication of the oncolytic virus within the cancerous ceil results in ceil death.
- 86. The method of claim 85, wherein the cancerous ceil has a reduced expression of a tumorsuppressive miR capable of binding to the one or more tumor-suppressive miR-target sequences compared to the expression of the tumor-suppressive miR in a non-cancerous ceil.
- 87. The oncolytic virus of claim 86, wherein the expression level of the tumor-suppressive miR in the cancerous ceil is at least 5% less than the expression level the tumor-suppressive miR in the non-cancerous cell.WO 2017/132552PCT/US2017/015417
- 88. The method of any of claims 85-87, wherein replication of the oncoly tic virus is increased or maintained in cancerous cells with a reduced expression of the tumor-suppressive miR capable of binding to the one or more tumor-suppressive miR-target sequences.
- 89. The method of claim 88, wherein the viral replication is at least 5% greater in the cancerous cells compared to the viral replication in the non-cancerous cell.
- 90. The method of any of claims 85-89, wherein the ceil is in vivo.
- 91. The method of claim 90, wherein the cell is within a tumor.
- 92. A method of treating cancer in a subject in need thereof, comprising administering the oncolytic virus of any of claims 1-81 or compositions thereof to the subject.
- 93. The method of any one of claims 85-92, wherein the subject is a mouse, a rat, a rabbit, a cat, a dog, a horse, a non-human primate, or a human.
- 94. The method of claim 92 or 93, wherein the oncolytic virus or compositions thereof are administered intravenously, subcutaneously, intratumorally, intramuscularly, or intranasally,
- 95. The method of claim 92, wherein the cancer is selected from lung cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer, testicular cancer, colorectal cancer, colon cancer, pancreatic cancer, liver cancer, gastric cancer, head and neck cancer, thyroid cancer, malignant glioma, glioblastoma, melanoma, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL).
- 96. The method of claim 95, wherein the lung cancer is small cell lung cancer or non-small cell lung cancer.
- 97. The method of claim 96, wherein the liver cancer is hepatocellular carcinoma (HCC).284WO 2017/132552PCT/US2017/0154171/49 £X Λ<*>CMFIG. 1 ex. ex οχΓ6X.^ro ex, ea? / ex. ex ex exxo cm to l'j ex...... 1 ' ' ' vr>ex.«W o.co ex. ex .... , .... . _______ n , e\i un > un in ~ utj T- co e%J en co u.i Xj i V i I ΟΏ ! i CO i I J I i i TO TO TO CO |140 Φ Gd co kf5 CO O i-0 CO dE riM’t O *3 CO dS O ¢0 Cft d5 ¢0 Γό iXi kDCd <5j C\J C«j CO 00 GD I CN l·- CD Cd O-J #7 CM CG C--J -r~ CO CD Cd CO T~* T~ v“~ V“ f*v. v“~ τ~* t* f*v. CO rc v~ ft· r~ r~ r~ 0>J Cq T~ V“ C0 ρίώώρίώώιώώώώώώώώώώόίώϋϊρίέίίώίχρίέίΐ g see be ‘gl'g'g'g’gl ΏεκΠ bbe ebb ex.co χ. j.ED56573T.SehwanE D48237Ai A. S c hwanED485l3T.SchwanIJ87U373LJ251SNB19ED48701T.SchwanE3T179HE 1.93ED57224T.Schvi.fanH3103A172H4105GLi.82GBM3DGli.68HI 382E D48697T. S e hwa nX687sh _ED77WSTBrainED78879T. BrainED77785T. BrainED77458T Brain non-cancerous brain cancerWO 2017/132552PCT/US2017/0154172/49CX 65..CX6X. CX¢5,.ex¢5,.£X¢5,. CO GO 65.. CX 65..., fη Γ1'ί m wi m wi m r~. ' (.!«g.5 wi m2 ι < rs « ι « ι « ι « ι cew/ikro j · ι . . -QS .·ί£ΤΌ CO 05 Lp Os| CO 05 Lp Γ-~ τ- C0 CO ’Τ’ O 05 Φ co h-·* Ο-q ’ i Oq co go co 05 h- m cm co -ςΐ- v~ χ-- co CO CO -sy νγ· CM COCi5 CO ~<f O' ~<f O'CggCgEXCgggEXCgEXCgiiEXCgEXCgEXCgEXCgEXCgEXCgEX £: S' £: S' £: S' £: S' £: S' £: !θ S' £: S' £: S' £: S' £: S' £: S' £: S' fC « <0 « <0 « <0 « <0 « <0 05 « <0 « <0 « <0 « <0 « <0 « <0 «FIG. 2Mean, normalED62595T. NormalED77354T. NormalPrimary. Bladder. EpithelialX5637HT1197UM.UC3T.24SW.780RT4HTI376CC.SUPED57197T. NormalWO 2017/132552PCT/US2017/0154173/49CN O v CO Ν' c\J Oa. ex. ex sxCXCklCX kO 1-Λ CXCXCakO CX. 6XCX iZ) ‘•V'·?'·? tc /).>-«, MvV--?™ rl, f’Λϋκοτ-φβ» «sr~-':i «ni£5t<n(n4sei>^OC’-J-'-t.Z'tJ’.tXi'i-- v-f'JOO(''!'r-i.L»-n i Ov-’OOiNiOifs αΑώίΧίχάαίώώώώίχάάόίώώώίΧίχάάόί&ώΕΕΕΕεεεεΕΕΕΕεεεεεεΕΕεεεεε rtjrtssisAdsAnifflrtSiisiisAAAffirerettiffeAAAffirereMJ MJ W) WJ 1Λ ‘.0 dI—I fc0 8 ,z' '.'' ® /( /( /(/(,z' ,z' /’11111 ’>n >n ,nHs.578THCG.1395BT.549Primary Mammary EpitheliealBT 20HCG1W7HCC1599HCC.1806HCC1937DU4475HCC98HCG1143HCC70ED77944T. NormalED77711T. NormalED7S411T. NormalWO 2017/132552PCT/US2017/0154174/49
OO ? CM O £X ·% CX ex. . ex. ex. Cl i-Jta ex . Ci. ex. £X . CX. ex .ota ex. . CX Kt ex. ex. . ex. .ota co ex to CX. ex ., tn J. Ota y to tn ου WO Ota Ota Pta Wtta Ota Ota CR rn ck Wta m ra ct? 'sr hfj eh e\i r** cm Ota ew Ota ου tta’j m •9~- r*- Ota w> tn m Ota 04 Ota to r--~ <Sta CG! Ota M- CM Ota V m O'J tita CM Ota ’i Gta Ota ώ ου X o' ·*# c-ta ¢74 *7 CM X γγ x □: Cl' X ώ os Ωί ώ O' X X ω: Ci/. ώ Ωί cc ώ Ω' □£ X Ω' X ώ g g £ E g £ E g £ E g g & g & E g g ?*- £7. g E g g g g ck fk da ck fk 4, ck da ck ck da da ck lk m ck da ck ck ro ck fk lk ck fk tf! cn LO tf! cn ϊΛ tf! cn to to cn to cn if) tn to tf! cn co ου cn cn • fi cn ./.7. .s:: Λ7. ./.7 .s:: .A .£:: ?;. ./.7 r- ¢.7 ,.t. .£7 .SS -ffi .SS -ffi 4K FIG. 4ED78495TED77609TED77780TT84SNLJ.C1SW948SWFI16LoVoSWB37LS.123SK.C0.1 cancer Non-cancerous colonWO 2017/132552PCT/US2017/0154175/49 ex. >Zx. ex. ex CXuD CM1-C, CD U>‘i CD cm sx , ί-’Ί sx ex. ud ex · 7 tx--7 ex new .. ...n- CD CN CM '2D CD i.jD CM CM CD teO £XCDCi? r CXCXCD CX CA.eft eta cb 'V re S* Φ «ϊτ tw -rer CD a™ CM CD W udM- CD CSJ v kiD -v#· CD go ---)- - i- η i - f CD r i γ r f re raCD Cft o ¢30 O >2D CD *?r ¢57- z^STCD w;j· GO 0D ¢55 M CM '2D CD i.jD CM CSI ¢37- i.jD ,J *># M- CD CM .. .£-.,j ¢3-, y~~ ~r~ ν·~ ·*— CD ar- C\| CM iXCt/AcXfXCt/AiyiXCXCXtXAcxAcXiXCXlXiVfXiyiXCi/iX...............ε'εΐζ'Ζεΐζ'εΈ'ε <s at ., .... TTg^£^e?E?£t........, .,.. ., .,............., ...MfiatbrtSfkffisfertiibfisAttittaAittsAisisffiitbrtSfkffisfertiA m c'j A ivi in (ij w Μ w ro » A A tri (A tri A A A A A A A A A 'i 'i'i 9,MD oH-l fcED771Q9TED76S79TED774SSTED77765T cancer non-cancerous brainWO 2017/132552PCT/US2017/0154176/49 , ci. ex ci. ex exCO CO 1,0 CO COCM OCO CM O £3, Cl. l”7CO iy-; &3 *8f CM O r- 02 ώ ώ ώCl.co da ci.W) ci. sx.i.-d co ex ci. ι cis ,χ'ά pc: ,&17 £1.CO1.SX. ex CO co ex ci. co co ce era ' ·' VV ce ftl JZi co t.sa co co i.7't wu u.c.i ι,η cm O' A't *za Ό· «·) CO ιΧΧώ CM o- &jΟ O CO CO ers CO *if W ·Ό *:? *8f -*3' co T- c.O CO ς / ζχ| *if- ur? eftC\l CM v-1- •'Τ'-'- v—' τ^· '»^· t^· v^· CO CM CO 're- 'ref· re1· τ^· oc rk rk rk rk rk ck cf. rd rk cd rk ok cd rk rk rk rk rk cd td. rdM fli. Mi. Mi Mt. /jj jM Xv gM fM Mi fM Mi fM Μι Μι Μ Μι Μι. Μι -M Mi Ml Mi c e c: r κ e c b c L b c d t: c κ t- h e c e c e b b stsffiiffisfertiibfflAttittafisrtaAiseffiitbsfertiibfflAttiffefistts os w in in tn tn tn tn tn tn w tn tn tn w tn tn tn tn tn tn tn tn tn tn .t~.:::..}::. .s::.s:: .jet: .s:: .x x:: .s.: x:: .s:: .<:: .::: .·;:: .s: .::: .s: ±7. .·::: ,x: .::: .£ ,e dM fcED68145TED53661TED49197TED77051TED56893TED53659TΑΞ53FaDuDetroit.S62 seesSCC. 15 sec.25Tongue Esophagus TongueQJU cro uWO 2017/132552PCT/US2017/0154177/49 oCX.Cl·. -CX. eX Cl·. CX. Obi7 Cl·, ex.COlzi'JtaDt'O6XCXXX.Cii’’· rocow.·:ex. CXXX.CLCXeUn CO ‘''J iXCX } A, ,Α, ,,vM II '-.1 t'raizJ JM .Ii' J. f'j ,.1.(01,.0As) (tjrXJ CVl i | I i' I I I (Γ5 i I 'Ο£.ί.·.>.'.ΗΛ.Ίΐ'<'·ζ.Ό·ί--·ζ'<'·ί'«··Κ.·νΐι.·ΎΊ(.'''-’.-”ί.'-ζ|·^UVN’4 W^-r·-·· x—CTWtwtf· ά'ώάά' ώώώώώώ ώώβ'ώώβ' άιΈχ/'ά fts. SSS ,,. fts. Μ fSS. SSJ jts. fSS. zn f'J i-· f· (* Z*·*' Z f· <» Z jZ*. V· f· Z Z*- (-*·* £ fc fc & ts. iz K ts. iz a. κ fc fc ·::. fc e; fc: fc e; ts. iz e: e fc fc ώΑήίώώώώιΜίΙίέΒώΜίβώώΜίόΑρΒώώώώώώ cn m tn cn tn ra, ra tn ra ra ra tn cn ra tn ra tn ra ra tn ra cn ra tn cnFIG. 7NCI.H197SBBAS.2BNCI.NCI,NCI.NCI.NCI.NCI.A949Lung. FibroblastsED78364T. NormalED77757T, NormalED7S750T. NormalHI 573HI 437H661H1299H2126H1563 non-cancerous lung cancerWO 2017/132552PCT/US2017/0154178/49CM •*r~ τ~ CO crrt xrpCMSX Ci, a. CL Ci, ex. ex a. ex. ex. ¢0 CL ex. Cl £XCG « ’ z 1 ClCG 0-) Lft CG l£? ex. £X ex.LG UG A CG fG lG Up Λ r** CM Cl CG 0-) rts jA Ja A A «5 CG tA 0-) up xS A co rn tn *:J· CM tG o <A i·-— <5Ί Φ i# Φ CG r-~ CM LC) en cG eh rer Yj- r-~. T rn CG Ή* «Ί CG cm CM Gfs cSj Tf~ T“ v v**· LG re? Gj* c5-j dn CG AJ AJ U') *7 fc ’u T~ v~- T~ Cm CM fc AJ CM fc V ία V T~ fc fc fc eg fc fc eg fc fc fc QC Eg Cg fc eg fc eg fc fc IX fc fc Έ @ g Έ @ g Έ E g £ E g & Έ g g Έ g Έ g g E g g A A A A A A A A A A A A A A A A A A A A A A A A A A to A A to ¢0 vi to to iff to to its tn to A A to A A to A A to A XL- xc ς™ JZ xc XL je XL- XL -XL .X.. XL -XL X.. ς™ XL. xl -XL -XL .X.. .XL -XL XL- XL dI—I fcHPAF.11CFPAC.1AsPc.1Pane.10.05CAP AN. 2BxPc.3SW1090EP78376TED68709TED77108T non-cancerous pancreas cancerWO 2017/132552PCT/US2017/0154179/49 ex. ex iX, £y*-i ζ<·ιΓ0 ClkCl ' . X irt ι U ra ’“.ί I iAt n^r.Cl.£?. ,&) £3CJ, era £J,l<? Cl.Cl. ftU-Ω G'-j Cx Cl. CX Cl. Cl. &Ϊ...... ............... J.reArS. rivi V.J i' fvMjCrl i I ' i Ctl CH Γ ’ | 1( ( ZW TO i' ι ja·. j kJ CH cr, co cn ΐ- i c6 cr> w;j: eft φ ό c<? m < t\i 6j cd *- v uo ό ex <m O r- V- C-.J CN i>J CN T- T- Cft O“i CO GJ GJ GJ.GjN Μ- Ο Ο O v- <Sj t£> t~ CX τ~ τ~· v~ Cr-jsj C\| <3ft v* v~ v*· τ~ τ~· ¢0 τ~ CX C-J C\J £\) ά ce ώ pc ά ώ cfe eh & & pc cc pi cc cc ώ ά. pc ce ώ pc cc ώ ώ pc ε ε ε’Ε SEES εεΕεε’Ε εεεΕ ε ε’Ε SEE E (is ώ re ά A m A re ra ns A A re A A sa (is A A A ά A re ά ea oi U) tn til in ii> Wi ι ϋ ίή in til in tn til tn tn tn m mi in til in tn tti in jrr ,rr jg? .z* ,rr xp. .g* ,.cr x?. xy. .c? ,rr x?. .cr ,.cr -Z ,-rr .z ,rr jg? ~z ,rr .z .g* /«FIG. 9E D48897T. S c h wa π n o iii aED48237A1 A. S c hwa rt no m aED28220A1Q.BM Lung. Fibroblast ED56573T. SchwannomaSchwannomaE D48701T. S c h wa π n o rri aED57224T. S e hwa nn o m a ED57197T.Esophagus •|| ED56S93T. E § op h a g us ED68482T. Liver j|ED07434T. Liver ED49197T. E s 0pha g us ED77609T. ColonED77W8T. Pancress ED76750T.Lung ED88145T.T o rig ue ED53661T. Tongue ED77711T, Breast ED53659T.T ongue Bladder. Epithelial Mammary. Epithelieal ED77109T. BrainED76879T. BrainED77765T, BrainED77458T. BrainAll non-Schwannoma = non-cancerous tissue BM = non-cancerous bone marrowWO 2017/132552PCT/US2017/01541710/49miR-451a CA 21.1 3.9 22.0 16.7 10.3 10.5 13.3 Norm 1402.9 2262.1 3606.9 4269.7 11919.8 31442.0 1035.8 Tissue Bladder Breast Colon Glioma N Έ H Lung Pancreatic WO 2017/132552PCT/US2017/01541711/49miR-1 CA 00 • o 0.3 CD • 1 o • 1 CD c\i • 1 • o Norm 175.0 3.0 149.3 75.2 2846.6 73.3 4.1 Tissue Bladder Breast Colon Glioma Η & N Lung Pancreatic WO 2017/132552PCT/US2017/01541712/49miR-559 CA • o 6Ό τ—1 c\i • o CM cm’ τ—1 • o LO • o Norm 14.0 00 00 00 • o 162.7 71.2 548.3 13.3 Tissue Bladder Breast Colon Glioma H&N Lung Pancreatic WO 2017/132552PCT/US2017/01541713/49145-5p CA 39.8 106.6 LH • o CM • 30.4 1.0 LH • o Norm 971.5 406.1 1177.3 2399.2 6Ό69 1547.5 81.7 Tissue Bladder Breast Colon Glioma Η & N Lung Pancreatic WO 2017/132552PCT/US2017/01541714/49FIG. 14miR-143-3p Η & N counts 144.5 214.2 123445.7 242.2 54.6 136.4 FaDu SCC-15 SCC-25 SCC9 A253 Detroit- 562 miR-143-3p Breast counts 132.1 20.1 503387.3 39.7 1011.5 4737.7 1858.7 33.2 21.9 174.9 495642.8 46.9 BT-549 DU4475 HCC-1395 HCC-1806 HCC1143 HCC1187 HCC1599 HCC1937 HCC38 HCC70 HS-578T BT-20 CA 14904.6 91543.1* 193.9 1248.6 20706.2 390.9 269.8 00 σ> ID 00 r\i 00 o Q. 00 rn uS ID l< on r\i un τ—1 m m un E O σ> on τ—1 o τ—1 un m σ> un on τ—1 ID un 00 r\i o τ—1 m m r\i τ—1 o τ—1 un un m +-» ilioma ro issue ladde reast olon N V ung Φ <_> c ro 1- co co u ο X 1 CL WO 2017/132552PCT/US2017/01541715/49 τWO 2017/132552PCT/US2017/01541716/49 coQJCLLLO ~aQJ coTOQJL_ uQJQTO uc co co coQJL_ΩΧQJM ’+->uTOΓΝΓΝOCECL = iITOM «Ν vi hfS «O’ mSOWO 2017/132552PCT/US2017/01541717/49co rH H CC fe /-- <N O _1 j— 1— Π3 rc H 03 fe c- ΓΝ φ rH _ί H H ΟΟΗ-1 feΓΝ A3 c- -4-J ...J H H ro fe ro fe fe feiCNCircled wells indicate reduced GFP expression levelsC\i fe ro <··-.! 00 fe T’*! m roItjWO 2017/132552PCT/US2017/01541718/49OO oI—I fc<& fc CU fc fc «Μ fc Qi Λ fc fc rs efi fc fS fc fc fc CU x-ti <w3 fc fc CU fc fc fc <a fc fc woo?fS mos vi fS mWO 2017/132552PCT/US2017/01541719/49Circled wells indicate reduced GFP expression levels>- CL £X cl CL Q. CX X X X X X o il t LU LU ω ill A ΓΜ tn σ> τ~) Lu CM cn LO O τ'Ή t-j WO 2017/132552PCT/US2017/01541720/49CL CL cl CL Cm X X X X O il t LU LU ω ft ΓΜ tn σ> Lj.. ΓΜ CM CTt o τ'Ή rH r~i 451 ExpWO 2017/132552PCT/US2017/01541721/49c o C o ω 'ω ω ω φ CD Ω- Ω- Χ Χ Lll LJ CN CN oo T- ά ά. Ajisuejui |Βΐοι dd9WO 2017/132552PCT/US2017/01541722/49C ο Ω ο 'ω 'ω CZ) ω φ φ Ω- Ω- Χ Χ LU LLI (ϋ Ν’ οο CO τ— ά ά Ε 'ΕΓΝΓΝ ϋΗ-1 fcWO 2017/132552PCT/US2017/01541723/49ΓΏΓΝ ϋΗ-1 fcI co £φ cο ωωΕΩΧC oω ω ω Q_ LJJ χLJJ ro to;ΦΝ’I 'ΕCO CM τ(suoiiHifli ui) /tysuauii |Β}οχ ddOWO 2017/132552PCT/US2017/01541724/49ΟCZ)CZ)9?Q.XLU coCZ)CZ)CDCLXLLICN 00 /tysuaiui |B)oi dd9WO 2017/132552PCT/US2017/01541725/49WO 2017/132552PCT/US2017/01541726/49 ωωΩΧLU cΟ 'co ωsΩΧLUΟ τΟ LO ά £E 'EGOCNOI—I fc σ>σ>Ajisuejui |B)oi dd9WO 2017/132552PCT/US2017/01541727/49c o 'ω w φ ο. X LU c o 'w w Φ i_ Ο- χ LU Lf> T— CN LO t— N ά or E Έ yqisuaiui |B)Oi dd9WO 2017/132552PCT/US2017/01541728/49c o c o ω '</) ω ω 2 Φ Ω- Ω- Χ Χ LU LU CD T— Cxi LO ώ ώ E E Aiisuajui |B»oi ddSWO 2017/132552PCT/US2017/01541729/49c o c o co ω ω ω 2 2 Ω- Ω- Χ Χ LJJ LU τ— CM LO x- ά ά E E Ajisuejui |B»oi dd9WO 2017/132552PCT/US2017/01541730/49133-451c o c o ω w ω ω Ε £ Ο- Ω- Χ Χ LU LU CO T— co ΙΌ ώ Ε ΕAjisuejui leioj. ddOWO 2017/132552PCT/US2017/01541731/49Ω Ω Ο Ο to co co to φ φ Ω. Ω.223-451CO τCN LO CM ώ [£ Ε ΕAjisuejui |B)oi dd9WO 2017/132552PCT/US2017/01541732/49FIG. 32W 00009 OS < z ex Kieeee E «e ex u 124 124 124 124 124 124 124 124 124 124 124 124 124 ΓΜ τ-1 φ W Kieeee ex S»00C E rx QJ , 34a, Let7 a-5p ex co ex up a-5p Ο a-3p ex op TO ex op a-3p _Q ex m ex u c o ΓΜ ΓΜ LD ΓΜ 43 45 66 m 33 23 51 26 rx ΓΜ 33 m tH ΓΜ «μ m o tH ΓΜ m LD rx 00 σι o ΓΜ u o τΗ ΓΜ ΓΜ ΓΜ □ o o o o o o o o o o o O O O Vxx I I I I I I I I I I I I I I ex ex ex ex ex ex ex ex ex ex ex ex ex ex o o o o o o o o o o o o o o o 2 2 2 2 2 2 2 2 2 2 2 2 2 2 u O O O O O O O O O O O O O O WO 2017/132552PCT/US2017/01541733/49FIG. 33CM E o o V <100 (8 CM o o o ££ o o cn r“I E Λ V M < C u Ξ5 z; a? Σ o3 u CL· X _ω ωο φοCOΟ οΰ co ιηCMS|PO OAWSOd ddO03 vs < Σ E r»·. CM a. y None tn CM ?Ή i c£ Έ φ «ΐί % < Z £ CM CM crH £L j c£ } ££ U E c cn tH o ?Ή o o Sx» J } as az u U & z Z > o o □) υ+->ο +->εI +->ω οο_S|po eAiiisod dd9WO 2017/132552PCT/US2017/01541734/49FIG. 34«$· CM vi ££ E o o V <100 (8 co CM o o o ££ o o co r“I E Λ V M < C u Ξ5 z as Σ o3 u CL· X O oo oo oo oco-I-i—I o o o o o o o oCM ΤΙ-1-1-1o o o o o o o o o o m o mCM T— T—as vs < Σ E r»·. fM a. y None LT! CM i c£ Έ as «ΐί Ίλ < Z ££ «a- 24 rt CM ?Ή J—« £L j c£ } ££ U E c co tH o ?Ή o o Sx» 1 } o £T CZ u u & z > o O □)Q_ co ooCE ozOOI oc uz oii saidop acuouagWO 2017/132552PCT/US2017/01541735/49FIG. 35S||93 aApisod d=IE>WO 2017/132552PCT/US2017/01541736/49FIG. 36in & 3 © U < Σ E o 4487 ίΛ ro 1395 s.n © fN u u < X © Ίλ < Σ £ 8**> O, U CL s.n t LTi «st s C£ © < z 0£ fe E CN xH a. ί ££ u E m o 6 © ac ts © u z: > O Γ oo o—I-1-1— o o o o o o o o oCD Tt CM seidoo euiouegWO 2017/132552PCT/US2017/01541737/49FIG. 37Φ < & E CM a u None m sR-143-3 p q_ in t ra σι σι rS t a E φ *»> < Z a vt g: CM CM CM tH a 1 C£ 1 C£ 1 C£ u s E E m CM ’s#' o r“I o o o 1 1 1 © a a a t3 u u u z. z > O O O D)QQCM ιω <LUQQ oo o o CO CNSIPO eAi)!SOd dJ9WO 2017/132552PCT/US2017/01541738/49FIG. 38Φ < & E 04 a u None m sR-143-3 p q_ tn t ra σι σ·ι rS t a E φ *»> < Z a g: r\f ΓΜ r\f tH tH a j C£ ί C£ l C£ u s E E m Oi ’s#' o r“I o o o I I I © a a a t3 u u u z. z > O O O OQCNI ω(0 φCDm o o ΓΝ t—1 o t—1 o cd cd cd o u u u o O O O o oo oio oo oo oo oioSaidCQ 91UOU90WO 2017/132552PCT/US2017/01541739/49ICP27 ICP4:TmiRNA UL19WO 2017/132552PCT/US2017/01541740/49 gB:NT: virus entry-enhancing double mutation in gB geneICP27:TmiRNA ICP4 UL19WO 2017/132552PCT/US2017/01541741/49 gB:NT: virus entry-enhancing double mutation in gB gene coQJICP27 ICP4 UL19:TmiRNAWO 2017/132552PCT/US2017/01541742/49ICP27:TmiRNA ICP4 UL19:TmiRNAWO 2017/132552PCT/US2017/01541743/49ICP27 ICP4:TmiRNA UL19:TmiRNAWO 2017/132552PCT/US2017/01541744/49ICP27:TmiRNA ICP4:TmiRNA UL19:TmiRNA gB:NT: virus entry-enhancing double mutation in gB geneWO 2017/132552PCT/US2017/01541745/49QCQLDΓΝIQCQC ’xl οΗ-1 feQJCQJ ΰβ ΰβCC οΕ ω_ΩΟΟ ΰβC '(_)CΠ3-£=CQJ ι>>UlQJ (JCQJCTQJ ui rxi o_ro cΠ3QJ (JCΠ3 +->LC uiQJO ucQJ i=CLEΠ3 oCQJUl i_ >(JDQJ-ZC roΜιΩΧΟQQM u<QQQJCQJCUOΟυQJ o>>CL o(JQJ co bfl .cT3 (J .c co bflQJΠ3QJCLQJΠ3CQJCLE ooQJ _QJQJC o<* >GOΠ3 coIQC >Π3QJ σ?LCΠ3UCQJQCDQJGJΠ3 bflQJ LD ui c QJ GJ C QJ 3CT CL QJ +->QJ > bfl ro ω E <ZQCUlQJCLCLUl >ΩQC bflQJGJQJCLUlI ωGJCL uCOLCΠ3QJCQJ bflΩUQJ ui .C <ZQCEH άίΩUSZ (27Ω.bfl c'c 'roEQJ i_QJ-C +->M—OQC coQJ-C +->o +->cU _Q (27 <CJQJ >uiC ouQJ oε oία.LD — ot—I ΩcnLCΠ3 uΠ3GO σ?LCΠ3U clGO ώQJQJ lcΠ3 _QJGJ aa oa aQJ aQJ +->ro uOUlUlΠ3QCΩLOQCUQJΙΛTO _qj aa oT5 azc (27 _Q ώqj ro abfl ao ’+->_ro >>aQJ aro >oCL <_>oΩ- loxP AJoint ICP4:TmiRNAWO 2017/132552PCT/US2017/01541746/49 ’xl ϋI—I fcQJCQJ tan tan cc o+->Π3 +->EQJ _QO tan c'u cΠ3-C cQJ uaQJ (_)CQJCTQJ ua rxiLJ _roD cΠ3QJ (_)CΠ3 uaQJ cQJ uaO u'cQJ-CCLEΠ3 o-CLJDQJ _az cΠ3ΩΧO • zS OQ < taO 00QJCQJ tan ουQJLH T-1 T-1 (N (N 1 1 Q_ OC C£ E d LO E r< T-1 1- t-1 Q_ < ΓΝ T-1 cL or 1 OC E 1- E E lap lap 1- qj QJ T-1 ·*—* cdΠ3 coICdQJ >>CL oLJQJ co tan .cT3 _3 (_) .C co ‘tanQJΠ3QJCLQJ ro cQJ +->.CQJ +->0JCLE oοQJC o’+->_0JQJD i*C o<* >GO >Π3 (_) +->QJ a?uaΠ3UC laO _ dj Cd ua _) QJ ω ld c QJ- £ +j — QJ CL £? QJ Π3 -Q <ZCd >ΩCd0ΩQJCL uCC M= ~ GJ QJ CL ua >>Π3QJGJ az ωΩo ua QJ ua c QJ QJQ. “ CL3 CL ua U O laO ε .εZS C .4-1 Π3 u-Q ω<cjQJ >QJ i_QJQJ * uaSZ O Cd ε s>Ω.U C ua coUQJ +->o εo ία.o _ oΩ.cn uaΠ3UΠ3GO a?uaΠ3U clGO tapQJQJ ua fO _0JGJ aa oa aQJ aQJ +->ro 'ljO ua uaTOCdCl.lOCdUQJΙΛ (0 _qj (J coT5 cCd oλ_LJELJ 'cQJ tan oο co o+->DQJ +->QJ tanΠ3 +-><ZCd λ_LJ <ZCd oSoΓΝIOCEΠΊIOCE lapQJCdQ zc ωQ lapQJ ro ctap 'ua co ’+->_ro >>cQJDΠ3 >OCL <_>oΩ.cd οICdCl· co 'uaM— <ZCdCd λ_LJ _0J tan cGO.. LO T-ι LO < ΪZ Cd oc c (ao EOCE tan cωDOEQJ cωE co λ_ >cQJ oλ_LJE o+->DQJ +->QJ tanΠ3 +-><ZOC λ_LJ (N <zCd (ao i°xp AJoint ICP4:TmiRNAWO 2017/132552PCT/US2017/01541747/49 gB:NT loxP BAC loxf> AJointICP27:TmiRNA ICP4:TmiRNAWO 2017/132552PCT/US2017/01541748/49 fe οI—I feQJCQJ tan tan .c co +J ro-t->EQJ _QOΌ tan inQJ (JCQJCTQJ in rxi (J roΌ croQJ (J cro-t->in 'inQJO u'cQJQJ _Q >>roE oin roQJ cQJ tan ου tan c© ;E qj ro lac E fe oQ_ sCJ QJQJ Έ >>CL o(JQJC otan cT3 (JCC o‘tanQJ roQJCLQJ i_ ro ci_QJ-t->CQJ-t->QJCLOCC mQJ-C-t->O-t->.cQJ-t->-t->QJ in in ro οQJ (JCQJCTQJ in-t->QJ tan l_ ro-t->ΓΜIOCΟυQJ ooc mQJ-C-t->O-t->.c inQJ-t->-t->QJ in in ro οQJ (JCQJCTQJ in-t->QJ tan l_ ro-t->cnLT)LT)IOCEΌC roCLLT)ILH feT-I IQCE ro”LT)IOCE ocCMOCECLO cr>LDLD cL·EI— CL Ε Μ— Μ— Ο C E ο Ο C ro ro ο C ο c O QJ ο +J c QJ JO (J -C Ί-> +J ι_ ι_ QJ 1 Μ— QJ ιη >* Ό Ο ιη ,__. .C -t-> C QJ QJ L4 C ro C ο +J .C < 0C Η Σ3 < Ζ in 3 l_ > Μ- ι Ω- Χ ο QJ QJ Ό Ζ 0C Ε LD .C 0C Έ Η h— Z ϋ < 00 +3 .C Η τί Ό QJ Ο ι< ΓΜ ώ tafl 'δ < Ω- υ ro CL Ω- υ LD .cΌQJ (J roQ.LDLH t—I cL·E ro t—I LD2 CL QJ JO >~ roO in roQJ cQJ tan r*.ΓΜΓΜCLO gB:NT loxP BAC loxP AJointICP27:TmiRNA ICP4:TmiRNAWO 2017/132552PCT/US2017/01541749/49 gB:NT loxP BAC loxf> AJointICP27:TmiRNA ICP4:TmiRNA
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662287619P | 2016-01-27 | 2016-01-27 | |
US62/287,619 | 2016-01-27 | ||
PCT/US2017/015417 WO2017132552A1 (en) | 2016-01-27 | 2017-01-27 | Oncolytic viral vectors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2017212713A1 true AU2017212713A1 (en) | 2018-07-26 |
AU2017212713B2 AU2017212713B2 (en) | 2023-01-19 |
Family
ID=57995301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017212713A Expired - Fee Related AU2017212713B2 (en) | 2016-01-27 | 2017-01-27 | Oncolytic viral vectors and uses thereof |
Country Status (18)
Country | Link |
---|---|
US (3) | US10391132B2 (en) |
EP (2) | EP4089166A1 (en) |
JP (4) | JP2019508063A (en) |
KR (1) | KR20180136435A (en) |
CN (2) | CN108884448B (en) |
AR (1) | AR107469A1 (en) |
AU (1) | AU2017212713B2 (en) |
BR (1) | BR112018015390A2 (en) |
CA (1) | CA3011933A1 (en) |
DK (1) | DK3408382T3 (en) |
ES (1) | ES2919953T3 (en) |
IL (2) | IL260790B (en) |
MX (1) | MX2018009126A (en) |
PT (1) | PT3408382T (en) |
RU (2) | RU2021114137A (en) |
SG (2) | SG10202107138TA (en) |
TW (1) | TWI798168B (en) |
WO (1) | WO2017132552A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108884448B (en) | 2016-01-27 | 2022-12-30 | 昂克诺斯公司 | Oncolytic viral vectors and uses thereof |
AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
US10682425B2 (en) * | 2016-12-14 | 2020-06-16 | The Regents Of The University Of California | Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them |
EP3594329A4 (en) * | 2017-04-19 | 2021-02-24 | The University Of Tokyo | Genetically engineered coxsackievirus, and pharmaceutical composition |
CN110546263B (en) * | 2017-04-28 | 2024-03-05 | 东丽株式会社 | Kit, device and method for detecting ovarian tumor |
EP3658165A4 (en) * | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
CN111065732A (en) | 2017-09-11 | 2020-04-24 | Imba-莫利库尔生物技术研究所 | Tumor organoid model |
TWI666321B (en) * | 2017-10-23 | 2019-07-21 | 大陸商深圳市亦諾微醫藥科技有限公司 | Construction of oncolytic herpes simplex viruses (ohsv) obligate vector and constructs for cancer therapy |
CN107723367A (en) * | 2017-10-27 | 2018-02-23 | 青岛大学 | The 3p of miRNA 885 application and apply its product |
CN107674918A (en) * | 2017-11-10 | 2018-02-09 | 上海交通大学医学院 | Applications of the 5p of has mir 195 as biomarker in pulmonary cancer diagnosis kit is prepared |
WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
EP3755344A1 (en) | 2018-02-19 | 2020-12-30 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
CA3096938A1 (en) | 2018-04-10 | 2019-10-17 | Ottawa Hospital Research Institute | Microrna-based compositions and methods used in disease treatment |
MA52542A (en) * | 2018-04-13 | 2021-02-24 | Bluebird Bio Inc | ADOPTIVE CELL THERAPY |
CN108707625B (en) * | 2018-07-03 | 2021-09-21 | 云笛生物科技有限公司 | mir-124 and HER2-shRNA double-gene expression cassette virus vector, construction method, virus and application |
CN109091492A (en) * | 2018-08-02 | 2018-12-28 | 广州安镝声生物医药科技有限公司 | The target miRNA miR-106b-5p of lncRNA H19 and its application |
CN109091491A (en) * | 2018-08-02 | 2018-12-28 | 广州安镝声生物医药科技有限公司 | The target miRNA miR19a-3p of lncRNA H19 and its application |
CN111117973A (en) * | 2018-10-30 | 2020-05-08 | 中国科学院武汉病毒研究所 | Recombinant oncolytic enterovirus 71 regulated and controlled by microRNA and application thereof |
WO2020102285A1 (en) * | 2018-11-13 | 2020-05-22 | Oncorus, Inc. | Encapsulated polynucleotides and methods of use |
TWI690597B (en) * | 2018-11-14 | 2020-04-11 | 國立中央大學 | Detection kit and detection method for urothelial carcinoma |
KR20210098483A (en) * | 2018-11-29 | 2021-08-10 | 바이로진 바이오테크 캐나다 리미티드 | HSV vector with reduced neurotoxicity |
KR20200069259A (en) * | 2018-12-06 | 2020-06-16 | 국립암센터 | A composition for promoting oncolytic virus activity or enhancing virus production comprising nc886 |
CN113453699A (en) * | 2019-01-04 | 2021-09-28 | 昂克诺斯公司 | Encapsulated RNA polynucleotides and methods of use |
CN109762903B (en) * | 2019-01-31 | 2022-02-01 | 山东大学齐鲁医院 | Application of miR-1246 and/or TERF2IP in diagnosis and treatment of glioma |
CN110283794B (en) * | 2019-05-30 | 2021-04-23 | 伍泽堂 | Recombinant oncolytic virus, preparation method, application and medicament thereof |
CN112011570B (en) * | 2019-05-31 | 2023-04-18 | 北京合生基因科技有限公司 | Oncolytic virus system for specifically killing tumor cells and application thereof |
JP2022541197A (en) * | 2019-07-16 | 2022-09-22 | ユニヴェルシテ・コート・ダジュール | Methods of assessing susceptibility or resistance of a subject to oncolytic viruses, recombinant viruses, their preparation and use |
CA3150053A1 (en) * | 2019-08-05 | 2021-02-11 | Virogin Biotech Canada Ltd | Genetically modified enterovirus vectors |
CN110468132B (en) * | 2019-08-15 | 2022-11-25 | 西南大学 | sgRNA, transgenic expression vector, expression strain and screening method |
CN110433171B (en) * | 2019-08-20 | 2022-08-19 | 中山大学附属第六医院 | Application of miRNA-1293 in preparation of anti-colorectal tumor medicine |
US20220380735A1 (en) | 2019-10-10 | 2022-12-01 | Oncorus, Inc. | Dual viruses and dual oncolytic viruses and methods of treatment |
KR102320430B1 (en) * | 2020-01-29 | 2021-11-03 | 서울대학교병원 | Use of miR-135b, miR-135a and their target gene AMOTL2 for medulloblastoma |
CA3179339A1 (en) * | 2020-04-14 | 2021-10-21 | Eidgenossische Technische Hochschule Zurich | Cell classifier circuits and methods of use thereof |
CN113583977A (en) * | 2020-04-30 | 2021-11-02 | 杭州康万达医药科技有限公司 | Isolated recombinant oncolytic poxvirus regulated by microRNA and application thereof |
CN115066261A (en) * | 2020-06-05 | 2022-09-16 | 上海宝济药业有限公司 | Pharmaceutical composition of enzyme and virus and application thereof |
BR112023001563A2 (en) | 2020-07-31 | 2023-10-10 | Combined Therapeutics Inc | COMPOSITIONS AND METHODS FOR IMPROVED VACCINATION |
WO2022100898A1 (en) * | 2020-11-13 | 2022-05-19 | Technische Universität Berlin | Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas |
CN116744951A (en) * | 2020-12-25 | 2023-09-12 | 苏州系统医学研究所 | Composition containing oncolytic virus and application thereof in tumor treatment |
WO2023034867A1 (en) * | 2021-08-31 | 2023-03-09 | Oncorus, Inc. | Engineered oncolytic herpesviruses |
CN113637761A (en) * | 2021-10-15 | 2021-11-12 | 北京百奥思科生物医学技术有限公司 | MiRNA marker for diagnosing and treating melanoma and related product thereof |
WO2023142040A1 (en) * | 2022-01-29 | 2023-08-03 | Virogin Biotech Canada Ltd. | Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors |
CN115381849A (en) * | 2022-06-27 | 2022-11-25 | 浙江大学 | Active component of anti-oral tumor medicine and application thereof |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5244792A (en) | 1984-04-06 | 1993-09-14 | Chiron Corporation | Expression of recombinant glyoprotein B from herpes simplex virus |
JPH0668B2 (en) | 1985-08-30 | 1994-01-05 | 財団法人化学及血清療法研究所 | Recombinant plasmid with herpes simplex virus gene |
GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
US5849571A (en) | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5849572A (en) | 1990-10-10 | 1998-12-15 | Regents Of The University Of Michigan | HSV-1 vector containing a lat promoter |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
US5879934A (en) | 1992-07-31 | 1999-03-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
GB9415369D0 (en) | 1994-07-29 | 1994-09-21 | Lynxvale Ltd | Mutant virus |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US6261552B1 (en) | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
US6071742A (en) | 1997-03-05 | 2000-06-06 | Board Of Regents Of The University Of Nebraska | Coxsackie virus as a vector for delivery of anti-inflammatory cytokines |
US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
WO1999006583A1 (en) | 1997-07-31 | 1999-02-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
ES2251120T3 (en) | 1997-12-17 | 2006-04-16 | Immunex Corporation | CELLULAR SURFACE GLICOPROTEINS ASSOCIATED WITH HUMAN B-LYMPHOMAS-ULBP, DNA AND POLYPEPTIDES. |
EP1002864A1 (en) | 1998-11-10 | 2000-05-24 | Universita' degli studi di Bologna | HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections |
US6897057B1 (en) | 1999-08-31 | 2005-05-24 | The General Hospital Corporation | Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression |
GB9930418D0 (en) | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
WO2002076216A1 (en) | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
WO2002088327A1 (en) | 2001-04-06 | 2002-11-07 | Mount Sinai School Of Medicine Of New York University | Methods for viral oncoapoptosis in cancer therapy |
CA2462790A1 (en) | 2001-10-04 | 2003-04-10 | Immunex Corporation | Ul16 binding protein 4 |
KR100900249B1 (en) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239 Immunogenic Plasmids And AIDS DNA Vaccine Containing The Same |
US8927251B2 (en) | 2002-10-07 | 2015-01-06 | The University Of Chicago | Targeting of herpes simplex virus to specific receptors |
GB0406389D0 (en) | 2004-03-22 | 2004-04-21 | Istituto Superiore Di Sanito | Recombinant herpes simplex virus and uses therefor |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
EP1793851B1 (en) | 2004-08-20 | 2016-10-05 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
WO2006050211A2 (en) | 2004-10-28 | 2006-05-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
CN101132798B (en) | 2005-01-17 | 2011-04-27 | 溶瘤病毒有限公司 | Application of nucleic acid molecule in preparing medicine for treatment of neoplasms and composition |
KR20130114758A (en) | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Gene vector comprising mi-rna |
DK2336362T3 (en) | 2005-08-26 | 2019-01-21 | Dupont Nutrition Biosci Aps | USE OF CRISPR-ASSOCIATED GENES (CAS) |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
US20080008686A1 (en) | 2006-07-10 | 2008-01-10 | The Brigham And Women's Hospital, Inc. | Tetracycline repressor regulated oncolytic viruses |
PL2049663T3 (en) | 2006-08-11 | 2015-08-31 | Dow Agrosciences Llc | Zinc finger nuclease-mediated homologous recombination |
US20100111873A1 (en) | 2007-02-20 | 2010-05-06 | Russell Stephen J | Treating cancer with viral nucleic acid |
CA2687301C (en) | 2007-05-09 | 2016-08-23 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses type-1 for treatment of cancers |
US20080289058A1 (en) | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
WO2009111892A1 (en) | 2008-03-14 | 2009-09-17 | Ottawa Health Research Institute | Microrna mediated oncolytic targeting |
US8703120B2 (en) | 2008-05-29 | 2014-04-22 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
ES2667622T3 (en) | 2008-05-29 | 2018-05-11 | Alma Mater Studiorum - Università di Bologna | Herpes simplex virus (HSV) with modified tropism, uses and preparation procedure |
GB0810912D0 (en) | 2008-06-13 | 2008-07-23 | Inst Animal Health Ltd | Vector |
US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
WO2010054108A2 (en) | 2008-11-06 | 2010-05-14 | University Of Georgia Research Foundation, Inc. | Cas6 polypeptides and methods of use |
MX337838B (en) | 2008-11-07 | 2016-03-22 | Dupont Nutrition Biosci Aps | Bifidobacteria crispr sequences. |
CA2755245A1 (en) | 2009-03-13 | 2010-09-16 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
WO2011125469A1 (en) | 2010-04-09 | 2011-10-13 | 国立大学法人東京大学 | Micro-rna-regulated recombinant vaccinia virus and utilization thereof |
WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
WO2012006181A2 (en) | 2010-06-29 | 2012-01-12 | Mount Sinai School Of Medicine | Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer |
EP2630156B1 (en) | 2010-10-20 | 2018-08-22 | DuPont Nutrition Biosciences ApS | Lactococcus crispr-cas sequences |
CA2834375C (en) | 2011-04-27 | 2020-07-14 | Amyris, Inc. | Methods for genomic modification |
WO2012164565A1 (en) | 2011-06-01 | 2012-12-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for downregulating prokaryotic genes |
PL3351261T3 (en) | 2011-10-11 | 2021-12-06 | Universität Zürich | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
EP2591796A1 (en) | 2011-11-10 | 2013-05-15 | Universität Zürich | Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
US20140363469A1 (en) * | 2012-01-19 | 2014-12-11 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
EP3272356A1 (en) | 2012-02-24 | 2018-01-24 | Fred Hutchinson Cancer Research Center | Compositions and methods for the treatment of hemoglobinopathies |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
JP6605957B2 (en) | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス,インコーポレイティド | Compositions and methods for detecting protease activity in biological systems |
EP3011034B1 (en) | 2013-06-17 | 2019-08-07 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
US10174341B2 (en) | 2013-07-17 | 2019-01-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production |
JP6588024B2 (en) | 2013-10-28 | 2019-10-09 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | Oncolytic HSV vector |
SG11201607130RA (en) | 2014-02-27 | 2016-09-29 | Viralytics Ltd | Combination method for treatment of cancer |
PL3169341T3 (en) | 2014-07-16 | 2019-12-31 | Transgene Sa | Oncolytic virus for expression of immune checkpoint modulators |
WO2016141320A2 (en) | 2015-03-05 | 2016-09-09 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
US10083137B2 (en) | 2015-04-02 | 2018-09-25 | Atmel Corporation | Peripheral interface circuit for serial memory |
EP3365062A4 (en) | 2015-10-19 | 2019-07-17 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
SG11201805835WA (en) | 2016-01-08 | 2018-08-30 | Replimune Ltd | Modified oncolytic virus |
CN108884448B (en) | 2016-01-27 | 2022-12-30 | 昂克诺斯公司 | Oncolytic viral vectors and uses thereof |
EP3426271A4 (en) | 2016-03-10 | 2019-10-16 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
AU2016403583B2 (en) | 2016-04-22 | 2020-05-28 | Immvira Co., Limited | Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy |
JP7200104B2 (en) | 2016-08-01 | 2023-01-06 | ヴァイロジン バイオテック カナダ リミテッド | Oncolytic Herpes Simplex Virus Vectors Expressing Immune System Stimulatory Molecules |
CA3033613A1 (en) | 2016-08-09 | 2018-02-15 | Almohanad ALKAYYAL | Oncolytic rhabdovirus expressing il12 |
WO2018049261A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
WO2018085461A1 (en) | 2016-11-01 | 2018-05-11 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
EP3565578A1 (en) | 2016-12-21 | 2019-11-13 | Memgen LLC | Armed replication-competent oncolytic adenoviruses |
GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
EP3658165A4 (en) | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
-
2017
- 2017-01-27 CN CN201780019076.0A patent/CN108884448B/en active Active
- 2017-01-27 EP EP22161034.8A patent/EP4089166A1/en active Pending
- 2017-01-27 CN CN202211588793.4A patent/CN116904404A/en active Pending
- 2017-01-27 KR KR1020187024583A patent/KR20180136435A/en active Search and Examination
- 2017-01-27 RU RU2021114137A patent/RU2021114137A/en unknown
- 2017-01-27 EP EP17704150.6A patent/EP3408382B1/en active Active
- 2017-01-27 ES ES17704150T patent/ES2919953T3/en active Active
- 2017-01-27 SG SG10202107138TA patent/SG10202107138TA/en unknown
- 2017-01-27 JP JP2018559162A patent/JP2019508063A/en active Pending
- 2017-01-27 AU AU2017212713A patent/AU2017212713B2/en not_active Expired - Fee Related
- 2017-01-27 SG SG11201806134SA patent/SG11201806134SA/en unknown
- 2017-01-27 AR ARP170100218A patent/AR107469A1/en unknown
- 2017-01-27 WO PCT/US2017/015417 patent/WO2017132552A1/en active Application Filing
- 2017-01-27 RU RU2018130673A patent/RU2749050C2/en active
- 2017-01-27 BR BR112018015390-7A patent/BR112018015390A2/en active Search and Examination
- 2017-01-27 CA CA3011933A patent/CA3011933A1/en active Pending
- 2017-01-27 DK DK17704150.6T patent/DK3408382T3/en active
- 2017-01-27 MX MX2018009126A patent/MX2018009126A/en unknown
- 2017-01-27 PT PT177041506T patent/PT3408382T/en unknown
- 2017-02-02 TW TW106103584A patent/TWI798168B/en active
-
2018
- 2018-07-26 IL IL260790A patent/IL260790B/en unknown
- 2018-07-27 US US16/047,499 patent/US10391132B2/en active Active
-
2019
- 2019-07-10 US US16/507,789 patent/US11452750B2/en active Active
-
2021
- 2021-05-27 JP JP2021089151A patent/JP7174109B2/en active Active
-
2022
- 2022-01-25 IL IL290102A patent/IL290102B2/en unknown
- 2022-08-18 US US17/820,694 patent/US20230115116A1/en active Pending
- 2022-11-04 JP JP2022177413A patent/JP2023001236A/en not_active Withdrawn
-
2024
- 2024-02-28 JP JP2024028567A patent/JP2024052881A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017212713A1 (en) | Oncolytic viral vectors and uses thereof | |
US20230241140A1 (en) | Oncolytic viral vectors and uses thereof | |
Liu et al. | CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment | |
Xie et al. | MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer | |
AU2018352221B2 (en) | Peptides and nanoparticles for intracellular delivery of mRNA | |
EP3647421A1 (en) | Using minivectors to treat ovarian cancer | |
Jiang et al. | Exploiting RIG-I-like receptor pathway for cancer immunotherapy | |
CN111936150A (en) | Anticancer microRNA and lipid preparation thereof | |
EP3851528A1 (en) | Composition for inducing death of cells having mutated gene, and method for inducing death of cells having modified gene by using composition | |
US20210155928A1 (en) | Rna-aided immunotherapeutics | |
Lakhani | The Role of Recurrently Observed Aneuploidy in Tumorigenesis | |
Acton | Cancer Gene Therapy: New Insights for the Healthcare Professional: 2013 Edition: ScholarlyBrief | |
Fils-Aimé | Understanding the Tgf-β Language or Getting Lost in Translation: The TGF-β MicroRNAome | |
Gemayel et al. | Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review | |
Kousar et al. | Review Article: Immune Landscape and Immunotherapy Options in Cervical Carcinoma. Cancers 2022, 14, 4458 | |
WO2023034867A1 (en) | Engineered oncolytic herpesviruses | |
Siolas et al. | Tumor-Intrinsic Gain-of-Function p53 R172H Mutation Drives Accumulation of Neutrophils in the Pancreatic Tumor Microenvironment that Promotes Resistance to Immunotherapy | |
Wei | Elucidating SNF5 Regulated Gene Expression in Malignant Rhabdoid Tumor Development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |